ABSTRACT
The present invention includes a chimeric protein comprising a VWF protein with D' domain
and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF
fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other.
The chimeric protein can further comprise one or more Ig constant region or a portion thereof
(e.g., an Fc region). A polypeptide chain of a VWF fragment is associated with a FVIII
polypeptide chain linked to an XTEN sequence. The VWF fragment polypeptide chain can
prevent or inhibit binding of endogenous VWF to FVIII protein linked to the XTEN sequence.
By preventing or inhibiting binding of endogenous VWF to FVIII protein, VWF fragment can
extend half-life of chimeric protein comprising FVIII protein. The invention includes
nucleotides, vectors, host cells, use of VWF fragment, or chimeric proteins.

  FACTOR VIII COMPLEX WITH XTEN AND VON WILLEBRAND FACTOR PROTEIN,
                                      AND USES THEREOF
[0001]          This application is a divisional of Australian Patent Application No.
2013290173, filed on 10 July 2013, and is related to International Patent Application No.
PCT/US2013/049989, filed on 10 July 2013, and claims priority from U.S. Provisional Patent
Application Nos. 61/670,401 filed on 11 July 2012, 61/759,819 filed on 1 February 2013,
61/801,504 filed on 15 March 2013, 61/801,544 filed on 15 March 2013, 61/827,158 filed on
24 May 2013, and 61/840,811 filed on 28 June 2013, each of which is incorporated herein by
reference in its entirety.
                             BACKGROUND OF THE INVENTION
[0001a]         Haemophilia A is a bleeding disorder caused by defects in the gene encoding
coagulation factor VIII (FVIII) and affects 1-2 in 10,000 male births. Graw et al., Nat. Rev.
Genet. 6(6): 488-501 (2005). Patients affected with hemophilia A can be treated with infusion
of purified or recombinantly produced FVIII. All commercially available FVIII products,
however, are known to have a half-life of about 8-12 hours, requiring frequent intravenous
administration to the patients. See Weiner M.A. and Cairo, M.S., Pediatric Hematology Secrets,
Lee, M.T., 12. Disorders of Coagulation, Elsevier Health Sciences, 2001; Lillicrap, D. Thromb.
Res. 122 Suppl 4:S2-8 (2008). In addition, a number of approaches have been tried in order to
extend the FVIII half-life. For example, the approaches in development to extend the half-life
of clotting factors include pegylation, glycopegylation, and conjugation with albumin. See
Dumont et al., Blood. 119(13): 3024-3030 (Published online Jan. 13, 2012). Regardless of the
protein engineering used, however, the long acting FVIII products currently under development
are reported to have limited half-lives - only to about 1.5 to 2 hours in preclinical animal
models. See id. Consistent results have been demonstrated in humans, for example, rFVIIIFc
was reported to improve half-life up to ~ 1.7 fold compared with ADVATE@ in hemophilia A
patients. See Id. Therefore, the half-life increases, despite minor improvements, may indicate
the presence of other Tl/2 limiting factors. See Liu, T. et al., 2007 ISTH meeting, abstract #P
M- 035; Henrik, A. et al., 2011 ISTH meeting, abstract #P=MO-181; Liu, T. et al., 2011 ISTH
meeting abstract #P-WE- 131.
[0002]          Plasma von Willebrand Factor (VWF) has a half-life of approximately 12 hours
(ranging from 9 to 15 hours).
                                                 -1-

http://www.nhlbi.nih.gov/guidelines/vwd/2_scientificoverview.htm (last visited October 22,
2011). The VWF half-life may be affected by a number of factors: glycosylation pattern,
ADAMTS-13 (a disintegrin and metalloprotease with thrombospondin motif- 13), and various
mutations in VWF.
[0003]        In plasma, 95-98% of FVIII circulates in a tight non-covalent complex with full
length VWF. The formation of this complex is important for the
                                 [Text continues on page 2.]
                                            - la -

       maintenance of appropriate plasma levels of FVIII in vivo. Lenting et al., Blood.
       92(11): 3983-96 (1998); Lenting et al., J. Thromb. Haemost. 5(7): 1353-60
       (2007). The full-length wild-type FVIII is mostly present as a heterodimer having
       a heavy chain (MW 200kD) and a light chain (MW 73kD). When FVIII is
       activated due to proteolysis at positions 372 and 740 in the heavy chain and at
       position 1689 in the light chain, the VWF bound to FVIII is removed from the
       activated FVIII. The activated FVIII, together with activated factor IX, calcium,
       and phospholipid ("tenase complex"), induces the activation of factor X,
       generating large amounts of thrombin. Thrombin, in turn, then cleaves fibrinogen
       to form soluble fibrin monomers, which then spontaneously polymerize to form
       the soluble fibrin polymer. Thrombin also activates factor XIII, which, together
       with calcium, serves to crosslink and stabilize the soluble fibrin polymer, forming
       crosslinked (insoluble) fibrin. The activated FVIII is cleared fast from the
       circulation by proteolysis.
[0004]          Due to the frequent dosing and inconvenience caused by the dosing
       schedule, there is still a need to develop FVIII products requiring less frequent
       administration, i.e., a FVIII product that has a half-life longer than the 1.5 to 2 fold
       half-life limitation.
                         BRIEF SUMMARY OF THE INVENTION
[00051          The present invention is directed to a chimeric protein comprising (i) a von
       Willebrand Factor (VWF) fragment comprising the D' domain and the D3 domain
       of VWF, (ii) an XTEN sequence, and (iii) a FVIII protein, wherein the VWF
       fragment and the XTEN sequence are linked by an optional linker and wherein the
       VWF fragment or the XTEN sequence is linked to or associated with the FVIII
       protein. The chimeric protein can comprise a single polypeptide chain comprising
       the VWF fragment, the XTEN sequence, and the FVIII protein, or two
       polypeptide chains, a first chain comprising the VWF fragment and the second
       chain comprising the FVIII protein, wherein the XTEN polypeptide is linked
       either to the VWF fragment or the FVIII protein.
[0006]          In one embodiment, the chimeric protein of the invention comprises a
       formula comprising:
                (a)     V-X-FVIII,
                                             -2-

                (b)     FVIII-X-V,
                (c)     V-X:FVIII,
                (d)     X-V:FVIII,
                (e)     FVIII:V-X, or
                (f)     FVIII:X-V,
       wherein V comprises a VWF fragment,
       X comprises one or more XTEN sequences, and
       FVIII comprises a FVIII protein. The hyphen (-) can be a peptide bond or a
       linker, e.g., a cleavable linker, while the colon (:) represents a chemical
       association or a physical association between the polypeptides, for example a
       covalent or non-covalent bond.
[00071          In another embodiment, the chimeric protein further comprises (iv) an
       immunoglobulin (Ig) constant region or a portion thereof (also indicated as F1 or a
       first Ig constant region or a portion thereof) linked to the VWF fragment, the
       XTEN sequence, the FVIII protein, or any combinations thereof. In other
       embodiments, the chimeric protein further comprises an additional Ig constant
       region or a portion thereof (also indicated as F2 or a second Ig constant region or a
       portion thereof). The first Ig constant region or a portion thereof can be linked to
       the VWF fragment or the XTEN sequence, and the second Ig constant region can
       be linked to the FVIII protein. The first Ig constant region, the second Ig constant
       region or a portion thereof, or both can extend the half-life of the FVIII protein.
[0008]          In some embodiments, the second Ig constant region or a portion thereof
       (F2) is linked to the VWF fragment by a linker, e.g., a processable linker. In other
       embodiments, the second Ig constant region or a portion thereof (F2) is associated
       with the (first) Ig constant region or a portion thereof (F 1). The second Ig
       constant region or a portion thereof (F2) and the first Ig constant region or a
       portion thereof (F1) can be identical or different. The second Ig constant region or
       a portion thereof can be associated with the Ig constant region or a portion thereof
       by a covalent bond, e.g., a disulfide bond. The VWF fragment linked to the first
       Ig constant region or a portion thereof may also be associated with the FVIII
       protein linked to the second Fc region by a non-covalent bond. In certain
       embodiments, the FVIII protein can further comprise one or more additional
       XTEN sequences which are linked to the C-terminus or N-terminus of the FVIII
                                             -3 -

       protein or inserted immediately downstream of one or more amino acids in the
       FVIII protein (e.g., one or more XTEN insertion sites). In some embodiments, the
       half-life of the FVIII protein is extended, compared to wild type FVIII or a FVIII
       protein without the VWF fragment.
[0009]          In some embodiments, the chimeric protein comprises a formula
       comprising:
                (g)     V-L2-X-L1-F 1:FVIII-L3-F2;
                (h)     V-L2-X-L1-F 1:F2-L3-FVIII;
                (i)     Fl-Li -X-L2-V:FVIII-L3-F2;
                (j)     F1-L1-X-L2-V:F2-L3-FVIII;
                (k)     V-L2-X-L 1-Fl -L4-FVIII-L3 -F2;
                (1)     F2-L3-FVIII-L4-F 1-L1 -X-L2-V;
                (m)     FVIII-L3-F2-L4-V-L2-X-L1-Fl; or
                (n)     F1-L1-X-L2-V-L4-F2-L3-FVIII,
       wherein V comprises a VWF fragment,
       each of L1, L2, and L3 comprises an optional linker, e.g., a cleavable linker,
       L4 is an optional linker, e.g., a processable linker,
       FVIII comprises a FVIII protein,
       X comprises one or more XTEN sequences,
       Fl comprises an optional first Ig constant region or a portion thereof,
       F2 comprises an optional second Ig constant region or a portion thereof, and
       (:) is a covalent bond or non-covalent bond.
[0010]          The present invention is also directed to a chimeric protein comprising (i) a
       FVIII protein, (ii) an XTEN sequence, and (iii) an Ig constant region or a portion
       thereof, wherein the XTEN sequence is linked to the FVIII protein by an optional
       linker at the N-terminus or C terminus of the FVIII protein or inserted
       immediately downstream of one or more amino acids in the FVIII protein (e.g.,
       one or more insertion sites) and wherein the Ig constant region or a portion thereof
       is linked to or associated with the FVIII protein or the XTEN sequence. In one
       embodiment, the Ig constant region or a portion thereof useful for the chimeric
       protein comprises a first Fc region. In another embodiment, the chimeric protein
       further comprises an additional Ig constant region or a portion thereof. The
       additional Ig constant region or a portion thereof useful for the invention can
                                             -4-

       comprise a second Fc region, which is linked to or associated with the first Fc
       region, e.g., by a covalent bond. In other embodiments, the first Fc region is
       linked to the second Fc region by a linker, e.g., a processable linker.
[0011]          In other aspects, a chimeric protein comprises (i) a FVIII protein, (ii) an
       XTEN sequence, (iii) a VWF fragment, and (iv) an Ig constant region or a portion
       thereof, which comprises the D' domain and the D3 domain of VWF, wherein the
       XTEN sequence is linked to the FVIII protein by an optional linker at the N
       terminus or C terminus of the FVIII protein or inserted immediately downstream
       of one or more amino acids in the FVIII protein (e.g., one or more insertion sites),
       the VWF fragment is linked to or associated with the FVIII protein or the XTEN
       sequence, and the Ig constant region or a portion thereof is linked to the FVIII
       protein, the XTEN sequence, the VWF fragment, or any combinations thereof.
       Non-limiting examples of the chimeric proteins may comprise a formula, which
       comprises:
                (1)     FVIII(Xi)-Li-Fi :V-L2-X2-L3-F2;
                (2)     FVIII(X1)-Li-Fl :F2-L3-X2-L2-V;
                (3)     FI-LI-FVIII(X):V-L2-X2-L3-F2;
                (4)     FI-LI-FVIII(X):F2-L3-X2-L2-V;
                (5)     FVIII(X1)-Li-Fl -L4-V-L2-X2-L3-F2;
                (6)     FVIII(X1)-Li-Fl -L4-F2-L3-X2-L2-V;
                (7)     Fl-Li-FVIII(X1)-L4-V-L2-X2-L3-F2, or
                (8)     F1-LI-FVIII(X1)-L4-F2-L3-X2-L2-V,
       wherein FVIII(XI) comprises a FVIII protein and one or more XTEN sequences,
       wherein one or more of the XTEN sequences are linked to the N-terminus or C
       terminus of the FVIII protein or inserted immediately downstream of one or more
       amino acids in the FVIII protein (e.g., one or more XTEN insertion sites);
       each of LI, L2, or L3 comprises an optional linker, e.g., a cleavable linker;
       L4 is a linker, a processable linker;
       X2 comprises one or more XTEN sequences;
       Fl comprises an Ig constant region or a portion thereof;
       F2 comprises an optional additional Ig constant region or a portion thereof, and
       V comprises a VWF fragment;
       (-) is a peptide bond or one or more amino acids; and
                                             -5 -

       (:) comprises a covalent bond or a non-covalent bond.
[0012]          One aspect of the invention is that the VWF fragment useful for the
       chimeric protein does not bind to a VWF clearance receptor, which prevents or
       inhibits interaction of the FVIII protein with endogenous VWF. The chimeric
       protein comprising the VWF fragment thus has reduced clearance or is not cleared
       through a VWF clearance pathway. Another aspect of the invention is that the
       VWF fragment is capable of protecting the FVIII protein from one or more
       protease cleavages, protecting the FVIII protein from activation, stabilizing the
       heavy chain and/or the light chain of the FVIII protein, or preventing clearance of
       the FVIII protein by one or more scavenger receptors.
[0013]          Because of the VWF fragment's ability to prevent or inhibit interaction
       between the FVIII protein and endogenous VWF, the half-life of the FVIII
       protein, is extended compared to a FVIII protein without the VWF fragment. In
       one embodiment, the half-life of the FVIII protein is extended at least about 1.5
       times, at least about 2 times, at least about 2.5 times, at least about 3 times, at least
       about 4 times, at least about 5 times, at least about 6 times, at least about 7 times,
       at least about 8 times, at least about 9 times, at least about 10 times, at least about
       11 times, or at least about 12 times longer than wild type FVIII. In another
       embodiment, the half-life of the FVIII protein is at least about 10 hours, at least
       about 11 hours, at least about 12 hours, at least about 13 hours, at least about 14
       hours, at least about 15 hours, at least about 16 hours, at least about 17 hours, at
       least about 18 hours, at least about 19 hours, at least about 20 hours, at least about
       21 hours, at least about 22 hours, at least about 23 hours, at least about 24 hours,
       at least about 36 hours, at least about 48 hours, at least about 60 hours, at least
       about 72 hours, at least about 84 hours, at least about 96 hours, or at least about
       108 hours.
[0014]          The Ig constant region or a portion thereof useful for the chimeric protein
       comprises a first Fc region, which is linked to the VWF fragment by an optional
       linker, e.g., a cleavable linker. The chimeric protein can further comprise an
       additional Ig constant region or a portion thereof, which is linked to the FVIII
       protein or the XTEN sequence, the Ig constant region or a portion thereof, the
       VWF fragment, or any combinations thereof by an optional linker. In one
       embodiment, the additional Ig constant region or a portion thereof is linked to the
                                              -6-

       FVIII protein by an optional linker. The additional Ig constant region or a portion
       thereof can comprise a second Fc region.
[00151         The Ig constant region or a portion thereof useful in the present invention
       and the additional Ig constant region or a portion thereof useful in the present
       invention are identical or different.
[0016]         In some aspects, the FVIII protein is linked to an XTEN sequence at the C
       terminus or the N-terminus of the FVIII protein or inserted immediately
       downstream of one or more amino acids in mature native human FVIII (e.g., one
       or more insertion sites) or any combinations thereof. One or more insertion sites
       in the FVIII protein can be located within one or more domains of the FVIII
       protein selected from the group consisting of the Al domain, the al acidic region,
       the A2 domain, the a2 acidic region, the A3 domain, the B domain, the Cl
       domain, the C2 domain, and any combinations thereof or between one or more
       domains of the FVIII protein selected from the group consisting of the Al domain
       and al acidic region, the al acidic region and A2 domain, the A2 domain and a2
       acidic region, the a2 acidic region and B domain, the B domain and A3 domain,
       the A3 domain and Cl domain, the Cl domain and C2 domain, and any
       combinations thereof or between two domains of the FVIII protein selected from
       the group consisting of the Al domain and al acidic region, the al acidic region
       and A2 domain, the A2 domain and a2 acidic region, the a2 acidic region and B
       domain, the B domain and A3 domain, the A3 domain and Cl domain, the Cl
       domain and C2 domain, and any combinations thereof.
[00171         In one embodiment, the one or more insertion sites are located
       immediately downstream of one or more amino acids in mature native human
       FVIII (e.g., SEQ ID NO: 4 [mature FVIII sequence-full length]) selected from the
       group consisting of the amino acid residues in Table 7, 8, 9, 10, 11, or any
       combinations thereof.
[0018]         In another embodiment, the one or more insertion sites are located in one
       or more permissive loops of mature native human FVIII. In other embodiments,
       the one or more insertion sites are located in the a3 region of mature native human
       FVIII. For example, an XTEN sequence can be inserted immediately downstream
       of amino acid 1656 corresponding to SEQ ID NO: 4 (full length mature FVIII). In
       other embodiments, a FVIII protein is linked to at least two XTEN sequences, a
                                             -7-

       first XTEN sequence inserted within the a3 region, and a second XTEN sequence
       inserted within a permissive loop in the FVIII protein (e.g., Al-1, A1-2, A2-1, A2
       2, A3-1, or A3-2). In still other embodiments, a FVIII protein is linked to at least
       three XTEN sequences, a first XTEN sequence inserted within the a3 region and a
       second XTEN sequence and a third XTEN sequence inserted within one or two
       permissive loop in the FVIII protein (e.g., Al-1, Al-2, A2-1, A2-2, A3-1, or A3
       2).
[0019]         In certain embodiments, the one or more insertion sites for one or more
       XTEN insertions are immediately downstream of one or more amino acids
       (numbered relative to mature FVIII sequence) selected from the group consisting
       of:
       (1) amino acid 3,              (2) amino acid 18,             (3) amino acid 22,
       (4) amino acid 26,             (5) amino acid 32,             (6) amino acid 40,
       (7) amino acid 60,             (8) amino acid 65,             (9) amino acid 81,
       (10) amino acid 116,           (11) amino acid 119,           (12) amino acid 130,
       (13) amino acid 188,           (14) amino acid 211,           (15) amino acid 216,
       (16) amino acid 220,           (17) amino acid 224,           (18) amino acid 230,
       (19) amino acid 333,           (20) amino acid 336,           (21) amino acid 339,
       (22) amino acid 375,           (23) amino acid 399,           (24) amino acid 403,
       (25) amino acid 409,           (26) amino acid 416,           (26) amino acid 442,
       (28) amino acid 487,           (29) amino acid 490,           (30) amino acid 494,
       (31) amino acid 500,           (32) amino acid 518,           (33) amino acid 599,
       (34) amino acid 603,           (35) amino acid 713,           (36) amino acid 745,
       (37) amino acid 1656,                  (38) amino acid 1711,                 (39)
       amino acid 1720,
       (40) amino acid 1725,                  (41) amino acid 1749,                 (42)
       amino acid 1796,
       (43) amino acid 1802,                  (44) amino acid 1827,                 (45)
       amino acid 1861,
       (46) amino acid 1896,                  (47) amino acid 1900,                 (48)
       amino acid 1904,
       (49) amino acid 1905,                  (50) amino acid 1910,                 (51)
       amino acid 1937,
                                            -8-

       (52) amino acid 2019,                    (53) amino acid 2068,             (54)
       amino acid 2111,
       (55) amino acid 2120,                    (56) amino acid 2171,             (57)
       amino acid 2188,
       (58) amino acid 2227,           (59) amino acid 2277, and
       (60)      two or more combinations thereof.
[0020]          In some embodiments, one XTEN is inserted in the FVIII protein. In some
       embodiments, two XTENs are inserted in the FVIII protein. In some
       embodiments, 3 XTENs are inserted in the FVIII protein.
[0021]          In a particular example, a first XTEN is inserted immediately downstream
       of amino acid 26 corresponding to SEQ ID NO: 4, and a second XTEN is inserted
       immediately downstream of amino acid 1720 corresponding to SEQ ID NO: 4
       (full-length mature FVIII). In another example, a first XTEN is inserted
       immediately downstream of amino acid 403 corresponding to SEQ ID NO: 4, and
       a second XTEN is inserted immediately downstream of amino acid 1720
       corresponding to SEQ ID NO: 4. In some examples, a first XTEN is inserted
       immediately downstream of amino acid 1656 corresponding to SEQ ID NO: 4,
       and a second XTEN is inserted immediately downstream of amino acid 1720
       corresponding to SEQ ID NO: 4. In other examples, a first XTEN is inserted
       immediately downstream of amino acid 26 corresponding to SEQ ID NO: 4, a
       second XTEN is inserted immediately downstream of amino acid 1656
       corresponding to SEQ ID NO: 4, and a third XTEN is inserted immediately
       downstream of amino acid 1720 corresponding to SEQ ID NO: 4. In yet other
       embodiments, a first XTEN is inserted immediately downstream of amino acid
       403 corresponding to SEQ ID NO: 4, a second XTEN is inserted immediately
       downstream of amino acid 1656 corresponding to SEQ ID NO: 4, and a third
       XTEN is inserted immediately downstream of amino acid 1720 corresponding to
       SEQ ID NO: 4. In still other embodiments, a first XTEN is inserted between
       amino acids 403 and 404 corresponding to SEQ ID NO: 4, a second XTEN is
       inserted immediately downstream of amino acid 1656 corresponding to SEQ ID
       NO: 4, and a third XTEN is inserted immediately downstream of amino acid 1720
       corresponding to SEQ ID NO: 4. In certain embodiments, a first XTEN is inserted
       immediately downstream of amino acid 26 corresponding to SEQ ID NO: 4 (full
                                              -9-

       length mature FVIII), a second XTEN is inserted immediately downstream of
       amino acid 1720 corresponding to SEQ ID NO: 4, and a third XTEN is inserted
       immediately downstream of amino acid 1900 corresponding to SEQ ID NO: 4. In
       some embodiments, a first XTEN is inserted immediately downstream of amino
       acid 26 corresponding to SEQ ID NO: 4, a second XTEN is inserted immediately
       downstream of amino acid 1656 corresponding to SEQ ID NO: 2, a third XTEN is
       inserted immediately downstream of amino acid 1720 corresponding to SEQ ID
       NO: 4, and a fourth XTEN is inserted immediately downstream of amino acid
       1900 corresponding to SEQ ID NO: 4. In another example, an XTEN is inserted
       immediately downstream of amino acid 745 corresponding to SEQ ID NO: 4. In
       an additional example, a first XTEN is inserted immediately downstream of amino
       acid 1656 corresponding to SEQ ID NO: 4 and a second XTEN is inserted
       immediately downstream of amino acid 1900 corresponding to SEQ ID NO: 4. In
       some embodiments, a first XTEN is inserted immediately downstream of amino
       acid 26 corresponding to SEQ ID NO: 4, a second XTEN is inserted immediately
       downstream of amino acid 1656 corresponding to SEQ ID NO: 4, and a third
       XTEN is inserted immediately downstream of amino acid 1900 corresponding to
       SEQ ID NO: 4. In another example, a first XTEN is immediately inserted
       downstream of amino acid 403 corresponding to SEQ ID NO: 4 and a second
       XTEN is inserted immediately downstream of amino acid 745 corresponding to
       SEQ ID NO: 4. In some embodiments, a first XTEN is inserted immediately
       downstream of amino acid 745 of corresponding to SEQ ID NO: 4, and a second
       XTEN is inserted immediately downstream of amino acid 1900 corresponding to
       SEQ ID NO: 4. In some embodiments, a first XTEN is inserted immediately
       downstream of amino acid 18 corresponding to SEQ ID NO: 4, and a second
       XTEN is inserted immediately downstream of amino acid 745 corresponding to
       SEQ ID NO: 4.
[0022]         In some embodiments, the FVIII protein is a dual chain FVIII isoform. In
       some embodiments, the FVIII protein is a single chain FVIII isoform.
[0023]         In some embodiments, the XTEN that is inserted is SEQ ID NO: 39
       (AE288). In some examples, the XTENs that are inserted are SEQ ID NOs: 38
       and 37 (AG144 and AE144). In some examples, the XTENs that are inserted are
       SEQ ID NOs: 37, 38 and 37 (AE144, AG144, and AE144). In some
                                          - 10 -

       embodiments. the XTENs that are inserted are SEQ ID NOs: 37 and 40 (AE144
       and AE288). In some embodiments, the XTENs that are inserted are AE42 (SEQ
       ID NO: 36), AE72 (SEQ ID NO: 127), AE144_2A (SEQ IDNO: 128), AE144_3B
       (SEQ ID NO: 129), AE144_4A (SEQ ID NO: 130), AE144_5A (SEQ IDNO:
       131), AE144_6B (SEQ IDNO: 132), AG144_A (SEQ ID NO: 133), AG144_B
       (SEQ IDNO: 134), AG144_C (SEQ ID NO: 135), AG144_F (SEQ IDNO: 136),
       AE864 (SEQ ID NO: 43), AE576 (SEQ ID NO: 41), AE288 (SEQ IDNO: 39),
       AE288_2 (SEQ ID NO: 137), AE144 (SEQ ID NO: 37), AG864 (SEQ ID NO:
       44), AG576 (SEQ ID NO: 42), AG288 (SEQ ID NO: 40), AG144 (SEQ ID NO:
       38), and any combinations thereof.
[0024]         The FVIII protein useful in the invention can comprise B domain or a
       portion thereof, e.g., SQ B domain deleted FVIII. In one embodiment, the FVIII
       protein comprises single chain FVIII. In another embodiment, the single chain
       FVIII contains at least one amino acid substitution at a residue corresponding to
       residue 1648, residue 1645, or both of full-length mature Factor VIII polypeptide
       (SEQ ID NO: 4) or residue 754, residue 751, or both of SQ BDD Factor VIII
       (SEQ ID NO: 6). In other embodiments, the amino acid substitution is an amino
       acid other than arginine. In some embodiments, the FVIII protein comprises a
       heavy chain of FVIII and a light chain of FVIII, wherein the heavy chain and the
       light chain are associated with each other by a metal bond.
[00251         The FVIII protein can have a low affinity to or does not bind to a low
       density lipoprotein receptor-related protein (LRP), e.g., by containing at least one
       amino acid substitution that lowers the affinity to or eliminates the binding to the
       LRP. Such at least one amino acid substitution can be at a residue corresponding
       to residue 471, residue 484, residue 487, residue 490, residue 497, residue 2092,
       residue 2093 or two or more combinations thereof of full-length mature FVIII. In
       a particular embodiment, the amino acid substitution at residue 471, 484, or 497 is
       an amino acid other than arginine, the amino acid substitution at residue 487 is an
       amino acid other than tyrosine, the amino acid substitution at residue 2092 is an
       amino acid other than lysine, or the amino acid substitution at residue 2093 is an
       amino acid other than phenylalanine.
[0026]         In some embodiments, the FVIII protein contains at least one amino acid
       substitution, which induces the FVIII protein to be more stable than a FVIII
                                           - 11 -

       protein without the substitution. Such substitutions can be located in the A2
       domain and the A3 domain of the FVIII protein, e.g., at a residue corresponding to
       residue 664, residue 1826, residue 662, residue 1828, or two or more combinations
       thereof of full-length mature FVIII.
[00271          The VWF fragment useful for the present invention comprises a D' domain
       and D3 domain, which together are capable of binding to FVIII. The VWF
       fragment can comprise the amino acid sequence of the D' domain is at least 90%,
       95%, 96%, 97%, 98%, 99%, or 100% identical to amino acids 764 to 866 of SEQ
       ID NO: 2 and/or the amino acid sequence of the D3 domain is at least 90%, 95%,
       96%, 97%, 98%, 99%, or 100% identical to amino acids 867 to 1240 of SEQ ID
       NO: 2. In one embodiment, the VWF fragment is a monomer. In another
       embodiment, the VWF fragment comprises at least two VWF fragments, at least
       three VWF fragments, at least four VWF fragments, at least five VWF fragments,
       or at least six VWF fragments. In one embodiment, the two or more VWF
       fragments may be identical or they may be different. The VWF fragment can
       comprise an amino acid at least 90%, 95%, 96%, 97%, 98%, 99%, or 100%
       identical to amino acids 764 to 1240 of SEQ ID NO: 2. The VWF fragment may
       consist essentially of or consist of amino acids 764 to 1240 of SEQ ID NO: 2. In
       certain embodiments, the VWF fragment can contain at least one amino acid
       substitution at a residue corresponding to residue 1099, residue 1142, or both
       residues 1099 and 1142 of SEQ ID NO: 2. In other embodiments, the VWF
       fragment further comprises the D1 domain, the D2 domain, or the D1 and D2
       domains of VWF.
[0028]          The VWF fragment may further comprise a VWF domain selected from
       the group consisting of the Al domain, the A2 domain, the A3 domain, the D4
       domain, the B 1 domain, the B2 domain, the B3 domain, the C1 domain, the C2
       domain, the CK domain, one or more fragments thereof, and any combinations
       thereof. For example, the VWF fragment can consist essentially of or consist of:
       (1) the D' and D3 domains of VWF or fragments thereof; (2) the D1, D', and D3
       domains of VWF or fragments thereof; (3) the D2, D', and D3 domains of VWF or
       fragments thereof; (4) the Dl, D2, D', and D3 domains of VWF or fragments
       thereof; or (5) the D1, D2, D', D3, and Al domains of VWF or fragments thereof.
                                             - 12 -

       In some embodiments, the VWF fragment further comprises a signal peptide of
       VWF or FVIII which is operably linked to the VWF fragment.
[0029]          One or more of the linkers useful in the invention have a length of at least
       about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170,
       180, 190,200,210,220,230,240,250,300,350,400,450,500,550,600,650,
       700, 750, 800, 850, 900, 950, 1000, 1200, 1400, 1600, 1800, or 2000 amino acids.
       In some embodiments, one or more of the linkers have a length of about 1 to about
       2000 amino acids. In one embodiment, one or more of the linkers have a length of
       at least about 20, 35, 42, 48, 73, 75, 95, 98, 144, 288, 324, 333, 576, or 864 amino
       acids. In another embodiment, one or more of the linkers comprise a gly/ser
       peptide, an XTEN sequence, or both. Examples of the gly/ser peptide include,
       but are not limited to, a formula of (Gly 4Ser). (SEQ ID NO: 139) or S(Gly 4 Ser).
       (SEQ ID NO: 140), wherein n is a positive integer selected from the group
       consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. For example, the (Gly 4Ser). linker can
       be (Gly 4 Ser)3 (SEQ ID NO: 63) or (Gly 4 Ser)4 (SEQ ID NO: 138). In one
       embodiment, the linker comprises at least one first cleavage site at the N-terminus
       of the linker, at least one second cleavage site at the C-terminus of the linker, or
       both. In another embodiment, the linker comprises 20 amino acids, 35 amino
       acids, 48 amino acids, 73 amino acids, or 95 amino acids thrombin cleavable
       linker. The cleavable linkers can comprise one or more of the cleavage sites by a
       protease selected from the group consisting of factor XIa, factor XIIa, kallikrein,
       factor VIIa, factor IXa, factor Xa, factor Ila (thrombin), Elastase-2, Granzyme-B,
       TEV, Enterokinase, Protease 3C, Sortase A, MMP-12, MMP-13, MMP-17, and
       MMP-20, e.g., TLDPRSFLLRNPNDKYEPFWEDEEK (SEQ ID NO: 8). Non
       limiting examples of one or more of the cleavage sites comprise an amino acid
       sequence selected from the group consisting of RRRR (SEQ ID NO: 9), RKRRKR
       (SEQ ID NO: 10), RRRRS (SEQ ID NO: 11), TQSFNDFTR (SEQ ID NO: 12),
       SVSQTSKLTR (SEQ ID NO: 13), DFLAEGGGVR (SEQ ID NO: 14), TTKIKPR
       (SEQ ID NO: 15), LVPRG (SEQ ID NO: 16), ALRPR (SEQ ID NO: 17),
       KLTRAET (SEQ ID NO: 18), DFTRVVG (SEQ ID NO: 19), TMTRIVGG (SEQ
       ID NO: 20), SPFRSTGG (SEQ ID NO: 21), LQVRIVGG (SEQ ID NO: 22),
       PLGRIVGG (SEQ ID NO:23), IEGRTVGG (SEQ ID NO: 24), LTPRSLLV (SEQ
       ID NO: 25), LGPVSGVP (SEQ ID NO: 26), VAGDSLEE (SEQ ID NO: 27),
                                               - 13 -

       GPAGLGGA (SEQ ID NO: 28), GPAGLRGA (SEQ ID NO: 29), APLGLRLR
       (SEQ ID NO: 30), PALPLVAQ (SEQ ID NO: 31), ENLYFQG (SEQ ID NO: 32),
       DDDKIVGG (SEQ ID NO: 33), LEVLFQGP (SEQ ID NO: 34), and LPKTGSES
       (SEQ ID NO: 35). In some embodiments, the first cleavage site and the second
       cleavage site are identical or different.
[0030]         The XTEN sequence useful for the invention can be selected from the
       group consisting of AE42 (SEQ ID NO: 36), AE144 (SEQ ID NO: 37), AG144
       (SEQ ID NO: 38), AE288 (SEQ ID NO: 39), AG288 (SEQ ID NO: 40), AE576
       (SEQ ID NO: 41). AG576 (SEQ ID NO: 42), AE864 (SEQ ID NO: 43), AE72
       (SEQ ID NO: 127), AE144_2A (SEQ ID NO: 128), AE144_3B (SEQ ID NO:
       129), AE144_4A (SEQ ID NO: 130), AE1445A (SEQ ID NO: 131), AE144_6B
       (SEQ ID NO: 132), AG144 A (SEQ ID NO: 133), AG144_B (SEQ ID NO: 134),
       AG144_C (SEQ ID NO:135), AG144_F (SEQ ID NO: 136), AE288_2 (SEQ ID
       NO: 137), or AG864 (SEQ ID NO: 44). In a particular embodiment, the XTEN
       sequence comprises AE288 or AG288.
[0031]         The chimeric protein of the invention can be polysialylated, pegylated, or
       hesylated.
[0032]         The present invention is also directed to a polynucleotide or a set of
       polynucleotides encoding the chimeric protein. The polynucleotide can further
       comprise a polynucleotide chain, which encodes PC5 or PC7. The invention is
       also directed to a vector comprising the polynucleotide or the set of
       polynucleotides and one or more promoter operably linked to the polynucleotide
       or the set of polynucleotides. The vector can further comprise an additional
       vector, which comprises a polynucleotide chain encoding PC5 or PC7. The
       invention is also drawn to a host cell comprising the polynucleotide or the vector.
       The host cell can be a mammalian cell, e.g., HEK293 cell, CHO cell, or BHK cell.
       In some embodiments, the PC5 or PC7 of the host cell cleaves the D1D2 domains
       of VWF.
[0033]         The invention is also directed to a pharmaceutical composition comprising
       the chimeric protein, the polynucleotide, the vector, or the host cell, and a
       pharmaceutically acceptable carrier. The composition of the invention thus has an
       extended half-life compared to wild type FVIII protein. The half-life of the FVIII
       protein is extended at least about 1.5 times, at least about 2 times, at least about
                                             - 14 -

       2.5 times, at least about 3 times, at least about 4 times, at least about 5 times, at
       least about 6 times, at least about 7 times, at least about 8 times, at least about 9
       times, at least about 10 times, at least about 11 times, or at least about 12 times
       longer than wild type FVIII. The half-life of Factor VIII is at least about 17 hours,
       at least about 18 hours, at least about 19 hours, at least about 20 hours, at least
       about 21 hours, at least about 22 hours, at least about 23 hours, at least about 24
       hours, at least about 25 hours, at least about 26 hours, at least about 27 hours, at
       least about 28 hours, at least about 29 hours, at least about 30 hours, at least about
       31 hours, at least about 32 hours, at least about 33 hours, at least about 34 hours,
       at least about 35 hours, at least about 36 hours, at least about 48 hours, at least
       about 60 hours, at least about 72 hours, at least about 84 hours, at least about 96
       hours, or at least about 108 hours.
[0034]          The composition of the present invention can be administered by a route
       selected from the group consisting of topical administration, intraocular
       administration, parenteral administration, intrathecal administration, subdural
       administration and oral administration. In one embodiment, the composition is
       administered via parenteral administration, e.g., intravenous or subcutaneous
       administration. The composition of the invention is useful to treat a bleeding
       disease or condition in a subject in need thereof. The bleeding disease or
       condition is selected from the group consisting of a bleeding coagulation disorder,
       hemarthrosis, muscle bleed, oral bleed, hemorrhage, hemorrhage into muscles,
       oral hemorrhage, trauma, trauma capitis, gastrointestinal bleeding, intracranial
       hemorrhage, intra-abdominal hemorrhage, intrathoracic hemorrhage, bone
       fracture, central nervous system bleeding, bleeding in the retropharyngeal space,
       bleeding in the retroperitoneal space, bleeding in the illiopsoas sheath and any
       combinations thereof. In one embodiment, the subject treated with the chimeric
       protein is scheduled to undergo a surgery. In another embodiment, the treatment
       is prophylactic or on-demand.
[00351          The invention is also directed to a method of preventing or inhibiting
       binding of a FVIII protein with endogenous VWF comprising adding an effective
       amount of the chimeric protein, the polynucleotide vector, the host cell, or the
       composition to a subject in need thereof, wherein the VWF fragment binds to the
       FVIII protein and thus prevents or inhibits binding of endogenous VWF. The
                                             - 15 -

       present invention is further directed to a method of extending or increasing the
       half-life of the FVIII protein, wherein the method comprises administering an
       effective amount of the chimeric protein, the polynucleotide, the vector, the host
       cell, or the composition to a subject in need thereof, wherein the VWF fragment
       binds to the FVIII protein and thus extends or increases the half-life of the FVIII
       protein. Also provided is a method of preventing or inhibiting clearance of a
       FVIII protein from a cell, wherein the method comprises administering an
       effective amount of the chimeric protein, the polynucleotide, the vector, the host
       cell, or the composition to a cell comprising a FVIII protein or a polynucleotide
       encoding the FVIII protein, wherein the protein having VWF activity binds to the
       FVIII protein. The subject useful for the present methods is an animal, e.g., a
       human, e.g., a patient suffering from hemophilia A.
[00361          The present invention also provides a method of treating a bleeding disease
       or disorder in a subject in need thereof comprising administering an effective
       amount of the chimeric protein, the polynucleotide, the vector, the host cell, or the
       composition, wherein the bleeding disease or disorder is selected from the group
       consisting of a bleeding coagulation disorder, hemarthrosis, muscle bleed, oral
       bleed, hemorrhage, hemorrhage into muscles, oral hemorrhage, trauma, trauma
       capitis, gastrointestinal bleeding, intracranial hemorrhage, intra-abdominal
       hemorrhage, intrathoracic hemorrhage, bone fracture, central nervous system
       bleeding, bleeding in the retropharyngeal space, bleeding in the retroperitoneal
       space, and bleeding in the illiopsoas sheath. The treatment can be prophylactic or
       on-demand. In one embodiment, the effective amount is 0.1 gg/kg to 500 mg/kg.
[00371          The invention also includes a method of making a chimeric protein,
       comprising transfecting one or more host cell with the polynucleotide or the vector
       and expressing the chimeric protein in the host cell.
                         BRIEF DESCRIPTION OF THE DRAWINGS/FIGURES
[00381          Figure 1A-D. Schematic diagrams of VWF fragments. Fig. 1A shows
       three exemplary VWF fragments useful for the invention, e.g., VWF-002, VWF
       010, and VWF-013. VWF-002 contains amino acids I to 477 of SEQ ID NO: 124
       (amino acids 764 to 1240 of SEQ ID NO: 2) and is synthesized without the
       pre/propeptide sequences. VWF-010 contains the D1D2 domains in addition to
       the D'D3 domains. VWF-013 contains the D1D2D'D3 domains in addition to
                                             - 16 -

       alanine residues substituting cysteines at residues 336 and 379 of SEQ ID NO:
       123 Fig. 1B shows VWF-03 1, which contains the D1D2D'D3 domains fused to an
       Ig constant region or a portion thereof, e.g., an Fc region, by a cleavable linker,
       e.g., a 48 amino acids thrombin cleavable linker. Fig. IC shows VWF-025, which
       is a nucleotide sequence encoding D1D2D'D3 domains contained in pLIVE
       vector, and VWF-029, which is a nucleotide sequence encoding D1D2D'D3
       domains with two amino acid substitutions, C336A and C379A, in pLIVE vector.
       Fig. ID shows full-length VWF fragment comprising propeptide (the D1 and D2
       domains) and mature subunits (the D', D3, A1, A2, A3, D4, B1-3, Cl-2 domains).
       The VWF fragment is about 250 kDa protein and forms multimers (> 20 MDa) by
       disulfide bonding. The VWF fragment associates with FVIII (95-98%) in non
       covalent complex and then extends half-life of FVIII by protecting FVIII from
       protease cleavage/activation, stabilizing heavy & light chain, and preventing
       clearance of FVIII by scavenger receptors. The VWF fragment also can limit
       half-life of FVIII by clearance of FVIII-VWF complex through VWF receptors
       and preventing pinocytosis and recycling of rFVIIIFc.
[0039]          Figure 2. Pharmacokinetic profile of rFVIII-XTEN (rFVIII-AE288 or
       rFVIII-288AE) in VWF D'D3 expression mice or in FVIII and VWF double
       knockout (DKO) mice. Figure 2A shows the timeline of hydrodynamic injection
       (HDI) of the D'D3 domain encoding plasmid DNA (VWF-025) (day -5),
       intravenous dosing of rFVIII-XTEN AE288 (day 0), and PK sample collection
       (day 5). Figure 2B shows FVIII activity measured by a FVIII chromogenic assay
       after IV dosing of rFVIII-XTEN288 in D1D2D'D3 mice (inverted triangle) and
       rFVIII-XTEN288 in DKO mice (diamond). Fig. 2C shows the D'D3 plasma level
       (ng/mL) after administration of VWF-025. The X axis represents time in hours.
[0040]          Figure 3. Schematic diagram of exemplary VWF:FVIII heterodimer
       constructs. The constructs have the common structure represented as formula
       FVIII-F1-L1-V-X-L2-F2, but contain examples of different variable linkers. The
       construct (FVIII- 161) shown contains a heterodimeric FVIII (the heavy chain and
       the light chain are associated by a metal bond) linked to a first Fc region and a
       VWF fragment, which is the D' and D3 domains of VWF (i.e., amino acids 1 to
       477 of SEQ ID NO: 2 with amino acid substitutions C336A and C379A) linked to
       an XTEN sequence, which is further linked to a cleavable linker and a second Fc
                                            - 17 -

       region. The XTEN sequence contained in FVIII-161 is an XTEN AE288
       sequence, and the linker is a thrombin cleavable linker, which has 35 amino acids.
       In FVIII- 161, the FVIII protein linked to the first Fc region is linked to the VWF
       fragment by a processable linker. Upon expression, the processable linker can be
       cleaved by an intracellular processing enzyme, thus making the construct three
       polypeptide chains associated with each other.
[0041]          Figure 4 is schematic diagrams of FVIII-VWF heterodimer or monomer
       examples. FVIII-168, FVIII-175, FVIII-172, FVIII-174, and FVIII170. Construct
       FVIII-168 comprises a single chain FVIII sequence (having an alanine residue
       substitute the arginine residues at residues 1645 and 1648) linked to a first Fc
       region, which is then fused to a VWF fragment linked to a second Fc region by a
       thrombin cleavable linker, which has 48 amino acids. AE288 XTEN is inserted in
       the B domain of the single chain FVIII sequence. The linkage between the first Fc
       region and the VWF fragment comprises a linker that is capable of being cleaved
       by an intracellular processing enzyme, i.e., processable linker. Construct FVIII
       175 comprises a single chain FVIII (having an alanine residue substitute the
       arginine residues at residues 1645 and 1648) linked to AE288 XTEN and a first Fc
       region, which is linked to a second Fc region by a linker, e.g., a processable linker.
       AE288 XTEN is inserted in the B domain of the single chain FVIII sequence.
       Construct FVIII-172 comprises two polypeptide chains, a first chain comprising a
       heavy chain FVIII sequence fused to AE288 XTEN, a second chain comprising a
       light chain FVIII sequence, a first Fc region, a linker (e.g., a processable linker), a
       VWF fragment, a thrombin cleavable linker (e.g., 48 amino acids), and a second
       Fc region. Construct FVIII-174 comprises two polypeptide chains, a first chain
       comprising a heavy chain FVIII sequence fused to AE288 XTEN and a second
       chain comprises a light chain FVIII, a first Fc region, a linker (e.g., a processable
       linker), and a second Fc region. Construct FVIII- 170 comprises a VWF fragment,
       AE288 XTEN, a linker (e.g., a thrombin cleavable linker, which is 35 amino acids
       in length), and a single chain FVIII sequence.
[0042]          Figure 5. Pharmacokinetic profile of FVIII/VWF heterodimers containing
       an XTEN sequence in combination with an Fc region. Constructs FVIII- 161,
       FVIII-168, and FVIII-172 were administered to FVIII:VWF double knockout
       (DKO) mice by Hydrodynamic injection (HDI) at 100ug/mouse dose. Construct
                                            - 18 -

       FVIII-170 was administered to FVIII:VWF DKO mice by HDI at 50 gg/mouse
       dose. The post-HDI plasma FVIII activity was analyzed by FVIII chromogenic
       assay for 24 hr post-HDI. The FVIII activity of the FVIII:VWF heterodimers
       containing an XTEN sequence and Fc domains was compared with the FVIII
       activity of BDD-FVIII without the VWF fragment, XTEN sequence, and Fc
       domains.
[0043]         Figure 6. Schematic diagrams of FVIII-VWF heterodimer examples co
       transfection system. Fig. 6A. Construct FVIII-169 contains the full-length FVIII
       sequence (with an alanine residue substituting the arginine residues at 1645 and
       1648 and with an XTEN sequence inserted in the single chain FVIII sequence),
       which is linked to an Fc region. VWF-031 contains the D1D2D'D3 fragment
       (with an alanine residue substituting the cysteine residues at 336 and 379) which is
       linked to another Fc region with a 48 thrombin cleavable linker. After
       intracellular processing, construct FVIII- 169 produces a full length single chain
       FVIII (SCFVIII) fused to one Fc fragment and an XTEN sequence, and construct
       VWF-031 produces a 477 amino acid D'D3 fragment linked to another Fc
       fragment. Two covalent bonds can be formed between the Fc fragments that are
       linked to the SC FVIII or the D'D3 fragment, this in turn allows a non-covalent
       association of FVIII and D'D3. Fig. 6B. Construct FVIII-173 contains a
       heterodimeric FVIII sequence, a heavy chain FVIII sequence linked to an XTEN
       sequence and a light chain FVIII sequence linked to an Fc region. VWF-031 is
       described above. After intracellular processing, construct FVIII-173 produces a
       heterodimeric protein, a heavy chain FVIII fused to an XTEN sequence, a light
       chain FVIII fused to one Fc fragment, and construct VWF-031 produces a 477
       amino acid D'D3 fragment linked to another Fc fragment. Two covalent bonds
       can be formed between the Fc fragments that are linked to the light chain FVIII or
       the D'D3 fragment, this in turn allows a non-covalent association of FVIII and
       D'D3.
[0044]         Figure 7. Binding Affinity of Exemplary FVIII:VWF containing an XTEN
       sequence and Fc domains to immobilized hVWF in Octet assay. The binding
       affinity for FVIII-169/VWF-031 and FVIII-057 (rFVIIIFc) fused to immobilized
       hVWF was tested using biolayer interferometry based measurements (Octet
       assay). Figure 7A shows binding response in nanomoles of FV111169 and FVIIIFc
                                            - 19 -

       drug substance (a positive control) to immobilized hVWF. Figure 7B shows
       binding response of human IgG 1 (a negative control) to immobilized human
       VWF.
[00451          Figure 8. Pharmacokinetic (PK) profile of FVIII- 169 in HemA and
       FVIII:VWF double knockout (DKO) mice. Figure 8A shows the PK profile of
       FVIII- 169/VWF-031 and FVIIIFc in HemA mice. HemA mice were treated with
       a single intravenous dose of FVIII-169/VWF-031 at 200 IU/kg. Plasma samples
       collected from the mice were tested by FVIII chromogenic assay. Half-life of
       FVIII-169/VWF-031 was calculated using WinNonlin program. Figure 8B shows
       the PK profile of FVIII- 169/VWF-03 1, FVIII- 169/Fc, and FVIIIFc in FVIII/VWF
       DKO mice.
[00461          Figure 9. PK profile of FVIII-XTEN variants in D'D3 expressing
       FVIII/VWF DKO mice. Figure 9A shows comparison of the PK profile of the
       FVIII-XTEN variants, FVIII with one XTEN, FVIII with two XTENs, and FVIII
       with three XTENs. One, two, or three XTENs were inserted in various portions of
       FVIII including C-terminus and B-domain. CT indicates that an XTEN is linked
       to the C-terminus of FVIII. Insertion site B/CT indicates that one XTEN is
       inserted between amino acid residue 745 and amino acid residue 746 of the FVIII
       protein and another XTEN is linked to the C-terminus of the FVIII protein. The
       amino acid residue numbering corresponds to the SQ BDD FVIII protein
       sequence. Insertion site 1900/B/CT indicates that a first XTEN is inserted
       between amino acid residue 1900 and amino acid residue 1901 of FVIII, a second
       XTEN is inserted between amino acid residue 745 and amino acid residue 746 of
       FVIII, and a third XTEN is linked to the C-terminus of FVIII. The mouse strain
       used to administer the FVIII-XTEN variants is a DKO mouse strain expressing
       D'D3 domains. Figure 9B shows the PK profile of FVIII-XTEN with three XTEN
       insertions. The FVIII-XTEN (1900/B/CT) variant was administered to either the
       FVIII/VWF DKO mice or HemA mice. The half-life of FVIII-XTEN
       (1900/B/CT) is compared.
[0047]          Figure 10. FVIII activity of FVIIIFc (hollow triangle), FVIII169:Fc (filled
       circle), and FVIII 169:VWF31 (hollow triangle) in mouse DKO plasma measured
       by chromogenic assay. FVIII:Fc contains a dual-chain FVIII (Heavy chain and
       Light chain) fused to an Fc dimer (i.e., monomer-dimer hybrid). FVIII169 is
                                           - 20 -

       described above (containing AE288 in the B domain, immediately downstream of
       amino acid 745 corresponding to mature FVIII sequence). FV111169:Fc contains
       FVIII169 fused to an Fc dimer. FVIII169:VWF31 contains VWF31 in addition to
       the Fc dimer, FVIII169 fused to the first Fc region and VWF31 fused to the
       second Fc region, wherein the first Fc region and the second Fc region form a
       covalent bond, e.g., one or more disulfide bonds.
[00481          Figure 11. Effects of Fc, XTEN, and VWF-D'D3 fragments on FVIII half
       life extension. BDD-FVIII (REFACTO@) (square), FVIIFc (circle), FVIII169/Fc
       (triangle), and FVIII 169NWFO31 (inverted triangle) were administered to FVIII
       and VWF double knockout (DKO) mice. The FVIII activity was measured by
       chromogenic assay, and the half-life was calculated using the WinNonlin-Phoenix
       program. X-axis shows time, and the Y-axis shows the FVIII plasma activity in
       mU/mL.
[0049]          Figure 12A-C. Effects of different XTENs in rFVIII-XTENNWF
       heterodimer in HemA mice. Figure 12A shows the FVIII plasma activity
       normalized to 5 min value (%) of two XTENs inserted immediately downstream
       of residues 1900 and 1656 corresponding to mature FVIII sequence (i.e., FVIII
       195 (dual chain FVIII isoform) and FVIII-199 (single chain FVIII isoform)),
       compared to FVIII-169 containing an XTEN immediately downstream of residue
       745 corresponding to mature FVIII sequence. FVIII- 169NWF-031 (filled circle),
       FVIII- 1 99NWF-031 (filled square), and FVIII- 195NWFO31 (hollow square)
       were administered in HemA mice to measure the FVIII plasma activity. Figure
       12B shows the half-life extension effect of the second XTEN insertion
       immediately downstream of residues 403 (A2 domain) and 745 (B domain) (i.e.,
       FVIII-203) and residues 745 (B domain) and 1900 (A3 domain) (FVIII-204)
       corresponding to mature FVIII sequence compared to FVIII- 169 (an XTEN
       insertion in B domain only). FVIII-204NWF031 (filled triangle), FVIII
       169NWF-031 (filled circle), FVIII-203NWF-031 (filled square), and scBDD
       FVIII (hollow diamond) were administered to HemA mice. The X-axis shows
       FVIII plasma activity normalized to 5 min value (%), and the y-axis shows time in
       hours. Figure 12C shows the half-life extension effect of the two XTEN insertions
       immediately downstream of residues 18 (Al domain) and 745 (B domain) (i.e.,
       FVIII-205) compared to FVIII-169 (a single XTEN insertion in the B domain) and
                                           - 21 -

       single chain FVIII without any Fc regions or any XTENs (i.e., FVIII-207). Figure
       12C additionally shows the half-life extension effect of three XTEN insertions
       incorporated immediately downstream of residues 26 (Al domain), 1656 (A3
       domain), and 1900 (A3 domain) (i.e., FVIII-201) compared to FVIII-169 (a single
       XTEN insertion immediately downstream of residue 745).. FVIII-205NWF-031
       (filled square), FVIII-20 1/NWF-031 (inverted triangle), FVIII- 169NWF-031
       (filled circle), and FVIII-207 (hollow diamond) were administered to HemA mice.
       The FVIII plasma activity normalized to 5 min value (%) (X-axis) was measured
       over time in hours (Y-axis).
[00501          Figure 13. FVIII activity of rFVIII-XTENNWF-XTEN heterodimer in
       FVIIINWF DKO mice. FVIII activity of plasma samples was analyzed by FVIII
       chromogenic assay, and the regression curve of plasma FVIII activity (X-axis) as
       a function of time (Y-axis) was plotted. FVIII-155 (scFVIIIFc without any
       XTENs) was co-expressed with VWF-034 (VWF-Fc with AE 288 XTEN plus a
       35 residue thrombin cleavable linker). The half-life of FVIII-155NWF-034 was
       compared with that of FVIII-169NWF-031, which has a AE 288 XTEN inserted
       into the B domain junction (immediately downstream of residue 745
       corresponding to mature FVIII polypeptide) of FVIII.
[00511          Figure 14A-H. Schematic diagrams of various rFVIII-XTENNWF
       constructs. These constructs are also described in other sections herein. Fig. 14A
       shows single chain B domain deleted FVIII protein (sometimes indicated herein as
       scBDD-FVIII). The scBDD-FVIII constructs contain two substitutions at residues
       1645 and 1648 from Arg to Ala. Figure 14B shows two polypeptide chain
       construct (FVIIIl 55/NWFO3 1), the first chain comprising single chain FVIII
       linked to an Fc region without any XTENS and the second chain comprising the
       VWF D'D3 fragment linked to an Fc region. This construct is used as a control.
       Fig. 14C shows two polypeptide chain construct (FVIIIl 99NWFO3 1), the first
       chain comprising single chain FVIII linked to an Fc region, in which a first XTEN
       is inserted immediately downstream of residue 1900 corresponding to mature
       FVIII sequence and a second XTEN is inserted immediately downstream of
       residue 1656 corresponding to mature FVIII sequence, and the second chain
       comprising the VWF D'D3 fragment linked to an Fc region. Fig. 14D shows two
       polypeptide chain construct (FVIII201/NWF03 1), the first chain comprising single
                                            - 22 -

       chain FVIII protein linked to an Fe region, in which a first XTEN is inserted
       immediately downstream of residue 26 corresponding to mature FVIII sequence, a
       second XTEN is inserted immediately downstream of residue 1656 corresponding
       to mature FVIII sequence, and a third XTEN is inserted immediately downstream
       of residue 1900 corresponding to mature FVIII sequence ,and the second chain
       comprising the VWF D'D3 fragment linked to an Fc region. Fig. 14E shows two
       polypeptide chain constructs (FVIII 169NWFO3 1), the first chain comprising
       single chain FVIII protein linked to an Fc region, in which an XTEN is inserted
       immediately downstream of residue 745 (indicated as "B") corresponding to
       mature FVIII sequence, and the second chain comprising the VWF D'D3 fragment
       linked to an Fc region. Fig. 14F shows two polypeptide chain construct
       (FV111203NWF03 1), the first chain comprising single chain FVIII protein, in
       which a first XTEN is inserted at residue 745 ("B") corresponding to mature FVIII
       sequence and a second XTEN is inserted at residue 1900 corresponding to mature
       FVIII sequence, and the second chain comprising the VWF D'D3 fragment linked
       to an Fc region. Fig. 14G shows two polypeptide chain construct
       (FV111204NWFO3 1), the first chain comprising single chain FVIII protein linked
       to an Fc region, in which a first XTEN is inserted immediately downstream of
       residue 403 corresponding to mature FVIII sequence and a second XTEN is
       inserted immediately downstream of residue 745 ("B") corresponding to mature
       FVIII sequence, and a second chain comprising the VWF D'D3 fragment linked to
       an Fc region. Fig. 14H shows two polypeptide chain construct
       (FV111205NWFO3 1), the first chain comprising single chain FVIII, in which a
       first XTEN is inserted immediately downstream of residue 18 corresponding to
       mature FVIII sequence and a second XTEN is inserted immediately downstream
       of residue 745 ("B") corresponding to mature FVIII sequence, and the second
       chain comprising the VWF D'D3 fragment linked to an Fc region.
[0052]         Figure 15. FVIII activity of rFVIII-XTENNWF and BDD-FVIII in
       FVIIINWF DKO mice. FVIII activity of plasma samples was analyzed by FVIII
       chromogenic assay, and the regression curve of plasma FVIII activity (X-axis) as
       a function of time (Y-axis) was plotted. The half-life of rFVIII-XTENNWF
       (FVIII-205NWF-03 1) was compared with that of BDD-FVIII and rFVIIIFc.
                                           - 23 -

[00531          Figure 16. Efficacy of FVIII-XTEN-Fc:VWF-Fc heterodimers in HemA
       mice using tail clip bleeding model. The HemA mice tail clip bleeding model was
       used to compare the efficacy of FV111169/VWFO34, FV111205/VWF031, and
       BDD-FVIII. The median blood loss in ml for 200 IU/kg of FV111169/VWFO34
       and FV111205/VWFO31 is compared with 200 IU/kg of BDD-FVIII, 65 IU/kg of
       BDD-FVIII, 20 IU/kg of BDD-FVIII, and vehicle.
                     DETAILED DESCRIPTION OF THE INVENTION
       DEFINITIONS
[0054]          It is to be noted that the term "a" or "an" entity refers to one or more of that
       entity; for example, "a nucleotide sequence," is understood to represent one or
       more nucleotide sequences. As such, the terms "a" (or "an"), "one or more," and
       "at least one" can be used interchangeably herein.
[0055]           The term "polynucleotide" or "nucleotide" is intended to encompass a
       singular nucleic acid as well as plural nucleic acids, and refers to an isolated
       nucleic acid molecule or construct, e.g., messenger RNA (mRNA) or plasmid
       DNA (pDNA). In certain embodiments, a polynucleotide comprises a
       conventional phosphodiester bond or a non-conventional bond (e.g., an amide
       bond, such as found in peptide nucleic acids (PNA)). The term "nucleic acid"
       refers to any one or more nucleic acid segments, e.g., DNA or RNA fragments,
       present in a polynucleotide. By "isolated" nucleic acid or polynucleotide is
       intended a nucleic acid molecule, DNA or RNA, which has been removed from its
       native environment. For example, a recombinant polynucleotide encoding a
       Factor VIII polypeptide contained in a vector is considered isolated for the
       purposes of the present invention. Further examples of an isolated polynucleotide
       include recombinant polynucleotides maintained in heterologous host cells or
       purified (partially or substantially) from other polynucleotides in a solution.
       Isolated RNA molecules include in vivo or in vitro RNA transcripts of
       polynucleotides of the present invention. Isolated polynucleotides or nucleic acids
       according to the present invention further include such molecules produced
       synthetically. In addition, a polynucleotide or a nucleic acid can include
       regulatory elements such as promoters, enhancers, ribosome binding sites, or
       transcription termination signals.
                                               - 24 -

[00561          As used herein, a "coding region" or "coding sequence" is a portion of
       polynucleotide which consists of codons translatable into amino acids. Although a
       "stop codon" (TAG, TGA, or TAA) is typically not translated into an amino acid,
       it may be considered to be part of a coding region, but any flanking sequences, for
       example promoters, ribosome binding sites, transcriptional terminators, introns,
       and the like, are not part of a coding region. The boundaries of a coding region
       are typically determined by a start codon at the 5' terminus, encoding the amino
       terminus of the resultant polypeptide, and a translation stop codon at the 3'
       terminus, encoding the carboxyl terminus of the resulting polypeptide. Two or
       more coding regions of the present invention can be present in a single
       polynucleotide construct, e.g., on a single vector, or in separate polynucleotide
       constructs, e.g., on separate (different) vectors. It follows, then, that a single
       vector can contain just a single coding region, or comprise two or more coding
       regions, e.g., a single vector can separately encode a binding domain-A and a
       binding domain-B as described below. In addition, a vector, polynucleotide, or
       nucleic acid of the invention can encode heterologous coding regions, either fused
       or unfused to a nucleic acid encoding a binding domain of the invention.
       Heterologous coding regions include without limitation specialized elements or
       motifs, such as a secretory signal peptide or a heterologous functional domain.
[00571          Certain proteins secreted by mammalian cells are associated with a
       secretory signal peptide which is cleaved from the mature protein once export of
       the growing protein chain across the rough endoplasmic reticulum has been
       initiated. Those of ordinary skill in the art are aware that signal peptides are
       generally fused to the N-terminus of the polypeptide, and are cleaved from the
       complete or "full-length" polypeptide to produce a secreted or "mature" form of
       the polypeptide. In certain embodiments, a native signal peptide or a functional
       derivative of that sequence that retains the ability to direct the secretion of the
       polypeptide that is operably associated with it. Alternatively, a heterologous
       mammalian signal peptide, e.g., a human tissue plasminogen activator (TPA) or
       mouse B-glucuronidase signal peptide, or a functional derivative thereof, can be
       used.
[0058]          The term "downstream" refers to a nucleotide sequence that is located 3' to
       a reference nucleotide sequence. In certain embodiments, downstream nucleotide
                                             - 25 -

       sequences relate to sequences that follow the starting point of transcription. For
       example, the translation initiation codon of a gene is located downstream of the
       start site of transcription.
[00591          The term "upstream" refers to a nucleotide sequence that is located 5' to a
       reference nucleotide sequence. In certain embodiments, upstream nucleotide
       sequences relate to sequences that are located on the 5' side of a coding region or
       starting point of transcription. For example, most promoters are located upstream
       of the start site of transcription.
[0060]          As used herein, the term "regulatory region" refers to nucleotide sequences
       located upstream (5' non-coding sequences), within, or downstream (3' non-coding
       sequences) of a coding region, and which influence the transcription, RNA
       processing, stability, or translation of the associated coding region. Regulatory
       regions may include promoters, translation leader sequences, introns,
       polyadenylation recognition sequences, RNA processing sites, effector binding
       sites and stem-loop structures. If a coding region is intended for expression in a
       eukaryotic cell, a polyadenylation signal and transcription termination sequence
       will usually be located 3' to the coding sequence.
[0061]          A polynucleotide which encodes a gene product, e.g., a polypeptide, can
       include a promoter and/or other transcription or translation control elements
       operably associated with one or more coding regions. In an operable association a
       coding region for a gene product, e.g., a polypeptide, is associated with one or
       more regulatory regions in such a way as to place expression of the gene product
       under the influence or control of the regulatory region(s). For example, a coding
       region and a promoter are "operably associated" if induction of promoter function
       results in the transcription of mRNA encoding the gene product encoded by the
       coding region, and if the nature of the linkage between the promoter and the
       coding region does not interfere with the ability of the promoter to direct the
       expression of the gene product or interfere with the ability of the DNA template to
       be transcribed. Other transcription control elements, besides a promoter, for
       example enhancers, operators, repressors, and transcription termination signals,
       can also be operably associated with a coding region to direct gene product
       expression.
                                             - 26 -

[00621          A variety of transcription control regions are known to those skilled in the
       art. These include, without limitation, transcription control regions which function
       in vertebrate cells, such as, but not limited to, promoter and enhancer segments
       from cytomegaloviruses (the immediate early promoter, in conjunction with
       intron-A), simian virus 40 (the early promoter), and retroviruses (such as Rous
       sarcoma virus). Other transcription control regions include those derived from
       vertebrate genes such as actin, heat shock protein, bovine growth hormone and
       rabbit B-globin, as well as other sequences capable of controlling gene expression
       in eukaryotic cells. Additional suitable transcription control regions include
       tissue-specific promoters and enhancers as well as lymphokine-inducible
       promoters (e.g., promoters inducible by interferons or interleukins).
[0063]           Similarly, a variety of translation control elements are known to those of
       ordinary skill in the art. These include, but are not limited to ribosome binding
       sites, translation initiation and termination codons, and elements derived from
       picornaviruses (particularly an internal ribosome entry site, or IRES, also referred
       to as a CITE sequence).
[0064]          The term "expression" as used herein refers to a process by which a
       polynucleotide produces a gene product, for example, an RNA or a polypeptide. It
       includes without limitation transcription of the polynucleotide into messenger
       RNA (mRNA), transfer RNA (tRNA), small hairpin RNA (shRNA), small
       interfering RNA (siRNA) or any other RNA product, and the translation of an
       mRNA into a polypeptide. Expression produces a "gene product." As used
       herein, a gene product can be either a nucleic acid, e.g., a messenger RNA
       produced by transcription of a gene, or a polypeptide which is translated from a
       transcript. Gene products described herein further include nucleic acids with post
       transcriptional modifications, e.g., polyadenylation or splicing, or polypeptides
       with post translational modifications, e.g., methylation, glycosylation, the addition
       of lipids, association with other protein subunits, or proteolytic cleavage.
[00651          A "vector" refers to any vehicle for the cloning of and/or transfer of a
       nucleic acid into a host cell. A vector may be a replicon to which another nucleic
       acid segment may be attached so as to bring about the replication of the attached
       segment. A "replicon" refers to any genetic element (e.g., plasmid, phage, cosmid,
       chromosome, virus) that functions as an autonomous unit of replication in vivo,
                                               - 27 -

       i.e., capable of replication under its own control. The term "vector" includes both
       viral and nonviral vehicles for introducing the nucleic acid into a cell in vitro, ex
       vivo or in vivo. A large number of vectors are known and used in the art
       including, for example, plasmids, modified eukaryotic viruses, or modified
       bacterial viruses. Insertion of a polynucleotide into a suitable vector can be
       accomplished by ligating the appropriate polynucleotide fragments into a chosen
       vector that has complementary cohesive termini.
[0066]          Vectors may be engineered to encode selectable markers or reporters that
       provide for the selection or identification of cells that have incorporated the
       vector. Expression of selectable markers or reporters allows identification and/or
       selection of host cells that incorporate and express other coding regions contained
       on the vector. Examples of selectable marker genes known and used in the art
       include: genes providing resistance to ampicillin, streptomycin, gentamycin,
       kanamycin, hygromycin, bialaphos herbicide, sulfonamide, and the like; and genes
       that are used as phenotypic markers, i.e., anthocyanin regulatory genes,
       isopentanyl transferase gene, and the like. Examples of reporters known and used
       in the art include: luciferase (Luc), green fluorescent protein (GFP),
       chloramphenicol acetyltransferase (CAT), -galactosidase (LacZ), -glucuronidase
       (Gus), and the like. Selectable markers may also be considered to be reporters.
[00671          The term "plasmid" refers to an extra-chromosomal element often
       carrying a gene that is not part of the central metabolism of the cell, and usually in
       the form of circular double-stranded DNA molecules. Such elements may be
       autonomously replicating sequences, genome integrating sequences, phage or
       nucleotide sequences, linear, circular, or supercoiled, of a single- or double
       stranded DNA or RNA, derived from any source, in which a number of nucleotide
       sequences have been joined or recombined into a unique construction which is
       capable of introducing a promoter fragment and DNA sequence for a selected
       gene product along with appropriate 3' untranslated sequence into a cell.
[0068]          Eukaryotic viral vectors that can be used include, but are not limited to,
       adenovirus vectors, retrovirus vectors, adeno-associated virus vectors, and
       poxvirus, e.g., vaccinia virus vectors, baculovirus vectors, or herpesvirus vectors.
       Non-viral vectors include plasmids, liposomes, electrically charged lipids
       (cytofectins), DNA-protein complexes, and biopolymers.
                                             -28-

[00691          A "cloning vector" refers to a "replicon," which is a unit length of a nucleic
       acid that replicates sequentially and which comprises an origin of replication, such
       as a plasmid, phage or cosmid, to which another nucleic acid segment may be
       attached so as to bring about the replication of the attached segment. Certain
       cloning vectors are capable of replication in one cell type, e.g., bacteria and
       expression in another, e.g., eukaryotic cells. Cloning vectors typically comprise
       one or more sequences that can be used for selection of cells comprising the vector
       and/or one or more multiple cloning sites for insertion of nucleic acid sequences
       of interest.
[00701          The term "expression vector" refers to a vehicle designed to enable the
       expression of an inserted nucleic acid sequence following insertion into a host
       cell. The inserted nucleic acid sequence is placed in operable association with
       regulatory regions as described above.
[00711          Vectors are introduced into host cells by methods well known in the art,
       e.g., transfection, electroporation, microinjection, transduction, cell fusion, DEAE
       dextran, calcium phosphate precipitation, lipofection (lysosome fusion), use of a
       gene gun, or a DNA vector transporter.
[0072]          "Culture," "to culture" and "culturing," as used herein, means to incubate
       cells under in vitro conditions that allow for cell growth or division or to maintain
       cells in a living state. "Cultured cells," as used herein, means cells that are
       propagated in vitro.
[0073]          As used herein, the term "polypeptide" is intended to encompass a singular
       "polypeptide" as well as plural "polypeptides," and refers to a molecule composed
       of monomers (amino acids) linearly linked by amide bonds (also known as peptide
       bonds). The term "polypeptide" refers to any chain or chains of two or more
       amino acids, and does not refer to a specific length of the product. Thus, peptides,
       dipeptides, tripeptides, oligopeptides, "protein," "amino acid chain," or any other
       term used to refer to a chain or chains of two or more amino acids, are included
       within the definition of "polypeptide," and the term "polypeptide" can be used
       instead of, or interchangeably with any of these terms. The term "polypeptide" is
       also intended to refer to the products of post-expression modifications of the
       polypeptide, including without limitation glycosylation, acetylation,
       phosphorylation, amidation, derivatization by known protecting/blocking groups,
                                             - 29 -

       proteolytic cleavage, or modification by non-naturally occurring amino acids. A
       polypeptide can be derived from a natural biological source or produced
       recombinant technology, but is not necessarily translated from a designated
       nucleic acid sequence. It can be generated in any manner, including by chemical
       synthesis.
[0074]          An "isolated" polypeptide or a fragment, variant, or derivative thereof
       refers to a polypeptide that is not in its natural milieu. No particular level of
       purification is required. For example, an isolated polypeptide can simply be
       removed from its native or natural environment. Recombinantly produced
       polypeptides and proteins expressed in host cells are considered isolated for the
       purpose of the invention, as are native or recombinant polypeptides which have
       been separated, fractionated, or partially or substantially purified by any suitable
       technique.
[00751          Also included in the present invention are fragments or variants of
       polypeptides, and any combination thereof. The term "fragment" or "variant"
       when referring to polypeptide binding domains or binding molecules of the
       present invention include any polypeptides which retain at least some of the
       properties (e.g., FcRn binding affinity for an FcRn binding domain or Fc variant,
       coagulation activity for an FVIII variant, or FVIII binding activity for the VWF
       fragment) of the reference polypeptide. Fragments of polypeptides include
       proteolytic fragments, as well as deletion fragments, in addition to specific
       antibody fragments discussed elsewhere herein, but do not include the naturally
       occurring full-length polypeptide (or mature polypeptide). Variants of
       polypeptide binding domains or binding molecules of the present invention
       include fragments as described above, and also polypeptides with altered amino
       acid sequences due to amino acid substitutions, deletions, or insertions. Variants
       can be naturally or non-naturally occurring. Non-naturally occurring variants can
       be produced using art-known mutagenesis techniques. Variant polypeptides can
       comprise conservative or non-conservative amino acid substitutions, deletions or
       additions.
[0076]          The term "VWF fragment" or "VWF fragments" used herein means any
       VWF fragments that interact with FVIII and retain at least one or more properties
       that are normally provided to FVIII by full-length VWF, e.g., preventing
                                             - 30 -

       premature activation to FVIIIa, preventing premature proteolysis, preventing
       association with phospholipid membranes that could lead to premature clearance,
       preventing binding to FVIII clearance receptors that can bind naked FVIII but not
       VWF-bound FVIII, and/or stabilizing the FVIII heavy chain and light chain
       interactions.
[00771           A "conservative amino acid substitution" is one in which the amino acid
       residue is replaced with an amino acid residue having a similar side chain.
       Families of amino acid residues having similar side chains have been defined in
       the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side
       chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g.,
       glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side
       chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine,
       methionine, tryptophan), beta-branched side chains (e.g., threonine, valine,
       isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan,
       histidine). Thus, if an amino acid in a polypeptide is replaced with another amino
       acid from the same side chain family, the substitution is considered to be
       conservative. In another embodiment, a string of amino acids can be
       conservatively replaced with a structurally similar string that differs in order
       and/or composition of side chain family members.
[0078]          As known in the art, "sequence identity" between two polypeptides is
       determined by comparing the amino acid sequence of one polypeptide to the
       sequence of a second polypeptide. When discussed herein, whether any particular
       polypeptide is at least about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 99%,
       or 100% identical to another polypeptide can be determined using methods and
       computer programs/software known in the art such as, but not limited to, the
       BESTFIT program (Wisconsin Sequence Analysis Package, Version 8 for Unix,
       Genetics Computer Group, University Research Park, 575 Science Drive,
       Madison, WI 53711). BESTFIT uses the local homology algorithm of Smith and
       Waterman, Advances in Applied Mathematics 2:482-489 (1981), to find the best
       segment of homology between two sequences. When using BESTFIT or any
       other sequence alignment program to determine whether a particular sequence is,
       for example, 95% identical to a reference sequence according to the present
       invention, the parameters are set, of course, such that the percentage of identity is
                                             -31  -

       calculated over the full-length of the reference polypeptide sequence and that gaps
       in homology of up to 5% of the total number of amino acids in the reference
       sequence are allowed.
[00791          As used herein, an "amino acid corresponding to" or an "equivalent amino
       acid" in a VWF sequence or a FVIII protein sequence is identified by alignment to
       maximize the identity or similarity between a first VWF or FVIII sequence and a
       second VWF or FVIII sequence. The number used to identify an equivalent amino
       acid in a second VWF or FVIII sequence is based on the number used to identify
       the corresponding amino acid in the first VWF or FVIII sequence.
[0080]          As used herein, the term "insertion site" refers to a position in a FVIII
       polypeptide, or fragment, variant, or derivative thereof, which is immediately
       upstream of the position at which a heterologous moiety can be inserted. An
       "insertion site" is specified as a number, the number being the number of the
       amino acid in mature native FVIII (SEQ ID NO:4) to which the insertion site
       corresponds, which is immediately N-terminal to the position of the insertion. For
       example, the phrase "a3 comprises an XTEN at an insertion site which
       corresponds to amino acid 1656 of SEQ ID NO: 4" indicates that the heterologous
       moiety is located between two amino acids corresponding to amino acid 1656 and
       amino acid 1657 of SEQ ID NO: 4.
[0081]          The phrase "immediately downstream of an amino acid" as used herein
       refers to position right next to the terminal carboxyl group of the amino acid.
       Similarly, the phrase "immediately upstream of an amino acid" refers to the
       position right next to the terminal amine group of the amino acid. Therefore, the
       phrase "between two amino acids of an insertion site" as used herein refers to a
       position in which an XTEN or any other polypeptide is inserted between two
       adjacent amino acids. Thus, the phrases "inserted immediately downstream of an
       amino acid" and "inserted between two amino acids of an insertion site" are used
       synonymously with "inserted at an insertion site."
[0082]          The terms "inserted," "is inserted," "inserted into" or grammatically related
       terms, as used herein refers to the position of an XTEN in a chimeric polypeptide
       relative to the analogous position in native mature human FVIII. As used herein
       the terms refer to the characteristics of the recombinant FVIII polypeptide relative
       to native mature human FVIII, and do not indicate, imply or infer any methods or
                                             - 32 -

       process by which the chimeric polypeptide was made. For example, in reference
       to a chimeric polypeptide provided herein, the phrase "an XTEN is inserted into
       immediately downstream of residue 745 of the FVIII polypeptide" means that the
       chimeric polypeptide comprises an XTEN immediately downstream of an amino
       acid which corresponds to amino acid 745 in native mature human FVIII, e.g.,
       bounded by amino acids corresponding to amino acids 745 and 746 of native
       mature human FVIII.
[0083]         A "fusion" or "chimeric" protein comprises a first amino acid sequence
       linked to a second amino acid sequence with which it is not naturally linked in
       nature. The amino acid sequences which normally exist in separate proteins can be
       brought together in the fusion polypeptide, or the amino acid sequences which
       normally exist in the same protein can be placed in a new arrangement in the
       fusion polypeptide, e.g., fusion of a Factor VIII domain of the invention with an Ig
       Fc domain. A fusion protein is created, for example, by chemical synthesis, or by
       creating and translating a polynucleotide in which the peptide regions are encoded
       in the desired relationship. A chimeric protein can further comprises a second
       amino acid sequence associated with the first amino acid sequence by a covalent,
       non-peptide bond or a non-covalent bond.
[0084]         As used herein, the term "half-life" refers to a biological half-life of a
       particular polypeptide in vivo. Half-life may be represented by the time required
       for half the quantity administered to a subject to be cleared from the circulation
       and/or other tissues in the animal. When a clearance curve of a given polypeptide
       is constructed as a function of time, the curve is usually biphasic with a rapid a
       phase and longer -phase. The a-phase typically represents an equilibration of the
       administered Fc polypeptide between the intra- and extra-vascular space and is, in
       part, determined by the size of the polypeptide. The P-phase typically represents
       the catabolism of the polypeptide in the intravascular space. In some
       embodiments, FVIII and chimeric proteins comprising FVIII are monophasic, and
       thus do not have an alpha phase, but just the single beta phase. Therefore, in
       certain embodiments, the term half-life as used herein refers to the half-life of the
       polypeptide in the -phase. The typical p-phase half-life of a human antibody in
       humans is 21 days.
                                            - 33 -

[00851           The term "linked" as used herein refers to a first amino acid sequence or
       nucleotide sequence covalently or non-covalently joined to a second amino acid
       sequence or nucleotide sequence, respectively. The first amino acid or nucleotide
       sequence can be directly joined or juxtaposed to the second amino acid or
       nucleotide sequence or alternatively an intervening sequence can covalently join
       the first sequence to the second sequence. The term "linked" means not only a
       fusion of a first amino acid sequence to a second amino acid sequence at the C
       terminus or the N-terminus, but also includes insertion of the whole first amino
       acid sequence (or the second amino acid sequence) into any two amino acids in
       the second amino acid sequence (or the first amino acid sequence, respectively).
       In one embodiment, the first amino acid sequence can be linked to a second amino
       acid sequence by a peptide bond or a linker. The first nucleotide sequence can be
       linked to a second nucleotide sequence by a phosphodiester bond or a linker. The
       linker can be a peptide or a polypeptide (for polypeptide chains) or a nucleotide or
       a nucleotide chain (for nucleotide chains) or any chemical moiety (for both
       polypeptide and polynucleotide chains). The term "linked" is also indicated by a
       hyphen (-).
[0086]          As used herein the term "associated with" refers to a covalent or non
       covalent bond formed between a first amino acid chain and a second amino acid
       chain. In one embodiment, the term "associated with" means a covalent, non
       peptide bond or a non-covalent bond. This association can be indicated by a
       colon, i.e., (:). In another embodiment, it means a covalent bond except a peptide
       bond. For example, the amino acid cysteine comprises a thiol group that can form
       a disulfide bond or bridge with a thiol group on a second cysteine residue. In most
       naturally occurring IgG molecules, the CHI and CL regions are associated by a
       disulfide bond and the two heavy chains are associated by two disulfide bonds at
       positions corresponding to 239 and 242 using the Kabat numbering system
       (position 226 or 229, EU numbering system). Examples of covalent bonds include,
       but are not limited to, a peptide bond, a metal bond, a hydrogen bond, a disulfide
       bond, a sigma bond, a pi bond, a delta bond, a glycosidic bond, an agnostic bond,
       a bent bond, a dipolar bond, a Pi backbond, a double bond, a triple bond, a
       quadruple bond, a quintuple bond, a sextuple bond, conjugation,
       hyperconjugation, aromaticity, hapticity, or antibonding. Non-limiting examples
                                            - 34 -

       of non-covalent bond include an ionic bond (e.g., cation-pi bond or salt bond), a
       metal bond, an hydrogen bond (e.g., dihydrogen bond, dihydrogen complex, low
       barrier hydrogen bond, or symmetric hydrogen bond), van der Walls force,
       London dispersion force, a mechanical bond, a halogen bond, aurophilicity,
       intercalation, stacking, entropic force, or chemical polarity.
[00871          The term "monomer-dimer hybrid" used herein refers to a chimeric protein
       comprising a first polypeptide chain and a second polypeptide chain, which are
       associated with each other by a disulfide bond, wherein the first chain comprises a
       clotting factor, e.g., Factor VIII, and a first Fc region and the second chain
       comprises, consists essentially of, or consists of a second Fc region without the
       clotting factor. The monomer-dimer hybrid construct thus is a hybrid comprising
       a monomer aspect having only one clotting factor and a dimer aspect having two
       Fc regions.
[0088]          As used herein, the term "cleavage site" or "enzymatic cleavage site" refers
       to a site recognized by an enzyme. Certain enzymatic cleavage sites comprise an
       intracellular processing site. In one embodiment, a polypeptide has an enzymatic
       cleavage site cleaved by an enzyme that is activated during the clotting cascade,
       such that cleavage of such sites occurs at the site of clot formation. Exemplary
       such sites include, e.g., those recognized by thrombin, Factor XIa or Factor Xa.
       Exemplary FXIa cleavage sites include, e.g., TQSFNDFTR (SEQ ID NO: 45) and
       SVSQTSKLTR (SEQ ID NO: 46). Exemplary thrombin cleavage sites include,
       e.g., DFLAEGGGVR (SEQ ID NO: 47), TTKIKPR (SEQ ID NO: 48), LVPRG
       (SEQ ID NO: 49) and ALRPR (amino acids I to 5 of SEQ ID NO: 50). Other
       enzymatic cleavage sites are known in the art.
[0089]           As used herein, the term "processing site" or "intracellular processing site"
       refers to a type of enzymatic cleavage site in a polypeptide which is a target for
       enzymes that function after translation of the polypeptide. In one embodiment,
       such enzymes function during transport from the Golgi lumen to the trans-Golgi
       compartment. Intracellular processing enzymes cleave polypeptides prior to
       secretion of the protein from the cell. Examples of such processing sites include,
       e.g., those targeted by the PACE/furin (where PACE is an acronym for Paired
       basic Amino acid Cleaving Enzyme) family of endopeptidases. These enzymes
       are localized to the Golgi membrane and cleave proteins on the carboxyterminal
                                             - 35 -

       side of the sequence motif Arg-[any residue]-(Lys or Arg)-Arg. As used herein the
       "furin" family of enzymes includes, e.g., PCSK1 (also known as PC1/Pc3), PCSK2
       (also known as PC2), PCSK3 (also known as furin or PACE), PCSK4 (also known
       as PC4), PCSK5 (also known as PC5 or PC6), PCSK6 (also known as PACE4), or
       PCSK7 (also known as PC7/LPC, PC8, or SPC7). Other processing sites are
       known in the art.
[0090]         In constructs that include more than one processing or cleavage site, it will
       be understood that such sites may be the same or different.
[0091]         The term "Furin" refers to the enzymes corresponding to EC No. 3.4.21.75.
       Furin is subtilisin-like proprotein convertase, which is also known as PACE
       (Paired basic Amino acid Cleaving Enzyme). Furin deletes sections of inactive
       precursor proteins to convert them into biologically active proteins. During its
       intracellular transport, pro-peptide of VWF can be cleaved from mature VWF
       molecule by a Furin enzyme. In some embodiments, Furin cleaves the D1D2
       from the D'D3 of VWF. In other embodiments, a nucleotide sequence encoding
       Furin can be expressed together with the nucleotide sequence encoding a VWF
       fragment so that D1 D2 domains can be cleaved off intracellularly by Furin.
[0092]         In constructs that include more than one processing or cleavage site, it will
       be understood that such sites may be the same or different.
[0093]         A "processable linker" as used herein refers to a linker comprising at least
       one intracellular processing site, which is described elsewhere herein.
[0094]         Hemostatic disorder, as used herein, means a genetically inherited or
       acquired condition characterized by a tendency to hemorrhage, either
       spontaneously or as a result of trauma, due to an impaired ability or inability to
       form a fibrin clot. Examples of such disorders include the hemophilias. The three
       main forms are hemophilia A (factor VIII deficiency), hemophilia B (factor IX
       deficiency or "Christmas disease") and hemophilia C (factor XI deficiency, mild
       bleeding tendency). Other hemostatic disorders include, e.g., Von Willebrand
       disease, Factor XI deficiency (PTA deficiency), Factor XII deficiency,
       deficiencies or structural abnormalities in fibrinogen, prothrombin, Factor V,
       Factor VII, Factor X or factor XIII, Bernard-Soulier syndrome, which is a defect
       or deficiency in GPIb. GPIb, the receptor for VWF, can be defective and lead to
       lack of primary clot formation (primary hemostasis) and increased bleeding
                                            - 36 -

       tendency), and thrombasthenia of Glanzman and Naegeli (Glanzmann
       thrombasthenia). In liver failure (acute and chronic forms), there is insufficient
       production of coagulation factors by the liver; this may increase bleeding risk.
[00951         The chimeric molecules of the invention can be used prophylactically. As
       used herein the term "prophylactic treatment" refers to the administration of a
       molecule prior to a bleeding episode. In one embodiment, the subject in need of a
       general hemostatic agent is undergoing, or is about to undergo, surgery. The
       chimeric protein of the invention can be administered prior to or after surgery as a
       prophylactic. The chimeric protein of the invention can be administered during or
       after surgery to control an acute bleeding episode. The surgery can include, but is
       not limited to, liver transplantation, liver resection, dental procedures, or stem cell
       transplantation.
[0096]         The chimeric protein of the invention is also used for on-demand
       treatment. The term "on-demand treatment" refers to the administration of a
       chimeric molecule in response to symptoms of a bleeding episode or before an
       activity that may cause bleeding. In one aspect, the on-demand treatment can be
       given to a subject when bleeding starts, such as after an injury, or when bleeding
       is expected, such as before surgery. In another aspect, the on-demand treatment
       can be given prior to activities that increase the risk of bleeding, such as contact
       sports.
[00971         As used herein the term "acute bleeding" refers to a bleeding episode
       regardless of the underlying cause. For example, a subject may have trauma,
       uremia, a hereditary bleeding disorder (e.g., factor VII deficiency) a platelet
       disorder, or resistance owing to the development of antibodies to clotting factors.
[0098]         Treat, treatment, treating, as used herein refers to, e.g., the reduction in
       severity of a disease or condition; the reduction in the duration of a disease course;
       the amelioration of one or more symptoms associated with a disease or condition;
       the provision of beneficial effects to a subject with a disease or condition, without
       necessarily curing the disease or condition, or the prophylaxis of one or more
       symptoms associated with a disease or condition. In one embodiment, the term
       "treating" or "treatment" means maintaining a FVIII trough level at least about 1
       IU/dL, 2 IU/dL, 3 IU/dL, 4 IU/dL, 5 IU/dL, 6 IU/dL, 7 IU/dL, 8 IU/dL, 9 IU/dL,
       10 IU/dL, 11 IU/dL, 12 IU/dL, 13 IU/dL, 14 IU/dL, 15 IU/dL, 16 IU/dL, 17
                                             - 37 -

       IU/dL, 18 IU/dL, 19 IU/dL, or 20 IU/dL in a subject by administering a chimeric
       protein or a VWF fragment of the invention. In another embodiment, treating or
       treatment means maintaining a FVIII trough level between about 1 and about 20
       IU/dL, about 2 and about 20 IU/dL, about 3 and about 20 IU/dL, about 4 and
       about 20 IU/dL, about 5 and about 20 IU/dL, about 6 and about 20 IU/dL, about 7
       and about 20 IU/dL, about 8 and about 20 IU/dL, about 9 and about 20 IU/dL, or
       about 10 and about 20 IU/dL. Treatment or treating of a disease or condition can
       also include maintaining FVIII activity in a subject at a level comparable to at
       least about 1%, 2%, 3%, 4%, 5%, 6%, 7 %, 8%, 9%, 10%, 11%, 12%, 13%, 14%,
       15%, 16%, 17%, 18%, 19%, or 20% of the FVIII activity in a non-hemophiliac
       subject. The minimum trough level required for treatment can be measured by
       one or more known methods and can be adjusted (increased or decreased) for each
       person.
       CHIMERIC PROTEINS
[0099]          The present invention is directed to extending the half-life of a Factor VIII
       protein using a VWF fragment and an XTEN sequence by preventing or inhibiting
       a FVIII half-life limiting factor, i.e., endogenous VWF, from associating with the
       FVIII protein. Endogenous VWF associates with about 95% to about 98% of
       FVIII in non-covalent complexes. While endogenous VWF is a FVIII half-life
       limiting factor, endogenous VWF bound to a FVIII protein is also known to
       protect FVIII in various ways. For example, full length VWF (as a multimer
       having about 250 kDa) can protect FVIII from protease cleavage and FVIII
       activation, stabilize the FVIII heavy chain and/or light chain, and prevent
       clearance of FVIII by scavenger receptors. But, at the same time, endogenous
       VWF limits the FVIII half-life by preventing pinocytosis and by clearing FVIII
       VWF complex from the system through the VWF clearance pathway. It is
       believed, while not bound by a theory, that endogenous VWF is a half-life limiting
       factor that prevents the half-life of a FVIII protein fused to a half-life extender
       from being longer than about two-fold that of wild-type FVIII. Therefore, the
       present invention is directed to preventing or inhibiting interaction between
       endogenous VWF and a FVIII protein using a VWF fragment, thereby increasing
       a half-life of the FVIII protein by using an XTEN sequence alone or an XTEN
       sequence in combination with an Ig constant region or a portion thereof. The
                                              - 38 -

       XTEN sequence can be linked to the FVIII protein or the VWF fragment. The
       FVIII protein associated with the VWF fragment is thus cleared from the
       circulation more slowly by one or more VWF clearance receptors and then can
       have the full half-life extension of the XTEN sequence or the XTEN sequence in
       combination of the Ig constant region, as compared to wild type FVIII or a FVIII
       protein without the VWF fragment.
[0100]         In one embodiment, a VWF fragment is associated (or linked) with the
       FVIII protein by a covalent or a non-covalent bond. In some instances, however,
       the physical blockage or chemical association (e.g., non-covalent bonding)
       between the VWF fragment and the FVIII protein may not be strong enough to
       provide a stable complex comprising the FVIII protein and the VWF fragment in
       the presence of endogenous VWF. For example, a VWF fragment forming a non
       covalent bond with a FVIII protein without any other connections may readily be
       dissociated in vivo from the FVIII protein in the presence of endogenous VWF,
       replacing the VWF fragment (e.g., recombinant VWF, i.e., rVWF) with
       endogenous VWF. Therefore, the FVIII protein non-covalently bound to
       endogenous VWF would undergo the VWF clearance pathway and be readily
       cleared from the system. In order to prevent the dissociation of the VWF
       fragment with the FVIII protein, in some embodiments, the association or linkage
       between the FVIII protein and the VWF fragment is a covalent bond, e.g., a
       peptide bond, one or more amino acids, or a disulfide bond. In certain
       embodiments, the association (i.e., linkage) between the adjunct moiety and the
       FVIII protein is a peptide bond or a linker between the FVIII protein and the VWF
       fragment ("FVIII/VWF linker"). Non-limiting examples of the linker are
       described elsewhere herein. In some embodiments, the VWF fragment is a
       polypeptide comprising, consisting essentially of, or consisting of at least about
       10,100,200,300,400,500,600,700,800,900,1000,1100,1200,1300,1400,
       1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, or 4000 amino acids. Non
       limiting examples of the VWF fragment are described elsewhere herein.
[0101]         In certain embodiments, the VWF fragment chemically (e.g., non
       covalently) binds to or physically blocks one or more VWF binding sites on a
       FVIII protein. The VWF binding site on a FVIII protein is located within the A3
       domain or the C2 domain of the FVIII protein. In still other embodiments, the
                                             - 39 -

       VWF binding site on a FVIII protein is located within the A3 domain and C2
       domain. For example, the VWF binding site on a FVIII protein can correspond to
       amino acids 1669 to 1689 and/or 2303 to 2332 of SEQ ID NO: 4 [full-length
       mature FVIII].
[0102]          The invention also provides a chimeric protein (comprising a FVIII protein
       and a VWF fragment) further comprising one or more XTEN sequences, which
       provide additional half-life extension properties. The one or more XTEN
       sequences can be inserted within the FVIII protein or the VWF fragment or linked
       to the N-terminus or the C-terminus of the FVIII protein or the VWF fragment.
       The invention also includes a FVIII protein linked to an XTEN sequence (a first
       half-life extending moiety) and an Ig constant region or a portion thereof (a
       second half-life extending moiety) so that the two half-life extending moieties
       extend the half-life of the FVIII protein through two different mechanisms.
[0103]          In some embodiments, a chimeric protein comprises a FVIII protein linked
       to a first Ig constant region or a portion thereof (e.g., a first FcRn binding partner),
       a VWF fragment linked to a second Ig constant region or a portion thereof (e.g., a
       second FcRn binding partner), and one or more XTEN sequences inserted or
       linked to the FVIII protein or the VWF fragment, wherein the VWF fragment
       prevents the FVIII half-life limiting factor (e.g., endogenous VWF) from binding
       to the FVIII protein, wherein the first and second Ig constant regions or portions
       thereof forms a covalent bond, e.g., a disulfide bond, and the one or more XTEN
       sequences extends the half-life of the FVIII protein.
[0104]          In certain embodiments, a chimeric protein of the invention comprises a
       FVIII protein linked to a VWF fragment by an optional linker (i.e., FVIII/VWF
       linker) and one or more XTEN sequences inserted or linked to the FVIII protein or
       the VWF fragment, wherein the VWF fragment prevents the FVIII half-life
       limiting factor (e.g., endogenous VWF) from binding to the FVIII protein and the
       one or more XTEN sequences extends the half-life of the FVIII protein. In one
       aspect, the optional linker (FVIII/VWF linker) comprises a sortase recognition
       motif. In another aspect, the optional linker (FVIII/VWF linker) comprises a
       cleavable site. Examples of the cleavage linker (i.e., linker containing one or
       more cleavage site) are described elsewhere herein.
                                             - 40 -

[01051         The chimeric protein of the present invention includes, but is not limited
       to:
       (1) a VWF fragment comprising a D' domain and a D3 domain, an XTEN
       sequence, and FVIII, wherein the XTEN sequence is linked to the VWF fragment;
       (2) a FVIII protein, an XTEN sequence, and an Ig constant region or a portion
       thereof, wherein the FVIII protein is linked to an XTEN sequence and the Ig
       constant region or a portion thereof, or
       (3) a FVIII protein, an XTEN sequence, and a VWF fragment, wherein the XTEN
       sequence is linked to the FVIII protein at the C-terminus or N-terminus or inserted
       immediately downstream of one or more amino acids (e.g., one or more XTEN
       insertion sites) of FVIII, and the VWF fragment and the FVIII protein are
       associated with each other.
       (1)     Von Willebrand Factor (VWF) fragment linked to XTEN, and FVIII
[0106]         The present invention is directed to a chimeric protein comprising (i) a
       VWF fragment comprising a D' domain and a D3 domain of VWF, (ii) an XTEN
       sequence, and (iii) a FVIII protein, wherein (i), (ii), and (iii) are linked to or
       associated with each other. The VWF fragment linked to the XTEN sequence, as
       a part of a chimeric protein in the present invention, associates with the FVIII
       protein, thus preventing or inhibiting interaction between endogenous VWF and
       the FVIII protein. In certain embodiments, the VWF fragment, which is capable
       of preventing or inhibiting binding of the FVIII protein with endogenous VWF,
       can at the same time have at least one VWF-like FVIII protecting property.
       Examples of the VWF-like FVIII protecting properties include, but are not limited
       to, protecting FVIII from protease cleavage and FVIII activation, stabilizing the
       FVIII heavy chain and/or light chain, and preventing clearance of FVIII by
       scavenger receptors. As a result, the VWF fragment can prevent clearance of the
       FVIII protein through the VWF clearance pathway, thus reducing clearance of
       FVIII from the circulatory system. In some embodiments, the VWF fragments of
       the present invention bind to or are associated with a FVIII protein and/or
       physically or chemically block the VWF binding site on the FVIII protein. The
       FVIII protein associated with the VWF fragment is thus cleared from the
       circulation more slowly, as compared to wild type FVIII or FVIII not associated
       with the VWF fragment.
                                            - 41 -

[01071          In one embodiment, the invention is directed to a chimeric protein
       comprising (i) a VWF fragment comprising the D' domain and the D3 domain of
       VWF, (ii) an XTEN sequence, and (iii) a FVIII protein, wherein the XTEN
       sequence is linked to the VWF fragment (e.g., (al) V-X or (a2) X-V, wherein V
       comprises a VWF fragment and X comprises an XTEN sequence), and the VWF
       fragment is linked to or associated with the FVIII protein. In another
       embodiment, the VWF fragment and the XTEN sequence can be linked by a linker
       (e.g., (a3) V-L-X or (a4) X-L-V) or a peptide bond. The linker can be a cleavable
       linker, e.g., a thrombin cleavable linker, which can be cleaved at the site of
       coagulation. In other embodiments, the VWF fragment, the XTEN sequence, and
       the FVIII protein are placed in a single polypeptide chain. In still other
       embodiments, the chimeric protein comprises two polypeptide chains, a first chain
       comprising the VWF fragment and the XTEN sequence and a second chain
       comprising the FVIII protein. In yet other embodiments, the chimeric protein
       comprises three polypeptide chains, a first chain comprising the VWF fragment
       and the XTEN sequence, a second chain comprising a light chain of FVIII and a
       third chain comprising a heavy chain of FVIII, wherein the first chain and the
       second chain are associated with each other (e.g., covalent bond, e.g., disulfide
       bond), and the second chain and the third chain are associated with each other
       (e.g., metal bond). In still other embodiments, the XTEN sequence can be linked
       to the N-terminus or the C-terminus of the VWF fragment or inserted immediately
       downstream of one or more amino acids in the VWF fragment.
[0108]          In certain embodiments, a chimeric protein of the invention comprises a
       formula comprising:
                (a)      V-X-FVIII,
                (b)      FVIII-X-V,
                (c)      V-X:FVIII,
                (d)      X-V:FVIII,
                (e)      FVIII:V-X,
                (f)      FVIII:X-V, or
                (a5)     X-V-FVIII,
       wherein V comprises a VWF fragment,
       X comprises one or more XTEN sequences,
                                            - 42 -

       FVIII comprises a FVIII protein;
       (-) represents a peptide bond or one or more amino acids; and
       (:) is a chemical association or a physical association. In one embodiment, (:)
       represents a chemical association, e.g., at least one non-peptide bond. In another
       embodiment, the chemical association, i.e., (:) is a covalent bond. In other
       embodiments, the chemical association, i.e., (:) is a non-covalent interaction, e.g.,
       an ionic interaction, a hydrophobic interaction, a hydrophilic interaction, a Van
       der Waals interaction, or a hydrogen bond. In other embodiments, (:) is a non
       peptide covalent bond. In still other embodiments, (:) is a peptide bond. In yet
       other embodiments, (:) represents a physical association between two sequences,
       wherein a portion of a first sequence is in close proximity to a second sequence
       such that the first sequence shields or blocks a portion of the second sequence
       from interacting with another moiety, and further that this physical association is
       maintained without allowing the second sequence to interact with other moieties.
       The orientation of the polypeptide formulas herein is listed from N-terminus (left)
       to C-terminus (right). For example, formula V-X-FVIII means formula NH2-V
       X-FVIII -COOH. In one embodiment, the formulas described herein can comprise
       any additional sequences between the two moieties. For example, formula V-X
       FVIII can further comprise any sequences at the N-terminus of V between V and
       X, between X and FVIII, or at the C-terminus of FVIII unless otherwise specified.
       In another embodiment, the hyphen (-) indicates a peptide bond.
[0109]          In other embodiments, a chimeric protein of the invention comprises a
       formula comprising:
                (a)     V(X1)-X2-FVIII,
                (b)     FVIII-X2-V(X1),
                (c)     V(X1):FVIII,
                (d)     FVIII:V(X1), or
                (a5)    X2-V(X1)-FVIII,
       wherein V(X1) comprises a VWF fragment and a first XTEN sequence (X1),
       wherein the XTEN sequence is inserted immediately downstream of one or more
       amino acids in the VWF fragment,
       X2 comprises one or more optional XTEN sequences,
       FVIII comprises a FVIII protein;
                                            - 43 -

       (-) is a peptide bond or one or more amino acids; and
       (:) is a chemical association or a physical association.
[0110]          In some embodiments, a chimeric protein comprises (i) a VWF fragment
       comprising a D' domain and a D3 domain of VWF, (ii) an XTEN sequence, (iii) a
       FVIII protein, (iv) a first optional linker, and (v) a second optional linker, wherein
       the XTEN sequence is linked to the VWF fragment and/or to the FVIII protein by
       the linker. In certain embodiments, a chimeric protein comprises a formula
       comprising:
                (b 1)   V-Li -X-L2-FVIII,
                (b2)    FVIII-L2-X-L1-V,
                (b3)    V-L1-X:FVIII,
                (b4)    X-L1-V:FVIII,
                (b5)    FVIII:V-LI-X,
                (b6)    FVIII:X-LI-V,
                (b7)    X-LI-V-L2-FVIII, or
                (b8)    FVIII-L2-V-L1-X,
       wherein V comprises a VWF fragment,
       X comprises one or more XTEN sequences,
       FVIII comprises a FVIII protein,
       LI comprises a first optional linker, e.g., a first cleavable linker,
       L2 comprises a second optional linker, e.g., a second cleavable linker or an
       optional processable linker;
       (-) is a peptide bond or one or amino acids; and
       (:) is a chemical association or a physical association. In one embodiment, (:)
       represents a chemical association, e.g., at least one non-peptide bond. In another
       embodiment, the chemical association, i.e., (:) is a covalent bond. In other
       embodiments, the chemical association, i.e., (:) is a non-covalent interaction, e.g.,
       an ionic interaction, a hydrophobic interaction, a hydrophilic interaction, a Van
       der Waals interaction, or a hydrogen bond. In other embodiments, (:) is a non
       peptide covalent bond. In still other embodiments, (:) is a peptide bond. In yet
       other embodiments, (:) represents a physical association between two sequences,
       wherein a portion of a first sequence is in close proximity to a second sequence
       such that the first sequence shields or blocks a portion of the second sequence
                                              - 44 -

       from interacting with another moiety, and further that this physical association is
       maintained without allowing the second sequence to interact with other moieties.
       The orientation of the polypeptide formulas herein is listed from N-terminus (left)
       to C-terminus (right). For example, formula (bl) V-L1-X-L2-FVIII means
       formula NH2-V-L1-X-L2-FVIII-COOH. In one embodiment, the formulas
       described herein can comprise any additional sequences between the two moieties.
       In another embodiment, the hyphen (-) indicates a peptide bond.
[0111]         Another aspect of the present invention is to provide a FVIII chimeric
       protein having reduced or no interactions with a FVIII half-life limiting factor,
       e.g., endogenous VWF, and at the same time maximizing the half-life of the FVIII
       protein using an XTEN sequence (a first half-life extender) in combination with a
       second half-life extender or a moiety providing a covalent bond between the FVIII
       protein and the VWF fragment, e.g., an Ig constant region or a portion thereof. In
       one embodiment, a chimeric protein of the invention comprises (i) a VWF
       fragment comprising a D' domain and a D3 domain of VWF, (ii) an XTEN
       sequence, (iii) a FVIII protein, and (iv) an Ig constant region or a portion thereof
       (also referred to herein as F), wherein (1) the VWF fragment is linked to the
       XTEN sequence by an optional linker, e.g., a cleavable linker, (2) the VWF
       fragment is associated with or linked to the FVIII protein by an additional optional
       linker, e.g., a cleavable linker, and (3) the Ig constant region or a portion thereof is
       linked to the VWF fragment, the XTEN sequence, or the FVIII protein. In another
       embodiment, a chimeric protein of the invention comprises (i) a VWF fragment
       comprising a D' domain and a D3 domain of VWF, (ii) an XTEN sequence, (iii) a
       FVIII protein, (iv) an Ig constant region or a portion thereof (F 1 or a first Ig
       constant region or a portion thereof), and (v) an additional Ig constant region or a
       portion thereof (F2 or a second Ig constant region or a portion thereof), wherein
       (1) the VWF fragment is linked to the XTEN sequence by an optional linker, e.g.,
       a cleavable linker, (2) the XTEN sequence or the VWF fragment is linked to the Ig
       constant region or a portion thereof, (3) the FVIII is linked to the additional Ig
       constant region or a portion thereof, and (4) the Ig constant region or a portion
       thereof is associated with or linked to the additional Ig constant region or a portion
       thereof. In one embodiment, the association or linkage between the two Ig
       constant regions or a portion thereof is a covalent bond, e.g., a disulfide bond. In
                                             - 45 -

       another embodiment, the association or linkage between the two Ig constant
       regions or a portion thereof is a processable linker, wherein the processable linker
       is intracellularly processed by a protease. For example, the chimeric protein
       comprises a formula comprising:
                (g)     V-L2-X-L1-F1: FVIII-L3-F2;
                (h)     V-L2-X-L1-F1:F2-L3-FVIII;
                (i)     F-L1-X-L2-V: FVIII-L3-F2;
                (j)     F-L1-X-L2-V:F2-L3-FVIII;
                (k)     V-L2-X-L 1-Fl -L4-FVIII-L3 -F2;
                (1)     F2-L3-FVIII-L4-F 1-Li -X-L2-V;
                (m)     FVIII-L2-F2-L4-V-L2-X-L1-Fl; or
                (n)     Fl -L 1-X-L2-V-L4-F2-L2-FVIII,
       wherein V comprises a VWF fragment,
       each of L 1 and L3 comprises an optional linker,
       L2 comprises an optional linker, e.g., a cleavable linker,
       L4 is an optional linker, e.g., a processable linker,
       FVIII comprises a FVIII protein,
       X comprises one or more XTEN sequences,
       Fl comprises an optional Ig constant region or a portion thereof,
       F2 comprises an optional additional Ig constant region or a portion thereof;
       (-) is a peptide bond or one or more amino acids; and
       (:) is a chemical association or a physical association.
[0112]          In some embodiments, the FVIII protein in any constructs or formulas
       disclosed herein can further comprises at least one, at least two, at least three, at
       least four, at least five, or at least six XTEN sequences, each of the XTEN
       sequences inserted immediately downstream of one or more amino acids in the
       FVIII protein or linked to the N-terminus or the C-terminus of the FVIII protein.
       Non-limiting examples of the XTEN insertion sites are disclosed elsewhere
       herein.
[0113]          In one embodiment, (:) represents a chemical association, e.g., at least one
       non-peptide bond. In another embodiment, the chemical association, i.e., (:) is a
       covalent bond. In other embodiments, the chemical association, i.e., (:) is a non
       covalent interaction, e.g., an ionic interaction, a hydrophobic interaction, a
                                                - 46 -

       hydrophilic interaction, a Van der Waals interaction, or a hydrogen bond. In other
       embodiments, (:) is a non-peptide covalent bond. In still other embodiments, (:) is
       a peptide bond. In yet other embodiments, (:) represents a physical association
       between two sequences, wherein a portion of a first sequence is in close proximity
       to a second sequence such that the first sequence shields or blocks a portion of the
       second sequence from interacting with another moiety, and further that this
       physical association is maintained without allowing the second sequence to
       interact with other moieties. The orientation of the polypeptide formulas herein is
       listed from N-terminus (left) to C-terminus (right). For example, formula (n) Fl
       Li -X-L2-V-L4-F2-L2-FVIII means formula NH2-F 1-Li -X-L2-V-L4-F2-L2
       FVIII -COOH. In one embodiment, the formulas described herein can comprise
       any additional sequences between the two moieties. In another embodiment, the
       hyphen (-) indicates a peptide bond.
[0114]          In one embodiment, either or both of the Ig constant region or a portion
       thereof (sometimes indicated herein by "F" or "F1 ") and the additional Ig constant
       region or a portion thereof (sometimes indicated herein by "F2") linked to the
       VWF fragment or the FVIII protein can extend the half-life of the VWF fragment,
       the FVIII protein, or both. In another embodiment, a pair of the Ig constant region
       or a portion thereof (sometimes indicated herein by "F" or "F I") and the additional
       Ig constant region or a portion thereof (sometimes indicated herein by "F2"), each
       of which are linked to the VWF fragment and the FVIII protein, provides a bond
       stronger than the non-covalent bond between the FVIII protein and the VWF
       fragment, i.e., a covalent bond, e.g., a disulfide bond, thereby preventing
       endogenous VWF from replacing the VWF fragment in vivo. Fi or F2 can
       comprise an Fc region or an FcRn binding partner. In other embodiments, either
       or both of F I and F2 linked to the VWF fragment and/or the FVIII protein form a
       covalent bond (e.g., a disulfide bond) between FI and F2, thereby placing the
       VWF fragment and the FVIII protein in close proximity to prevent interaction of
       the FVIII protein with the VWF fragment. In some embodiments, FI and F2 are
       identical or different. Non-limiting examples of FI and F2 can be selected from
       the group consisting of a CHI domain, a CH2 domain, a CH3 domain, a CH4
       domain, a hinge domain, any functional fragments, derivatives, or analogs thereof,
       and two or more combinations thereof. In one embodiment, F 1, F2, or both
                                             - 47 -

       comprise at least one CHI domain, at least one CH2 domain, at least one CH3
       domain, at least one CH4 domain, or the functional fragments, derivatives, or
       analogs thereof. In another embodiment, F1, F2, or both comprise at least one
       hinge domain or portion thereof and at least one CH2 domain or portion thereof
       (e.g., in the hinge-CH2 orientation). In other embodiments, F1, F2, or both
       comprise at least one CH2 domain or portion thereof and at least one CH3 domain
       or portion thereof (e.g., in the CH2-CH3 orientation.) Examples of the
       combination include, but are not limited to, a CH2 domain, a CH3 domain, and a
       hinge domain, which are also known as an Fc region (or Fc domain), e.g., a first
       Fc region or a first FcRn binding partner for F 1 and a second Fc region or a
       second FcRn binding partner for F2. In other embodiments, F1 is linked to the
       VWF fragment by a linker, and/or F2 is linked to the FVIII protein by a linker. In
       some embodiments, F1 and/or F2 comprises, consisting essentially of, or
       consisting of a hinge region. Additional non-limiting examples of the Fc regions
       or the FcRn binding partners are described elsewhere herein.
[0115]          In certain embodiments, a chimeric protein of the invention comprises two
       polypeptide chains, a first polypeptide chain comprising, consisting essentially of,
       or consisting of a VWF fragment comprising a D' domain and a D3 domain, an
       XTEN sequence, a first Ig constant region or a portion thereof (e.g., a first Fc
       region), and an optional linker between the VWF fragment and the XTEN
       sequence or the XTEN sequence or the first Ig constant region or a portion thereof
       and a second polypeptide chain comprising, consisting essentially of, or consisting
       of a FVIII protein and a second Ig constant region or a portion thereof (e.g., a
       second Fc region). The linker between the VWF fragment and the first Ig constant
       region or a portion thereof can be a cleavable linker, e.g., a thrombin cleavable
       linker, which can be cleaved at the site of coagulation. In some embodiments, the
       first polypeptide chain and the second polypeptide chain are associated with each
       other. The association between the first chain and the second chain prevents
       replacement of the first chain comprising the VWF fragment with endogenous
       VWF in vivo. In one embodiment, the association between the first chain and the
       second chain can be a covalent bond. In a particular embodiment, the covalent
       bond is a disulfide bond. In some embodiments, the FVIII protein in the second
       chain further comprises one or more XTEN sequences linked to the C-terminus or
                                            -48-

       N-terminus of the FVIII protein or inserted immediately downstream of one or
       more amino acids (e.g., at least one insertion site disclosed herein) in the FVIII
       protein. Non-limiting examples of the insertion sites are described elsewhere
       herein.
[01161          In other embodiments, a chimeric protein of the invention comprises three
       polypeptide chains, wherein a first polypeptide chain comprises, consists
       essentially of, or consists of a heavy chain of a FVIII protein, a second
       polypeptide chain comprises, consists essentially of, or consists of a light chain of
       a FVIII protein fused to a first Ig constant region or a portion thereof (e.g., a first
       Fc region), and a third polypeptide chain comprises, consists essentially of, or
       consists of a VWF fragment comprising a D' domain and a D3 domain, an XTEN
       sequence, a second Ig constant region or a portion thereof (e.g., a second Fc
       region), and an optional linker between the XTEN sequence and the second Ig
       constant region or a portion thereof or the VWF fragment and the XTEN
       sequence. The linker in the third chain can be a cleavable linker, which is cleaved
       at the site of coagulation, e.g., a thrombin cleavage site. In some embodiments,
       the heavy chain FVIII or the light chain FVIII is linked to one or more XTEN
       sequences, which can be linked to the N-terminus, the C-terminus, or inserted
       within one or more insertion sites within the FVIII sequence. Non-limiting
       examples of the insertion sites are disclosed elsewhere herein.
[0117]          In yet other embodiments, a chimeric protein of the invention comprises
       two polypeptide chains, a first polypeptide chain comprising, consisting
       essentially of, or consisting of a heavy chain of a FVIII protein and a second
       polypeptide chain comprising, consisting essentially of, or consisting of a light
       chain of a FVIII protein, a first Ig constant region or a portion thereof (e.g., a first
       Fc region), a first linker (e.g., a processable linker, which contains one or more
       protease cleavage sites comprising one or more intracellular processing sites), a
       VWF fragment, a second linker (e.g., a thrombin cleavable linker), an XTEN
       sequence, and a second Ig constant region or a portion thereof (e.g., a second Fc
       region), wherein the light chain of the FVIII protein is linked to the first Ig
       constant region or a portion thereof (e.g., the first Fc region), which is further
       linked to the VWF fragment by the first linker, and wherein the VWF fragment is
       linked to the XTEN sequence, which is further linked to the second Ig constant
                                              - 49 -

       region or a portion thereof by the second linker. In certain embodiments, the first
       linker is a processable linker, and the second linker is a cleavable linker. Upon
       expression, the chimeric protein can be processed by an intracellular processing
       enzyme, which cleaves the processable linker, and thus the chimeric protein can
       comprise, consists essentially of, or consists of three polypeptide chains. In
       addition, the VWF fragment can be cleaved off at the site of coagulation due to the
       cleavable linker.
[01181          In certain embodiments, a chimeric protein of the invention comprises one
       polypeptide chain, which comprises a single chain FVIII protein, a first Ig
       constant region or a portion thereof (e.g., a first Fc region), a first linker (e.g., a
       processable linker), a VWF fragment, an XTEN sequence, a second linker (e.g., a
       thrombin cleavable linker), and a second Ig constant region or a portion thereof
       (e.g., a second Fc region), wherein the single chain FVIII protein is linked to the
       first Ig constant region or a portion thereof, which is also linked to the VWF
       fragment by the first linker, and the VWF fragment is linked to the XTEN
       sequence, which is further linked to the second Ig constant region or a portion
       thereof. In one embodiment, the VWF fragment and the XTEN sequence are
       linked by the second linker. In another embodiment, the XTEN sequence and the
       second Ig constant region or a portion thereof are linked by the second linker. In
       other embodiments, the second chain further comprises a third linker. The single
       polypeptide chain can thus comprise the VWF fragment linked to the XTEN
       sequence by the second linker and the XTEN linked to the second Ig constant
       region or a portion thereof by the third linker. The second linker and the third
       linker can be identical or different. In one embodiment, the first linker is a
       processable linker. In another embodiment, the second linker or the third linker is
       a cleavable linker comprising one or two cleavable sites. In a specific
       embodiment, the second linker is a thrombin cleavable linker. The linkers useful
       in the invention are described elsewhere herein.
       (2)      FVIII, XTEN, and Fc
[0119]          A chimeric protein of the invention also comprises (i) a FVIII protein, (ii)
       an XTEN sequence (a first half-life extender), and (iii) an Ig constant region or a
       portion thereof (a second half-life extender), in which the XTEN sequence is
       linked to the FVIII protein by an optional linker and the Ig constant region or a
                                             - 50 -

       portion thereof by an additional optional linker. The XTEN sequence and the Ig
       constant region or a portion thereof can be used together to extend half-life of the
       FVIII protein. In one embodiment, the chimeric protein is a monomer. In another
       embodiment, the chimeric protein is a dimer (a homodimer or a heterodimer).
[0120]         The present invention is also directed to a chimeric protein comprising (i) a
       FVIII protein, (ii) an XTEN sequence, (iii) an Ig constant region or a portion
       thereof (i.e., a first Ig constant region or a portion thereof, "F," or "Fl"), and (iv)
       an additional Ig constant region or a portion thereof (i.e., a second Ig constant
       region or a portion thereof or "F2"). In one embodiment, the XTEN sequence is
       linked to the FVIII protein at the C-terminus or the N-terminus or inserted
       immediately downstream of one or more amino acids in the FVIII protein (e.g.,
       one or more XTEN insertion sites), the FVIII protein is linked to the first Ig
       constant region or a portion thereof, and the first Ig constant region or a portion
       thereof and the second Ig constant region or a portion thereof are associated with
       or linked to each other by an optional linker. In certain aspects, the chimeric
       protein is a monomer-dimer hybrid, which comprises a first polypeptide chain and
       a second polypeptide chain, wherein the first polypeptide chain comprises a FVIII
       protein, an XTEN sequence, and a first Ig constant region or a portion thereof, and
       the second polypeptide chain comprises, consists essentially of, or consists of a
       second Ig constant region or a portion thereof without the FVIII protein and
       wherein the first chain and the second chain are associated with each other. The
       association between the Ig constant region or a portion thereof (e.g., the first Fc
       region) and the additional Ig constant region or a portion thereof (e.g., a second Fc
       region) is a chemical association or a physical association. In certain
       embodiments, the chemical association is a covalent bond. In other embodiments,
       the chemical association is a non-covalent interaction, e.g., an ionic interaction, a
       hydrophobic interaction, a hydrophilic interaction, a Van der Waals interaction, or
       a hydrogen bond. In other embodiments, the association is a non-peptide covalent
       bond. In still other embodiments, the association is a peptide bond.
[0121]         In other aspects, the chimeric protein is a single polypeptide chain
       comprising a FVIII protein, an XTEN sequence, a first Ig constant region or a
       portion thereof, a linker, e.g., a processable linker, and a second Ig constant region
                                              -51  -

       or a portion thereof, wherein the single polypeptide chain is processed after
       expression by an intracellular enzyme and becomes two polypeptide chains.
[0122]          In one embodiment, the Ig constant region or a portion thereof (sometimes
       indicated herein by "F" or "Fl ") linked to the FVIII protein can extend the half-life
       of the FVIII protein together with the XTEN sequence. In another embodiment,
       the Ig constant region or a portion thereof ("F" or "F 1") is an Fc region or an FcRn
       binding partner described elsewhere herein.
[0123]          In other embodiments, the additional Ig constant region or a portion
       thereof (sometimes indicated herein by "F2" or a second Ig constant region or a
       portion thereof) associated with or linked to the first Ig constant region or a
       portion thereof can also extend the half-life of the FVIII protein. In other
       embodiments, the second Ig constant region or a portion thereof ("F2") together
       with the first Ig constant region or a portion thereof and the XTEN sequence can
       extend the half-life of the FVIII protein. The additional Ig constant region or a
       portion thereof can be an Fc region or an FcRn binding partner described
       elsewhere herein.
[0124]          In certain embodiments, the second Ig constant region or a portion thereof
       associated with the first Ig constant region or a portion thereof is further linked to
       a VWF fragment described elsewhere herein and an optional XTEN sequence.
[0125]          In some embodiments, either or both of the Ig constant region or a portion
       thereof ("F" or "F1" or a first Ig constant region or a portion thereof) and an
       additional Ig constant region or a portion thereof (i.e., a second Ig constant region
       or a portion thereof or "F2") (indicated in this paragraph as "the Ig constant
       regions or portion thereof") can include, but not limited to, a CHI domain, a CH2
       domain, a CH3 domain, a CH4 domain, a hinge domain, any functional fragments,
       derivatives, or analogs thereof or two or more combinations thereof. In one
       embodiment, the Ig constant region or a portion thereof comprises at least one
       CHI domain, at least one CH2 domain, at least one CH3 domain, at least one CH4
       domain, or the functional fragments, derivatives, or analogues thereof. In another
       embodiment, the Ig constant region or a portion thereof comprises at least one
       hinge domain or portion thereof and at least one CH2 domain or portion thereof
       (e.g., in the hinge-CH2 orientation). In other embodiments, the Ig constant
       domain or portion thereof comprises at least one CH2 domain or portion thereof
                                            - 52 -

       and at least one CH3 domain or portion thereof (e.g., in the CF2-CH3 orientation).
       Examples of the combination include, but are not limited to, a CH2 domain, a
       CH3 domain, and a hinge domain, which are also known as an Fc region (or Fc
       domain), e.g., first Fc region. Additional examples of the Ig constant regions or
       portion thereof are described elsewhere herein.
[0126]          The chimeric protein of the invention can have an extended half-life of the
       FVIII protein compared to wild-type FVIII. In one embodiment, the half-life of
       the FVIII protein is extended at least about 1.5 times, at least about 2 times, at
       least about 2.5 times, at least about 3 times, at least about 4 times, at least about 5
       times, at least about 6 times, at least about 7 times, at least about 8 times, at least
       about 9 times, at least about 10 times, at least about 11 times, or at least about 12
       times longer than the half-life of wild type FVIII. In another embodiment, the
       half-life of the FVIII protein is at least about 10 hours, at least about 11 hours, at
       least about 12 hours, at least about 13 hours, at least about 14 hours, at least about
       15 hours, at least about 16 hours, at least about 17 hours, at least about 18 hours,
       at least about 19 hours, at least about 20 hours, at least about 21 hours, at least
       about 22 hours, at least about 23 hours, at least about 24 hours, at least about 36
       hours, at least about 48 hours, at least about 60 hours, at least about 72 hours, at
       least about 84 hours, at least about 96 hours, or at least about 108 hours.
       (3)      FVIII, XTEN, and VWF
[0127]          In one aspect, a chimeric protein of the present invention comprises (i) a
       FVIII protein, (ii) an XTEN sequence, and (iii) a VWF fragment comprising a D'
       domain and a D3 domain of VWF, wherein the FVIII protein is linked to the
       XTEN sequence and wherein the FVIII protein is associated with or linked to the
       VWF fragment. In one embodiment, the VWF fragment of the chimeric protein
       described herein is not capable of binding to a VWF clearance receptor. In
       another embodiment, the VWF fragment is capable of protecting the FVIII protein
       from one or more protease cleavages, protecting the FVIII protein from activation,
       stabilizing the heavy chain and/or the light chain of the FVIII protein, or
       preventing clearance of the FVIII protein by one or more scavenger receptors. In
       other embodiments, the VWF fragment prevents or inhibits binding of endogenous
       VWF to the VWF binding site in the FVIII protein. The VWF binding site can be
       located in the A3 domain or the C2 domain of the FVIII protein or both the A3
                                              - 53 -

       domain and the C2 domain. In a specific embodiment, the VWF binding site
       comprises the amino acid sequence corresponding to amino acids 1669 to 1689
       and/or amino acids 2303 to 2332 of SEQ ID NO: 2.
[0128]           In another aspect, a chimeric protein comprises (i) a FVIII protein, (ii) an
       XTEN sequence, (iii) a VWF fragment, which comprises a D' domain and a D3
       domain of VWF, and (iv) an Ig constant region or a portion thereof, wherein the
       XTEN sequence is linked to the FVIII protein at the C-terminus or the N-terminus
       or inserted immediately downstream of one or more amino acids (e.g., one or
       more XTEN insertion sites disclosed herein) in the FVIII protein, the VWF
       fragment is linked to or associated with the FVIII protein or the XTEN sequence,
       and the Ig constant region or a portion thereof is linked to the FVIII protein, the
       XTEN sequence, the VWF fragment, or any combinations thereof. The Ig
       constant region or a portion thereof useful for chimeric proteins of the invention is
       described elsewhere herein. In one embodiment, the Ig constant region or a
       portion thereof is capable of extending the half-life of a FVIII protein. In another
       embodiment, the Ig constant region or a portion thereof comprises a first Fc region
       or a first FcRn binding partner. In yet other embodiments, the Ig constant region
       or a portion thereof is linked to the FVIII protein by an optional linker. In still
       other embodiments, the linker comprises a cleavable linker. The chimeric protein
       can be a single polypeptide chain, i.e., a monomer (i.e., a single chain), containing
       (i), (ii), (iii), and (iv) or two chains containing a first chain comprising (i) and (ii)
       and a second chain comprising (iii) and (iv). In other aspects, the chimeric protein
       is a dimer (e.g., a homodimer or a heterodimer). In one embodiment, the chimeric
       protein comprises two chains, each comprising (i), (ii), (iii), and (iv).
[0129]           In certain embodiments, a chimeric protein comprises (i) a FVIII protein,
       (ii) an XTEN sequence, (iii) a VWF fragment, which comprises a D' domain and a
       D3 domain of VWF, (iv) an Ig constant region or a portion thereof (sometimes
       also indicated as "F," "a first Ig constant region or a portion thereof', or "F2"), and
       (v) an additional Ig constant region or a portion thereof (sometimes also indicated
       as "F2" or "a second Ig constant region or a portion thereof"), wherein (1) the
       FVIII protein is linked to the XTEN sequence at the C-terminus or N-terminus of
       the FVIII protein or inserted immediately downstream of one or more amino acids
       (e.g., one or more XTEN insertion sites disclosed herein) in the FVIII protein, (2)
                                                - 54 -

       either the XTEN sequence or the FVIII protein is linked to the Ig constant region
       or a portion thereof, (3) the VWF fragment is linked to the second Ig constant
       region or a portion thereof, and (4) the Ig constant region or a portion thereof is
       associated with the second Ig constant region or a portion thereof. In one
       embodiment, the Ig constant region or a portion thereof linked to the FVII protein
       or the XTEN sequence is further linked to the VWF fragment by a linker, e.g., a
       processable linker. In another embodiment, the additional Ig constant region or a
       portion thereof useful for chimeric proteins of the invention can further be linked
       to the FVIII protein or the Ig constant region or a portion thereof by an optional
       linker, e.g., a processable linker. In some embodiments, a pair of the Ig constant
       region or a portion thereof and the additional Ig constant region or a portion
       thereof, each of which are linked to the VWF fragment and the FVIII protein,
       provides a bond stronger than the non-covalent bond between the FVIII protein
       and the VWF fragment, i.e., a covalent bond, e.g., a disulfide bond, thereby
       preventing endogenous VWF from replacing the VWF fragment in vivo. In other
       embodiments, either or both of the Ig constant region or a portion thereof and the
       additional Ig constant region or a portion thereof are capable of extending a half
       life of the FVIII protein or the VWF fragment. In other embodiments, the
       additional Ig constant region or a portion thereof comprises a second Fc region or
       an FcRn binding partner. The Ig constant region or a portion thereof and the
       additional Ig constant region or a portion thereof in the chimeric proteins are
       identical or different.
[01301          In certain embodiments, the Ig constant region or a portion thereof and the
       additional Ig constant region or a portion thereof are associated by a chemical
       association or a physical association. In one embodiment, the chemical
       association, i.e., (:), is at least one non-peptide bond. In certain embodiments, the
       chemical association, i.e., (:), is a covalent bond. In other embodiments, the
       chemical association, i.e., (:), is a non-covalent interaction, e.g., an ionic
       interaction, a hydrophobic interaction, a hydrophilic interaction, a Van der Waals
       interaction, or a hydrogen bond. In other embodiments, (:) is a non-peptide
       covalent bond. In still other embodiments, (:) is a peptide bond. In yet other
       embodiments, (:) represents a physical association between two sequences,
       wherein a portion of a first sequence is in close proximity to a second sequence
                                                - 55 -

       such that the first sequence shields or blocks a portion of the second sequence
       from interacting with another moiety. In some embodiments, the association
       between the Ig constant region or a portion thereof and the additional Ig constant
       region or a portion thereof can be a covalent bond, e.g., a disulfide bond, which
       prevents replacement the VWF fragment or the polypeptide containing the VWF
       fragment with endogenous VWF. Therefore, preventing interaction between the
       FVIII protein and endogenous VWF reduces or eliminates this half-life limiting
       factor for the FVIII protein, and thus the half-life of the FVIII protein is extended
       compared to a FVIII protein without the VWF protein or wild-type FVIII.
[01311         In other aspects, a chimeric protein comprises a formula comprising:
       (1)     FVIII(X1)-L1-F1 :V-L2-X2-L3-F2;
       (2)     FVIII(Xi)-Li-Fi :F2-L3-X2-L2-V;
       (3)     FI-LI-FVIII(X):V-L2-X2-L3-F2;
       (4)     FI-LI-FVIII(X):F2-L3-X2-L2-V;
       (5)     FVIII(X1)-Li-Fl -L4-V-L2-X2-L3-F2;
       (6)     FVIII(X1)-Li-Fl -L4-F2-L3-X2-L2-V;
       (7)     Fl-Li-FVIII(X1)-L4-V-L2-X2-L3-F2, or
       (8)     F1-LI-FVIII(X1)-L4- F2-L3-X2-L2-V,
       wherein FVIII(XI) comprises a FVIII protein and one or more XTEN sequences,
       wherein the one or more XTEN sequence are linked to the N-terminus or C
       terminus of the FVIII protein or inserted immediately downstream of one or more
       amino acids (e.g., one or more XTEN insertion sites disclosed herein) in the FVIII
       protein;
       each of LI, L2, or L3 comprises an optional linker, e.g., a cleavable linker;
       L4 is a linker, e.g., a processable linker;
       X2 comprises one or more optional XTEN sequences;
       Fl comprises an Ig constant region or a portion thereof;
       F2 comprises an optional additional Ig constant region or a portion thereof, and
       V comprises a VWF fragment;
                                             - 56 -

       (-) is a peptide bond or one or more amino acids; and
       (:) comprises a chemical association or a physical association. In one embodiment,
       (:) represents a chemical association, e.g., at least one non-peptide bond. In
       another embodiment, the chemical association, i.e., (:) is a covalent bond. In other
       embodiments, the chemical association, i.e., (:) is a non-covalent interaction, e.g.,
       an ionic interaction, a hydrophobic interaction, a hydrophilic interaction, a Van
       der Waals interaction, or a hydrogen bond. In other embodiments, (:) is a non
       peptide covalent bond. In still other embodiments, (:) is a peptide bond. In yet
       other embodiments, (:) represents a physical association between two sequences,
       wherein a portion of a first sequence is in close proximity to a second sequence
       such that the first sequence shields or blocks a portion of the second sequence
       from interacting with another moiety, and further that this physical association is
       maintained without allowing the second sequence to interact with other moieties.
       The orientation of the polypeptide formulas herein is listed from N-terminus (left)
       to C-terminus (right). For example, formula V-X-FVIII means formula NH2-V
       X-FVIII -COOH. In one embodiment, the formulas described herein can comprise
       any additional sequences between the two moieties. For example, formula V-X
       FVIII can further comprise any sequences at the N-terminus of V between V and
       X, between X and FVIII, or at the C-terminus of FVIII unless otherwise specified.
       In another embodiment, the hyphen (-) indicates a peptide bond.
[0132]          In one aspect, the chimeric protein comprises two polypeptide chains, (A)
       a first chain comprising (i) a single chain FVIII protein (ii) an XTEN sequence,
       and (iii) a first Ig constant region or a portion thereof, e.g., a first Fc region or
       FcRn binding partner, wherein the XTEN sequence is linked to the FVIII protein
       at the N-terminus or C-terminus or inserted immediately downstream of one or
       more amino acids of the FVIII protein (e.g., one or more XTEN insertion sites
       disclosed herein) and the first Ig constant region or a portion thereof is linked to
       the XTEN sequence when the XTEN sequence is linked to the FVIII protein at the
       N-terminus or the C-terminus or the FVIII protein when the XTEN sequence is
       inserted within the FVIII protein, and (B) a second chain comprising (iv) a VWF
       fragment comprising a D' domain and a D3 domain, (v) a linker, and (vi) a second
       Ig constant region or a portion thereof, e.g., a second Fc region or a second FcRn
       binding partner, wherein the VWF fragment is linked to the linker, e.g., a
                                             - 57 -

       cleavable linker, which is further linked to the second Ig constant region or a
       portion thereof, and wherein the first polypeptide chain and the second
       polypeptide chain are associated with each other, e.g., a covalent bond, e.g., a
       disulfide bond. In one embodiment, the linker is a cleavable linker described
       elsewhere herein, e.g., a thrombin cleavable linker. In some embodiments, the
       second chain comprises one or more XTEN sequences between (iv) and (v) or (v)
       and (vi).
[01331          In other aspects, the chimeric protein comprises one polypeptide chain
       comprising (i) a single chain FVIII protein (ii) an XTEN sequence, (iii) a first Ig
       constant region or a portion thereof, e.g., a first Fc region or a first FcRn binding
       partner, (iv) a first linker, (v) a VWF fragment comprising a D' domain and a D3
       domain, (vi) a second linker, and (vii) a second Ig constant region or a portion
       thereof, e.g., a second Fc region or a second FcRn binding partner, wherein (i) to
       (vii) are linked in the order or in any orders. In one embodiment, the first linker is
       a processable linker, which can be intracellularly processed or cleaved after
       expression and makes the single polypeptide chain into two polypeptide chains.
       In another embodiment, the second linker is a cleavable linker described herein,
       e.g., a thrombin cleavable linker. The XTEN sequence used herein can be linked
       to the FVIII protein by an optional linker at the N-terminus or the C terminus of
       the FVIII protein or inserted immediately downstream of one or more amino acids
       (e.g., one or more XTEN insertion sites) in the FVIII protein.
[0134]          In certain aspects, a chimeric protein comprises three polypeptide chains,
       (A) a first polypeptide chain comprising (i) a heavy chain of a FVIII protein and
       (ii) an XTEN sequence, which are linked to each other and (B) a second
       polypeptide chain comprising (iii) a light chain of the FVIII protein and (iv) a first
       Ig constant region or a portion thereof, e.g., a first Fc region or a first FcRn
       binding partner, which are linked to each other, and (C) a third polypeptide chain
       comprising (v) a VWF fragment comprising a D' domain and a D3 domain, (vi) a
       linker, and (vii) a second Ig constant region or a portion thereof, e.g., a second Fc
       region or a second FcRn binding partner, wherein the second chain is associated
       with the first chain and the third chain. In one embodiment, the association
       between the first chain and the second chain is a chemical association or a
       physical association. For example, the association between the first chain and the
                                             - 58 -

       second chain can be a metal bond. In another embodiment, the association
       between the second chain and the third chain is also a chemical association or a
       physical association, e.g., a covalent bond or a non-covalent bond. In certain
       embodiments, the association between the second chain and the third chain is
       through the two Ig constant regions or a portion thereof and is a disulfide bond.
       The bonding between the second chain and the third chain prevents or inhibits
       binding of the FVIII protein with endogenous VWF, thus preventing the FVIII
       protein being cleared by the VWF clearance pathway. In some embodiments, the
       linker is a processable linker, which is intracellularly cleaved after expression in a
       host cell. The XTEN sequence used herein is linked to the FVIII protein by an
       optional linker at the N-terminus or C terminus of the FVIII protein or inserted
       immediately downstream of one or more amino acids (e.g., one or more XTEN
       insertion sites) in the FVIII protein.
[0135]          In certain embodiments, the VWF fragment is directly linked to the FVIII
       protein, which comprises one or more XTENs, by a peptide bond or a linker. As
       one way of linking the VWF fragment and the FVIII protein, in which one or more
       XTENs are inserted or linked, through a direct link (e.g. a peptide bond) or a
       linker, an enzymatic ligation (e.g., sortase) can be employed. For example, sortase
       refers to a group of prokaryotic enzymes that modify surface proteins by
       recognizing and cleaving a carboxyl-terminal sorting signal. For most substrates
       of sortase enzymes, the recognition signal consists of the motif LPXTG (Leu-Pro
       any-Thr-Gly (SEQ ID NO: 51), then a highly hydrophobic transmembrane
       sequence, then a cluster of basic residues such as arginine. Cleavage occurs
       between the Thr and Gly, with transient attachment through the Thr residue to the
       active site Cys residue of a ligation partner, followed by transpeptidation that
       attaches the protein covalently to the cell wall. In some embodiments, the ligation
       partner contains Gly(n). In other embodiments, the chimeric protein further
       comprises a sortase recognition motif. In some embodiments, the VWF fragment
       is attached to FVIII comprising one or more XTENs inserted within or linked to
       using sortase mediated in vitro protein ligation.
[01361           In one embodiment, a VWF fragment linked to a sortase recognition motif
       by an optional linker can be fused to a FVIII protein linked to Gly(n) by a sortase,
       wherein n can be any integer and wherein one or more XTENs are inserted within
                                             - 59 -

       or linked to the FVIII protein. A ligation construct comprises the VWF fragment
       (N-terminal portion of the construct) and the FVIII protein, in which one or more
       XTENs are inserted or linked (C-terminal portion of the construct), wherein the
       sortase recognition motif is inserted in between. Another ligation construct
       comprises the VWF fragment (N-terminal portion of the construct, the linker, the
       sortase recognition motif, and the FVIII protein, in which one or more XTENs are
       inserted or linked (C-terminal portion of the construct). In another embodiment, a
       FVIII protein linked to a sortase recognition motif by an optional linker can be
       fused to a VWF fragment linked to Gly(n) by a sortase, wherein n is any integer.
       A resulting ligation construct comprises the FVIII protein (N-terminal portion of
       the construct), in which one or more XTENs are inserted or linked, and the VWF
       fragment (C-terminal portion of the construct), wherein the sortase recognition
       motif is inserted in between. Another resulting ligation construct comprises the
       FVIII protein (N-terminal portion of the construct), in which one or more XTENs
       are inserted or linked, the linker, the sortase recognition motif, and the VWF
       fragment (C-terminal portion of the construct). In other embodiments, a VWF
       fragment linked to a sortase recognition motif by a first optional linker can be
       fused to a heterologous moiety, e.g., an immunoglobulin constant region or a
       portion thereof, e.g., an Fc region, linked to a thrombin cleavage site by a second
       optional linker. A resulting construct can comprise the VWF fragment (N
       terminal portion), the first linker, the sortase recognition motif, the protease
       cleavage site, the second optional linker, and the heterologous moiety.
[0137]         In some embodiments, the VWF fragment is associated with the FVIII
       protein. The association between the VWF fragment and the FVIII protein can be
       a chemical association or a physical association. The chemical association can be
       a non-covalent interaction, e.g., an ionic interaction, a hydrophobic interaction, a
       hydrophilic interaction, a Van der Waals interaction, or a hydrogen bond. In yet
       other embodiments, the association between the FVIII protein and the VWF
       fragment is a physical association between two sequences, e.g., due to an
       additional association between the sequence having the FVIII protein and the
       sequence having the VWF fragment, wherein a portion of a first sequence is in
       close proximity to a second sequence such that the first sequence shields or blocks
       a portion of the second sequence from interacting with another moiety.
                                              - 60 -

[01381          As a result of preventing or inhibiting endogenous VWF interaction with
       the FVIII protein by the VWF fragment, the chimeric protein described herein
       have an extended half-life compared to wild-type FVIII or the corresponding
       chimeric protein without the VWF fragment. In one embodiment, the half-life of
       the FVIII protein is extended at least about 1.5 times, at least about 2 times, at
       least about 2.5 times, at least about 3 times, at least about 4 times, at least about 5
       times, at least about 6 times, at least about 7 times, at least about 8 times, at least
       about 9 times, at least about 10 times, at least about 11 times, or at least about 12
       times longer than a FVIII protein without the VWF fragment. In another
       embodiment, the half-life of the FVIII protein is at least about 10 hours, at least
       about 11 hours, at least about 12 hours, at least about 13 hours, at least about 14
       hours, at least about 15 hours, at least about 16 hours, at least about 17 hours, at
       least about 18 hours, at least about 19 hours, at least about 20 hours, at least about
       21 hours, at least about 22 hours, at least about 23 hours, at least about 24 hours,
       at least about 36 hours, at least about 48 hours, at least about 60 hours, at least
       about 72 hours, at least about 84 hours, at least about 96 hours, or at least about
       108 hours. In a particular embodiment, the half-life of the FVIII protein is
       extended at least 10 hours, at least about 11 hours, at least about 12 hours, at least
       about 13 hours, at least about 14 hours, at least about 15 hours, at least about 16
       hours, at least about 17 hours, at least about 18 hours, at least about 19 hours, at
       least about 20 hours, at least about 21 hours, at least about 22 hours, at least about
       23 hours, at least about 24 hours, at least about 25 hours, at least about 26 hours,
       or at least about 27 hours in HemA mice.
       A)       Von Willebrand Factor (VWF) Fragments
[01391          VWF (also known as F8VWF) is a large multimeric glycoprotein present
       in blood plasma and produced constitutively in endothelium (in the Weibel-Palade
       bodies), megakaryocytes (a-granules of platelets), and subendothelian connective
       tissue. The basic VWF monomer is a 2813 amino acid protein. Every monomer
       contains a number of specific domains with a specific function, the D'/D3 domain
       (which binds to Factor VIII), the Al domain (which binds to platelet GPIb
       receptor, heparin, and/or possibly collagen), the A3 domain (which binds to
       collagen), the C1 domain (in which the RGD domain binds to platelet integrin
       aIIb 3 when this is activated), and the "cysteine knot" domain at the C-terminal
                                             - 61 -

        end of the protein (which VWF shares with platelet-derived growth factor
        (PDGF), transforming growth factor-P (TGF ) and P-human chorionic
        gonadotropin (PHCG).
[0140]          The term "a VWF fragment" as used herein includes, but is not limited to,
        functional VWF fragments comprising a D' domain and a D3 domain, which are
        capable of inhibiting binding of endogenous VWF to FVIII. In one embodiment,
        the VWF fragment binds to the FVIII protein. In another embodiment, the VWF
        fragment blocks the VWF binding site on the FVIII protein, thereby inhibiting
        interaction of the FVIII protein with endogenous VWF. The VWF fragments
        include derivatives, variants, mutants, or analogues that retain these activities of
        VWF.
[0141]          The 2813 monomer amino acid sequence for human VWF is reported as
        Accession Number _NP_000543.2__ in Genbank. The nucleotide sequence
        encoding the human VWF is reported as Accession Number __NM_000552.3                 in
        Genbank. The nucleotide sequence of human VWF is designated as SEQ ID NO:
        1. SEQ ID NO: 2 is the amino acid sequence encoded by SEQ ID NO: 1. Each
        domain of VWF is listed in Table 1.
        TABLE 1. VWF Sequences
       VWF domains              Amino acid Sequence
       VWF Signal Peptide        1           MIPARFAGVL       LALALILPGT       LC
       (Amino acids 1 to 22                22
       of SEQ ID NO: 2)
       VWF D1D2 region           2_3                                               AEGTRGRS
                                           STARCSLFGS      DFVNTFDGSM
       (Amino acids 23 to        5         YSFAGYCSYL      LAGGCQKRSF SIIGDFQNGK
       763 of SEQ ID NO: 2)                RVSLSVYLGE      FFDIHLFVNG
                                 101       TVTQGDQRVS      MPYASKGLYL ETEAGYYKLS
                                           GEAYGFVARI           DGSGNFQVLL
                                 151       SDRYFNKTCG      LCGNFNIFAE DDFMTQEGTL
                                           TSDPYDFANS      WALSSGEQWC
                                 201       ERASPPSSSC      NISSGEMQKG LWEQCQLLKS
                                           TSVFARCHPL      VDPEPFVALC
                                 251       EKTLCECAGG      LECACPALLE YARTCAQEGM
                                          VLYGWTDHSA       CSPVCPAGME
                                 301       YRQCVSPCAR      TCQSLHINEM CQERCVDGCS
                                           CPEGQLLDEG      LCVESTECPC
                                 351      VHSGKRYPPG       TSLSRDCNTC ICRNSQWICS
                                          NEECPGECLV       TGQSHFKSFD
                                 401      NRYFTFSGIC       QYLLARDCQD HSFSIVIETV
                                            -62-

                     QCADDRDAVC    TRSVTVRLPG
              451    LHNSLVKLKH    GAGVAMDGQD   IQLPLLKGDL
                     RIQHTVTASV    RLSYGEDLQM
              501    DWDGRGRLLV    KLSPVYAGKT   CGLCGNYNGN
                     QGDDFLTPSG    LAEPRVEDFG
              551    NAWKLHGDCQ    DLQKQHSDPC   ALNPRMTRFS
                     EEACAVLTSP    TFEACHRAVS
              6u1    PLPYLRNCRY    DVCSCSDGRE   CLCGALASYA
                     AACAGRGVRV    AWREPGRCEL
              651]   NCPKGQVYLQ    CGTPCNLTCR   SLSYPDEECN
                     EACLEGCFCP    PGLYMDERGD
              701    CVPKAQCPCY    YDGEIFQPED   IFSDHHTMCY
                     CEDGFMHCTM    SGVPGSLLPD
              751    AVLSSPLSHR                            SKR
                S763
VWF D'Domain  764                        SLSCRPP MVKLVCPADN
              LRAEGLECTK
                         TCQNYDLECM
              801    SMGCVSGCLC PPGMVRHENR CVALERCPCF
                     HQGKEYAPGE TVKIGCNTCV
              851    CRDRKWNCTD                        HVCDAT
                      c66
VWFD3Domain   867                           CSTI GMAHYLTFDG
                     LKYLFPGECQ    YVLVQDYCGS
              90     NPGTFRILVG    NKGCSHPSVK CKKRVTILVE
                     GGEIELFDGE    VNVKRPMKDE
              951    THFEVVESGR    YIILLLGKAL   SVVWDRHLSI
                     SVVLKQTYQE    KVCGLCGNFD
              100 1  GIQNNDLTSS    NLQVEEDPVD FGNSWKVSSQ
                     CADTRKVPLD     SSPATCHNNI
              1051   MKQTMVDSSC    RILTSDVFQD CNKLVDPEPY
                     LDVCIYDTCS    CESIGDCACF
              1101   CDTIAAYAHV    CAQHGKVVTW RTATLCPQSC
                     EERNLRENGY    ECEWRYNSCA
              1151   PACQVTCQHP    EPLACPVQCV EGCHAHCPPG
                     KILDELLQTC    VDPEDCPVCE
              1201   VAGRRFASGK   _KVTLNPSDPE      HCQICHCDVV
                     NLTCEACQEP
VWF Al Domain 1241       GGLVVPPTDA
              1251   PVSPTTLYVE DISEPPLHDF      YCSRLLDLVF
                     LLDGSSRLSE AEFEVLKAFV
              1301   VDMMERLRIS QKWVRVAVVE      YHDGSHAYIG
                     LKDRKRPSEL RRIASQVKYA
              1351   GSQVASTSEV LKYTLFQIFS      KIDRPEASRI
                     ALLLMASQEP QRMSRNFVRY
              1401   VQGLKKKKVI VIPVGIGPHA      NLKQIRLIEK
                        -63-

      QAPENKAFVL SSVDELEQQR
1451  DEIVSYLCDL APEAPPPTLP PDMAQVTVG
      1479
14 80                          P
      GLLGVSTLGP KRNSMVLDVA
1501  FVLEGSDKIG EADFNRSKEF MEEVIQRMDV
      GQDSIHVTVL QYSYMVTVEY
1551  PFSEAQSKGD ILQRVREIRY QGGNRTNTGL
      ALRYLSDHSF LVSQGDREQA
      1600
1601  PNLVYMVTGN PASDEIKRLP GDIQVVPIGV
      GPNANVQELE RIGWPNAPIL
1651  IQDFETLPRE APDLVLQRCC SGEGLQIPTL
      SPAPDCSQPL DVILLLDGSS
1.701 SFPASYFDEM KSFAKAFISK ANIGPRLTQV
      SVLQYGSITT IDVPWNVVPE
1751  KAHLLSLVDV MQREGGPSQI GDALGFAVRY
      LTSEMHGARP GASKAVVILV
18001 TDVSVDSVDA AADAARSNRV TVFPIGIGDR
      YDAAQLRILA GPAGDSNVVK
1851  LQRIEDLPTM VTLGNSFLHK LCSGFVRICM
      DEDGNEKRPG DVWTLPDQCH
I1901 TVTCQPDGQT LLKSHRVNCD RGLRPSCPNS
      QSPVKVEETC GCRWTCPCVC
1951  TGSSTRHIVT FDGQNFKLTG SCSYVLFQNK
      EQDLEVILHN GACSPGARQG
2001  CMKSIEVKHS ALSVEXHSDM EVTVNGRLVS
      VPYVGGNMEV NVYGAIMHEV
2051  RFNHLGHIFT FTPQNNEFQL QLSPKTFASK
      TYGLCGICDE NGANDFMLRD
20 1  GTVTTDWKTL VQEWTVQRPG QTCQPILEEQ
      CLVPDSSHCQ VLLLPLFAEC
2151  HKVLAPATFY AICQQDSCHQ EQVCEVIASY
      AHLCRTNGVC VDWRTPDFCA
2201  MSCPPSLVYN HCEHGCPRHC DGNVSSCGDH
      PSEGCFCPPD KVMLEGSCVP
2251  EEACTQCIGE DGVQHQFLEA WVPDHQPCQI
      CTCLSGRKVN CTTQPCPTAK
2301  APTCGLCEVA RLRQNADQCC PEYECVCDPV
      SCDLPPVPHC ERGLQPTLTN
235.  PGECRPNFTC ACRKEECKRV SPPSCPPHRL
      PTLRKTQCCD EYECACNCVN
2401  STVSCPLGYL ASTATNDCGC TTTTCLPDKV
      CVHRSTIYPV GQFWEEGCDV
2451  CTCTDMEDAV MGLRVAQCSQ KPCEDSCRSG
      FTYVLHEGEC CGRCLPSACE
2501  VVTGSPRGDS QSSWKSVGSQ WASPENPCLI
      NECVRVKEEV FIQQRNVSCP
2551  QLEVPVCPSG FQLSCKTSAC CPSCRCERME
      ACMLNGTVIG PGKTVMIDVC
       -64-

                2601      TTCRCMVQVG    VISGFKLECR KTTCNPCPLG
                          YKEENNTGEC    CGRCLPTACT
                2651      IQLRGGQIMT    LKRDETLQDG CDTHFCKVNE
                          RGEYFWEKRV    TGCPPFDEHK
                2701      CLAEGGKIMK    IPGTCCDTCE EPECNDITAR
                          LQYVKVGSCK    SEVEVDIHYC
                2751      QGKCASKAMY    SIDINDVQDQ CSCCSPTRTE
                          PMQVALHCTN    GSVVYHEVLN
                2801      AMECKCSPRK    CSK
                Nucleotide Sequence (SEQ ID NO: 1)
Full-length VWF          1          ATGATTCCTG CCAGATTTGC
                          CGGGGTGCTG CTTGCTCTGG CCCTCATTTT
                         51     GCCAGGGACC CTTTGTGCAG
                          AAGGAACTCG CGGCAGGTCA TCCACGGCCC
                        101     GATGCAGCCT TTTCGGAAGT
                          GACTTCGTCA ACACCTTTGA TGGGAGCATG
                        151     TACAGCTTTG CGGGATACTG
                          CAGTTACCTC CTGGCAGGGG GCTGCCAGAA
                       201      ACGCTCCTTC TCGATTATTG
                          GGGACTTCCA GAATGGCAAG AGAGTGAGCC
                       251      TCTCCGTGTA TCTTGGGGAA
                          TTTTTTGACA TCCATTTGTT TGTCAATGGT
                        301     ACCGTGACAC AGGGGGACCA
                          AAGAGTCTCC ATGCCCTATG CCTCCAAAGG
                        351     GCTGTATCTA GAAACTGAGG
                          CTGGGTACTA CAAGCTGTCC GGTGAGGCCT
                        401     ATGGCTTTGT GGCCAGGATC
                          GATGGCAGCG GCAACTTTCA AGTCCTGCTG
                        451     TCAGACAGAT ACTTCAACAA
                          GACCTGCGGG CTGTGTGGCA ACTTTAACAT
                        501     CTTTGCTGAA GATGACTTTA
                          TGACCCAAGA AGGGACCTTG ACCTCGGACC
                        551     CTTATGACTT TGCCAACTCA
                          TGGGCTCTGA GCAGTGGAGA ACAGTGGTGT
                        601     GAACGGGCAT CTCCTCCCAG
                          CAGCTCATGC AACATCTCCT CTGGGGAAAT
                        651     GCAGAAGGGC CTGTGGGAGC
                          AGTGCCAGCT TCTGAAGAGC ACCTCGGTGT
                        701     TTGCCCGCTG CCACCCTCTG
                          GTGGACCCCG AGCCTTTTGT GGCCCTGTGT
                        751     GAGAAGACTT TGTGTGAGTG
                          TGCTGGGGGG CTGGAGTGCG CCTGCCCTGC
                        801     CCTCCTGGAG TACGCCCGGA
                          CCTGTGCCCA GGAGGGAATG GTGCTGTACG
                        851     GCTGGACCGA CCACAGCGCG
                          TGCAGCCCAG TGTGCCCTGC TGGTATGGAG
                        901     TATAGGCAGT GTGTGTCCCC
                          TTGCGCCAGG ACCTGCCAGA GCCTGCACAT
                        951     CAATGAAATG TGTCAGGAGC
                           -65-

   GATGCGTGGA TGGCTGCAGC TGCCCTGAGG
1001    GACAGCTCCT GGATGAAGGC
   CTCTGCGTGG AGAGCACCGA GTGTCCCTGC
1051    GTGCATTCCG GAAAGCGCTA
   CCCTCCCGGC ACCTCCCTCT CTCGAGACTG
1101    CAACACCTGC ATTTGCCGAA
   ACAGCCAGTG GATCTGCAGC AATGAAGAAT
1151    GTCCAGGGGA GTGCCTTGTC
   ACTGGTCAAT CCCACTTCAA GAGCTTTGAC
1201    AACAGATACT TCACCTTCAG
   TGGGATCTGC CAGTACCTGC TGGCCCGGGA
1251    TTGCCAGGAC CACTCCTTCT
   CCATTGTCAT TGAGACTGTC CAGTGTGCTG
1301    ATGACCGCGA CGCTGTGTGC
   ACCCGCTCCG TCACCGTCCG GCTGCCTGGC
1351    CTGCACAACA GCCTTGTGAA
   ACTGAAGCAT GGGGCAGGAG TTGCCATGGA
1401    TGGCCAGGAC ATCCAGCTCC
   CCCTCCTGAA AGGTGACCTC CGCATCCAGC
1451    ATACAGTGAC GGCCTCCGTG
   CGCCTCAGCT ACGGGGAGGA CCTGCAGATG
1501    GACTGGGATG GCCGCGGGAG
   GCTGCTGGTG AAGCTGTCCC CCGTCTATGC
1551    CGGGAAGACC TGCGGCCTGT
   GTGGGAATTA CAATGGCAAC CAGGGCGACG
1601    ACTTCCTTAC CCCCTCTGGG
   CTGGCRGAGC CCCGGGTGGA GGACTTCGGG
1651    AACGCCTGGA AGCTGCACGG
   GGACTGCCAG GACCTGCAGA AGCAGCACAG
1701    CGATCCCTGC GCCCTCAACC
   CGCGCATGAC CAGGTTCTCC GAGGAGGCGT
1751    GCGCGGTCCT GACGTCCCCC
   ACATTCGAGG CCTGCCATCG TGCCGTCAGC
1801    CCGCTGCCCT ACCTGCGGAA
   CTGCCGCTAC GACGTGTGCT CCTGCTCGGA
1851    CGGCCGCGAG TGCCTGTGCG
   GCGCCCTGGC CAGCTATGCC GCGGCCTGCG
1901    CGGGGAGAGG CGTGCGCGTC
   GCGTGGCGCG AGCCAGGCCG CTGTGAGCTG
1951    AACTGCCCGA AAGGCCAGGT
   GTACCTGCAG TGCGGGACCC CCTGCAACCT
2001    GACCTGCCGC TCTCTCTCTT
   ACCCGGATGA GGAATGCAAT GAGGCCTGCC
2051    TGGAGGGCTG CTTCTGCCCC
   CCAGGGCTCT ACATGGATGA GAGGGGGGAC
2101    TGCGTGCCCA AGGCCCAGTG
   CCCCTGTTAC TATGACGGTG AGATCTTCCA
2151    GCCAGAAGAC ATCTTCTCAG
   ACCATCACAC CATGTGCTAC TGTGAGGATG
2201    GCTTCATGCA CTGTACCATG
   AGTGGAGTCC CCGGAAGCTT GCTGCCTGAC
    -66-

2251    GCTGTCCTCA GCAGTCCCCT
   GTCTCATCGC AGCAAAAGGA GCCTATCCTG
2301    TCGGCCCCCC ATGGTCAAGC
   TGGTGTGTCC CGCTGACAAC CTGCGGGCTG
2351    AAGGGCTCGA GTGTACCAAA
   ACGTGCCAGA ACTATGACCT GGAGTGCATG
2401    AGCATGGGCT GTGTCTCTGG
   CTGCCTCTGC CCCCCGGGCA TGGTCCGGCA
2451    TGAGAACAGA TGTGTGGCCC
   TGGAAAGGTG TCCCTGCTTC CATCAGGGCA
2501    AGGAGTATGC CCCTGGAGAA
   ACAGTGAAGA TTGGCTGCAA CACTTGTGTC
2551    TGTCGGGACC GGAAGTGGAA
   CTGCACAGAC CATGTGTGTG ATGCCACGTG
2601    CTCCACGATC GGCATGGCCC
   ACTACCTCAC CTTCGACGGG CTCAAATACC
2651    TGTTCCCCGG GGAGTGCCAG
   TACGTTCTGG TGCAGGATTA CTGCGGCAGT
2701    AACCCTGGGA CCTTTCGGAT
   CCTAGTGGGG AATAAGGGAT GCAGCCACCC
2751    CTCAGTGAAA TGCAAGAAAC
   GGGTCACCAT CCTGGTGGAG GGAGGAGAGA
2801    TTGAGCTGTT TGACGGGGAG
   GTGAATGTGA AGAGGCCCAT GAAGGATGAG
2851    ACTCACTTTG AGGTGGTGGA
   GTCTGGCCGG TACATCATTC TGCTGCTGGG
2901    CAAAGCCCTC TCCGTGGTCT
   GGGACCGCCA CCTGAGCATC TCCGTGGTCC
2951    TGAAGCAGAC ATACCAGGAG
   AAAGTGTGTG GCCTGTGTGG GAATTTTGAT
3001    GGCATCCAGA ACAATGACCT
   CACCAGCAGC AACCTCCAAG TGGAGGAAGA
3051    CCCTGTGGAC TTTGGGAACT
   CCTGGAAAGT GAGCTCGCAG TGTGCTGACA
3101    CCAGAAAAGT GCCTCTGGAC
   TCATCCCCTG CCACCTGCCA TAACAACATC
3151    ATGAAGCAGA CGATGGTGGA
   TTCCTCCTGT AGAATCCTTA CCAGTGACGT
3201    CTTCCAGGAC TGCAACAAGC
   TGGTGGACCC CGAGCCATAT CTGGATGTCT
3251    GCATTTACGA CACCTGCTCC
   TGTGAGTCCA TTGGGGACTG CGCCTGCTTC
3301    TGCGACACCA TTGCTGCCTA
   TGCCCACGTG TGTGCCCAGC ATGGCAAGGT
3351    GGTGACCTGG AGGACGGCCA
   CATTGTGCCC CCAGAGCTGC GAGGAGAGGA
3401    ATCTCCGGGA GAACGGGTAT
   GAGTGTGAGT GGCGCTATAA CAGCTGTGCA
3451    CCTGCCTGTC AAGTCACGTG
   TCAGCACCCT GAGCCACTGG CCTGCCCTGT
3501    GCAGTGTGTG GAGGGCTGCC
    -67-

   ATGCCCACTG CCCTCCAGGG AAAATCCTGG
3551    ATGAGCTTTT GCAGACCTGC
   GTTGACCCTG AAGACTGTCC AGTGTGTGAG
3601    GTGGCTGGCC GGCGTTTTGC
   CTCAGGAAAG AAAGTCACCT TGAATCCCAG
3651    TGACCCTGAG CACTGCCAGA
   TTTGCCACTG TGATGTTGTC AACCTCACCT
3701    GTGAAGCCTG CCAGGAGCCG
   GGAGGCCTGG TGGTGCCTCC CACAGATGCC
3751    CCGGTGAGCC CCACCACTCT
   GTATGTGGAG GACATCTCGG AACCGCCGTT
3801    GCACGATTTC TACTGCAGCA
   GGCTACTGGA CCTGGTCTTC CTGCTGGATG
3851    GCTCCTCCAG GCTGTCCGAG
   GCTGAGTTTG AAGTGCTGAA GGCCTTTGTG
3901    GTGGACATGA TGGAGCGGCT
   GCGCATCTCC CAGAAGTGGG TCCGCGTGGC
3951    CGTGGTGGAG TACCACGACG
   GCTCCCACGC CTACATCGGG CTCAAGGACC
4001    GGAAGCGACC GTCAGAGCTG
   CGGCGCATTG CCAGCCAGGT GAAGTATGCG
4051    GGCAGCCAGG TGGCCTCCAC
   CAGCGAGGTC TTGAAATACA CACTGTTCCA
4101    AATCTTCAGC AAGATCGACC
   GCCCTGAAGC CTCCCGCATC GCCCTGCTCC
4151    TGATGGCCAG CCAGGAGCCC
   CAACGGATGT CCCGGAACTT TGTCCGCTAC
4201    GTCCAGGGCC TGAAGAAGAA
   GAAGGTCATT GTGATCCCGG TGGGCATTGG
4251    GCCCCATGCC AACCTCAAGC
   AGATCCGCCT CATCGAGAAG CAGGCCCCTG
4301    AGAACAAGGC CTTCGTGCTG
   AGCAGTGTGG ATGAGCTGGA GCAGCAAAGG
4351    GACGAGATCG TTAGCTACCT
   CTGTGACCTT GCCCCTGAAG CCCCTCCTCC
4401    TACTCTGCCC CCCGACATGG
   CACAAGTCAC TGTGGGCCCG GGGCTCTTGG
4451    GGGTTTCGAC CCTGGGGCCC
   AAGAGGAACT CCATGGTTCT GGATGTGGCG
4501    TTCGTCCTGG AAGGATCGGA
   CAAAATTGGT GAAGCCGACT TCAACAGGAG
4551    CAAGGAGTTC ATGGAGGAGG
   TGATTCAGCG GATGGATGTG GGCCAGGACA
4601    GCATCCACGT CACGGTGCTG
   CAGTACTCCT ACATGGTGAC CGTGGAGTAC
4651    CCCTTCAGCG AGGCACAGTC
   CAAAGGGGAC ATCCTGCAGC GGGTGCGAGA
4701    GATCCGCTAC CAGGGCGGCA
   ACAGGACCAA CACTGGGCTG GCCCTGCGGT
4751    ACCTCTCTGA CCACAGCTTC
   TTGGTCAGCC AGGGTGACCG GGAGCAGGCG
    -68-

4801    CCCAACCTGG TCTACATGGT
   CACCGGAAAT CCTGCCTCTG ATGAGATCAA
4851    GAGGCTGCCT GGAGACATCC
   AGGTGGTGCC CATTGGAGTG GGCCCTAATG
4901    CCAACGTGCA GGAGCTGGAG
   AGGATTGGCT GGCCCAATGC CCCTATCCTC
4951    ATCCAGGACT TTGAGACGCT
   CCCCCGAGAG GCTCCTGACC TGGTGCTGCA
5001    GAGGTGCTGC TCCGGAGAGG
   GGCTGCAGAT CCCCACCCTC TCCCCTGCAC
5051    CTGACTGCAG CCAGCCCCTG
   GACGTGATCC TTCTCCTGGA TGGCTCCTCC
5101    AGTTTCCCAG CTTCTTATTT
   TGATGAAATG AAGAGTTTCG CCAAGGCTTT
5151    CATTTCAAAA GCCAATATAG
   GGCCTCGTCT CACTCAGGTG TCAGTGCTGC
5201    AGTATGGAAG CATCACCACC
   ATTGACGTGC CATGGAACGT GGTCCCGGAG
5251    AAAGCCCATT TGCTGAGCCT
   TGTGGACGTC ATGCAGCGGG AGGGAGGCCC
5301    CAGCCAAATC GGGGATGCCT
   TGGGCTTTGC TGTGCGATAC TTGACTTCAG
5351    AAATGCATGG TGCCAGGCCG
   GGAGCCTCAA AGGCGGTGGT CATCCTGGTC
5401    ACGGACGTCT CTGTGGATTC
   AGTGGATGCA GCAGCTGATG CCGCCAGGTC
5451    CAACAGAGTG ACAGTGTTCC
   CTATTGGAAT TGGAGATCGC TACGATGCAG
5501    CCCAGCTACG GATCTTGGCA
   GGCCCAGCAG GCGACTCCAA CGTGGTGAAG
5551    CTCCAGCGAA TCGAAGACCT
   CCCTACCATG GTCACCTTGG GCAATTCCTT
5601    CCTCCACAAA CTGTGCTCTG
   GATTTGTTAG GATTTGCATG GATGAGGATG
5651    GGAATGAGAA GAGGCCCGGG
   GACGTCTGGA CCTTGCCAGA CCAGTGCCAC
5701    ACCGTGACTT GCCAGCCAGA
   TGGCCAGACC TTGCTGAAGA GTCATCGGGT
5751    CAACTGTGAC CGGGGGCTGA
   GGCCTTCGTG CCCTAACAGC CAGTCCCCTG
5801    TTAAAGTGGA AGAGACCTGT
   GGCTGCCGCT GGACCTGCCC CTGYGTGTGC
5851    ACAGGCAGCT CCACTCGGCA
   CATCGTGACC TTTGATGGGC AGAATTTCAA
5901    GCTGACTGGC AGCTGTTCTT
   ATGTCCTATT TCAAAACAAG GAGCAGGACC
5951    TGGAGGTGAT TCTCCATAAT
   GGTGCCTGCA GCCCTGGAGC AAGGCAGGGC
6001    TGCATGAAAT CCATCGAGGT
   GAAGCACAGT GCCCTCTCCG TCGAGSTGCA
6051    CAGTGACATG GAGGTGACGG
    -69-

   TGAATGGGAG ACTGGTCTCT GTTCCTTACG
6101    TGGGTGGGAA CATGGAAGTC
   AACGTTTATG GTGCCATCAT GCATGAGGTC
6151    AGATTCAATC ACCTTGGTCA
   CATCTTCACA TTCACTCCAC AAAACAATGA
6201    GTTCCAACTG CAGCTCAGCC
   CCAAGACTTT TGCTTCAAAG ACGTATGGTC
6251    TGTGTGGGAT CTGTGATGAG
   AACGGAGCCA ATGACTTCAT GCTGAGGGAT
6301    GGCACAGTCA CCACAGACTG
   GAAAACACTT GTTCAGGAAT GGACTGTGCA
6351    GCGGCCAGGG CAGACGTGCC
   AGCCCATCCT GGAGGAGCAG TGTCTTGTCC
6401    CCGACAGCTC CCACTGCCAG
   GTCCTCCTCT TACCACTGTT TGCTGAATGC
6451    CACAAGGTCC TGGCTCCAGC
   CACATTCTAT GCCATCTGCC AGCAGGACAG
6501    TTGCCACCAG GAGCAAGTGT
   GTGAGGTGAT CGCCTCTTAT GCCCACCTCT
6551    GTCGGACCAA CGGGGTCTGC
   GTTGACTGGA GGACACCTGA TTTCTGTGCT
6601    ATGTCATGCC CACCATCTCT
   GGTCTACAAC CACTGTGAGC ATGGCTGTCC
6651    CCGGCACTGT GATGGCAACG
   TGAGCTCCTG TGGGGACCAT CCCTCCGAAG
6701    GCTGTTTCTG CCCTCCAGAT
   AAAGTCATGT TGGAAGGCAG CTGTGTCCCT
6751    GAAGAGGCCT GCACTCAGTG
   CATTGGTGAG GATGGAGTCC AGCACCAGTT
6801    CCTGGAAGCC TGGGTCCCGG
   ACCACCAGCC CTGTCAGATC TGCACATGCC
6851    TCAGCGGGCG GAAGGTCAAC
   TGCACAACGC AGCCCTGCCC CACGGCCAAA
6901    GCTCCCACGT GTGGCCTGTG
   TGAAGTAGCC CGCCTCCGCC AGAATGCAGA
6951    CCAGTGCTGC CCCGAGTATG
   AGTGTGTGTG TGACCCAGTG AGCTGTGACC
7001    TGCCCCCAGT GCCTCACTGT
   GAACGTGGCC TCCAGCCCAC ACTGACCAAC
7051    CCTGGCGAGT GCAGACCCAA
   CTTCACCTGC GCCTGCAGGA AGGAGGAGTG
7101    CAAAAGAGTG TCCCCACCCT
   CCTGCCCCCC GCACCGTTTG CCCACCCTTC
7151    GGAAGACCCA GTGCTGTGAT
   GAGTATGAGT GTGCCTGCAA CTGTGTCAAC
7201    TCCACAGTGA GCTGTCCCCT
   TGGGTACTTG GCCTCAACCG CCACCAATGA
7251    CTGTGGCTGT ACCACAACCA
   CCTGCCTTCC CGACAAGGTG TGTGTCCACC
7301    GAAGCACCAT CTACCCTGTG
   GGCCAGTTCT GGGAGGAGGG CTGCGATGTG
    -70-

                                  7351     TGCACCTGCA CCGACATGGA
                                     GGATGCCGTG ATGGGCCTCC GCGTGGCCCA
                                  7401     GTGCTCCCAG AAGCCCTGTG
                                     AGGACAGCTG TCGGTCGGGC TTCACTTACG
                                  7451     TTCTGCATGA AGGCGAGTGC
                                     TGTGGAAGGT GCCTGCCATC TGCCTGTGAG
                                  7501     GTGGTGACTG GCTCACCGCG
                                     GGGGGACTCC CAGTCTTCCT GGAAGAGTGT
                                  7551     CGGCTCCCAG TGGGCCTCCC
                                     CGGAGAACCC CTGCCTCATC AATGAGTGTG
                                  7601     TCCGAGTGAA GGAGGAGGTC
                                     TTTATACAAC AAAGGAACGT CTCCTGCCCC
                                  7651     CAGCTGGAGG TCCCTGTCTG
                                     CCCCTCGGGC TTTCAGCTGA GCTGTAAGAC
                                  7701     CTCAGCGTGC TGCCCAAGCT
                                     GTCGCTGTGA GCGCATGGAG GCCTGCATGC
                                  7751     TCAATGGCAC TGTCATTGGG
                                     CCCGGGAAGA CTGTGATGAT CGATGTGTGC
                                  7801     ACGACCTGCC GCTGCATGGT
                                     GCAGGTGGGG GTCATCTCTG GATTCAAGCT
                                  7851     GGAGTGCAGG AAGACCACCT
                                     GCAACCCCTG CCCCCTGGGT TACAAGGAAG
                                  7901     AAAATAACAC AGGTGAATGT
                                     TGTGGGAGAT GTTTGCCTAC GGCTTGCACC
                                  7951     ATTCAGCTAA GAGGAGGACA
                                     GATCATGACA CTGAAGCGTG ATGAGACGCT
                                  8001     CCAGGATGGC TGTGATACTC
                                     ACTTCTGCAA GGTCAATGAG AGAGGAGAGT
                                  8051     ACTTCTGGGA GAAGAGGGTC
                                     ACAGGCTGCC CACCCTTTGA TGAACACAAG
                                  8101     TGTCTTGCTG AGGGAGGTAA
                                     AATTATGAAA ATTCCAGGCA CCTGCTGTGA
                                  8151     CACATGTGAG GAGCCTGAGT
                                     GCAACGACAT CACTGCCAGG CTGCAGTATG
                                  8201     TCAAGGTGGG AAGCTGTAAG
                                     TCTGAAGTAG AGGTGGATAT CCACTACTGC
                                  8251     CAGGGCAAAT GTGCCAGCAA
                                     AGCCATGTAC TCCATTGACA TCAACGATGT
                                  8301     GCAGGACCAG TGCTCCTGCT
                                     GCTCTCCGAC ACGGACGGAG CCCATGCAGG
                                  8351     TGGCCCTGCA CTGCACCAAT
                                     GGCTCTGTTG TGTACCATGA GGTTCTCAAT
                                  8401      GCCATGGAGT GCAAATGCTC
                            CCCCAGGAAG      TGCAGCAAGT GA
[0142]       The VWF fragment as used herein can be a VWF fragment comprising a
       D' domain and a D3 domain of VWF, wherein the VWF fragment binds to Factor
                                      -71-

       VIII (FVIII) and inhibits binding of endogenous VWF (full-length VWF) to FVIII.
       The VWF fragment comprising the D' domain and the D3 domain can further
       comprise a VWF domain selected from the group consisting of an Al domain, an
       A2 domain, an A3 domain, a D1 domain, a D2 domain, a D4 domain, a B 1
       domain, a B2 domain, a B3 domain, a Cl domain, a C2 domain, a CK domain,
       one or more fragments thereof, and any combinations thereof. In one
       embodiment, a VWF fragment comprises, consists essentially of, or consists of:
       (1) the D' and D3 domains of VWF or fragments thereof; (2) the D1, D', and D3
       domains of VWF or fragments thereof; (3) the D2, D', and D3 domains of VWF or
       fragments thereof; (4) the Dl, D2, D', and D3 domains of VWF or fragments
       thereof; or (5) the Dl, D2, D', D3, and Al domains of VWF or fragments thereof.
       The VWF fragment described herein does not contain a site binding to a VWF
       clearance receptor. In another embodiment, the VWF fragment described herein is
       not amino acids 764 to 1274 of SEQ ID NO: 2. The VWF fragment of the present
       invention can comprise any other sequences linked to or fused to the VWF
       fragment. For example, a VWF fragment described herein can further comprise a
       signal peptide.
[0143]          In one embodiment, the VWF fragment binds to or is associated with a
       FVIII protein. By binding to or associating with a FVIII protein, a VWF fragment
       of the invention protects FVIII from protease cleavage and FVIII activation,
       stabilizes the heavy chain and light chain of FVIII, and prevents clearance of
       FVIII by scavenger receptors. In another embodiment, the VWF fragment binds
       to or associates with a FVIII protein and blocks or prevents binding of the FVIII
       protein to phospholipid and activated Protein C. By preventing or inhibiting
       binding of the FVIII protein with endogenous, full-length VWF, the VWF
       fragment of the invention reduces the clearance of FVIII by VWF clearance
       receptors and thus extends half-life of the FVIII protein. In one embodiment, the
       half-life extension of a FVIII protein is thus due to the binding of or associating
       with the VWF fragment lacking a VWF clearance receptor binding site to the
       FVIII protein and shielding or protecting of the FVIII protein by the VWF
       fragment from endogenous VWF which contains the VWF clearance receptor
       binding site. The FVIII protein bound to or protected by the VWF fragment can
       also allow recycling of a FVIII protein. By eliminating the VWF clearance
                                            - 72 -

       pathway receptor binding sites contained in the full length VWF molecule, the
       FVIII/VWF heterodimers of the invention are shielded from the VWF clearance
       pathway, further extending FVIII half-life.
[0144]         In one embodiment, a VWF fragment of the present invention comprises
       the D' domain and the D3 domain of VWF, wherein the D' domain is at least 60%,
       70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to amino
       acids 764 to 866 of SEQ ID NO: 2, wherein the VWF fragment prevents binding
       of endogenous VWF to FVIII. In another embodiment, a VWF fragment
       comprises the D' domain and the D3 domain of VWF, wherein the D3 domain is at
       least 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical
       to amino acids 867 to 1240 of SEQ ID NO: 2, wherein the VWF fragment
       prevents binding of endogenous VWF to FVIII. In some embodiments, a VWF
       fragment described herein comprises, consists essentially of, or consists of the D'
       domain and D3 domain of VWF, which are at least 60%, 7 0%, 80%, 85%, 90%,
       95%, 96%, 97%, 98%, 99%, or 100% identical to amino acids 764 to 1240 of SEQ
       ID NO: 2, wherein the VWF fragment prevents binding of endogenous VWF to
       FVIII. In other embodiments, a VWF fragment comprises, consists essentially of,
       or consists of the D1, D2, D', and D3 domains at least 60%, 7 0%, 80%, 85%, 90%,
       95%, 96%, 97%, 98%, 99%, or 100% identical to amino acids 23 to 1240 of SEQ
       ID NO: 2, wherein the VWF fragment prevents binding of endogenous VWF to
       FVIII. In still other embodiments, the VWF fragment further comprises a signal
       peptide operably linked thereto.
[0145]         In some embodiments, a VWF fragment of the invention consists
       essentially of or consists of (1) the D'D3 domain, the D1D'D3 domain, D2D'D3
       domain, or D1D2D'D3 domain and (2) an additional VWF sequence up to about
       10 amino acids (e.g., any sequences from amino acids 764 to 1240 of SEQ ID NO:
       2 to amino acids 764 to 1250 of SEQ ID NO: 2), up to about 15 amino acids (e.g.,
       any sequences from amino acids 764 to 1240 of SEQ ID NO: 2 to amino acids 764
       to 1255 of SEQ ID NO: 2), up to about 20 amino acids (e.g., any sequences from
       amino acids 764 to 1240 of SEQ ID NO: 2 to amino acids 764 to 1260 of SEQ ID
       NO: 2), up to about 25 amino acids (e.g., any sequences from amino acids 764 to
       1240 of SEQ ID NO: 2 to amino acids 764 to 1265 of SEQ ID NO: 2), or up to
       about 30 amino acids (e.g., any sequences from amino acids 764 to 1240 of SEQ
                                             - 73 -

       ID NO: 2 to amino acids 764 to 1260 of SEQ ID NO: 2). In a particular
       embodiment, the VWF fragment comprising or consisting essentially of the D'
       domain and the D3 domain is neither amino acids 764 to 1274 of SEQ ID NO: 2
       nor the full-length mature VWF. In some embodiments, the D1D2 domain is
       expressed in trans with the D'D3 domain. In some embodiments, the D1D2
       domain is expressed in cis with the D'D3 domain.
[0146]         In other embodiments, the VWF fragment comprising the D'D3 domains
       linked to the D1D2 domains further comprises an intracellular cleavage site, e.g.,
       (a cleavage site by PACE (furin) or PC5), allowing cleavage of the D1D2 domains
       from the D'D3 domains upon expression. Non-limiting examples of the
       intracellular cleavage site are disclosed elsewhere herein.
[0147]         In yet other embodiments, a VWF fragment comprises the D' domain and
       the D3 domain, but does not comprise an amino acid sequence selected from the
       group consisting of (1) amino acids 1241 to 2813 of SEQ ID NO: 2, (2) amino
       acids 1270 to amino acids 2813 of SEQ ID NO: 2, (3) amino acids 1271 to amino
       acids 2813 of SEQ ID NO: 2, (4) amino acids 1272 to amino acids 2813 of SEQ
       ID NO: 2, (5) amino acids 1273 to amino acids 2813 of SEQ ID NO: 2, (6) amino
       acids 1274 to amino acids 2813 of SEQ ID NO: 2, and any combinations thereof.
[0148]         In still other embodiments, a VWF fragment of the present invention
       comprises, consists essentially of, or consists of an amino acid sequence
       corresponding to the D' domain, D3 domain, and Al domain, wherein the amino
       acid sequence is at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%,
       99%, or 100% identical to amino acid 764 to 1479 of SEQ ID NO: 2, wherein the
       VWF fragment prevents binding of endogenous VWF to FVIII. In a particular
       embodiment, the VWF fragment is not amino acids 764 to 1274 of SEQ ID NO: 2.
[0149]         In some embodiments, a VWF fragment of the invention comprises the D'
       domain and the D3 domain, but does not comprise at least one VWF domain
       selected from the group consisting of (1) an Al domain, (2) an A2 domain, (3) an
       A3 domain, (4) a D4 domain, (5) a BI domain, (6) a B2 domain, (7) a B3 domain,
       (8) a C1 domain, (9) a C2 domain, (10) a CK domain, (11) a CK domain and C2
       domain, (12) a CK domain, a C2 domain, and a Cl domain, (13) a CK domain, a
       C2 domain, a Cl domain, a B3 domain, (14) a CK domain, a C2 domain, a Cl
       domain, a B3 domain, a B2 domain, (15) a CK domain, a C2 domain, a C1
                                             - 74 -

       domain, a B3 domain, a B2 domain, and a BI domain, (16) a CK domain, a C2
       domain, a C1 domain, a B3 domain, a B2 domain, a B 1 domain, and a D4 domain,
       (17) a CK domain, a C2 domain, a C1 domain, a B3 domain, a B2 domain, a B 1
       domain, a D4 domain, and an A3 domain, (18) a CK domain, a C2 domain, a Cl
       domain, a B3 domain, a B2 domain, a B 1 domain, a D4 domain, an A3 domain,
       and an A2 domain, (19) a CK domain, a C2 domain, a Cl domain, a B3 domain, a
       B2 domain, a BI domain, a D4 domain, an A3 domain, an A2 domain, and an Al
       domain, and (20) any combinations thereof.
[0150]         In yet other embodiments, the VWF fragment comprises the D'D3 domains
       and one or more domains or modules. Examples of such domains or modules
       include, but are not limited to, the domains and modules disclosed in Zhour et al.,
       Blood published online April 6, 2012: DOI 10.1182/blood-2012-01-405134. For
       example, the VWF fragment can comprise the D'D3 domain and one or more
       domains or modules selected from the group consisting of Al domain, A2 domain,
       A3 domain, D4N module, VWD4 module, C8-4 module, TIL-4 module, C1
       module, C2 module, C3 module, C4 module, C5 module, C5 module, C6 module,
       and any combinations thereof.
[0151]         In still other embodiments, the VWF fragment is linked to a heterologous
       moiety, wherein the heterologous moiety is linked to the N-terminus or the C
       terminus of the VWF fragment or inserted immediately downstream of one or
       more amino acids (e.g., one or more XTEN insertion sites) in the FVIII protein in
       the VWF fragment. For example, the insertion sites for the heterologous moiety
       in the VWF fragment can be in the D' domain, the D3 domain, or both. The
       heterologous moiety can be a half-life extender.
[0152]         In certain embodiments, a VWF fragment of the invention forms a
       multimer, e.g., dimer, trimer, tetramer, pentamer, hexamer, heptamer, or the
       higher order multimers. In other embodiments, the VWF fragment is a monomer
       having only one VWF fragment. In some embodiments, the VWF fragment of the
       present invention can have one or more amino acid substitutions, deletions,
       additions, or modifications. In one embodiment, the VWF fragment can include
       amino acid substitutions, deletions, additions, or modifications such that the VWF
       fragment is not capable of forming a disulfide bond or forming a dimer or a
       multimer. In another embodiment, the amino acid substitution is within the D'
                                             - 75 -

       domain and the D3 domain. In a particular embodiment, a VWF fragment of the
       invention contains at least one amino acid substitution at a residue corresponding
       to residue 1099, residue 1142, or both residues 1099 and 1142 of SEQ ID NO: 2.
       The at least one amino acid substitution can be any amino acids that are not
       occurring naturally in the wild type VWF. For example, the amino acid
       substitution can be any amino acids other than cysteine, e.g., Isoleucine, Alanine,
       Leucine, Asparagine, Lysine, Aspartic acid, Methionine, Phenylalanine, Glutamic
       acid, Threonine, Glutamine, Tryptophan, Glycine, Valine, Proline, Serine,
       Tyrosine, Arginine, or Histidine. In another example, the amino acid substitution
       has one or more amino acids that prevent or inhibit the VWF fragments from
       forming multimers.
[0153]          In certain embodiments, the VWF fragment useful herein can be further
       modified to improve its interaction with FVIII, e.g., to improve binding affinity to
       FVIII. As a non-limiting example, the VWF fragment comprises a serine residue
       at the residue corresponding to amino acid 764 of SEQ ID NO: 2 and a lysine
       residue at the residue corresponding to amino acid 773 of SEQ ID NO: 2.
       Residues 764 and/or 773 can contribute to the binding affinity of the VWF
       fragments to FVIII. In other embodiments, the VWF fragments useful for the
       invention can have other modifications, e.g., the protein can be pegylated,
       glycosylated, hesylated, or polysialylated.
       B)       XTEN Sequences
[0154]          As used here "XTEN sequence" refers to extended length polypeptides
       with non-naturally occurring, substantially non-repetitive sequences that are
       composed mainly of small hydrophilic amino acids, with the sequence having a
       low degree or no secondary or tertiary structure under physiologic conditions. As
       a chimeric protein partner, XTENs can serve as a carrier, conferring certain
       desirable pharmacokinetic, physicochemical and pharmaceutical properties when
       linked to a VWF fragment or a FVIII sequence of the invention to create a
       chimeric protein. Such desirable properties include but are not limited to
       enhanced pharmacokinetic parameters and solubility characteristics. As used
       herein, "XTEN" specifically excludes antibodies or antibody fragments such as
       single-chain antibodies or Fc fragments of a light chain or a heavy chain.
                                           - 76 -

[01551         In some embodiments, the XTEN sequence of the invention is a peptide or
       a polypeptide having greater than about 20, 30, 40, 50, 60, 70, 80, 90, 100, 150,
       200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950,
       1000, 1200, 1400, 1600, 1800, or 2000 amino acid residues. In certain
       embodiments, XTEN is a peptide or a polypeptide having greater than about 20 to
       about 3000 amino acid residues, greater than 30 to about 2500 residues, greater
       than 40 to about 2000 residues, greater than 50 to about 1500 residues, greater
       than 60 to about 1000 residues, greater than 70 to about 900 residues, greater than
       80 to about 800 residues, greater than 90 to about 700 residues, greater than 100 to
       about 600 residues, greater than 110 to about 500 residues, or greater than 120 to
       about 400 residues.
[0156]         The XTEN sequence of the invention can comprise one or more sequence
       motif of 9 to 14 amino acid residues or an amino acid sequence at least 80%, 90%,
       91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence
       motif, wherein the motif comprises, consists essentially of, or consists of 4 to 6
       types of amino acids selected from the group consisting of glycine (G), alanine
       (A), serine (S), threonine (T), glutamate (E) and proline (P). See US 20 10
       0239554 Al.
[0157]         In some embodiments, the XTEN comprises non-overlapping sequence
       motifs in which about 80%, or at least about 85%, or at least about 90%, or about
       91%, or about 92%, or about    9 3 %, or about 94%, or about 95%, or about 96%, or
       about 97%, or about 98%, or about 99% or about 100% of the sequence consists
       of multiple units of non-overlapping sequences selected from a single motif family
       selected from Table 2A, resulting in a family sequence. As used herein, "family"
       means that the XTEN has motifs selected only from a single motif category from
       Table 2A; i.e., AD, AE, AF, AG, AM, AQ, BC, or BD XTEN, and that any other
       amino acids in the XTEN not from a family motif are selected to achieve a needed
       property, such as to permit incorporation of a restriction site by the encoding
       nucleotides, incorporation of a cleavage sequence, or to achieve a better linkage to
       FVIII or VWF. In some embodiments of XTEN families, an XTEN sequence
       comprises multiple units of non-overlapping sequence motifs of the AD motif
       family, or of the AE motif family, or of the AF motif family, or of the AG motif
       family, or of the AM motif family, or of the AQ motif family, or of the BC family,
                                             - 77 -

or of the BD family, with the resulting XTEN exhibiting the range of homology
described above. In other embodiments, the XTEN comprises multiple units of
motif sequences from two or more of the motif families of Table 2A. These
sequences can be selected to achieve desired physical/chemical characteristics,
including such properties as net charge, hydrophilicity, lack of secondary
structure, or lack of repetitiveness that are conferred by the amino acid
composition of the motifs, described more fully below. In the embodiments
hereinabove described in this paragraph, the motifs incorporated into the XTEN
can be selected and assembled using the methods described herein to achieve an
XTEN of about 36 to about 3000 amino acid residues.
Table 2A. XTEN Sequence Motifs of 12 Amino Acids and Motif Families
             Motif Famiv*               MOTI F SEQUENCE
                   AD                      GESPGGSSGSES
                   AD                      GSEGSSGPGESS
                   AD                      GSSESGSSEGGP
                   AD                      GSGGEPSESGSS
                 AL, AM                    GSPAGSPTSTEE
              AL, AM, AQ                   GSEPATSGSETP
              AL, AM, AQ                   GTSESATPESGP
              AL, AM, AQ                   GTSTEPSEGSAP
                 AF, AM                    GSTSESPSGTAP
                 AF, AM                    GTSTPLSGSASP
                 AF, AM                    GTSPSGESSTAP
                 AF, AM                    GSTSSTAESPGP
                 AG, AM                    GTPGSGTASSSP
                 AG, AM                    GSSTPSGATGSP
                 AG, AM                    GSSPSASTGTGP
                 AG, AM                    GASPGTSSTGSP
                   AQ                      GEPAGSPTSTSE
                   AQ                      GTGEPSSTPASE
                   AQ                      GSGPSTESAPTE
                   AQ                      GSETPSGPSETA
                   AQ                      GPSETSTSEPGA
                   AQ                      GSPSEPTEGTSA
                   BC                      GSGASEPTSTEP
                   BC                      GSEPATSGTEPS
                   BC                      GTSEPSTSEPGA
                   BC                      GTSTEPSEPGSA
                   BD                      GSTAGSETSTEA
                   BD                      GSETATSGSETA
                   BD                      GTSESATSESGA
                   BD                      GTSTEASEGSAS
                                      - 78 -

                 . Denotes individual motif sequences that, when used together in
                     various permutations, results in a "family sequence"
[0158]         XTEN can have varying lengths for insertion into or linkage to FVIII or
       VWF. In one embodiment, the length of the XTEN sequence(s) is chosen based
       on the property or function to be achieved in the fusion protein. Depending on the
       intended property or function, XTEN can be short or intermediate length sequence
       or longer sequence that can serve as carriers. In certain embodiments, the XTEN
       include short segments of about 6 to about 99 amino acid residues, intermediate
       lengths of about 100 to about 399 amino acid residues, and longer lengths of about
       400 to about 1000 and up to about 3000 amino acid residues. Thus, the XTEN
       inserted into or linked to FVIII or VWF can have lengths of about 6, about 12,
       about 36, about 40, about 42, about 72, about 96, about 144, about 288, about 400,
       about 500, about 576, about 600, about 700, about 800, about 864, about 900,
       about 1000, about 1500, about 2000, about 2500, or up to about 3000 amino acid
       residues in length. In other embodiments, the XTEN sequences is about 6 to about
       50, about 50 to about 100, about 100 to 150, about 150 to 250, about 250 to 400,
       about 400 to about 500, about 500 to about 900, about 900 to 1500, about 1500 to
       2000, or about 2000 to about 3000 amino acid residues in length. The precise
       length of an XTEN inserted into or linked to FVIII or VWF can vary without
       adversely affecting the activity of the FVIII or VWF. In one embodiment, one or
       more of the XTEN used herein has 36 amino acids, 42 amino acids, 72 amino
       acids, 144 amino acids, 288 amino acids, 576 amino acids, or 864 amino acids in
       length and can be selected from one or more of the XTEN family sequences; i.e.,
       AD, AE, AF, AG, AM, AQ, BC or BD.
[0159]         In some embodiments, the XTEN sequence used in the invention is at least
       60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%,
       or 100% identical to a sequence selected from the group consisting of AE42,
       AG42, AE48, AM48, AE72, AG72, AE108, AG108, AE144, AF144, AG144,
       AE180, AG180, AE216, AG216, AE252, AG252, AE288, AG288, AE324,
       AG324, AE360, AG360, AE396, AG396, AE432, AG432, AE468, AG468,
       AE504, AG504, AF504, AE540, AG540, AF540, AD576, AE576, AF576,
       AG576, AE612, AG612, AE624, AE648, AG648, AG684, AE720, AG720,
       AE756, AG756, AE792, AG792, AE828, AG828, AD836, AE864, AF864,
                                            - 79 -

       AG864, AM875, AE912, AM923, AM1318, BC864, BD864, AE948, AE1044,
       AE1140, AE1236, AE1332, AE1428, AE1524, AE1620, AE1716, AE1812,
       AE1908, AE2004A, AG948, AG1044, AGI 140, AG1236, AG1332, AG1428,
       AG1524, AG1620, AG1716, AG1812, AG1908, and AG2004. See US 2010
       0239554 Al.
[01601         In one embodiment, the XTEN sequence is at least 60%, 70%, 80%, 90%,
       95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected
       from the group consisting of AE42 (SEQ ID NO: 36), AE72 (SEQ ID NO: 127),
       AE144_2A (SEQ IDNO: 128), AE144_3B (SEQ ID NO: 129), AE144_4A (SEQ
       ID NO: 130), AE144_5A (SEQ IDNO: 131), AE144_6B (SEQ IDNO: 132),
       AG144_A (SEQ ID NO: 133), AG144_B (SEQ IDNO: 134), AG144_C (SEQ ID
       NO: 135), AG144_F (SEQ IDNO: 136), AE864 (SEQ ID NO: 43), AE576 (SEQ
       ID NO: 41), AE288 (SEQ IDNO: 39), AE288_2 (SEQ ID NO: 137), AE144 (SEQ
       ID NO: 37), AG864 (SEQ ID NO: 44), AG576 (SEQ ID NO: 42), AG288 (SEQ
       ID NO: 40), AG144 (SEQ ID NO: 38), and any combinations thereof.
[01611         In some embodiments, less than 100% of amino acids of an XTEN are
       selected from glycine (G), alanine (A), serine (S), threonine (T), glutamate (E) and
       proline (P), or less than 100% of the sequence consists of the sequence motifs
       from Table 2A or the XTEN sequences of Table 2B. In such embodiments, the
       remaining amino acid residues of the XTEN are selected from any of the other 14
       natural L-amino acids, but may be preferentially selected from hydrophilic amino
       acids such that the XTEN sequence contains at least about 90%, 91%, 92%,      9 3 %,
       9 4 %, 95%,  96%, 97%, 98%, or at least about 99% hydrophilic amino acids. The
       content of hydrophobic amino acids in the XTEN utilized in the conjugation
       constructs may be less than 5%, or less than 2%, or less than 1% hydrophobic
       amino acid content. Hydrophobic residues that are less favored in construction of
       XTEN include tryptophan, phenylalanine, tyrosine, leucine, isoleucine, valine, and
       methionine. Additionally, XTEN sequences may contain less than 5% or less than
       4% or less than 30% or less than 2% or less than 1% or none of the following
       amino acids: methionine (for example, to avoid oxidation), or asparagine and
       glutamine (to avoid desamidation).
[0162]         In another embodiment, the XTEN sequence is selected from the group
       consisting of AE42 (SEQ ID NO: 36), AE72 (SEQ ID NO: 127), AE144_2A
                                           - 80 -

     (SEQ IDNO: 128), AE144_3B (SEQ ID NO: 129), AE144_4A (SEQ ID NO:
     130), AE144_5A (SEQ IDNO: 131), AE144_6B (SEQ IDNO: 132), AG144_A
     (SEQ ID NO: 133), AG144_B (SEQ IDNO: 134), AG144_C (SEQ ID NO: 135),
     AG144_F (SEQ IDNO: 136), AE864 (SEQ ID NO: 43), AE576 (SEQ ID NO: 41),
     AE288 (SEQ IDNO: 39), AE288_2 (SEQ ID NO: 137), AE144 (SEQ ID NO: 37),
     AG864 (SEQ ID NO: 44), AG576 (SEQ ID NO: 42), AG288 (SEQ ID NO: 40),
     AG144 (SEQ ID NO: 38), and any combinations thereof In a specific
     embodiment, the XTEN sequence is AE288. The amino acid sequences for
     certain XTEN sequences of the invention are shown in Table 2B.
     TABLE 2B. XTEN Sequences
XTEN            Amino Acid Sequence
AE42            GAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPASS
SEQ ID NO:
36
AE72            GAPTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPA
SEQ ID NO:      TSGSETPGTSESATPESGPGTSTEPSEGSAPGASS
127
AE144           GSEPATSGSETPGTSESATPESGPGSEPATSGSETPGSPAGSPTSTE
SEQ          ID EGTSTEPSEG
NO:37           SAPGSEPATSGSETPGSEPATSGSETPGSEPATSGSETPGTSTEPSE
                GSAPGTSESA
                PESGPGSEPATSGSETPGTSTEPSEGSAP
AE144_2A        TSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGSAPGTSTEPSEGSAP
(SEQ ID NO:     GTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSEPATSGSET
                PGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESATPES
128)            GPG
AE144_3B        SPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGP
(SEQ ID NO:     GTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSA
                PGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEGS
129)            APG
AE144_4A        TSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETP
(SEQ ID NO:     GTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSPTSTE
                EGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGS
130)            APG
AE144_5A        TSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSETP
(SEQ ID NO:     GTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESG
                PGSEPATSGSETPGTSESATPESGPGSPAGSPTSTEEGSPAGSPTST
                                      -81  -

131)        EEG
AE144_6B    TSTEPSEGSAPGTSESATPESGPGTSESATPESGPGTSESATPESGP
(SEQ ID NO: GSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGSA
            PGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPSEGS
132)        APG
AG144       GTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTG
SEQ      ID PGASPGTSST
NO:38       GSPGASPGTSSTGSPGSSTPSGATGSPGSSPSASTGTGPGASPGTSS
            TGSPGSSPSA
            STGTGPGTPGSGTASSSPGSSTPSGATGSP
AG144_A     GASPGTSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSS
(SEQ ID NO: PGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASS
            SPGSSTPSGATGSPGTPGSGTASSSPGASPGTSSTGSPGASPGTSST
133)        GSP
AG144_B     GTPGSGTASSSPGSSTPSGATGSPGASPGTSSTGSPGTPGSGTASSS
(SEQ ID NO: PGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGSSTPSGATG
            SPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSST
134)        GSP
AG144_C     GTPGSGTASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGS
(SEQ ID NO: PGSSPSASTGTGPGTPGSGTASSSPGASPGTSSTGSPGASPGTSSTG
            SPGASPGTSSTGSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSST
135)        GSP
AG144_F     GSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGS
(SEQ ID NO: PGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGT
            GPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGATGSPGASPGTSST
136)        GSP
AE288       GTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSGSET
SEQ      ID PGTSESATPESG
            PGTSTEPSEGSAPGSPAGSPTSTEEGTSESATPESGPGSEPATSGSE
NO:39       TPGTSESATPES
            GPGSPAGSPTSTEEGSPAGSPTSTEEGTSTEPSEGSAPGTSESATPE
            SGPGTSESATPE
            SGPGTSESATPESGPGSEPATSGSETPGSEPATSGSETPGSPAGSPT
            STEEGTSTEPSE
            GSAPGTSTEPSEGSAPGSEPATSGSETPGTSESATPESGPGTSTEPS
            EGSAP
AE288_2     GSPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESG
(SEQ ID NO: PGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGS
            APGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTSTEEGTSTEPSEG
137)        SAPGTSESATPESGPGSEPATSGSETPGTSESATPESGPGSEPATSG
            SETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSPAGSP
            TSTEEGSPAGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEP
            SEGSAP
AG288       PGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATG
                           -82-

SEQ   ID SPGTPGSGTASS
NO:4     SPGSSTPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPSGAT
         GSPGSSPSASTG
         TGPGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGA
         TGSPGSSPSAST
         GTGPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGSSTPSG
         ATGSPGSSPSAS
         TGTGPGASPGTSSTGSPGSSPSASTGTGPGTPGSGTASSSPGSSTPS
         GATGS
AE576    GSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTE
SEQ   ID EGTSTEPSEGSA
         PGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSE
NO:41    TPGSPAGSPTST
         EEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTS
         TEEGTSTEPSEG
         SAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATP
         ESGPGSEPATSG
         SETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESAT
         PESGPGSPAGSP
         TSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEP
         SEGSAPGTSTEP
         SEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTE
         PSEGSAPGSPAG
         SPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSE
         SATPESGPGSEP
         ATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSP
         AGSPTSTEEGSP
         AGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAP
AG576    PGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSASTGT
SEQ   ID GPGSSTPSGATG
         SPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSST
NO:42    GSPGTPGSGTAS
         SSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSAST
         GTGPGTPGSGTA
         SSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTPSG
         ATGSPGSSTPSG
         ATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSSTPS
         GATGSPGSSTPS
         GATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTPGS
         GTASSSPGASPG
         TSSTGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGTPG
         SGTASSSPGSST
         PSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPGSS
         TPSGATGSPGSS
         TPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSPGT
         PGSGTASSSPGS
         STPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGS
AE864    GSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGSPAGSPTSTE
         EGTSTEPSEGSA
                        -83-

SEQ   ID PGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGSEPATSGSE
NO:43    TPGSPAGSPTST
         EEGTSESATPESGPGTSTEPSEGSAPGTSTEPSEGSAPGSPAGSPTS
         TEEGTSTEPSEG
         SAPGTSTEPSEGSAPGTSESATPESGPGTSTEPSEGSAPGTSESATP
         ESGPGSEPATSG
         SETPGTSTEPSEGSAPGTSTEPSEGSAPGTSESATPESGPGTSESAT
         PESGPGSPAGSP
         TSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGPGTSTEP
         SEGSAPGTSTEP
         SEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTEPSEGSAPGTSTE
         PSEGSAPGSPAG
         SPTSTEEGTSTEPSEGSAPGTSESATPESGPGSEPATSGSETPGTSE
         SATPESGPGSEP
         ATSGSETPGTSESATPESGPGTSTEPSEGSAPGTSESATPESGPGSP
         AGSPTSTEEGSP
         AGSPTSTEEGSPAGSPTSTEEGTSESATPESGPGTSTEPSEGSAPGT
         SESATPESGPGS
         EPATSGSETPGTSESATPESGPGSEPATSGSETPGTSESATPESGPG
         TSTEPSEGSAPG
         SPAGSPTSTEEGTSESATPESGPGSEPATSGSETPGTSESATPESGP
         GSPAGSPTSTEE
         GSPAGSPTSTEEGTSTEPSEGSAPGTSESATPESGPGTSESATPESG
         PGTSESATPESG
         PGSEPATSGSETPGSEPATSGSETPGSPAGSPTSTEEGTSTEPSEGS
         APGTSTEPSEGS
         APGSEPATSGSETPGTSESATPESGPGTSTEPSEGSAP
AG864    GASPGTSSTGSPGSSPSASTGTGPGSSPSASTGTGPGTPGSGTASSS
SEQ   ID PGSSTPSGATGS
         PGSSPSASTGTGPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATG
NO:44    SPGTPGSGTASS
         SPGASPGTSSTGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGAT
         GSPGASPGTSST
         GSPGTPGSGTASSSPGSSTPSGATGSPGSSPSASTGTGPGSSPSAST
         GTGPGSSTPSGA
         TGSPGSSTPSGATGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTS
         STGSPGTPGSGT
         ASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSPSA
         STGTGPGTPGSG
         TASSSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGSSTP
         SGATGSPGSSTP
         SGATGSPGASPGTSSTGSPGTPGSGTASSSPGSSTPSGATGSPGSST
         PSGATGSPGSST
         PSGATGSPGSSPSASTGTGPGASPGTSSTGSPGASPGTSSTGSPGTP
         GSGTASSSPGAS
         PGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGASPGTSSTGSPGT
         PGSGTASSSPGS
         STPSGATGSPGTPGSGTASSSPGSSTPSGATGSPGTPGSGTASSSPG
         SSTPSGATGSPG
         SSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGSP
         GTPGSGTASSSP
                        -84-

                     GSSTPSGATGSPGSSPSASTGTGPGSSPSASTGTGPGASPGTSSTGS
                      PGASPGTSSTGS
                      PGSSTPSGATGSPGSSPSASTGTGPGASPGTSSTGSPGSSPSASTGT
                     GPGTPGSGTASS
                      SPGSSTPSGATGSPGSSTPSGATGSPGASPGTSSTGSP
[01631          In further embodiments, the XTEN sequence used in the invention affects
       the physical or chemical property, e.g., pharmacokinetics, of the chimeric protein
       of the present invention. The XTEN sequence used in the present invention can
       exhibit one or more of the following advantageous properties: conformational
       flexibility, enhanced aqueous solubility, high degree of protease resistance, low
       immunogenicity, low binding to mammalian receptors, or increased hydrodynamic
       (or Stokes) radii. In a specific embodiment, the XTEN sequence linked to a FVIII
       protein in this invention increases pharmacokinetic properties such as longer
       terminal half-life or increased area under the curve (AUC), so that the chimeric
       protein described herein stays in vivo for an increased period of time compared to
       wild type FVIII. In further embodiments, the XTEN sequence used in this
       invention increases pharmacokinetic properties such as longer terminal half-life or
       increased area under the curve (AUC), so that FVIII protein stays in vivo for an
       increased period of time compared to wild type FVIII.
[0164]          A variety of methods and assays can be employed to determine the
       physical/chemical properties of proteins comprising the XTEN sequence. Such
       methods include, but are not limited to analytical centrifugation, EPR, HPLC-ion
       exchange, HPLC-size exclusion, HPLC-reverse phase, light scattering, capillary
       electrophoresis, circular dichroism, differential scanning calorimetry,
       fluorescence, HPLC-ion exchange, HPLC-size exclusion, IR, NMR, Raman
       spectroscopy, refractometry, and UV/Visible spectroscopy. Additional methods
       are disclosed in Amau et al., ProtExpr and Purif 48, 1-13 (2006).
[0165]          Additional examples of XTEN sequences that can be used according to the
       present invention and are disclosed in US Patent Publication Nos. 2010/0239554
       Al, 2010/0323956 Al, 2011/0046060 A1, 2011/0046061 Al, 2011/0077199 A1,
       or 2011/0172146 Al, or International Patent Publication Nos. WO 2010091122
       Al, WO 2010144502 A2, WO 2010144508 Al, WO 2011028228 Al, WO
       2011028229 Al, or WO 2011028344 A2.
       C)       Factor VIII (FVIII) Protein
                                            - 85 -

[01661          "A FVIII protein" as used herein means a functional FVIII polypeptide in
       its normal role in coagulation, unless otherwise specified. The term a FVIII
       protein includes a functional fragment, variant, analog, or derivative thereof that
       retains the function of full-length wild-type Factor VIII in the coagulation
       pathway. "A FVIII protein" is used interchangeably with FVIII polypeptide (or
       protein) or FVIII. Examples of the FVIII functions include, but not limited to, an
       ability to activate coagulation, an ability to act as a cofactor for factor IX, or an
       ability to form a tenase complex with factor IX in the presence of Ca2 and
       phospholipids, which then converts Factor X to the activated form Xa. The FVIII
       protein can be the human, porcine, canine, rat, or murine FVIII protein. In
       addition, comparisons between FVIII from humans and other species have
       identified conserved residues that are likely to be required for function (Cameron
       et al., Thromb. Haemost. 79:317-22 (1998); US 6,251,632).
[0167]          A number of tests are available to assess the function of the coagulation
       system: activated partial thromboplastin time (aPTT) test, chromogenic assay,
       ROTEM assay, prothrombin time (PT) test (also used to determine INR),
       fibrinogen testing (often by the Clauss method), platelet count, platelet function
       testing (often by PFA-100), TCT, bleeding time, mixing test (whether an
       abnormality corrects if the patient's plasma is mixed with normal plasma),
       coagulation factor assays, antiphospholipid antibodies, D-dimer, genetic tests
       (e.g., factor V Leiden, prothrombin mutation G202 10A), dilute Russell's viper
       venom time (dRVVT), miscellaneous platelet function tests, thromboelastography
       (TEG or Sonoclot), thromboelastometry (TEM*, e.g., ROTEM*), or euglobulin
       lysis time (ELT).
[01681          The aPTT test is a performance indicator measuring the efficacy of both
       the "intrinsic" (also referred to the contact activation pathway) and the common
       coagulation pathways. This test is commonly used to measure clotting activity of
       commercially available recombinant clotting factors, e.g., FVIII or FIX. It is used
       in conjunction with prothrombin time (PT), which measures the extrinsic pathway.
[01691          ROTEM analysis provides information on the whole kinetics of
       haemostasis: clotting time, clot formation, clot stability and lysis. The different
       parameters in thromboelastometry are dependent on the activity of the plasmatic
       coagulation system, platelet function, fibrinolysis, or many factors which
                                             - 86 -

       influence these interactions. This assay can provide a complete view of secondary
       haemostasis.
[0170]            The FVIII polypeptide and polynucleotide sequences are known, as are
       many functional fragments, mutants and modified versions. Examples of human
       FVIII sequences (full-length) are shown below.
       TABLE 3. Amino Acid Sequence of Full-length Factor VIII
         (Full-length FVIII (FVIII signal peptide underlined; FVIII heavy chain is double
              underlined; B domain is italicized; and FVIII light chain is in plain text)
       Signal Peptide: (SEQ ID NO: 3)
       MQ I E LS T CL F LF       R FCFS
       Mature Factor VIII (SEQ ID NO: 4)*
       ATRXVNG7. --AVEISWYMQS                            PE VDA-FPPNVPKSFPFNTSVVWKK-LFVEFT
       DHLFNIAKPRPPWMGLL T TIQAEVYDTVVT IT KNAASHPVSLIAVGVSYWKASE
       GAEYDDQTSQREK\EDDKVFPG SHTYVWIQVLKENGPMASDPLCLTY ~fSYLSVDLV
       KDTN SGLIGALLVrPEGSLAKEKTQTLHKFLLFVFDEGKSWHEKNSLMQDR
       DAIASPARIAWPKMH T'VNGYVNRI                  L     IGC RKSVYVHVI CMGT:T PEVSIFLEGHT
       FL VRNHRQAST E S)I'TiLlAQLMLGQFLC HTSSHQI G: MEAVKViSCr
       EEQ0' MKNNEEA.PYDDDL-T-SEMD'F VFEKDDPNSPSFIQIRSVAKKHPK-TWNX7
          T
            EEEEDYAPV' V' APDT)DRSYKYLNNGPQRIGRKYKKVRFMAYTDETFKTEE
             AIQHESGI L'LGEGDTLLIIFKNQASRPYNi YIH1GITDVRPLYSaRLPKGV
                               KHKDPIPEIKYWVEDGPITKSDPRCLIT'R'-YYS SFVNMERDLASGL-'IGP
        LL IY:7KESVDQRGNQIMSDKRNV                    IL FW KVFDENRSWYL          TEN _IR FPNVPAGV :QL D
     PFQAS,-'NTMHS'INGYVFDSLTQI LSVCL-EVAYWYILSfAQTDFLS                                    VFFSGYF K
       KMVYEDTTLFPFGETVFMSMENPGL-WILGCi)NSDFRNRGM-A T ALLKVSSCDKNT
       GDYYEDSYED           TY     I 0 KNNAIE PRISON                    T    T RT
         PWv2"-'Z"_ A2 R T MKGVSSLRLQP                             PN~SLSLEY             T       C'DSPA
               DSNNSSEMT             T ERQj SGDMVT        PEGQLRELG                  T A   T        _ KKD 'DS
        LY7S          WRS PHLNSSQFPKKVVQLFG
                       EFKDGLEMFPSNLLTLDL                                          S
                                                                              SFEQNLR
                                                                      NT NZKGEIKKTLQEV     EKNKHLGKG
       LPF        TTTNMNELSRNESDAAVQDRLDTRKI!
             ARSKE             _NtLGQ
                                   J                  K3TRIPTQNETRKRL~R
                J-LEETELEK1 1,DDTSTiWSKN1K LTPTLQDYEKKAA.,~DL
               RSSIGNRPLIKVSESRPYLRLEJN.7LAAYKKSGQ
       T lRLMDSNAETIAYLRTLNV:MNTTSKMQKKEDDYE
                    GKKvLLILTPMTD"RVGSGTSTNSTYKVENVL2
                                                J."L                           EPSFPDAQKT DMHYFIA PDM
        7-TSGVELLZV7IY-                   DL    PET7NSPG7LDLVEG7LLGTEGAIK7NEArj
                                                                -g 87                       f-71   ""'T
                                              D        -   87 -

 PYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTY
 FWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQ
 VTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYI
 MDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYP
 GVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDF
 QITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGAR
 QKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPII
 ARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMF
 ATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSM
 YVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHP
 QSWVHQIALRMEVLGCEAQDLY
 TABLE 4. Nucleotide Sequence Encoding Full-Length FVIII (SEQ ID NO:
 5)*
  661_                                                     ATG
       CAAATAGAGC TCTCCACCTG
 721      CTTCTTTCTG TGCCTTTTGC      GATTCTGCTT TAGTGCCACC
      AGAAGATACT ACCTGGGTGC
 781      AGTGGAACTG TCATGGGACT      ATATGCAAAG TGATCTCGGT
       GAGCTGCCTG TGGACGCAAG
 P4       ATTTCCTCCT AGAGTGCCAA      AATCTTTTCC ATTCAACACC
       TCAGTCGTGT ACAAAAAGAC
  901     TCTGTTTGTA GAATTCACGG      ATCACCTTTT CAACATCGCT
      AAGCCAAGGC CACCCTGGAT
  961     GGGTCTGCTA GGTCCTACCA      TCCAGGCTGA GGTTTATGAT
      ACAGTGGTCA TTACACTTAA
1021      GAACATGGCT TCCCATCCTG      TCAGTCTTCA TGCTGTTGGT
       GTATCCTACT GGAAAGCTTC
1081      TGAGGGAGCT GAATATGATG      ATCAGACCAG TCAAAGGGAG
      AAAGAAGATG ATAAAGTCTT
1141      CCCTGGTGGA AGCCATACAT      ATGTCTGGCA GGTCCTGAAA
       GAGAATGGTC CAATGGCCTC
1.201     TGACCCACTG TGCCTTACCT      ACTCATATCT TTCTCATGTG
       GACCTGGTAA AAGACTTGAA
1261      TTCAGGCCTC ATTGGAGCCC      TACTAGTATG TAGAGAAGGG
      AGTCTGGCCA AGGAAAAGAC
1321      ACAGACCTTG CACAAATTTA      TACTACTTTT TGCTGTATTT
       GATGAAGGGA AAAGTTGGCA
1381      CTCAGAAACA AAGAACTCCT      TGATGCAGGA TAGGGATGCT
       GCATCTGCTC GGGCCTGGCC
1441      TAAAATGCAC ACAGTCAATG      GTTATGTAAA CAGGTCTCTG
       CCAGGTCTGA TTGGATGCCA
1501      CAGGAAATCA GTCTATTGGC      ATGTGATTGG AATGGGCACC
      ACTCCTGAAG TGCACTCAAT
                               - 88-

1561  ATTCCTCGAA GGTCACACAT     TTCTTGTGAG GAACCATCGC
   CAGGCGTCCT TGGAAATCTC
1621   GCCAATAACT TTCCTTACTG    CTCAAACACT CTTGATGGAC
   CTTGGACAGT TTCTACTGTT
1681   TTGTCATATC TCTTCCCACC    AACATGATGG CATGGAAGCT
   TATGTCAAAG TAGACAGCTG
1741   TCCAGAGGAA CCCCAACTAC    GAATGAAAAA TAATGAAGAA
   GCGGAAGACT ATGATGATGA
1801   TCTTACTGAT TCTGAAATGG    ATGTGGTCAG GTTTGATGAT
   GACAACTCTC CTTCCTTTAT
1861   CCAAATTCGC TCAGTTGCCA    AGAAGCATCC TAAAACTTGG
   GTACATTACA TTGCTGCTGA
1921  AGAGGAGGAC TGGGACTATG     CTCCCTTAGT CCTCGCCCCC
   GATGACAGAA GTTATAAAAG
1931   TCAATATTTG AACAATGGCC    CTCAGCGGAT TGGTAGGAAG
   TACAAAAAAG TCCGATTTAT
2041   GGCATACACA GATGAAACCT    TTAAGACTCG TGAAGCTATT
   CAGCATGAAT CAGGAATCTT
2101   GGGACCTTTA CTTTATGGGG    AAGTTGGAGA CACACTGTTG
   ATTATATTTA AGAATCAAGC
2161  AAGCAGACCA TATAACATCT     ACCCTCACGG AATCACTGAT
   GTCCGTCCTT TGTATTCAAG
2221   GAGATTACCA AAAGGTGTAA    AACATTTGAA GGATTTTCCA
   ATTCTGCCAG GAGAAATATT
2281   CAAATATAAA TGGACAGTGA    CTGTAGAAGA TGGGCCAACT
   AAATCAGATC CTCGGTGCCT
2341   GACCCGCTAT TACTCTAGTT    TCGTTAATAT GGAGAGAGAT
   CTAGCTTCAG GACTCATTGG
2401   CCCTCTOCTC ATCTGCTACA    AAGAATCTGT AGATCAAAGA
   GGAAACCAGA TAATGTCAGA
2461   CAAGAGGAAT GTCATCCTGT    TTTCTGTATT TGATGAGAAC
   CGAAGCTGGT ACCTCACAGA
2521   GAATATACAA CGCTTTCTCC    CCAATCCAGC TGGAGTGCAG
   CTTGAGGATC CAGAGTTCCA
2581  AGCCTCCAAC ATCATGCACA     GCATCAATGG CTATGTTTTT
   GATAGTTTGC AGTTGTCAGT
2641   TTGTTTGCAT GAGGTGGCAT    ACTGGTACAT TCTAAGCATT
   GGAGCACAGA CTGACTTCCT
2701   TTCTGTCTTC TTCTCTGGAT    ATACCTTCAA ACACAAAATG
   GTCTATGAAG ACACACTCAC
2761   CCTATTCCCA TTCTCAGGAG    AAACTGTCTT CATGTCGATG
   GAAAACCCAG GTCTATGGAT
2821   TCTGGGGTGC CACAACTCAG    ACTTTCGGAA CAGAGGCATG
   ACCGCCTTAC TGAAGGTTTC
2881   TAGTTGTGAC AAGAACACTG    GTGATTATTA CGAGGACAGT
   TATGAAGATA TTTCAGCATA
2941   CTTGCTGAGT AAAAACAATG    CCATTGAACC AAGAAGCTTC
   TCCCAGAATT CAAGACACCC
3001   TAGCACTAGG CAAAAGCAAT    TTAATGCCAC CACAATTCCA
   GAAAATGACA TAGAGAAGAC
                          - 89-

3061    TGACCCTTGG TTTGCACACA    GAACACCTAT GCCTAAAATA
     CAAAATGTCT CCTCTAGTGA
321     TTTGTTGATG CTCTTGCGAC    AGAGTCCTAC TCCACATGGG
     CTATCCTTAT CTGATCTCCA
3181    AGAAGCCAAA TATGAGACTT    TTTCTGATGA TCCATCACCT
     GGAGCAATAG ACAGTAATAA
3241    CAGCCTGTCT GAAATGACAC    ACTTCAGGCC ACAGCTCCAT
     CACAGTGGGG ACATGGTATT
3301    TACCCCTGAG TCAGGCCTCC    AATTAAGATT AAATGAGAAA
     CTGGGGACAA CTGCAGCAAC
3361    AGAGTTGAAG AAACTTGATT    TCAAAGTTTC TAGTACATCA
    AATAATCTGA TTTCAACAAT
3421    TCCATCAGAC AATTTGGCAG    CAGGTACTGA TAATACAAGT
     TCCTTAGGAC CCCCAAGTAT
3431    GCCAGTTCAT TATGATAGTC    AATTAGATAC CACTCTATTT
     GGCAAAAAGT CATCTCCCCT
3541    TACTGAGTCT GGTGGACCTC    TGAGCTTGAG TGAAGAAAAT
    AATGATTCAA AGTTGTTAGA
3601    ATCAGGTTTA ATGAATAGCC    AAGAAAGTTC ATGGGGAAAA
    AATGTATCGT CAACAGAGAG
3661    TGGTAGGTTA TTTAAAGGGA    AAAGAGCTCA TGGACCTGCT
     TTGTTGACTA AAGATAATGC
3721    CTTATTCAAA GTTAGCATCT    CTTTGTTAAA GACAAACAAA
    ACTTCCAATA ATTCAGCAAC
3781    TAATAGAAAG ACTCACATTG    ATGGCCCATC ATTATTAATT
     GAGAATAGTC CATCAGTCTG
3841    GCAAAATATA TTAGAAAGTG    ACACTGAGTT TAAAAAAGTG
    ACACCTTTGA TTCATGACAG
3901    AATGCTTATG GACAAAAATG    CTACAGCTTT GAGGCTAAAT
     CATATGTCAA ATAAAACTAC
3961    TTCATCAAAA AACATGGAAA    TGGTCCAACA GAAAAAAGAG
     GGCCCCATTC CACCAGATGC
4021 ACAAAATCCA GATATGTCGT       TCTTTAAGAT GCTATTCTTG
     CCAGAATCAG CAAGGTGGAT
4(D81   ACAAAGGACT CATGGAAAGA    ACTCTCTGAA CTCTGGGCAA
     GGCCCCAGTC CAAAGCAATT
4141    AGTATCCTTA GGACCAGAAA    AATCTGTGGA AGGTCAGAAT
     TTCTTGTCTG AGAAAAACAA
4201    AGTGGTAGTA GGAAAGGGTG    AATTTACAAA GGACGTAGGA
     CTCAAAGAGA TGGTTTTTCC
426,1   AAGCAGCAGA AACCTATTTC    TTACTAACTT GGATAATTTA
     CATGAAAATA ATACACACAA
4-32.1  TCAAGAAAAA AAAATTCAGG    AAGAAATAGA AAAGAAGGAA
    ACATTAATCC AAGAGAATGT
4381    AGTTTTGCCT CAGATACATA    CAGTGACTGG CACTAAGAAT
     TTCATGAAGA ACCTTTTCTT
4441    ACTGAGCACT AGGCAAAATG    TAGAAGGTTC ATATGACGGG
     GCATATGCTC CAGTACTTCA
4501    AGATTTTAGG TCATTAAATG    ATTCAACAAA TAGAACAAAG
    AAACACACAG CTCATTTCTC
                           - 90-

4561    AAAAAAAGGG GAGGAAGAAA    ACTTGGAAGG CTTGGGAAAT
    CAAACCAAGC AAATTGTAGA
46211   GAAATATGCA TGCACCACAA    GGATATCTCC TAATACAAGC
    CAGCAGAATT TTGTCACGCA
4681    ACGTAGTAAG AGAGCTTTGA    AACAATTCAG ACTCCCACTA
    GAAGAAACAG AACTTGAAAA
 '741   AAGGATAATT GTGGATGACA    CCTCAACCCA GTGGTCCAAA
    AACATGAAAC ATTTGACCCC
4801    GAGCACCCTC ACACAGATAG    ACTACAATGA GAAGGAGAAA
    GGGGCCATTA CTCAGTCTCC
4861    CTTATCAGAT TGCCTTACGA    GGAGTCATAG CATCCCTCAA
    GCAAATAGAT CTCCATTACC
4921    CATTGCAAAG GTATCATCAT    TTCCATCTAT TAGACCTATA
    TATCTGACCA GGGTCCTATT
4931    CCAAGACAAC TCTTCTCATC    TTCCAGCAGC ATCTTATAGA
    AAGAAAGATT CTGGGGTCCA
5041    AGAAAGCAGT CATTTCTTAC    AAGGAGCCAA AAAAAATAAC
    CTTTCTTTAG CCATTCTAAC
5101    CTTGGAGATG ACTGGTGATC    AAAGAGAGGT TGGCTCCCTG
    GGGACAAGTG CCACAAATTC
5161    AGTCACATAC AAGAAAGTTG    AGAACACTGT TCTCCCGAAA
    CCAGACTTGC CCAAAACATC
5221    TGGCAAAGTT GAATTGCTTC    CAAAAGTTCA CATTTATCAG
    AAGGACCTAT TCCCTACGGA
5281    AACTAGCAAT GGGTCTCCTG    GCCATCTGGA TCTCGTGGAA
    GGGAGCCTTC TTCAGGGAAC
 341    AGAGGGAGCG ATTAAGTGGA    ATGAAGCAAA CAGACCTGGA
    AAAGTTCCCT TTCTGAGAGT
5401    AGCAACAGAA AGCTCTGCAA    AGACTCCCTC CAAGCTATTG
    GATCCTCTTG CTTGGGATAA
5461    CCACTATGGT ACTCAGATAC    CAAAAGAAGA GTGGAAATCC
    CAAGAGAAGT CACCAGAAAA
5521    AACAGCTTTT AAGAAAAAGG    ATACCATTTT GTCCCTGAAC
    GCTTGTGAAA GCAATCATGC
5581    AATAGCAGCA ATAAATGAGG    GACAAAATAA GCCCGAAATA
    GAAGTCACCT GGGCAAAGCA
5641    AGGTAGGACT GAAAGGCTGT    GCTCTCAAAA CCCACCAGTC
    TTGAAACGCC ATCAACGGGA
5701    AATAACTCGT ACTACTCTTC    AGTCAGATCA AGAGGAAATT
    GACTATGATG ATACCATATC
5761    AGTTGAAATG AAGAAGGAAG    ATTTTGACAT TTATGATGAG
    GATGAAAATC AGAGCCCCCG
5?21    CAGCTTTCAA AAGAAAACAC    GACACTATTT TATTGCTGCA
    GTGGAGAGGC TCTGGGATTA
5881    TGGGATGAGT AGCTCCCCAC    ATGTTCTAAG AAACAGGGCT
    CAGAGTGGCA GTGTCCCTCA
5941    GTTCAAGAAA GTTGTTTTCC    AGGAATTTAC TGATGGCTCC
    TTTACTCAGC CCTTATACCG
6001    TGGAGAACTA AATGAACATT    TGGGACTCCT GGGGCCATAT
    ATAAGAGCAG AAGTTGAAGA
                           - 91-

6061   TAATATCATG GTAACTTTCA    GAAATCAGGC CTCTCGTCCC
   TATTCCTTCT ATTCTAGCCT
6121   TATTTCTTAT GAGGAAGATC    AGAGGCAAGG AGCAGAACCT
   AGAAAAAACT TTGTCAAGCC
6181   TAATGAAACC AAAACTTACT    TTTGGAAAGT GCAACATCAT
   ATGGCACCCA CTAAAGATGA
6241   GTTTGACTGC AAAGCCTGGG    CTTATTTCTC TGATGTTGAC
   CTGGAAAAAG ATGTGCACTC
6301   AGGCCTGATT GGACCCCTTC    TGGTCTGCCA CACTAACACA
   CTGAACCCTG CTCATGGGAG
6361   ACAAGTGACA GTACAGGAAT    TTGCTCTGTT TTTCACCATC
   TTTGATGAGA CCAAAAGCTG
6421   GTACTTCACT GAAAATATGG    AAAGAAACTG CAGGGCTCCC
   TGCAATATCC AGATGGAAGA
6431   TCCCACTTTT AAAGAGAATT    ATCGCTTCCA TGCAATCAAT
   GGCTACATAA TGGATACACT
6541   ACCTGGCTTA GTAATGGCTC    AGGATCAAAG GATTCGATGG
   TATCTGCTCA GCATGGGCAG
6601   CAATGAAAAC ATCCATTCTA    TTCATTTCAG TGGACATGTG
   TTCACTGTAC GAAAAAAAGA
6661   GGAGTATAAA ATGGCACTGT    ACAATCTCTA TCCAGGTGTT
   TTTGAGACAG TGGAAATGTT
6721   ACCATCCAAA GCTGGAATTT    GGCGGGTGGA ATGCCTTATT
   GGCGAGCATC TACATGCTGG
6781   GATGAGCACA CTTTTTCTGG    TGTACAGCAA TAAGTGTCAG
   ACTCCCCTGG GAATGGCTTC
6841   TGGACACATT AGAGATTTTC    AGATTACAGC TTCAGGACAA
   TATGGACAGT GGGCCCCAAA
6901   GCTGGCCAGA CTTCATTATT    CCGGATCAAT CAATGCCTGG
   AGCACCAAGG AGCCCTTTTC
6961   TTGGATCAAG GTGGATCTGT    TGGCACCAAT GATTATTCAC
   GGCATCAAGA CCCAGGGTGC
7C21   CCGTCAGAAG TTCTCCAGCC    TCTACATCTC TCAGTTTATC
   ATCATGTATA GTCTTGATGG
7081   GAAGAAGTGG CAGACTTATC    GAGGAAATTC CACTGGAACC
   TTAATGGTCT TCTTTGGCAA
  4711 TGTGGATTCA TCTGGGATAA    AACACAATAT TTTTAACCCT
   CCAATTATTG CTCGATACAT
7201   CCGTTTGCAC CCAACTCATT    ATAGCATTCG CAGCACTCTT
   CGCATGGAGT TGATGGGCTG
7261   TGATTTAAAT AGTTGCAGCA    TGCCATTGGG AATGGAGAGT
   AAAGCAATAT CAGATGCACA
7321   GATTACTGCT TCATCCTACT    TTACCAATAT GTTTGCCACC
   TGGTCTCCTT CAAAAGCTCG
7381   ACTTCACCTC CAAGGGAGGA    GTAATGCCTG GAGACCTCAG
   GTGAATAATC CAAAAGAGTG
7441   GCTGCAAGTG GACTTCCAGA    AGACAATGAA AGTCACAGGA
   GTAACTACTC AGGGAGTAAA
7501   ATCTCTGCTT ACCAGCATGT    ATGTGAAGGA GTTCCTCATC
   TCCAGCAGTC AAGATGGCCA
                          - 92-

       7561      TCAGTGGACT CTCTTTTTTC AGAATGGCAA AGTAAAGGTT
            TTTCAGGGAA ATCAAGACTC
       7621      CTTCACACCT GTGGTGAACT CTCTAGACCC ACCGTTACTG
           ACTCGCTACC TTCGAATTCA
       7681      CCCCCAGAGT TGGGTGCACC AGATTGCCCT GAGGATGGAG
            GTTCTGGGCT GCGAGGCACA
       7741      GGACCTCTAC
        *The underlined nucleic acids encode a signal peptide.
[0171]          FVIII polypeptides include full-length FVIII, full-length FVIII minus Met
        at the N-terminus, mature FVIII (minus the signal sequence), mature FVIII with
        an additional Met at the N-terminus, and/or FVIII with a full or partial deletion of
        the B domain. In certain embodiments, FVIII variants include B domain
        deletions, whether partial or full deletions.
[0172]          The sequence of native mature human FVIII is presented as SEQ ID NO:
        4. A native FVIII protein has the following formula: Al-al-A2-a2-B-a3-A3-C1
        C2, where Al, A2, and A3 are the structurally-related "A domains," B is the "B
        domain," Cl and C2 are the structurally-related "C domains," and al, a2 and a3
        are acidic spacer regions. Referring to the primary amino acid sequence position
        in SEQ ID NO:4, the Al domain of human FVIII extends from Alal to about
        Arg336, the al spacer region extends from about Met337 to about Val374, the A2
        domain extends from about Ala375 to about Tyr719, the a2 spacer region extends
        from about Glu720 to about Arg740, the B domain extends from about Ser741 to
        about Arg 1648, the a3 spacer region extends from about Glu1649 to about
        Arg1689, the A3 domain extends from about Ser1690 to about Leu2025, the Cl
        domain extends from about Gly2026 to about Asn2072, and the C2 domain
        extends from about Ser2073 to Tyr2332. Other than specific proteolytic cleavage
        sites, designation of the locations of the boundaries between the domains and
        regions of FVIII can vary in different literature references. The boundaries noted
        herein are therefore designated as approximate by use of the term "about."
[0173]          The human FVIII gene was isolated and expressed in mammalian cells
        (Toole, J. J., et al., Nature 312:342-347 (1984); Gitschier, J., et al., Nature
        312:326-330 (1984); Wood, W. I., et al., Nature 312:330-337 (1984); Vehar, G.
        A., et al., Nature 312:337-342 (1984); WO 87/04187; WO 88/08035; WO
        88/03558; and U.S. Pat. No. 4,757,006). The FVIII amino acid sequence was
                                              - 93 -

       deduced from cDNA as shown in U.S. Pat. No. 4,965,199. In addition, partially or
       fully B-domain deleted FVIII is shown in U.S. Pat. Nos. 4,994,371 and 4,868,112.
       In some embodiments, the human FVIII B-domain is replaced with the human
       Factor V B-domain as shown in U.S. Pat. No. 5,004,803. The cDNA sequence
       encoding human Factor VIII and amino acid sequence are shown in SEQ ID NOs:
       4 and 5, respectively, of US Application Publ. No. 2005/0100990.
[0174]         The porcine FVIII sequence is published in Toole, J. J., et al., Proc.Nati.
       Acad. Sci. USA 83:5939-5942 (1986). Further, the complete porcine cDNA
       sequence obtained from PCR amplification of FVIII sequences from a pig spleen
       cDNA library has been reported in Healey, J. F., et al., Blood 88:4209-4214
       (1996). Hybrid human/porcine FVIII having substitutions of all domains, all
       subunits, and specific amino acid sequences were disclosed in U.S. Pat. No.
       5,364,771 by Lollar and Runge, and in WO 93/20093. More recently, the
       nucleotide and corresponding amino acid sequences of the Al and A2 domains of
       porcine FVIII and a chimeric FVIII with porcine Al and/or A2 domains
       substituted for the corresponding human domains were reported in WO 94/11503.
       U.S. Pat. No. 5,859,204, Lollar, J. S., also discloses the porcine cDNA and
       deduced amino acid sequences. U.S. Pat. No. 6,458,563 discloses a B-domain
       deleted porcine FVIII.
[0175]         U.S. Pat. No. 5,859,204 to Lollar, J. S. reports functional mutants of FVIII
       having reduced antigenicity and reduced immunoreactivity. U.S. Pat. No.
       6,376,463 to Lollar, J. S. also reports mutants of FVIII having reduced
       immunoreactivity. US Appl. Publ. No. 2005/0100990 to Saenko et al. reports
       functional mutations in the A2 domain of FVIII.
[0176]         In one embodiment, the FVIII (or FVIII portion of a chimeric protein) may
       be at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%
       identical to a FVIII amino acid sequence of amino acids 1 to 1438 of SEQ ID NO:
       6 or amino acids I to 2332 of SEQ ID NO: 4 (without a signal sequence) or a
       FVIII amino acid sequence of amino acids I to 19 of SEQ ID NO: 3 and I to 1438
       of SEQ ID NO: 6 or amino acids I to 19 of SEQ ID NO: 3 and amino acids I to
       2332 of SEQ ID NO: 4 (with a signal sequence), wherein the FVIII has a clotting
       activity, e.g., activates Factor IX as a cofactor to convert Factor X to activated
       Factor X. The FVIII (or FVIII portion of a chimeric protein) may be identical to a
                                             - 94 -

       FVIII amino acid sequence of amino acids 1 to 1438 of SEQ ID NO: 6 or amino
       acids 1 to 2332 of SEQ ID NO: 4 (without a signal sequence). The FVIII may
       further comprise a signal sequence.
[0177]         The "B-domain" of FVIII, as used herein, is the same as the B-domain
       known in the art that is defined by internal amino acid sequence identity and sites
       of proteolytic cleavage, e.g., residues Ser741-Arg1648 of full-length human FVIII.
       The other human FVIII domains are defined by the following amino acid residues:
       Al, residues Alal-Arg372; A2, residues Ser373-Arg740; A3, residues Ser1690
       Asn2019; C1, residues Lys2020-Asn2172; C2, residues Ser2173-Tyr2332. The
       A3-C1-C2 sequence includes residues Serl690-Tyr2332. The remaining sequence,
       residues Glul649-Arg1689, is usually referred to as the a3 acidic region. The
       locations of the boundaries for all of the domains, including the B-domains, for
       porcine, mouse and canine FVIII are also known in the art. In one embodiment,
       the B domain of FVIII is deleted ("B-domain-deleted factor VIII" or "BDD
       FVIII"). An example of a BDD FVIII is REFACTO* (recombinant BDD FVIII),
       which has the same sequence as the Factor VIII portion of the sequence in Table
       5. (BDD FVIII heavy chain is double underlined; B domain is italicized; and
       BDD FVIII light chain is in plain text). A nucleotide sequence encoding the
       amino acid sequence set forth in Table 5 (SEQ ID NO: 7) is shown in Table 6.
       TABLE 5. Amino Acid Sequence of B-domain Deleted Factor VIII (BDD
FVIII)
       BDD FVIII (SEQ ID NO: 6)
       A TRRYY LGAVE L S WDYMQS DL GE LPVDAR FPPPRVPKS F P FNT SVVYKKTLPj' VE IT
       DLF NIAKP_RPPW       MGLLPTQAEVYDTV
                       R PPVSLH                  L      TL
                                                      I 1KNMAS,'         I-IAVGVSYWKASE
       CAE YDDQ TSOREKEDDKVF P' G S,HTYVWQVLKENG PMAS D 'l LT YL S-VDLV
       KD NS.GITGALLVCREG S'AKEKTQT HKFT, L                 A.VFDE GK' JFSETKNS-' QDR
       DAA.SARAWPKMHTVNGVNR S{ D-               (G3-GRKSVYWHIGTGT-PEVHS         IE    G T
       EL VR\ITIRIQASTEIS PI TET TAQTLM DLGQELLECI1               S
       EEPQ RMKNNE EAEDYDDDLT DSE iDVVR FDDDNSP SFIQIRSVAKKH PK TWVH Y
         AAEEEDWDYA P:LV .A'PDDR- YKSQY LNNG PQRIIGRKYKKVR FMAY T DETFK'T'RE
       AI Q"HE S G I'L      YG E    DT L JIiF                  P CYT DVRILYS' RLKGV
                                                   -. Kib'KNOASRPYN
                                                            -HG'I
       KHTKDF IPGE IFFKW'V'TVE DGPKS          P      D R(CRVYS S FNMERDLASGG , G
         IICYKE SVDQGN--_      IS  DKIRNyJIlI FSVFDENERSWYJ'_TEN! QERPNAG',Q70 E
       PEFQaYSNIM1S INGYVFDSLQLSVCLI---EVAYWYILS IGAQTDFLSVFFSGYTFK 7
       KMVYE DL  TLTLFPFS GE TVFMSMEN PGL W I L GCI- NS DFRNRGMTAL LKVS SC DKNT
       CDYYEDSYEDISAYLLSKNNAIEPRS.QNPEWL4KCOREITRTTLQSDQEEIDY
       DDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLR
                                            - 95 -

 NRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVT
  FRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDE
  FDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFD
 ETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQR
  IRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAG
  IWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPK
  LARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIM
  YSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIR
  STLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQG
 RSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGH
  QWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVL
  GCEAQDLY
 TABLE 6. Nucleotide Sequence Encoding BDD FVIII (SEQ ID NO: 7)*
  661                                         A TGCAAATAGA
    GCTCTCCACC TGCTTCTTTC
  721   TGTGCCTTTT GCGATTCTGC        TTTAGTGCCA CCAGAAGATA
    CTACCTGGGT GCAGTGGAAC
  781   TGTCATGGGA CTATATGCAA        AGTGATCTCG GTGAGCTGCC
    TGTGGACGCA AGATTTCCTC
  841   CTAGAGTGCC AAAATCTTTT        CCATTCAACA CCTCAGTCGT
    GTACAAAAAG ACTCTGTTTG
  901   TAGAATTCAC GGATCACCTT        TTCAACATCG CTAAGCCAAG
    GCCACCCTGG ATGGGTCTGC
  961   TAGGTCCTAC CATCCAGGCT        GAGGTTTATG ATACAGTGGT
    CATTACACTT AAGAACATGG
1.021   CTTCCCATCC TGTCAGTCTT        CATGCTGTTG GTGTATCCTA
    CTGGAAAGCT TCTGAGGGAG
1081    CTGAATATGA TGATCAGACC        AGTCAAAGGG AGAAAGAAGA
    TGATAAAGTC TTCCCTGGTG
1141    GAAGCCATAC ATATGTCTGG        CAGGTCCTGA AAGAGAATGG
    TCCAATGGCC TCTGACCCAC
1201    TGTGCCTTAC CTACTCATAT        CTTTCTCATG TGGACCTGGT
    AAAAGACTTG AATTCAGGCC
1261    TCATTGGAGC CCTACTAGTA        TGTAGAGAAG GGAGTCTGGC
    CAAGGAAAAG ACACAGACCT
1.321 TGCACAAATT TATACTACTT          TTTGCTGTAT TTGATGAAGG
    GAAAAGTTGG CACTCAGAAA
1.381   CAAAGAACTC CTTGATGCAG        GATAGGGATG CTGCATCTGC
    TCGGGCCTGG CCTAAAATGC
14Z.41 ACACAGTCAA TGGTTATGTA         AACAGGTCTC TGCCAGGTCT
    GATTGGATGC CACAGGAAAT
1501    CAGTCTATTG GCATGTGATT        GGAATGGGCA CCACTCCTGA
    AGTGCACTCA ATATTCCTCG
1561   AAGGTCACAC ATTTCTTGTG         AGGAACCATC GCCAGGCGTC
    CTTGGAAATC TCGCCAATAA
1621    CTTTCCTTAC TGCTCAAACA        CTCTTGATGG ACCTTGGACA
    GTTTCTACTG TTTTGTCATA
                               - 96-

1681    TCTCTTCCCA CCAACATGAT    GGCATGGAAG CTTATGTCAA
    AGTAGACAGC TGTCCAGAGG
1741    AACCCCAACT ACGAATGAAA    AATAATGAAG AAGCGGAAGA
    CTATGATGAT GATCTTACTG
1801    ATTCTGAAAT GGATGTGGTC    AGGTTTGATG ATGACAACTC
    TCCTTCCTTT ATCCAAATTC
1861    GCTCAGTTGC CAAGAAGCAT    CCTAAAACTT GGGTACATTA
    CATTGCTGCT GAAGAGGAGG
1921    ACTGGGACTA TGCTCCCTTA    GTCCTCGCCC CCGATGACAG
    AAGTTATAAA AGTCAATATT
1.981   TGAACAATGG CCCTCAGCGG    ATTGGTAGGA AGTACAAAAA
    AGTCCGATTT ATGGCATACA
2041    CAGATGAAAC CTTTAAGACT    CGTGAAGCTA TTCAGCATGA
    ATCAGGAATC TTGGGACCTT
2101    TACTTTATGG GGAAGTTGGA    GACACACTGT TGATTATATT
    TAAGAATCAA GCAAGCAGAC
2161    CATATAACAT CTACCCTCAC    GGAATCACTG ATGTCCGTCC
    TTTGTATTCA AGGAGATTAC
2221    CAAAAGGTGT AAAACATTTG    AAGGATTTTC CAATTCTGCC
    AGGAGAAATA TTCAAATATA
2281    AATGGACAGT GACTGTAGAA    GATGGGCCAA CTAAATCAGA
    TCCTCGGTGC CTGACCCGCT
2341    ATTACTCTAG TTTCGTTAAT    ATGGAGAGAG ATCTAGCTTC
    AGGACTCATT GGCCCTCTCC
2401    TCATCTGCTA CAAAGAATCT    GTAGATCAAA GAGGAAACCA
    GATAATGTCA GACAAGAGGA
2461    ATGTCATCCT GTTTTCTGTA    TTTGATGAGA ACCGAAGCTG
    GTACCTCACA GAGAATATAC
2521    AACGCTTTCT CCCCAATCCA    GCTGGAGTGC AGCTTGAGGA
    TCCAGAGTTC CAAGCCTCCA
2581    ACATCATGCA CAGCATCAAT    GGCTATGTTT TTGATAGTTT
    GCAGTTGTCA GTTTGTTTGC
2641    ATGAGGTGGC ATACTGGTAC    ATTCTAAGCA TTGGAGCACA
    GACTGACTTC CTTTCTGTCT
2701    TCTTCTCTGG ATATACCTTC    AAACACAAAA TGGTCTATGA
    AGACACACTC ACCCTATTCC
2761    CATTCTCAGG AGAAACTGTC    TTCATGTCGA TGGAAAACCC
    AGGTCTATGG ATTCTGGGGT
2821    GCCACAACTC AGACTTTCGG    AACAGAGGCA TGACCGCCTT
    ACTGAAGGTT TCTAGTTGTG
2881    ACAAGAACAC TGGTGATTAT    TACGAGGACA GTTATGAAGA
    TATTTCAGCA TACTTGCTGA
2941    GTAAAAACAA TGCCATTGAA    CCAAGAAGCT TCTCTCAAAA
    CCCACCAGTC TTGAAACGCC
3001    ATCAACGGGA AATAACTCGT    ACTACTCTTC AGTCAGATCA
    AGAGGAAATT GACTATGATG
3061    ATACCATATC AGTTGAAATG    AAGAAGGAAG ATTTTGACAT
    TTATGATGAG GATGAAAATC
3121    AGAGCCCCCG CAGCTTTCAA    AAGAAAACAC GACACTATTT
    TATTGCTGCA GTGGAGAGGC
                           - 97-

3181     TCTGGGATTA TGGGATGAGT    AGCTCCCCAC ATGTTCTAAG
    AAACAGGGCT CAGAGTGGCA
3241     GTGTCCCTCA GTTCAAGAAA    GTTGTTTTCC AGGAATTTAC
    TGATGGCTCC TTTACTCAGC
3301     CCTTATACCG TGGAGAACTA    AATGAACATT TGGGACTCCT
    GGGGCCATAT ATAAGAGCAG
3361     AAGTTGAAGA TAATATCATG    GTAACTTTCA GAAATCAGGC
    CTCTCGTCCC TATTCCTTCT
3421     ATTCTAGCCT TATTTCTTAT    GAGGAAGATC AGAGGCAAGG
    AGCAGAACCT AGAAAAAACT
3481     TTGTCAAGCC TAATGAAACC    AAAACTTACT TTTGGAAAGT
    GCAACATCAT ATGGCACCCA
3541     CTAAAGATGA GTTTGACTGC    AAAGCCTGGG CTTATTTCTC
    TGATGTTGAC CTGGAAAAAG
3601     ATGTGCACTC AGGCCTGATT    GGACCCCTTC TGGTCTGCCA
    CACTAACACA CTGAACCCTG
3661     CTCATGGGAG ACAAGTGACA    GTACAGGAAT TTGCTCTGTT
    TTTCACCATC TTTGATGAGA
3721     CCAAAAGCTG GTACTTCACT    GAAAATATGG AAAGAAACTG
    CAGGGCTCCC TGCAATATCC
3781     AGATGGAAGA TCCCACTTTT    AAAGAGAATT ATCGCTTCCA
    TGCAATCAAT GGCTACATAA
3841     TGGATACACT ACCTGGCTTA    GTAATGGCTC AGGATCAAAG
    GATTCGATGG TATCTGCTCA
3901     GCATGGGCAG CAATGAAAAC    ATCCATTCTA TTCATTTCAG
    TGGACATGTG TTCACTGTAC
3961     GAAAAAAAGA GGAGTATAAA    ATGGCACTGT ACAATCTCTA
    TCCAGGTGTT TTTGAGACAG
4021     TGGAAATGTT ACCATCCAAA    GCTGGAATTT GGCGGGTGGA
    ATGCCTTATT GGCGAGCATC
     .81 TACATGCTGG GATGAGCACA    CTTTTTCTGG TGTACAGCAA
    TAAGTGTCAG ACTCCCCTGG
4141     GAATGGCTTC TGGACACATT    AGAGATTTTC AGATTACAGC
    TTCAGGACAA TATGGACAGT
4201     GGGCCCCAAA GCTGGCCAGA    CTTCATTATT CCGGATCAAT
    CAATGCCTGG AGCACCAAGG
4261     AGCCCTTTTC TTGGATCAAG    GTGGATCTGT TGGCACCAAT
    GATTATTCAC GGCATCAAGA
4321     CCCAGGGTGC CCGTCAGAAG    TTCTCCAGCC TCTACATCTC
    TCAGTTTATC ATCATGTATA
4381     GTCTTGATGG GAAGAAGTGG    CAGACTTATC GAGGAAATTC
    CACTGGAACC TTAATGGTCT
4441     TCTTTGGCAA TGTGGATTCA    TCTGGGATAA AACACAATAT
    TTTTAACCCT CCAATTATTG
'501     CTCGATACAT CCGTTTGCAC    CCAACTCATT ATAGCATTCG
    CAGCACTCTT CGCATGGAGT
4561     TGATGGGCTG TGATTTAAAT    AGTTGCAGCA TGCCATTGGG
    AATGGAGAGT AAAGCAATAT
4621     CAGATGCACA GATTACTGCT    TCATCCTACT TTACCAATAT
    GTTTGCCACC TGGTCTCCTT
                            - 98-

       4681       CAAAAGCTCG ACTTCACCTC                CAAGGGAGGA GTAATGCCTG
           GAGACCTCAG GTGAATAATC
       4741       CAAAAGAGTG GCTGCAAGTG                GACTTCCAGA        AGACAATGAA
           AGTCACAGGA GTAACTACTC
       4O1        AGGGAGTAAA ATCTCTGCTT                ACCAGCATGT        ATGTGAAGGA
           GTTCCTCATC TCCAGCAGTC
        S861      AAGATGGCCA TCAGTGGACT                CTCTTTTTTC        AGAATGGCAA
           AGTAAAGGTT TTTCAGGGAA
       4921       ATCAAGACTC CTTCACACCT                GTGGTGAACT        CTCTAGACCC
           ACCGTTACTG ACTCGCTACC
       4981       TTCGAATTCA CCCCCAGAGT                TGGGTGCACC        AGATTGCCCT
           GAGGATGGAG GTTCTGGGCT
        50)       GCGAGGCACA GGACCTCTAC
        *The underlined nucleic acids encode a signal peptide.
[0178]            A "B-domain-deleted FVIII" may have the full or partial deletions
        disclosed in U.S. Pat. Nos. 6,316,226, 6,346,513, 7,041,635, 5,789,203, 6,060,447,
        5,595,886, 6,228,620, 5,972,885, 6,048,720, 5,543,502, 5,610,278, 5,171,844,
        5,112,950, 4,868,112, and 6,458,563. In some embodiments, a B-domain-deleted
        FVIII sequence of the present invention comprises any one of the deletions
        disclosed at col. 4, line 4 to col. 5, line 28 and Examples 1-5 of U.S. Pat. No.
        6,316,226 (also in US 6,346,513). In another embodiment, a B-domain deleted
        Factor VIII is the S743/Q1638 B-domain deleted Factor VIII (SQ BDD FVIII)
        (e.g., Factor VIII having a deletion from amino acid 744 to amino acid 1637, e.g.,
        Factor VIII having amino acids 1-743 and amino acids 1638-2332 of SEQ ID NO:
        4, i.e., SEQ ID NO: 6). In some embodiments, a B-domain-deleted FVIII of the
        present invention has a deletion disclosed at col. 2, lines 26-51 and examples 5-8
        of U.S. Patent No. 5,789,203 (also US 6,060,447, US 5,595,886, and US
        6,228,620). In some embodiments, a B-domain-deleted Factor VIII has a deletion
        described in col. 1, lines 25 to col. 2, line 40 of US Patent No. 5,972,885; col. 6,
        lines 1-22 and example 1 of U.S. Patent no. 6,048,720; col. 2, lines 17-46 of U.S.
        Patent No. 5,543,502; col. 4, line 22 to col. 5, line 36 of U.S. Patent no. 5,171,844;
        col. 2, lines 55-68, figure 2, and example 1 of U.S. Patent No. 5,112,950; col. 2,
        line 2 to col. 19, line 21 and table 2 of U.S. Patent No. 4,868,112; col. 2, line I to
        col. 3, line 19, col. 3, line 40 to col. 4, line 67, col. 7, line 43 to col. 8, line 26, and
        col. 11, line 5 to col. 13, line 39 of U.S. Patent no. 7,041,635; or col. 4, lines 25
        53, of U.S. Patent No. 6,458,563. In some embodiments, a B-domain-deleted
        FVIII has a deletion of most of the B domain, but still contains amino-terminal
                                                - 99 -

       sequences of the B domain that are essential for in vivo proteolytic processing of
       the primary translation product into two polypeptide chain, as disclosed in WO
       91/09122. In some embodiments, a B-domain-deleted FVIII is constructed with a
       deletion of amino acids 747-1638, i.e., virtually a complete deletion of the B
       domain. Hoeben R.C., et al. J. Biol. Chem. 265 (13): 7318-7323 (1990). A B
       domain-deleted Factor VIII may also contain a deletion of amino acids 771-1666
       or amino acids 868-1562 of FVIII. Meulien P., et al. ProteinEng. 2(4): 301-6
       (1988). Additional B domain deletions that are part of the invention include:
       deletion of amino acids 982 through 1562 or 760 through 1639 (Toole et al., Proc.
       Natl. Acad. Sci. U.S.A. (1986) 83, 5939-5942)), 797 through 1562 (Eaton, et al.
       Biochemistry (1986) 25:8343-8347)), 741 through 1646 (Kaufman (PCT
       published application No. WO 87/04187)), 747-1560 (Sarver, et al., DNA (1987)
       6:553-564)), 741 through 1648 (Pasek (PCT application No.88/00831)), or 816
       through 1598 or 741 through 1648 (Lagner (Behring Inst. Mitt. (1988) No 82:16
       25, EP 295597)). In other embodiments, BDD FVIII includes a FVIII polypeptide
       containing fragments of the B-domain that retain one or more N-linked
       glycosylation sites, e.g., residues 757, 784, 828, 900, 963, or optionally 943,
       which correspond to the amino acid sequence of the full-length FVIII sequence.
       Examples of the B-domain fragments include 226 amino acids or 163 amino acids
       of the B-domain as disclosed in Miao, H.Z., et al., Blood 103(a): 3412-3419
       (2004), Kasuda, A, et al., J. Thromb. Haemost. 6: 1352-1359 (2008), and Pipe,
       S.W., et al., J. Thromb. Haemost. 9: 2235-2242 (2011) (i.e., the first 226 amino
       acids or 163 amino acids of the B domain are retained). In still other
       embodiments, BDD FVIII further comprises a point mutation at residue 309 (from
       Phe to Ser) to improve expression of the BDD FVIII protein. See Miao, H.Z., et
       al., Blood 103(a): 3412-3419 (2004). In still other embodiments, the BDD FVIII
       includes a FVIII polypeptide containing a portion of the B-domain, but not
       containing one or more furin cleavage sites (e.g., Arg1313 and Arg 1648). See
       Pipe, S.W., et al., J. Thromb. Haemost. 9: 2235-2242 (2011). Each of the
       foregoing deletions may be made in any FVIII sequence.
[0179]         In some embodiments, the FVIII has a partial B-domain. In some
       embodiments, the FVIII protein with a partial B-domain is FVIII198 (SEQ ID
       NO: 89). FV111198 is a partial B-domain containing single chain FVIIIFc
                                            - 100 -

       molecule-226N6. 226 represents the N-terminus 226 amino acid of the FVIII B
       domain, and N6 represents six N-glycosylation sites in the B-domain.
[01801         In one embodiment, FVIII is cleaved right after arginine at amino acid
       1648 (in full-length Factor VIII or SEQ ID NO: 4), amino acid 754 (in the
       S743/Q1638 B-domain deleted Factor VIII or SEQ ID NO: 6), or the
       corresponding arginine residue (in other variants), thereby resulting in a heavy
       chain and a light chain. In another embodiment, FVIII comprises a heavy chain
       and a light chain, which are linked or associated by a metal ion-mediated non
       covalent bond.
[01811         In other embodiments, FVIII is a single chain FVIII that has not been
       cleaved right after Arginine at amino acid 1648 (in full-length FVIII or SEQ ID
       NO: 4), amino acid 754 (in the S743/Q1638 B-domain-deleted FVIII or SEQ ID
       NO: 6), or the corresponding Arginine residue (in other variants). A single chain
       FVIII may comprise one or more amino acid substitutions. In one embodiment,
       the amino acid substitution is at a residue corresponding to residue 1648, residue
       1645, or both of full-length mature Factor VIII polypeptide (SEQ ID NO: 4) or
       residue 754, residue 751, or both of SQ BDD Factor VIII (SEQ ID NO: 6). The
       amino acid substitution can be any amino acids other than arginine, e.g.,
       isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan,
       valine, alanine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine,
       glycine, proline, selenocysteine, serine, tyrosine, histidine, ornithine, pyrrolysine,
       or taurine.
[0182]         FVIII can further be cleaved by thrombin and then activated as FVIIIa,
       serving as a cofactor for activated Factor IX (FIXa). And the activated FIX
       together with activated FVIII forms a Xase complex and converts Factor X to
       activated Factor X (FXa). For activation, FVIII is cleaved by thrombin after three
       Arginine residues, at amino acids 372, 740, and 1689 (corresponding to amino
       acids 372, 740, and 795 in the B-domain deleted FVIII sequence), the cleavage
       generating FVIIIa having the 50kDa Al, 43kDa A2, and 73kDa A3-C1-C2 chains.
       In one embodiment, the FVIII protein useful for the present invention is non
       active FVIII. In another embodiment, the FVIII protein is an activated FVIII.
[01831         The protein having FVIII polypeptide linked to or associated with the
       VWF fragment can comprise a sequence at least 50%, 60%, 70%, 80%, 90%,
                                           - 101  -

       95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 4 or 6, wherein the
       sequence has the FVIII clotting activity, e.g., activating Factor IX as a cofactor to
       convert Factor X to activated Factor X (FXa).
[0184]          "Hybrid" or "chimeric" polypeptides and proteins, as used herein, includes
       a combination of a first polypeptide chain, e.g., the VWF fragment, optionally
       fused to a first Ig constant region or a portion thereof, with a second polypeptide
       chain, e.g., a FVIII protein linked to an XTEN sequence, optionally fused to a
       second Ig constant region or a portion thereof, thereby forming a heterodimer. In
       one embodiment, the first polypeptide and the second polypeptide in a hybrid are
       associated with each other via protein-protein interactions, such as charge-charge
       or hydrophobic interactions. In another embodiment, the first polypeptide and the
       second polypeptide in a hybrid are associated with each other via disulfide or
       other covalent bond(s). Hybrids are described, for example, in US 2004/101740
       and US 2006/074199. The second polypeptide may be an identical copy of the
       first polypeptide or a non-identical polypeptide. In one embodiment, the first
       polypeptide is a FVIII protein(X)-Fc fusion protein, and the second polypeptide is
       a polypeptide comprising, consisting essentially of, or consisting of an Fc region,
       wherein the first polypeptide and the second polypeptide are associated with each
       other. In another embodiment, the first polypeptide comprises a VWF fragment
       XTEN-Fc fusion protein, and the second polypeptide comprises FVIII-Fc fusion
       protein, making the hybrid a heterodimer. In other embodiments, the first
       polypeptide comprises a VWF fragment-Fc fusion protein, and the second
       polypeptide comprises FVIII(X)-Fc fusion protein, making the hybrid a
       heterodimer. In yet other embodiments, the first polypeptide comprises a VWF
       fragment-XTEN-Fc fusion protein, and the second polypeptide comprises
       FVIII(X)-Fc fusion protein. The first polypeptide and the second polypeptide can
       be associated through a covalent bond, e.g., a disulfide bond, between the first Fc
       region and the second Fc region. The first polypeptide and the second polypeptide
       can further be associated with each other by binding between the VWF fragment
       and the FVIII protein.
[0185]          A FVIII protein useful in the present invention can include FVIII having
       one or more additional XTEN sequences, which do not affect the FVIII
       coagulation activity. Such XTEN sequences can be fused to the C-terminus or N
                                            - 102 -

       terminus of the FVIII protein or inserted between one or more of the two amino
       acid residues in the FVIII protein wherein the insertions do not affect the FVIII
       coagulation activity or FVIII function. In one embodiment, the insertions improve
       pharmacokinetic properties of the FVIII protein (e.g., half-life). In another
       embodiment, the insertions can be multiple insertions, e.g., more than two, three,
       four, five, six, seven, eight, nine, or ten insertions. Examples of the insertion sites
       include, but are not limited to, the sites listed in Tables 7, 8, 9, 10, 11, 12, 13, 14,
       15 or any combinations thereof.
[01861          The FVIII protein linked to one or more XTEN sequences can be
       represented as FVIII(X), FVIII(X1), FVIII(a-)-X-FVIII(c-d),wherein FVIII(a,-b)
       comprises, consists essentially of, or consists of a first portion of a FVIII protein
       from amino acid residue "a" to amino acid residue "b";X or X1 comprises,
       consists essentially of, or consists of one or more XTEN sequences, FVIII(c-d)
       comprises, consists essentially of, or consists of a second portion of a FVIII
       protein from amino acid residue "c" to amino acid residue "d";
       a is the N-terminal amino acid residue of the first portion of the FVIII protein,
       b is the C-terminal amino acid residue of the first portion of the FVIII protein but
       is also the N-terminal amino acid residue of the two amino acids of an insertion
       site in which the XTEN sequence is inserted,
       c is the N-terminal amino acid residue of the second portion of the FVIII protein
       but is also the C-terminal amino acid residue of the two amino acids of an
       insertion site in which the XTEN sequence is inserted, and
       d is the C-terminal amino acid residue of the FVIII protein, and
       wherein the first portion of the FVIII protein and the second portion of the FVIII
       protein are not identical to each other and are of sufficient length together such
       that the FVIII protein has a FVIII coagulation activity.
[0187]          In one embodiment, the first portion of the FVIII protein and the second
       portion of the FVIII protein are fragments of SEQ ID NO: 4 [full length mature
       FVIII sequence] or SEQ ID NO: 6 [B-domain deleted FVIII], e.g., N-terminal
       portion and C-terminal portion, respectively. In certain embodiments, the first
       portion of the FVIII protein comprises the Al domain and the A2 domain of the
       FVIII protein. The second portion of the FVIII protein comprises the A3 domain,
       the Cl domain, and optionally the C2 domain. In yet other embodiments, the first
                                             - 103  -

       portion of the FVIII protein comprises the Al domain and A2 domain, and the
       second portion of the FVIII protein comprises a portion of the B domain, the A3
       domain, the Cl domain, and optionally the C2 domain. In still other
       embodiments, the first portion of the FVIII protein comprises the Al domain, A2
       domain, and a portion of the B domain of the FVIII protein, and the second
       portion of the FVIII protein comprises the A3 domain, the Cl domain, and
       optionally the C2 domain. In still other embodiments, the first portion of the
       FVIII protein comprises the Al domain, A2 domain, and a first portion of the B
       domain of the FVIII protein. The second portion of the FVIII protein comprises a
       second portion of the B domain, the A3 domain, the Cl domain, and optionally
       the C2 domain. In some embodiments, the two amino acids ("b" and "c") can be
       any one or more of the amino acid residues insertion sites shown in Tables 7, 8, 9,
       10, 11, 12, 13, 14, and 15. For example, "b" can be the amino acid residue
       immediately upstream of the site in which one or more XTEN sequences are
       inserted or linked, and "c" can be the amino acid residue immediately downstream
       of the site in which the one or more XTEN sequences are inserted or linked. In
       some embodiments, "a" is the first mature amino acid sequence of a FVIII protein,
       and "d" is the last amino acid sequence of a FVIII protein. For example,
       FVIII(a,-) can be an amino acid sequence at least 70%, 80%, 90%, 95%, 96%,
       97%, 98%, 99%, or 100% identical to amino acids I to 745 of SEQ ID NO: 6 [B
       domain deleted FVIII amino acid sequence] or SEQ ID NO: 4 [full length FVIII]
       and FVIII(,-d) can be amino acids 746 to 1438 of SEQ ID NO: 6 or amino acids
       1641 to 2332 of SEQ ID NO: 4, respectively.
[01881         In some aspects, the insertion site in the FVIII protein is located in one or
       more domains of the FVIII protein, which is the N-terminus, the Al domain, the
       A2 domain, the A3 domain, the B domain, the Cl domain, the C2 domain, the C
       terminus, or two or more combinations thereof or between two domains of the
       FVIII protein, which are the Al domain and al acidic region, and the al acidic
       region and A2 domain, the A2 domain and a2 acidic region, the a2 acidic region
       and B domain, the B domain and A3 domain, and the A3 domain and Cl domain,
       the Cl domain and C2 domain, or any combinations thereof. For example, the
       insertion sites in which the XTEN sequence can be inserted are selected from the
       group consisting of the N-terminus and Al domain, the N-terminus and A2
                                           - 104 -

       domain, the N-terminus and A3 domain, the N-terminus and B domain, the N
       terminus and C1 domain, the N-terminus and C2 domain, the N-terminus and the
       C-terminus, the Al and A2 domains, the Al and A3 domains, the Al and B
       domains, the Al and C1 domains, the Al and C2 domains, the Al domain and the
       C-terminus, the A2 and A3 domains, the A2 and B domains, the A2 and C1
       domains, the A2 and C2 domains, the A2 domain and the C-terminus, the A3 and
       B domains, the A3 and C1 domains, the A3 and C2 domains, the A3 domain and
       the C-terminus, the B and C1 domains, the B and C2 domains, the B domain and
       the C-terminus, the C1 and C2 domains, the C1 and the C-terminus, the C2
       domain, and the C-terminus, and two or more combinations thereof Non-limiting
       examples of the insertion sites are listed in Tables 7, 8, 9, 10, 11, 12, 13, 14, and
       15.
[01891          The FVIII protein, in which the XTEN sequence is inserted immediately
       downstream of one or more amino acids (e.g., one or more XTEN insertion sites)
       in the FVIII protein or linked at the C-terminus or the N-terminus, retains the
       FVIII activity after linkage to or insertion by the XTEN sequence. The XTEN
       sequence can be inserted in the FVIII protein once or more than once, twice, three
       times, four times, five times, or six times such that the insertions do not affect the
       FVIII activity (i.e., the FVIII protein still retains the coagulation property).
[0190]          The FVIII protein useful in the present invention can be linked to one or
       more XTEN polypeptides at the N-terminus or C-terminus of the FVIII protein by
       an optional linker or inserted immediately downstream of one or more amino acids
       (e.g., one or more XTEN insertion sites) in the FVIII protein by one or more
       optional linkers. In one embodiment, the two amino acid residues in which the
       XTEN sequence is inserted or the amino acid residue to which the XTEN
       sequence is linked correspond to the two or one amino acid residues of SEQ ID
       NO: 4 [full length mature FVIII] selected from the group consisting of the
       residues in Table 7, Table 8, Table 9, and Table 10 and any combinations thereof.
[0191]          In other embodiments, at least one XTEN sequence is inserted in any one
       or more XTEN insertion sites disclosed herein or any combinations thereof. In
       one aspect, at least one XTEN sequence is inserted in one or more XTEN insertion
       sites disclosed in one or more amino acids disclosed in Table 7.
                                            - 105  -

TABLE 7: Exemplary XTEN Insertion Sites
            XTEN      Insertion       FVIII BDD FVIII Domain
  No.      Insertion   Residue       Downstream
            Point*                     Sequence
    1          0         (N-             ATR         Al
                      terminus)
    2          3          R              RYY         Al
    3          17         M              QSD         Al
    4          18         Q              SDL         Al
    5         22          G              ELP         Al
    6         24          L              PVD         Al
    7         26          V              DAR         Al
    8         28          A              RFP         Al
    9         32          P              RVP         Al
   10         38          F              PFN         Al
   11         40          F              NTS         Al
   12         41          N              TSV         Al
   13         60          N              IAK         Al
   14         61          I              AKP         Al
   15         65          R              PPW         Al
   16          81         Y              DTV         Al
   17         111         G              AEY         Al
   18         116         D              QTS         Al
   19         119         S              QRE         Al
   20         120         Q              REK         Al
   21         128         V              FPG         Al
   22         129         F              PGG         Al
   23         130         P              GGS         Al
   24         182         G              SLA         Al
   25         185         A              KEK         Al
   26         188         K              TQT         Al
   27        205          G              KSW         Al
   28        210          S              ETK         Al
   29        211          E              TKN         Al
   30        216          L              MQD         Al
   31        220          R              DAA         Al
   32        222          A              ASA         Al
   33        223          A              SAR         Al
   34        224          S              ARA         Al
   35        230          K              MHT         Al
   36        243          P              GLI         Al
   37        244          G              LIG         Al
   38        250          R              KSV         Al
   39        318          D              GME         Al
   40        333          P              QLR         Al
   42        334          Q              LRM         Al
   43        336          R              MKN          al
                            - 106 -

     XTEN     Insertion     FVIII BDD  FVIII Domain
No. Insertion  Residue      Downstream
     Point*                  Sequence
44    339         N            NEE           al
45    345         D            YDD           al
46    357         V            VRF           al
47    367         S             FIQ          al
48    370         S            RPY           al
49    375         A            KKH          A2
50    376         K            KHP          A2
51    378         H            PKT          A2
52    399         V            LAP          A2
53    403         D            DRS          A2
54    405         R            SYK          A2
55    409         S            QYL          A2
56    416         P             QRI         A2
57    434         E            TFK          A2
58    438         T            REA          A2
59    441         A            IQH          A2
60    442         I            QHE          A2
61    463         I             IFK         A2
62    487         Y            SRR          A2
63    490         R            LPK          A2
64    492         P            KGV          A2
65    493         K            GVK          A2
66    494         G            VKH          A2
67    500         D             FPI         A2
68    506         G             EIF         A2
69    518         E            DGP          A2
70    556         K            ESV          A2
71    565         Q            IMS          A2
72    566         I            MSD          A2
73    598         P            AGV          A2
74    599         A            GVQ          A2
75    603         L            EDP          A2
76    616         S            ING          A2
77    686         G            LWI          A2
78    713         K            NTG          A2
79    719         Y            EDS          A2
80    730         L            LSK          A2
81    733         K            NNA          A2
82    745         N           PPV**          B
83    1640        P            PVL           B
84    1652        R            TTL           B
85    1656        Q            SDQ          A3
86    1685        N            QSP          A3
87    1711        M             SSS         A3
88    1713        S            SPH          A3
                    - 107 -

     XTEN     Insertion     FVIII BDD  FVIII Domain
No. Insertion  Residue      Downstream
     Point*                  Sequence
 89   1720        N            RAQ          A3
90    1724        S            GSV          A3
91    1725        G            SVP          A3
92    1726        S            VPQ          A3
93    1741        G            SFT          A3
94    1744        T            QPL          A3
95    1749        R            GEL          A3
96    1773        V            TFR          A3
97    1792        Y            EED          A3
98    1793        E            EDQ          A3
99    1796        Q            RQG          A3
100   1798        Q            GAE          A3
101   1799        G            AEP          A3
102   1802        P            RKN          A3
103   1803        R            KNF          A3
104   1807        V            KPN          A3
105   1808        K            PNE          A3
106   1827        K            DEF          A3
107   1844        E            KDV          A3
108   1861        N            TLN          A3
109   1863        L            NPA          A3
110   1896        E            RNC          A3
111   1900        R            APC          A3
112   1904        N            IQM          A3
113   1905        I            QME          A3
114   1910        P            TFK          A3
115   1920        A            ING          A3
116   1937        D            QRI          A3
117   1981        G            VFE          A3
118   2019        N            KCQ          A3
119   2020        K            CQT          C1
120   2044        G            QWA          C1
121   2068        F            SWI          C1
122   2073        V            DLL          C1
123   2090        R            QKF          C1
124   2092        K            FSS          C1
125   2093        F            SSL          C1
126   2111        K            WQT          C1
127   2115        Y            RGN          C1
128   2120        T            GTL          C1
129   2125        V            FFG          C1
130   2171        L            NSC          C1
131   2173        S            CSM          C2
132   2188        A            QIT          C2
133   2223        V            NNP          C2
                    - 108 -

                         XTEN                 .            FVIII BDD        FVIII Domain
            No.        Insertion      Insertion           Downstream
                         Point*        Residue              Sequence
            134           2224            N                   NPK                C2
            135           2227            K                   EWL                C2
            136           2268            G                   HQW                C2
            137           2277            N                   GKV                C2
            138           2278            G                   KVK                C2
            139           2290            F                   TPV                C2
            140           2332            Y           C terminus of FVIII        CT
  * Indicates an insertion point for XTEN based on the amino acid number of mature full
  length human FVIII, wherein the insertion could be either on the N- or C-terminal side
  of the indicated amino acid.
[0192]          In some embodiments, one or more XTEN sequences are inserted within
        about six amino acids up or down from amino acids 32, 220, 224, 336, 339, 399,
        416, 603, 1656, 1711, 1725, 1905, or 1910, corresponding to SEQ ID NO: 4 or
        any combinations thereof.
        TABLE 8. Exemplary XTEN Insertion Ranges
                                                                                Distance
                    Insertion      Insertion         FVw BDD          FVIII        from
           No.
                      Pot           Residue         m Se             Domain     insertion
                                                    in Sequence                 residue*
             9          32              P                RVP           Al         -3,+6
            31         220              R                DAA           Al
            34         224              S                ARA           Al           +5
            43         336              R               MKN            al         -1,+6
            44         339             N                 NEE           al         -4,+5
            52         399             V                 LAP           A2         -6,+3
            56         416              P                QRI           A2           +6
            75         603              L                EDP           A2           6,+6
            85        1656              Q                SDQ            B         -3,+6
            87        1711             M                  SSS          A3         -6,+1
            91        1725              G                SVP           A3           +6
           113        1905              I                QME           A3           +6
           114        1910              P                TFK           A3         -5, +6
        *Distance from insertion residue refers to the relative number of amino acids away
        from the N-terminus (negative numbers) or C-terminus (positive numbers) of the
        designated insertion residue (residue "0") where an insertion may be made. The
        designation "-x" refers to an insertion site which is x amino acids away on the N
        terminal side of the designated insertion residue. Similarly, the designation "+x"
                                            -   109 -

         refers to an insertion site which is x amino acids away on the C-terminal side of
         the designated insertion residue.
         For example, "-1, +2" indicates that the insertion is made at the N-terminus or C
         terminus of amino acid residues denoted -1, 0, +1 or +2.
[01931            In other embodiments, one or more XTEN sequences are inserted
         immediately down stream of one or more amino acids corresponding to the full
         length mature human FVIII selected from the group consisting of one or more
         insertion sites in Table 9.
         TABLE 9. Exemplary XTEN Insertion Sites or Ranges
               No.          XTEN Insertion Point           First Insertion  FVIII Domain
                                     Range*                    Residue
                3                     18-32                       Q               Al
                8                       40                        F               Al
                18                   211-224                      E               Al
               27                    336-403                      R             A1, A2
               43                      599                        A               A2
               47                  745-1640                       N                B
               50                  1656-1728                      Q            B, a3, A3
               57                  1796-1804                      R               A3
               65                  1900-1912                      R               A3
               81                 2171-2332                       L              C1,C2
       *   indicates range of insertion sites numbered relative to the amino acid number of
         mature human FVIII
[0194]            In yet other embodiments, one or more XTENs are inserted in the B
         domain of FVIII. In one example, an XTEN is inserted between amino acids 740
         and 1640 corresponding to SEQ ID NO: 4, wherein the FVIII sequence between
         amino acids 740 and 1640 is optionally not present. In another example, an
         XTEN is inserted between amino acids 741 and 1690 corresponding to SEQ ID
         NO: 4, wherein the FVIII sequence between amino acids 740 and 1690 is
         optionally not present. In other examples, an XTEN is inserted between amino
         acids 741 and 1648 corresponding to SEQ ID NO: 4, wherein the FVIII sequence
         between amino acids 741 and 1648 is optionally not present. In yet other
         examples, an XTEN is inserted between amino acids 743 and 1638 corresponding
         to SEQ ID NO: 4, wherein the FVIII sequence between amino acids 743 and 1638
         is optionally not present. In still other examples, an XTEN is inserted between
                                              -110-

       amino acids 745 and 1656 corresponding to SEQ ID NO: 4, wherein the FVIII
       sequence between amino acids 745 and 1656 is optionally not present. In some
       examples, an XTEN is inserted between amino acids 745 and 1657 corresponding
       to SEQ ID NO: 4, wherein the FVIII sequence between amino acids 745 and 1657
       is optionally not present. In certain examples, an XTEN is inserted between
       amino acids 745 and 1667 corresponding to SEQ ID NO: 4, wherein the FVIII
       sequence between amino acids 745 and 1667 is optionally not present. In still
       other examples, an XTEN is inserted between amino acids 745 and 1686
       corresponding to SEQ ID NO: 4, wherein the FVIII sequence between amino
       acids 745 and 1686 is optionally not present. In some other examples, an XTEN
       is inserted between amino acids 747 and 1642 corresponding to SEQ ID NO: 4,
       wherein the FVIII sequence between amino acids 747 and 1642 is optionally not
       present. In still other examples, an XTEN is inserted between amino acids 751
       and 1667 corresponding to SEQ ID NO: 4, wherein the FVIII sequence between
       amino acids 751 and 1667 is optionally not present.
[0195]          In some embodiments, one or more XTENs are inserted in one or more
       amino acids immediately downstream of an amino acid of an insertion site
       selected from the group consisting of the amino acid residues in Table 10.
                                           - 111 -

TABLE 10: FVIII XTEN insertion sites and construct designations
                       Upstream     Downstream
  Construct            Residuc        Residuc     Upstream   Downstream
   Number     Domain     No.*          No.*       Sequence     Sequence
   F8X-1        Al          3             4         ATR          RYY
   F8X-2        Al         18            19         YMQ          SDL
   F8X-3        Al         22            23         DLG          ELP
   F8X-4        Al         26            27         LPV          DAR
   F8X-5        Al         40            41          FPF         NTS
   F8X-6        Al         60            61         LFN          IAK
   F8X-7        Al        116           117         YDD          QTS
   F8X-8        Al        130           131         VFP          GGS
   F8X-9        Al        188           189         KEK          TQT
   F8X-10       Al       216            217         NSL          MQD
   F8X-11       Al       230            231         WPK          MHT
   F8X-12       Al        333           334         EEP          QLR
   F8X-13       A2        375           376         SVA          KKH
   F8X-14       A2       403            404         APD          DRS
   F8X-15       A2       442            443          EAI         QHE
   F8X-16       A2       490            491         RRL          PKG
   F8X-17       A2        518           519         TVE          DGP
   F8X-18       A2        599           600         NPA          GVQ
   F8X-19       A2        713           714         CDK          NTG
   F8X-20       BD        745           746         SQN          PPV
   F8X-21       BD        745           746         SQN          PPV
   F8X-22      BD**       745           746         SQN          PPV
   F8X-23       A3       1720          1721         APT          KDE
   F8X-24       A3       1796          1797         EDQ          RQG
   F8X-25       A3       1802          1803         AEP          RKN
   F8X-26       A3       1827          1828         PTK          DEF
   F8X-27       A3       1861          1862         HTN          TLN
   F8X-28       A3       1896          1897         NME          RNC
   F8X-29       A3       1900          1901         NCR          APC
   F8X-30       A3       1904          1905         PCN          IQM
   F8X-31       A3       1937          1938         AQD          QRI
   F8X-32       C1       2019          2020         YSN          KCQ
   F8X-33       C1       2068          2069         EPF          SWI
   F8X-34       C1       2111          2112         GKK          WQT
   F8X-35       C1       2120          2121         NST          GTL
   F8X-36       C2       2171          2172         CDL          NSC
   F8X-37       C2       2188          2189         SDA          QIT
   F8X-38       C2       2227          2228         NPK          EWL
   F8X-39       C2       2277          2278         FQN          GKV
   F8X-40       CT       2332           NA          DLY          NA
   F8X-41       CT       2332           NA          DLY          NA
   F8X-42       Al          3             4         ATR          ATR
  pSDOOO        A2       403            404
  pSDO002       A2        599           600
                              -112-

            pSDO021        N-term          0              1
            pSDO022          Al           32             33
            pSDO023          Al           65             66
            pSDO024          Al           81             82
            pSDO025          Al          119            120
            pSDO026          Al         211             212
            pSDO027          Al         220             221
            pSDO028          Al         224             225
            pSDO029          Al          336            337
            pSDO030          Al          339            340
            pSDO031          A2          378            379
            pSDO032          A2          399            400
            pSDO033          A2         409             410
            pSDO034          A2         416             417
            pSDO035          A2         487             488
            pSDO036          A2         494             495
            pSDO037          A2          500            501
            pSDO038          A2          603            604
            pSDO039          A3         1656           1657
            pSDO040          A3         1711           1712
            pSDO041          A3         1725           1726
            pSDO042          A3         1749           1750
            pSDO043          A3         1905           1906
            pSDO044          A3         1910           1911
            pDS0062          A3         1900           1901
           * Indicates the amino acid number of the mature FVIII protein
[01961           In one embodiment, the one or more XTEN insertion sites are located
       within one or more surface-exposed, flexible loop structure of the FVIII protein
       (e.g., a permissive loop). For example, at least one XTEN sequence can be
       inserted in each FVIII "A" domain comprising at least two "permissive loops" into
       which at least one XTEN polypeptide can be inserted without eliminating
       procoagulant activity of the recombinant protein, or the ability of the recombinant
       proteins to be expressed in vivo or in vitro in a host cell. The permissive loops are
       regions that allow insertion of at least one XTEN sequence with, among other
       attributes, high surface or solvent exposure and high conformational flexibility.
       The Al domain comprises a permissive loop-1 (Al-1) region and a permissive
       loop-2 (Al-2) region, the A2 domain comprises a permissive loop-1 (A2-1) region
       and a permissive loop-2 (A2-2) region, the A3 domain comprises a permissive
       loop-i (A3-1) region and a permissive loop-2 (A3-2) region.
                                             -113 -

[01971           In one aspect, a first permissive loop in the FVIII Al domain (Al-1) is
       located between beta strand 1 and beta strand 2, and a second permissive loop in
       the FVIII A2 domain (A 1-2) is located between beta strand 11 and beta strand 12.
       A first permissive loop in the FVIII A2 domain (A2-1) is located between beta
       strand 22 and beta strand 23, and a second permissive loop in the FVIII A2
       domain (A2-2) is located between beta strand 32 and beta strand 33. A first
       permissive loop in the FVIII A3 domain (A3-1) is located between beta strand 38
       and beta strand 39, and a second permissive loop in the FVIII A3 (A3-2) is located
       between beta strand 45 and beta strand 46. In certain aspects, the surface-exposed,
       flexible loop structure comprising Al-1 corresponds to a region in native mature
       human FVIII from about amino acid 15 to about amino acid 45 of SEQ IDNO: 4,
       e.g., from about amino acid 18 to about amino acid 41 of SEQ ID NO: 4. In other
       aspects, the surface-exposed, flexible loop structure comprising Al-2 corresponds
       to a region in native mature human FVIII from about amino acid 201 to about
       amino acid 232 of SEQ ID NO: 4, e.g., from about amino acid 218 to about amino
       acid 229 of SEQ ID NO: 4. In yet other aspects, the surface-exposed, flexible
       loop structure comprising A2-1 corresponds to a region in native mature human
       FVIII from about amino acid 395 to about amino acid 421 of SEQ ID NO: 4, e.g.
       from about amino acid 397 to about amino acid 418 of SEQ ID NO: 4. In still
       other embodiments, the surface-exposed, flexible loop structure comprising A2-2
       corresponds to a region in native mature human FVIII from about amino acid 577
       to about amino acid 635 of SEQ ID NO: 4, e.g., from about amino acid 595 to
       about amino acid 607 of SEQ ID NO: 4. In certain aspects the surface-exposed,
       flexible loop structure comprising A3-1 corresponds to a region in native mature
       human FVIII from about amino acid 1705 to about amino acid 1732 of SEQ ID
       NO: 4, e.g., from about amino acid 1711 to about amino acid 1725 of SEQ ID NO:
       4. In yet other aspects, the surface-exposed, flexible loop structure comprising
       A3-2 corresponds to a region in native mature human FVIII from about amino
       acid 1884 to about amino acid 1917 of SEQ ID NO: 4, e.g., from about amino acid
       1899 to about amino acid 1911 of SEQ ID NO: 4.
[0198]          In another embodiment, the one or more amino acids in which at least one
       XTEN sequence is inserted is located within a3 domain, e.g., amino acids 1649 to
       1689, corresponding to full-length mature FVIII polypeptide. In a particular
                                            -114-

       embodiment, an XTEN sequence is inserted between amino acids 1656 and 1657
       of SEQ ID NO: 4 (full-length mature FVIII). In a specific embodiment, a FVIII
       protein comprising an XTEN sequence inserted immediately downstream of
       amino acid 1656 corresponding to SEQ ID NO: 4 further comprises a deletion
       from amino acid 745 to amino acid 1656 corresponding to SEQ ID NO: 4.
[0199]         In some embodiments, the one or more insertion sites for one or more
       XTEN insertions are immediately downstream of one or more amino acids
       selected from the group consisting of:
       (1) amino acid 3,             (2) amino acid 18,            (3) amino acid 22,
       (4) amino acid 26,            (5) amino acid 32,            (6) amino acid 40,
       (7) amino acid 60,            (8) amino acid 65,            (9) amino acid 81,
       (10) amino acid 116,          (11) amino acid 119,          (12) amino acid 130,
       (13) amino acid 188,          (14) amino acid 211,          (15) amino acid 216,
       (16) amino acid 220,          (17) amino acid 224,          (18) amino acid 230,
       (19) amino acid 333,          (20) amino acid 336,          (21) amino acid 339,
       (22) amino acid 375,          (23) amino acid 399,          (24) amino acid 403,
       (25) amino acid 409,          (26) amino acid 416,          (26) amino acid 442,
       (28) amino acid 487,          (29) amino acid 490,          (30) amino acid 494,
       (31) amino acid 500,          (32) amino acid 518,          (33) amino acid 599,
       (34) amino acid 603,          (35) amino acid 713,          (36) amino acid 745,
       (37) amino acid 1656,                 (38) amino acid 1711,                (39)
       amino acid 1720,
       (40) amino acid 1725,                 (41) amino acid 1749,                (42)
       amino acid 1796,
       (43) amino acid 1802,                 (44) amino acid 1827,                (45)
       amino acid 1861,
       (46) amino acid 1896,                 (47) amino acid 1900,                (48)
       amino acid 1904,
       (49) amino acid 1905,                 (50) amino acid 1910,                (51)
       amino acid 1937,
       (52) amino acid 2019,                 (53) amino acid 2068,                (54)
       amino acid 2111,
                                          -115 -

       (55) amino acid 2120,                  (56) amino acid 2171,               (57)
       amino acid 2188,
       (58) amino acid 2227,          (59) amino acid 2277, and
       (60)      two or more combinations thereof.
[0200]          In one embodiment, a FVIII protein useful for the invention comprises two
       XTEN sequences, a first XTEN sequence inserted into a first XTEN insertion site
       and a second XTEN inserted into a second XTEN insertion site. Non-limiting
       examples of the first XTEN insertion site and the second XTEN insertion site are
       listed in Table 11.
       TABLE 11. Exemplary Insertion Sites for Two XTENs
                        Insertion 1                              Insertion 2
            Insertion Site          Domain           Insertion Site          Domain
                  745                  B                 2332                  CT
                   26                 Al                  403                  A2
                   40                 Al                  403                  A2
                   18                 Al                  403                  A2
                   26                 Al                  599                  A2
                   40                 Al                  599                  A2
                   18                 Al                  599                  A2
                  1720                A3                  1900                 A3
                  1725                A3                  1900                 A3
                  1711                A3                  1905                 A3
                  1720                A3                  1905                 A3
                  1725                A3                  1905                 A3
                  1656                A3                   26                  Al
                  1656                A3                   18                  Al
                  1656                A3                   40                  Al
                  1656                A3                  399                  A2
                  1656                A3                  403                  A2
                  1656                A3                  1725                 A3
                  1656                A3                  1720                 A3
                  1900                A3                   18                  Al
                  1900                A3                   26                  Al
                  1900                A3                   40                  Al
                  1905                A3                   18                  Al
                  1905                A3                   40                  Al
                  1905                A3                   26                  Al
                  1910                A3                   26                  Al
                   18                 Al                  399                  A2
                   26                 Al                  399                  A2
                   40                 Al                  399                  A2
                   18                 Al                  403                  A2
                                           -116-

                         Insertion 1                            Insertion 2
             Insertion Site          Domain         Insertion Site          Domain
                 1656                  A3                1900                  A3
                 1656                  A3                1905                  A3
                 1711                  A3                 40                   Al
                 1711                  A3                 26                   Al
                 1720                  A3                 26                   Al
                 1720                  A3                 40                   Al
                 1720                  A3                 18                   Al
                 1725                  A3                 26                   Al
                 1725                  A3                 40                   Al
                 1725                  A3                 18                   Al
                 1720                  A3                403                   A2
                 1720                  A3                399                   A2
                 1711                  A3                403                   A2
                 1720                  A3                403                   A2
                 1725                  A3                403                   A2
                 1725                  A3                399                   A2
                 1711                  A3                403                   A2
                 1900                  A3                399                   A2
                 1900                  A3                403                   A2
                 1905                  A3                403                   A2
                 1905                  A3                399                   A2
                 1910                  A3                403                   A2
[02011          The two XTENs inserted or linked to the FVIII protein can be identical or
       different. In some embodiments, a FVIII protein useful for the invention
       comprises two XTEN sequences inserted in the FVIII protein, a first XTEN
       sequence inserted immediately downstream of amino acid 745 corresponding to
       SEQ ID NO: 4, and a second XTEN sequence inserted immediately downstream
       of amino acid 2332 corresponding to SEQ ID NO: 4 (the C-terminus). In other
       embodiments, the first XTEN sequence is inserted immediately downstream of
       amino acid 18, 26, 40, 1656, or 1720 corresponding to SEQ ID NO: 4, and a
       second XTEN sequence inserted immediately downstream of amino acid 403
       corresponding to SEQ ID NO: 4. In yet other embodiments, the first XTEN
       sequence is inserted immediately downstream of amino acid 18, 26, or 40
       corresponding to SEQ ID NO: 4, and a second XTEN sequence inserted
       immediately downstream of amino acid 599 corresponding to SEQ ID NO: 4. In
       still other embodiments, the first XTEN sequence is inserted immediately
       downstream of amino acid 1656 corresponding to SEQ ID NO: 4, and a second
       XTEN sequence inserted immediately downstream of amino acid 18, 26, 40, 399,
                                           -117-

       403, 1725, 1720, 1900, 1905, or 2332 corresponding to SEQ ID NO: 4. In certain
       embodiments, the first XTEN sequence is inserted immediately downstream of
       amino acid 1900 corresponding to SEQ ID NO: 4, and a second XTEN sequence
       inserted immediately downstream of amino acid 18, 26, or 40 corresponding to
       SEQ ID NO: 4. In some embodiments, the first XTEN sequence is inserted
       immediately downstream of amino acid 18, 26, or 40 corresponding to SEQ ID
       NO: 4, and a second XTEN sequence inserted immediately downstream of amino
       acid 399 corresponding to SEQ ID NO: 4. In other embodiments, the first XTEN
       sequence is inserted immediately downstream of amino acid 1720 corresponding
       to SEQ ID NO: 4, and a second XTEN sequence inserted immediately
       downstream of amino acid 18, 26, or 40 corresponding to SEQ ID NO: 4. In still
       other embodiments, the first XTEN sequence is inserted immediately downstream
       of amino acid 1720 corresponding to SEQ ID NO: 4, and a second XTEN
       sequence inserted immediately downstream of amino acid 18 corresponding to
       SEQ ID NO: 4. In a particular embodiment, the FVIII protein comprising two
       XTEN sequences, a first XTEN sequence inserted immediately downstream of
       amino acid 745 corresponding to SEQ ID NO: 4 and a second XTEN sequence
       inserted immediately downstream of amino acid 2332 corresponding to SEQ ID
       NO: 4, wherein the FVIII protein further has a deletion from amino acid 745
       corresponding to SEQ ID NO: 4 to amino acid 1685 corresponding to SEQ ID
       NO: 4, a mutation or substitution at amino acid 1680 corresponding to SEQ ID
       NO: 4, e.g., Y1680F, a mutation or substitution at amino acid 1648 corresponding
       to SEQ ID NO: 4, e.g., R1648A, or at least two mutations or substitutions at
       amino acid 1648 corresponding to SEQ ID NO: 4, e.g., R1648A, and amino acid
       1680 corresponding to SEQ ID NO: 4, e.g., Y1680F. In a specific embodiment,
       the FVIII protein comprises two XTEN sequences, a first XTEN inserted
       immediately downstream of amino acid 1656 corresponding to SEQ ID NO: 4 and
       a second XTEN sequence inserted immediately downstream of amino acid 2332
       of SEQ ID NO: 4, wherein the FVIII protein further has a deletion from amino
       acid 745 to amino acid 1656 corresponding to SEQ ID NO: 4.
[0202]          In certain embodiments, a FVIII protein comprises three XTEN sequences,
       a first XTEN sequence inserted into a first XTEN insertion site, a second XTEN
       sequence inserted into a second XTEN sequence, and a third XTEN sequence
                                          -118-

       inserted into a third XTEN insertion site. The first, second, or third XTEN
       sequences can be identical or different. The first, second, and third insertion sites
       can be selected from the group of any one of the insertion sites disclosed herein.
       In some embodiments, the FVIII protein comprising three XTEN sequences can
       further comprise a mutation or substitution, e.g., amino acid 1648 corresponding
       to SEQ ID NO: 4, e.g., R1648A. For example, non-limiting examples of the first,
       second, and third XTEN insertion sites are listed in Table 12.
       TABLE 12. Exemplary Insertion Sites for Three XTENs
                  Insertion 1               Insertion 2                  Insertion 3
          Insertion         Domain    Insertion       Doin         Insertion      Doin
             Site                        Site                         Site
              26              Al         403             A2          1656            A3
              26              Al         403             A2          1720            A3
              26              Al         403             A2          1900            A3
              26              Al         1656            A3          1720            A3
              26              Al         1656            A3          1900            A3
              26              Al         1720            A3          1900            A3
             403              A2         1656            A3          1720            A3
             403              A2         1656            A3          1900            A3
             403              A2         1720            A3          1900            A3
             1656             A3         1720            A3          1900            A3
             745              B          1900                        2332            CT
              18              Al         745             B           2332            CT
              26              Al         745             B           2332            CT
              40              Al         745             B           2332            CT
              18              Al         745             B           2332            CT
              40              Al         745             B           2332            CT
             403              A2         745             B           2332            CT
             399              A2         745             B           2332            CT
             1725             A3         745             B           2332            CT
             1720             A3         745             B           2332            CT
             1711             A3         745             B           2332            CT
             1900             A3         745             B           2332            CT
             1905             A3         745             B           2332            CT
             1910             A3         745             B           2332            CT
[02031          In some embodiments, a FVIII protein comprises three XTEN sequences, a
       first XTEN sequence inserted immediately downstream of amino acid 26
       corresponding to SEQ ID NO: 4, a second XTEN sequence inserted downstream
       of amino acid 403 corresponding to SEQ ID NO: 4, and a third XTEN sequence
       inserted downstream of amino acid 1656, 1720, or 1900 corresponding to SEQ ID
                                          -119-

       NO: 4. In other embodiments, the first XTEN sequence is inserted immediately
       downstream of amino acid 26 corresponding to SEQ ID NO: 4, a second XTEN
       sequence is inserted downstream of amino acid 1656 corresponding to SEQ ID
       NO: 4, and a third XTEN sequence is inserted downstream of amino acid 1720 or
       1900 corresponding to SEQ ID NO: 4. In yet other embodiments, the first XTEN
       sequence is inserted immediately downstream of amino acid 26 corresponding to
       SEQ ID NO: 4, a second XTEN sequence is inserted downstream of amino acid
       1720 corresponding to SEQ ID NO: 4, and a third XTEN sequence is inserted
       downstream of amino acid 1900 corresponding to SEQ ID NO: 4. In still other
       embodiments, the first XTEN sequence is inserted immediately downstream of
       amino acid 403 corresponding to SEQ ID NO: 4, a second XTEN sequence is
       inserted downstream of amino acid 1656 corresponding to SEQ ID NO: 4, and a
       third XTEN sequence is inserted downstream of amino acid 1720 or 1900
       corresponding to SEQ ID NO: 4. In other embodiments, the first XTEN sequence
       is inserted immediately downstream of amino acid 403 or 1656 corresponding to
       SEQ ID NO: 4, a second XTEN sequence is inserted downstream of amino acid
       1720 corresponding to SEQ ID NO: 4, and a third XTEN sequence is inserted
       downstream of amino acid 1900 corresponding to SEQ ID NO: 4. In other
       embodiments, the first XTEN sequence is inserted immediately downstream of
       amino acid 18, 26, 40, 399, 403, 1711, 1720, 1725, 1900, 1905, or 1910
       corresponding to SEQ ID NO: 4, a second XTEN sequence is inserted
       downstream of amino acid 745 corresponding to SEQ ID NO: 4, and a third
       XTEN sequence is inserted downstream of amino acid 2332 corresponding to
       SEQ ID NO: 4.
[0204]          In other embodiments, a FVIII protein in the invention comprises four
       XTEN sequences, a first XTEN sequence inserted into a first insertion site, a
       second XTEN sequence inserted into a second insertion site, a third XTEN
       sequence inserted into a third insertion site, and a fourth XTEN sequence inserted
       into a fourth insertion site. The first, second, third, and fourth XTEN sequences
       can be identical, different, or combinations thereof. In some embodiments, the
       FVIII protein comprising four XTEN sequences can further comprise a mutation
       or substitution, e.g., amino acid 1648 corresponding to SEQ ID NO: 4, e.g.,
                                            - 120  -

       R1648A. Non-limiting examples of the first, second, third, and fourth XTEN
       insertion sites are listed in Table 13.
       TABLE 13. Exemplary Insertion Sites for Four XTENs
      Insertion 1                 Insertion 2              Insertion 3        Insertion 4
Insertion      Doin          Insertion     Domai       Insertion    Domai Insertion   Domai
   Site                         Site           n          Site         n     Site        n
    26           Al             403          A2          1656          a3   1720        A3
    26           Al             403          A2          1656          a3   1900        A3
    26           Al             403          A2          1720         A3    1900        A3
    26           Al             1656          a3         1720         A3    1900        A3
   403           A2             1656          a3         1720         A3    1900        A3
  0040           Al            0403          A2           745          B    2332        CT
  0040           Al            0403          A2           745          B    2332        CT
  0018           Al            0409          A2           745          B    2332        CT
  0040           Al            0409          A2           745          B    2332        CT
  0040           Al            0409          A2           745          B    2332        CT
  0018           Al            0409          A2           745          B    2332        CT
  0040           Al             1720         A3           745          B    2332        CT
  0026           Al             1720         A3           745          B    2332        CT
  0018           Al             1720         A3           745          B    2332        CT
  0018           Al             1720         A3           745          B    2332        CT
  0018           Al             1720         A3           745          B    2332        CT
  0026           Al             1720         A3           745          B    2332        CT
  0018           Al             1720         A3           745          B    2332        CT
  0018           Al             1900         A3           745          B    2332        CT
  0018           Al             1900         A3           745          B    2332        CT
  0026           Al             1900         A3           745          B    2332        CT
  0040           Al             1900         A3           745          B    2332        CT
  0040           Al             1905         A3           745          B    2332        CT
  0018           Al             1905         A3           745          B    2332        CT
  0040           Al             1905         A3           745          B    2332        CT
  0026           Al             1905         A3           745          B    2332        CT
  0018           Al             1905         A3           745          B    2332        CT
  0018           Al             1905         A3           745          B    2332        CT
  0018           Al             1910         A3           745          B    2332        CT
  0018           Al             1910         A3           745          B    2332        CT
  0040           Al             1910         A3           745          B    2332        CT
  0026           Al             1910         A3           745          B    2332        CT
  0018           Al             1910         A3           745          B    2332        CT
  0026           Al             1910         A3           745          B    2332        CT
  0040           Al             1910         A3           745          B    2332        CT
  0018           Al             1910         A3           745          B    2332        CT
  0409           A2             1720         A3           745          B    2332        CT
  0403           A2             1720         A3           745          B    2332        CT
  0409           A2             1720         A3           745          B    2332        CT
  0403           A2             1720         A3           745          B    2332        CT
                                              -  121 -

    0403         A2        1720         A3           745           B       2332     CT
    0403         A2        1900         A3           745           B       2332     CT
    0403         A2        1900         A3           745           B       2332     CT
    0409         A2        1900         A3           745           B       2332     CT
    0403         A2        1900         A3           745           B       2332     CT
    0403         A2        1900         A3           745           B       2332     CT
    0409         A2        1900         A3           745           B       2332     CT
    0409         A2        1905         A3           745           B       2332     CT
    0403         A2        1905         A3           745           B       2332     CT
    0403         A2        1905         A3           745           B       2332     CT
    0403         A2        1905         A3           745           B       2332     CT
    0409         A2        1905         A3           745           B       2332     CT
    0403         A2        1905         A3           745           B       2332     CT
    0409         A2        1910         A3           745           B       2332     CT
    0403         A2        1910         A3           745           B       2332     CT
    0403         A2        1910         A3           745           B       2332     CT
    0403         A2        1910         A3           745           B       2332     CT
    0403         A2        1910         A3           745           B       2332     CT
    1720         A3        1900         A3           745           B       2332     CT
    1720         A3        1905         A3           745           B       2332     CT
    1720         A3        1910         A3           745           B       2332     CT
    1720         A3        1910         A3           745           B       2332     CT
    0403         A2        1656         a3          1720          A3       2332     CT
    0403         A2        1656         a3          1900          A3       2332     CT
    0403         A2        1720         A3          1900          A3       2332     CT
    1656          a3       1720         A3          1900          A3       2332     CT
    0018         Al        0403         A2          1656           a3      2332     CT
    0018         Al        0403         A2          1720          A3       2332     CT
    0018         Al        0403         A2          1900          A3       2332     CT
    0018         Al        1656         a3          1720          A3       2332     CT
    0018         Al        1656         a3          1900          A3       2332     CT
    0018         Al        1720         A3          1900          A3       2332     CT
    0018         Al        0403         A2          0745           B       2332     CT
    0018         Al        0745          B          1720          A3       2332     CT
    0018         Al        0745          B          1900          A3       2332     CT
    0403         A2        0745          B          1720          A3       2332     CT
    0403         A2        0745          B          1900          A3       2332     CT
    0745          B        1720         A3          1900          A3       2332     CT
    0188         Al        1900         A3          0745           B       2332     CT
    0599                   1900         A3          0745           B       2332     CT
    2068                   1900         A3          0745           B       2332     CT
    2171                   1900         A3          0745           B       2332     CT
    2227                   1900         A3          0745           B       2332     CT
    2277                   1900         A3          0745           B       2332     CT
[0205]         In some embodiments, a FVIII protein comprises five XTEN sequences, a
       first XTEN sequence inserted into a first insertion site, a second XTEN sequence
                                         - 122  -

       inserted into a second insertion site, a third XTEN sequence inserted into a third
       XTEN insertion site, a fourth XTEN sequence inserted into a fourth XTEN
       insertion site, and a fifth XTEN sequence inserted into a fifth XTEN insertion site.
       The first, second, third, fourth, of fifth XTEN sequences can be identical,
       different, or combinations thereof. Non-limiting examples of the first, second,
       third, fourth, and fifth insertion sites are listed in Table 14.
       TABLE 14. Exemplary Insertion Sites for Five XTENs
  XTEN insertioni      XTEN inser-tioni         XTEN               XTEN             XTEN
         1                     2             Inser-tionl 3       Insertioni 4     Iser-tioni 5
       0403                  1656                1720               1900             2332
       0018                  0403                1656               1720             2332
       0018                  0403                1656               1900             2332
       0018                  0403                1720               1900             2332
       0018                  1656                1720               1900             2332
       0018                  0403                0745               1720             2332
       0018                  0403                0745               1900             2332
       0018                  0745                1720               1900             2332
       0403                  0745                1720               1900             2332
[02061          In certain embodiments, a FVIII protein comprises six XTEN sequences, a
       first XTEN sequence inserted into a first XTEN insertion site, a second XTEN
       sequence inserted into a second XTEN insertion site, a third XTEN sequence
       inserted into a third XTEN insertion site, a fourth XTEN sequence inserted into a
       fourth XTEN insertion site, a fifth XTEN sequence inserted into a fifth XTEN
       insertion site, and a sixth XTEN sequence inserted into a sixth XTEN insertion
       site. The first, second, third, fourth, fifth, or sixth XTEN sequences can be
       identical, different, or combinations thereof. Examples of the six XTEN insertion
       sites include, but are not limited to the insertion sites listed in Table 15.
       TABLE 15. Exemplary XTEN Insertion Sites for Six XTENs
           XTEN           XTEN           XTEN             XTEN             XTEN          XTEN
        Insertion 1     insertion 2    Insertion 3      Insertion 4     Insertion 5         6
            0018           0403           1656             1720             1900          2332
            0018           0403           0745             1720             1900          2332
[0207]          In a particular example, a first XTEN is inserted between amino acids 26
       and 27 corresponding to SEQ ID NO: 4, and a second XTEN is inserted between
                                              - 123   -

       amino acids 1720 and 1721 corresponding to SEQ ID NO: 4 (full-length mature
       FVIII). In another example, a first XTEN is inserted between amino acids 403
       and 404 corresponding to SEQ ID NO: 4, and a second XTEN is inserted between
       amino acids 1720 and 1721 corresponding to SEQ ID NO: 4. In some examples, a
       first XTEN is inserted between amino acids 1656 and 1657 corresponding to SEQ
       ID NO: 4, and a second XTEN is inserted between amino acids 1720 and 1721
       corresponding to SEQ ID NO: 4. In other examples, a first XTEN is inserted
       between amino acids 26 and 27 corresponding to SEQ ID NO: 4, a second XTEN
       is inserted between amino acids 1656 and 1657 corresponding to SEQ ID NO: 4,
       and a third XTEN is inserted between amino acids 1720 and 1721 corresponding
       to SEQ ID NO: 4. In yet other embodiments, a first XTEN is inserted between
       amino acids 403 and 404 corresponding to SEQ ID NO: 4, a second XTEN is
       inserted between amino acids 1656 and 1657 corresponding to SEQ ID NO: 4, and
       a third XTEN is inserted between amino acids 1720 and 1721 corresponding to
       SEQ ID NO: 4. In still other embodiments, a first XTEN is inserted between
       amino acids 403 and 404 corresponding to SEQ ID NO: 4, a second XTEN is
       inserted between amino acids 1656 and 1657 corresponding to SEQ ID NO: 4, and
       a third XTEN is inserted between amino acids 1720 and 1721 corresponding to
       SEQ ID NO: 4. In certain embodiments, a first XTEN is inserted between amino
       acids 26 and 27 corresponding to SEQ ID NO: 4, a second XTEN is inserted
       between amino acids 1720 and 1721 corresponding to SEQ ID NO: 4, and a third
       XTEN is inserted between amino acids 1900 and 1901 corresponding to SEQ ID
       NO: 4. In some embodiments, a first XTEN is inserted between amino acids 26
       and 27 corresponding to SEQ ID NO: 4, a second XTEN is inserted between
       amino acids 1656 and 1657 corresponding to SEQ ID NO: 4, a third XTEN is
       inserted between amino acids 1720 and 1721 corresponding to SEQ ID NO: 4, and
       a fourth XTEN is inserted between 1900 and 1901 corresponding to SEQ ID NO:
       4.
[0208]          In a particular embodiment, an XTEN sequence is inserted between amino
       acids 745 and 746 of a full-length Factor VIII or the corresponding insertion site
       of the B-domain deleted Factor VIII.
[0209]          In some embodiments, a chimeric protein of the invention comprises two
       polypeptide sequences, a first polypeptide sequence comprising an amino acid
                                          - 124 -

       sequence at least about 80%, 90%, 95%, or 100% identical to a sequence selected
       from FVIII-161 (SEQ ID NO: 101), FVIII-169 (SEQ ID NO: 103), FVIII-170
       (SEQ ID NO: 102), FVIII-173 (SEQ ID NO: 104); FVIII-195 (SEQ ID NO: 105);
       FVIII-196 (SEQ ID NO: 106), FVIII-199 (SEQ ID NO: 107), FVIII-201 (SEQ ID
       NO: 108); FVIII-203 (SEQ ID NO: 109), FVIII-204 (SEQ ID NO: 110), FVIII
       205 (SEQ ID NO: 111), FVIII-266 (SEQ ID NO: 112), FVIII-267 (SEQ ID NO:
       113), FVIII-268 (SEQ ID NO: 114), FVIII-269 (SEQ ID NO: 115), FVIII-271
       (SEQ ID NO: 116), or FVIII-272 (SEQ ID NO: 117) and a second polypeptide
       sequence comprising an amino acid sequence at least about 80%, 90%, 95%, or
       100% identical to a sequence selected from VWF031 (SEQ ID NO: 118),
       VWF034 (SEQ ID NO: 119), or VWF-036 (SEQ ID NO: 120).
       D)      Ig Constant Region or a portion thereof
[0210]         The VWF fragment or the FVIII protein linked to an XTEN sequence in
       the present invention can further comprise an Ig constant region or a portion
       thereof. The Ig constant region or a portion thereof can improve pharmacokinetic
       or pharmacodynamic properties of the VWF fragment or the FVIII protein in
       combination with the XTEN sequence. In certain embodiments, the Ig constant
       region or a portion thereof extends a half-life of a molecule fused to the Ig
       constant region or a portion thereof.
[0211]         An Ig constant region is comprised of domains denoted CH (constant
       heavy) domains (CHI, CH2, etc.). Depending on the isotype, (i.e. IgG, IgM, IgA,
       IgD, or IgE), the constant region can be comprised of three or four CH domains.
       Some isotypes (e.g. IgG) constant regions also contain a hinge region. See
       Janeway et al. 2001, Immunobiology, Garland Publishing, N.Y., N.Y.
[0212]         An Ig constant region or a portion thereof for producing the chimeric
       protein of the present invention may be obtained from a number of different
       sources. In some embodiments, an Ig constant region or a portion thereof is
       derived from a human 1g. It is understood, however, that the Ig constant region or
       a portion thereof may be derived from an Ig of another mammalian species,
       including for example, a rodent (e.g. a mouse, rat, rabbit, guinea pig) or non
       human primate (e.g. chimpanzee, macaque) species. Moreover, the Ig constant
       region or a portion thereof may be derived from any Ig class, including IgM, IgG,
                                          -  125 -

       IgD, IgA, and IgE, and any Ig isotype, including IgGl, IgG2, IgG3, and IgG4. In
       one embodiment, the human isotype IgGI is used.
[0213]          A variety of the Ig constant region gene sequences (e.g., human constant
       region gene sequences) are available in the form of publicly accessible deposits.
       Constant region domains sequence can be selected having a particular effector
       function (or lacking a particular effector function) or with a particular
       modification to reduce immunogenicity. Many sequences of antibodies and
       antibody-encoding genes have been published and suitable Ig constant region
       sequences (e.g., hinge, CH2, and/or CH3 sequences, or portions thereof) can be
       derived from these sequences using art recognized techniques. The genetic
       material obtained using any of the foregoing methods may then be altered or
       synthesized to obtain polypeptides of the present invention. It will further be
       appreciated that the scope of this invention encompasses alleles, variants and
       mutations of constant region DNA sequences.
[0214]          The sequences of the Ig constant region or a portion thereof can be cloned,
       e.g., using the polymerase chain reaction and primers which are selected to
       amplify the domain of interest. To clone a sequence of the Ig constant region or a
       portion thereof from an antibody, mRNA can be isolated from hybridoma, spleen,
       or lymph cells, reverse transcribed into DNA, and antibody genes amplified by
       PCR. PCR amplification methods are described in detail in U.S. Pat. Nos.
       4,683,195; 4,683,202; 4,800,159; 4,965,188; and in, e.g., "PCR Protocols: A
       Guide to Methods and Applications" Innis et al. eds., Academic Press, San Diego,
       CA (1990); Ho et al. 1989. Gene 77:5 1; Horton et al. 1993. Methods Enzymol.
       217:270). PCR may be initiated by consensus constant region primers or by more
       specific primers based on the published heavy and light chain DNA and amino
       acid sequences. As discussed above, PCR also may be used to isolate DNA clones
       encoding the antibody light and heavy chains. In this case the libraries may be
       screened by consensus primers or larger homologous probes, such as mouse
       constant region probes. Numerous primer sets suitable for amplification of
       antibody genes are known in the art (e.g., 5' primers based on the N-terminal
       sequence of purified antibodies (Benhar and Pastan. 1994. Protein Engineering
       7:1509); rapid amplification of cDNA ends (Ruberti, F. et al. 1994. J. Immunol.
       Methods 173:33); antibody leader sequences (Larrick et al. 1989 Biochem.
                                           -  126 -

       Biophys. Res. Commun. 160:1250). The cloning of antibody sequences is further
       described in Newman et al., U.S. Pat. No. 5,658,570, filed January 25, 1995,
       which is incorporated by reference herein.
[0215]          An Ig constant region used herein can include all domains and the hinge
       region or portions thereof. In one embodiment, the Ig constant region or a portion
       thereof comprises CH2 domain, CH3 domain, and a hinge region, i.e., an Fc
       region or an FcRn binding partner.
[0216]          As used herein, the term "Fc region" is defined as the portion of a
       polypeptide which corresponds to the Fc region of native Ig, i.e., as formed by the
       dimeric association of the respective Fc domains of its two heavy chains. A native
       Fc region forms a homodimer with another Fc region. In contrast, the term
       "genetically-fused Fc region" or "single-chain Fc region" (scFc region), as used
       herein, refers to a synthetic dimeric Fc region comprised of Fc domains
       genetically linked within a single polypeptide chain (i.e., encoded in a single
       contiguous genetic sequence).
[0217]          In one embodiment, the "Fc region" refers to the portion of a single Ig
       heavy chain beginning in the hinge region just upstream of the papain cleavage
       site (i.e. residue 216 in IgG, taking the first residue of heavy chain constant region
       to be 114) and ending at the C-terminus of the antibody. Accordingly, a complete
       Fc domain comprises at least a hinge domain, a CH2 domain, and a CH3 domain.
[0218]          The Fc region of an Ig constant region, depending on the Ig isotype can
       include the CH2, CH3, and CH4 domains, as well as the hinge region. Chimeric
       proteins comprising an Fc region of an Ig bestow several desirable properties on a
       chimeric protein including increased stability, increased serum half-life (see
       Capon et al., 1989, Nature 337:525) as well as binding to Fc receptors such as the
       neonatal Fc receptor (FcRn) (U.S. Pat. Nos. 6,086,875, 6,485,726, 6,030,613; WO
       03/077834; US2003-0235536A1), which are incorporated herein by reference in
       their entireties.
[0219]          An Ig constant region or a portion thereof can be an FcRn binding partner.
       FcRn is active in adult epithelial tissues and expressed in the lumen of the
       intestines, pulmonary airways, nasal surfaces, vaginal surfaces, colon and rectal
       surfaces (U.S. Pat. No. 6,485,726). An FcRn binding partner is a portion of an Ig
       that binds to FcRn.
                                            - 127  -

[02201          The FcRn receptor has been isolated from several mammalian species
       including humans. The sequences of the human FcRn, monkey FcRn, rat FcRn,
       and mouse FcRn are known (Story et al. 1994, J. Exp. Med. 180:2377). The FcRn
       receptor binds IgG (but not other Ig classes such as IgA, IgM, IgD, and IgE) at
       relatively low pH, actively transports the IgG transcellularly in a luminal to
       serosal direction, and then releases the IgG at relatively higher pH found in the
       interstitial fluids. It is expressed in adult epithelial tissue (U.S. Pat. Nos.
       6,485,726, 6,030,613, 6,086,875; WO 03/077834; US2003-0235536A1) including
       lung and intestinal epithelium (Israel et al. 1997, Immunology 92:69) renal
       proximal tubular epithelium (Kobayashi et al. 2002, Am. J. Physiol. Renal
       Physiol. 282:F358) as well as nasal epithelium, vaginal surfaces, and biliary tree
       surfaces.
[0221]          FcRn binding partners useful in the present invention encompass
       molecules that can be specifically bound by the FcRn receptor including whole
       IgG, the Fc fragment of IgG, and other fragments that include the complete
       binding region of the FcRn receptor. The region of the Fc portion of IgG that
       binds to the FcRn receptor has been described based on X-ray crystallography
       (Burmeister et al. 1994, Nature 372:379). The major contact area of the Fc with
       the FcRn is near the junction of the CH2 and CH3 domains. Fc-FcRn contacts are
       all within a single Ig heavy chain. The FcRn binding partners include whole IgG,
       the Fc fragment of IgG, and other fragments of IgG that include the complete
       binding region of FcRn. The major contact sites include amino acid residues 248,
       250-257, 272, 285, 288, 290-291, 308-311, and 314 of the CH2 domain and amino
       acid residues 385-387, 428, and 433-436 of the CH3 domain. References made to
       amino acid numbering of Igs or Ig fragments, or regions, are all based on Kabat et
       al. 1991, Sequences of Proteins of Immunological Interest, U.S. Department of
       Public Health, Bethesda, Md.
[0222]          Fc regions or FcRn binding partners bound to FcRn can be effectively
       shuttled across epithelial barriers by FcRn, thus providing a non-invasive means to
       systemically administer a desired therapeutic molecule. Additionally, fusion
       proteins comprising an Fc region or an FcRn binding partner are endocytosed by
       cells expressing the FcRn. But instead of being marked for degradation, these
       fusion proteins are recycled out into circulation again, thus increasing the in vivo
                                              - 128  -

       half-life of these proteins. In certain embodiments, the portions of Ig constant
       regions are an Fc region or an FcRn binding partner that typically associates, via
       disulfide bonds and other non-specific interactions, with another Fc region or
       another FcRn binding partner to form dimers and higher order multimers.
[0223]          Two FcRn receptors can bind a single Fc molecule. Crystallographic data
       suggest that each FcRn molecule binds a single polypeptide of the Fc homodimer.
       In one embodiment, linking the FcRn binding partner, e.g., an Fc fragment of an
       IgG, to a biologically active molecule provides a means of delivering the
       biologically active molecule orally, buccally, sublingually, rectally, vaginally, as
       an aerosol administered nasally or via a pulmonary route, or via an ocular route. In
       another embodiment, the chimeric protein can be administered invasively, e.g.,
       subcutaneously, intravenously.
[0224]          An FcRn binding partner region is a molecule or a portion thereof that can
       be specifically bound by the FcRn receptor with consequent active transport by the
       FcRn receptor of the Fc region. Specifically bound refers to two molecules
       forming a complex that is relatively stable under physiologic conditions. Specific
       binding is characterized by a high affinity and a low to moderate capacity as
       distinguished from nonspecific binding which usually has a low affinity with a
       moderate to high capacity. Typically, binding is considered specific when the
       affinity constant KA is higher than 106 M-1, or higher than 108 M- 1. If necessary,
       non-specific binding can be reduced without substantially affecting specific
       binding by varying the binding conditions. The appropriate binding conditions
       such as concentration of the molecules, ionic strength of the solution, temperature,
       time allowed for binding, concentration of a blocking agent (e.g. serum albumin,
       milk casein), etc., may be optimized by a skilled artisan using routine techniques.
[0225]          In certain embodiments, a chimeric protein of the invention comprises one
       or more truncated Fc regions that are nonetheless sufficient to confer Fc receptor
       (FcR) binding properties to the Fc region. For example, the portion of an Fc
       region that binds to FcRn (i.e., the FcRn binding portion) comprises from about
       amino acids 282-438 of IgGI, EU numbering (with the primary contact sites being
       amino acids 248, 250-257, 272, 285, 288, 290-291, 308-311, and 314 of the CH2
       domain and amino acid residues 385-387, 428, and 433-436 of the CH3 domain.
       Thus, an Fc region of the invention may comprise or consist of an FcRn binding
                                            - 129 -

       portion. FcRn binding portions may be derived from heavy chains of any isotype,
       including IgGl, IgG2, IgG3 and IgG4. In one embodiment, an FcRn binding
       portion from an antibody of the human isotype IgGI is used. In another
       embodiment, an FcRn binding portion from an antibody of the human isotype
       IgG4 is used.
[0226]         In another embodiment, the "Fc region" includes an amino acid sequence
       of an Fc domain or derived from an Fc domain. In certain embodiments, an Fc
       region comprises at least one of: a hinge (e.g., upper, middle, and/or lower hinge
       region) domain (about amino acids 216-230 of an antibody Fc region according to
       EU numbering), a CH2 domain (about amino acids 231-340 of an antibody Fc
       region according to EU numbering), a CH3 domain (about amino acids 341-438 of
       an antibody Fc region according to EU numbering), a CH4 domain, or a variant,
       portion, or fragment thereof. In other embodiments, an Fc region comprises a
       complete Fc domain (i.e., a hinge domain, a CH2 domain, and a CH3 domain). In
       some embodiments, an Fc region comprises, consists essentially of, or consists of
       a hinge domain (or a portion thereof) fused to a CH3 domain (or a portion
       thereof), a hinge domain (or a portion thereof) fused to a CH2 domain (or a
       portion thereof), a CH2 domain (or a portion thereof) fused to a CH3 domain (or a
       portion thereof), a CH2 domain (or a portion thereof) fused to both a hinge
       domain (or a portion thereof) and a CH3 domain (or a portion thereof). In still
       other embodiments, an Fc region lacks at least a portion of a CH2 domain (e.g., all
       or part of a CH2 domain). In a particular embodiment, an Fc region comprises or
       consists of amino acids corresponding to EU numbers 221 to 447.
[0227]         The Fc regions denoted as F, F1, or F2 herein may be obtained from a
       number of different sources. In one embodiment, an Fc region of the polypeptide
       is derived from a human Ig. It is understood, however, that an Fc region may be
       derived from an Ig of another mammalian species, including for example, a rodent
       (e.g. a mouse, rat, rabbit, or guinea pig) or non-human primate (e.g. chimpanzee,
       macaque) species. Moreover, the polypeptide of the Fc domains or portions
       thereof may be derived from any Ig class, including IgM, IgG, IgD, IgA and IgE,
       and any Ig isotype, including IgGl, IgG2, IgG3 and IgG4. In another embodiment,
       the human isotype IgGI is used.
                                            - 130 -

[02281          In certain embodiments, the Fe variant confers a change in at least one
       effector function imparted by an Fc region comprising said wild-type Fc domain
       (e.g., an improvement or reduction in the ability of the Fc region to bind to Fc
       receptors (e.g. FcyRI, FcyRII, or FcyRIII) or complement proteins (e.g. Cl q), or
       to trigger antibody-dependent cytotoxicity (ADCC), phagocytosis, or
       complement-dependent cytotoxicity (CDCC)). In other embodiments, the Fc
       variant provides an engineered cysteine residue.
[0229]          The Fc regions of the invention may employ art-recognized Fc variants
       which are known to impart a change (e.g., an enhancement or reduction) in
       effector function and/or FcR or FcRn binding. Specifically, a binding molecule of
       the invention may include, for example, a change (e.g., a substitution) at one or
       more of the amino acid positions disclosed in International PCT Publications
       W088/07089A1, W096/14339A1, W098/05787A1, W098/23289A1,
       W099/51642A1, W099/58572A1, WOOO/09560A2, WOOO/32767A1,
       WOOO/42072A2, W002/44215A2, W002/060919A2, W003/074569A2,
       W004/016750A2, W004/029207A2, W004/035752A2, W004/063351A2,
       W004/074455A2, W004/099249A2, WO05/040217A2, W004/044859,
       WO05/070963A1, WO05/077981A2, WO05/092925A2, WO05/123780A2,
       W006/019447A1, W006/047350A2, and W006/085967A2; US Patent
       Publication Nos. US2007/0231329, US2007/0231329, US2007/0237765,
       US2007/0237766, US2007/0237767, US2007/0243188, US20070248603,
       US20070286859, US20080057056 ; or US Patents 5,648,260; 5,739,277;
       5,834,250; 5,869,046; 6,096,871; 6,121,022; 6,194,551; 6,242,195; 6,277,375;
       6,528,624; 6,538,124; 6,737,056; 6,821,505; 6,998,253; 7,083,784; 7,404,956, and
       7,317,091, each of which is incorporated by reference herein. In one embodiment,
       the specific change (e.g., the specific substitution of one or more amino acids
       disclosed in the art) may be made at one or more of the disclosed amino acid
       positions. In another embodiment, a different change at one or more of the
       disclosed amino acid positions (e.g., the different substitution of one or more
       amino acid position disclosed in the art) may be made.
[0230]          The Fc region or FcRn binding partner of IgG can be modified according
       to well recognized procedures such as site directed mutagenesis and the like to
       yield modified IgG or Fc fragments or portions thereof that will be bound by
                                           - 131 -

       FcRn. Such modifications include modifications remote from the FcRn contact
       sites as well as modifications within the contact sites that preserve or even
       enhance binding to the FcRn. For example, the following single amino acid
       residues in human IgGI Fc (Fc yl) can be substituted without significant loss of
       Fc binding affinity for FcRn: P238A, S239A, K246A, K248A, D249A, M252A,
       T256A, E258A, T260A, D265A, S267A, H268A, E269A, D270A, E272A,
       L274A, N276A, Y278A, D280A, V282A, E283A, H285A, N286A, T289A,
       K290A, R292A, E293A, E294A, Q295A, Y296F, N297A, S298A, Y300F,
       R301A, V303A, V305A, T307A, L309A, Q311A, D312A, N315A, K317A,
       E318A, K320A, K322A, S324A, K326A, A327Q, P329A, A330Q, P331A,
       E333A, K334A, T335A, S337A, K338A, K340A, Q342A, R344A, E345A,
       Q347A, R355A, E356A, M358A, T359A, K360A, N361A, Q362A, Y373A,
       S375A, D376A, A378Q, E380A, E382A, S383A, N384A, Q386A, E388A,
       N389A, N390A, Y391F, K392A, L398A, S400A, D401A, D413A, K414A,
       R416A, Q418A, Q419A, N421A, V422A, S424A, E430A, N434A, T437A,
       Q438A, K439A, S440A, S444A, and K447A, where for example P238A
       represents wild type proline substituted by alanine at position number 238. As an
       example, a specific embodiment incorporates the N297A mutation, removing a
       highly conserved N-glycosylation site. In addition to alanine other amino acids
       may be substituted for the wild type amino acids at the positions specified above.
       Mutations may be introduced singly into Fc giving rise to more than one hundred
       Fc regions distinct from the native Fc. Additionally, combinations of two, three, or
       more of these individual mutations may be introduced together, giving rise to
       hundreds more Fc regions. Moreover, one of the Fc region of a construct of the
       invention may be mutated and the other Fc region of the construct not mutated at
       all, or they both may be mutated but with different mutations.
[0231]          Certain of the above mutations may confer new functionality upon the Fc
       region or FcRn binding partner. For example, one embodiment incorporates
       N297A, removing a highly conserved N-glycosylation site. The effect of this
       mutation is to reduce immunogenicity, thereby enhancing circulating half-life of
       the Fc region, and to render the Fc region incapable of binding to FcyRI, FcyRIIA,
       FcyRIIB, and FcyRIIIA, without compromising affinity for FcRn (Routledge et al.
       1995, Transplantation 60:847; Friend et al. 1999, Transplantation 68:1632; Shields
                                           - 132 -

       et al. 1995, J. Biol. Chem. 276:6591). As a further example of new functionality
       arising from mutations described above affinity for FcRn may be increased
       beyond that of wild type in some instances. This increased affinity may reflect an
       increased "on" rate, a decreased "off' rate or both an increased "on" rate and a
       decreased "off' rate. Examples of mutations believed to impart an increased
       affinity for FcRn include, but not limited to, T256A, T307A, E380A, and N434A
       (Shields et al. 2001, J. Biol. Chem. 276:6591).
[0232]          Additionally, at least three human Fc gamma receptors appear to recognize
       a binding site on IgG within the lower hinge region, generally amino acids 234
       237. Therefore, another example of new functionality and potential decreased
       immunogenicity may arise from mutations of this region, as for example by
       replacing amino acids 233-236 of human IgGI "ELLG" to the corresponding
       sequence from IgG2 "PVA" (with one amino acid deletion). It has been shown
       that FcyRI, FcyRII, and FcyRIII, which mediate various effector functions will not
       bind to IgGI when such mutations have been introduced. Ward and Ghetie 1995,
       Therapeutic Immunology 2:77 and Armour et al. 1999, Eur. J. Immunol. 29:2613.
[0233]          In one embodiment, the Ig constant region or a portion thereof, e.g, an Fc
       region, is a polypeptide including the sequence PKNSSMISNTP (SEQ ID NO: 52)
       and optionally further including a sequence selected from HQSLGTQ (SEQ ID
       NO: 53), HQNLSDGK (SEQ ID NO: 54), HQNISDGK (SEQ ID NO: 55), or
       VISSHLGQ (SEQ ID NO: 56) (U.S. Pat. No. 5,739,277).
[0234]          In another embodiment, the immunoglobulin constant region or a portion
       thereof comprises an amino acid sequence in the hinge region or a portion thereof
       that forms one or more disulfide bonds with another immunoglobulin constant
       region or a portion thereof. The disulfide bond by the immunoglobulin constant
       region or a portion thereof places the first polypeptide comprising FVIII and the
       second polypeptide comprising the VWF fragment together so that endogenous
       VWF does not replace the VWF fragment and does not bind to the FVIII.
       Therefore, the disulfide bond between the first immunoglobulin constant region or
       a portion thereof and a second immunoglobulin constant region or a portion
       thereof prevents interaction between endogenous VWF and the FVIII protein.
       This inhibition of interaction between the VWF and the FVIII protein allows the
       half-life of the FVIII protein to go beyond the two fold limit. The hinge region or
                                             - 133 -

       a portion thereof can further be linked to one or more domains of CHI, CH2,
       CH3, a fragment thereof, and any combinations thereof. In a particular
       embodiment, the immunoglobulin constant region or a portion thereof is a hinge
       region and CH2.
[0235]         In certain embodiments, the Ig constant region or a portion thereof is hemi
       glycosylated. For example, the chimeric protein comprising two Fc regions or
       FcRn binding partners may contain a first, glycosylated, Fc region (e.g., a
       glycosylated CH2 region) or FcRn binding partner and a second, aglycosylated, Fc
       region (e.g., an aglycosylated CH2 region) or FcRn binding partner. In one
       embodiment, a linker may be interposed between the glycosylated and
       aglycosylated Fc regions. In another embodiment, the Fc region or FcRn binding
       partner is fully glycosylated, i.e., all of the Fc regions are glycosylated. In other
       embodiments, the Fc region may be aglycosylated, i.e., none of the Fc moieties are
       glycosylated.
[0236]         In certain embodiments, a chimeric protein of the invention comprises an
       amino acid substitution to an Ig constant region or a portion thereof (e.g., Fc
       variants), which alters the antigen-independent effector functions of the Ig
       constant region, in particular the circulating half-life of the protein.
[0237]          Such proteins exhibit either increased or decreased binding to FcRn when
       compared to proteins lacking these substitutions and, therefore, have an increased
       or decreased half-life in serum, respectively. Fc variants with improved affinity
       for FcRn are anticipated to have longer serum half-lives, and such molecules have
       useful applications in methods of treating mammals where long half-life of the
       administered polypeptide is desired, e.g., to treat a chronic disease or disorder
       (see, e.g., US Patents 7,348,004, 7,404,956, and 7,862,820). In contrast, Fc
       variants with decreased FcRn binding affinity are expected to have shorter half
       lives, and such molecules are also useful, for example, for administration to a
       mammal where a shortened circulation time may be advantageous, e.g. for in vivo
       diagnostic imaging or in situations where the starting polypeptide has toxic side
       effects when present in the circulation for prolonged periods. Fc variants with
       decreased FcRn binding affinity are also less likely to cross the placenta and, thus,
       are also useful in the treatment of diseases or disorders in pregnant women. In
       addition, other applications in which reduced FcRn binding affinity may be
                                             - 134  -

       desired include those applications in which localization the brain, kidney, and/or
       liver is desired. In one exemplary embodiment, the chimeric protein of the
       invention exhibit reduced transport across the epithelium of kidney glomeruli from
       the vasculature. In another embodiment, the chimeric protein of the invention
       exhibit reduced transport across the blood brain barrier (BBB) from the brain, into
       the vascular space. In one embodiment, a protein with altered FcRn binding
       comprises at least one Fc region or FcRn binding partner (e.g, one or two Fc
       regions or FcRn binding partners) having one or more amino acid substitutions
       within the "FcRn binding loop" of an Ig constant region. The FcRn binding loop
       is comprised of amino acid residues 280-299 (according to EU numbering) of a
       wild-type, full-length, Fc region. In other embodiments, an Ig constant region or a
       portion thereof in a chimeric protein of the invention having altered FcRn binding
       affinity comprises at least one Fc region or FcRn binding partner having one or
       more amino acid substitutions within the 15   A FcRn "contact zone."   As used
       herein, the term 15  A FcRn "contact zone" includes residues at the following
       positions of a wild-type, full-length Fc moiety: 243-261, 275-280, 282-293, 302
       319, 336- 348, 367, 369, 372-389, 391, 393, 408, 424, 425-440 (EU numbering).
       In other embodiments, a Ig constant region or a portion thereof of the invention
       having altered FcRn binding affinity comprises at least one Fc region or FcRn
       binding partner having one or more amino acid substitutions at an amino acid
       position corresponding to any one of the following EU positions: 256, 277-28 1,
       283-288, 303-309, 313, 338, 342, 376, 381, 384, 385, 387, 434 (e.g., N434A or
       N434K), and 438. Exemplary amino acid substitutions which altered FcRn
       binding activity are disclosed in International PCT Publication No. W005/047327
       which is incorporated by reference herein.
[02381          An Fc region or FcRn binding partner used in the invention may also
       comprise an art recognized amino acid substitution which alters the glycosylation
       of the chimeric protein. For example, the Fc region or FcRn binding partner of the
       chimeric protein linked to a VWF fragment or a FVIII protein may comprise an Fc
       region having a mutation leading to reduced glycosylation (e.g., N- or O-linked
       glycosylation) or may comprise an altered glycoform of the wild-type Fc moiety
       (e.g., a low fucose or fucose-free glycan).
                                           - 135 -

[02391         In one embodiment, an unprocessed chimeric protein of the invention may
       comprise a genetically fused Fc region (i.e., scFc region) having two or more of its
       constituent Ig constant region or a portion thereof independently selected from the
       Ig constant region or a portion thereof described herein. In one embodiment, the
       Fc regions of a dimeric Fc region are the same. In another embodiment, at least
       two of the Fc regions are different. For example, the Fc regions or FcRn binding
       partners of the proteins of the invention comprise the same number of amino acid
       residues or they may differ in length by one or more amino acid residues (e.g., by
       about 5 amino acid residues (e.g., 1, 2, 3, 4, or 5 amino acid residues), about 10
       residues, about 15 residues, about 20 residues, about 30 residues, about 40
       residues, or about 50 residues). In yet other embodiments, the Fc regions or FcRn
       binding partners of the protein of the invention may differ in sequence at one or
       more amino acid positions. For example, at least two of the Fc regions or FcRn
       binding partners may differ at about 5 amino acid positions (e.g., 1, 2, 3, 4, or 5
       amino acid positions), about 10 positions, about 15 positions, about 20 positions,
       about 30 positions, about 40 positions, or about 50 positions).
       E)      Linkers
[0240]         The chimeric protein of the present invention further comprises one or
       more linkers. One type of the linkers is a cleavable linker, which can be cleaved
       by various proteases when administered to a subject in vivo, e.g., at a site of
       coagulation. In one embodiment, the cleavable linker allows cleavage of moiety,
       e.g., a VWF fragment, from the chimeric protein at the site of the coagulation
       cascade, thus allowing activated FVIII (FVIIIa) to have its FVIIIa activity.
       Another type of the linkers is a processable linker, which contains an intracellular
       cleavage site and thus can be cleaved by an intracellular processing enzyme in a
       host cell, allowing convenient expression of a polypeptide and formation of a
       chimeric protein.
[0241]         One or more linkers can be present between any two proteins in the
       chimeric protein. In one embodiment, a chimeric protein comprises (i) a VWF
       fragment, (ii) an XTEN sequence, and (iii) a FVIII protein, wherein the VWF
       fragment is linked to the XTEN sequence by a linker, e.g., a cleavable linker, and
       the XTEN sequence is further linked to the FVIII protein (i.e., V-L-X-FVIII). In
       another embodiment, a chimeric protein comprises (i) a VWF fragment, (ii) an
                                           - 136 -

       XTEN sequence, and (iii) a FVIII protein, wherein the VWF fragment is linked to
       the XTEN sequence, and the XTEN sequence is linked to the FVIII protein by a
       linker, e.g., a cleavable linker (i.e., V-X-L-FVIII).
[0242]          In certain embodiments, a chimeric protein comprises (i) a VWF fragment,
       (ii) an XTEN sequence, (iii) a first Ig constant region or a portion thereof (e.g., a
       first Fc region), (iv) a FVIII protein, and (v) a second Ig constant region or a
       portion thereof (e.g., a second Fc region), wherein the VWF fragment is linked to
       the XTEN sequence by an optional linker, e.g., a cleavable linker. The XTEN
       sequence can be further linked to the first Ig constant region or a portion thereof
       by a linker, e.g., a cleavable linker. The FVIII protein (with or without an XTEN
       sequence) can also be linked to the second Ig constant region or a portion thereof
       by an optional linker, e.g. a cleavable linker. In certain embodiments, the
       chimeric protein further comprises one or more linkers, e.g., processable linkers,
       between the first Ig constant region or a portion thereof (e.g., first Fc region) and
       the second Ig constant region or a portion thereof (e.g., second Fc region),
       between the VWF fragment and the second Ig constant region or a portion thereof,
       or between the FVIII protein and the first Ig constant region or a portion thereof
       (e.g., first Fc region).
[0243]          In some embodiments, the present invention includes a chimeric protein
       comprising (i) a FVIII protein, (ii) an XTEN sequence, (iii) a first Ig constant
       region or a portion thereof, and (iv) a second Ig constant region or a portion
       thereof, wherein the first Ig constant region or a portion thereof and the second Ig
       constant region or a portion thereof are linked by a processable linker.
[0244]          The linker useful in the present invention can comprise any organic
       molecule. In one embodiment, the linker comprises a polymer, e.g., polyethylene
       glycol (PEG) or hydroxyethyl starch (HES). In another embodiment, the linker
       comprises an amino acids sequence. The linker can comprise at least about 10,
       20,30,40,50,60,70,80,90, 100, 150,200,300,400,500,600,700,800,900,
       1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, or 2000 amino
       acids. The linker can comprise 1-5 amino acids, 1-10 amino acids, 1-20 amino
       acids, 10-50 amino acids, 50-100 amino acids, 100-200 amino acids, 200-300
       amino acids, 300-400 amino acids, 400-500 amino acids, 500-600 amino acids,
       600-700 amino acids, 700-800 amino acids, 800-900 amino acids, or 900-1000
                                              - 137 -

       amino acids. In one embodiment, the linker comprises an XTEN sequence.
       Additional examples of XTEN can be used according to the present invention and
       are disclosed in US Patent Publication Nos. 2010/0239554 Al, 2010/0323956 Al,
       2011/0046060 A1, 2011/0046061 A1, 2011/0077199 A1, or 2011/0172146 A1, or
       International Patent Publication Nos. WO 2010091122 Al, WO 2010144502 A2,
       WO 2010144508 Al, WO 2011028228 Al, WO 2011028229 Al, or WO
       2011028344 A2. In another embodiment, the linker is a PAS sequence.
[0245]          The linker useful in the present invention can comprise any organic
       molecule. In one embodiment, the linker is a polymer, e.g., polyethylene glycol
       (PEG) or hydroxyethyl starch (HES). In another embodiment, the linker is an
       amino acid sequence. The linker can comprise at least about 10, 20, 30, 40, 50,
       60,70,80,90,100,150,200,300,400,500,600,700,800,900,1000,1100,
       1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, or 2000 amino acids. The linker
       can comprise 1-5 amino acids, 1-10 amino acids, 1-20 amino acids, 10-50 amino
       acids, 50-100 amino acids, 100-200 amino acids, 200-300 amino acids, 300-400
       amino acids, 400-500 amino acids, 500-600 amino acids, 600-700 amino acids,
       700-800 amino acids, 800-900 amino acids, or 900-1000 amino acids.
[0246]          Examples of linkers are well known in the art. In one embodiment, the
       linker comprises the sequence G.. The linker can comprise the sequence (GA)..
       The linker can comprise the sequence (GGS).. In other embodiments, the linker
       comprises (GGGS). (SEQ ID NO: 57). In still other embodiments, the linker
       comprises the sequence (GGS)(GGGGS). (SEQ ID NO: 58). In these instances,
       n may be an integer from 1-100. In other instances, n may be an integer from 1
       20, i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
       Examples of linkers include, but are not limited to, GGG, SGGSGGS (SEQ ID
       NO: 59), GGSGGSGGSGGSGGG (SEQ ID NO: 60), GGSGGSGGGGSGGGGS
       (SEQ ID NO: 61), GGSGGSGGSGGSGGSGGS (SEQ ID NO: 62), or
       GGGGSGGGGSGGGGS (SEQ ID NO: 63). The linker does not eliminate or
       diminish the VWF fragment activity or the clotting activity of Factor VIII.
       Optionally, the linker enhances the VWF fragment activity or the clotting activity
       of Factor VIII protein, e.g., by further diminishing the effects of steric hindrance
       and making the VWF fragment or Factor VIII portion more accessible to its target
       binding site.
                                                - 138 -

[02471          In one embodiment, the linker useful for the chimeric protein is 15-25
       amino acids long. In another embodiment, the linker useful for the chimeric
       protein is 15-20 amino acids long. In some embodiments, the linker for the
       chimeric protein is 10-25 amino acids long. In other embodiments, the linker for
       the chimeric protein is 15 amino acids long. In still other embodiments, the linker
       for the chimeric protein is (GGGGS). (SEQ ID NO: 64) where G represents
       glycine, S represents serine and n is an integer from 1-20.
       F)       Cleavage Sites
[0248]          The linker may also incorporate a moiety capable of being cleaved either
       chemically (e.g., hydrolysis of an ester bond), enzymatically (i.e., incorporation of
       a protease cleavage sequence), or photolytically (e.g., a chromophore such as 3
       amino-3-(2-nitrophenyl) proprionic acid (ANP)) in order to release one molecule
       from another.
[0249]          In one embodiment, the linker is a cleavable linker. The cleavable linkers
       can comprise one or more cleavage sites at the N-terminus or C-terminus or both.
       In another embodiment, the cleavable linker consists essentially of or consists of
       one or more cleavable sites. In other embodiments, the cleavable linker comprises
       heterologous amino acid linker sequences described herein or polymers and one or
       more cleavable sites.
[0250]          In certain embodiments, a cleavable linker comprises one or more cleavage
       sites that can be cleaved in a host cell (i.e., intracellular processing sites). Non
       limiting examples of the cleavage site include RRRR (SEQ ID NO: 9), RKRRKR
       (SEQ ID NO: 10), and RRRRS (SEQ ID NO: 11).
[0251]          In other embodiments, a cleavable linker comprises one or more cleavage
       sites that are cleaved by a protease after a chimeric protein comprising the
       cleavable linker is administered to a subject. In one embodiment, the cleavage site
       is cleaved by a protease selected from the group consisting of factor XIa, factor
       XIIa, kallikrein, factor VIIa, factor IXa, factor Xa, factor IIa (thrombin), Elastase
       2, MMP-12, MMP-13, MMP-17, and MMP-20. In another embodiment, the
       cleavage site is selected from the group consisting of a FXIa cleavage site (e.g.,
       KLTRJAET (SEQ ID NO: 65)), a FXIa cleavage site (e.g, DFTRJVVG (SEQ ID
       NO: 66)), a FXIIa cleavage site (e.g., TMTRJIVGG (SEQ ID NO: 67)), a
       Kallikrein cleavage site (e.g., SPFRISTGG (SEQ ID NO: 68)), a FVIIa cleavage
                                            - 139  -

       site (e.g., LQVRIIVGG (SEQ ID NO: 69)), a FIXa cleavage site (e.g.,
       PLGRjIVGG (SEQ ID NO: 70)), a FXa cleavage site (e.g., IEGRITVGG (SEQ
       ID NO: 71)), a FIIa (thrombin) cleavage site (e.g, LTPRISLLV (SEQ ID NO:
       72)), a Elastase-2 cleavage site (e.g, LGPVISGVP (SEQ ID NO: 73)), a
       Granzyme-B cleavage (e.g, VAGDISLEE (SEQ ID NO: 74)), a MMP-12
       cleavage site (e.g., GPAGILGGA (SEQ ID NO: 75)), a MMP-13 cleavage site
       (e.g., GPAGILRGA (SEQ ID NO: 76)), a MMP-17 cleavage site (e.g.,
       APLGILRLR (SEQ ID NO: 77)), a MMP-20 cleavage site (e.g., PALPILVAQ
       (SEQ ID NO: 78)), a TEV cleavage site (e.g., ENLYFQJG (SEQ ID NO: 79)), a
       Enterokinase cleavage site (e.g., DDDKIIVGG (SEQ ID NO: 80)), a Protease 3C
       (PRESCISSION TM) cleavage site (e.g., LEVLFQIGP (SEQ ID NO: 81)), and a
       Sortase A cleavage site (e.g., LPKTIGSES) (SEQ ID NO: 82). In certain
       embodiments, the FXIa cleavage sites include, but are not limited to, e.g.,
       TQSFNDFTR (SEQ ID NO: 83) and SVSQTSKLTR (SEQ ID NO: 84). Non
       limiting exemplary thrombin cleavage sites include, e.g., DFLAEGGGVR (SEQ
       ID NO: 85), TTKIKPR (SEQ ID NO: 86), or LVPRG (SEQ ID NO: 87), and a
       sequence comprising, consisting essentially of, or consisting of ALRPR (SEQ ID
       NO: 17) (e.g., ALRPRVVGGA (SEQ ID NO: 88)).
[0252]          In a specific embodiment, the cleavage site is
       TLDPRSFLLRNPNDKYEPFWEDEEK (SEQ ID NO: 8).
       POLYNUCLEOTIDES, VECTORS, AND HOST CELLS
[0253]          Also provided in the invention is a polynucleotide encoding (a) a VWF
       fragment linked to an XTEN sequence and a FVIII protein, (b) a FVIII protein
       linked to an XTEN sequence and Fc, or (c) a FVIII protein linked to an XTEN
       sequence and a VWF fragment described herein. When a chimeric protein is a
       single polypeptide chain (e.g., F2-L2-X-V-L1-F1-FVIII, wherein FVIII comprises
       a FVIII protein, F1 comprises a first Ig constant region or a portion thereof, e.g., a
       first Fc region, LI comprises a first linker, V comprises a VWF fragment, X
       comprises an XTEN sequence, L2 comprises a second linker, and F2 comprises a
       second Ig constant region or a portion thereof, e.g., a second Fc region), the
       invention is drawn to a single polynucleotide chain encoding the single
       polypeptide chain. When the chimeric protein comprises a first and a second
       polypeptide chains (F2-L2-X-V:FVIII-F 1), the first polypeptide chain comprising
                                           - 140  -

       a VWF fragment linked to a XTEN sequence, which is further linked to a first Ig
       constant region or a portion thereof (e.g., a first Fc region) by a cleavable linker
       (e.g., F2-L2-X-V) and the second polypeptide chain comprising a FVIII protein
       and a second Ig constant region or a portion thereof (e.g., a second Fc region) (e.g,
       FVIII-F 1), wherein the first polypeptide chain and the second polypeptide chain
       are associated with each other, a polynucleotide can comprise the first nucleotide
       sequence and the second nucleotide sequence. In one embodiment, the first
       polypeptide chain and the second polypeptide chain can be encoded by a single
       polynucleotide chain. In another embodiment, the first polypeptide chain and the
       second polypeptide chain are encoded by two different polynucleotides, i.e., a first
       nucleotide sequence and a second nucleotide sequence. In another embodiment,
       the first nucleotide sequence and the second nucleotide sequence are on two
       different polynucleotides (e.g., different vectors). In certain embodiments, the
       present invention is directed to a set of polynucleotides comprising a first
       nucleotide chain and a second nucleotide chain, wherein the first nucleotide chain
       encodes the VWF fragment of the chimeric protein and the second nucleotide
       chain encodes the FVIII protein. In some embodiments, a chimeric protein
       comprising two polypeptide chains or three polypeptide chains can be encoded by
       a single polynucleotide chain, and then processed into two or three (or more)
       polypeptide chains. In yet other embodiments, a chimeric protein comprising
       these polypeptide chains can be encoded by two or three polynucleotide chains.
[0254]          In other embodiments, the set of the polynucleotides further comprises an
       additional nucleotide chain (e.g., a second nucleotide chain when the chimeric
       polypeptide is encoded by a single polynucleotide chain or a third nucleotide chain
       when the chimeric protein is encoded by two polynucleotide chains) which
       encodes a protein convertase. The protein convertase can be selected from the
       group consisting of proprotein convertase subtilisin/kexin type 5 (PCSK5 or PC5),
       proprotein convertase subtilisin/kexin type 7 (PCSK7 or PC5), a yeast Kex 2,
       proprotein convertase subtilisin/kexin type 3 (PACE or PCSK3), and two or more
       combinations thereof. In some embodiments, the protein convertase is PACE,
       PC5, or PC7. In a specific embodiment, the protein convertase is PC5 or PC7.
       See International Application no. PCT/US2011/043568.
                                           - 141  -

[02551         As used herein, an expression vector refers to any nucleic acid construct
       which contains the necessary elements for the transcription and translation of an
       inserted coding sequence, or in the case of an RNA viral vector, the necessary
       elements for replication and translation, when introduced into an appropriate host
       cell. Expression vectors can include plasmids, phagemids, viruses, and derivatives
       thereof.
[0256]         Expression vectors of the invention will include polynucleotides encoding
       the chimeric protein described herein. In one embodiment, one or more of the
       coding sequences for the VWF fragment and XTEN, the FVIII protein and XTEN,
       or both are operably linked to an expression control sequence. As used herein,
       two nucleic acid sequences are operably linked when they are covalently linked in
       such a way as to permit each component nucleic acid sequence to retain its
       functionality. A coding sequence and a gene expression control sequence are said
       to be operably linked when they are covalently linked in such a way as to place the
       expression or transcription and/or translation of the coding sequence under the
       influence or control of the gene expression control sequence. Two DNA sequences
       are said to be operably linked if induction of a promoter in the 5' gene expression
       sequence results in the transcription of the coding sequence and if the nature of the
       linkage between the two DNA sequences does not (1) result in the introduction of
       a frame-shift mutation, (2) interfere with the ability of the promoter region to
       direct the transcription of the coding sequence, or (3) interfere with the ability of
       the corresponding RNA transcript to be translated into a protein. Thus, a gene
       expression sequence would be operably linked to a coding nucleic acid sequence if
       the gene expression sequence were capable of effecting transcription of that
       coding nucleic acid sequence such that the resulting transcript is translated into the
       desired protein or polypeptide.
[0257]         A gene expression control sequence as used herein is any regulatory
       nucleotide sequence, such as a promoter sequence or promoter-enhancer
       combination, which facilitates the efficient transcription and translation of the
       coding nucleic acid to which it is operably linked. The gene expression control
       sequence may, for example, be a mammalian or viral promoter, such as a
       constitutive or inducible promoter. Constitutive mammalian promoters include,
       but are not limited to, the promoters for the following genes: hypoxanthine
                                           - 142 -

       phosphoribosyl transferase (HPRT), adenosine deaminase, pyruvate kinase, beta
       actin promoter, and other constitutive promoters. Exemplary viral promoters
       which function constitutively in eukaryotic cells include, for example, promoters
       from the cytomegalovirus (CMV), simian virus (e.g., SV40), papilloma virus,
       adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus,
       cytomegalovirus, the long terminal repeats (LTR) of Moloney leukemia virus, and
       other retroviruses, and the thymidine kinase promoter of herpes simplex virus.
       Other constitutive promoters are known to those of ordinary skill in the art. The
       promoters useful as gene expression sequences of the invention also include
       inducible promoters. Inducible promoters are expressed in the presence of an
       inducing agent. For example, the metallothionein promoter is induced to promote
       transcription and translation in the presence of certain metal ions. Other inducible
       promoters are known to those of ordinary skill in the art.
[0258]          In general, the gene expression control sequence shall include, as
       necessary, 5' non-transcribing and 5' non-translating sequences involved with the
       initiation of transcription and translation, respectively, such as a TATA box,
       capping sequence, CAAT sequence, and the like. Especially, such 5' non
       transcribing sequences will include a promoter region which includes a promoter
       sequence for transcriptional control of the operably joined coding nucleic acid.
       The gene expression sequences optionally include enhancer sequences or
       upstream activator sequences as desired.
[0259]          Viral vectors include, but are not limited to, nucleic acid sequences from
       the following viruses: retrovirus, such as Moloney murine leukemia virus, Harvey
       murine sarcoma virus, murine mammary tumor virus, and Rous sarcoma virus;
       adenovirus, adeno-associated virus; SV40-type viruses; polyomaviruses; Epstein
       Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA
       virus such as a retrovirus. One can readily employ other vectors well-known in the
       art. Certain viral vectors are based on non-cytopathic eukaryotic viruses in which
       non-essential genes have been replaced with the gene of interest. Non-cytopathic
       viruses include retroviruses, the life cycle of which involves reverse transcription
       of genomic viral RNA into DNA with subsequent proviral integration into host
       cellular DNA. Retroviruses have been approved for human gene therapy trials.
       Most useful are those retroviruses that are replication-deficient (i.e., capable of
                                            - 143 -

       directing synthesis of the desired proteins, but incapable of manufacturing an
       infectious particle). Such genetically altered retroviral expression vectors have
       general utility for the high efficiency transduction of genes in vivo. Standard
       protocols for producing replication-deficient retroviruses (including the steps of
       incorporation of exogenous genetic material into a plasmid, transfection of a
       packaging cell line with plasmid, production of recombinant retroviruses by the
       packaging cell line, collection of viral particles from tissue culture media, and
       infection of the target cells with viral particles) are provided in Kriegler, M., Gene
       Transfer and Expression, A Laboratory Manual, W.H. Freeman Co., New York
       (1990) and Murry, E. J., Methods in Molecular Biology, Vol. 7, Humana Press,
       Inc., Cliffton, N.J. (1991).
[0260]          In one embodiment, the virus is an adeno-associated virus, a double
       stranded DNA virus. The adeno-associated virus can be engineered to be
       replication-deficient and is capable of infecting a wide range of cell types and
       species. It further has advantages such as heat and lipid solvent stability; high
       transduction frequencies in cells of diverse lineages, including hematopoietic
       cells; and lack of superinfection inhibition thus allowing multiple series of
       transductions. Reportedly, the adeno-associated virus can integrate into human
       cellular DNA in a site-specific manner, thereby minimizing the possibility of
       insertional mutagenesis and variability of inserted gene expression characteristic
       of retroviral infection. In addition, wild-type adeno-associated virus infections
       have been followed in tissue culture for greater than 100 passages in the absence
       of selective pressure, implying that the adeno-associated virus genomic integration
       is a relatively stable event. The adeno-associated virus can also function in an
       extrachromosomal fashion.
[0261]          Other vectors include plasmid vectors. Plasmid vectors have been
       extensively described in the art and are well-known to those of skill in the art. See,
       e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition,
       Cold Spring Harbor Laboratory Press, 1989. In the last few years, plasmid vectors
       have been found to be particularly advantageous for delivering genes to cells in
       vivo because of their inability to replicate within and integrate into a host genome.
       These plasmids, however, having a promoter compatible with the host cell, can
       express a peptide from a gene operably encoded within the plasmid. Some
                                             - 144 -

        commonly used plasmids available from commercial suppliers include pBR322,
        pUC 18, pUC 19, various pcDNA plasmids, pRC/CMV, various pCMV plasmids,
        pSV40, and pBlueScript. Additional examples of specific plasmids include
        pcDNA3.1, catalog number V79020; pcDNA3.1/hygro, catalog number V87020;
        pcDNA4/myc-His, catalog number V86320; and pBudCE4. 1, catalog number
        V53220, all from Invitrogen (Carlsbad, CA.). Other plasmids are well-known to
        those of ordinary skill in the art. Additionally, plasmids may be custom designed
        using standard molecular biology techniques to remove and/or add specific
        fragments of DNA.
[0262]           In one insect expression system that may be used to produce the proteins
        of the invention, Autographa californicanuclear polyhidrosis virus (AcNPV) is
        used as a vector to express the foreign genes. The virus grows in Spodoptera
       frugiperda cells. A coding sequence may be cloned into non-essential regions (for
        example, the polyhedron gene) of the virus and placed under control of an
        ACNPV promoter (for example, the polyhedron promoter). Successful insertion of
        a coding sequence will result in inactivation of the polyhedron gene and
        production of non-occluded recombinant virus (i.e., virus lacking the
        proteinaceous coat coded for by the polyhedron gene). These recombinant viruses
        are then used to infect Spodopterafrugiperdacells in which the inserted gene is
        expressed. (see, e.g., Smith et al. (1983) J Virol 46:584; U.S. Pat. No. 4,215,051).
        Further examples of this expression system may be found in Ausubel et al., eds.
        (1989) Current Protocols in Molecular Biology, Vol. 2, Greene Publish. Assoc. &
        Wiley Interscience.
[0263]           Another system which can be used to express the proteins of the invention
        is the glutamine synthetase gene expression system, also referred to as the "GS
        expression system" (Lonza Biologics PLC, Berkshire UK). This expression
        system is described in detail in U.S. Pat. No. 5,981,216.
[0264]           In mammalian host cells, a number of viral based expression systems may
        be utilized. In cases where an adenovirus is used as an expression vector, a coding
        sequence may be ligated to an adenovirus transcription/translation control
        complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene
        may then be inserted in the adenovirus genome by in vitro or in vivo
        recombination. Insertion in a non-essential region of the viral genome (e.g., region
                                             - 145 -

       E l or E3) will result in a recombinant virus that is viable and capable of
       expressing peptide in infected hosts. See, e.g., Logan & Shenk (1984) Proc Natl
       Acad Sci USA 81:3655). Alternatively, the vaccinia 7.5 K promoter may be used.
       See, e.g., Mackett et al. (1982) Proc Natl Acad Sci USA 79:7415; Mackett et al.
       (1984) J Virol 49:857; Panicali et al. (1982) Proc Natl Acad Sci USA 79:4927.
[0265]          To increase efficiency of production, the polynucleotides can be designed
       to encode multiple units of the protein of the invention separated by enzymatic
       cleavage sites. The resulting polypeptide can be cleaved (e.g., by treatment with
       the appropriate enzyme) in order to recover the polypeptide units. This can
       increase the yield of polypeptides driven by a single promoter. When used in
       appropriate viral expression systems, the translation of each polypeptide encoded
       by the mRNA is directed internally in the transcript; e.g., by an internal ribosome
       entry site, IRES. Thus, the polycistronic construct directs the transcription of a
       single, large polycistronic mRNA which, in turn, directs the translation of
       multiple, individual polypeptides. This approach eliminates the production and
       enzymatic processing of polyproteins and may significantly increase the yield of
       polypeptides driven by a single promoter.
[0266]          Vectors used in transformation will usually contain a selectable marker
       used to identify transformants. In bacterial systems, this can include an antibiotic
       resistance gene such as ampicillin or kanamycin. Selectable markers for use in
       cultured mammalian cells include genes that confer resistance to drugs, such as
       neomycin, hygromycin, and methotrexate. The selectable marker may be an
       amplifiable selectable marker. One amplifiable selectable marker is the
       dihydrofolate reductase (DHFR) gene. Simonsen C C et al. (1983) Proc Natl Acad
       Sci USA 80:2495-9. Selectable markers are reviewed by Thilly (1986) Mammalian
       Cell Technology, Butterworth Publishers, Stoneham, Mass., and the choice of
       selectable markers is well within the level of ordinary skill in the art.
[0267]          Selectable markers may be introduced into the cell on a separate plasmid at
       the same time as the gene of interest, or they may be introduced on the same
       plasmid. If on the same plasmid, the selectable marker and the gene of interest
       may be under the control of different promoters or the same promoter, the latter
       arrangement producing a dicistronic message. Constructs of this type are known in
       the art (for example, U.S. Pat. No. 4,713,339).
                                           - 146 -

[02681         The expression vectors can encode for tags that permit easy purification of
       the recombinantly produced protein. Examples include, but are not limited to,
       vector pUR278 (Ruther et al. (1983) EMBO J2:1791), in which coding sequences
       for the protein to be expressed may be ligated into the vector in frame with the lac
       z coding region so that a tagged fusion protein is produced; pGEX vectors may be
       used to express proteins of the invention with a glutathione S-transferase (GST)
       tag. These proteins are usually soluble and can easily be purified from cells by
       adsorption to glutathione-agarose beads followed by elution in the presence of free
       glutathione. The vectors include cleavage sites (thrombin or Factor Xa protease or
       PRESCISSION PROTEASE T M (Pharmacia, Peapack, N.J.)) for easy removal of
       the tag after purification.
[02691         The expression vector or vectors are then transfected or co-transfected into
       a suitable target cell, which will express the polypeptides. Transfection techniques
       known in the art include, but are not limited to, calcium phosphate precipitation
       (Wigler et al. (1978) Cell 14:725), electroporation (Neumann et al. (1982) EMBO
       J 1:841), and liposome-based reagents. A variety of host-expression vector
       systems may be utilized to express the proteins described herein including both
       prokaryotic and eukaryotic cells. These include, but are not limited to,
       microorganisms such as bacteria (e.g., E. coli) transformed with recombinant
       bacteriophage DNA or plasmid DNA expression vectors containing an appropriate
       coding sequence; yeast or filamentous fungi transformed with recombinant yeast
       or fungi expression vectors containing an appropriate coding sequence; insect cell
       systems infected with recombinant virus expression vectors (e.g., baculovirus)
       containing an appropriate coding sequence; plant cell systems infected with
       recombinant virus expression vectors (e.g., cauliflower mosaic virus or tobacco
       mosaic virus) or transformed with recombinant plasmid expression vectors (e.g.,
       Ti plasmid) containing an appropriate coding sequence; or animal cell systems,
       including mammalian cells (e.g., HEK 293, CHO, Cos, HeLa, HKB 11, and BHK
       cells).
[0270]         In one embodiment, the host cell is a eukaryotic cell. As used herein, a
       eukaryotic cell refers to any animal or plant cell having a definitive nucleus.
       Eukaryotic cells of animals include cells of vertebrates, e.g., mammals, and cells
       of invertebrates, e.g., insects. Eukaryotic cells of plants specifically can include,
                                            - 147 -

       without limitation, yeast cells. A eukaryotic cell is distinct from a prokaryotic
       cell, e.g., bacteria.
[0271]          In certain embodiments, the eukaryotic cell is a mammalian cell. A
       mammalian cell is any cell derived from a mammal. Mammalian cells specifically
       include, but are not limited to, mammalian cell lines. In one embodiment, the
       mammalian cell is a human cell. In another embodiment, the mammalian cell is a
       HEK 293 cell, which is a human embryonic kidney cell line. HEK 293 cells are
       available as CRL-1533 from American Type Culture Collection, Manassas, VA,
       and as 293-H cells, Catalog No. 11631-017 or 293-F cells, Catalog No. 11625-019
       from Invitrogen (Carlsbad, Calif.). In some embodiments, the mammalian cell is a
       PER.C6* cell, which is a human cell line derived from retina. PER.C6* cells are
       available from Crucell (Leiden, The Netherlands). In other embodiments, the
       mammalian cell is a Chinese hamster ovary (CHO) cell. CHO cells are available
       from American Type Culture Collection, Manassas, VA. (e.g., CHO-KI; CCL
       61). In still other embodiments, the mammalian cell is a baby hamster kidney
       (BHK) cell. BHK cells are available from American Type Culture Collection,
       Manassas, Va. (e.g., CRL-1632). In some embodiments, the mammalian cell is a
       HKB1 1 cell, which is a hybrid cell line of a HEK293 cell and a human B cell line.
       Mei et al., Mol. Biotechnol. 34(2): 165-78 (2006).
[0272]          In one embodiment, a plasmid including a FVIII(X)-Fc fusion coding
       sequence, a VWF fragment-L-Fc fusion coding sequence, or both and a selectable
       marker, e.g., zeocin resistance, are transfected into HEK 293 cells, for production
       of a chimeric protein.
[0273]          In another embodiment, a plasmid including a FVIII-Fc fusion coding
       sequence, a VWF fragment-XTEN-L-Fc fusion coding sequence, or both and a
       selectable marker, e.g., zeocin resistance, are transfected into HEK 293 cells, for
       production of a chimeric protein.
[0274]          In other embodiments, a plasmid including a FVIII(X)-Fc fusion coding
       sequence, a Fc coding sequence, or both and a selectable marker, e.g., zeocin
       resistance, are transfected into HEK 293 cells, for production of a chimeric
       protein.
[0275]          In some embodiments, a first plasmid including a FVIII(X)-Fc fusion
       coding sequence and a first selectable marker, e.g., a zeocin resistance gene, and a
                                           - 148  -

       second plasmid including an Fc coding sequence or a VWF fragment-L-Fc coding
       sequence and a second selectable marker, e.g., a neomycin resistance gene, and a
       third plasmid including a protein convertase coding sequence and a third
       selectable marker, e.g., a hygromycin resistance gene, are cotransfected into HEK
       293 cells, for production of the chimeric protein. The first and second plasmids
       can be introduced in equal amounts (i.e., 1:1 molar ratio), or they can be
       introduced in unequal amounts.
[0276]          In still other embodiments, a first plasmid including a FVIII-Fc fusion
       coding sequence and a first selectable marker, e.g., a zeocin resistance gene, and a
       second plasmid including a VWF fragment-XTEN-L-Fc coding sequence and a
       second selectable marker, e.g., a neomycin resistance gene, and a third plasmid
       including a protein convertase coding sequence and a third selectable marker, e.g.,
       a hygromycin resistance gene, are cotransfected into HEK 293 cells, for
       production of the chimeric protein. The first and second plasmids can be
       introduced in equal amounts (i.e., 1:1 molar ratio), or they can be introduced in
       unequal amounts.
[0277]          In yet other embodiments, a first plasmid including a FVIII(X)-Fc fusion
       coding sequence and a first selectable marker, e.g., a zeocin resistance gene, and a
       second plasmid including a VWF fragment-XTEN-L-Fc coding sequence and a
       second selectable marker, e.g., a neomycin resistance gene, and a third plasmid
       including a protein convertase coding sequence and a third selectable marker, e.g.,
       a hygromycin resistance gene, are cotransfected into HEK 293 cells, for
       production of the chimeric protein. The first and second plasmids can be
       introduced in equal amounts (i.e., 1:1 molar ratio), or they can be introduced in
       unequal amounts.
[0278]          In certain embodiments, a first plasmid, including a chimeric protein
       encoding FVIII (with or without XTEN)-F1-L1-V-XTEN-L2-F2 coding sequence
       and a first selectable marker, e.g., a zeocin resistance gene, and a second plasmid
       including a protein convertase coding sequence and a second selectable marker,
       e.g., a hygromycin resistance gene, are cotransfected into HEK 293 cells, for
       production of the chimeric protein. The promoters for the FVIII(X)-Fc coding
       sequence and the VWF-XTEN-Fc coding sequence can be different or they can be
       the same.
                                            - 149  -

[02791          In still other embodiments, transfected cells are stably transfected. These
       cells can be selected and maintained as a stable cell line, using conventional
       techniques known to those of skill in the art.
[0280]          Host cells containing DNA constructs of the protein are grown in an
       appropriate growth medium. As used herein, the term "appropriate growth
       medium" means a medium containing nutrients required for the growth of cells.
       Nutrients required for cell growth may include a carbon source, a nitrogen source,
       essential amino acids, vitamins, minerals, and growth factors. Optionally, the
       media can contain one or more selection factors. Optionally the media can contain
       bovine calf serum or fetal calf serum (FCS). In one embodiment, the media
       contains substantially no IgG. The growth medium will generally select for cells
       containing the DNA construct by, for example, drug selection or deficiency in an
       essential nutrient which is complemented by the selectable marker on the DNA
       construct or co-transfected with the DNA construct. Cultured mammalian cells are
       generally grown in commercially available serum-containing or serum-free media
       (e.g., MEM, DMEM, DMEM/F 12). In one embodiment, the medium is CD293
       (Invitrogen, Carlsbad, CA.). In another embodiment, the medium is CD17
       (Invitrogen, Carlsbad, CA.). Selection of a medium appropriate for the particular
       cell line used is within the level of those ordinary skilled in the art.
[0281]          In order to co-express the two polypeptide chains of the chimeric protein,
       the host cells are cultured under conditions that allow expression of both chains.
       As used herein, culturing refers to maintaining living cells in vitro for at least a
       definite time. Maintaining can, but need not include, an increase in population of
       living cells. For example, cells maintained in culture can be static in population,
       but still viable and capable of producing a desired product, e.g., a recombinant
       protein or recombinant fusion protein. Suitable conditions for culturing
       eukaryotic cells are well known in the art and include appropriate selection of
       culture media, media supplements, temperature, pH, oxygen saturation, and the
       like. For commercial purposes, culturing can include the use of any of various
       types of scale-up systems including shaker flasks, roller bottles, hollow fiber
       bioreactors, stirred-tank bioreactors, airlift bioreactors, Wave bioreactors, and
       others.
                                            - 150 -

[02821         The cell culture conditions are also selected to allow association of the
       VWF fragment with the FVIII protein. Conditions that allow expression of the
       VWF fragment and/or the FVIII protein may include the presence of a source of
       vitamin K. For example, in one embodiment, stably transfected HEK 293 cells are
       cultured in CD293 media (Invitrogen, Carlsbad, CA) or OptiCHO media
       (Invitrogen, Carlsbad, CA) supplemented with 4 mM glutamine.
[0283]         In one aspect, the present invention is directed to a method of expressing,
       making, or producing the chimeric protein of the invention comprising a)
       transfecting a host cell comprising a polynucleotide encoding the chimeric protein
       and b) culturing the host cell in a culture medium under a condition suitable for
       expressing the chimeric protein, wherein the chimeric protein is expressed.
[0284]         In further embodiments, the protein product containing the VWF fragment
       linked to an XTEN sequence or the FVIII protein linked to an XTEN sequence is
       secreted into the media. Media is separated from the cells, concentrated, filtered,
       and then passed over two or three affinity columns, e.g., a protein A column and
       one or two anion exchange columns.
[0285]         In certain aspects, the present invention relates to the chimeric protein
       produced by the methods described herein.
[0286]         In vitro production allows scale-up to give large amounts of the desired
       altered polypeptides of the invention. Techniques for mammalian cell cultivation
       under tissue culture conditions are known in the art and include homogeneous
       suspension culture, e.g. in an airlift reactor or in a continuous stirrer reactor, or
       immobilized or entrapped cell culture, e.g. in hollow fibers, microcapsules, on
       agarose microbeads or ceramic cartridges. If necessary and/or desired, the
       solutions of polypeptides can be purified by the customary chromatography
       methods, for example gel filtration, ion-exchange chromatography, hydrophobic
       interaction chromatography (HIC, chromatography over DEAE-cellulose or
       affinity chromatography.
       PHARMACEUTICAL COMPOSITION
[0287]         Compositions containing the chimeric protein of the present invention may
       contain a suitable pharmaceutically acceptable carrier. For example, they may
       contain excipients and/or auxiliaries that facilitate processing of the active
       compounds into preparations designed for delivery to the site of action.
                                            -  151 -

[02881         The pharmaceutical composition can be formulated for parenteral
       administration (i.e. intravenous, subcutaneous, or intramuscular) by bolus
       injection. Formulations for injection can be presented in unit dosage form, e.g., in
       ampoules or in multidose containers with an added preservative. The compositions
       can take such forms as suspensions, solutions, or emulsions in oily or aqueous
       vehicles, and contain formulatory agents such as suspending, stabilizing and/or
       dispersing agents. Alternatively, the active ingredient can be in powder form for
       constitution with a suitable vehicle, e.g., pyrogen free water.
[02891         Suitable formulations for parenteral administration also include aqueous
       solutions of the active compounds in water-soluble form, for example, water
       soluble salts. In addition, suspensions of the active compounds as appropriate oily
       injection suspensions may be administered. Suitable lipophilic solvents or vehicles
       include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for
       example, ethyl oleate or triglycerides. Aqueous injection suspensions may contain
       substances, which increase the viscosity of the suspension, including, for example,
       sodium carboxymethyl cellulose, sorbitol and dextran. Optionally, the suspension
       may also contain stabilizers. Liposomes also can be used to encapsulate the
       molecules of the invention for delivery into cells or interstitial spaces. Exemplary
       pharmaceutically acceptable carriers are physiologically compatible solvents,
       dispersion media, coatings, antibacterial and antifungal agents, isotonic and
       absorption delaying agents, water, saline, phosphate buffered saline, dextrose,
       glycerol, ethanol and the like. In some embodiments, the composition comprises
       isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or
       sodium chloride. In other embodiments, the compositions comprise
       pharmaceutically acceptable substances such as wetting agents or minor amounts
       of auxiliary substances such as wetting or emulsifying agents, preservatives or
       buffers, which enhance the shelf life or effectiveness of the active ingredients.
[0290]         Compositions of the invention may be in a variety of forms, including, for
       example, liquid (e.g., injectable and infusible solutions), dispersions, suspensions,
       semi-solid and solid dosage forms. The preferred form depends on the mode of
       administration and therapeutic application.
[0291]         The composition can be formulated as a solution, micro emulsion,
       dispersion, liposome, or other ordered structure suitable to high drug
                                           - 152  -

       concentration. Sterile injectable solutions can be prepared by incorporating the
       active ingredient in the required amount in an appropriate solvent with one or a
       combination of ingredients enumerated above, as required, followed by filtered
       sterilization. Generally, dispersions are prepared by incorporating the active
       ingredient into a sterile vehicle that contains a basic dispersion medium and the
       required other ingredients from those enumerated above. In the case of sterile
       powders for the preparation of sterile injectable solutions, the preferred methods
       of preparation are vacuum drying and freeze-drying that yields a powder of the
       active ingredient plus any additional desired ingredient from a previously sterile
       filtered solution. The proper fluidity of a solution can be maintained, for example,
       by the use of a coating such as lecithin, by the maintenance of the required particle
       size in the case of dispersion and by the use of surfactants. Prolonged absorption
       of injectable compositions can be brought about by including in the composition
       an agent that delays absorption, for example, monostearate salts and gelatin.
[0292]          The active ingredient can be formulated with a controlled-release
       formulation or device. Examples of such formulations and devices include
       implants, transdermal patches, and microencapsulated delivery systems.
       Biodegradable, biocompatible polymers can be used, for example, ethylene vinyl
       acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and
       polylactic acid. Methods for the preparation of such formulations and devices are
       known in the art. See e.g., Sustained and Controlled Release Drug Delivery
       Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.
[0293]          Injectable depot formulations can be made by forming microencapsulated
       matrices of the drug in biodegradable polymers such as polylactide-polyglycolide.
       Depending on the ratio of drug to polymer, and the nature of the polymer
       employed, the rate of drug release can be controlled. Other exemplary
       biodegradable polymers are polyorthoesters and polyanhydrides. Depot injectable
       formulations also can be prepared by entrapping the drug in liposomes or
       microemulsions.
[0294]          Supplementary active compounds can be incorporated into the
       compositions. In one embodiment, the chimeric protein of the invention is
       formulated with another clotting factor, or a variant, fragment, analogue, or
       derivative thereof. For example, the clotting factor includes, but is not limited to,
                                            - 153 -

       factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor
       XIII, prothrombin, fibrinogen, von Willebrand factor or recombinant soluble
       tissue factor (rsTF) or activated forms of any of the preceding. The clotting factor
       of hemostatic agent can also include anti-fibrinolytic drugs, e.g., epsilon-amino
       caproic acid, tranexamic acid.
[0295]         Dosage regimens may be adjusted to provide the optimum desired
       response. For example, a single bolus may be administered, several divided doses
       may be administered over time, or the dose may be proportionally reduced or
       increased as indicated by the exigencies of the therapeutic situation. It is
       advantageous to formulate parenteral compositions in dosage unit form for ease of
       administration and uniformity of dosage. See, e.g., Remington's Pharmaceutical
       Sciences (Mack Pub. Co., Easton, Pa. 1980).
[0296]         In addition to the active compound, the liquid dosage form may contain
       inert ingredients such as water, ethyl alcohol, ethyl carbonate, ethyl acetate,
       benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol,
       dimethylformamide, oils, glycerol, tetrahydrofurfuryl alcohol, polyethylene
       glycols, and fatty acid esters of sorbitan.
[0297]         Non-limiting examples of suitable pharmaceutical carriers are also
       described in Remington's Pharmaceutical Sciences by E. W. Martin. Some
       examples of excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice,
       flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium
       chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, and the like.
       The composition can also contain pH buffering reagents, and wetting or
       emulsifying agents.
[0298]         For oral administration, the pharmaceutical composition can take the form
       of tablets or capsules prepared by conventional means. The composition can also
       be prepared as a liquid for example a syrup or a suspension. The liquid can include
       suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated
       edible fats), emulsifying agents (lecithin or acacia), non-aqueous vehicles (e.g.,
       almond oil, oily esters, ethyl alcohol, or fractionated vegetable oils), and
       preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The
       preparations can also include flavoring, coloring and sweetening agents.
                                            - 154  -

       Alternatively, the composition can be presented as a dry product for constitution
       with water or another suitable vehicle.
[0299]          For buccal administration, the composition may take the form of tablets or
       lozenges according to conventional protocols.
[0300]          For administration by inhalation, the compounds for use according to the
       present invention are conveniently delivered in the form of a nebulized aerosol
       with or without excipients or in the form of an aerosol spray from a pressurized
       pack or nebulizer, with optionally a propellant, e.g., dichlorodifluoromethane,
       trichlorofluoromethane, dichlorotetrafluoromethane, carbon dioxide or other
       suitable gas. In the case of a pressurized aerosol the dosage unit can be determined
       by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g.,
       gelatin for use in an inhaler or insufflator can be formulated containing a powder
       mix of the compound and a suitable powder base such as lactose or starch.
[03011          The pharmaceutical composition can also be formulated for rectal
       administration as a suppository or retention enema, e.g., containing conventional
       suppository bases such as cocoa butter or other glycerides.
[0302]          In one embodiment, a pharmaceutical composition comprises a chimeric
       protein, the polynucleotide encoding the chimeric protein, the vector comprising
       the polynucleotide, or the host cell comprising the vector, and a pharmaceutically
       acceptable carrier. The FVIII protein in a chimeric protein has extended half-life
       compared to wild type FVIII protein or the corresponding FVIII protein without
       the VWF fragment. In one embodiment, wherein the half-life of the FVIII protein
       is extended at least about 1.5 times, at least about 2 times, at least about 2.5 times,
       at least about 3 times, at least about 4 times, at least about 5 times, at least about 6
       times, at least about 7 times, at least about 8 times, at least about 9 times, at least
       about 10 times, at least about 11 times, or at least about 12 times longer than wild
       type FVIII. In another embodiment, the half-life of Factor VIII is at least about 17
       hours, at least about 18 hours, at least about 19 hours, at least about 20 hours, at
       least about 21 hours, at least about 22 hours, at least about 23 hours, at least about
       24 hours, at least about 25 hours, at least about 26 hours, at least about 27 hours,
       at least about 28 hours, at least about 29 hours, at least about 30 hours, at least
       about 31 hours, at least about 32 hours, at least about 33 hours, at least about 34
       hours, at least about 35 hours, at least about 36 hours, at least about 48 hours, at
                                            - 155 -

       least about 60 hours, at least about 72 hours, at least about 84 hours, at least about
       96 hours, or at least about 108 hours.
[03031         In some embodiments, the composition is administered by a route selected
       from the group consisting of topical administration, intraocular administration,
       parenteral administration, intrathecal administration, subdural administration and
       oral administration. The parenteral administration can be intravenous or
       subcutaneous administration.
[0304]         In other embodiments, the composition is used to treat a bleeding disease
       or condition in a subject in need thereof. The bleeding disease or condition is
       selected from the group consisting of a bleeding coagulation disorder,
       hemarthrosis, muscle bleed, oral bleed, hemorrhage, hemorrhage into muscles,
       oral hemorrhage, trauma, trauma capitis, gastrointestinal bleeding, intracranial
       hemorrhage, intra-abdominal hemorrhage, intrathoracic hemorrhage, bone
       fracture, central nervous system bleeding, bleeding in the retropharyngeal space,
       bleeding in the retroperitoneal space, bleeding in the illiopsoas sheath and any
       combinations thereof. In still other embodiments, the subject is scheduled to
       undergo a surgery. In yet other embodiments, the treatment is prophylactic or on
       demand.
       GENE THERAPY
[0305]         A chimeric protein thereof of the invention can be produced in vivo in a
       mammal, e.g., a human patient, using a gene therapy approach to treatment of a
       bleeding disease or disorder selected from the group consisting of a bleeding
       coagulation disorder, hemarthrosis, muscle bleed, oral bleed, hemorrhage,
       hemorrhage into muscles, oral hemorrhage, trauma, trauma capitis,
       gastrointestinal bleeding, intracranial hemorrhage, intra-abdominal hemorrhage,
       intrathoracic hemorrhage, bone fracture, central nervous system bleeding,
       bleeding in the retropharyngeal space, bleeding in the retroperitoneal space, and
       bleeding in the illiopsoas sheath would be therapeutically beneficial. In one
       embodiment, the bleeding disease or disorder is hemophilia. In another
       embodiment, the bleeding disease or disorder is hemophilia A. This involves
       administration of a suitable chimeric protein-encoding nucleic acid operably
       linked to suitable expression control sequences. In certain embodiment, these
       sequences are incorporated into a viral vector. Suitable viral vectors for such gene
                                           - 156 -

       therapy include adenoviral vectors, lentiviral vectors, baculoviral vectors, Epstein
       Barr viral vectors, papovaviral vectors, vaccinia viral vectors, herpes simplex viral
       vectors, and adeno associated virus (AAV) vectors. The viral vector can be a
       replication-defective viral vector. In other embodiments, an adenoviral vector has
       a deletion in its E l gene or E3 gene. When an adenoviral vector is used, the
       mammal may not be exposed to a nucleic acid encoding a selectable marker gene.
       In other embodiments, the sequences are incorporated into a non-viral vector
       known to those skilled in the art.
       METHODS OF USING CHIMERIC PROTEIN
[03061          The present invention is directed to a method of using a chimeric protein
       described herein to prevent or inhibit endogenous VWF binding to a FVIII
       protein. The present invention is also directed to a method of using a chimeric
       protein having a FVIII protein linked to XTEN and an Ig constant region or a
       portion thereof.
[0307]          One aspect of the present invention is directed to preventing or inhibiting
       FVIII interaction with endogenous VWF by blocking or shielding the VWF
       binding site on the FVIII from endogenous VWF and at the same time extending
       half-life of the FVIII protein using an XTEN sequence in combination with an Ig
       constant region or a portion thereof, which can also be a half-life extender. In one
       embodiment, the invention is directed to a method of constructing a FVIII protein
       having half-life longer than wild-type FVIII. In one embodiment, an XTEN
       sequence inhibits or prevents interaction of a FVIII protein in a chimeric protein
       with endogenous VWF. In another embodiment, an Ig constant region or a
       portion thereof inhibits or prevents interaction of the FVIII protein with
       endogenous VWF. The chimeric protein useful in the method includes any one or
       more chimeric protein described herein.
[03081          Another aspect of the invention includes a method of administering to a
       subject in need thereof a chimeric protein comprising a FVIII protein having half
       life longer than wild-type FVIII, wherein the method comprises administering the
       chimeric protein described herein to the subject.
[03091          In one embodiment, the invention is directed to a method of using an
       XTEN sequence and an Ig constant region or a portion thereof to extend a half-life
       of a FVIII protein and a VWF fragment to prevent or inhibit endogenous VWF
                                           - 157  -

       interaction with a FVIII protein. A FVIII protein linked to an XTEN sequence
       (e.g., FVIII(X)) and then bound to or associated with a VWF fragment is shielded
       or protected from the clearance pathway of VWF and thus has reduced clearance
       compared to the FVIII protein not bound to the VWF fragment. The shielded
       FVIII protein thus has maximum extension of a half-life compared to a FVIII
       protein not bound to or associated with the XTEN sequence and the VWF
       fragment. In certain embodiments, the FVIII protein associated with or protected
       by a VWF fragment and linked to an XTEN sequence is not cleared by a VWF
       clearance receptor. In other embodiments, the FVIII protein associated with or
       protected by a VWF fragment and linked to an XTEN sequence is cleared from
       the system slower than the FVIII protein that is not associated with or protected by
       the VWF fragment and linked to the XTEN sequence.
[03101         In one aspect, the chimeric protein comprising the FVIII protein linked to
       an XTEN sequence or the FVIII protein bound to or associated with a VWF
       fragment linked to XTEN has reduced clearance from circulation as the VWF
       fragment does not contain a VWF clearance receptor binding site. The VWF
       fragment prevents or inhibits clearance of FVIII bound to or associated with the
       VWF fragment from the system through the VWF clearance pathway. The VWF
       fragments useful for the present invention can also provide at least one or more
       VWF-like FVIII protection properties that are provided by endogenous VWF. In
       certain embodiments, the VWF fragment or the XTEN sequence can also mask
       one or more FVIII clearance receptor binding site, thereby preventing clearance of
       FVIII by its own clearance pathway.
[03111         In some embodiments, the prevention or inhibition of a FVIII protein
       binding to endogenous VWF by the VWF fragment or the XTEN sequence can be
       in vitro or in vivo.
[0312]         Also provided is a method of increasing the half-life of a FVIII protein
       comprising administering the chimeric protein described herein to a subject in
       need thereof. The half-life of non-activated FVIII bound to or associated with
       full-length VWF is about 12 to 14 hours in plasma. In VWD type 3, wherein there
       is almost no VWF in circulation, the half-life of FVIII is only about six hours,
       leading to symptoms of mild to moderate hemophilia A in such patients due to
       decreased concentrations of FVIII. The half-life of the FVIII protein linked to or
                                          - 158  -

       associated with the VWF fragment or the XTEN sequence of the present invention
       can increase at least about 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2.0
       times, 2.1 times, 2.2 times, 2.3 times, 2.4 times, 2.6 times, 2.7. times, 2.8 times,
       2.9 times, 3.0 times, 3.1 times, 3.2 times, 3.3 times, 3.4 times, 3.5 times, 3.6 times,
       3.7 times, 3.8 times, 3.9 times, or 4.0 times higher than the half-life of the non
       activated FVIII bound to or associated with full-length VWF.
[0313]         In one embodiment, the half-life of the FVIII protein linked to or
       associated with the VWF fragment or linked to an Ig constant region or a portion
       thereof in the chimeric protein comprising an XTEN sequence increases at least
       about 2 times, 2.5 times, 3.0 times, 3.5 times, 4.0 times, 4.5 times, 5.0 times, 5.5
       times, 6.0 times, 7 times, 8 times, 9 times, or 10 times higher than the half-life of
       the non-activated FVIII bound to or associated with full-length VWF. In another
       embodiment, the half-life of the FVIII protein linked to or associated with the
       VWF fragment or an Ig constant region or a portion thereof in the chimeric protein
       comprising an XTEN sequence increases about 2 to about 5 times, about 3 to
       about 10 times, about 5 to about 15 times, about 10 to about 20 times, about 15 to
       about 25 times, about 20 to about 30 times, about 25 to about 35 times, about 30 to
       about 40 times, about 35 to about 45 times higher than the half-life of the non
       activated FVIII bound to or associated with full-length VWF or wild type FVIII.
       In a specific embodiment, the half-life of the FVIII protein linked to or associated
       with the VWF fragment or linked to an Ig constant region in the chimeric protein
       comprising an XTEN sequence increases at least about 30, 31, 32, 33, 34, 35, 36,
       37, 38, 39, or 40 times higher than the half-life of the wild type FVIII in a FVIII
       and VWF double knockout mouse.
[0314]         In some embodiments, the half-life of the chimeric protein comprising the
       VWF fragment fused to a first Ig constant region or a portion thereof, e.g., a first
       Fc region and an XTEN sequence, and a FVIII protein linked to an XTEN
       sequence and a second Ig constant region or a portion thereof, e.g., a second Fc
       region, is longer than the half-life of a FVIII associated with endogenous VWF.
       In other embodiments, the half-life of the chimeric protein is at least about 1.5
       times, 2 times, 2.5 times, 3.5 times, 3.6 times, 3.7 times, 3.8 times, 3.9 times, 4.0
       times, 4.5 times, or 5.0 times the half-life of wild type FVIII or a FVIII protein
       associated with endogenous VWF.
                                            - 159 -

[03151          In some embodiments, as a result of the invention the half-life of the FVIII
       protein is extended compared to a FVIII protein without the VWF fragment or
       wild-type FVIII. The half-life of the chimeric protein of the invention is at least
       about 1.5 times, at least about 2 times, at least about 2.5 times, at least about 3
       times, at least about 4 times, at least about 5 times, at least about 6 times, at least
       about 7 times, at least about 8 times, at least about 9 times, at least about 10 times,
       at least about 11 times, or at least about 12 times longer than the half-life of a
       FVIII protein without the VWF fragment or wild-type FVIII. In one embodiment,
       the half-life of FVIII is about 1.5-fold to about 20-fold, about 1.5 fold to about 15
       fold, or about 1.5 fold to about 10 fold longer than the half-life of wild-type FVIII.
       In another embodiment, the half-life of the FVIII is extended about 2-fold to about
       10-fold, about 2-fold to about 9-fold, about 2-fold to about 8-fold, about 2-fold to
       about 7-fold, about 2-fold to about 6-fold, about 2-fold to about 5-fold, about 2
       fold to about 4-fold, about 2-fold to about 3-fold, about 2.5-fold to about 10-fold,
       about 2.5-fold to about 9-fold, about 2.5-fold to about 8-fold, about 2.5-fold to
       about 7-fold, about 2.5-fold to about 6-fold, about 2.5-fold to about 5-fold, about
       2.5-fold to about 4-fold, about 2.5-fold to about 3-fold, about 3-fold to about 10
       fold, about 3-fold to about 9-fold, about 3-fold to about 8-fold, about 3-fold to
       about 7-fold, about 3-fold to about 6-fold, about 3-fold to about 5-fold, about 3
       fold to about 4-fold, about 4-fold to about 6 fold, about 5-fold to about 7-fold, or
       about 6-fold to about 8 fold as compared to wild-type FVIII or a FVIII protein
       without the VWF fragment. In other embodiments, the half-life of the chimeric
       protein of the invention is at least about 17 hours, at least about 18 hours, at least
       about 19 hours, at least about 20 hours, at least about 21 hours, at least about 22
       hours, at least about 23 hours, at least about 24 hours, at least about 25 hours, at
       least about 26 hours, at least about 27 hours, at least about 28 hours, at least about
       29 hours, at least about 30 hours, at least about 31 hours, at least about 32 hours,
       at least about 33 hours, at least about 34 hours, at least about 35 hours, at least
       about 36 hours, at least about 48 hours, at least about 60 hours, at least about 72
       hours, at least about 84 hours, at least about 96 hours, or at least about 108 hours.
       In still other embodiments, the half-life of the chimeric protein of the invention is
       about 15 hours to about two weeks, about 16 hours to about one week, about 17
       hours to about one week, about 18 hours to about one week, about 19 hours to
                                            - 160 -

       about one week, about 20 hours to about one week, about 21 hours to about one
       week, about 22 hours to about one week, about 23 hours to about one week, about
       24 hours to about one week, about 36 hours to about one week, about 48 hours to
       about one week, about 60 hours to about one week, about 24 hours to about six
       days, about 24 hours to about five days, about 24 hours to about four days, about
       24 hours to about three days, or about 24 hours to about two days.
[03161          In some embodiments, the average half-life of the chimeric protein of the
       invention per subject is about 15 hours, about 16 hours, about 17 hours, about 18
       hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23
       hours, about 24 hours (1 day), about 25 hours, about 26 hours, about 27 hours,
       about 28 hours, about 29 hours, about 30 hours, about 31 hours, about 32 hours,
       about 33 hours, about 34 hours, about 35 hours, about 36 hours, about 40 hours,
       about 44 hours, about 48 hours (2 days), about 54 hours, about 60 hours, about 72
       hours (3 days), about 84 hours, about 96 hours (4 days), about 108 hours, about
       120 hours (5 days), about six days, about seven days (one week), about eight days,
       about nine days, about 10 days, about 11 days, about 12 days, about 13 days, or
       about 14 days.
[0317]          In addition, the invention provides a method of treating or preventing a
       bleeding disease or disorder comprising administering an effective amount of a
       chimeric protein. In one embodiment, the bleeding disease or disorder is selected
       from the group consisting of a bleeding coagulation disorder, hemarthrosis,
       muscle bleed, oral bleed, hemorrhage, hemorrhage into muscles, oral hemorrhage,
       trauma, trauma capitis, gastrointestinal bleeding, intracranial hemorrhage, intra
       abdominal hemorrhage, intrathoracic hemorrhage, bone fracture, central nervous
       system bleeding, bleeding in the retropharyngeal space, bleeding in the
       retroperitoneal space, and bleeding in the illiopsoas sheath. In a specific
       embodiment, the bleeding disease or disorder is hemophilia A.
[03181          The chimeric protein comprising an XTEN sequence and an Ig constant
       region or a portion thereof in combination with a VWF fragment described herein,
       that prevents or inhibits interaction of the FVIII protein with endogenous VWF
       prepared by the invention, has many uses as will be recognized by one skilled in
       the art, including, but not limited to methods of treating a subject having a
       hemostatic disorder and methods of treating a subject in need of a general
                                            - 161 -

       hemostatic agent. In one embodiment, the invention relates to a method of
       treating a subject having a hemostatic disorder comprising administering a
       therapeutically effective amount of the chimeric protein.
[03191         The FVIII protein portion in the chimeric protein treats or prevents a
       hemostatic disorder by serving as a cofactor to Factor IX on a negatively charged
       phospholipid surface, thereby forming a Xase complex. The binding of activated
       coagulation factors to a phospholipid surface localizes this process to sites of
       vascular damage. On a phospholipid surface, Factor VIIla increases the maximum
       velocity of Factor X activation by Factor IXa, by approximately 200,000-fold,
       leading to the large second burst of thrombin generation.
[0320]         The chimeric protein of the invention can be used to treat any hemostatic
       disorder. The hemostatic disorders that may be treated by administration of the
       chimeric protein of the invention include, but are not limited to, hemophilia A, as
       well as deficiencies or structural abnormalities relating to Factor VIII. In one
       embodiment, the hemostatic disorder is hemophilia A.
[0321]         The chimeric protein of the invention can be used prophylactically to treat
       a subject with a hemostatic disorder. The chimeric protein of the invention can be
       used to treat an acute bleeding episode in a subject with a hemostatic disorder. In
       another embodiment, the hemostatic disorder can be the result of a defective
       clotting factor, e.g., von Willebrand's factor. In one embodiment, the hemostatic
       disorder is an inherited disorder. In another embodiment, the hemostatic disorder
       is an acquired disorder. The acquired disorder can result from an underlying
       secondary disease or condition. The unrelated condition can be, as an example, but
       not as a limitation, cancer, an auto-immune disease, or pregnancy. The acquired
       disorder can result from old age or from medication to treat an underlying
       secondary disorder (e.g. cancer chemotherapy).
[0322]         The invention also relates to methods of treating a subject that does not
       have a congenital hemostatic disorder, but has a secondary disease or condition
       resulting in acquisition of a hemostatic disorder, e.g., due to development of an
       anti-FVIII antibody or a surgery. The invention thus relates to a method of
       treating a subject in need of a general hemostatic agent comprising administering a
       therapeutically effective amount of the chimeric protein prepared by the present
       methods.
                                           - 162  -

[03231         The present invention is also related to methods of reducing
       immunogenicity of FVIII or inducing less immunogenicity against FVIII
       comprising administering an effective amount of the chimeric proteins described
       herein, or the polynucleotides encoding the same.
[0324]         In one embodiment, the subject in need of a general hemostatic agent is
       undergoing, or is about to undergo, surgery. The chimeric protein of the invention
       can be administered prior to, during, or after surgery as a prophylactic regimen.
       The chimeric protein of the invention can be administered prior to, during, or after
       surgery to control an acute bleeding episode..
[0325]         The chimeric protein of the invention can be used to treat a subject having
       an acute bleeding episode who does not have a hemostatic disorder. The acute
       bleeding episode can result from severe trauma, e.g., surgery, an automobile
       accident, wound, laceration gun shot, or any other traumatic event resulting in
       uncontrolled bleeding. Non limiting examples of bleeding episodes include a
       bleeding coagulation disorder, hemarthrosis, muscle bleed, oral bleed,
       hemorrhage, hemorrhage into muscles, oral hemorrhage, trauma, trauma capitis,
       gastrointestinal bleeding, intracranial hemorrhage, intra-abdominal hemorrhage,
       intrathoracic hemorrhage, bone fracture, central nervous system bleeding,
       bleeding in the retropharyngeal space, bleeding in the retroperitoneal space,
       bleeding in the illiopsoas sheath, and any combinations thereof.
[0326]         In prophylactic applications, one or more compositions containing the
       chimeric protein of the invention or a cocktail thereof are administered to a patient
       not already in the disease state to enhance the patient's resistance or reduce
       symptoms associated with a disease or disorder. Such an amount is defined to be
       a "prophylactic effective dose." In therapeutic applications, a relatively high
       dosage (e.g., from about I to 400 mg/kg of polypeptide per dose, with dosages of
       from 5 to 25 mg being more commonly used for radioimmuno conjugates and
       higher doses for cytotoxin-drug modified polypeptides) at relatively short intervals
       is sometimes required until progression of the disease is reduced or terminated,
       and until the patient shows partial or complete amelioration of symptoms of
       disease. Thereafter, the patient can be administered a prophylactic regime.
[0327]         In some embodiments, a chimeric protein or a composition of the invention
       is used for on-demand treatment, which includes treatment for a bleeding episode,
                                            - 163 -

       hemarthrosis, muscle bleed, oral bleed, hemorrhage, hemorrhage into muscles,
       oral hemorrhage, trauma, trauma capitis (head trauma), gastrointestinal bleeding,
       intracranial hemorrhage, intra-abdominal hemorrhage, intrathoracic hemorrhage,
       bone fracture, central nervous system bleeding, bleeding in the retropharyngeal
       space, bleeding in the retroperitoneal space, or bleeding in the illiopsoas sheath.
       The subject may be in need of surgical prophylaxis, peri-operative management,
       or treatment for surgery. Such surgeries include, e.g., minor surgery, major
       surgery, tooth extraction, tonsillectomy, inguinal herniotomy, synovectomy, total
       knee replacement, craniotomy, osteosynthesis, trauma surgery, intracranial
       surgery, intra-abdominal surgery, intrathoracic surgery, or joint replacement
       surgery.
[03281         In one embodiment, the chimeric protein of the present invention is
       administered intravenously, subcutaneously, intramuscularly, or via any mucosal
       surface, e.g., orally, sublingually, buccally, nasally, rectally, vaginally or via
       pulmonary route. The chimeric protein comprising a VWF fragment and a FVIII
       protein of the present invention can be implanted within or linked to a biopolymer
       solid support that allows for the slow release of the chimeric protein to the site of
       bleeding or implanted into bandage/dressing. The dose of the chimeric protein
       will vary depending on the subject and upon the particular route of administration
       used. Dosages can range from 0.1 to 100,000 jig/kg body weight. In one
       embodiment, the dosing range is 0.1-1,000 pig/kg. In another embodiment, the
       dosing range is 0.1-500 pig/kg. The protein can be administered continuously or at
       specific timed intervals. In vitro assays may be employed to determine optimal
       dose ranges and/or schedules for administration. In vitro assays that measure
       clotting factor activity are known in the art, e.g., STA-CLOT VIIa-rTF clotting
       assay or ROTEM clotting assay. Additionally, effective doses may be
       extrapolated from dose-response curves obtained from animal models, e.g., a
       hemophiliac dog (Mount et al. 2002, Blood 99(8):2670).
[0329]         Having now described the present invention in detail, the same will be
       more clearly understood by reference to the following examples, which are
       included herewith for purposes of illustration only and are not intended to be
       limiting of the invention. All patents, publications, and articles referred to herein
       are expressly and specifically incorporated herein by reference.
                                            - 164 -

                                          Examples
[03301         Throughout the examples, the following materials and methods were used
       unless otherwise stated.
       Materials and Methods
[03311         In general, the practice of the present invention employs, unless otherwise
       indicated, conventional techniques of chemistry, biophysics, molecular biology,
       recombinant DNA technology, immunology (especially, e.g., antibody
       technology), and standard techniques in electrophoresis. See, e.g., Sambrook,
       Fritsch and Maniatis, Molecular Cloning: Cold Spring Harbor Laboratory Press
       (1989); Antibody Engineering Protocols (Methods in Molecular Biology), 510,
       Paul, S., Humana Pr (1996); Antibody Engineering: A Practical Approach
       (Practical Approach Series, 169), McCafferty, Ed., Irl Pr (1996); Antibodies: A
       Laboratory Manual, Harlow et al., CS.H.L. Press, Pub. (1999); and Current
       Protocols in Molecular Biology, eds. Ausubel et al., John Wiley & Sons (1992).
       Example 1: Cloning different VWF domains (Figure 1)
               (a)    Cloning of pSYN-VWF-002
[0332]         pSYN-VWF-002 contains nucleotide sequences encoding a VWF
       fragment, which are amino acids 1-477 of SEQ ID NO: 100. [VWF-D'D3 protein
       sequence] Amino acid numbering represents the mature VWF sequence without
       propeptide and corresponds to amino acids 764-1240 of SEQ ID NO: 2. pSYN
       VWF-002 construct has the FVIII signal peptide at N-terminus, which allows
       proper secretion of the synthesized protein and followed by a 6xHis tag at C
       terminus, which is used for protein purification. It was synthesized by using
       following primer combinations:
       ESC48- Fwd - VWF-D'D3 with VIII signal and BsiWl site
       TCGCGACGTACGGCCGCCACCATGCAAATAGAGCTCTCCACCTGCTTCTTTCTGT
       GCCTTTTGCGATTCTGCTTTAGCCTATCCTGTCGGCCCCCCATG                         (SEQ ID NO:
       90)
       ESC51- Rev- VWF D'D3 (1-477 amino acid) with 6His and Not 1 site
       TGACCTCGAGCGGCCGCTCAGTGGTGATGGTGATGATGCGGCTCCTGGCAGGCTT
       CACAGGTGAGGTTGACAAC             (SEQ ID NO: 91)
[03331         A 50 gl PCR reaction was carried out with ESC 48/ESC 51 primer
       combinations and full length VWF plasmid as the template, using the 2 step PCR
                                            - 165 -

       amplification cycle: 94 'C 2minutes; 21 cycles of (96 'C 30 seconds, 68 'C 2
       minute). The 1460bp band was gel purified with a Gel Extraction kit (Qiagen,
       Valencia, Calif.) and cloned into the BsiWI and Notl restriction sites of pcDNA 4
       to generate pSYN-VWF 002.
                (b)    Cloning of pSYN-VWF- 010 and 013
[0334]          pSYN-VWF-010 was constructed using pSYN-VWF-008 and pSYN
       VWF-002. pSYN-VWF-008 contains the full-length VWF sequence in pcDNA
       3.1 (amino acids 1-2813 of SEQ ID NO: 2), it includes 763 amino acid propeptide
       (i.e., D1D2 domains) followed by remaining 2050 amino acids sequence of mature
       VWF. The FVIII signal peptide in pSYN-VWF-002 was replaced with D1D2
       domains from pSYN-VWF-008, the resulting construct is pSYN-VWF-0 10.
       pSYN-VWF- 008 has a BamH1 site at Arg907 and Notl site at the end of coding
       region (after stop codon). pSYN- VWF- 008 and 002 were digested with BamH1
       and Notl restriction enzymes. Inserts from pSYN- VWF-002 (1026 bp) were
       ligated into bamHI/Notl digested pSYN-VWF- 008 (8242bp) to obtain pSYN
       VWF -010 (D1D2D'D3: amino acid 1-1240 of SEQ ID NO: 2), a 6xHis tag was
       also added at the C-terminus. In transformed cells pSYN-VWF-010 is synthesized
       with propeptide but due to intracellular processing the secreted products do not
       contain any propeptide (D1D2). Protein from VWF-010 exists as dimer.
[0335]          pSYN-VWF-010 was used to generate pSYN-VWF-013 which has two
       point mutations at C336A and C379A corresponding to SEQ ID NO: 100 (amino
       acid numbering represents mature VWF sequence without D1 D2 domain-VWF
       sequence 2). These mutations are predicted to prevent dimerization of VWF D'D3
       domain.
                (c)    Cloning of pSYN-VWF-025 and pSYN-VWF-029
[03361          pSYN-VWF-025 contains wild type D1D2D'D3 sequences of full-length
       VWF in pLIVE vector, and pSYN-VWF-029 contains D1D2D'D3 sequence with
       C336A and C379A mutation. For cloning pSYN-VWF-025, the following primer
       combination was used:
       ESC 89-fwd with Nhelsite= CTCACTATAGGGAGACCCAAGCTGGCTAGCCG
       (SEQ ID NO: 92)
                                          - 166  -

       ESC 91-rev with Sall=
       CTGGATCCCGGGAGTCGACTCGTCAGTGGTGATGGTGATGATG                        (SEQ ID NO:
       93)
[0337]         A 50 gl PCR reaction was carried out with ESC 89/ESC91 primer
       combinations and either pSYN-VWF 010 (for pSYN-VWF-025) or pSYN-VWF
       013 ( for pSYN-VWF-029) plasmid as the template using the 3 step PCR
       amplification cycle: 94 'C 2minutes; 21 cycles of (96 'C -30 seconds, 55 'C-30
       second, 68 'C-4 minutes). The expected sized band (~3800bp) was gel purified
       with a Gel Extraction kit (Qiagen, Valencia, Calif.) and cloned into the Nhe land
       Sall restriction sites of pLIVE-Mirus vector (Invitrogen, Carlsbad, Calif.) to
       generate pSYN-VWF 025 and 029.
               (d)     Cloning pSYN-VWF-031
[03381         pSYN-VWF-031 is a D1D2D'D3(C336A/C379A) -Fc construct which has
       a 48 amino acid long thrombin cleavable linker (8x GGGGS (SEQ ID NO 94) +
       thrombin site) in between the VWF D1D2D'D3(C336A/C379A) and the Fc
       sequences. To make this construct, VWF-Fc region was amplified from construct
       pSYN-FVIII-064 (refer FVIII-VWF construct below). pSYN-FVIII-VWF was
       digested with Xbal and Nhel. Resulting insert region of 4165bp, containing the
       VWF fragment and Fc region was used as a template for amplifying the VWF and
       Fc region by primer combinations LW 22/LW23.
       LW 22-FWD-VWF-D'D3 with FVIII signal sequence and BsiWl site
       GCGCCGGCCGTACGATGCAAATAGAGCTCTCCACCTGCTTCTTTCTGTGCCTTTT
       GCGATTCTGCTTTAGCCTATCCTGTCGGCCCCCCATG (SEQ ID NO: 95)
       LW 23-Rev- Fc with stop codon and Notl site
       TCATCAATGTATCTTATCATGTCTGAATTCGCGGCCGCTCATTTACC                           (SEQ   ID
       NO:96)
[03391         The PCR product obtained from LW22/LW23 amplification (~2300bp)
       was cloned in BsiW1/Notl digested pSYN-VWF-002 to obtain pSYN-VWF-014
       intermediate. pSYN-VWF-014 contains FVIII signal peptide-D'D3-20 amino acid
       thrombin cleavable linker followed by the Fc region.
[0340]         To generate the D1D2D'D3-Fc construct, the D1D2D'D3 region was
       amplified from pSYN-VWF-013 using primer combination LW24/LW27 by
       standard PCR method.
       LW24- Fwd- VWF D1D2D'D3 cloning oligo with BsiWl site
                                          - 167 -

       GCGCCGGCCGTACGATGATT CCTGCCAGAT T TGCCGGGGTG (SEQ ID NO:97)
       LW27-Rev-VWF D'D3 oligo with EcoRV
       CCACCGCCAGATAT CGGCT CCTGGCAGGCT T CACAGGTGAG              (SEQ ID NO:98)
[0341]        The PCR product obtained from LW22/LW23 amplification (~3750bp)
       was cloned in BsiW1/EcoRV digested pSYN-VWF-014 to obtain pSYN-VWF
       015 intermediate. The linker length between the VWF fragment and Fc region was
       changed to obtain pSYN-VWF-03 1.
          VWF-D1D2D'D3 protein sequence 1 (SEQ ID NO: 99)
         I    MIPARFAGVL       LALALILPGT LCAEGTRGRS STARCSLFGS
DFVNTFDGSM
         51    YSFAGYCSYL      LAGGCQKRSF SIIGDFQNGK RVSLSVYLGE
          FFDIHLFVNG
       101     TVTQGDQRVS      MPYASKGLYL ETEAGYYKLS GEAYGFVARI
          DGSGNFQVLL
       151     SDRYFNKTCG      LCGNFNIFAE DDFMTQEGTL TSDPYDFANS
          WALSSGEQWC
       201    ERASPPSSSC       NISSGEMQKG LWEQCQLLKS TSVFARCHPL
          VDPEPFVALC
       251    EKTLCECAGG       LECACPALLE YARTCAQEGM VLYGWTDHSA
          CSPVCPAGME
       301     YRQCVSPCAR      TCQSLHINEM CQERCVDGCS CPEGQLLDEG
          LCVESTECPC
       351    VHSGKRYPPG       TSLSRDCNTC ICRNSQWICS NEECPGECLV
          TGQSHFKSFD
       401    NRYFTFSGIC       QYLLARDCQD HSFSIVIETV QCADDRDAVC
          TRSVTVRLPG
       451     LHNSLVKLKH      GAGVAMDGQD IQLPLLKGDL RIQHTVTASV
          RLSYGEDLQM
       501     DWDGRGRLLV      KLSPVYAGKT CGLCGNYNGN QGDDFLTPSG
          LAEPRVEDFG
       551    NAWKLHGDCQ       DLQKQHSDPC ALNPRMTRFS EEACAVLTSP
          TFEACHRAVS
       601     PLPYLRNCRY      DVCSCSDGRE CLCGALASYA AACAGRGVRV
          AWREPGRCEL
       651    NCPKGQVYLQ       CGTPCNLTCR SLSYPDEECN EACLEGCFCP
          PGLYMDERGD
       701     CVPKAQCPCY      YDGEIFQPED IFSDHHTMCY CEDGFMHCTM
          SGVPGSLLPD
       751    AVLSSPLSHR       SKRSLSCRPP MVKLVCPADN LRAEGLECTK
          TCQNYDLECM
       O01     SMGCVSGCLC      PPGMVRHENR CVALERCPCF HQGKEYAPGE
          TVKIGCNTCV
       851     CRDRKWNCTD      HVCDATCSTI GMAHYLTFDG LKYLFPGECQ
          YVLVQDYCGS
       901    NPGTFRILVG       NKGCSHPSVK CKKRVTILVE GGEIELFDGE
          VNVKRPMKDE
                                         - 168 -

         951    THFEVVESGR YIILLLGKAL SVVWDRHLSI SVVLKQTYQE
           KVCGLCGNFD
       1001     GIQNNDLTSS NLQVEEDPVD FGNSWKVSSQ CADTRKVPLD
           SSPATCHNNI
       1051     MKQTMVDSSC RILTSDVFQD CNKLVDPEPY LDVCIYDTCS
           CESIGDCACF
       1101     CDTIAAYAHV CAQHGKVVTW RTATLCPQSC EERNLRENGY
           ECEWRYNSCA
       1151     PACQVTCQHP EPLACPVQCV EGCHAHCPPG KILDELLQTC
           VDPEDCPVCE
       1.201    VAGRRFASGK KVTLNPSDPE HCQICHCDVV NLTCEACQEP*
           VWF-D'D3 protein sequence 2                   (SEQ ID NO: 100)
                SLSCRPPMVK LVCPADNLRA EGLECTKTCQ NYDLECMSMG
           CVSGCLCPPG
          51    MVRHENRCVA LERCPCFHQG KEYAPGETVK IGCNTCVCRD
           RKWNCTDHVC
         101    DATCSTIGMA HYLTFDGLKY LFPGECQYVL VQDYCGSNPG
           TFRILVGNKG
        151     CSHPSVKCKK RVTILVEGGE IELFDGEVNV KRPMKDETHF
           EVVESGRYII
        201     LLLGKALSVV WDRHLSISVV LKQTYQEKVC GLCGNFDGIQ
           NNDLTSSNLQ
        251     VEEDPVDFGN SWKVSSQCAD TRKVPLDSSP ATCHNNIMKQ
           TMVDSSCRIL
         301    TSDVFQDCNK LVDPEPYLDV CIYDTCSCES IGDCACFCDT
           IAAYAHVCAQ
        351     HGKVVTWRTA TLCPQSCEER NLRENGYECE WRYNSCAPAC
           QVTCQHPEPL
        401     ACPVQCVEGC HAHCPPGKIL DELLQTCVDP EDCPVCEVAG
           RRFASGKKVT
        451     LNPSDPEHCQ ICHCDVVNLT CEACQEP
        Example 2: Effects of D'D3 and XTEN fusion on FVIII half-life extension
[0342]          To evaluate D'D3 FVIII half-life extension potential on rFVIII-XTEN
        fusion protein, a VWF D'D3 dimer was introduced into FVIII-VWF DKO mice by
        hydrodynamic injection of its corresponding DNA construct VWF-025 (Example
        1). After D'D3 has reached the steady state expression (day5 post injection), a
        single dose of rFVIII-XTEN was administered by IV injection at 200 IU/kg dose.
        Blood samples were collected up to 120hrs post rFVIII-XTEN dosing. Plasma
        FVIII activity was analyzed by a FVIII chromogenic assay. The D'D3 expression
        level was measured by VWF ELISA, and rFVIIIFc PK profile was analyzed using
        WinNonlin program.
[0343]          The study results were shown in Figure 2, and the PK parameter of rFVIII
        XTEN with/without D'D3 in circulation was listed in Table 16. The D'D3 dimer
        further extended rFIII-XTEN t 1 /2 from 3.4hr to 17.8hr, a 5 fold increase. In
                                            - 169 -

        addition to half-life, 5 fold of increase on MRT, 3.6 fold increases on AUC, 3.8
        fold decreases on clearance were also observed.
[0344]           We have observed a synergistic effect of D'D3 fragment and XTEN
        technology, a serial of FVIII/VWF/XTEN constructs will be evaluated for their
        FVIII half-life extension potential in Hemophilic animals.
       TABLE 16: rFVIII-XTEN PK parameter with/without D'D3 in blood
        circulation
                        5min       t      MRT           Cl       Vss       AUCD
         Treatment Recovery       (1 2             (mL                   (hr*kg*mIU
                         (%)      (hr)     (hr)    (mL/hr/kg) (m      g) /mL/mIU)
       rFVIIIXTE
             N            80      17.8     19.3        3.5       67.4        0.29
        VWF-025
       rFVIIIXTE          74       3.4      3.8        13.1     63.68        0.08
             N
       Improveme
             nt           1.1      5.2      5.1        3.8        0.9         3.6
            fold
        Protein purification of FVIII-XTEN
[0345]           An AE288 XTEN was inserted at the C-terminus of BDD-FVIII for this
        study. To purify this protein, a tangential flow filtration (TFF) step was used first
        to buffer exchange the conditioned media. Products in the filtrate were then
        captured using a strong anion exchange chromatography, and then further purified
        using affinity chromatography. Purity of the molecule was acceptable by HPLC
        SEC and was further confirmed by western blotting. The specific activity of the
        molecule was comparable to B-domain deleted FVIII, as measured by aPTT assay
        and ELISA.
        FVIII chromogenic assay
[0346]           The FVIII activity was measured using the COATEST SP FVIII kit from
        DiaPharma (lot# N089019) and all incubations were performed on a 37 0 C plate
        heater with shaking.
[0347]           The range of rFVIII standard was from 100 mIU/mL to 0.78 mIU/mL. A
        pooled normal human plasma assay control and plasma samples (diluted with 1X
        Coatest buffer) were added into Immulon 2HB 96-well plates in duplicate (25
        pL/well). Freshly prepared IXa/FX/Phospholipid mix (50 pL), 25 pL of 25mM
        CaCl2, and 50 pL of FXa substrate were added sequentially into each well with 5
                                               - 170 -

       minutes incubation between each addition. After incubating with the substrate, 25
       ptL of 20% Acetic Acid was added to terminate the color reaction, and the
       absorbance of OD405 was measured with a SpectraMAX plus (Molecular
       Devices) instrument. Data were analyzed with SoftMax Pro software (version
       5.2). The Lowest Level of Quantification (LLOQ) is 7.8 mIU/mL.
       VWF ELISA:
[03481         Goat anti-human VWF antibody (Affinity purified, affinity biological,
       GAVWF-AP) was used as the capture antibody at 0.5ug/well and VWF-EIA-D
       (Affinity Biologicals, VWF-EIA-D, 1:100 dilution) was used as the detecting
       antibody for the VWF ELISA. ELISA assay was performed following the
       standard ELISA procedure, TMB was used as the HRP substrate, PBST/1.5%
       BSA/0.5M NaCl buffer was used as blocking and binding buffer. The assay
       standard range is 1OOng to 0.78ng, and assay's lowest limit of quantification
       (LLOQ) is 7.8ng/mL.
       Example 3: Plasmid construction of XTEN containing FVIII/VWF constructs
               (a)    Cloning of pSYN-FVIII-161 (Figure 3)
[0349]         The FVIII- 161 plasmid comprises a single chain Fc (scFc) scaffold with
       enzyme cleavage sites which are processed during synthesis in a cell. The
       construct has a FVIII binding domain of full-length VWF ( D'D3).
[0350]         Plasmid (pSYN-FVIII-161) was designed for the expression FVIII-Fc and
       VWF-Fc heterodimer, where the D'D3 domains to bind FVIII and prevents FVIII
       interaction with phospholipids and activated protein C. Protein from pSYN-FVIII
       161 is expressed in the cell as a single polypeptide where the C-terminus of the
       FVIII-Fc subunit is linked to the N-terminus of the VWF D'D3-Fc subunit by a 6x
       (GGGGS) polypeptide linker (SEQ ID NO: 64). In addition, RRRRS (SEQ ID
       NO: 11) and RKRRKR (SEQ ID NO: 10) sequences were inserted at the 5' and 3'
       end of the polypeptide linker, respectively, for intracellular cleavage by proprotein
       convertases following the last Arg at each sequence. Hence, the cells can express a
       double chain FVIII-Fc/D'D3-Fc heterodimer where the FVIII-Fc chain has a
       RRRRS sequence (SEQ ID NO: 11) at the C-terminus, but the remainder of the
       linker sequence has been removed. An AE288 XTEN fragment immediately
       followed by IS{5X(GGGGS)}LVPRGSGG (SEQ ID NO: 122) polypeptide
       (contains thrombin cleavage site) is introduced in between the VWF domains and
                                            - 171 -

       the Fe region to facilitate release of the VWF fragment from FVIII once the FVIII
       VWF hetero-dimeric protein is activated by thrombin allowing interaction of
       FVIII with other clotting factors.
[0351]         pSYN-FVIII-161 (SEQ ID NO: 101).protein sequence (FVIII sequence
       amino acid position 1-1457; underlined region represents Fc region; curvy
       underline represents cleavable linker in between first Fc and VWF fragment;
       double underlined region represents VWF fragment; bold region represents
       cleavable linker in between VWF fragment and Fc.
          1    MQIELSTCFF        LCLLRFCFSA TRRYYLGAVE LSWDYMQSDL
          GELPVDARFP
         o1    PRVPKSFPFN        TSVVYKKTLF VEFTDHLFNI AKPRPPWMGL
          LGPTIQAEVY
       101     DTVVITLKNM        ASHPVSLHAV GVSYWKASEG AEYDDQTSQR
          EKEDDKVFPG
               GSHTYVWQVL        KENGPMASDP LCLTYSYLSH VDLVKDLNSG
          LIGALLVCRE
       201     GSLAKEKTQT        LHKFILLFAV FDEGKSWHSE TKNSLMQDRD
          AASARAWPKM
       251     HTVNGYVNRS        LPGLIGCHRK SVYWHVIGMG TTPEVHSIFL
          EGHTFLVRNH
       301     RQASLEISPI        TFLTAQTLLM DLGQFLLFCH ISSHQHDGME
          AYVKVDSCPE
       351     EPQLRMKNNE        EAEDYDDDLT DSEMDVVRFD DDNSPSFIQI
          RSVAKKHPKT
       401     WVHYIAAEEE        DWDYAPLVLA PDDRSYKSQY LNNGPQRIGR
          KYKKVRFMAY
       451     TDETFKTREA        IQHESGILGP LLYGEVGDTL LIIFKNQASR
          PYNIYPHGIT
       501     DVRPLYSRRL        PKGVKHLKDF PILPGEIFKY KWTVTVEDGP
          TKSDPRCLTR
       551     YYSSFVNMER        DLASGLIGPL LICYKESVDQ RGNQIMSDKR
          NVILFSVFDE
        601    NRSWYLTENI        QRFLPNPAGV QLEDPEFQAS NIMHSINGYV
          FDSLQLSVCL
        651    HEVAYWYILS        IGAQTDFLSV FFSGYTFKHK MVYEDTLTLF
          PFSGETVFMS
        701    MENPGLWILG        CHNSDFRNRG MTALLKVSSC DKNTGDYYED
          SYEDISAYLL
       75.1    SKNNAIEPRS        FSQNPPVLKR HQREITRTTL QSDQEEIDYD
          DTISVEMKKE
       801     DFDIYDEDEN        QSPRSFQKKT RHYFIAAVER LWDYGMSSSP
          HVLRNRAQSG
       851     SVPQFKKVVF        QEFTDGSFTQ PLYRGELNEH LGLLGPYIRA
          EVEDNIMVTF
        901    RNQASRPYSF        YSSLISYEED QRQGAEPRKN FVKPNETKTY
          FWKVQHHMAP
                                            - 172  -

  951   TKDEFDCKAW AYFSDVDLEK DVHSGLIGPL LVCHTNTLNP
    AHGRQVTVQE
1001    FALFFTIFDE TKSWYFTENM ERNCRAPCNI QMEDPTFKEN
    YRFHAINGYI
1051   MDTLPGLVMA  QDQRIRWYLL SMGSNENIHS IHFSGHVFTV
    RKKEEYKMAL
1101    YNLYPGVFET VEMLPSKAGI WRVECLIGEH LHAGMSTLFL
    VYSNKCQTPL
1151    GMASGHIRDF QITASGQYGQ WAPKLARLHY SGSINAWSTK
    EPFSWIKVDL
1201    LAPMIIHGIK TQGARQKFSS LYISQFIIMY SLDGKKWQTY
    RGNSTGTLMV
1251    FFGNVDSSGI KHNIFNPPII ARYIRLHPTH YSIRSTLRME
    LMGCDLNSCS
1301   MPLGMESKAI  SDAQITASSY FTNMFATWSP SKARLHLQGR
    SNAWRPQVNN
1351    PKEWLQVDFQ KTMKVTGVTT QGVKSLLTSM YVKEFLISSS
    QDGHQWTLFF
1401    QNGKVKVFQG NQDSFTPVVN SLDPPLLTRY LRIHPQSWVH
    QIALRMEVLG
1451    CEAQDLYDKT HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI
    SRTPEVTCVV
1501   VDVSHEDPEV  KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV
    SVLTVLHQDW
1551    LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP
    SRDELTKNQV
16(01   SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS
    FFLYSKLTVD
1651   KSRWQQGNVF  SCSVMHEALH NHYTQKSLSL SPGKRRRRSG
    GGGSGGGGSG
1701    GGGSGGOGSG GOSGGGSR KRRKRSLSCR PPMVKLVCPA
    DNLRAEGLEC
1751    TKTCQNYDLE CMSMGCVSGC LCPPGMVRHE NRCVALERCP
    CFHQGKEYAP
1801    GETVKIGCNT CVCRDRKWNC TDHVCDATCS TIGMAHYLTF
    DGLKYLFPGE
1851    CQYVLVQDYC GSNPGTFRIL VGNKGCSHPS VKCKKRVTIL
    VEGGEIELFD
1901    GEVNVKRPMK DETHFEVVES GRYIILLLGK ALSVVWDRHL
    SISVVLKQTY
1951    QEKVCGLCGN FDGIQNNDLT SSNLQVEEDP VDFGNSWKVS
    SQCADTRKVP
2001    LDSSPATCHN NIMKQTMVDS SCRILTSDVF QDCNKLVDPE
    PYLDVCIYDT
2051    CSCESIGDCA AFCDTIAAYA HVCAQHGKVV TWRTATLCPQ
    SCEERNLREN
2101    GYEAEWRYNS CAPACQVTCQ HPEPLACPVQ CVEGCHAHCP
    PGKILDELLQ
2151    TCVDPEDCPV CEVAGRRFAS GKKVTLNPSD PEHCQICHCD
    VVNLTCEACQ
                          -173 -

       2.201         EPISGTSESA TPESGPGSEP ATSGSETPGT SESATPESGP
GSEPATSGSE
       2251          TPGTSESATP ESGPGTSTEP SEGSAPGSPA GSPTSTEEGT
SESATPESGP
       2301          GSEPATSGSE TPGTSESATP ESGPGSPAGS PTSTEEGSPA
GSPTSTEEGT
       2351          STEPSEGSAP GTSESATPES GPGTSESATP ESGPGTSESA
TPESGPGSEP
       2401          ATSGSETPGS EPATSGSETP GSPAGSPTST EEGTSTEPSE
GSAPGTSTEP
       2451          SEGSAPGSEP ATSGSETPGT SESATPESGP GTSTEPSEGS
APDSGGGGSG
       2501          GGGSGGGGSG GGGSGGGGSL VPRGSGGDKT HTCPPCPAPE
LLGGPSVFLF
       2551          PPKPKDTLMI      SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE
VHNAKTKPRE
       2601          EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE
KTISKAKGQP
       2651          REPQVYTLPP SRDELTKNQV SLTCLVKGFY PSDIAVEWES
NGQPENNYKT
       2701          TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH
NHYTQKSLSL
     2751             SPGK
           (b)        Cloning of pSYN-FVIII-168, 175, 172 and 174 (Figure 4A-4D)
[0352]           pSYN-FVIII-168, 172, 174 and 175 are derivatives of pSYN-FVIII-161.
        R1645A/R1648A mutations were introduced into pSYN-FVIII-161 to form
        pSYN-FVIII-168, which produces a SC-FVIII isoform, and an AE288 XTEN was
        directly fused into the C-terminus of FVIII-HC for further half-life extension. To
        construct pSYN-FVIII-175, the D'D3 codon sequence was remove form pSYN
        FVIII-168 for evaluation of the effect of Fc and XTEN technology on FVIII half
        life extension.
[0353]           To construct pSYN-FVIII-172, the AE288 XTEN fragment was directly
        fused into the C-terminus of FVIII-HC for further half-life extension, and the
        D'D3 codon sequence was removed from pSYN-FVIII-172 to form pSYN-FVIII
        174 for evaluation of the effect of Fc and XTEN technology on FVIII half-life
        extension.
                 (c)    Cloning of pSYN-FVIII-170 (Figure 4E)
[0354]           pSYN-FVIII-170 was constructed to evaluate the effect of XTEN and
        D'D3 fragment on FVIII half-life extension. The codon sequence VWF
        D1D2D'D3 fragment and BDD-FVIII were introduced into the 5' and 3' end of
        expression casket, an AE288 XTEN codon sequence which followed by a 35 aa
                                            - 174 -

thrombin cleavable linker was used to connect the VWF and FVIII molecule.
After intra cellular processing, the secreted protein comprises a polypeptide
contains the D'D3 fragment of mature VWF molecule which is linked to the N
terminus of mature BDD-FVIII by an AE288 XTEN/35 aa thrombin cleavable
linker.
pSYN-FVIII-170 protein sequence (SEO ID NO: 102)
    1 SLSCRPPMVK          LVCPADNLRA EGLECTKTCQ NYDLECMSMG
   CVSGCLCPPG
  51    MVRHENRCVA        LERCPCFHQG KEYAPGETVK IGCNTCVCRD
   RKWNCTDHVC
101     DATCSTIGMA        HYLTFDGLKY LFPGECQYVL VQDYCGSNPG
   TFRILVGNKG
1 tiCSHPSVKCKK            RVTILVEGGE IELFDGEVNV KRPMKDETHF
   EVVESGRYII
201     LLLGKALSVV       WDRHLSISVV LKQTYQEKVC GLCGNFDGIQ
   NNDLTSSNLQ
251     VEEDPVDFGN        SWKVSSQCAD TRKVPLDSSP ATCHNNIMKQ
   TMVDSSCRIL
3(01    TSDVFQDCNK        LVDPEPYLDV CIYDTCSCES IGDCAAFCDT
   IAAYAHVCAQ
351     HGKVVTWRTA        TLCPQSCEER NLRENGYEAE WRYNSCAPAC
   QVTCQHPEPL
401     ACPVQCVEGC        HAHCPPGKIL DELLQTCVDP EDCPVCEVAG
   RRFASGKKVT
451     LNPSDPEHCQ        ICHCDVVNLT CEACQEPISG TSESATPESG
   PGSEPATSGS
501     ETPGTSESAT        PESGPGSEPA TSGSETPGTS ESATPESGPG
   TSTEPSEGSA
551     PGSPAGSPTS        TEEGTSESAT PESGPGSEPA TSGSETPGTS
   ESATPESGPG
 601    SPAGSPTSTE        EGSPAGSPTS TEEGTSTEPS EGSAPGTSES
   ATPESGPGTS
 651    ESATPESGPG        TSESATPESG PGSEPATSGS ETPGSEPATS
   GSETPGSPAG
 701    SPTSTEEGTS        TEPSEGSAPG TSTEPSEGSA PGSEPATSGS
   ETPGTSESAT
75.1    PESGPGTSTE        PSEGSAPDSG GGGSGGGGSG GGGSGGGGSG
   GGGSLVPRGS
801     GGASATRRYY        LGAVELSWDY MQSDLGELPV DARFPPRVPK
   SFPFNTSVVY
    1 KKTLFVEFTD          HLFNIAKPRP PWMGLLGPTI QAEVYDTVVI
   TLKNMASHPV
 901    SLHAVGVSYW        KASEGAEYDD QTSQREKEDD KVFPGGSHTY
   VWQVLKENGP
 951    MASDPLCLTY        SYLSHVDLVK DLNSGLIGAL LVCREGSLAK
   EKTQTLHKFI
                                    - 175  -

1001   LLFAVFDEGK SWHSETKNSL MQDRDAASAR AWPKMHTVNG
   YVNRSLPGLI
1051   GCHRKSVYWH VIGMGTTPEV HSIFLEGHTF LVRNHRQASL
   EISPITFLTA
1101   QTLLMDLGQF LLFCHISSHQ HDGMEAYVKV DSCPEEPQLR
   MKNNEEAEDY
1151   DDDLTDSEMD VVRFDDDNSP SFIQIRSVAK KHPKTWVHYI
   AAEEEDWDYA
1201   PLVLAPDDRS YKSQYLNNGP QRIGRKYKKV RFMAYTDETF
   KTREAIQHES
1251   GILGPLLYGE VGDTLLIIFK NQASRPYNIY PHGITDVRPL
   YSRRLPKGVK
1301   HLKDFPILPG EIFKYKWTVT VEDGPTKSDP RCLTRYYSSF
   VNMERDLASG
1351   LIGPLLICYK ESVDQRGNQI MSDKRNVILF SVFDENRSWY
   LTENIQRFLP
1401  NPAGVQLEDP  EFQASNIMHS INGYVFDSLQ LSVCLHEVAY
   WYILSIGAQT
1451   DFLSVFFSGY TFKHKMVYED TLTLFPFSGE TVFMSMENPG
   LWILGCHNSD
1501   FRNRGMTALL KVSSCDKNTG DYYEDSYEDI SAYLLSKNNA
   IEPRSFSQNP
1551   PVLKRHQREI TRTTLQSDQE EIDYDDTISV EMKKEDFDIY
   DEDENQSPRS
1601   FQKKTRHYFI AAVERLWDYG MSSSPHVLRN RAQSGSVPQF
   KKVVFQEFTD
1651   GSFTQPLYRG ELNEHLGLLG PYIRAEVEDN IMVTFRNQAS
   RPYSFYSSLI
1701   SYEEDQRQGA EPRKNFVKPN ETKTYFWKVQ HHMAPTKDEF
   DCKAWAYFSD
1751  VDLEKDVHSG  LIGPLLVCHT NTLNPAHGRQ VTVQEFALFF
   TIFDETKSWY
1801   FTENMERNCR APCNIQMEDP TFKENYRFHA INGYIMDTLP
   GLVMAQDQRI
1851  RWYLLSMGSN  ENIHSIHFSG HVFTVRKKEE YKMALYNLYP
   GVFETVEMLP
1901   SKAGIWRVEC LIGEHLHAGM STLFLVYSNK CQTPLGMASG
   HIRDFQITAS
1951   GQYGQWAPKL ARLHYSGSIN AWSTKEPFSW IKVDLLAPMI
   IHGIKTQGAR
2001   QKFSSLYISQ FIIMYSLDGK KWQTYRGNST GTLMVFFGNV
   DSSGIKHNIF
2051  NPPIIARYIR  LHPTHYSIRS TLRMELMGCD LNSCSMPLGM
   ESKAISDAQI
2101   TASSYFTNMF ATWSPSKARL HLQGRSNAWR PQVNNPKEWL
   QVDFQKTMKV
2151   TGVTTQGVKS LLTSMYVKEF LISSSQDGHQ WTLFFQNGKV
   KVFQGNQDSF
2201   TPVVNSLDPP LLTRYLRIHP QSWVHQIALR MEVLGCEAQD LY
                         -176-

        Example 4: Hydrodynamic injection of XTEN containing FVIIIF/VWF constructs
        in FVIII and VWF deficient mice
[0355]           The XTEN containing DNA constructs in Figures 3 and 4 have combined
        2-3 half-life extension elements together. To evaluate their FVIII half-life
        extension potential, a selective group of DNA constructs in figure 3 and figure 4
        were introduced into FVIII/VWF double knockout (DKO) mice by Hydrodynamic
        injection (HDI) at 100ug/mouse dose. Blood samples were then collected by retro
        orbital blood collection at 24hr post HDI. The post HDI plasma FVIII activity was
        analyzed by FVIII chromogenic assay, and results were listed in Table 17 and
        Figure 5. Compared to wild type BDD-FVIII, all XTEN containing DNA
        constructs yield significantly higher FVIII plasma activity at 24hr post HDI,
        indicating the corresponding molecules had significant longer circulating protein
        half-life than BDD-FVIII. The application of the combination of those half-life
        extending elements was further evaluated in Hemophilic animals.
          TABLE 17: FVIII plasma activity 24hr post HDI in FVIII/VWF DKO mice
           DNA           BDD-                     FVIII-      FVIII-       BDD-       FVIII
        Construct         FVIII     FVIII-161       168         172        FVIII       170
       DNA Dose
       (gg/mouse)          100         100          100         100         50         50
           FVIII
          Activity
         (mU/mL)        219+72     2446+1012    2209+609    1671+223      197+21     399+30
        Hydrodynamic injection:
[0356]           Hydrodynamic Injection is an efficient and safe non-viral gene delivery
        method to the liver in small animals, such as mice and rats. It was originally
        described as a rapid injection of a naked plasmid DNA/saline solution free of
        endotoxin at a tenth volume of the animal's body weight in about 5-7 seconds.
        The naked plasmid DNA contains the gene of interest and the liver produced in a
        tenth volume of the animal's body weight. The targeted protein is produced in the
        liver from the injected DNA and can be detected within 24 hours post-injection.
        Plasma samples were then collected to study the therapeutic property of the
        expressed protein.
[0357]           For all the hydrodynamic injections that were performed herein, 2 ml of
        plasmid DNA in 0.9% sterile saline solution was delivered via intravenous tail
        vein injection within about 4-7 seconds to mice weighing 20-35 grams. The mice
                                            - 177 -

       were closely monitored for the first couple of hours until the normal activity
       resumed. After the blood samples were collected via retro orbital blood
       collection, plasma samples were then obtained and stored at -80 'C for further
       analysis.
       Example 5: Plasmid construction of co-transfection system for FVIIIFc-VWF
       Heterodimer contain XTEN insertions (Figure 6)
[03581         To increase the protein production yield, two co-transfection systems were
       generated for protein production, which contains three DNA constructs. The first
       DNA construct encoded a FVIII-Fc fusion protein in which a AE288 XTEN
       fragment was directly fuse to the C-terminus of the FVIII heavy chain and
       followed by either a wild type FVIII light chain fragment (pSYN-FVIII-173,
       Figure 6B) or a FVIII light chain fragment with R1645A/R1648A mutations
       (pSYN-FVIII-169, Figure 6A), the FVIII light chain was then directly fused to a
       single Fc fragment. The second DNA construct is pSYN-VWF-031 which
       encoding a D'D3-Fc fusion protein (Example 1). HEK293F cells were transfected
       with the two plasmid along with a third plasmid (PC5) at 80:15:5 ratio. The
       synthesized proteins were secreted as FVIII (XTEN) Fc/D'D3Fc heterodimer and
       D'D3Fc dimer and the FVIII (XTEN) Fc/D'D3Fc heterodimer was separated from
       the D'D3Fc dimer by protein purification.
       pSYN-FVIII-169 mature Protein sequence (SEO ID NO: 103):
           1   ATRRYYLGAV       ELSWDYMQSD LGELPVDARF PPRVPKSFPF
          NTSVVYKKTL
         51    FVEFTDHLFN       IAKPRPPWMG LLGPTIQAEV YDTVVITLKN
          MASHPVSLHA
       101     VGVSYWKASE       GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV
          LKENGPMASD
       151     PLCLTYSYLS       HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ
          TLHKFILLFA
       201     VFDEGKSWHS       ETKNSLMQDR DAASARAWPK MHTVNGYVNR
          SLPGLIGCHR
       251     KSVYWHVIGM       GTTPEVHSIF LEGHTFLVRN HRQASLEISP
          ITFLTAQTLL
       301     MDLGQFLLFC       HISSHQHDGM EAYVKVDSCP EEPQLRMKNN
          EEAEDYDDDL
       351     TDSEMDVVRF       DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE
          EDWDYAPLVL
       401     APDDRSYKSQ       YLNNGPQRIG RKYKKVRFMA YTDETFKTRE
          AIQHESGILG
       451     PLLYGEVGDT       LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR
          LPKGVKHLKD
                                          - 178 -

 501   FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME
   RDLASGLIGP
 551   LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN
   IQRFLPNPAG
 601  VQLEDPEFQA  SNIMHSINGY VFDSLQLSVC LHEVAYWYIL
   SIGAQTDFLS
 651  VFFSGYTFKH  KMVYEDTLTL FPFSGETVFM SMENPGLWIL
   GCHNSDFRNR
 701   GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR
   SFSQNGAPGT
 751   SESATPESGP GSEPATSGSE TPGTSESATP ESGPGSEPAT
   SGSETPGTSE
 801   SATPESGPGT STEPSEGSAP GSPAGSPTST EEGTSESATP
   ESGPGSEPAT
 851   SGSETPGTSE SATPESGPGS PAGSPTSTEE GSPAGSPTST
   EEGTSTEPSE
 901   GSAPGTSESA TPESGPGTSE SATPESGPGT SESATPESGP
   GSEPATSGSE
 951   TPGSEPATSG SETPGSPAGS PTSTEEGTST EPSEGSAPGT
   STEPSEGSAP
1001   GSEPATSGSE TPGTSESATP ESGPGTSTEP SEGSAPASSP
   PVLKRHQAEI
1651   TRTTLQSDQE EIDYDDTISV EMKKEDFDIY DEDENQSPRS
   FQKKTRHYFI
1101  AAVERLWDYG  MSSSPHVLRN RAQSGSVPQF KKVVFQEFTD
   GSFTQPLYRG
1151  ELNEHLGLLG  PYIRAEVEDN IMVTFRNQAS RPYSFYSSLI
   SYEEDQRQGA
1201  EPRKNFVKPN  ETKTYFWKVQ HHMAPTKDEF DCKAWAYFSD
   VDLEKDVHSG
1251   LIGPLLVCHT NTLNPAHGRQ VTVQEFALFF TIFDETKSWY
   FTENMERNCR
1301  APCNIQMEDP  TFKENYRFHA INGYIMDTLP GLVMAQDQRI
   RWYLLSMGSN
1351  ENIHSIHFSG  HVFTVRKKEE YKMALYNLYP GVFETVEMLP
   SKAGIWRVEC
1401   LIGEHLHAGM STLFLVYSNK CQTPLGMASG HIRDFQITAS
   GQYGQWAPKL
1451  ARLHYSGSIN  AWSTKEPFSW IKVDLLAPMI IHGIKTQGAR
   QKFSSLYISQ
1501   FIIMYSLDGK KWQTYRGNST GTLMVFFGNV DSSGIKHNIF
   NPPIIARYIR
1551   LHPTHYSIRS TLRMELMGCD LNSCSMPLGM ESKAISDAQI
   TASSYFTNMF
1601  ATWSPSKARL  HLQGRSNAWR PQVNNPKEWL QVDFQKTMKV
   TGVTTQGVKS
1651   LLTSMYVKEF LISSSQDGHQ WTLFFQNGKV KVFQGNQDSF
   TPVVNSLDPP
1701   LLTRYLRIHP QSWVHQIALR MEVLGCEAQD LYDKTHTCPP
   CPAPELLGGP
                         -179-

1751   SVFLFPPKPK   DTLMISRTPE VTCVVVDVSH EDPEVKFNWY
   VDGVEVHNAK
1801   TKPREEQYNS   TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL
   PAPIEKTISK
1851  AKGQPREPQV    YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA
   VEWESNGQPE
1901  NNYKTTPPVL    DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM
   HEALHNHYTQ
1951  KSLSLSPGK
 pSYN-FVIII-173 mature Protein sequencing (SEO ID NO: 104):
      ATRRYYLGAV    ELSWDYMQSD LGELPVDARF PPRVPKSFPF
   NTSVVYKKTL
  51   FVEFTDHLFN   IAKPRPPWMG LLGPTIQAEV YDTVVITLKN
   MASHPVSLHA
 101  VGVSYWKASE    GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV
   LKENGPMASD
 151   PLCLTYSYLS   HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ
   TLHKFILLFA
 201  VFDEGKSWHS    ETKNSLMQDR DAASARAWPK MHTVNGYVNR
   SLPGLIGCHR
 251  KSVYWHVIGM    GTTPEVHSIF LEGHTFLVRN HRQASLEISP
   ITFLTAQTLL
 301  MDLGQFLLFC    HISSHQHDGM EAYVKVDSCP EEPQLRMKNN
   EEAEDYDDDL
 351   TDSEMDVVRF   DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE
   EDWDYAPLVL
 401  APDDRSYKSQ    YLNNGPQRIG RKYKKVRFMA YTDETFKTRE
   AIQHESGILG
 451   PLLYGEVGDT   LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR
   LPKGVKHLKD
 501   FPILPGEIFK   YKWTVTVEDG PTKSDPRCLT RYYSSFVNME
   RDLASGLIGP
 551   LLICYKESVD   QRGNQIMSDK RNVILFSVFD ENRSWYLTEN
   IQRFLPNPAG
 601  VQLEDPEFQA    SNIMHSINGY VFDSLQLSVC LHEVAYWYIL
   SIGAQTDFLS
 651  VFFSGYTFKH    KMVYEDTLTL FPFSGETVFM SMENPGLWIL
   GCHNSDFRNR
 701   GMTALLKVSS   CDKNTGDYYE DSYEDISAYL LSKNNAIEPR
   SFSQNGAPGT
 751   SESATPESGP   GSEPATSGSE TPGTSESATP ESGPGSEPAT
   SGSETPGTSE
 801   SATPESGPGT   STEPSEGSAP GSPAGSPTST EEGTSESATP
   ESGPGSEPAT
 851   SGSETPGTSE   SATPESGPGS PAGSPTSTEE GSPAGSPTST
   EEGTSTEPSE
 901   GSAPGTSESA   TPESGPGTSE SATPESGPGT        SESATPESGP
   GSEPATSGSE
 951   TPGSEPATSG   SETPGSPAGS PTSTEEGTST EPSEGSAPGT
   STEPSEGSAP
                              -180-

       1001      GSEPATSGSE TPGTSESATP ESGPGTSTEP SEGSAPASSP
           PVLKRHQREI
       1051      TRTTLQSDQE EIDYDDTISV EMKKEDFDIY DEDENQSPRS
           FQKKTRHYFI
       1101      AAVERLWDYG MSSSPHVLRN RAQSGSVPQF KKVVFQEFTD
           GSFTQPLYRG
       1151      ELNEHLGLLG PYIRAEVEDN IMVTFRNQAS RPYSFYSSLI
           SYEEDQRQGA
       1201      EPRKNFVKPN ETKTYFWKVQ HHMAPTKDEF DCKAWAYFSD
           VDLEKDVHSG
       1251      LIGPLLVCHT NTLNPAHGRQ VTVQEFALFF TIFDETKSWY
           FTENMERNCR
       1301      APCNIQMEDP TFKENYRFHA INGYIMDTLP GLVMAQDQRI
           RWYLLSMGSN
       1351      ENIHSIHFSG HVFTVRKKEE YKMALYNLYP GVFETVEMLP
           SKAGIWRVEC
       1401      LIGEHLHAGM STLFLVYSNK CQTPLGMASG HIRDFQITAS
           GQYGQWAPKL
       1451      ARLHYSGSIN AWSTKEPFSW IKVDLLAPMI IHGIKTQGAR
           QKFSSLYISQ
       1501      FIIMYSLDGK KWQTYRGNST GTLMVFFGNV DSSGIKHNIF
           NPPIIARYIR
       1551      LHPTHYSIRS TLRMELMGCD LNSCSMPLGM ESKAISDAQI
           TASSYFTNMF
       1601      ATWSPSKARL HLQGRSNAWR PQVNNPKEWL QVDFQKTMKV
           TGVTTQGVKS
       1651      LLTSMYVKEF LISSSQDGHQ WTLFFQNGKV KVFQGNQDSF
           TPVVNSLDPP
       1701      LLTRYLRIHP QSWVHQIALR MEVLGCEAQD LYDKTHTCPP
           CPAPELLGGP
       1751      SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY
           VDGVEVHNAK
       1801      TKPREEQYNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL
           PAPIEKTISK
     1-851     AKGQPREPQV YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA
           VEWESNGQPE
       1901      NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM
           HEALHNHYTQ
       1951      KSLSLSPGK
        Example 6.      Protein purification for FVIII-169/VWF-031 and FVIII-173/VWF
        031
[0359]           A tangential flow filtration (TFF) step was used to buffer exchange the
        clarified conditioned media. The FVIII- 169/VWF-031 or FVIII- 173/VWF-031
        heterodimer was then purified using a two-step chromatography process. A weak
        anion exchange resin was used, followed by affinity chromatography. The final
        purified product had acceptable purity by SEC-HPLC. The specific activity was
                                             - 181 -

       compatible to B-domain deleted FVIII, as measured by FVIII chromogenic assay
       and A280 concentration. Purity and the presence of each moiety of this molecule
       were confirmed by SDS-PAGE and western blotting.
       Example 7. Evaluation the VWF binding ability of FVIII-169/VWF-031 by Octet
       assay
[03601         The VWF binding ability of FVIII- 169/VWF-031 was obtained by Bio
       Layer Interferometry (BLI) based measurements (Octet assay) at 25 'C with a
       ForteBio Octet 384 instrument, using Tris binding buffer (50 mM Tris, pH 7.2,
       150 mM NaCl, 5 mM CaCl 2). The Octet assay for determining FVIII binding was
       based on the hydrophobic immobilization of Human von Willebrand Factor
       (Haematologic Technologies Catalog No. HCVWF-0191) onto the APS
       Biosensor, then followed by the binding of 1.0% Bovine Serum Albumin (Jackson
       ImmunoResearch Catalog No. 001-000-161). Briefly, hvWF (20 gg/mL) was
       diluted in Tris buffer and loaded across APS Biosensors for 600 sec, yielding
       approximately 3.0 - 3.5 nm binding on the reaction probes. Control APS probes
       were loaded with 1.0% BSA in the absence of hvWF for reference subtraction.
       After loading, all probes were incubated in Tris buffer for 300 see to establish a
       new baseline. Subsequently, biosensor probes were incubated in solutions of
       FVIII-XTEN 169 or FVIIIFc Drug Substance (0, 0.6, 2, 6, 20, 60, 200, 600
       IU/mL) for 5 min at room temperature, followed by a 5 min dissociation step.
       Using the Octet data analysis software, the binding response (nm) was derived
       from the subtracted data (Reaction probe minus Reference probe). No binding to
       immobilized VWF was detected for FVIII- 169/VWF-031 (Figure 7), indicating a
       complete shielding of FVIII from full length VWF molecule by the D'D3
       fragment.
       Example 8. FVIII- 169/VWF-031 PK in HemA and FVIII/VWF DKO mice
[03611         The PK profile of FVIII- 169/VWF-031 was tested in HemA and
       FVIII/VWF DKO mice to evaluate the ability of the D'D3 fragment to shield the
       FVIII moiety from the endogenous VWF. HemA or FVIII/VWF DKO mice were
       treated with a single intravenous dose of FVIII- 169/VWF-031 at 200 IU/kg,
       plasma samples were then collected at 5min, 8hr, 24hr, 48hr and 72 hours post
       dosing. The FVIII activity of plasma sample was tested by FVIII chromogenic
                                          - 182 -

        assay, and half-life of FVIII-169/VWF-031 was calculated using WinNonlin
        program.
[0362]           Complete inhibition of the constructs' binding to immobilized VWF was
        demonstrated by biolayer interferometry (Figure 7) for FVIII- 169/VWF-03 1. This
        indicates the D'D3 fragment in the molecule had successfully blocked the FVIII
        binding to native VWF molecules, therefor similar half-life of FVIII- 169/VWF
        031 was predicted in the two different mouse strains. As shown in Figure 8A and
        Table 18, as expected, FVIII- 169/VWF-031 had similar PK profile in both HemA
        and FVIII/VWF DKO mice, which has demonstrated that the half-life of
        FVIIIFc/VWF heterodimer is independent from the half-life of endogenous VWF.
        The separation of the FVIIIFc/VWF heterodimer half-life from the endogenous
        VWF half-life , eliminated the FVIII extension ceiling and opened the possibility
        of further extending FVIII half-life beyond the 2 fold half-life limit imposed by
        endogenous VWF.
          TABLE 18: FVIII-169/VWF-031 PK in HemA and FVIII/VWF DKO mice
                     Recover                            Cl         Vss           AUC
         Mouse                     t1 /2   MRT
                          y                          (mL/hr/k    (mL/kg   (hr*kg*mIU/mL
          Strain        (0)        (hr)     (hr)        g                        mU
                        (%                              g)          )/mIU)
       FVIII/VW
                         69       17.94     20.1       4.06       81.69         0.2461
         FDKO
         HemA            83       16.65    18.44       3.57       85.72          0.28
[03631           The FVIII protecting ability of the XTEN insertion and D'D3 fragment was
        evaluated by comparing the half-life of FVIII- 169/VWF-031 with FVIII- 169/Fc
        and FVIIIFc in FVIII/VWF DKO mice. After a single IV administration, blood
        samples were collected at 5min, 8hr, 24hr, 48hr and 72hr for FVIII-169/VWF
        031, 5min, 8hr, 24hr, 32hr, 48hr for FVIII-169/Fc and at 5min, 1, 2, 4, 6 and 8hrs
        for FVIIIFc. The FVIII activity of plasma sample was tested by FVIII
        chromogenic assay, and half-life of FVIII-155/VWF-031 was calculated using
        WinNonlin program.
[0364]           The study results were summarized in Figure 8B and Table 19, rFVIIIFc
        has a 1.6hr half-life in DKO mice due to the loss of VWF protection. When an
        XTEN insertion was introduced into the FVIIIFc molecule, the resulting FVIII
                                            - 183 -

         169/Fe molecule has a 7hr half-life, a 4 fold half-life extension by the XTEN
        insertion. Finally, when D'D3 fragment was incorporated into the molecule to
        form FVIII- 169/VWF-03 1, a 17hr half-life was observed, another 2.5 fold further
        increase by the D'D3 fragment. In addition of the half-life improvement,
        improved Mean residency time (MRT), Clearance (Cl) and AUC were also
        observed as shown in Table 19.
[0365]          FVIII- 169/VWF-031 has achieved 17-18hr             t1 / 2  in both HemA and
        FVIII/VWF DKO mice, which is the upper limit of the                  t 1 /2 extension ceiling that
        imposed by VWF clearance. More         t 1 /2 extension elements can be further
        incorporated into this molecule, such as a second XTEN insertion within FVIII.
        The synergistic effect of D'D3 fragment and XTEN insertions provided the
        possibility of the complete protection for FVIII from its clearance pathway, a final
        breakthrough of the 2 fold FVIII   t 1/2   extension limit might be achieved by the
        FVIIIFc/XTEN/VWF variants.
        TABLE 19. FVIII-169/VWF-031 PK in FVIII/VWF DKO mice
                              MousecoR                                    Cl             Vss      AUC/D
   Mouse                      Recover      t12           MRT               l             Vss      (hr*kg*
    Strain      Tae                       (hr)           (hr)     (mL/hr/k             (mL/kg     mIU/mL
                                                                                                   /mIU)
                rFVIIIFc         35        1.6            2.1          57.7             120.2      0.0173
                 rFVIII
 FVIII/VW          169/          77        7.0            6.2            6.4             39.2      0.1573
   F DKO            Fc
                 rFVIII
                   169/          69       17.9           20.1            4.1             81.7      0.2461
                VWF-031
        Example 9: FVIII-XTEN variants cell media concentrate PK in D'D3 expressing
        FVIII/VWF DKO mice
[03661          The ability of D'D3 fragment to extend the         t1/ 2   of FVII-XTEN was
        evaluated in the D'D3 expressing FVIII/VWF DKO mouse model (described in
        example 2). In this study, instead of using VWF-025 to introduce the D'D3 dimer
        into the circulation, VWF-029 construct was used to introduce the D'D3 monomer
        into the circulation. To prepare FVIII-XTEN variants protein, a small scale (50
         100 mL) transient transfection culture media was prepared, at day 4 post
        transfection, cell culture was harvested and concentrated to reach 10-20 IU/mL of
                                             -   184   -

       FVIII activity range which is suitable for PK study. The concentrated cell media
       were then used for standard PK study in FVIII/VWF DKO mice with or without
       D'D3 in the circulation.
[0367]         Total of 6 FVIII-XTEN variants that contains 1-3 XTEN insertions were
       tested in the system, their     t 1 /2 were summarized in Table 20 and data from
       representative variants were plotted in Figure 9A.
[03681         Longer half-life was observed for all the FVIII-XTEN variants with the
       presents of D'D3 fragment in the circulation (Table 20), which demonstrated the
       D'D3 protection for FVIII-XTEN from its clearance pathways. Furthermore,
       when compared to its 14hr half-life in HemA mice, LSDO055.021 has a 20.4hr           t 1 /2
       in D'D3 expressing DKO mice (Figure 9B, Table 20), indicates the final
       breakthrough of the 2 fold half-life extension ceiling for FVIII molecules. By
       further modify the FVIII(XTEN)/VWF molecule, we could potentially achieve
       even longer FVIII   t 1/2 , and provide HemA patients a FVIII protein that only
       requires once weekly or less frequent dosing regimen.
       TABLE 20. FVIII-XTEN                t1/2 in D'D3 expressing FVIII/VWF DKO mice
                                                                                 t1 /2 (hr)       t1 / 2
   FVIII-XTEN         # of           insertion                      t  2  (hr)   pLIVE-          (hr)
        ID         .XTN              Isetie            XTEN size      DKO         D'D3/      HemA
                    nsertions             smice                                DKO mice        mice
    pSD-0013            1                  CT              144         3.3           7.9
  LSDO003.009          2              B*/CT              144/288       9.7          16.4
  LSDO038.015          2              1656/26            144/144       7.8          17.2
  LSDO049.002          3             18/B*/CT          144/144/288    12.6          17.5
  LSDO051.002          3            403/B*/CT 144/144/288             11.1          19.9
  LSDO055.021          3           1900/B*/CT 144/144/288                16        20.4            14
       *B indicates an XTEN sequence (e.g., 144) is inserted immediately downstream
       of amino acid residue 745 corresponding to mature FVIII sequence.
       Example 10: Stability of VWF- and XTEN-containing FVIII variants in
       FVIII/VWF double knockout (DKO) plasma
[03691         Plasma stability of rFVIIIFc protein variants was tested in FVIII/VWF
       double knockout (DKO) mouse plasma. For the stability assay, HEK293 cells
       were co-transfected with plasmids directing the expression of rFVIIIFc or FVIII
       169 (rFVIIIFc with 288 AE XTEN inserted at the B-domain junction) and
       plasmids directing the expression of either IgG-Fc or VWF-031 (VWF D'D3
       region fused to IgG-Fc). At day four post-transfection, cell culture media was
                                                   - 185 -

       harvested and concentrated to 30 IU/mL based on FVIII chromogenic activity.
       Concentrated cell culture medium was then added into DKO mouse plasma to
       yield a FVIII activity of 5 IU/mL and incubated at 37'C. Aliquots were collected
       at different time points for activity measurement by chromogenic assay. Activity
       at each time point was measured in duplicate, and the average activity was plotted
       as a function of time. The activity of FVIIIFc, a dual chain (dc) FVIII molecule in
       which heavy and light chains are held together by non-covalent interaction,
       decreases with time in DKO mouse plasma (Figure 10). The activity of FVIII
       169:Fc, which contains a 288 AE XTEN insertion at the B-domain junction,
       decays at a reduced rate relative to rFVIIIFc, indicating that enhanced stability is
       conferred by the XTEN insertion. Given that VWF has been proposed to enhance
       the stability of FVIII in vivo, we evaluated the plasma stability of FVIII
       169:VWF-03 1. This heterodimeric molecule, in which the FVIII element and the
       VWF D'D3 element are fused to respective hemi-domains of Fc, exhibited
       additional plasma stability relative to FVIII-169:Fc, indicating that the VWF D'D3
       domain and XTEN have a synergistic effect on the plasma stability of rFVIIIFc.
       Example 11: The effect on FVIII half-life of Fc fusion, XTEN insertion and the
       D'D3 fragment of VWF.
[0370]          To assess the effect of Fc fusion, XTEN insertion and D'D3 fragment of
       VWF on the half-life of FVIII, the pharmacokinetic properties of B domain
       deleted recombinant FVIII (rBDD-FVIII), rFVIIIFc, FVIII-169:Fc and FVIII
       169:VWF-031 were evaluated in FVIII/VWF double knockout (DKO) mice.
[0371]          DKO mice were treated with a single intra venous administration of 200
       IU/kg of FVIII proteins, and plasma samples were collected at designated time
       points as indicated in Figure 11. FVIII activity of the plasma samples were
       analyzed by FVIII chromogenic assay and half-life was calculated using the
       WinNonlin-Phoenix program. The pharmacokinetic parameters of the tested
       molecules are listed in Table 21. The time regression curve of plasma FVIII
       activity for each FVIII variants were plotted in Figure 11.
[0372]          Unmodified BDD-FVIII had a half-life of 0.23 hr in DKO mice, the
       FVIIIFc fusion protein has an extended half-life of 1.66 hr in DKO mice due to
       the recycling of FVIIIFc protein through the Fc:FcRn interaction. When a 288
       residue of AEXTEN polypeptide was incorporated into the B domain region of
                                            - 186 -

        FVIII within the FVIIIFc molecule, the half-life of the resulting FVIII 169/Fc
        protein was further extended to 7.41 hr in DKO mice. Finally, with the addition of
        the D'D3 domain of VWF, the half-life of FVIII 169/VWFO31 heterodimer has
        reached 17.9 hr in DKO mice (Figure 11, Table 21). In addition of the half-life, all
        of the other PK parameters also improved proportionally with the addition of each
        element (Table 21). FVIII can tolerate multiple half-life extension elements, and
        this synergistic effect of the three elements on FVIII half-life extension, enabled
        the further improvement of the half-life of FVIII-XTEN VWF heterodimers.
        Table 21: PK parameters of FVIII variants
                               XTEN Insertions
                     FVIII FVIIIT                                       C1     Vss   AUC_
                                                               MRT      Cl     Vs       D
       FVIII         Isofor                XTEN         ()1/2   (r)  (mL/hr (mL/kg k
                       m                  Length        (hr)   (hr     /kg)      )     mL
   BDD-FVIII           dc                               0.23   0.24 407.72    97.42  0.0025
     FVIIIFc           dc                               1.66   2.06   62.66   128.82 0.0161
   FV111169/Fc         sc       B*         AE288        7.41   6.67    6.24   41.61  0.1603
 FVIII169VWFO          sc       B*         AE288       17.94   20.1    4.06   81.69  0.2463
        *B indicates an XTEN sequence (e.g., 144) is inserted immediately downstream
        of amino acid residue 745 corresponding to mature FVIII sequence.
        Example      12:  Pharmacokinetic      properties    of different   FVIII-XTENVWF
        heterodimers
[0373]          To evaluate the combined effect of the VWF-D'D3 fragment and XTEN
        insertions on the FVIII half-life, the pharmacokinetic properties of FVIII-XTEN
        Fc:VWF-Fc heterodimers were tested in HemA mice and compared to those of the
        single chain isoform of BDD-FVIII (scBDD-FVIII) and FVIII-169:VWF-031
        (example 10). Seven new FVIII-XTEN-Fc constructs were generated (protein
        sequences were listed in Table 24). Schematic diagrams of those constructs are
        shown in Figure 14A-H. FVIII-195 and FVIII-199, respectively, are the FVIII
        dual chain and single chain isoforms that each contains two XTEN insertions at
        positions 1900 and 1656. FVIII-196 and FVIII-201, respectively, are the FVIII
        dual chain and single chain isoforms that each contains three XTEN insertions at
        positions 26, 1656 and 1900. FVIII-203, -204 and -205 are sc-FVIIIFc molecules
        with two XTEN insertions at the B domain junction and at positions 1900, 403 or
        18, respectively. Each FVIII-XTEN-Fc construct was co-expressed with VWF
                                             -  187 -

       031 in HEK293 cells to produce FVIII-XTEN-Fc/VWF heterodimeric proteins.
       At day four post-transfection, cell culture medium was harvested and either
       concentrated to 20 IU/mL based on FVIII chromogenic activity (FVIII- 195:VWF
       031, FVIII-196:VWF-031, FVIII-199:VWF-031, FVIII-203:VWF-031 and FVIII
       204:VWF-03 1) or purified (scBDD-FVIII, FVIII- 169:VWF-03 1, FVIII
       201 :VWF-031 and FVIII-205:VWF-03 1). Having demonstrated the complete
       intra-molecular shielding of FVIII molecule from the endogenous VWF by the
       D'D3 fragment in the FVIII-XTEN-Fc:VWF-Fc heterodimer (FVIII-169:VWF
       031, Example 5), HemA mice was chosen for the PK evaluations.          Purified
       protein or concentrated cell culture medium was administered to 8-12 week-old
       HemA mice by intravenous administration at a dose of 200 IU/10 mL/kg. Plasma
       samples were collected at 5 min, 8 hr, 16 hr, 24 hr, 32 hr, 48 hr, 72 hr and 96 hr
       post-dosing. FVIII activity of the plasma samples were analyzed by FVIII
       chromogenic assay and half-life was calculated using the WinNonlin-Phoenix
       program. The pharmacokinetic parameters of the tested molecules are listed in
       Table 22. The plasma FVIII activities at selected time points for FVIII-XTEN
       Fc/VWF-Fc variants were plotted in Figures 12A-C.
[0374]         When XTEN was inserted into positions 1900 and 1656 (FVIII-195,
       FVIII-199), moderate improvement in half-life was observed for the scFVIII
       isoform (FVIII- 199:VWF-03 1) compared to FVIII- 169:VWF-03 1. However, the
       dcFVIII isoform exhibited a shorter half-life than did FVIII- 169:VWF-03 1,
       indicating that the single chain isoform might be significantly more stable than the
       corresponding dual chain isoform (Table 22 and Figure 12A). When a third
       XTEN insertion was incorporated into FVIII-199 at position 26, the half-life of the
       resulting molecule FVIII-201:VWF-031 had reached 24.6 hr, which represents
       greater than a threefold half-life improvement relative to scBDD-FVIII (Table 22
       and Figure 12C). We have also tested the half-life extension effect of the second
       XTEN insertion at position 403 (A2 domain), 1900 (A3 domain) and 18 (Al
       domain) each in combination with the B domain XTEN insertion. While the
       addition of the A2 or A3 XTEN insertion did not confer an additional half-life
       benefit (Table 22, Figure 12b), the addition of the Al insertion further extended
       the half-life of the FVIII-XTEN-Fc:VWF-Fc heterodimer to 29.4 hr (Table 22,
       Figure 12C), which is greater than threefold longer than that of scBDD-FVIII.
                                           - 188 -

[03751           When XTENs were incorporated into the FVIIIFc/VWF heterodimer
        construct, degree of half-life improvement of the resulting molecules was variable,
        and no obvious correlation was observed between half-lives and either the site or
        number of XTEN insertion, suggesting that the half-life of the FVIII-XTEN
        Fc/VWF heterodimer is determined by the integrity of the whole molecule rather
        than by the number or placement of XTEN insertions.
[0376]           The 24.6 hr and 29.4 hr half-lives observed for FVIII-XTEN-Fc:VWF-Fc
        heterodimers clearly exceeded the 1.6- to 2-fold limitation on FVIII half-life
        extension. If this finding translates for HemA patients, it will allow once-weekly
        or less frequent dosing for FVIII prophylaxis.
Table 22: PK parameters of FVI-XTEN-F/VWF-Fc heterodimers
                                      XTEN Insertions                      Cl    Vss AUC_
                     FVIII
       FVIII         Isofor                                  T1 MRT (mL/h(mL/k          D
                         mI      Site     XTEN Length        (hr) (hr) r/kg)      g) kg*hr/
                                                                                      mL
  scBDD-FVIII           sc                                  7.16 1061 4.38 44.44      0.23
FVIII169/WFO            sc       B*            AE288         16.6 18.4 3.57 65.79     0.28
        31                                                    5     4
FVIII195/VWFO           de   1656/190         AG144/         12.5 13.8 9.04 125.4     011
        31                        0            AE144          6     8             8     ~
FV111199/VWFO           se   1656/190         AG144/         18.5 20.0 6.24 125.2     0.16
        31                        0            AE144          7     9             8     ~
FVIII201/VWFO           sc   26/1656/ AG144/AG144/AE1 24.6 33.6 1.9 63.97             0.53
        31                      1900             44           3     7
FVII203/VWFO            sc    403/B*      AE144/AE288        15.5 18 3.65 65.61       0.27
        31           __    _   _   _   _2                                       _  _  _
FVI1204/VWF0            sc   1900/B*      AE144/AE288        16.3 20.6 2.87 59.14     0.35
FV      31205/WFO       sc     18/B*      AE144/AE288       29.4 37.0 1.82 67.39      0.55
        *B indicates an XTEN sequence (e.g., 144) is inserted immediately downstream
        of amino acid residue 745 corresponding to mature FVIII sequence.
[0377]           In addition to incorporating XTEN into the FVIII molecule, we also
        evaluated the potential half-life extension benefit of incorporating XTEN as a
        linker between the D'D3 and Fc fragment. FVIII-155 (scFVIIIFc) was co
        expressed with VWF-034 (VWF-Fc with AE 288 XTEN plus a 35 residue
        thrombin cleavable linker) in HEK293 cells. At day 4 post-transfection, cell
        culture medium was harvested and concentrated to 20 IU/mL based on FVIII
        activity assay. FVIII/VWF DKO mice were dosed with concentrated cell culture
                                             - 189  -

       media at 200 IU/10 mL/kg with a single intravenous injection. Plasma samples
       were collected at 5 min, 8 hr, 24 hr, 48 hr, 72 hr and 96 hr post-dosing. The FVIII
       activity of plasma samples was analyzed by FVIII chromogenic assay, and the
       regression curve of plasma FVIII activity as a function of time was plotted (Figure
       13). FVIII-155/VWF-034 exhibited the same improvement in half-life as FVIII
       169/VWF-03 1, which has AE 288 XTEN inserted into the B domain junction of
       FVIII, as illustrated by the over lapping regression curves for the two molecules
       (Figure 13). The demonstration that XTEN insertion into the VWF-Fc
       polypeptide confers half-life improvement of a magnitude similar to that conferred
       by XTEN insertion at the B domain junction of the FVIII polypeptide suggests
       that further half-life improvement may be possible in a heterodimeric molecule in
       which intra-molecular XTEN insertion in the FVIII polypeptide is combined with
       inter-domain XTEN insertion between the VWF and Fc elements of the VWF-Fc
       polypeptide.
       Example 13A: Pharmacokinetic properties of additional FVIII-XTEN_VWF
       heterodimers
[03781          In addition to the FVIII-XTEN VWF heterodimers that were listed in
       Table 22, FVIII-XTEN VWF heterodimers containing different composition of
       XTEN insertions, single chain and dual chain version of FVIII (Table 23A) are
       either tested or will be tested in HemA for their pharmacokinetic properties.
       Various FVIII constructs (Table 23B) and VWF constructs (Table 23C) are also
       disclosed below. HemA mice will be treated with a single dose of intravenous
       administration of the heterodimer proteins at 200 IU/ 10 mL/kg. Plasma samples
       will then be collected at 5 min, 24, 48, 72, 96 and 120 hrs post-dosing. FVIII
       activity of the plasma samples will be analyzed by FVIII chromogenic assay and
       half-life will be calculated using the WinNonlin-Phoenix program. The protein
       sequences of the listed heterodimers were listed in Table 25.
       Table 23A. Plausible FVIIH-XTEN-Fc:VWF-Fc heterodimer combinations
          for PK and activity improvement.
                             pSYN VWF-         pSYN VWF-         pSYN VWF-       pSYN
                             015               031               034 **          VWF-036
          pSYN FVIII                   _          t1 / 2 8.7 hr   To be tested
          010                                    DKO mice
          pSYN FVIII           t1 / 2 6.3 hr     t1 /2   10.8 hr   t1 /2 18.6 hr  t 1 /2 13.3 hr
          155                  DKO mice         HemA mice         HemA mice      HemA mice
                                             - 190     -

       pSYN FVIII                         t 112 16.7 hr   t 12 31.1 hr
       169 **                            HemA mice       HemA mice
       pSYN FVIII                         t 112 15.2 hr   t112 28.9 hr      To be tested
       173 **                            DKO mice        HemA mice
       pSYN FVIII                         t 112 29.4  hr  t 112  32.4 hr     t 1 /2 29.7 hr
       205                    -          HemA mice       HemA mice          HemA mice
       pSYN FVIII                         t 1 /2 24.5 hr  t 1/2 27.4  hr
       266                    -          HemA mice       HemA mice
         pSYN FVII            -           t 1/2  23.0 hr  t 1/ 2 25.7 hr
             267                         HemA mice       HemA mice
       pSYN FVIII
       268                    -          To be tested    To be tested       To be tested
       Dual chain
       isoform of                        To be tested    To be tested       To be tested
       pSYN FVIII
       268
       **Length of XTEN can be changed to 72, 144, 288, 324, 333, 576, or 864.
     Table 23B. FVIII Constructs:
pSYN FVIII       dual chain FVIIIFc
010
pSYN FVIII       Single chain FVIIIFc with 288 AE XTEN in B-domain
169
pSYN FVIII       dual chain FVIIIFc with 288 AE XTEN in B-domain
173
pSYN FVIII       dual chain FVIIIFc with two 144 XTENs at amino acid 1656 and
195              1900
pSYN FVIII       dual chain FVIIIFc with three 144 XTENs at amino acid 26, 1656
196              and 1900
pSYN FVIII       Single chain FVIIIFc with two 144 XTENs at amino acid 1656 and
199              1900
pSYN FVIII       Single chain FVIIIFc with three 144 XTENs       at amino acid 26, 1656
201              and 1900
pSYN FVIII       Single chain FVIIIFc with 144 AE XTEN at        amino acid 1900 and
203              288 AE XTEN in B-domain
pSYN FVIII       Single chain FVIIIFc with 144 AE XTEN at        amino acid 403 and 288
204              AE XTEN in B-domain
pSYN FVIII       Single chain FVIIIFc with 144 AE XTEN at        amino acid 18 and 288
205              AE XTEN in B-domain
pSYN FVIII       Single chain FVIII (no Fc, no XTEN)
207
pSYN FVIII       Single chain FVIIIFc with 42 AE XTEN at amino acid 18 and 288
266              AE XTEN in B-domain
pSYN FVIII       Single chain FVIIIFc with 72 AE XTEN at amino acid 18 and 288
267              AE XTEN in B-domain
pSYN FVIII       Single chain FVIIIFc with 144 AE XTEN at amino acid 18
268
pSYN FVIII       Single chain FVIIIFc with 72 AE XTEN at amino acid 18
                                      - 191     -

269
pSYN FVIII           Single chain FVIIIFc with 42 AE XTEN at amino acid 18
271
pSYN FVIII           Single chain FVIII with 144 AE XTEN at amino acid 18 and 288
272                 AE XTEN in B-domain (no Fc)
       Table 23C. VWF Constructs:
pSYN VWF031         VWF-D1D2D'D3- 48aa long thrombin cleavable GS linker-Fc with
                     C1099A/C1 142A
pSYN VWF034         VWF-D1D2D'D3- 288AE XTEN +35aalong thrombin cleavable
                     GS linker-Fc with C1099A/C1 142A
pSYN VWF035         VWF-D1D2D'D3- 72aa long thrombin cleavable GS linker-Fc with
                     C1099A/C1 142A
pSYN VWF036         VWF-D1D2D'D3- 98aa long thrombin cleavable GS linker-Fc with
                     C1099A/C1 142A
pSYN VWF041         VWF-D1D2D'D3 with 288 AE XTEN in D3 and 48aa long
                    thrombin cleavable GS linker after D3 -Fc with C1 099A/C 1142A
       Example 13B: Pharmacokinetic properties of additional FVIII-XTEN_VWF
       heterodimers.
[0379]         FVIII-XTEN_VWF heterodimers were tested in HemA mice for their
       pharmacokinetic properties. The heterodimers tested are FV111169/VWFO34,
       FV111205/VWFO34, FV111205/VWFO36 and FV111266/VWFO3 1. HemA mice
       were administered with a single intravenous dose of various heterodimer proteins
       at 200 IU/10 mL/kg. Plasma samples were collected at 5 min, 24, 48, 72, 96 and
       120 hrs post-dosing. FVIII activity of the plasma samples were analyzed by FVIII
       chromogenic assay, and half-lives were calculated using the WinNonlin-Phoenix
       program. The PK results are shown below in Table 24.
       Table 24. Additional FVIII-XTENVWF - PK in HemA Mice
                                                                                  Fold of
                  5min                             Cl                AUC_D          t1
                recovery       HL    MRT       (mL/hr/      Vss     (hr*kg*m     increase
  Treatment
                   (%)e(hr)            (hr)      kg)     (mL/kg)        IU/         vs
                                                                    mL/mIU)      scBDD
                                                                                  FVIII
   ScBDD-                      7.16   10.16      4.83     44.44        0.23
    FVIII
 FV111169/V         76         31.1  34.57       1.73      59.77       0.58         4.3
   WF034
 FV111205/V         68        32.41  39.79       1.55      61.73       0.64         4.6
   WF034I
 FVIII205/V         74        29.71  36.35       1.61      58.43       0.62         4.1
   WF036
 FV111266/V         66        24.45  22.75       2.67      60.83       0.37         3.4
                                           - 192 -

WF031
   pSYNFVIII 010 nucleotide sequence-(Dual chain FVIIIFc) (SEO ID NO:
      125)
      1    ATGCAAATAG  AGCTCTCCAC CTGCTTCTTT CTGTGCCTTT
      TGCGATTCTG
    51     CTTTAGTGCC  ACCAGAAGAT ACTACCTGGG TGCAGTGGAA
      CTGTCATGGG
   101     ACTATATGCA  AAGTGATCTC GGTGAGCTGC CTGTGGACGC
     AAGATTTCCT
   151     CCTAGAGTGC  CAAAATCTTT TCCATTCAAC ACCTCAGTCG
      TGTACAAAAA
   201     GACTCTGTTT  GTAGAATTCA CGGATCACCT TTTCAACATC
      GCTAAGCCAA
   251     GGCCACCCTG  GATGGGTCTG CTAGGTCCTA CCATCCAGGC
      TGAGGTTTAT
   301     GATACAGTGG  TCATTACACT TAAGAACATG GCTTCCCATC
      CTGTCAGTCT
   351     TCATGCTGTT  GGTGTATCCT ACTGGAAAGC TTCTGAGGGA
      GCTGAATATG
   401     ATGATCAGAC  CAGTCAAAGG GAGAAAGAAG ATGATAAAGT
      CTTCCCTGGT
   451     GGAAGCCATA  CATATGTCTG GCAGGTCCTG AAAGAGAATG
      GTCCAATGGC
   501     CTCTGACCCA  CTGTGCCTTA CCTACTCATA TCTTTCTCAT
      GTGGACCTGG
   551     TAAAAGACTT  GAATTCAGGC CTCATTGGAG CCCTACTAGT
     ATGTAGAGAA
   601     GGGAGTCTGG  CCAAGGAAAA GACACAGACC TTGCACAAAT
      TTATACTACT
   651     TTTTGCTGTA  TTTGATGAAG GGAAAAGTTG GCACTCAGAA
     ACAAAGAACT
   701     CCTTGATGCA  GGATAGGGAT GCTGCATCTG CTCGGGCCTG
      GCCTAAAATG
   751     CACACAGTCA  ATGGTTATGT AAACAGGTCT CTGCCAGGTC
      TGATTGGATG
   801     CCACAGGAAA  TCAGTCTATT GGCATGTGAT TGGAATGGGC
     ACCACTCCTG
   851     AAGTGCACTC  AATATTCCTC GAAGGTCACA CATTTCTTGT
      GAGGAACCAT
   901     CGCCAGGCGT  CCTTGGAAAT CTCGCCAATA ACTTTCCTTA
      CTGCTCAAAC
   951     ACTCTTGATG  GACCTTGGAC AGTTTCTACT GTTTTGTCAT
     ATCTCTTCCC
  1001     ACCAACATGA  TGGCATGGAA GCTTATGTCA AAGTAGACAG
      CTGTCCAGAG
  1051     GAACCCCAAC  TACGAATGAA AAATAATGAA GAAGCGGAAG
     ACTATGATGA
  1101     TGATCTTACT  GATTCTGAAA TGGATGTGGT CAGGTTTGAT
      GATGACAACT
                                - 193 -

1151   CTCCTTCCTT TATCCAAATT    CGCTCAGTTG CCAAGAAGCA
   TCCTAAAACT
1201   TGGGTACATT ACATTGCTGC    TGAAGAGGAG GACTGGGACT
   ATGCTCCCTT
1251   AGTCCTCGCC CCCGATGACA GAAGTTATAA AAGTCAATAT
   TTGAACAATG
1301   GCCCTCAGCG GATTGGTAGG AAGTACAAAA AAGTCCGATT
   TATGGCATAC
1351   ACAGATGAAA CCTTTAAGAC    TCGTGAAGCT ATTCAGCATG
   AATCAGGAAT
1401   CTTGGGACCT TTACTTTATG    GGGAAGTTGG AGACACACTG
   TTGATTATAT
1451   TTAAGAATCA AGCAAGCAGA CCATATAACA    TCTACCCTCA
   CGGAATCACT
1501   GATGTCCGTC CTTTGTATTC AAGGAGATTA CCAAAAGGTG
   TAAAACATTT
1551   GAAGGATTTT CCAATTCTGC CAGGAGAAAT    ATTCAAATAT
   AAATGGACAG
1601   TGACTGTAGA AGATGGGCCA ACTAAATCAG    ATCCTCGGTG
   CCTGACCCGC
1651   TATTACTCTA GTTTCGTTAA TATGGAGAGA GATCTAGCTT
   CAGGACTCAT
1701   TGGCCCTCTC CTCATCTGCT ACAAAGAATC TGTAGATCAA
   AGAGGAAACC
1751   AGATAATGTC AGACAAGAGG AATGTCATCC    TGTTTTCTGT
   ATTTGATGAG
1801   AACCGAAGCT GGTACCTCAC AGAGAATATA CAACGCTTTC
   TCCCCAATCC
1851   AGCTGGAGTG CAGCTTGAGG ATCCAGAGTT    CCAAGCCTCC
   AACATCATGC
1901   ACAGCATCAA TGGCTATGTT    TTTGATAGTT TGCAGTTGTC
   AGTTTGTTTG
1951   CATGAGGTGG CATACTGGTA CATTCTAAGC    ATTGGAGCAC
   AGACTGACTT
2001   CCTTTCTGTC TTCTTCTCTG    GATATACCTT CAAACACAAA
   ATGGTCTATG
2051   AAGACACACT CACCCTATTC CCATTCTCAG GAGAAACTGT
   CTTCATGTCG
2101   ATGGAAAACC CAGGTCTATG GATTCTGGGG    TGCCACAACT
   CAGACTTTCG
2151   GAACAGAGGC ATGACCGCCT    TACTGAAGGT TTCTAGTTGT
   GACAAGAACA
2201   CTGGTGATTA TTACGAGGAC AGTTATGAAG ATATTTCAGC
   ATACTTGCTG
2251   AGTAAAAACA ATGCCATTGA ACCAAGAAGC    TTCTCTCAAA
   ACCCACCAGT
2301   CTTGAAACGC CATCAACGGG AAATAACTCG    TACTACTCTT
   CAGTCAGATC
2351   AAGAGGAAAT TGACTATGAT    GATACCATAT CAGTTGAAAT
   GAAGAAGGAA
                         -19.4-

2401   GATTTTGACA TTTATGATGA GGATGAAAAT CAGAGCCCCC
   GCAGCTTTCA
2451   AAAGAAAACA CGACACTATT  TTATTGCTGC AGTGGAGAGG
   CTCTGGGATT
2501   ATGGGATGAG TAGCTCCCCA  CATGTTCTAA GAAACAGGGC
   TCAGAGTGGC
2551   AGTGTCCCTC AGTTCAAGAA AGTTGTTTTC  CAGGAATTTA
   CTGATGGCTC
2601   CTTTACTCAG CCCTTATACC  GTGGAGAACT AAATGAACAT
   TTGGGACTCC
2651   TGGGGCCATA TATAAGAGCA GAAGTTGAAG ATAATATCAT
   GGTAACTTTC
2701   AGAAATCAGG CCTCTCGTCC  CTATTCCTTC TATTCTAGCC
   TTATTTCTTA
2751   TGAGGAAGAT CAGAGGCAAG  GAGCAGAACC TAGAAAAAAC
   TTTGTCAAGC
2801   CTAATGAAAC CAAAACTTAC  TTTTGGAAAG TGCAACATCA
   TATGGCACCC
2851   ACTAAAGATG AGTTTGACTG  CAAAGCCTGG GCTTATTTCT
   CTGATGTTGA
2901   CCTGGAAAAA GATGTGCACT  CAGGCCTGAT TGGACCCCTT
   CTGGTCTGCC
2951   ACACTAACAC ACTGAACCCT  GCTCATGGGA GACAAGTGAC
   AGTACAGGAA
3001   TTTGCTCTGT TTTTCACCAT  CTTTGATGAG ACCAAAAGCT
   GGTACTTCAC
3051   TGAAAATATG GAAAGAAACT GCAGGGCTCC  CTGCAATATC
   CAGATGGAAG
3101   ATCCCACTTT TAAAGAGAAT TATCGCTTCC  ATGCAATCAA
   TGGCTACATA
3151   ATGGATACAC TACCTGGCTT  AGTAATGGCT CAGGATCAAA
   GGATTCGATG
3201   GTATCTGCTC AGCATGGGCA GCAATGAAAA CATCCATTCT
   ATTCATTTCA
3251   GTGGACATGT GTTCACTGTA  CGAAAAAAAG AGGAGTATAA
   AATGGCACTG
3301   TACAATCTCT ATCCAGGTGT  TTTTGAGACA GTGGAAATGT
   TACCATCCAA
3351   AGCTGGAATT TGGCGGGTGG AATGCCTTAT  TGGCGAGCAT
   CTACATGCTG
3401   GGATGAGCAC ACTTTTTCTG  GTGTACAGCA ATAAGTGTCA
   GACTCCCCTG
3451   GGAATGGCTT CTGGACACAT TAGAGATTTT  CAGATTACAG
   CTTCAGGACA
3501   ATATGGACAG TGGGCCCCAA AGCTGGCCAG  ACTTCATTAT
   TCCGGATCAA
3551   TCAATGCCTG GAGCACCAAG GAGCCCTTTT  CTTGGATCAA
   GGTGGATCTG
3601   TTGGCACCAA TGATTATTCA CGGCATCAAG ACCCAGGGTG
   CCCGTCAGAA
                         -195 -

3651   GTTCTCCAGC CTCTACATCT   CTCAGTTTAT CATCATGTAT
   AGTCTTGATG
3701   GGAAGAAGTG GCAGACTTAT   CGAGGAAATT CCACTGGAAC
   CTTAATGGTC
3751   TTCTTTGGCA ATGTGGATTC   ATCTGGGATA AAACACAATA
   TTTTTAACCC
3801   TCCAATTATT GCTCGATACA   TCCGTTTGCA CCCAACTCAT
   TATAGCATTC
3851   GCAGCACTCT TCGCATGGAG   TTGATGGGCT GTGATTTAAA
   TAGTTGCAGC
3901   ATGCCATTGG GAATGGAGAG TAAAGCAATA TCAGATGCAC
   AGATTACTGC
3951   TTCATCCTAC TTTACCAATA TGTTTGCCAC   CTGGTCTCCT
   TCAAAAGCTC
4001   GACTTCACCT CCAAGGGAGG AGTAATGCCT   GGAGACCTCA
   GGTGAATAAT
4051   CCAAAAGAGT GGCTGCAAGT   GGACTTCCAG AAGACAATGA
   AAGTCACAGG
4101   AGTAACTACT CAGGGAGTAA AATCTCTGCT   TACCAGCATG
   TATGTGAAGG
4151   AGTTCCTCAT CTCCAGCAGT   CAAGATGGCC ATCAGTGGAC
   TCTCTTTTTT
4201   CAGAATGGCA AAGTAAAGGT TTTTCAGGGA   AATCAAGACT
   CCTTCACACC
4251   TGTGGTGAAC TCTCTAGACC   CACCGTTACT GACTCGCTAC
   CTTCGAATTC
4301   ACCCCCAGAG TTGGGTGCAC   CAGATTGCCC TGAGGATGGA
   GGTTCTGGGC
4351   TGCGAGGCAC AGGACCTCTA   CGACAAAACT CACACATGCC
   CACCGTGCCC
4401   AGCTCCAGAA CTCCTGGGCG   GACCGTCAGT CTTCCTCTTC
   CCCCCAAAAC
4451   CCAAGGACAC CCTCATGATC   TCCCGGACCC CTGAGGTCAC
   ATGCGTGGTG
4501   GTGGACGTGA GCCACGAAGA CCCTGAGGTC   AAGTTCAACT
   GGTACGTGGA
4551   CGGCGTGGAG GTGCATAATG CCAAGACAAA GCCGCGGGAG
   GAGCAGTACA
4601   ACAGCACGTA CCGTGTGGTC   AGCGTCCTCA CCGTCCTGCA
   CCAGGACTGG
4651   CTGAATGGCA AGGAGTACAA GTGCAAGGTC   TCCAACAAAG
   CCCTCCCAGC
4701   CCCCATCGAG AAAACCATCT   CCAAAGCCAA AGGGCAGCCC
   CGAGAACCAC
4751   AGGTGTACAC CCTGCCCCCA   TCCCGGGATG AGCTGACCAA
   GAACCAGGTC
4801   AGCCTGACCT GCCTGGTCAA AGGCTTCTAT   CCCAGCGACA
   TCGCCGTGGA
4851   GTGGGAGAGC AATGGGCAGC   CGGAGAACAA CTACAAGACC
   ACGCCTCCCG
                         -196-

4901   TGTTGGACTC CGACGGCTCC TTCTTCCTCT ACAGCAAGCT
   CACCGTGGAC
4951   AAGAGCAGGT GGCAGCAGGG GAACGTCTTC TCATGCTCCG
   TGATGCATGA
5001   GGCTCTGCAC AACCACTACA CGCAGAAGAG CCTOTCCCTG
   TCTCCGGGTA
5051   AATGA
 pSYNFVIII 010 protein sequence-(Dual chain FVIIIFc) (SEO ID NO: 126)
    1  MQIELSTCFF    LCLLRFCFSA TRRYYLGAVE        LSWDYMQSDL
   GELPVDARFP
  51   PRVPKSFPFN    TSVVYKKTLF VEFTDHLFNI        AKPRPPWMGL
   LGPTIQAEVY
 101   DTVVITLKNM    ASHPVSLHAV     GVSYWKASEG AEYDDQTSQR
   EKEDDKVFPG
 151   GSHTYVWQVL    KENGPMASDP     LCLTYSYLSH VDLVKDLNSG
   LIGALLVCRE
 201   GSLAKEKTQT    LHKFILLFAV FDEGKSWHSE        TKNSLMQDRD
   AASARAWPKM
 251   HTVNGYVNRS    LPGLIGCHRK SVYWHVIGMG        TTPEVHSIFL
   EGHTFLVRNH
 301   RQASLEISPI    TFLTAQTLLM DLGQFLLFCH ISSHQHDGME
   AYVKVDSCPE
 351   EPQLRMKNNE    EAEDYDDDLT DSEMDVVRFD DDNSPSFIQI
   RSVAKKHPKT
 401   WVHYIAAEEE    DWDYAPLVLA PDDRSYKSQY        LNNGPQRIGR
   KYKKVRFMAY
 451   TDETFKTREA    IQHESGILGP     LLYGEVGDTL LIIFKNQASR
   PYNIYPHGIT
 501   DVRPLYSRRL    PKGVKHLKDF PILPGEIFKY        KWTVTVEDGP
   TKSDPRCLTR
 551   YYSSFVNMER    DLASGLIGPL LICYKESVDQ RGNQIMSDKR
   NVILFSVFDE
 601   NRSWYLTENI    QRFLPNPAGV QLEDPEFQAS NIMHSINGYV
   FDSLQLSVCL
 651   HEVAYWYILS    IGAQTDFLSV FFSGYTFKHK MVYEDTLTLF
   PFSGETVFMS
 701   MENPGLWILG    CHNSDFRNRG MTALLKVSSC        DKNTGDYYED
   SYEDISAYLL
 751   SKNNAIEPRS    FSQNPPVLKR HQREITRTTL QSDQEEIDYD
   DTISVEMKKE
 801   DFDIYDEDEN    QSPRSFQKKT RHYFIAAVER LWDYGMSSSP
   HVLRNRAQSG
 851   SVPQFKKVVF    QEFTDGSFTQ PLYRGELNEH        LGLLGPYIRA
   EVEDNIMVTF
 901   RNQASRPYSF    YSSLISYEED QRQGAEPRKN FVKPNETKTY
   FWKVQHHMAP
 951   TKDEFDCKAW    AYFSDVDLEK DVHSGLIGPL LVCHTNTLNP
   AHGRQVTVQE
1001   FALFFTIFDE    TKSWYFTENM ERNCRAPCNI        QMEDPTFKEN
   YRFHAINGYI
                              -197-

       1051      MDTLPGLVMA      QDQRIRWYLL SMGSNENIHS               IHFSGHVFTV
           RKKEEYKMAL
       1101      YNLYPGVFET      VEMLPSKAGI WRVECLIGEH LHAGMSTLFL
           VYSNKCQTPL
       1151      GMASGHIRDF      QITASGQYGQ WAPKLARLHY               SGSINAWSTK
           EPFSWIKVDL
       1201      LAPMIIHGIK      TQGARQKFSS LYISQFIIMY SLDGKKWQTY
           RGNSTGTLMV
       1251      FFGNVDSSGI      KHNIFNPPII ARYIRLHPTH YSIRSTLRME
            LMGCDLNSCS
       1301      MPLGMESKAI      SDAQITASSY FTNMFATWSP SKARLHLQGR
            SNAWRPQVNN
       1351      PKEWLQVDFQ      KTMKVTGVTT QGVKSLLTSM YVKEFLISSS
            QDGHQWTLFF
       1401      QNGKVKVFQG      NQDSFTPVVN SLDPPLLTRY LRIHPQSWVH
            QIALRMEVLG
       1451      CEAQDLYDKT      HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI
            SRTPEVTCVV
       1501      VDVSHEDPEV      KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV
            SVLTVLHQDW
       1551      LNGKEYKCKV      SNKALPAPIE KTISKAKGQP REPQVYTLPP
            SRDELTKNQV
       1601      SLTCLVKGFY      PSDIAVEWES NGQPENNYKT TPPVLDSDGS
            FFLYSKLTVD
       1651      KSRWQQGNVF      SCSVMHEALH NHYTQKSLSL               SPGK*
Example 14: A new class of coagulation factor VIII molecules with greater than three
fold half-life extension in hemophilia A mice
[03801           The new class of FVIII molecules was designed to contain two
        polypeptides; one that consists of a single chain B-domain deleted (BDD) FVIII
        with XTEN inserted at one or more locations within the FVIII sequence, and one
        that is composed of the D'D3 region of VWF. Each polypeptide was also
        recombinantly fused to the Fc region of IgGI to enable the D'D3 region to be
        correctly aligned to bind the FVIII moiety. The resulting FVIII variants were
        expressed in HEK 293 cells by transient transfection, and purified from the
        conditioned media. FVIII activity was evaluated by FVIII chromogenic assay and
        the pharmacokinetic properties were assessed in both FVIII knockout (HemA) and
        FVIII/VWF double knock-out (DKO) mice.
[03811           Incorporating XTEN and D'D3 region of VWF into rFVIII led to the
        uncoupling of the clearance of the fusion proteins from endogenous VWF while
        extending their circulating half-life.  FVIII in this fusion configuration is
        completely shielded from interacting with VWF, as measured by biolayer
                                             - 198 -

       interferometry (Octet) analysis. Consistent with this, their pharmacokinetic
       profiles in HemA and DKO mice were found to be identical, indicating that their
       clearance rate in mice was effectively disconnected from VWF. Optimization of
       XTEN length and the locations for inserting XTEN identified a subset of the
       proteins that have exceeded the VWF limitation (16 hours), reaching a circulating
       half-life of up to 30 hours in HemA mice representing a 4-fold improvement over
       BDD-FVIII. Importantly, these proteins maintained their functionality, as judged
       by FVIII chromogenic assay.
[0382]          The VWF dependency has set a fundamental limitation for half-life of
       therapeutic FVIII. Uncoupling FVIII from VWF clearance pathways while
       extending half-life by the fusion of D'D3 region of VWF and XTEN has generated
       a novel FVIII molecule with a 4-fold half-life extension. This is the first report of
       an engineered FVIII that has exceeded the half-life limitation observed through
       industry-wide efforts in development of long-lasting FVIII, representing a
       potentially significant advancement in prophylactic treatment of hemophilia A.
       Table 25: Protein sequences of FVIII-XTEN-Fc and VWF-Fc constructs
       FVIII 195 protein sequence (dual chain FVIIIFc with two 144 AE XTENs at
       amino acid 1656 and 1900) (SEO ID NO: 105)
           1            MQIELSTCFF LCLLRFCFSA TRRYYLGAVE LSWDYMQSDL
          GELPVDARFP
         51     PRVPKSFPFN TSVVYKKTLF VEFTDHLFNI AKPRPPWMGL
          LGPTIQAEVY
       101      DTVVITLKNM ASHPVSLHAV GVSYWKASEG AEYDDQTSQR
          EKEDDKVFPG
       151      GSHTYVWQVL KENGPMASDP LCLTYSYLSH VDLVKDLNSG
          LIGALLVCRE
       201      GSLAKEKTQT LHKFILLFAV FDEGKSWHSE TKNSLMQDRD
          AASARAWPKM
       251      HTVNGYVNRS LPGLIGCHRK SVYWHVIGMG TTPEVHSIFL
          EGHTFLVRNH
       301      RQASLEISPI TFLTAQTLLM DLGQFLLFCH ISSHQHDGME
          AYVKVDSCPE
       351      EPQLRMKNNE EAEDYDDDLT DSEMDVVRFD DDNSPSFIQI
          RSVAKKHPKT
       401      WVHYIAAEEE DWDYAPLVLA PDDRSYKSQY LNNGPQRIGR
          KYKKVRFMAY
       451      TDETFKTREA IQHESGILGP LLYGEVGDTL LIIFKNQASR
          PYNIYPHGIT
       501      DVRPLYSRRL PKGVKHLKDF PILPGEIFKY KWTVTVEDGP
          TKSDPRCLTR
       551      YYSSFVNMER DLASGLIGPL LICYKESVDQ RGNQIMSDKR
          NVILFSVFDE
                                          - 199 -

 601  NRSWYLTENI  QRFLPNPAGV QLEDPEFQAS NIMHSINGYV
   FDSLQLSVCL
 651   HEVAYWYILS IGAQTDFLSV FFSGYTFKHK MVYEDTLTLF
   PFSGETVFMS
 701  MENPGLWILG  CHNSDFRNRG MTALLKVSSC DKNTGDYYED
   SYEDISAYLL
 751   SKNNAIEPRS FSQNPPVLKR HQREITRTTL QGAPGTPGSG
   TASSSPGASP
 801   GTSSTGSPGA SPGTSSTGSP GASPGTSSTG SPGSSPSAST
   GTGPGTPGSG
 851   TASSSPGASP GTSSTGSPGA SPGTSSTGSP GASPGTSSTG
   SPGSSTPSGA
 901   TGSPGSSTPS GATGSPGASP GTSSTGSPAS SSDQEEIDYD
   DTISVEMKKE
 951   DFDIYDEDEN QSPRSFQKKT RHYFIAAVER LWDYGMSSSP
   HVLRNRAQSG
1001   SVPQFKKVVF QEFTDGSFTQ PLYRGELNEH LGLLGPYIRA
   EVEDNIMVTF
1051  RNQASRPYSF  YSSLISYEED QRQGAEPRKN FVKPNETKTY
   FWKVQHHMAP
1101   TKDEFDCKAW AYFSDVDLEK DVHSGLIGPL LVCHTNTLNP
   AHGRQVTVQE
1151   FALFFTIFDE TKSWYFTENM ERNCRGAPTS ESATPESGPG
   SEPATSGSET
1201   PGTSESATPE SGPGSEPATS GSETPGTSES ATPESGPGTS
   TEPSEGSAPG
1251   TSESATPESG PGSPAGSPTS TEEGSPAGSP TSTEEGSPAG
   SPTSTEEGTS
1301  ESATPESGPG  TSTEPSEGSA PGASSAPCNI QMEDPTFKEN
   YRFHAINGYI
1351  MDTLPGLVMA  QDQRIRWYLL SMGSNENIHS IHFSGHVFTV
   RKKEEYKMAL
1401   YNLYPGVFET VEMLPSKAGI WRVECLIGEH LHAGMSTLFL
   VYSNKCQTPL
1451   GMASGHIRDF QITASGQYGQ WAPKLARLHY SGSINAWSTK
   EPFSWIKVDL
1501   LAPMIIHGIK TQGARQKFSS LYISQFIIMY SLDGKKWQTY
   RGNSTGTLMV
1551   FFGNVDSSGI KHNIFNPPII ARYIRLHPTH YSIRSTLRME
   LMGCDLNSCS
1601  MPLGMESKAI  SDAQITASSY FTNMFATWSP SKARLHLQGR
   SNAWRPQVNN
1651   PKEWLQVDFQ KTMKVTGVTT QGVKSLLTSM YVKEFLISSS
   QDGHQWTLFF
1701   QNGKVKVFQG NQDSFTPVVN SLDPPLLTRY LRIHPQSWVH
   QIALRMEVLG
1751   CEAQDLYDKT HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI
   SRTPEVTCVV
1801  VDVSHEDPEV  KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV
   SVLTVLHQDW
                         -200-

1851    LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP
   SRDELTKNQV
1901    SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS
   FFLYSKLTVD
1951   KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK*
 FVIII 196 protein sequence (dual chain FVIIIFc with three 144 AE XTENs at
 amino acid 26, 1656 and 1900) (SEO ID NO: 106)
   1           MQIELSTCFF LCLLRFCFSA TRRYYLGAVE LSWDYMQSDL
   GELPVGAPGS
  51    SPSASTGTGP GSSPSASTGT GPGASPGTSS TGSPGASPGT
   SSTGSPGSST
 101    PSGATGSPGS SPSASTGTGP GASPGTSSTG SPGSSPSAST
   GTGPGTPGSG
 151    TASSSPGSST PSGATGSPGS STPSGATGSP GASPGTSSTG
   SPASSDARFP
 201    PRVPKSFPFN TSVVYKKTLF VEFTDHLFNI AKPRPPWMGL
   LGPTIQAEVY
 251    DTVVITLKNM ASHPVSLHAV GVSYWKASEG AEYDDQTSQR
   EKEDDKVFPG
 301    GSHTYVWQVL KENGPMASDP LCLTYSYLSH VDLVKDLNSG
   LIGALLVCRE
 351    GSLAKEKTQT LHKFILLFAV FDEGKSWHSE TKNSLMQDRD
   AASARAWPKM
 401    HTVNGYVNRS LPGLIGCHRK SVYWHVIGMG TTPEVHSIFL
   EGHTFLVRNH
 451   RQASLEISPI TFLTAQTLLM DLGQFLLFCH ISSHQHDGME
   AYVKVDSCPE
 501   EPQLRMKNNE EAEDYDDDLT DSEMDVVRFD DDNSPSFIQI
   RSVAKKHPKT
 551   WVHYIAAEEE DWDYAPLVLA PDDRSYKSQY LNNGPQRIGR
   KYKKVRFMAY
 601    TDETFKTREA IQHESGILGP LLYGEVGDTL LIIFKNQASR
   PYNIYPHGIT
 651    DVRPLYSRRL PKGVKHLKDF PILPGEIFKY KWTVTVEDGP
   TKSDPRCLTR
 701    YYSSFVNMER DLASGLIGPL LICYKESVDQ RGNQIMSDKR
   NVILFSVFDE
 751   NRSWYLTENI QRFLPNPAGV QLEDPEFQAS NIMHSINGYV
   FDSLQLSVCL
 801    HEVAYWYILS IGAQTDFLSV FFSGYTFKHK MVYEDTLTLF
   PFSGETVFMS
 851   MENPGLWILG CHNSDFRNRG MTALLKVSSC DKNTGDYYED
   SYEDISAYLL
 901    SKNNAIEPRS FSQNPPVLKR HQREITRTTL QGAPGTPGSG
   TASSSPGASP
 951    GTSSTGSPGA SPGTSSTGSP GASPGTSSTG SPGSSPSAST
   GTGPGTPGSG
1001    TASSSPGASP GTSSTGSPGA SPGTSSTGSP GASPGTSSTG
   SPGSSTPSGA
                                 -201-

1051    TGSPGSSTPS     GATGSPGASP GTSSTGSPAS SSDQEEIDYD
    DTISVEMKKE
1101    DFDIYDEDEN     QSPRSFQKKT RHYFIAAVER LWDYGMSSSP
    HVLRNRAQSG
1151    SVPQFKKVVF     QEFTDGSFTQ PLYRGELNEH LGLLGPYIRA
    EVEDNIMVTF
1201    RNQASRPYSF     YSSLISYEED QRQGAEPRKN FVKPNETKTY
    FWKVQHHMAP
1251    TKDEFDCKAW     AYFSDVDLEK DVHSGLIGPL LVCHTNTLNP
    AHGRQVTVQE
1301    FALFFTIFDE     TKSWYFTENM ERNCRGAPTS ESATPESGPG
    SEPATSGSET
1351    PGTSESATPE     SGPGSEPATS GSETPGTSES ATPESGPGTS
    TEPSEGSAPG
1401    TSESATPESG     PGSPAGSPTS TEEGSPAGSP TSTEEGSPAG
    SPTSTEEGTS
1451    ESATPESGPG     TSTEPSEGSA PGASSAPCNI QMEDPTFKEN
    YRFHAINGYI
1501    MDTLPGLVMA     QDQRIRWYLL SMGSNENIHS          IHFSGHVFTV
    RKKEEYKMAL
1551    YNLYPGVFET     VEMLPSKAGI WRVECLIGEH LHAGMSTLFL
    VYSNKCQTPL
1601    GMASGHIRDF     QITASGQYGQ WAPKLARLHY          SGSINAWSTK
    EPFSWIKVDL
1651    LAPMIIHGIK     TQGARQKFSS LYISQFIIMY SLDGKKWQTY
    RGNSTGTLMV
1701    FFGNVDSSGI     KHNIFNPPII ARYIRLHPTH YSIRSTLRME
    LMGCDLNSCS
1751    MPLGMESKAI     SDAQITASSY FTNMFATWSP SKARLHLQGR
    SNAWRPQVNN
1801    PKEWLQVDFQ     KTMKVTGVTT QGVKSLLTSM YVKEFLISSS
    QDGHQWTLFF
1851    QNGKVKVFQG     NQDSFTPVVN SLDPPLLTRY LRIHPQSWVH
    QIALRMEVLG
1901    CEAQDLYDKT     HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI
    SRTPEVTCVV
1951    VDVSHEDPEV     KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV
    SVLTVLHQDW
2001    LNGKEYKCKV     SNKALPAPIE KTISKAKGQP REPQVYTLPP
    SRDELTKNQV
2051    SLTCLVKGFY     PSDIAVEWES NGQPENNYKT TPPVLDSDGS
    FFLYSKLTVD
2101    KSRWQQGNVF     SCSVMHEALH NHYTQKSLSL          SPGK*
 FVIII 199 protein sequence (single chain FVIIIFc with three 144 AE XTENs
 at amino acid 1656 and 1900) (SEO ID NO: 107)
    1          MQIELSTCFF LCLLRFCFSA TRRYYLGAVE LSWDYMQSDL
    GELPVDARFP
   51   PRVPKSFPFN TSVVYKKTLF VEFTDHLFNI AKPRPPWMGL
    LGPTIQAEVY
                                 -202-

 101   DTVVITLKNM ASHPVSLHAV GVSYWKASEG AEYDDQTSQR
   EKEDDKVFPG
 151   GSHTYVWQVL KENGPMASDP LCLTYSYLSH VDLVKDLNSG
   LIGALLVCRE
 201   GSLAKEKTQT LHKFILLFAV FDEGKSWHSE TKNSLMQDRD
   AASARAWPKM
 251   HTVNGYVNRS LPGLIGCHRK SVYWHVIGMG TTPEVHSIFL
   EGHTFLVRNH
 301  RQASLEISPI  TFLTAQTLLM DLGQFLLFCH ISSHQHDGME
   AYVKVDSCPE
 351  EPQLRMKNNE  EAEDYDDDLT DSEMDVVRFD DDNSPSFIQI
   RSVAKKHPKT
 401  WVHYIAAEEE  DWDYAPLVLA PDDRSYKSQY LNNGPQRIGR
   KYKKVRFMAY
 451   TDETFKTREA IQHESGILGP LLYGEVGDTL LIIFKNQASR
   PYNIYPHGIT
 501   DVRPLYSRRL PKGVKHLKDF PILPGEIFKY KWTVTVEDGP
   TKSDPRCLTR
 551   YYSSFVNMER DLASGLIGPL LICYKESVDQ RGNQIMSDKR
   NVILFSVFDE
 601  NRSWYLTENI  QRFLPNPAGV QLEDPEFQAS NIMHSINGYV
   FDSLQLSVCL
 651   HEVAYWYILS IGAQTDFLSV FFSGYTFKHK MVYEDTLTLF
   PFSGETVFMS
 701  MENPGLWILG  CHNSDFRNRG MTALLKVSSC DKNTGDYYED
   SYEDISAYLL
 751   SKNNAIEPRS FSQNPPVLKR HQAEITRTTL QGAPGTPGSG
   TASSSPGASP
 801   GTSSTGSPGA SPGTSSTGSP GASPGTSSTG SPGSSPSAST
   GTGPGTPGSG
 851   TASSSPGASP GTSSTGSPGA SPGTSSTGSP GASPGTSSTG
   SPGSSTPSGA
 901   TGSPGSSTPS GATGSPGASP GTSSTGSPAS SSDQEEIDYD
   DTISVEMKKE
 951   DFDIYDEDEN QSPRSFQKKT RHYFIAAVER LWDYGMSSSP
   HVLRNRAQSG
1001   SVPQFKKVVF QEFTDGSFTQ PLYRGELNEH LGLLGPYIRA
   EVEDNIMVTF
1051  RNQASRPYSF  YSSLISYEED QRQGAEPRKN FVKPNETKTY
   FWKVQHHMAP
1101   TKDEFDCKAW AYFSDVDLEK DVHSGLIGPL LVCHTNTLNP
   AHGRQVTVQE
1151   FALFFTIFDE TKSWYFTENM ERNCRGAPTS ESATPESGPG
   SEPATSGSET
1201   PGTSESATPE SGPGSEPATS GSETPGTSES ATPESGPGTS
   TEPSEGSAPG
1251   TSESATPESG PGSPAGSPTS TEEGSPAGSP TSTEEGSPAG
   SPTSTEEGTS
1301  ESATPESGPG  TSTEPSEGSA PGASSAPCNI QMEDPTFKEN
   YRFHAINGYI
                         -203 -

1351    MDTLPGLVMA      QDQRIRWYLL SMGSNENIHS         IHFSGHVFTV
    RKKEEYKMAL
1401    YNLYPGVFET     VEMLPSKAGI WRVECLIGEH LHAGMSTLFL
    VYSNKCQTPL
1451    GMASGHIRDF      QITASGQYGQ WAPKLARLHY         SGSINAWSTK
    EPFSWIKVDL
1501    LAPMIIHGIK      TQGARQKFSS LYISQFIIMY SLDGKKWQTY
    RGNSTGTLMV
1551    FFGNVDSSGI      KHNIFNPPII ARYIRLHPTH YSIRSTLRME
    LMGCDLNSCS
1601    MPLGMESKAI      SDAQITASSY FTNMFATWSP SKARLHLQGR
    SNAWRPQVNN
1651    PKEWLQVDFQ      KTMKVTGVTT QGVKSLLTSM YVKEFLISSS
    QDGHQWTLFF
1701    QNGKVKVFQG     NQDSFTPVVN SLDPPLLTRY LRIHPQSWVH
    QIALRMEVLG
1751    CEAQDLYDKT      HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI
    SRTPEVTCVV
1801    VDVSHEDPEV      KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV
    SVLTVLHQDW
1851    LNGKEYKCKV      SNKALPAPIE KTISKAKGQP REPQVYTLPP
    SRDELTKNQV
1901    SLTCLVKGFY      PSDIAVEWES NGQPENNYKT TPPVLDSDGS
    FFLYSKLTVD
1951    KSRWQQGNVF      SCSVMHEALH NHYTQKSLSL         SPGK*
 FVIII 201 protein sequence (single chain FVIIIFc with three 144 AE XTENs
 at amino acid 26, 1656 &1900) (SEO ID NO: 108)
     1 MQIELSTCFF       LCLLRFCFSA TRRYYLGAVE LSWDYMQSDL
    GELPVGAPGS
   51   SPSASTGTGP      GSSPSASTGT GPGASPGTSS TGSPGASPGT
    SSTGSPGSST
 101    PSGATGSPGS      SPSASTGTGP GASPGTSSTG SPGSSPSAST
    GTGPGTPGSG
 151    TASSSPGSST      PSGATGSPGS STPSGATGSP GASPGTSSTG
    SPASSDARFP
 201    PRVPKSFPFN      TSVVYKKTLF VEFTDHLFNI AKPRPPWMGL
    LGPTIQAEVY
 251    DTVVITLKNM     ASHPVSLHAV GVSYWKASEG AEYDDQTSQR
    EKEDDKVFPG
 301    GSHTYVWQVL      KENGPMASDP LCLTYSYLSH VDLVKDLNSG
    LIGALLVCRE
 351    GSLAKEKTQT      LHKFILLFAV FDEGKSWHSE TKNSLMQDRD
    AASARAWPKM
 401    HTVNGYVNRS      LPGLIGCHRK SVYWHVIGMG TTPEVHSIFL
    EGHTFLVRNH
 451    RQASLEISPI      TFLTAQTLLM DLGQFLLFCH ISSHQHDGME
    AYVKVDSCPE
 501    EPQLRMKNNE      EAEDYDDDLT DSEMDVVRFD DDNSPSFIQI
    RSVAKKHPKT
                                 -204-

 551  WVHYIAAEEE  DWDYAPLVLA PDDRSYKSQY LNNGPQRIGR
   KYKKVRFMAY
 601   TDETFKTREA IQHESGILGP LLYGEVGDTL LIIFKNQASR
   PYNIYPHGIT
 651   DVRPLYSRRL PKGVKHLKDF PILPGEIFKY KWTVTVEDGP
   TKSDPRCLTR
 701   YYSSFVNMER DLASGLIGPL LICYKESVDQ RGNQIMSDKR
   NVILFSVFDE
 751  NRSWYLTENI  QRFLPNPAGV QLEDPEFQAS NIMHSINGYV
   FDSLQLSVCL
 801   HEVAYWYILS IGAQTDFLSV FFSGYTFKHK MVYEDTLTLF
   PFSGETVFMS
 851  MENPGLWILG  CHNSDFRNRG MTALLKVSSC DKNTGDYYED
   SYEDISAYLL
 901   SKNNAIEPRS FSQNPPVLKR HQAEITRTTL QGAPGTPGSG
   TASSSPGASP
 951   GTSSTGSPGA SPGTSSTGSP GASPGTSSTG SPGSSPSAST
   GTGPGTPGSG
1001   TASSSPGASP GTSSTGSPGA SPGTSSTGSP GASPGTSSTG
   SPGSSTPSGA
1051   TGSPGSSTPS GATGSPGASP GTSSTGSPAS SSDQEEIDYD
   DTISVEMKKE
1101   DFDIYDEDEN QSPRSFQKKT RHYFIAAVER LWDYGMSSSP
   HVLRNRAQSG
1151   SVPQFKKVVF QEFTDGSFTQ PLYRGELNEH LGLLGPYIRA
   EVEDNIMVTF
1201  RNQASRPYSF  YSSLISYEED QRQGAEPRKN FVKPNETKTY
   FWKVQHHMAP
1251   TKDEFDCKAW AYFSDVDLEK DVHSGLIGPL LVCHTNTLNP
   AHGRQVTVQE
1301   FALFFTIFDE TKSWYFTENM ERNCRGAPTS ESATPESGPG
   SEPATSGSET
1351   PGTSESATPE SGPGSEPATS GSETPGTSES ATPESGPGTS
   TEPSEGSAPG
1401   TSESATPESG PGSPAGSPTS TEEGSPAGSP TSTEEGSPAG
   SPTSTEEGTS
1451  ESATPESGPG  TSTEPSEGSA PGASSAPCNI QMEDPTFKEN
   YRFHAINGYI
1501  MDTLPGLVMA  QDQRIRWYLL SMGSNENIHS IHFSGHVFTV
   RKKEEYKMAL
1551   YNLYPGVFET VEMLPSKAGI WRVECLIGEH LHAGMSTLFL
   VYSNKCQTPL
1601   GMASGHIRDF QITASGQYGQ WAPKLARLHY SGSINAWSTK
   EPFSWIKVDL
1651   LAPMIIHGIK TQGARQKFSS LYISQFIIMY SLDGKKWQTY
   RGNSTGTLMV
1701   FFGNVDSSGI KHNIFNPPII ARYIRLHPTH YSIRSTLRME
   LMGCDLNSCS
1751  MPLGMESKAI  SDAQITASSY FTNMFATWSP SKARLHLQGR
   SNAWRPQVNN
                         -205 -

1801    PKEWLQVDFQ     KTMKVTGVTT QGVKSLLTSM YVKEFLISSS
    QDGHQWTLFF
1851    QNGKVKVFQG     NQDSFTPVVN SLDPPLLTRY LRIHPQSWVH
    QIALRMEVLG
1901    CEAQDLYDKT     HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI
    SRTPEVTCVV
1951    VDVSHEDPEV     KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV
    SVLTVLHQDW
2001    LNGKEYKCKV     SNKALPAPIE KTISKAKGQP REPQVYTLPP
    SRDELTKNQV
2051    SLTCLVKGFY     PSDIAVEWES NGQPENNYKT TPPVLDSDGS
    FFLYSKLTVD
2101    KSRWQQGNVF     SCSVMHEALH NHYTQKSLSL          SPGK*
 FVIII 203 protein sequence (single chain FVIIIFc with two AE XTENs; one
    288AE XTEN
 in B-domain and one 144 AE XTEN at amino acid 1900) (SEO ID NO: 109)
     1 MQIELSTCFF      LCLLRFCFSA TRRYYLGAVE LSWDYMQSDL
    GELPVDARFP
   51   PRVPKSFPFN     TSVVYKKTLF VEFTDHLFNI AKPRPPWMGL
    LGPTIQAEVY
 101    DTVVITLKNM     ASHPVSLHAV GVSYWKASEG AEYDDQTSQR
    EKEDDKVFPG
 151    GSHTYVWQVL     KENGPMASDP LCLTYSYLSH VDLVKDLNSG
    LIGALLVCRE
 201    GSLAKEKTQT     LHKFILLFAV FDEGKSWHSE TKNSLMQDRD
    AASARAWPKM
 251    HTVNGYVNRS     LPGLIGCHRK SVYWHVIGMG TTPEVHSIFL
    EGHTFLVRNH
 301    RQASLEISPI     TFLTAQTLLM DLGQFLLFCH ISSHQHDGME
    AYVKVDSCPE
 351    EPQLRMKNNE     EAEDYDDDLT DSEMDVVRFD DDNSPSFIQI
    RSVAKKHPKT
 401    WVHYIAAEEE     DWDYAPLVLA PDDRSYKSQY LNNGPQRIGR
    KYKKVRFMAY
 451    TDETFKTREA     IQHESGILGP LLYGEVGDTL LIIFKNQASR
    PYNIYPHGIT
 501    DVRPLYSRRL     PKGVKHLKDF PILPGEIFKY KWTVTVEDGP
    TKSDPRCLTR
 551    YYSSFVNMER     DLASGLIGPL LICYKESVDQ RGNQIMSDKR
    NVILFSVFDE
  601   NRSWYLTENI     QRFLPNPAGV QLEDPEFQAS NIMHSINGYV
    FDSLQLSVCL
  651   HEVAYWYILS     IGAQTDFLSV FFSGYTFKHK MVYEDTLTLF
    PFSGETVFMS
 701    MENPGLWILG     CHNSDFRNRG MTALLKVSSC DKNTGDYYED
    SYEDISAYLL
 751    SKNNAIEPRS     FSQNGAPGTS ESATPESGPG SEPATSGSET
    PGTSESATPE
 801    SGPGSEPATS     GSETPGTSES ATPESGPGTS TEPSEGSAPG
    SPAGSPTSTE
                                 -206-

 851  EGTSESATPE  SGPGSEPATS GSETPGTSES ATPESGPGSP
   AGSPTSTEEG
 901   SPAGSPTSTE EGTSTEPSEG SAPGTSESAT PESGPGTSES
   ATPESGPGTS
 951  ESATPESGPG  SEPATSGSET PGSEPATSGS ETPGSPAGSP
   TSTEEGTSTE
1001   PSEGSAPGTS TEPSEGSAPG SEPATSGSET PGTSESATPE
   SGPGTSTEPS
1051  EGSAPASSPP  VLKRHQAEIT RTTLQSDQEE IDYDDTISVE
   MKKEDFDIYD
1101  EDENQSPRSF  QKKTRHYFIA AVERLWDYGM SSSPHVLRNR
   AQSGSVPQFK
1151  KVVFQEFTDG  SFTQPLYRGE LNEHLGLLGP YIRAEVEDNI
   MVTFRNQASR
1201   PYSFYSSLIS YEEDQRQGAE PRKNFVKPNE TKTYFWKVQH
   HMAPTKDEFD
1251   CKAWAYFSDV DLEKDVHSGL IGPLLVCHTN TLNPAHGRQV
   TVQEFALFFT
1301   IFDETKSWYF TENMERNCRG APTSESATPE SGPGSEPATS
   GSETPGTSES
1351  ATPESGPGSE  PATSGSETPG TSESATPESG PGTSTEPSEG
   SAPGTSESAT
1401   PESGPGSPAG SPTSTEEGSP AGSPTSTEEG SPAGSPTSTE
   EGTSESATPE
1451   SGPGTSTEPS EGSAPGASSA PCNIQMEDPT FKENYRFHAI
   NGYIMDTLPG
1501   LVMAQDQRIR WYLLSMGSNE NIHSIHFSGH VFTVRKKEEY
   KMALYNLYPG
1551  VFETVEMLPS  KAGIWRVECL IGEHLHAGMS TLFLVYSNKC
   QTPLGMASGH
1601   IRDFQITASG QYGQWAPKLA RLHYSGSINA WSTKEPFSWI
   KVDLLAPMII
1651   HGIKTQGARQ KFSSLYISQF IIMYSLDGKK WQTYRGNSTG
   TLMVFFGNVD
1701   SSGIKHNIFN PPIIARYIRL HPTHYSIRST LRMELMGCDL
   NSCSMPLGME
1751   SKAISDAQIT ASSYFTNMFA TWSPSKARLH LQGRSNAWRP
   QVNNPKEWLQ
1801  VDFQKTMKVT  GVTTQGVKSL LTSMYVKEFL ISSSQDGHQW
   TLFFQNGKVK
1851  VFQGNQDSFT  PVVNSLDPPL LTRYLRIHPQ SWVHQIALRM
   EVLGCEAQDL
1901   YDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV
   TCVVVDVSHE
1951   DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL
   HQDWLNGKEY
2001  KCKVSNKALP  APIEKTISKA KGQPREPQVY TLPPSRDELT
   KNQVSLTCLV
2051  KGFYPSDIAV  EWESNGQPEN NYKTTPPVLD SDGSFFLYSK
   LTVDKSRWQQ
2101   GNVFSCSVMH EALHNHYTQK SLSLSPGK*
                         -207-

 FVIII 204 protein sequence (single chain FVIIIFc with two AE XTENs; one
    288AE XTEN
 in B-domain and one 144 AE XTEN at amino acid 403) (SEO ID NO: 110)
     1 MQIELSTCFF      LCLLRFCFSA TRRYYLGAVE LSWDYMQSDL
    GELPVDARFP
   51   PRVPKSFPFN     TSVVYKKTLF VEFTDHLFNI AKPRPPWMGL
    LGPTIQAEVY
 101    DTVVITLKNM     ASHPVSLHAV GVSYWKASEG AEYDDQTSQR
    EKEDDKVFPG
 151    GSHTYVWQVL     KENGPMASDP LCLTYSYLSH VDLVKDLNSG
    LIGALLVCRE
 201    GSLAKEKTQT     LHKFILLFAV FDEGKSWHSE TKNSLMQDRD
    AASARAWPKM
 251    HTVNGYVNRS     LPGLIGCHRK SVYWHVIGMG TTPEVHSIFL
    EGHTFLVRNH
 301    RQASLEISPI     TFLTAQTLLM DLGQFLLFCH ISSHQHDGME
    AYVKVDSCPE
 351    EPQLRMKNNE     EAEDYDDDLT DSEMDVVRFD DDNSPSFIQI
    RSVAKKHPKT
 401    WVHYIAAEEE     DWDYAPLVLA PDGAPTSTEP SEGSAPGSPA
    GSPTSTEEGT
 451    STEPSEGSAP     GTSTEPSEGS APGTSESATP ESGPGTSTEP
    SEGSAPGTSE
 501    SATPESGPGS     EPATSGSETP GTSTEPSEGS APGTSTEPSE
    GSAPGTSESA
 551    TPESGPGTSE     SATPESGPGA SSDRSYKSQY LNNGPQRIGR
    KYKKVRFMAY
  601   TDETFKTREA     IQHESGILGP LLYGEVGDTL LIIFKNQASR
    PYNIYPHGIT
  651   DVRPLYSRRL     PKGVKHLKDF PILPGEIFKY KWTVTVEDGP
    TKSDPRCLTR
 701    YYSSFVNMER     DLASGLIGPL LICYKESVDQ RGNQIMSDKR
    NVILFSVFDE
 751    NRSWYLTENI     QRFLPNPAGV QLEDPEFQAS NIMHSINGYV
    FDSLQLSVCL
 801    HEVAYWYILS     IGAQTDFLSV FFSGYTFKHK MVYEDTLTLF
    PFSGETVFMS
 851    MENPGLWILG     CHNSDFRNRG MTALLKVSSC DKNTGDYYED
    SYEDISAYLL
  901   SKNNAIEPRS     FSQNGAPGTS ESATPESGPG SEPATSGSET
    PGTSESATPE
  951   SGPGSEPATS     GSETPGTSES ATPESGPGTS TEPSEGSAPG
    SPAGSPTSTE
1001    EGTSESATPE     SGPGSEPATS GSETPGTSES ATPESGPGSP
    AGSPTSTEEG
1051    SPAGSPTSTE     EGTSTEPSEG SAPGTSESAT          PESGPGTSES
    ATPESGPGTS
1101    ESATPESGPG     SEPATSGSET PGSEPATSGS ETPGSPAGSP
    TSTEEGTSTE
                                 -208-

1151    PSEGSAPGTS    TEPSEGSAPG SEPATSGSET         PGTSESATPE
   SGPGTSTEPS
1201   EGSAPASSPP     VLKRHQAEIT RTTLQSDQEE IDYDDTISVE
   MKKEDFDIYD
1251   EDENQSPRSF     QKKTRHYFIA AVERLWDYGM SSSPHVLRNR
   AQSGSVPQFK
1301   KVVFQEFTDG     SFTQPLYRGE LNEHLGLLGP YIRAEVEDNI
   MVTFRNQASR
1351    PYSFYSSLIS    YEEDQRQGAE PRKNFVKPNE TKTYFWKVQH
   HMAPTKDEFD
1401    CKAWAYFSDV    DLEKDVHSGL IGPLLVCHTN TLNPAHGRQV
   TVQEFALFFT
1451    IFDETKSWYF    TENMERNCRA PCNIQMEDPT FKENYRFHAI
   NGYIMDTLPG
1501    LVMAQDQRIR    WYLLSMGSNE NIHSIHFSGH VFTVRKKEEY
   KMALYNLYPG
1551   VFETVEMLPS     KAGIWRVECL IGEHLHAGMS TLFLVYSNKC
   QTPLGMASGH
1601    IRDFQITASG    QYGQWAPKLA RLHYSGSINA WSTKEPFSWI
   KVDLLAPMII
1651    HGIKTQGARQ    KFSSLYISQF IIMYSLDGKK WQTYRGNSTG
   TLMVFFGNVD
1701    SSGIKHNIFN    PPIIARYIRL HPTHYSIRST LRMELMGCDL
   NSCSMPLGME
1751    SKAISDAQIT    ASSYFTNMFA TWSPSKARLH LQGRSNAWRP
   QVNNPKEWLQ
1801   VDFQKTMKVT     GVTTQGVKSL LTSMYVKEFL ISSSQDGHQW
   TLFFQNGKVK
1851   VFQGNQDSFT     PVVNSLDPPL LTRYLRIHPQ SWVHQIALRM
   EVLGCEAQDL
1901    YDKTHTCPPC    PAPELLGGPS VFLFPPKPKD TLMISRTPEV
   TCVVVDVSHE
1951    DPEVKFNWYV    DGVEVHNAKT KPREEQYNST YRVVSVLTVL
   HQDWLNGKEY
2001   KCKVSNKALP     APIEKTISKA KGQPREPQVY TLPPSRDELT
   KNQVSLTCLV
2051   KGFYPSDIAV     EWESNGQPEN NYKTTPPVLD SDGSFFLYSK
   LTVDKSRWQQ
2101    GNVFSCSVMH    EALHNHYTQK SLSLSPGK*
 FVIII 205 protein sequence (single chain FVIIIFc with two AE XTENs; one
 288AE XTEN in B-domain and one 144 AE XTEN at amino acid 18) (SEO ID
 NO: 111)
    1 MQIELSTCFF         LCLLRFCFSA         TRRYYLGAVE       LSWDYMQGAP
 TSESATPESG
  51    PGSEPATSGS ETPGTSESAT PESGPGSEPA TSGSETPGTS
   ESATPESGPG
 101    TSTEPSEGSA PGSPAGSPTS TEEGTSESAT PESGPGSEPA
   TSGSETPGTS
                                -209-

 151  ESATPESGPG  SPAGSPTSTE EGSPAGSPTS TEEGASSSDL
   GELPVDARFP
 201   PRVPKSFPFN TSVVYKKTLF VEFTDHLFNI AKPRPPWMGL
   LGPTIQAEVY
 251   DTVVITLKNM ASHPVSLHAV GVSYWKASEG AEYDDQTSQR
   EKEDDKVFPG
 301   GSHTYVWQVL KENGPMASDP LCLTYSYLSH VDLVKDLNSG
   LIGALLVCRE
 351   GSLAKEKTQT LHKFILLFAV FDEGKSWHSE TKNSLMQDRD
   AASARAWPKM
 401   HTVNGYVNRS LPGLIGCHRK SVYWHVIGMG TTPEVHSIFL
   EGHTFLVRNH
 451  RQASLEISPI  TFLTAQTLLM DLGQFLLFCH ISSHQHDGME
   AYVKVDSCPE
 501  EPQLRMKNNE  EAEDYDDDLT DSEMDVVRFD DDNSPSFIQI
   RSVAKKHPKT
 551  WVHYIAAEEE  DWDYAPLVLA PDDRSYKSQY LNNGPQRIGR
   KYKKVRFMAY
 601   TDETFKTREA IQHESGILGP LLYGEVGDTL LIIFKNQASR
   PYNIYPHGIT
 651   DVRPLYSRRL PKGVKHLKDF PILPGEIFKY KWTVTVEDGP
   TKSDPRCLTR
 701   YYSSFVNMER DLASGLIGPL LICYKESVDQ RGNQIMSDKR
   NVILFSVFDE
 751  NRSWYLTENI  QRFLPNPAGV QLEDPEFQAS NIMHSINGYV
   FDSLQLSVCL
 801   HEVAYWYILS IGAQTDFLSV FFSGYTFKHK MVYEDTLTLF
   PFSGETVFMS
 851  MENPGLWILG  CHNSDFRNRG MTALLKVSSC DKNTGDYYED
   SYEDISAYLL
 901   SKNNAIEPRS FSQNGAPGTS ESATPESGPG SEPATSGSET
   PGTSESATPE
 951   SGPGSEPATS GSETPGTSES ATPESGPGTS TEPSEGSAPG
   SPAGSPTSTE
1001  EGTSESATPE  SGPGSEPATS GSETPGTSES ATPESGPGSP
   AGSPTSTEEG
1051   SPAGSPTSTE EGTSTEPSEG SAPGTSESAT PESGPGTSES
   ATPESGPGTS
1101  ESATPESGPG  SEPATSGSET PGSEPATSGS ETPGSPAGSP
   TSTEEGTSTE
1151   PSEGSAPGTS TEPSEGSAPG SEPATSGSET PGTSESATPE
   SGPGTSTEPS
1201  EGSAPASSPP  VLKRHQAEIT RTTLQSDQEE IDYDDTISVE
   MKKEDFDIYD
1251  EDENQSPRSF  QKKTRHYFIA AVERLWDYGM SSSPHVLRNR
   AQSGSVPQFK
1301  KVVFQEFTDG  SFTQPLYRGE LNEHLGLLGP YIRAEVEDNI
   MVTFRNQASR
1351   PYSFYSSLIS YEEDQRQGAE PRKNFVKPNE TKTYFWKVQH
   HMAPTKDEFD
                         -210-

1401    CKAWAYFSDV    DLEKDVHSGL IGPLLVCHTN TLNPAHGRQV
    TVQEFALFFT
1451    IFDETKSWYF    TENMERNCRA PCNIQMEDPT FKENYRFHAI
   NGYIMDTLPG
1501    LVMAQDQRIR    WYLLSMGSNE NIHSIHFSGH VFTVRKKEEY
   KMALYNLYPG
1551    VFETVEMLPS    KAGIWRVECL IGEHLHAGMS TLFLVYSNKC
    QTPLGMASGH
1601    IRDFQITASG    QYGQWAPKLA RLHYSGSINA WSTKEPFSWI
   KVDLLAPMII
1651    HGIKTQGARQ    KFSSLYISQF IIMYSLDGKK WQTYRGNSTG
    TLMVFFGNVD
1701    SSGIKHNIFN    PPIIARYIRL HPTHYSIRST LRMELMGCDL
   NSCSMPLGME
1751    SKAISDAQIT    ASSYFTNMFA TWSPSKARLH LQGRSNAWRP
    QVNNPKEWLQ
1801    VDFQKTMKVT    GVTTQGVKSL LTSMYVKEFL ISSSQDGHQW
    TLFFQNGKVK
1851    VFQGNQDSFT    PVVNSLDPPL LTRYLRIHPQ SWVHQIALRM
   EVLGCEAQDL
1901    YDKTHTCPPC    PAPELLGGPS VFLFPPKPKD TLMISRTPEV
    TCVVVDVSHE
1951    DPEVKFNWYV    DGVEVHNAKT KPREEQYNST YRVVSVLTVL
    HQDWLNGKEY
2001    KCKVSNKALP    APIEKTISKA KGQPREPQVY TLPPSRDELT
   KNQVSLTCLV
2051    KGFYPSDIAV    EWESNGQPEN NYKTTPPVLD SDGSFFLYSK
    LTVDKSRWQQ
2101    GNVFSCSVMH    EALHNHYTQK SLSLSPGK*
 pSYN FVIII 266 protein sequence (FVIII Fc with 42 AE-XTEN at amino
 acid 18 and 288 AE XTEN in B-domain) SEO ID NO: 112
    1 MQIELSTCFF      LCLLRFCFSA TRRYYLGAVE LSWDYMQGAP
    GSPAGSPTST
  51    EEGTSESATP    ESGPGSEPAT SGSETPASSS DLGELPVDAR
    FPPRVPKSFP
 101    FNTSVVYKKT    LFVEFTDHLF NIAKPRPPWM GLLGPTIQAE
   VYDTVVITLK
 151    NMASHPVSLH    AVGVSYWKAS EGAEYDDQTS QREKEDDKVF
    PGGSHTYVWQ
 201    VLKENGPMAS    DPLCLTYSYL SHVDLVKDLN SGLIGALLVC
   REGSLAKEKT
 251    QTLHKFILLF    AVFDEGKSWH SETKNSLMQD RDAASARAWP
   KMHTVNGYVN
 301    RSLPGLIGCH    RKSVYWHVIG MGTTPEVHSI FLEGHTFLVR
   NHRQASLEIS
 351    PITFLTAQTL    LMDLGQFLLF CHISSHQHDG MEAYVKVDSC
    PEEPQLRMKN
 401    NEEAEDYDDD    LTDSEMDVVR FDDDNSPSFI QIRSVAKKHP
   KTWVHYIAAE
                               -211-

 451  EEDWDYAPLV  LAPDDRSYKS QYLNNGPQRI GRKYKKVRFM
   AYTDETFKTR
 501  EAIQHESGIL  GPLLYGEVGD TLLIIFKNQA SRPYNIYPHG
   ITDVRPLYSR
 551  RLPKGVKHLK  DFPILPGEIF KYKWTVTVED GPTKSDPRCL
   TRYYSSFVNM
 601  ERDLASGLIG  PLLICYKESV DQRGNQIMSD KRNVILFSVF
   DENRSWYLTE
 651  NIQRFLPNPA  GVQLEDPEFQ ASNIMHSING YVFDSLQLSV
   CLHEVAYWYI
 701   LSIGAQTDFL SVFFSGYTFK HKMVYEDTLT LFPFSGETVF
   MSMENPGLWI
 751   LGCHNSDFRN RGMTALLKVS SCDKNTGDYY EDSYEDISAY
   LLSKNNAIEP
 801  RSFSQNGAPG  TSESATPESG PGSEPATSGS ETPGTSESAT
   PESGPGSEPA
 851   TSGSETPGTS ESATPESGPG TSTEPSEGSA PGSPAGSPTS
   TEEGTSESAT
 901   PESGPGSEPA TSGSETPGTS ESATPESGPG SPAGSPTSTE
   EGSPAGSPTS
 951   TEEGTSTEPS EGSAPGTSES ATPESGPGTS ESATPESGPG
   TSESATPESG
1001   PGSEPATSGS ETPGSEPATS GSETPGSPAG SPTSTEEGTS
   TEPSEGSAPG
1051   TSTEPSEGSA PGSEPATSGS ETPGTSESAT PESGPGTSTE
   PSEGSAPASS
1101   PPVLKRHQAE ITRTTLQSDQ EEIDYDDTIS VEMKKEDFDI
   YDEDENQSPR
1151   SFQKKTRHYF IAAVERLWDY GMSSSPHVLR NRAQSGSVPQ
   FKKVVFQEFT
1201   DGSFTQPLYR GELNEHLGLL GPYIRAEVED NIMVTFRNQA
   SRPYSFYSSL
1251   ISYEEDQRQG AEPRKNFVKP NETKTYFWKV QHHMAPTKDE
   FDCKAWAYFS
1301   DVDLEKDVHS GLIGPLLVCH TNTLNPAHGR QVTVQEFALF
   FTIFDETKSW
1351   YFTENMERNC RAPCNIQMED PTFKENYRFH AINGYIMDTL
   PGLVMAQDQR
1401   IRWYLLSMGS NENIHSIHFS GHVFTVRKKE EYKMALYNLY
   PGVFETVEML
1451   PSKAGIWRVE CLIGEHLHAG MSTLFLVYSN KCQTPLGMAS
   GHIRDFQITA
1501   SGQYGQWAPK LARLHYSGSI NAWSTKEPFS WIKVDLLAPM
   IIHGIKTQGA
1551  RQKFSSLYIS  QFIIMYSLDG KKWQTYRGNS TGTLMVFFGN
   VDSSGIKHNI
1601   FNPPIIARYI RLHPTHYSIR STLRMELMGC DLNSCSMPLG
   MESKAISDAQ
1651   ITASSYFTNM FATWSPSKAR LHLQGRSNAW RPQVNNPKEW
   LQVDFQKTMK
                         -212-

1701   VTGVTTQGVK    SLLTSMYVKE FLISSSQDGH QWTLFFQNGK
   VKVFQGNQDS
1751    FTPVVNSLDP   PLLTRYLRIH PQSWVHQIAL RMEVLGCEAQ
   DLYDKTHTCP
1801    PCPAPELLGG   PSVFLFPPKP KDTLMISRTP EVTCVVVDVS
   HEDPEVKFNW
1851    YVDGVEVHNA   KTKPREEQYN STYRVVSVLT VLHQDWLNGK
   EYKCKVSNKA
1901    LPAPIEKTIS   KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC
   LVKGFYPSDI
1951   AVEWESNGQP    ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
   QQGNVFSCSV
2001   MHEALHNHYT    QKSLSLSPGK      *
 pSYN FVIII 267 protein sequence (FVIII Fc with 72 AE-XTEN at amino
   acid 18 and 288
 AE XTEN in B-domain) SEO ID NO: 113
    1 MQIELSTCFF     LCLLRFCFSA TRRYYLGAVE LSWDYMQGAP
   TSESATPESG
  51    PGSEPATSGS   ETPGTSESAT PESGPGSEPA TSGSETPGTS
   ESATPESGPG
 101    TSTEPSEGSA   PGASSSDLGE LPVDARFPPR VPKSFPFNTS
   VVYKKTLFVE
 151    FTDHLFNIAK   PRPPWMGLLG PTIQAEVYDT VVITLKNMAS
   HPVSLHAVGV
 201    SYWKASEGAE   YDDQTSQREK EDDKVFPGGS HTYVWQVLKE
   NGPMASDPLC
 251    LTYSYLSHVD   LVKDLNSGLI GALLVCREGS LAKEKTQTLH
   KFILLFAVFD
 301   EGKSWHSETK    NSLMQDRDAA SARAWPKMHT VNGYVNRSLP
   GLIGCHRKSV
 351    YWHVIGMGTT   PEVHSIFLEG HTFLVRNHRQ ASLEISPITF
   LTAQTLLMDL
 401    GQFLLFCHIS   SHQHDGMEAY VKVDSCPEEP QLRMKNNEEA
   EDYDDDLTDS
 451   EMDVVRFDDD    NSPSFIQIRS VAKKHPKTWV HYIAAEEEDW
   DYAPLVLAPD
 501    DRSYKSQYLN   NGPQRIGRKY KKVRFMAYTD ETFKTREAIQ
   HESGILGPLL
 551    YGEVGDTLLI   IFKNQASRPY NIYPHGITDV RPLYSRRLPK
   GVKHLKDFPI
 601    LPGEIFKYKW   TVTVEDGPTK SDPRCLTRYY SSFVNMERDL
   ASGLIGPLLI
 651    CYKESVDQRG   NQIMSDKRNV ILFSVFDENR SWYLTENIQR
   FLPNPAGVQL
 701   EDPEFQASNI    MHSINGYVFD SLQLSVCLHE VAYWYILSIG
   AQTDFLSVFF
 751    SGYTFKHKMV   YEDTLTLFPF SGETVFMSME NPGLWILGCH
   NSDFRNRGMT
 801   ALLKVSSCDK    NTGDYYEDSY EDISAYLLSK NNAIEPRSFS
   QNGAPGTSES
                               -213-

 851  ATPESGPGSE  PATSGSETPG TSESATPESG PGSEPATSGS
   ETPGTSESAT
 901   PESGPGTSTE PSEGSAPGSP AGSPTSTEEG TSESATPESG
   PGSEPATSGS
 951  ETPGTSESAT  PESGPGSPAG SPTSTEEGSP AGSPTSTEEG
   TSTEPSEGSA
1001   PGTSESATPE SGPGTSESAT PESGPGTSES ATPESGPGSE
   PATSGSETPG
1051   SEPATSGSET PGSPAGSPTS TEEGTSTEPS EGSAPGTSTE
   PSEGSAPGSE
1101   PATSGSETPG TSESATPESG PGTSTEPSEG SAPASSPPVL
   KRHQAEITRT
1151   TLQSDQEEID YDDTISVEMK KEDFDIYDED ENQSPRSFQK
   KTRHYFIAAV
1201  ERLWDYGMSS  SPHVLRNRAQ SGSVPQFKKV VFQEFTDGSF
   TQPLYRGELN
1251  EHLGLLGPYI  RAEVEDNIMV TFRNQASRPY SFYSSLISYE
   EDQRQGAEPR
1301  KNFVKPNETK  TYFWKVQHHM APTKDEFDCK AWAYFSDVDL
   EKDVHSGLIG
1351   PLLVCHTNTL NPAHGRQVTV QEFALFFTIF DETKSWYFTE
   NMERNCRAPC
1401  NIQMEDPTFK  ENYRFHAING YIMDTLPGLV MAQDQRIRWY
   LLSMGSNENI
1451   HSIHFSGHVF TVRKKEEYKM ALYNLYPGVF ETVEMLPSKA
   GIWRVECLIG
1501  EHLHAGMSTL  FLVYSNKCQT PLGMASGHIR DFQITASGQY
   GQWAPKLARL
1551   HYSGSINAWS TKEPFSWIKV DLLAPMIIHG IKTQGARQKF
   SSLYISQFII
1601  MYSLDGKKWQ  TYRGNSTGTL MVFFGNVDSS GIKHNIFNPP
   IIARYIRLHP
1651   THYSIRSTLR MELMGCDLNS CSMPLGMESK AISDAQITAS
   SYFTNMFATW
1701   SPSKARLHLQ GRSNAWRPQV NNPKEWLQVD FQKTMKVTGV
   TTQGVKSLLT
1751   SMYVKEFLIS SSQDGHQWTL FFQNGKVKVF QGNQDSFTPV
   VNSLDPPLLT
1801  RYLRIHPQSW  VHQIALRMEV LGCEAQDLYD KTHTCPPCPA
   PELLGGPSVF
1851   LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG
   VEVHNAKTKP
1901  REEQYNSTYR  VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP
   IEKTISKAKG
1951   QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW
   ESNGQPENNY
2001  KTTPPVLDSD  GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA
   LHNHYTQKSL
2051   SLSPGK*
                         -214-

 pSYN FVIII 268 protein sequence (FVIII Fc with 144 AE-XTEN at amino
 acid 18) SEO ID NO: 114
    1 MQIELSTCFF      LCLLRFCFSA TRRYYLGAVE LSWDYMQGAP
    TSESATPESG
  51    PGSEPATSGS    ETPGTSESAT PESGPGSEPA TSGSETPGTS
   ESATPESGPG
 101    TSTEPSEGSA    PGSPAGSPTS TEEGTSESAT PESGPGSEPA
    TSGSETPGTS
 151    ESATPESGPG    SPAGSPTSTE EGSPAGSPTS TEEGASSSDL
    GELPVDARFP
 201    PRVPKSFPFN    TSVVYKKTLF VEFTDHLFNI AKPRPPWMGL
    LGPTIQAEVY
 251    DTVVITLKNM   ASHPVSLHAV GVSYWKASEG AEYDDQTSQR
   EKEDDKVFPG
 301    GSHTYVWQVL    KENGPMASDP LCLTYSYLSH VDLVKDLNSG
    LIGALLVCRE
 351    GSLAKEKTQT    LHKFILLFAV FDEGKSWHSE TKNSLMQDRD
   AASARAWPKM
 401    HTVNGYVNRS    LPGLIGCHRK SVYWHVIGMG TTPEVHSIFL
   EGHTFLVRNH
 451    RQASLEISPI    TFLTAQTLLM DLGQFLLFCH ISSHQHDGME
   AYVKVDSCPE
 501    EPQLRMKNNE    EAEDYDDDLT DSEMDVVRFD DDNSPSFIQI
   RSVAKKHPKT
 551    WVHYIAAEEE    DWDYAPLVLA PDDRSYKSQY LNNGPQRIGR
   KYKKVRFMAY
 601    TDETFKTREA    IQHESGILGP LLYGEVGDTL LIIFKNQASR
    PYNIYPHGIT
 651    DVRPLYSRRL    PKGVKHLKDF PILPGEIFKY KWTVTVEDGP
    TKSDPRCLTR
 701    YYSSFVNMER    DLASGLIGPL LICYKESVDQ RGNQIMSDKR
   NVILFSVFDE
 751    NRSWYLTENI    QRFLPNPAGV QLEDPEFQAS NIMHSINGYV
    FDSLQLSVCL
 801    HEVAYWYILS    IGAQTDFLSV FFSGYTFKHK MVYEDTLTLF
    PFSGETVFMS
 851    MENPGLWILG    CHNSDFRNRG MTALLKVSSC DKNTGDYYED
    SYEDISAYLL
 901    SKNNAIEPRS    FSQNPPVLKR HQAEITRTTL QSDQEEIDYD
    DTISVEMKKE
 951    DFDIYDEDEN    QSPRSFQKKT RHYFIAAVER LWDYGMSSSP
    HVLRNRAQSG
1001    SVPQFKKVVF    QEFTDGSFTQ PLYRGELNEH LGLLGPYIRA
   EVEDNIMVTF
1051    RNQASRPYSF    YSSLISYEED QRQGAEPRKN FVKPNETKTY
    FWKVQHHMAP
1101    TKDEFDCKAW   AYFSDVDLEK DVHSGLIGPL LVCHTNTLNP
   AHGRQVTVQE
1151    FALFFTIFDE    TKSWYFTENM ERNCRAPCNI QMEDPTFKEN
    YRFHAINGYI
                               -215 -

1201   MDTLPGLVMA    QDQRIRWYLL SMGSNENIHS          IHFSGHVFTV
   RKKEEYKMAL
1251   YNLYPGVFET    VEMLPSKAGI WRVECLIGEH LHAGMSTLFL
   VYSNKCQTPL
1301   GMASGHIRDF    QITASGQYGQ WAPKLARLHY          SGSINAWSTK
   EPFSWIKVDL
1351   LAPMIIHGIK    TQGARQKFSS LYISQFIIMY SLDGKKWQTY
   RGNSTGTLMV
1401   FFGNVDSSGI    KHNIFNPPII ARYIRLHPTH YSIRSTLRME
   LMGCDLNSCS
1451   MPLGMESKAI    SDAQITASSY FTNMFATWSP SKARLHLQGR
   SNAWRPQVNN
1501   PKEWLQVDFQ    KTMKVTGVTT QGVKSLLTSM YVKEFLISSS
   QDGHQWTLFF
1551   QNGKVKVFQG    NQDSFTPVVN SLDPPLLTRY LRIHPQSWVH
   QIALRMEVLG
1601   CEAQDLYDKT    HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI
   SRTPEVTCVV
1651   VDVSHEDPEV    KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV
   SVLTVLHQDW
1701   LNGKEYKCKV    SNKALPAPIE KTISKAKGQP REPQVYTLPP
   SRDELTKNQV
1751   SLTCLVKGFY    PSDIAVEWES NGQPENNYKT TPPVLDSDGS
   FFLYSKLTVD
1801   KSRWQQGNVF    SCSVMHEALH NHYTQKSLSL          SPGK*
 pSYN FVIII 269 protein sequence (FVIII Fc with 72 AE-XTEN at amino acid
 18) SEO ID NO: 115
    1 MQIELSTCFF     LCLLRFCFSA TRRYYLGAVE LSWDYMQGAP
   TSESATPESG
  51   PGSEPATSGS    ETPGTSESAT PESGPGSEPA TSGSETPGTS
   ESATPESGPG
 101   TSTEPSEGSA    PGASSSDLGE LPVDARFPPR VPKSFPFNTS
   VVYKKTLFVE
 151   FTDHLFNIAK    PRPPWMGLLG PTIQAEVYDT VVITLKNMAS
   HPVSLHAVGV
 201   SYWKASEGAE    YDDQTSQREK EDDKVFPGGS HTYVWQVLKE
   NGPMASDPLC
 251   LTYSYLSHVD    LVKDLNSGLI GALLVCREGS LAKEKTQTLH
   KFILLFAVFD
 301   EGKSWHSETK    NSLMQDRDAA SARAWPKMHT VNGYVNRSLP
   GLIGCHRKSV
 351   YWHVIGMGTT    PEVHSIFLEG HTFLVRNHRQ ASLEISPITF
   LTAQTLLMDL
 401   GQFLLFCHIS    SHQHDGMEAY VKVDSCPEEP QLRMKNNEEA
   EDYDDDLTDS
 451   EMDVVRFDDD    NSPSFIQIRS VAKKHPKTWV HYIAAEEEDW
   DYAPLVLAPD
 501   DRSYKSQYLN    NGPQRIGRKY KKVRFMAYTD ETFKTREAIQ
   HESGILGPLL
                               -216-

 551   YGEVGDTLLI IFKNQASRPY NIYPHGITDV RPLYSRRLPK
   GVKHLKDFPI
 601   LPGEIFKYKW TVTVEDGPTK SDPRCLTRYY SSFVNMERDL
   ASGLIGPLLI
 651   CYKESVDQRG NQIMSDKRNV ILFSVFDENR SWYLTENIQR
   FLPNPAGVQL
 701  EDPEFQASNI  MHSINGYVFD SLQLSVCLHE VAYWYILSIG
   AQTDFLSVFF
 751   SGYTFKHKMV YEDTLTLFPF SGETVFMSME NPGLWILGCH
   NSDFRNRGMT
 801  ALLKVSSCDK  NTGDYYEDSY EDISAYLLSK NNAIEPRSFS
   QNPPVLKRHQ
 851  AEITRTTLQS  DQEEIDYDDT ISVEMKKEDF DIYDEDENQS
   PRSFQKKTRH
 901   YFIAAVERLW DYGMSSSPHV LRNRAQSGSV PQFKKVVFQE
   FTDGSFTQPL
 951   YRGELNEHLG LLGPYIRAEV EDNIMVTFRN QASRPYSFYS
   SLISYEEDQR
1001   QGAEPRKNFV KPNETKTYFW KVQHHMAPTK DEFDCKAWAY
   FSDVDLEKDV
1051   HSGLIGPLLV CHTNTLNPAH GRQVTVQEFA LFFTIFDETK
   SWYFTENMER
1101  NCRAPCNIQM  EDPTFKENYR FHAINGYIMD TLPGLVMAQD
   QRIRWYLLSM
1151   GSNENIHSIH FSGHVFTVRK KEEYKMALYN LYPGVFETVE
   MLPSKAGIWR
1201  VECLIGEHLH  AGMSTLFLVY SNKCQTPLGM ASGHIRDFQI
   TASGQYGQWA
1251   PKLARLHYSG SINAWSTKEP FSWIKVDLLA PMIIHGIKTQ
   GARQKFSSLY
1301   ISQFIIMYSL DGKKWQTYRG NSTGTLMVFF GNVDSSGIKH
   NIFNPPIIAR
1351   YIRLHPTHYS IRSTLRMELM GCDLNSCSMP LGMESKAISD
   AQITASSYFT
1401  NMFATWSPSK  ARLHLQGRSN AWRPQVNNPK EWLQVDFQKT
   MKVTGVTTQG
1451  VKSLLTSMYV  KEFLISSSQD GHQWTLFFQN GKVKVFQGNQ
   DSFTPVVNSL
1501   DPPLLTRYLR IHPQSWVHQI ALRMEVLGCE AQDLYDKTHT
   CPPCPAPELL
1551   GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF
   NWYVDGVEVH
1601  NAKTKPREEQ  YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN
   KALPAPIEKT
1651   ISKAKGQPRE PQVYTLPPSR DELTKNQVSL TCLVKGFYPS
   DIAVEWESNG
1701   QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC
   SVMHEALHNH
1751   YTQKSLSLSP GK*
                         -217-

 pSYNFVIII 271 protein sequence (FVIII Fc with 42 AE-XTEN at amino acid
 18) SEO ID NO: 116
    1 MQIELSTCFF    LCLLRFCFSA TRRYYLGAVE LSWDYMQGAP
   GSPAGSPTST
  51   EEGTSESATP   ESGPGSEPAT SGSETPASSS DLGELPVDAR
   FPPRVPKSFP
 101   FNTSVVYKKT   LFVEFTDHLF NIAKPRPPWM GLLGPTIQAE
   VYDTVVITLK
 151   NMASHPVSLH   AVGVSYWKAS EGAEYDDQTS QREKEDDKVF
   PGGSHTYVWQ
 201   VLKENGPMAS   DPLCLTYSYL SHVDLVKDLN SGLIGALLVC
   REGSLAKEKT
 251   QTLHKFILLF   AVFDEGKSWH SETKNSLMQD RDAASARAWP
   KMHTVNGYVN
 301   RSLPGLIGCH   RKSVYWHVIG MGTTPEVHSI FLEGHTFLVR
   NHRQASLEIS
 351   PITFLTAQTL   LMDLGQFLLF CHISSHQHDG MEAYVKVDSC
   PEEPQLRMKN
 401   NEEAEDYDDD   LTDSEMDVVR FDDDNSPSFI QIRSVAKKHP
   KTWVHYIAAE
 451   EEDWDYAPLV   LAPDDRSYKS QYLNNGPQRI GRKYKKVRFM
   AYTDETFKTR
 501   EAIQHESGIL   GPLLYGEVGD TLLIIFKNQA SRPYNIYPHG
   ITDVRPLYSR
 551   RLPKGVKHLK   DFPILPGEIF KYKWTVTVED GPTKSDPRCL
   TRYYSSFVNM
 601   ERDLASGLIG   PLLICYKESV DQRGNQIMSD KRNVILFSVF
   DENRSWYLTE
 651   NIQRFLPNPA   GVQLEDPEFQ ASNIMHSING YVFDSLQLSV
   CLHEVAYWYI
 701   LSIGAQTDFL   SVFFSGYTFK HKMVYEDTLT LFPFSGETVF
   MSMENPGLWI
 751   LGCHNSDFRN   RGMTALLKVS SCDKNTGDYY EDSYEDISAY
   LLSKNNAIEP
 801   RSFSQNPPVL   KRHQAEITRT TLQSDQEEID YDDTISVEMK
   KEDFDIYDED
 851   ENQSPRSFQK   KTRHYFIAAV ERLWDYGMSS SPHVLRNRAQ
   SGSVPQFKKV
 901   VFQEFTDGSF   TQPLYRGELN EHLGLLGPYI         RAEVEDNIMV
   TFRNQASRPY
 951   SFYSSLISYE   EDQRQGAEPR KNFVKPNETK TYFWKVQHHM
   APTKDEFDCK
1001   AWAYFSDVDL   EKDVHSGLIG PLLVCHTNTL NPAHGRQVTV
   QEFALFFTIF
1051   DETKSWYFTE   NMERNCRAPC NIQMEDPTFK ENYRFHAING
   YIMDTLPGLV
1101   MAQDQRIRWY   LLSMGSNENI HSIHFSGHVF TVRKKEEYKM
   ALYNLYPGVF
1151   ETVEMLPSKA   GIWRVECLIG EHLHAGMSTL FLVYSNKCQT
   PLGMASGHIR
                              -218-

1201    DFQITASGQY    GQWAPKLARL HYSGSINAWS TKEPFSWIKV
   DLLAPMIIHG
1251    IKTQGARQKF    SSLYISQFII MYSLDGKKWQ TYRGNSTGTL
   MVFFGNVDSS
1301    GIKHNIFNPP    IIARYIRLHP THYSIRSTLR MELMGCDLNS
   CSMPLGMESK
1351   AISDAQITAS     SYFTNMFATW SPSKARLHLQ GRSNAWRPQV
   NNPKEWLQVD
1401    FQKTMKVTGV    TTQGVKSLLT SMYVKEFLIS        SSQDGHQWTL
   FFQNGKVKVF
1451    QGNQDSFTPV    VNSLDPPLLT RYLRIHPQSW VHQIALRMEV
   LGCEAQDLYD
1501   KTHTCPPCPA     PELLGGPSVF LFPPKPKDTL MISRTPEVTC
   VVVDVSHEDP
1551   EVKFNWYVDG     VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ
   DWLNGKEYKC
1601   KVSNKALPAP     IEKTISKAKG QPREPQVYTL PPSRDELTKN
   QVSLTCLVKG
1651    FYPSDIAVEW    ESNGQPENNY KTTPPVLDSD GSFFLYSKLT
   VDKSRWQQGN
1701   VFSCSVMHEA     LHNHYTQKSL SLSPGK*
 pSYN FVIII protein sequence 272 (FVIII with 144 AE XTEN at amino acid
 18 and 244 AE XTEN in B-domain- no Fc) SEO ID NO: 117
    1 MQIELSTCFF      LCLLRFCFSA TRRYYLGAVE LSWDYMQGAP
   TSESATPESG
  51    PGSEPATSGS    ETPGTSESAT PESGPGSEPA TSGSETPGTS
   ESATPESGPG
 101    TSTEPSEGSA    PGSPAGSPTS TEEGTSESAT PESGPGSEPA
   TSGSETPGTS
 151   ESATPESGPG     SPAGSPTSTE EGSPAGSPTS TEEGASSSDL
   GELPVDARFP
 201    PRVPKSFPFN    TSVVYKKTLF VEFTDHLFNI AKPRPPWMGL
   LGPTIQAEVY
 251    DTVVITLKNM    ASHPVSLHAV GVSYWKASEG AEYDDQTSQR
   EKEDDKVFPG
 301    GSHTYVWQVL    KENGPMASDP LCLTYSYLSH VDLVKDLNSG
   LIGALLVCRE
 351    GSLAKEKTQT    LHKFILLFAV FDEGKSWHSE TKNSLMQDRD
   AASARAWPKM
 401    HTVNGYVNRS    LPGLIGCHRK SVYWHVIGMG TTPEVHSIFL
   EGHTFLVRNH
 451   RQASLEISPI     TFLTAQTLLM DLGQFLLFCH ISSHQHDGME
   AYVKVDSCPE
 501   EPQLRMKNNE     EAEDYDDDLT DSEMDVVRFD DDNSPSFIQI
   RSVAKKHPKT
 551   WVHYIAAEEE     DWDYAPLVLA PDDRSYKSQY LNNGPQRIGR
   KYKKVRFMAY
 601    TDETFKTREA    IQHESGILGP LLYGEVGDTL LIIFKNQASR
   PYNIYPHGIT
                               -219-

 651   DVRPLYSRRL PKGVKHLKDF PILPGEIFKY KWTVTVEDGP
   TKSDPRCLTR
 701   YYSSFVNMER DLASGLIGPL LICYKESVDQ RGNQIMSDKR
   NVILFSVFDE
 751  NRSWYLTENI  QRFLPNPAGV QLEDPEFQAS NIMHSINGYV
   FDSLQLSVCL
 801   HEVAYWYILS IGAQTDFLSV FFSGYTFKHK MVYEDTLTLF
   PFSGETVFMS
 851  MENPGLWILG  CHNSDFRNRG MTALLKVSSC DKNTGDYYED
   SYEDISAYLL
 901   SKNNAIEPRS FSQNGAPGTS ESATPESGPG SEPATSGSET
   PGTSESATPE
 951   SGPGSEPATS GSETPGTSES ATPESGPGTS TEPSEGSAPG
   SPAGSPTSTE
1001  EGTSESATPE  SGPGSEPATS GSETPGTSES ATPESGPGSP
   AGSPTSTEEG
1051   SPAGSPTSTE EGTSTEPSEG SAPGTSESAT PESGPGTSES
   ATPESGPGTS
1101  ESATPESGPG  SEPATSGSET PGSEPATSGS ETPGSPAGSP
   TSTEEGTSTE
1151   PSEGSAPGTS TEPSEGSAPG SEPATSGSET PGTSESATPE
   SGPGTSTEPS
1201  EGSAPASSPP  VLKRHQAEIT RTTLQSDQEE IDYDDTISVE
   MKKEDFDIYD
1251  EDENQSPRSF  QKKTRHYFIA AVERLWDYGM SSSPHVLRNR
   AQSGSVPQFK
1301  KVVFQEFTDG  SFTQPLYRGE LNEHLGLLGP YIRAEVEDNI
   MVTFRNQASR
1351   PYSFYSSLIS YEEDQRQGAE PRKNFVKPNE TKTYFWKVQH
   HMAPTKDEFD
1401   CKAWAYFSDV DLEKDVHSGL IGPLLVCHTN TLNPAHGRQV
   TVQEFALFFT
1451   IFDETKSWYF TENMERNCRA PCNIQMEDPT FKENYRFHAI
   NGYIMDTLPG
1501   LVMAQDQRIR WYLLSMGSNE NIHSIHFSGH VFTVRKKEEY
   KMALYNLYPG
1551  VFETVEMLPS  KAGIWRVECL IGEHLHAGMS TLFLVYSNKC
   QTPLGMASGH
1601   IRDFQITASG QYGQWAPKLA RLHYSGSINA WSTKEPFSWI
   KVDLLAPMII
1651   HGIKTQGARQ KFSSLYISQF IIMYSLDGKK WQTYRGNSTG
   TLMVFFGNVD
1701   SSGIKHNIFN PPIIARYIRL HPTHYSIRST LRMELMGCDL
   NSCSMPLGME
1751   SKAISDAQIT ASSYFTNMFA TWSPSKARLH LQGRSNAWRP
   QVNNPKEWLQ
1801  VDFQKTMKVT  GVTTQGVKSL LTSMYVKEFL ISSSQDGHQW
   TLFFQNGKVK
1851  VFQGNQDSFT  PVVNSLDPPL LTRYLRIHPQ SWVHQIALRM
   EVLGCEAQDL
1901   Y*
                         -220-

 pSYN VWF 031 protein sequence (VWF D1D2D'D3- 48aa long thrombin
 cleavable GS
 linker-Fc) SEO ID NO: 118
   1    MIPARFAGVL   LALALILPGT LCAEGTRGRS STARCSLFGS
    DFVNTFDGSM
   51   YSFAGYCSYL   LAGGCQKRSF SIIGDFQNGK RVSLSVYLGE
    FFDIHLFVNG
 101    TVTQGDQRVS   MPYASKGLYL ETEAGYYKLS GEAYGFVARI
    DGSGNFQVLL
 151    SDRYFNKTCG   LCGNFNIFAE DDFMTQEGTL TSDPYDFANS
    WALSSGEQWC
 201    ERASPPSSSC   NISSGEMQKG LWEQCQLLKS TSVFARCHPL
    VDPEPFVALC
 251    EKTLCECAGG   LECACPALLE YARTCAQEGM VLYGWTDHSA
    CSPVCPAGME
 301    YRQCVSPCAR   TCQSLHINEM CQERCVDGCS CPEGQLLDEG
    LCVESTECPC
 351    VHSGKRYPPG   TSLSRDCNTC ICRNSQWICS NEECPGECLV
    TGQSHFKSFD
 401    NRYFTFSGIC   QYLLARDCQD HSFSIVIETV QCADDRDAVC
    TRSVTVRLPG
 451    LHNSLVKLKH   GAGVAMDGQD IQLPLLKGDL RIQHTVTASV
    RLSYGEDLQM
 501    DWDGRGRLLV   KLSPVYAGKT CGLCGNYNGN QGDDFLTPSG
    LAEPRVEDFG
 551    NAWKLHGDCQ   DLQKQHSDPC ALNPRMTRFS EEACAVLTSP
    TFEACHRAVS
  601   PLPYLRNCRY   DVCSCSDGRE CLCGALASYA AACAGRGVRV
    AWREPGRCEL
  651   NCPKGQVYLQ   CGTPCNLTCR SLSYPDEECN EACLEGCFCP
    PGLYMDERGD
 701    CVPKAQCPCY   YDGEIFQPED IFSDHHTMCY CEDGFMHCTM
    SGVPGSLLPD
 751    AVLSSPLSHR   SKRSLSCRPP MVKLVCPADN LRAEGLECTK
    TCQNYDLECM
 801    SMGCVSGCLC   PPGMVRHENR CVALERCPCF HQGKEYAPGE
    TVKIGCNTCV
 851    CRDRKWNCTD   HVCDATCSTI GMAHYLTFDG LKYLFPGECQ
    YVLVQDYCGS
  901   NPGTFRILVG   NKGCSHPSVK CKKRVTILVE GGEIELFDGE
    VNVKRPMKDE
  951   THFEVVESGR   YIILLLGKAL SVVWDRHLSI    SVVLKQTYQE
    KVCGLCGNFD
1001    GIQNNDLTSS   NLQVEEDPVD FGNSWKVSSQ CADTRKVPLD
    SSPATCHNNI
1051    MKQTMVDSSC   RILTSDVFQD CNKLVDPEPY LDVCIYDTCS
    CESIGDCAAF
1101    CDTIAAYAHV   CAQHGKVVTW RTATLCPQSC EERNLRENGY
    EAEWRYNSCA
                             - 221 -

1151    PACQVTCQHP     EPLACPVQCV EGCHAHCPPG KILDELLQTC
    VDPEDCPVCE
1201    VAGRRFASGK     KVTLNPSDPE HCQICHCDVV NLTCEACQEP
     ISGGGGSGGG
1251    GSGGGGSGGG     GSGGGGSGGG GSLVPRGSGG GGSGGGGSDK
     THTCPPCPAP
1301    ELLGGPSVFL     FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE
    VKFNWYVDGV
1351    EVHNAKTKPR     EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK
    VSNKALPAPI
1401    EKTISKAKGQ     PREPQVYTLP PSRDELTKNQ VSLTCLVKGF
     YPSDIAVEWE
1451    SNGQPENNYK     TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV
     FSCSVMHEAL
1501    HNHYTQKSLS     LSPGK*
 pSYN VWF 034 protein sequence (VWF D1D2D'D3- 288AE XTEN- 35aa
 long thrombin cleavable GS linker-Fc) SEO ID NO: 119
   1    MIPARFAGVL     LALALILPGT LCAEGTRGRS STARCSLFGS
     DFVNTFDGSM
   51   YSFAGYCSYL     LAGGCQKRSF SIIGDFQNGK RVSLSVYLGE
     FFDIHLFVNG
 101    TVTQGDQRVS     MPYASKGLYL ETEAGYYKLS GEAYGFVARI
     DGSGNFQVLL
 151    SDRYFNKTCG     LCGNFNIFAE DDFMTQEGTL TSDPYDFANS
    WALSSGEQWC
 201    ERASPPSSSC     NISSGEMQKG LWEQCQLLKS TSVFARCHPL
    VDPEPFVALC
 251    EKTLCECAGG     LECACPALLE YARTCAQEGM VLYGWTDHSA
     CSPVCPAGME
 301    YRQCVSPCAR     TCQSLHINEM CQERCVDGCS CPEGQLLDEG
     LCVESTECPC
 351    VHSGKRYPPG     TSLSRDCNTC ICRNSQWICS NEECPGECLV
     TGQSHFKSFD
 401    NRYFTFSGIC     QYLLARDCQD HSFSIVIETV QCADDRDAVC
     TRSVTVRLPG
 451    LHNSLVKLKH     GAGVAMDGQD IQLPLLKGDL RIQHTVTASV
    RLSYGEDLQM
 501    DWDGRGRLLV     KLSPVYAGKT CGLCGNYNGN QGDDFLTPSG
     LAEPRVEDFG
 551    NAWKLHGDCQ     DLQKQHSDPC ALNPRMTRFS EEACAVLTSP
     TFEACHRAVS
  601   PLPYLRNCRY     DVCSCSDGRE CLCGALASYA AACAGRGVRV
    AWREPGRCEL
  651   NCPKGQVYLQ     CGTPCNLTCR SLSYPDEECN EACLEGCFCP
     PGLYMDERGD
 701    CVPKAQCPCY     YDGEIFQPED IFSDHHTMCY CEDGFMHCTM
     SGVPGSLLPD
 751    AVLSSPLSHR     SKRSLSCRPP MVKLVCPADN LRAEGLECTK
     TCQNYDLECM
                                -222-

 801    SMGCVSGCLC   PPGMVRHENR CVALERCPCF HQGKEYAPGE
    TVKIGCNTCV
 851    CRDRKWNCTD   HVCDATCSTI GMAHYLTFDG LKYLFPGECQ
    YVLVQDYCGS
  901   NPGTFRILVG   NKGCSHPSVK CKKRVTILVE GGEIELFDGE
    VNVKRPMKDE
  951   THFEVVESGR   YIILLLGKAL SVVWDRHLSI   SVVLKQTYQE
    KVCGLCGNFD
1001    GIQNNDLTSS   NLQVEEDPVD FGNSWKVSSQ CADTRKVPLD
    SSPATCHNNI
1051    MKQTMVDSSC   RILTSDVFQD CNKLVDPEPY LDVCIYDTCS
    CESIGDCAAF
1101    CDTIAAYAHV   CAQHGKVVTW RTATLCPQSC EERNLRENGY
    EAEWRYNSCA
1151    PACQVTCQHP   EPLACPVQCV EGCHAHCPPG KILDELLQTC
    VDPEDCPVCE
1201    VAGRRFASGK   KVTLNPSDPE HCQICHCDVV NLTCEACQEP
    ISGTSESATP
1251    ESGPGSEPAT   SGSETPGTSE SATPESGPGS EPATSGSETP
    GTSESATPES
1301    GPGTSTEPSE   GSAPGSPAGS PTSTEEGTSE   SATPESGPGS
    EPATSGSETP
1351    GTSESATPES   GPGSPAGSPT STEEGSPAGS   PTSTEEGTST
    EPSEGSAPGT
1401    SESATPESGP   GTSESATPES GPGTSESATP ESGPGSEPAT
    SGSETPGSEP
1451    ATSGSETPGS   PAGSPTSTEE GTSTEPSEGS APGTSTEPSE
    GSAPGSEPAT
1501    SGSETPGTSE   SATPESGPGT STEPSEGSAP DIGGGGGSGG
    GGSLVPRGSG
1551    GDKTHTCPPC   PAPELLGGPS VFLFPPKPKD TLMISRTPEV
    TCVVVDVSHE
1601    DPEVKFNWYV   DGVEVHNAKT KPREEQYNST YRVVSVLTVL
    HQDWLNGKEY
1651    KCKVSNKALP   APIEKTISKA KGQPREPQVY TLPPSRDELT
    KNQVSLTCLV
1701    KGFYPSDIAV   EWESNGQPEN NYKTTPPVLD SDGSFFLYSK
    LTVDKSRWQQ
1751    GNVFSCSVMH   EALHNHYTQK SLSLSPGK*
 pSYN VWF 036 protein sequence (VWF D1D2D'D-98aa long thrombin
 cleavable GS
 linker-Fc) SEO ID NO: 120
     1 MIPARFAGVL    LALALILPGT LCAEGTRGRS STARCSLFGS
    DFVNTFDGSM
   51   YSFAGYCSYL   LAGGCQKRSF SIIGDFQNGK RVSLSVYLGE
    FFDIHLFVNG
 101    TVTQGDQRVS   MPYASKGLYL ETEAGYYKLS GEAYGFVARI
    DGSGNFQVLL
 151    SDRYFNKTCG   LCGNFNIFAE DDFMTQEGTL TSDPYDFANS
    WALSSGEQWC
                             -223 -

 201  ERASPPSSSC  NISSGEMQKG LWEQCQLLKS TSVFARCHPL
   VDPEPFVALC
 251  EKTLCECAGG  LECACPALLE YARTCAQEGM VLYGWTDHSA
   CSPVCPAGME
 301   YRQCVSPCAR TCQSLHINEM CQERCVDGCS CPEGQLLDEG
   LCVESTECPC
 351  VHSGKRYPPG  TSLSRDCNTC ICRNSQWICS NEECPGECLV
   TGQSHFKSFD
 401  NRYFTFSGIC  QYLLARDCQD HSFSIVIETV QCADDRDAVC
   TRSVTVRLPG
 451   LHNSLVKLKH GAGVAMDGQD IQLPLLKGDL RIQHTVTASV
   RLSYGEDLQM
 501   DWDGRGRLLV KLSPVYAGKT CGLCGNYNGN QGDDFLTPSG
   LAEPRVEDFG
 551  NAWKLHGDCQ  DLQKQHSDPC ALNPRMTRFS EEACAVLTSP
   TFEACHRAVS
 601   PLPYLRNCRY DVCSCSDGRE CLCGALASYA AACAGRGVRV
   AWREPGRCEL
 651  NCPKGQVYLQ  CGTPCNLTCR SLSYPDEECN EACLEGCFCP
   PGLYMDERGD
 701   CVPKAQCPCY YDGEIFQPED IFSDHHTMCY CEDGFMHCTM
   SGVPGSLLPD
 751  AVLSSPLSHR  SKRSLSCRPP MVKLVCPADN LRAEGLECTK
   TCQNYDLECM
 801   SMGCVSGCLC PPGMVRHENR CVALERCPCF HQGKEYAPGE
   TVKIGCNTCV
 851   CRDRKWNCTD HVCDATCSTI GMAHYLTFDG LKYLFPGECQ
   YVLVQDYCGS
 901  NPGTFRILVG  NKGCSHPSVK CKKRVTILVE GGEIELFDGE
   VNVKRPMKDE
 951   THFEVVESGR YIILLLGKAL SVVWDRHLSI SVVLKQTYQE
   KVCGLCGNFD
1001   GIQNNDLTSS NLQVEEDPVD FGNSWKVSSQ CADTRKVPLD
   SSPATCHNNI
1051  MKQTMVDSSC  RILTSDVFQD CNKLVDPEPY LDVCIYDTCS
   CESIGDCAAF
1101   CDTIAAYAHV CAQHGKVVTW RTATLCPQSC EERNLRENGY
   EAEWRYNSCA
1151   PACQVTCQHP EPLACPVQCV EGCHAHCPPG KILDELLQTC
   VDPEDCPVCE
1201  VAGRRFASGK  KVTLNPSDPE HCQICHCDVV NLTCEACQEP
   ISGGGGSGGG
1251   GSGGGGSGGG GSGGGGSGGG GSGGGGSGGG GSGGGGSGGG
   GSGGGGSGGG
1301   GSGGGGSGGG GSGGGGSGGG GSLVPRGSGG GGSGGGGSDK
   THTCPPCPAP
1351  ELLGGPSVFL  FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE
   VKFNWYVDGV
1401  EVHNAKTKPR  EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK
   VSNKALPAPI
                         -224-

       1451     EKTISKAKGQ PREPQVYTLP PSRDELTKNQ VSLTCLVKGF
            YPSDIAVEWE
       1501     SNGQPENNYK TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV
            FSCSVMHEAL
       1551     HNHYTQKSLS LSPGK*
        pSYN Fc-015 protein sequence (IgG-Fc domain) SEO ID NO: 121
            1   METDTLLLWV       LLLWVPGSTG DKTHTCPPCP APELLGGPSV
            FLFPPKPKDT
          51    LMISRTPEVT       CVVVDVSHED PEVKFNWYVD GVEVHNAKTK
            PREEQYNSTY
        101     RVVSVLTVLH       QDWLNGKEYK CKVSNKALPA PIEKTISKAK
            GQPREPQVYT
        151     LPPSRDELTK       NQVSLTCLVK GFYPSDIAVE WESNGQPENN
            YKTTPPVLDS
        201     DGSFFLYSKL       TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS
            LSLSPGK*
           Example 15: FVIII-XTEN-Fc:VWF-Fc heterodimers have maintained
            normal FVIII specific activity as compared to wild type BDD-FVIII.
[03831          The FVIII specific activity of FVIII-XTEN-Fc:VWF-Fc heterodimers were
        determined. Heterodimers were purified using a two-step chromatography process.
        A weak anion exchange resin was used, followed by affinity chromatography. The
        final purified product had acceptable purity by SEC-HPLC. The specific activity
        was compared to B-domain deleted FVIII (BDD-FVIII), as measured by FVIII
        chromogenic assay and A280 concentration. The data are presented in Table 26.
        All tested molecules had demonstrated comparable FVIII specific activities to
        BDD-FVIII. Purity and the presence of each moiety of the molecules were
        confirmed by SDS-PAGE and western blotting.
        Table 26: FVIII specific activity of FVIII-XTEN-Fc:VWF-Fc heterodimers
                                FVIII-66       FVIII    FVIII      FVIII   FVIII       FVIII
                 FVIII 207
 Construct scBDDFVIII           dcBDD          155 /    155 /       169 /   205 /      169 /
                                 FVIII)       vWF31    vWF39      vWF31   vWF31       vWF34
 Measured
   Specific         1473          1592         1534     1796        1511    1345       1505
  Activity
 (IU/nmol)
[0384]          The half-lives of rFVIII-XTEN/D'D3 and BDD-FVIII were compared in
        HemA Mice (Figure 15; Table 27). As Figure 15 shows, rFVIII-XTEN/D'D3
                                            - 225 -

       achieved a half-life that was four fold longer than the half-life achieved by BDD
       FVIII.
       Table 27: rFVIII-XTEN/D'D3 and BDD-FVIII in HemA mice
                  5 minutes    HL     MRT           Cl        Vss             AUC D
   Treatment      Recovery     (hr)    (hr)    (mL/hr/kg)  (mL/kg)    (hr*kg*mIU/mL/mIU)
  BDD-FVIII           89       7.6       11        4.5       49.2               0.22
    rFVIIIFc          78        16      20         2.9        57.8              0.35
  XTEN/'D3            86        30      36          1.8       63.4              0.57
        Example 16: FVIII-XTEN-Fc:VWF-Fc heterodimer's potency (FVIII activity) in
                          hemostasis as measured by one stage aPTT assay
[0385]         The potency of FVIII-XTEN-Fc:VWF-Fc heterodimers in hemostasis was
       evaluated by their FVIII specific aPTT activity as summarized in Table 28. As
       demonstrated by Table 28, while the addition of the VWF D'D3 fragment and the
       insertion of XTEN into the intra-domains of FVIII reduce the FVIII specific aPTT
       activity of the heterodimers (as indicated by the FVIII155/VWFO3 1 data and the
       FV111205/VWFO31 data), XTEN insertions in the FVIII B domain region or C
       terminus of the VWF D'D3 fragment have no negative effect on the FVIII specific
       aPTT activity (as indicated by the FVIII 1 69/VWFO31 data and the
       FV111169/VWFO34 data). Compared to dual-chain BDD-FVIII (dcBDD-FVIII),
       FVIIIl55/VWFO31, FVIII169/VWFO31, FVIII169/VWFO34 and
       VWF205/VWFO31 showed reduction of specific aPTT activity by 2.5-fold, 2.8
       fold, 2.6-fold and 5.5-fold, respectively.
       Table    28:   FVIII     specific    aPTT activity    of   FVIII-XTEN-Fc:VWF-Fc
       heterodimers
               FVIII 207      FVIII-66          FVIII     FVIII 169     FVIII      FVIII 169
 Construct      scBDD-         dcBDD-            155 /     VWF31        205/         VWF34
                 FVIII           FVIII         VWF31                   VWF31
 Measured
  Specific
                                                448
   aPTT        818    153    1188     213                 416    70   214    38    436    189
  Activity
 (IU/nmol)
                                             - 226  -

       FVIII specific aPTT assay
[03861         FVIII variants were diluted with aPTT buffer (0.15 M NaCl, 0.05 M Tris
       HCl, 1% BSA, pH 7.4) to the linear assay range (200- 1.6 mU/mL). 50 gL of
       diluted samples or standards were sequentially mixed with 50 gL of 37 0 C naYve
       human HemA pooled plasma, 50 gL of 37 0 C aPTT reagent (ACTIN@ FSL
       activated cephaloplastin reagent - Dade Behring, reference # B4219-2) and
       incubated at 37 0C for 4 minutes. 50 pl of 20 mM CaCl 2 (Dade Behring [reference
       # ORF037]) was then added to the reaction mixture to start the clotting reactions.
       Using the clotting time of each sample (the length of time from the addition of
       CaCl 2 until the onset of clot formation), the aPTT activity was calculated against
       the standard that was generated with the 811 international standard FVIII
       concentrate. Specific aPTT activity was calculated against the protein
       concentration of each molecule that measured by OD280.
        Example 17: In vivo efficacy of FVIII-XTEN-Fc:VWF-Fc heterodimer in HemA
                                   mice Tail Clip bleeding model
[0387]         To further access the hemostasis potency of the heterodimers, the acute
       efficacy of FVIII 169/VWFO34 and FV111205/VWFO31 was evaluated in
       comparison with BDD-FVIII in the HemA mice Tail clip bleeding model. HemA
       mice were treated with a single IV injection of BDD-FVIII at 200, 65 and 20
       IU/kg to generate the post tail clip injury blood loss control level. Blood loss from
       mice treated with 200 IU/kg of FVIII169/VWFO34 or FVIII205/VWFO31 was
       compared to that of the BDD-FVIII treated control group mice to estimate their
       potency on hemostasis. Vehicle treated animals were used to generate blood loss
       baseline for the model. As shown in Figure 16, significant reduction in blood loss
       was observed from all FVIII treatment groups compared to that of the vehicle
       treated animals (p<0.05). Both FVIIII69/VWFO34 and FV111205/VWFO31 are
       efficacious in the HemA mice Tail Clip model. Compared to BDD-FVIII, about 3
       fold lower potency was observed for FVIIII69/VWFO34, as demonstrated by the
       similar blood loss reduction achieved by 65 IU/kg BDD-FVIII and 200 IU/kg
       FV111169/VWFO34. As for FV111205/VWFO34, a 10 fold potency reduction has
       been observed, as demonstrated by the similar blood loss reduction achieved by 20
       IU/kg BDD-FVIII and 200 IU/kg FV111205/VWFO3 1.
                                            - 227 -

[03881          Even though FV11169/VWF034 and FV111205/VWF031 had similar
       specific FVIII chromogenic activity compared to rBDD-FVIII, their FVIII aPTT
       activity and in vivo potency were both reduced due to the modifications of the
       molecules. Those data indicate that the aPTT activity of a FVIII molecule is a
       more accurate measurement on predicating its in vivo potency on hemostasis than
       the FVIII chromogenic activity.
       HemA mice Tail clip bleeding model
[03891          8-10 weeks old male HemA mice were used for the study. Prior to tail clip
       injury, mice were anesthetized with a 50 mg/kg Ketamine/0.5 mg/kg
       Dexmedetomidine cocktail and placed on a 37 0 C heating pad to help maintain the
       body temperature. The tails of the mice were then be immersed in 37 0 C water for
       10 minutes to dilate the lateral vein. After vein dilation, rFVIII or vehicle solution
       were injected via the tail vein and 5 min later, the distal 1 cm of the tail was cut
       off using a #11 scalpel with straight edge. The shed blood was collected into 13
       ml of 37 0 C warm saline for 30 minutes and the mice were then euthanized while
       still under anesthesia by bilateral thoracotomy. Blood loss was quantified
       gravimetrically by weight change of the blood collection tubes before and after
       blood was collected in gram, which translated into milliliter (mL) of blood loss
       volume (Ig weight change      = 1 mL blood loss).
[03901          The foregoing description of the specific embodiments will so fully reveal
       the general nature of the invention that others can, by applying knowledge within
       the skill of the art, readily modify and/or adapt for various applications such
       specific embodiments, without undue experimentation, without departing from the
       general concept of the present invention. Therefore, such adaptations and
       modifications are intended to be within the meaning and range of equivalents of
       the disclosed embodiments, based on the teaching and guidance presented
       herein. It is to be understood that the phraseology or terminology herein is for the
       purpose of description and not of limitation, such that the terminology or
       phraseology of the present specification is to be interpreted by the skilled artisan
       in light of the teachings and guidance.
[03911          Other embodiments of the invention will be apparent to those skilled in the
       art from consideration of the specification and practice of the invention disclosed
       herein. It is intended that the specification and examples be considered as
                                            -228-

       exemplary only, with a true scope and spirit of the invention being indicated by
       the following claims.
[0392]         All patents and publications cited herein are incorporated by reference
       herein in their entirety.
                                          - 229  -

WHAT IS CLAIMED IS:
1.       A chimeric protein comprising (i) a von Willebrand Factor (VWF) protein
comprising the D' domain and the D3 domain of VWF, (ii) an XTEN sequence, and (iii) a
FVIII protein, wherein the VWF fragment and the XTEN sequence are linked by an
optional linker, wherein the VWF fragment or the XTEN sequence is linked to or
associated with the FVIII protein.
2.       A chimeric protein comprising a formula, which comprises:
         (a)     V-X-FVIII,
         (b)     FVIII-X-V,
         (c)     V-X:FVIII,
         (d)     X-V:FVIII,
         (e)     FVIII:V-X, or
         (f)     FVIII:X-V,
    wherein V comprises a VWF fragment,
    X comprises one or more XTEN sequences,
    FVIII comprises a FVIII protein;
    (-) is a peptide bond or one or more amino acids; and
    (:) is a covalent bond or a non-covalent bond.
3.       The chimeric protein of claim 1 or 2, wherein the XTEN sequence is linked to the
FVIII protein by a linker.
4.       The chimeric protein of claim 3, wherein the linker is a cleavable linker.
5.       The chimeric protein of any one of claims 1 to 4, which comprises a single
polypeptide chain comprising the VWF fragment, the XTEN sequence and the FVIII
protein.
6.       The chimeric protein of any one of claims 1 to 4, which comprises a first
polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain
comprises FVIII and the second polypeptide chain comprises the VWF fragment and the
XTEN sequence.
                                           -230-

7.      The chimeric protein of any one of claims 1 to 6, further comprising (iv) an Ig
constant region or a portion thereof linked to either the VWF fragment, the XTEN
sequence, or the FVIII protein, or any combination thereof.
8.      A chimeric protein comprising a formula, which comprises:
        (g)      V-L2-X-Ll-F 1:FVIII-L3-F2;
        (h)      V-L2-X-Ll-F 1:F2-L3-FVIII;
        (i)      Fl-Ll-X-L2-V: FVIII-L3-F2;
        (j)      Fl-Ll-X-L2-V:F2-L3-FVIII;
        (k)      V-L2-X-L 1-Fl -L4-FVIII-L3 -F2;
        (1)      F2-L3-FVIII-L4-F 1-Li -X-L2-V;
        (m)      FVIII-L3-F2-L4-V-L2-X-Ll-Fl; and
        (n)      Fl-L1-X-L2-V-L4-F2-L3-FVIII,
        wherein V comprises a VWF fragment,
        each of L1, L2, and L3 comprises an optional linker,
        L4 is an optional linker,
        FVIII comprises a FVIII protein,
        X comprises one or more XTEN sequences,
        Fl comprises an optional Ig constant region or a portion thereof,
        F2 comprises an optional additional Ig constant region or a portion thereof;
        (-) is a peptide bond or one or more amino acids; and
        (:) is a covalent bond or a non-covalent bond.
9.      The chimeric protein of any one of claims 7 or 8, wherein the Ig constant region or
a portion thereof extends a half-life of the VWF fragment.
10.     The chimeric protein of any one of claims 7 to 9, wherein the Ig constant region or
a portion thereof comprises a first Fc region, which is linked to the XTEN sequence or the
VWF fragment.
11.     The chimeric protein of claim 10, wherein the Ig constant region or a portion
thereof is linked to the XTEN sequence by a linker.
12.     The chimeric protein of claim 12, wherein the linker comprises a cleavable linker.
                                            -231-

13.     The chimeric protein of any one of claims 7 to 12, further comprising an
additional Ig constant region or a portion thereof.
14.     The chimeric protein of claim 13, wherein the additional Ig constant region or a
portion thereof comprises an additional Fc region.
15.     The chimeric protein of claim 14, wherein the additional Ig constant region or a
portion thereof extends the half-life of a FVIII protein.
16.     The chimeric protein of any one of claims 13 to 15, wherein the additional Ig
constant region or a portion thereof is linked to the FVIII protein.
17.     The chimeric protein of claim 16, wherein the second Fc region is further linked to
the VWF fragment by a linker.
18.     The chimeric protein of claim 17, wherein the linker is a processable linker.
19.     The chimeric protein of any one of claims 8 to 18, wherein L4 is a processable
linker.
20.     The chimeric protein of any one of claims 7 to 19, wherein the additional Ig
constant region or a portion thereof is associated with the Ig constant region or a portion
thereof.
21.     The chimeric protein of claim 20, wherein the additional Ig constant region or a
portion thereof is associated with the Ig constant region or a portion thereof by a covalent
bond.
22.     The chimeric protein of claim 21, wherein the covalent bond is a disulfide bond.
23.     The chimeric protein of any one of claims 1 to 22, wherein the VWF fragment is
associated with the FVIII protein by a non-covalent bond.
24.     The chimeric protein of any one of claims 1 to 23, wherein the half-life of the
FVIII protein, is extended compared to a FVIII protein without the VWF fragment or
compared to wild type FVIII.
                                            -232-

25.      The chimeric protein of claim 24, wherein the half-life of the FVIII is extended at
least about 1.5 times, at least about 2 times, at least about 2.5 times, at least about 3 times,
at least about 4 times, at least about 5 times, at least about 6 times, at least about 7 times,
at least about 8 times, at least about 9 times, at least about 10 times, at least about 11
times, or at least about 12 times longer than a FVIII protein without the VWF fragment or
compared to wild type FVIII..
26.      The chimeric protein of claim 24, wherein the half-life of the Factor VIII is at least
about 17 hours, at least about 18 hours, at least about 19 hours, at least about 20 hours, at
least about 21 hours, at least about 22 hours, at least about 23 hours, at least about 24
hours, at least about 25 hours, at least about 26 hours, at least about 27 hours, at least
about 28 hours, at least about 29 hours, at least about 30 hours, at least about 31 hours, at
least about 32 hours, at least about 33 hours, at least about 34 hours, at least about 35
hours, at least about 36 hours, at least about 48 hours, at least about 60 hours, at least
about 72 hours, at least about 84 hours, at least about 96 hours, or at least about 108 hours.
27.      A chimeric protein comprising (i) a FVIII protein, (ii) an XTEN sequence, and
(iii) an Ig constant region or a portion thereof, wherein the XTEN sequence is linked to
the FVIII protein by an optional linker at the N-terminus or C terminus of the FVIII
protein or is inserted between two amino acids of at least one or more insertion sites in the
FVIII protein and wherein the Ig constant region or a portion thereof is linked to or
associated with the FVIII protein or the XTEN sequence.
28.      The chimeric protein of claim 27, wherein the XTEN sequence and the Ig constant
region or a portion thereof extends the half-life of the FVIII protein.
29.      The chimeric protein of claim 27 or 28, wherein the VWF binding site is located
in the A3 domain or the C2 domain of the FVIII protein or both the A3 domain and the
C2 domain.
30.      The chimeric protein of claim 29, wherein the VWF binding site comprises the
amino acid sequence corresponding to amino acids 1669 to 1689 and 2303 to 2332 of
SEQ ID NO: 4.
                                            -233-

31.      The chimeric protein of any one of claims 27 to 30, wherein the half-life of the
FVIII protein is extended compared to a FVIII protein without the Ig constant region or a
portion thereof or a FVIII protein without the XTEN sequence.
32.      The chimeric protein of claim 31, wherein the half-life of the FVIII protein is
extended at least about 1.5 times, at least about 2 times, at least about 2.5 times, at least
about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least
about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least
about 11 times, or at least about 12 times longer than a FVIII protein without the Ig
constant region or a portion thereof or a FVIII protein without the XTEN sequence or
wild-type FVIII.
33.      The chimeric protein of claim 31, wherein the half-life of the FVIII protein is at
least about 10 hours, at least about 11 hours, at least about 12 hours, at least about 13
hours, at least about 14 hours, at least about 15 hours, at least about 16 hours, at least
about 17 hours, at least about 18 hours, at least about 19 hours, at least about 20 hours, at
least about 21 hours, at least about 22 hours, at least about 23 hours, at least about 24
hours, at least about 36 hours, at least about 48 hours, at least about 60 hours, at least
about 72 hours, at least about 84 hours, at least about 96 hours, or at least about 108 hours.
34.      The chimeric protein of any one of claims 27 to 33, wherein the Ig constant region
or a portion thereof comprises a first Fc region.
35.      The chimeric protein of any one of claims 27 to 34, further comprising an
additional Ig constant region or a portion thereof.
36.      The chimeric protein of claim 35, wherein the additional Ig constant region or a
portion thereof comprises a second Fc region, which is linked to or associated with the
first Fc region.
37.      The chimeric protein of claim 36, wherein the second Fc region is associated with
the first Fc region by a covalent bond.
38.      The chimeric protein of claim 36, wherein the first Fc region is linked to the
second Fc region by a linker.
39.      The chimeric protein of claim 38, wherein the linker is a processable linker.
                                            -234-

40.      The chimeric protein of any one of claims 27 to 34, which comprises a single
polypeptide chain comprising the FVIII protein, the XTEN sequence, and the Ig constant
region or a portion thereof.
41.      The chimeric protein of any one of claims 27 to 34, which comprises a first
polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain
comprises a heavy chain of the FVIII protein, the second polypeptide chain comprises a
light chain of the FVIII protein and the XTEN sequence and the Ig constant region or a
portion thereof.
42.      The chimeric protein of any one of claims 35 to 39, which comprises a first
polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain
comprises the FVIII protein, the XTEN sequence, and the Ig constant region and the
second polypeptide chain comprises the additional Ig constant region or a portion thereof.
43.      The chimeric protein of any one of claims 35 to 39, which comprises a first
polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the
first polypeptide chain comprises a heavy chain of the FVIII protein and the XTEN
sequence, the second polypeptide chain comprises a light chain of the FVIII protein and
the Ig constant region or a portion thereof, and the third polypeptide chain comprises the
additional Ig constant region or a portion thereof.
44.      The chimeric protein of any one of claims 35 to 39, which comprises a single
chain polypeptide comprising the FVIII protein, the XTEN sequence, the Ig constant
region or a portion thereof, and the additional Ig constant region or a portion thereof.
45. A chimeric protein comprising (i) a FVIII protein, (ii) an XTEN sequence, (iii) a
     VWF fragment, and (iv) an Ig constant region or a portion thereof, which comprises
     the D' domain and the D3 domain of VWF, wherein the XTEN sequence is linked to
     the FVIII protein by an optional linker at the N-terminus or C terminus of the FVIII
     protein or inserted immediately downstream of one or more          insertion sites in the
     FVIII protein, the VWF fragment is linked to or associated with the FVIII protein or
     the XTEN sequence, and the Ig constant region or a portion thereof is linked to the
     FVIII protein, the XTEN sequence, the VWF fragment, or any combinations thereof.
                                            -235-

46.     A chimeric protein comprising a formula, which comprises:
        (1)      FVIII(X1)-L1-F1:V-L2-X2-L3-F2;
        (2)      FVIII(X1)-L1-F1:F2-L3-X2-L2-V;
        (3)      F1-L1-FVIII(X1):V-L2-X2-L3-F2;
        (4)      Fl-L1-FVIII(X1);F2-L3-X2-L2-V;
        (5)      FVIII(X1)-Li-F1-L4-V-L2-X2-L3-F2;
        (6)      FVIII(X1)-Li-F1-L4-F2-L3-X2-L2-V;
        (7)      Fl-Li-FVIII(X1)-L4-V-L2-X2-L3-F2, or
        (8)      F1-LI-FVIII(X1)-L4-F2-L3-X2-L2-V,
        wherein FVIII(XI) comprises a FVIII protein and an XTEN sequence, wherein the
        XTEN sequence is linked to the N-terminus or C-terminus of the FVIII protein or
        inserted immediately downstream of one or more amino acids ("one or more
        insertion site") in the FVIII protein;
        each of LI, L2, or L3 comprises an optional linker;
        L4 is a linker;
        X2 comprises one or more XTEN sequences;
        Fl comprises an Ig constant region or a portion thereof;
        F2 comprises an optional additional Ig constant region or a portion thereof, and
        V comprises a VWF fragment;
        (-) is a peptide bond or one or more amino acids; and
        (:) comprises a covalent bond or a non-covalent bond.
47.     The chimeric protein of claim 45 or 46, wherein the VWF fragment does not bind
to a VWF clearance receptor.
48.     The chimeric protein of any one of claims 45 to 47, wherein the VWF fragment is
capable of protecting the FVIII protein from cleavage by one or more protease, protecting
the FVIII protein from activation, stabilizing the heavy chain and/or the light chain of the
FVIII protein, or preventing clearance of the FVIII protein by one or more scavenger
receptors.
49.     The chimeric protein of any one of claims 45 to 48, wherein the Ig constant region
or a portion thereof inhibits or prevents endogenous VWF from binding to the FVIII
protein by shielding or blocking a VWF binding site on the FVIII protein.
                                             -236-

50.     The chimeric protein of claim 49, wherein the VWF binding site is located in the
A3 domain or the C2 domain of the FVIII protein or both the A3 domain and the C2
domain.
51.     The chimeric protein of claim 49 or 50, wherein the VWF binding site comprises
the amino acid sequence corresponding to amino acids 1669 to 1689 and 2303 to 2332 of
SEQ ID NO: 4.
52.     The chimeric protein of any one of claims 45 to 51, wherein a half-life of the
FVIII protein is extended compared to a FVIII protein without the VWF fragment.
53.     The chimeric protein of claim 52, wherein the half-life of the FVIII protein is
extended at least about 1.5 times, at least about 2 times, at least about 2.5 times, at least
about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least
about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least
about 11 times, or at least about 12 times longer than wild type FVIII.
54.     The chimeric protein of claim 52, wherein the half-life of the FVIII protein is at
least about 10 hours, at least about 11 hours, at least about 12 hours, at least about 13
hours, at least about 14 hours, at least about 15 hours, at least about 16 hours, at least
about 17 hours, at least about 18 hours, at least about 19 hours, at least about 20 hours, at
least about 21 hours, at least about 22 hours, at least about 23 hours, at least about 24
hours, at least about 36 hours, at least about 48 hours, at least about 60 hours, at least
about 72 hours, at least about 84 hours, at least about 96 hours, or at least about 108 hours.
55.     The chimeric protein of any one of claims 45 to 54, which comprises a single
polypeptide chain comprising the FVIII protein, the XTEN sequence, the VWF fragment,
and the Ig constant region or a portion thereof.
56.     The chimeric protein of any one of claims 45 to 54, wherein the Ig constant region
or a portion thereof comprises a first Fc region.
57.     The chimeric protein of any one of claims 45 to 54, wherein the Ig constant region
or a portion thereof is linked to the VWF fragment by an optional linker.
58.     The chimeric protein of claim 57, wherein the linker comprises a cleavable linker.
                                            -237-

59.     The chimeric protein of claim 45 to 50, which further comprises an additional Ig
constant region or a portion thereof, which is linked to the FVIII protein, the Ig constant
region or a portion thereof, the VWF fragment, or any combinations thereof by an
optional linker.
60.     The chimeric protein of claim 59, wherein the additional Ig constant region or a
portion thereof is linked to the FVIII protein by an optional linker.
61.     The chimeric protein of claim 59 or 60, wherein the Ig constant region or a portion
thereof is a second Fc region.
62.     The chimeric protein of any one of claims 8 to 26, 42 to 44, and 46 to 61, wherein
the Ig constant region or a portion thereof and the additional Ig constant region or a
portion thereof are identical or different.
63.     The chimeric protein of any one of claims 46 to 62, which comprises a first
polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain
comprises the FVIII protein, the XTEN sequence, and the Ig constant region or a portion
thereof and the second polypeptide chain comprises the VWF fragment and the additional
Ig constant region or a portion thereof.
64.     The chimeric protein of any one of claims 46 to 62, which comprises a first
polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the
first polypeptide chain comprises a heavy chain of the FVIII protein and the XTEN
sequence, the second polypeptide chain comprises a light chain of the FVIII protein and
the Ig constant region or a portion thereof, and the third polypeptide chain comprises the
VWF fragment and the additional Ig constant region or a portion thereof.
65.     The chimeric protein of any one of claims 46 to 62, which comprises a first
polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the
first polypeptide chain comprises a heavy chain of the FVIII protein, the second
polypeptide chain comprises a light chain of the FVIII protein, the XTEN sequence, and
the Ig constant region or a portion thereof, and the third polypeptide chain comprises the
VWF fragment and the additional Ig constant region or a portion thereof.
                                            -238-

66.     The chimeric protein of any one of claims 46 to 62, wherein a first polypeptide
chain and a second polypeptide chain, wherein the first polypeptide chain comprises a
heavy chain of the FVIII protein and the XTEN sequence and the second polypeptide
chain comprises a light chain of the FVIII protein, the Ig constant region or a portion
thereof, the VWF fragment, and the additional Ig constant region or a portion thereof.
67.     The chimeric protein of any one of claims 63 to 66, which further comprises an
additional XTEN sequence linked to the VWF fragment or to the additional Ig constant
region or a portion thereof.
68.     The chimeric protein of any one of claims 1 to 26, wherein the FVIII protein is
linked to an XTEN sequence at the C-terminus or the N-terminus of the FVIII protein or
inserted immediately downstream of one or more amino acids in the FVIII protein or any
combinations thereof.
69. The chimeric protein of any one of claims 27 to 68, wherein the FVIII protein is
linked to at least two XTEN sequences, at least three XTEN sequences, at least four
XTEN sequences, at least five XTEN sequences, or at least six XTEN sequences.
70. The chimeric protein of any one of claims 1 to 69, wherein the FVIII protein
comprises one or more domains of FVIII selected from the group consisting of an Al
domain, al acidic region, an A2 domain, a2 acidic region, a B domain, an A3 domain, a3
acidic region, a Cl domain, a C2 domain, one or more fragments thereof, and any
combinations thereof.
71. The chimeric protein of any one of claims 27 to 70, wherein the one or more insertion
sites in the FVIII protein is located within one or more domains of the FVIII protein
selected from the group consisting of the Al domain, the al acidic region, the A2 domain,
the a2 acidic region, the A3 domain, the B domain, the Cl domain, the C2 domain, and
any combinations thereof or between one or more domains of the FVIII protein selected
from the group consisting of the Al domain and al acidic region, the al acidic region and
A2 domain, the A2 domain and a2 acidic region, the a2 acidic region and B domain, the B
domain and A3 domain, the A3 domain and Cl domain, the Cl domain and C2 domain,
and any combinations thereof or between two domains of the FVIII protein selected from
the group consisting of the Al domain and al acidic region, the al acidic region and A2
domain, the A2 domain and a2 acidic region, the a2 acidic region and B domain, the B
                                          -239-

domain and A3 domain, the A3 domain and C1 domain, the C1 domain and C2 domain,
and any combinations thereof.
72. The chimeric protein of any one of claims 27 to 71, wherein the one or more insertion
sites in the FVIII protein are one or more amino acids selected from the group consisting
of the amino acid residues in Table 7, Table 8, Table 9 and Table 10.
73. The chimeric protein of claim 72, wherein the XTEN sequence inserted at the
insertion site corresponding to amino acids 3R of SEQ ID NO: 4 further comprises an
amino acid sequence of ATR.
74. The chimeric protein of any one of claims 27 to 71, wherein the one or more insertion
    sites in the FVIII protein are located immediately downstream of one or more amino
    acids selected from the group consisting of:
         (1) amino acid 3,             (2) amino acid 18,            (3) amino acid 22,
         (4) amino acid 26,            (5) amino acid 32,            (6) amino acid 40,
         (7) amino acid 60,            (8) amino acid 65,            (9) amino acid 81,
         (10) amino acid 116,          (11) amino acid 119,          (12) amino acid 130,
         (13) amino acid 188,          (14) amino acid 211,          (15) amino acid 216,
         (16) amino acid 220,          (17) amino acid 224,          (18) amino acid 230,
         (19) amino acid 333,          (20) amino acid 336,          (21) amino acid 339,
         (22) amino acid 375,          (23) amino acid 399,          (24) amino acid 403,
         (25) amino acid 409,          (26) amino acid 416,          (26) amino acid 442,
         (28) amino acid 487,          (29) amino acid 490,          (30) amino acid 494,
         (31) amino acid 500,          (32) amino acid 518,          (33) amino acid 599,
         (34) amino acid 603,          (35) amino acid 713,          (36) amino acid 745,
         (37) amino acid 1656,                 (38) amino acid 1711,                (39)
         amino acid 1720,
         (40) amino acid 1725,                 (41) amino acid 1749,                (42)
         amino acid 1796,
         (43) amino acid 1802,                 (44) amino acid 1827,                (45)
         amino acid 1861,
         (46) amino acid 1896,                 (47) amino acid 1900,                (48)
         amino acid 1904,
                                            - 240 -

         (49) amino acid 1905,                 (50) amino acid 1910,                  (51)
         amino acid 1937,
         (52) amino acid 2019,                 (53) amino acid 2068,                  (54)
         amino acid 2111,
         (55) amino acid 2120,                 (56) amino acid 2171,                  (57)
         amino acid 2188,
         (58) amino acid 2227,         (59) amino acid 2277, and
         (60)    two or more combinations thereof.
75. The chimeric protein of any one of claims 1 to 74, wherein the FVIII protein
comprises B domain or a portion thereof.
76. The chimeric protein of claim 75, wherein the FVIII protein is SQ B domain deleted
FVIII.
77. The chimeric protein of any one of claims 1 to 76, wherein the FVIII protein
comprises single chain FVIII.
78. The chimeric protein of claim 77, wherein the single chain FVIII contains at least one
amino acid substitution at a residue corresponding to residue 1648, residue 1645, or both
of full-length mature Factor VIII polypeptide (SEQ ID NO: 4) or residue 754, residue 751,
or both of SQ BDD Factor VIII (SEQ ID NO: 6).
79. The chimeric protein of claim 78, wherein the amino acid substitution is an amino
acid other than arginine.
80. The chimeric protein of any one of claims 1 to 76, wherein the FVIII protein
comprises a heavy chain of FVIII and a light chain of Factor VIII, wherein the heavy
chain and the light chain are associated with each other by a metal bond.
81. The chimeric protein of any one of claims 1 to 80, wherein the FVIII protein has a low
affinity to or does not bind to a low-density lipoprotein receptor-related protein (LRP).
82. The chimeric protein of claim 81, wherein the FVIII protein contains at least one
amino acid substitution that lowers the affinity to or eliminates the binding to the LRP.
83. The chimeric protein of claim 82, wherein the at least one amino acid substitution is at
a residue corresponding to residue 471, residue 484, residue 487, residue 490, residue 497,
                                            - 241 -

residue 2092, residue 2093 or two or more combinations thereof of full-length mature
FVIII.
84. The chimeric protein of claim 83, wherein the amino acid substitution at residue 471,
484, or 497 is an amino acid other than Arginine, the amino acid substitution at residue
487 is an amino acid other than Tyrosine, the amino acid substitution at residue 2092 is an
amino acid other than Lysine, or the amino acid substitution at residue 2093 is an amino
acid other than phenylalanine.
85. The chimeric protein of any one of claims 1 to 84, wherein the FVIII protein contains
at least one amino acid substitution, which induces the FVIII protein to be more stable
than a FVIII protein without the substitution.
86. The chimeric protein of claim 85, wherein the A2 domain and the A3 domain of the
FVIII protein are associated to each other by a covalent bond.
87. The chimeric protein of claim 85 or 86, wherein the at least one amino acid
substitution is at a residue corresponding to residue 664, residue 1826, residue 662, or
residue 1828 of full-length mature FVIII, or two or more combinations thereof.
88. The chimeric protein of claim 87, wherein the FVIII protein contains (a) cysteine at
the residue corresponding to residue 664 of full-length mature FVIII and cysteine at the
residue corresponding to residue 1826 of full-length mature FVIII or (b) cysteine at the
residue corresponding to residue 662 of full-length mature FVIII and cysteine at the
residue corresponding to residue 1828 of full-length mature FVIII.
89. The chimeric protein of any one of claims 1 to 26 and 45 to 88, wherein the VWF
fragment is not amino acids 764 to 1274 of SEQ ID NO: 2.
90. The chimeric protein of any one of claims 1 to 26 and 45 to 89, wherein the amino
acid sequence of the D' domain is at least    9 0%, 9 5 %, 9 6 %, 9 7 %, 9 8 %, 9 9 %, or 100%
identical to amino acids 764 to 866 of SEQ ID NO: 2.
91. The chimeric protein of any one of claims 1 to 26 and 45 to 90, wherein the amino
acid sequence of the D3 domain is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100%
identical to amino acids 867 to 1240 of SEQ ID NO: 2.
                                           - 242 -

92. The chimeric protein of any one of claims 1 to 26 and 45 to 91, wherein the VWF
fragment is a monomer.
93. The chimeric protein of any one of claims 1 to 26 and 45 to 91, wherein the VWF
fragment comprises at least two VWF fragments, at least three VWF fragments, at least
four VWF fragments, at least five VWF fragments, or at least six VWF fragments.
94. The chimeric protein of any one of claims 1 to 26 and 45 to 93, wherein the VWF
fragment comprises an amino acid at least 90%, 95%, 96%, 97%, 98%, 99%, or 100%
identical to amino acids 764 to 1240 of SEQ ID NO: 2.
95. The chimeric protein of claim 94, wherein the VWF fragment consists essentially of
or consists of amino acids 764 to 1240 of SEQ ID NO: 2.
96. The chimeric protein of any one of claims 1 to 26 and 45 to 95, wherein the VWF
fragment contains at least one amino acid substitution at a residue corresponding to
residue 1099, residue 1142, or both residues 1099 and 1142 of SEQ ID NO: 2.
97. The chimeric protein of claim 96, wherein the VWF fragment contains an amino acid
other than cysteine substituted for a residue corresponding to residue 1099, residue 1142,
or both residues 1099 and 1142 of SEQ ID NO: 2.
98. The chimeric protein of any one of claims 1 to 26 and 45 to 97, wherein the VWF
fragment further comprises the D1 domain, the D2 domain, or the D1 and D2 domains of
VWF.
99. The chimeric protein of any one of claims 1 to 27 and 45 to 98, wherein the VWF
fragment further comprises a VWF domain selected from the group consisting of the Al
domain, the A2 domain, the A3 domain, the D4 domain, the B1 domain, the B2 domain,
the B3 domain, the Cl domain, the C2 domain, the CK domain, one or more fragments
thereof, and any combinations thereof.
100.    The chimeric protein of any one of claims 1 to 27 and 45 to 99, wherein the VWF
fragment consists essentially of or consists of: (1) the D' and D3 domains of VWF or
fragments thereof; (2) the Dl, D', and D3 domains of VWF or fragments thereof; (3) the
D2, D', and D3 domains of VWF or fragments thereof; (4) the Dl, D2, D', and D3
                                           - 243 -

domains of VWF or fragments thereof; or (5) the Dl, D2, D', D3, and Al domains of
VWF or fragments thereof.
101.    The chimeric protein of any one of claims 1 to 27 and 45 to 100, wherein the
VWF fragment further comprises a signal peptide of VWF or FVIII which is operably
linked to the VWF fragment.
102.    The chimeric protein of any one of claims 1 to 101, wherein one or more of the
linkers have a length of at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130,
140, 150, 160, 170, 180, 190,200,210,220,230,240,250,300,350,400,450,500,550,
600, 650, 700, 750, 800, 850, 900, 950, 1000, 1200, 1400, 1600, 1800, or 2000 amino
acids.
103.    The chimeric protein of any one of claims 1 to 101, wherein one or more of the
linkers have a length of about 1 to about 2000 amino acids.
104.    The chimeric protein of claim 103, wherein one or more of the linkers have a
length of at least about 20, 35, 42, 48, 73, 75, 95, 98, 144, 288, 324, 333, 576, or 864
amino acids.
105.    The chimeric protein of any one of claims 1 to 104, wherein one or more of the
linkers comprise a Gly/Ser peptide.
106.    The chimeric protein of claim 105, wherein the Gly/Ser peptide has a formula of
(Gly 4Ser). (SEQ ID NO: 139) or Ser(Gly 4Ser). (SEQ ID NO: 140), wherein n is a positive
integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.
107.    The chimeric protein of claim 106, wherein the (Gly 4Ser). linker is (Gly 4 Ser)3
(SEQ ID NO: 63) or (Gly 4 Ser)4 (SEQ ID NO: 138).
108.    The chimeric protein of any one of claims 1 to 107, wherein the XTEN sequence
is selected from the group consisting of AE42, AE72, AE864, AE576, AE288, AE144,
AG864, AG576, AG288, and AG144.
109.    The chimeric protein of claim 108, wherein the XTEN sequence is selected from
the group consisting of SEQ ID NO: 36; SEQ ID NO: 37; SEQ ID NO: 38; SEQ ID NO:
                                            - 244 -

39; SEQ ID NO: 40; SEQ ID NO: 41; SEQ ID NO: 42; SEQ ID NO: 43, SEQ ID NO: 44,
and SEQ ID NO: 127.
110.     The chimeric protein of claim 109, wherein the XTEN sequence is AE288 or
AG288.
111.     The chimeric protein of any one of claims 1 to 110, wherein the linker comprises
at least one first cleavage site at the N-terminus of the linker, at least one second cleavage
site at the C-terminus of the linker, or both.
112.     The chimeric protein of any one of claims 1 to 111, wherein the linker comprises
20 amino acids, 35 amino acids, 48 amino acids, 73 amino acids, or 95 amino acids.
113.     The chimeric protein of claim 112, wherein the linker is 48 amino acids thrombin
cleavage linker.
114.     The chimeric protein of claim 112, wherein the linker is 35 amino acids thrombin
cleavage linker.
115.     The chimeric protein of claim 111, wherein the one or more of the cleavage sites
is TLDPRSFLLRNPNDKYEPFWEDEEK (SEQ ID NO: 8).
116.     The chimeric protein of claim 111, wherein one or more of the cleavage sites is
cleaved by a protease selected from the group consisting of factor XIa, factor XIIa,
kallikrein, factor VIIa, factor IXa, factor Xa, factor Ila (thrombin), Elastase-2, Granzyme
B, TEV, Enterokinase, Protease 3C, Sortase A, MMP-12, MMP-13, MMP-17, and MMP
20.
117.     The chimeric protein of claim 111 or 116, wherein one or more of the cleavage
sites comprise an amino acid sequence selected from the group consisting of RRRR (SEQ
ID NO: 9), RKRRKR (SEQ ID NO: 10), RRRRS (SEQ ID NO: 11), TQSFNDFTR (SEQ
ID NO: 12), SVSQTSKLTR (SEQ ID NO: 13), DFLAEGGGVR (SEQ ID NO: 14),
TTKIKPR (SEQ ID NO: 15), LVPRG (SEQ ID NO: 16), ALRPR (SEQ ID NO: 17),
KLTRAET (SEQ ID NO: 18), DFTRVVG (SEQ ID NO: 19), TMTRIVGG (SEQ ID NO:
20), SPFRSTGG (SEQ ID NO: 21), LQVRIVGG (SEQ ID NO: 22), PLGRIVGG (SEQ
ID NO: 23), IEGRTVGG (SEQ ID NO: 24), LTPRSLLV (SEQ ID NO: 25), LGPVSGVP
(SEQ ID NO: 26), VAGDSLEE (SEQ ID NO: 27), GPAGLGGA (SEQ ID NO: 28),
                                             - 245 -

GPAGLRGA (SEQ ID NO: 29), APLGLRLR (SEQ ID NO: 30), PALPLVAQ (SEQ ID
NO: 31), ENLYFQG (SEQ ID NO: 32), DDDKIVGG (SEQ ID NO: 33), LEVLFQGP
(SEQ ID NO: 34), and LPKTGSES (SEQ ID NO: 35).
118.    The chimeric protein of any one of claims 111 to 117, wherein the first cleavage
site and the second cleavage site are identical or different.
119.    The chimeric protein of any one of claims 1 to 118, which is polysialylated,
pegylated, or hesylated.
120.    A polynucleotide or a set of polynucleotides encoding the chimeric protein of any
one of claims I to 120.
121.    The polynucleotide of claim 120, further comprising a polynucleotide chain,
which encodes PC5 or PC7.
122.    A vector comprising the polynucleotide of claim 120 or 121 and one or more
promoter operably linked to the polynucleotide or the set of polynucleotides.
123.    The vector of claim 122, further comprising an additional vector, which comprises
a polynucleotide chain encoding PC5 or PC7.
124.    A host cell comprising the polynucleotide of any one of claims 120 or 121 or the
vector of claim 122 or 123.
125.    The host cell of claim 124, which is a mammalian cell.
126.    The host cell of claim 125, wherein the mammalian cell is selected from the group
consisting of HEK293 cell, CHO cell, and BHK cell.
127.    A pharmaceutical composition comprising the chimeric protein of any one of
claims I to 119, the polynucleotide of claim 120 or 121, the vector of claim 122 or 123, or
the host cell of any one of claims 124 to 125, and a pharmaceutically acceptable carrier.
128.    The composition of claim 127, wherein the FVIII protein has extended half-life
compared to wild type FVIII protein.
                                            - 246 -

129.     The composition of claim 127 or 128, wherein the half-life of the FVIII protein is
extended at least about 1.5 times, at least about 2 times, at least about 2.5 times, at least
about 3 times, at least about 4 times, at least about 5 times, at least about 6 times, at least
about 7 times, at least about 8 times, at least about 9 times, at least about 10 times, at least
about 11 times, or at least about 12 times longer than wild type FVIII.
130.     The composition of claim 128 or 129, wherein the half-life of Factor VIII is at
least about 17 hours, at least about 18 hours, at least about 19 hours, at least about 20
hours, at least about 21 hours, at least about 22 hours, at least about 23 hours, at least
about 24 hours, at least about 25 hours, at least about 26 hours, at least about 27 hours, at
least about 28 hours, at least about 29 hours, at least about 30 hours, at least about 31
hours, at least about 32 hours, at least about 33 hours, at least about 34 hours, at least
about 35 hours, at least about 36 hours, at least about 48 hours, at least about 60 hours, at
least about 72 hours, at least about 84 hours, at least about 96 hours, or at least about 108
hours.
131.     The composition of any one of claims 127 to 130, which is administered by a
route selected from the group          consisting of topical       administration,  intraocular
administration,    parenteral     administration,    intrathecal    administration,    subdural
administration and oral administration.
132.     The composition     of claim     131,   wherein the parenteral      administration is
intravenous or subcutaneous administration.
133.     The composition of any one of claims 127 to 132, which is used to treat a bleeding
disease or condition in a subject in need thereof.
134.     The composition of claim 133, wherein the bleeding disease or condition is
selected from the group consisting of a bleeding coagulation disorder, hemarthrosis,
muscle bleed, oral bleed, hemorrhage, hemorrhage into muscles, oral hemorrhage, trauma,
trauma capitis,    gastrointestinal  bleeding, intracranial      hemorrhage, intra-abdominal
hemorrhage, intrathoracic hemorrhage, bone fracture, central nervous system bleeding,
bleeding in the retropharyngeal space, bleeding in the retroperitoneal space, bleeding in
the illiopsoas sheath and any combinations thereof.
                                            -  247 -

135.    The composition of claim 133 or 134, wherein the subject is scheduled to undergo
    a surgery.
136.    The composition of any one of claims 133 to 135, wherein the treatment is
    prophylactic or on-demand.
137.    A method of preventing or inhibiting binding of a FVIII protein with endogenous
VWF comprising adding an effective amount of the chimeric protein of any one of claims
I to 26 and 45 to 119, the polynucleotide of claim 120 or 121, the vector of claim 122 or
123, the host cell of any one of claims 124 to 126, or the composition of any one of
claims 127 to 136 to a subject in need thereof, wherein the VWF fragment binds to the
FVIII protein and thus prevents or inhibits binding of endogenous VWF.
138.    A method of extending or increasing half-life of a FVIII protein, wherein the
method comprises adding an effective amount of the chimeric protein of any one of
claims I to 26 and 45 to 119, the polynucleotide of claim 120 or 121, the vector of claim
122 or 123, the host cell of any one of claims 124 to 126, or the composition of any one of
claims 127 to 136 to a subject in need thereof, wherein the VWF fragment binds to the
FVIII protein and thus extends or increases half-life of the FVIII protein.
139.    A method of preventing or inhibiting clearance of a FVIII protein from a cell,
wherein the method comprises adding an effective amount of the chimeric protein of any
one of claims I to 26 and 45 to 119, the polynucleotide of claim 120 or 121, the vector of
claim 122 or 123, the host cell of any one of claims 124 to 126, or the composition of any
one of claims 127 to 136 to a cell comprising a FVIII protein or a polynucleotide
encoding the FVIII protein, wherein the protein having VWF activity binds to the FVIII
protein.
140.    The method of any one of claims 137 to 139, wherein the subject is an animal.
141.    The method of claim 140, wherein the animal is a human.
142.    The method of claim 140, wherein the subject is suffering from hemophilia A.
143.    A method of treating a bleeding disease or disorder in a subject in need thereof
comprising administering an effective amount of the chimeric protein of any one of
claims I to 26 and 45 to 119, the polynucleotide of claim 120 or 121, the vector of claim
                                            -248-

122 or 123, the host cell of any one of claims 124 to 126, or the composition of any one of
claims 127 to 136, wherein the bleeding disease or disorder is selected from the group
consisting of a bleeding coagulation disorder, hemarthrosis, muscle bleed, oral bleed,
hemorrhage, hemorrhage into muscles,            oral hemorrhage, trauma, trauma capitis,
gastrointestinal  bleeding,    intracranial    hemorrhage,     intra-abdominal    hemorrhage,
intrathoracic hemorrhage, bone fracture, central nervous system bleeding, bleeding in the
retropharyngeal space, bleeding in the retroperitoneal space, and bleeding in the illiopsoas
sheath.
144.     The method of claim 143, wherein the treatment is prophylactic or on-demand.
145.     The method of claim 143 or 144, wherein the effective amount is 0.1 gg/kg to 500
mg/kg.
146.     The method of any one of claims 143 to 145, wherein the chimeric protein of any
one of claims I to 119, the polynucleotide of claim 120 or 121, the vector of claim 122 or
123, the host cell of any one of claims 124 to 126, or the composition of any one of
claims 127 to 136 is administered by a route selected from the group consisting of topical
administration,   intraocular    administration,    parenteral    administration,   intrathecal
administration, subdural administration and oral administration.
147.     The method of claim 146, wherein the parenteral administration is selected from
the group consisting of intravenous           administration,   subcutaneous   administration,
intramuscular administration, and intradermal administration,
148.     A method of making a chimeric protein, comprising transfecting one or more host
cell with the polynucleotide of claim 120 or 121 or the vector of claim 122 or 123 and
expressing the chimeric protein in the host cell.
149.     The chimeric protein of any one of claims 27-119, wherein the XTEN insertion
site is immediately downstream of residue 745 corresponding to the mature FVIII protein
(SEQ ID NO: 4).
150.     The chimeric protein of any one of claims 27-119, where the XTEN insertion sites
are immediately downstream of residue 1656 and residue 1900 of the FVIII protein.
                                            - 249 -

151.    The chimeric protein of any one of claims 27-119, wherein the XTEN insertion
sites are immediately downstream of residues 26, 1656, and 1900 of the FVIII protein.
152.    The chimeric protein of any one of claims 27-119, wherein the XTEN insertion
sites are immediately downstream of residues 403 and 745 of the FVIII protein.
153.    The chimeric protein of any one of claims 27-119, wherein the XTEN insertion
sites are immediately downstream of residues 745 and 1900 of the FVIII protein.
154.    The chimeric protein of any one of claims 27-119, wherein the XTEN insertion
sites are immediately downstream of residues 18 and 745 of the FVIII protein.
155.    The chimeric protein of any one of claims 149-154, wherein the FVIII protein is a
dual chain FVIII isoform.
156.    The chimeric protein of any one of claims 149-154, wherein the FVIII protein is a
single chain FVIII isoform.
157.    The chimeric protein of any one of claims 149-156, comprising one XTEN.
158.    The chimeric protein of any one of claims 149-156, comprising two XTENs.
159.    The chimeric protein of any one of claims 149-156, comprising three XTENS are
inserted.
160.    The chimeric protein of any one of claims 149-157, wherein the XTEN is SEQ ID
NO: 39 (AE288).
161.    The chimeric protein of any one of claims 149-156 and 158, wherein the XTENs
are SEQ ID NOs: 38 and 37 (AG144 and AE144).
162.    The chimeric protein of any one of claims 149-156, and 159 wherein the XTENs
are SEQ ID NOs: 37, 38 and 37 (AE144, AG144, and AE144).
163.    The chimeric protein of any one of claims 149-156 and 157, wherein the XTENs
are SEQ ID NOs: 38 and 39(AE144 and AE288).
164.    The host cell of claim 124, wherein the PC5 or PC7 cleaves the D1D2 domains of
VWF.
                                          -250-

165. The chimeric protein of any one of claims 1 to 27, which comprises at least two
XTENs, at least three XTENs, at least four XTENs, at least five XTENs, or at least six
XTENs.
                                        -251 -

<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
                                                            97047_1
<removed-date>
                                               SEQUENCE LI STI NG
              <110>   Bi ogen I dec MA I nc .
                      Chhabr a, Ek t a Set h
                      Li u, Tongy ao
              <120>   FACTOR VI I I COMPLEX WI TH XTEN AND VON WI LLEBRAND FACTOR PROTEI N,
<removed-apn>
                      AND USES THEREOF
              <130>   2159. 365PC06/ EKS/ C- K/ E- H
              <140>   To be as s i gned
              <141>   Her ewi t h
              <150>   US 61/ 840, 811
              <151>   2013- 06- 28
              <150>   US 61/ 827, 158
              <151>   2013- 05- 24
              <150>   US 61/ 801, 544
              <151>   2013- 03- 15
              <150>   US 61/ 801, 504
              <151>   2013- 03- 15
              <150>   US 61/ 759, 819
              <151>   2013- 02- 01
              <150>   US 61/ 670, 401
              <151>   2012- 07- 11
              <160>   140
                                                            Page 1

                                                                     97047_1
<removed-date>
              <170>     Pat ent I n v er s i on 3. 5
              <210>     1
              <211>     8442
              <212>     DNA
              <213>     Homo s api ens
<removed-apn>
              <400>     1
              at gat t c c t g c c agat t t gc c ggggt gc t g c t t gc t c t gg c c c t c at t t t gc c agggac c    60
              c t t t gt gc ag aaggaac t c g c ggc aggt c a t c c ac ggc c c gat gc agc c t t t t c ggaagt         120
              gac t t c gt c a ac ac c t t t ga t gggagc at g t ac agc t t t g c gggat ac t g c agt t ac c t c     180
              c t ggc agggg gc t gc c agaa ac gc t c c t t c t c gat t at t g gggac t t c c a gaat ggc aag         240
              agagt gagc c t c t c c gt gt a t c t t ggggaa t t t t t t gac a t c c at t t gt t t gt c aat ggt     300
              ac c gt gac ac agggggac c a aagagt c t c c at gc c c t at g c c t c c aaagg gc t gt at c t a         360
              gaaac t gagg c t gggt ac t a c aagc t gt c c ggt gaggc c t at ggc t t t gt ggc c aggat c             420
              gat ggc agc g gc aac t t t c a agt c c t gc t g t c agac agat ac t t c aac aa gac c t gc ggg         480
              c t gt gt ggc a ac t t t aac at c t t t gc t gaa gat gac t t t a t gac c c aaga agggac c t t g       540
              ac c t c ggac c c t t at gac t t t gc c aac t c a t gggc t c t ga gc agt ggaga ac agt ggt gt         600
              gaac gggc at c t c c t c c c ag c agc t c at gc aac at c t c c t c t ggggaaat gc agaagggc            660
              c t gt gggagc agt gc c agc t t c t gaagagc ac c t c ggt gt t t gc c c gc t g c c ac c c t c t g      720
              gt ggac c c c g agc c t t t t gt ggc c c t gt gt gagaagac t t t gt gt gagt g t gc t gggggg           780
                                                                      Page 2

                                                                      97047_1
<removed-date>
              c t ggagt gc g c c t gc c c t gc c c t c c t ggag t ac gc c c gga c c t gt gc c c a ggagggaat g      840
              gt gc t gt ac g gc t ggac c ga c c ac agc gc g t gc agc c c ag t gt gc c c t gc t ggt at ggag        900
              t at aggc agt gt gt gt c c c c t t gc gc c agg ac c t gc c aga gc c t gc ac at c aat gaaat g         960
              t gt c aggagc gat gc gt gga t ggc t gc agc t gc c c t gagg gac agc t c c t ggat gaaggc              1020
<removed-apn>
              c t c t gc gt gg agagc ac c ga gt gt c c c t gc gt gc at t c c g gaaagc gc t a c c c t c c c ggc    1080
              ac c t c c c t c t c t c gagac t g c aac ac c t gc at t t gc c gaa ac agc c agt g gat c t gc agc    1140
              aat gaagaat gt c c agggga gt gc c t t gt c ac t ggt c aat c c c ac t t c aa gagc t t t gac          1200
              aac agat ac t t c ac c t t c ag t gggat c t gc c agt ac c t gc t ggc c c ggga t t gc c aggac        1260
              c ac t c c t t c t c c at t gt c at t gagac t gt c c agt gt gc t g at gac c gc ga c gc t gt gt gc   1320
              ac c c gc t c c g t c ac c gt c c g gc t gc c t ggc c t gc ac aac a gc c t t gt gaa ac t gaagc at   1380
              ggggc aggag t t gc c at gga t ggc c aggac at c c agc t c c c c c t c c t gaa aggt gac c t c         1440
              c gc at c c agc at ac agt gac ggc c t c c gt g c gc c t c agc t ac ggggagga c c t gc agat g         1500
              gac t gggat g gc c gc gggag gc t gc t ggt g aagc t gt c c c c c gt c t at gc c gggaagac c           1560
              t gc ggc c t gt gt gggaat t a c aat ggc aac c agggc gac g ac t t c c t t ac c c c c t c t ggg       1620
              c t ggc r gagc c c c gggt gga ggac t t c ggg aac gc c t gga agc t gc ac gg ggac t gc c ag           1680
              gac c t gc aga agc agc ac ag c gat c c c t gc gc c c t c aac c c gc gc at gac c aggt t c t c c      1740
              gaggaggc gt gc gc ggt c c t gac gt c c c c c ac at t c gagg c c t gc c at c g t gc c gt c agc       1800
                                                                     Page 3

                                                                     97047_1
<removed-date>
              c c gc t gc c c t ac c t gc ggaa c t gc c gc t ac gac gt gt gc t c c t gc t c gga c ggc c gc gag    1860
              t gc c t gt gc g gc gc c c t ggc c agc t at gc c gc ggc c t gc g c ggggagagg c gt gc gc gt c        1920
              gc gt ggc gc g agc c aggc c g c t gt gagc t g aac t gc c c ga aaggc c aggt gt ac c t gc ag          1980
              t gc gggac c c c c t gc aac c t gac c t gc c gc t c t c t c t c t t ac c c ggat ga ggaat gc aat     2040
<removed-apn>
              gaggc c t gc c t ggagggc t g c t t c t gc c c c c c agggc t c t ac at ggat ga gaggggggac            2100
              t gc gt gc c c a aggc c c agt g c c c c t gt t ac t at gac ggt g agat c t t c c a gc c agaagac      2160
              at c t t c t c ag ac c at c ac ac c at gt gc t ac t gt gaggat g gc t t c at gc a c t gt ac c at g   2220
              agt ggagt c c c c ggaagc t t gc t gc c t gac gc t gt c c t c a gc agt c c c c t gt c t c at c gc    2280
              agc aaaagga gc c t at c c t g t c ggc c c c c c at ggt c aagc t ggt gt gt c c c gc t gac aac        2340
              c t gc gggc t g aagggc t c ga gt gt ac c aaa ac gt gc c aga ac t at gac c t ggagt gc at g           2400
              agc at gggc t gt gt c t c t gg c t gc c t c t gc c c c c c gggc a t ggt c c ggc a t gagaac aga      2460
              t gt gt ggc c c t ggaaaggt g t c c c t gc t t c c at c agggc a aggagt at gc c c c t ggagaa          2520
              ac agt gaaga t t ggc t gc aa c ac t t gt gt c t gt c gggac c ggaagt ggaa c t gc ac agac             2580
              c at gt gt gt g at gc c ac gt g c t c c ac gat c ggc at ggc c c ac t ac c t c ac c t t c gac ggg    2640
              c t c aaat ac c t gt t c c c c gg ggagt gc c ag t ac gt t c t gg t gc aggat t a c t gc ggc agt      2700
              aac c c t ggga c c t t t c ggat c c t agt gggg aat aagggat gc agc c ac c c c t c agt gaaa           2760
              t gc aagaaac gggt c ac c at c c t ggt ggag ggaggagaga t t gagc t gt t t gac ggggag                  2820
                                                                     Page 4

                                                            97047_1
<removed-date>
              gt gaat gt ga agaggc c c at gaaggat gag ac t c ac t t t g aggt ggt gga gt c t ggc c gg               2880
              t ac at c at t c t gc t gc t ggg c aaagc c c t c t c c gt ggt c t gggac c gc c a c c t gagc at c     2940
              t c c gt ggt c c t gaagc agac at ac c aggag aaagt gt gt g gc c t gt gt gg gaat t t t gat             3000
              ggc at c c aga ac aat gac c t c ac c agc agc aac c t c c aag t ggaggaaga c c c t gt ggac             3060
<removed-apn>
              t t t gggaac t c c t ggaaagt gagc t c gc ag t gt gc t gac a c c agaaaagt gc c t c t ggac             3120
              t c at c c c c t g c c ac c t gc c a t aac aac at c at gaagc aga c gat ggt gga t t c c t c c t gt    3180
              agaat c c t t a c c agt gac gt c t t c c aggac t gc aac aagc t ggt ggac c c c gagc c at at           3240
              c t ggat gt c t gc at t t ac ga c ac c t gc t c c t gt gagt c c a t t ggggac t g c gc c t gc t t c   3300
              t gc gac ac c a t t gc t gc c t a t gc c c ac gt g t gt gc c c agc at ggc aaggt ggt gac c t gg       3360
              aggac ggc c a c at t gt gc c c c c agagc t gc gaggagagga at c t c c ggga gaac gggt at                3420
              gagt gt gagt ggc gc t at aa c agc t gt gc a c c t gc c t gt c aagt c ac gt g t c agc ac c c t        3480
              gagc c ac t gg c c t gc c c t gt gc agt gt gt g gagggc t gc c at gc c c ac t g c c c t c c aggg      3540
              aaaat c c t gg at gagc t t t t gc agac c t gc gt t gac c c t g aagac t gt c c agt gt gt gag          3600
              gt ggc t ggc c ggc gt t t t gc c t c aggaaag aaagt c ac c t t gaat c c c ag t gac c c t gag          3660
              c ac t gc c aga t t t gc c ac t g t gat gt t gt c aac c t c ac c t gt gaagc c t g c c aggagc c g     3720
              ggaggc c t gg t ggt gc c t c c c ac agat gc c c c ggt gagc c c c ac c ac t c t gt at gt ggag         3780
              gac at c t c gg aac c gc c gt t gc ac gat t t c t ac t gc agc a ggc t ac t gga c c t ggt c t t c     3840
                                                                      Page 5

                                                                      97047_1
<removed-date>
              c t gc t ggat g gc t c c t c c ag gc t gt c c gag gc t gagt t t g aagt gc t gaa ggc c t t t gt g       3900
              gt ggac at ga t ggagc ggc t gc gc at c t c c c agaagt ggg t c c gc gt ggc c gt ggt ggag                3960
              t ac c ac gac g gc t c c c ac gc c t ac at c ggg c t c aaggac c ggaagc gac c gt c agagc t g            4020
              c ggc gc at t g c c agc c aggt gaagt at gc g ggc agc c agg t ggc c t c c ac c agc gaggt c              4080
<removed-apn>
              t t gaaat ac a c ac t gt t c c a aat c t t c agc aagat c gac c gc c c t gaagc c t c c c gc at c        4140
              gc c c t gc t c c t gat ggc c ag c c aggagc c c c aac ggat gt c c c ggaac t t t gt c c gc t ac         4200
              gt c c agggc c t gaagaagaa gaaggt c at t gt gat c c c gg t gggc at t gg gc c c c at gc c               4260
              aac c t c aagc agat c c gc c t c at c gagaag c aggc c c c t g agaac aaggc c t t c gt gc t g            4320
              agc agt gt gg at gagc t gga gc agc aaagg gac gagat c g t t agc t ac c t c t gt gac c t t               4380
              gc c c c t gaag c c c c t c c t c c t ac t c t gc c c c c c gac at gg c ac aagt c ac t gt gggc c c g   4440
              gggc t c t t gg gggt t t c gac c c t ggggc c c aagaggaac t c c at ggt t c t ggat gt ggc g              4500
              t t c gt c c t gg aaggat c gga c aaaat t ggt gaagc c gac t t c aac aggag c aaggagt t c                 4560
              at ggaggagg t gat t c agc g gat ggat gt g ggc c aggac a gc at c c ac gt c ac ggt gc t g                4620
              c agt ac t c c t ac at ggt gac c gt ggagt ac c c c t t c agc g aggc ac agt c c aaaggggac               4680
              at c c t gc agc gggt gc gaga gat c c gc t ac c agggc ggc a ac aggac c aa c ac t gggc t g               4740
              gc c c t gc ggt ac c t c t c t ga c c ac agc t t c t t ggt c agc c agggt gac c g ggagc aggc g          4800
              c c c aac c t gg t c t ac at ggt c ac c ggaaat c c t gc c t c t g at gagat c aa gaggc t gc c t         4860
                                                                       Page 6

                                                              97047_1
<removed-date>
              ggagac at c c aggt ggt gc c c at t ggagt g ggc c c t aat g c c aac gt gc a ggagc t ggag                  4920
              aggat t ggc t ggc c c aat gc c c c t at c c t c at c c aggac t t t gagac gc t c c c c c gagag            4980
              gc t c c t gac c t ggt gc t gc a gaggt gc t gc t c c ggagagg ggc t gc agat c c c c ac c c t c            5040
              t c c c c t gc ac c t gac t gc ag c c agc c c c t g gac gt gat c c t t c t c c t gga t ggc t c c t c c   5100
<removed-apn>
              agt t t c c c ag c t t c t t at t t t gat gaaat g aagagt t t c g c c aaggc t t t c at t t c aaaa         5160
              gc c aat at ag ggc c t c gt c t c ac t c aggt g t c agt gc t gc agt at ggaag c at c ac c ac c            5220
              at t gac gt gc c at ggaac gt ggt c c c ggag aaagc c c at t t gc t gagc c t t gt ggac gt c                5280
              at gc agc ggg agggaggc c c c agc c aaat c ggggat gc c t t gggc t t t gc t gt gc gat ac                   5340
              t t gac t t c ag aaat gc at gg t gc c aggc c g ggagc c t c aa aggc ggt ggt c at c c t ggt c              5400
              ac ggac gt c t c t gt ggat t c agt ggat gc a gc agc t gat g c c gc c aggt c c aac agagt g                5460
              ac agt gt t c c c t at t ggaat t ggagat c gc t ac gat gc ag c c c agc t ac g gat c t t ggc a             5520
              ggc c c agc ag gc gac t c c aa c gt ggt gaag c t c c agc gaa t c gaagac c t c c c t ac c at g            5580
              gt c ac c t t gg gc aat t c c t t c c t c c ac aaa c t gt gc t c t g gat t t gt t ag gat t t gc at g     5640
              gat gaggat g ggaat gagaa gaggc c c ggg gac gt c t gga c c t t gc c aga c c agt gc c ac                   5700
              ac c gt gac t t gc c agc c aga t ggc c agac c t t gc t gaaga gt c at c gggt c aac t gt gac               5760
              c gggggc t ga ggc c t t c gt g c c c t aac agc c agt c c c c t g t t aaagt gga agagac c t gt             5820
              ggc t gc c gc t ggac c t gc c c c t gy gt gt gc ac aggc agc t c c ac t c ggc a c at c gt gac c           5880
                                                                        Page 7

                                                                97047_1
<removed-date>
              t t t gat gggc agaat t t c aa gc t gac t ggc agc t gt t c t t at gt c c t at t t c aaaac aag         5940
              gagc aggac c t ggaggt gat t c t c c at aat ggt gc c t gc a gc c c t ggagc aaggc agggc                6000
              t gc at gaaat c c at c gaggt gaagc ac agt gc c c t c t c c g t c gags t gc a c agt gac at g          6060
              gaggt gac gg t gaat gggag ac t ggt c t c t gt t c c t t ac g t gggt gggaa c at ggaagt c              6120
<removed-apn>
              aac gt t t at g gt gc c at c at gc at gaggt c agat t c aat c ac c t t ggt c a c at c t t c ac a      6180
              t t c ac t c c ac aaaac aat ga gt t c c aac t g c agc t c agc c c c aagac t t t t gc t t c aaag      6240
              ac gt at ggt c t gt gt gggat c t gt gat gag aac ggagc c a at gac t t c at gc t gagggat               6300
              ggc ac agt c a c c ac agac t g gaaaac ac t t gt t c aggaat ggac t gt gc a gc ggc c aggg              6360
              c agac gt gc c agc c c at c c t ggaggagc ag t gt c t t gt c c c c gac agc t c c c ac t gc c ag       6420
              gt c c t c c t c t t ac c ac t gt t t gc t gaat gc c ac aaggt c c t ggc t c c agc c ac at t c t at   6480
              gc c at c t gc c agc aggac ag t t gc c ac c ag gagc aagt gt gt gaggt gat c gc c t c t t at           6540
              gc c c ac c t c t gt c ggac c aa c ggggt c t gc gt t gac t gga ggac ac c t ga t t t c t gt gc t      6600
              at gt c at gc c c ac c at c t c t ggt c t ac aac c ac t gt gagc at ggc t gt c c c c ggc ac t gt      6660
              gat ggc aac g t gagc t c c t g t ggggac c at c c c t c c gaag gc t gt t t c t g c c c t c c agat     6720
              aaagt c at gt t ggaaggc ag c t gt gt c c c t gaagaggc c t gc ac t c agt g c at t ggt gag             6780
              gat ggagt c c agc ac c agt t c c t ggaagc c t gggt c c c gg ac c ac c agc c c t gt c agat c          6840
              t gc ac at gc c t c agc gggc g gaaggt c aac t gc ac aac gc agc c c t gc c c c ac ggc c aaa           6900
                                                                      Page 8

                                                                   97047_1
<removed-date>
              gc t c c c ac gt gt ggc c t gt g t gaagt agc c c gc c t c c gc c agaat gc aga c c agt gc t gc        6960
              c c c gagt at g agt gt gt gt g t gac c c agt g agc t gt gac c t gc c c c c agt gc c t c ac t gt      7020
              gaac gt ggc c t c c agc c c ac ac t gac c aac c c t ggc gagt gc agac c c aa c t t c ac c t gc        7080
              gc c t gc agga aggaggagt g c aaaagagt g t c c c c ac c c t c c t gc c c c c c gc ac c gt t t g       7140
<removed-apn>
              c c c ac c c t t c ggaagac c c a gt gc t gt gat gagt at gagt gt gc c t gc aa c t gt gt c aac         7200
              t c c ac agt ga gc t gt c c c c t t gggt ac t t g gc c t c aac c g c c ac c aat ga c t gt ggc t gt   7260
              ac c ac aac c a c c t gc c t t c c c gac aaggt g t gt gt c c ac c gaagc ac c at c t ac c c t gt g    7320
              ggc c agt t c t gggaggaggg c t gc gat gt g t gc ac c t gc a c c gac at gga ggat gc c gt g            7380
              at gggc c t c c gc gt ggc c c a gt gc t c c c ag aagc c c t gt g aggac agc t g t c ggt c gggc        7440
              t t c ac t t ac g t t c t gc at ga aggc gagt gc t gt ggaaggt gc c t gc c at c t gc c t gt gag        7500
              gt ggt gac t g gc t c ac c gc g gggggac t c c c agt c t t c c t ggaagagt gt c ggc t c c c ag         7560
              t gggc c t c c c c ggagaac c c c t gc c t c at c aat gagt gt g t c c gagt gaa ggaggaggt c            7620
              t t t at ac aac aaaggaac gt c t c c t gc c c c c agc t ggagg t c c c t gt c t g c c c c t c gggc     7680
              t t t c agc t ga gc t gt aagac c t c agc gt gc t gc c c aagc t gt c gc t gt ga gc gc at ggag         7740
              gc c t gc at gc t c aat ggc ac t gt c at t ggg c c c gggaaga c t gt gat gat c gat gt gt gc           7800
              ac gac c t gc c gc t gc at ggt gc aggt gggg gt c at c t c t g gat t c aagc t ggagt gc agg            7860
              aagac c ac c t gc aac c c c t g c c c c c t gggt t ac aaggaag aaaat aac ac aggt gaat gt              7920
                                                                      Page 9

                                                                  97047_1
<removed-date>
              t gt gggagat gt t t gc c t ac ggc t t gc ac c at t c agc t aa gaggaggac a gat c at gac a            7980
              c t gaagc gt g at gagac gc t c c aggat ggc t gt gat ac t c ac t t c t gc aa ggt c aat gag           8040
              agaggagagt ac t t c t ggga gaagagggt c ac aggc t gc c c ac c c t t t ga t gaac ac aag               8100
              t gt c t t gc t g agggaggt aa aat t at gaaa at t c c aggc a c c t gc t gt ga c ac at gt gag         8160
<removed-apn>
              gagc c t gagt gc aac gac at c ac t gc c agg c t gc agt at g t c aaggt ggg aagc t gt aag             8220
              t c t gaagt ag aggt ggat at c c ac t ac t gc c agggc aaat gt gc c agc aa agc c at gt ac             8280
              t c c at t gac a t c aac gat gt gc aggac c ag t gc t c c t gc t gc t c t c c gac ac ggac ggag       8340
              c c c at gc agg t ggc c c t gc a c t gc ac c aat ggc t c t gt t g t gt ac c at ga ggt t c t c aat   8400
              gc c at ggagt gc aaat gc t c c c c c aggaag t gc agc aagt ga                                        8442
              <210>     2
              <211>     2813
              <212>     PRT
              <213>     Homo s api ens
              <220>
              <221>     mi s c _f eat ur e
              <222>     ( 1) . . ( 22)
              <223>     VWF Si gnal Pept i de
              <220>
              <221>     mi s c _f eat ur e
              <222>     ( 23) . . ( 763)
              <223>     VWF D1D2 r egi on
                                                                     Page 10

                                                            97047_1
<removed-date>
              <220>
              <221>   mi s c _f eat ur e
              <222>   ( 764) . . ( 866)
              <223>   VWF D' Domai n
              <220>
<removed-apn>
              <221>   mi s c _f eat ur e
              <222>   ( 867) . . ( 1240)
              <223>   VWF D3 Domai n
              <220>
              <221>   mi s c _f eat ur e
              <222>   ( 1241) . . ( 1479)
              <223>   VWF A1 Domai n
              <220>
              <221>   mi s c _f eat ur e
              <222>   ( 2016) . . ( 2016)
              <223>   Xaa c an be any nat ur al l y oc c ur r i ng ami no ac i d
              <400>   2
              Met I l e Pr o Al a Ar g Phe Al a Gl y Val Leu Leu Al a Leu Al a Leu I l e
              1                     5                      10                           15
              Leu Pr o Gl y Thr Leu Cy s Al a Gl u Gl y Thr Ar g Gl y Ar g Ser Ser Thr
                               20                     25                           30
              Al a Ar g Cy s Ser Leu Phe Gl y Ser As p Phe Val As n Thr Phe As p Gl y
                          35                     40                       45
                                                            Page 11

                                                                    97047_1
<removed-date>
              Ser Met Ty r Ser Phe Al a Gl y Ty r Cy s Ser Ty r Leu Leu Al a Gl y Gl y
                    50                            55                            60
              Cy s Gl n Ly s Ar g Ser Phe Ser I l e I l e Gl y As p Phe Gl n As n Gl y Ly s
              65                            70                            75                            80
<removed-apn>
              Ar g Val Ser Leu Ser Val Ty r Leu Gl y Gl u Phe Phe As p I l e Hi s Leu
                                      85                            90                            95
              Phe Val As n Gl y Thr Val Thr Gl n Gl y As p Gl n Ar g Val Ser Met Pr o
                                100                           105                           110
              Ty r Al a Ser Ly s Gl y Leu Ty r Leu Gl u Thr Gl u Al a Gl y Ty r Ty r Ly s
                          115                           120                           125
              Leu Ser Gl y Gl u Al a Ty r Gl y Phe Val Al a Ar g I l e As p Gl y Ser Gl y
                    130                           135                           140
              As n Phe Gl n Val Leu Leu Ser As p Ar g Ty r Phe As n Ly s Thr Cy s Gl y
              145                           150                           155                           160
              Leu Cy s Gl y As n Phe As n I l e Phe Al a Gl u As p As p Phe Met Thr Gl n
                                      165                           170                           175
              Gl u Gl y Thr Leu Thr Ser As p Pr o Ty r As p Phe Al a As n Ser Tr p Al a
                                                                    Page 12

                                                                    97047_1
<removed-date>
                                180                           185                           190
              Leu Ser Ser Gl y Gl u Gl n Tr p Cy s Gl u Ar g Al a Ser Pr o Pr o Ser Ser
                          195                           200                           205
<removed-apn>
              Ser Cy s As n I l e Ser Ser Gl y Gl u Met Gl n Ly s Gl y Leu Tr p Gl u Gl n
                    210                           215                           220
              Cy s Gl n Leu Leu Ly s Ser Thr Ser Val Phe Al a Ar g Cy s Hi s Pr o Leu
              225                           230                           235                           240
              Val As p Pr o Gl u Pr o Phe Val Al a Leu Cy s Gl u Ly s Thr Leu Cy s Gl u
                                      245                           250                           255
              Cy s Al a Gl y Gl y Leu Gl u Cy s Al a Cy s Pr o Al a Leu Leu Gl u Ty r Al a
                                260                           265                           270
              Ar g Thr Cy s Al a Gl n Gl u Gl y Met Val Leu Ty r Gl y Tr p Thr As p Hi s
                          275                           280                           285
              Ser Al a Cy s Ser Pr o Val Cy s Pr o Al a Gl y Met Gl u Ty r Ar g Gl n Cy s
                    290                           295                           300
              Val Ser Pr o Cy s Al a Ar g Thr Cy s Gl n Ser Leu Hi s I l e As n Gl u Met
              305                           310                           315                           320
                                                                    Page 13

                                                                    97047_1
<removed-date>
              Cy s Gl n Gl u Ar g Cy s Val As p Gl y Cy s Ser Cy s Pr o Gl u Gl y Gl n Leu
                                      325                           330                           335
              Leu As p Gl u Gl y Leu Cy s Val Gl u Ser Thr Gl u Cy s Pr o Cy s Val Hi s
                                340                           345                           350
<removed-apn>
              Ser Gl y Ly s Ar g Ty r Pr o Pr o Gl y Thr Ser Leu Ser Ar g As p Cy s As n
                          355                           360                           365
              Thr Cy s I l e Cy s Ar g As n Ser Gl n Tr p I l e Cy s Ser As n Gl u Gl u Cy s
                    370                           375                           380
              Pr o Gl y Gl u Cy s Leu Val Thr Gl y Gl n Ser Hi s Phe Ly s Ser Phe As p
              385                           390                           395                           400
              As n Ar g Ty r Phe Thr Phe Ser Gl y I l e Cy s Gl n Ty r Leu Leu Al a Ar g
                                      405                           410                           415
              As p Cy s Gl n As p Hi s Ser Phe Ser I l e Val I l e Gl u Thr Val Gl n Cy s
                                420                           425                           430
              Al a As p As p Ar g As p Al a Val Cy s Thr Ar g Ser Val Thr Val Ar g Leu
                          435                           440                           445
              Pr o Gl y Leu Hi s As n Ser Leu Val Ly s Leu Ly s Hi s Gl y Al a Gl y Val
                                                                    Page 14

                                                                    97047_1
<removed-date>
                    450                           455                           460
              Al a Met As p Gl y Gl n As p I l e Gl n Leu Pr o Leu Leu Ly s Gl y As p Leu
              465                           470                           475                           480
<removed-apn>
              Ar g I l e Gl n Hi s Thr Val Thr Al a Ser Val Ar g Leu Ser Ty r Gl y Gl u
                                      485                           490                           495
              As p Leu Gl n Met As p Tr p As p Gl y Ar g Gl y Ar g Leu Leu Val Ly s Leu
                                500                           505                           510
              Ser Pr o Val Ty r Al a Gl y Ly s Thr Cy s Gl y Leu Cy s Gl y As n Ty r As n
                          515                           520                           525
              Gl y As n Gl n Gl y As p As p Phe Leu Thr Pr o Ser Gl y Leu Al a Gl u Pr o
                    530                           535                           540
              Ar g Val Gl u As p Phe Gl y As n Al a Tr p Ly s Leu Hi s Gl y As p Cy s Gl n
              545                           550                           555                           560
              As p Leu Gl n Ly s Gl n Hi s Ser As p Pr o Cy s Al a Leu As n Pr o Ar g Met
                                      565                           570                           575
              Thr Ar g Phe Ser Gl u Gl u Al a Cy s Al a Val Leu Thr Ser Pr o Thr Phe
                                580                           585                           590
                                                                    Page 15

                                                                    97047_1
<removed-date>
              Gl u Al a Cy s Hi s Ar g Al a Val Ser Pr o Leu Pr o Ty r Leu Ar g As n Cy s
                          595                           600                           605
              Ar g Ty r As p Val Cy s Ser Cy s Ser As p Gl y Ar g Gl u Cy s Leu Cy s Gl y
                    610                           615                           620
<removed-apn>
              Al a Leu Al a Ser Ty r Al a Al a Al a Cy s Al a Gl y Ar g Gl y Val Ar g Val
              625                           630                           635                           640
              Al a Tr p Ar g Gl u Pr o Gl y Ar g Cy s Gl u Leu As n Cy s Pr o Ly s Gl y Gl n
                                      645                           650                           655
              Val Ty r Leu Gl n Cy s Gl y Thr Pr o Cy s As n Leu Thr Cy s Ar g Ser Leu
                                660                           665                           670
              Ser Ty r Pr o As p Gl u Gl u Cy s As n Gl u Al a Cy s Leu Gl u Gl y Cy s Phe
                          675                           680                           685
              Cy s Pr o Pr o Gl y Leu Ty r Met As p Gl u Ar g Gl y As p Cy s Val Pr o Ly s
                    690                           695                           700
              Al a Gl n Cy s Pr o Cy s Ty r Ty r As p Gl y Gl u I l e Phe Gl n Pr o Gl u As p
              705                           710                           715                           720
              I l e Phe Ser As p Hi s Hi s Thr Met Cy s Ty r Cy s Gl u As p Gl y Phe Met
                                                                    Page 16

                                                                     97047_1
<removed-date>
                                      725                           730                           735
              Hi s Cy s Thr Met Ser Gl y Val Pr o Gl y Ser Leu Leu Pr o As p Al a Val
                                740                           745                           750
<removed-apn>
              Leu Ser Ser Pr o Leu Ser Hi s Ar g Ser Ly s Ar g Ser Leu Ser Cy s Ar g
                          755                           760                           765
              Pr o Pr o Met Val Ly s Leu Val Cy s Pr o Al a As p As n Leu Ar g Al a Gl u
                    770                           775                           780
              Gl y Leu Gl u Cy s Thr Ly s Thr Cy s Gl n As n Ty r As p Leu Gl u Cy s Met
              785                           790                           795                           800
              Ser Met Gl y Cy s Val Ser Gl y Cy s Leu Cy s Pr o Pr o Gl y Met Val Ar g
                                      805                           810                           815
              Hi s Gl u As n Ar g Cy s Val Al a Leu Gl u Ar g Cy s Pr o Cy s Phe Hi s Gl n
                                820                           825                           830
              Gl y Ly s Gl u Ty r Al a Pr o Gl y Gl u Thr Val Ly s I l e Gl y Cy s As n Thr
                          835                           840                           845
              Cy s Val Cy s Ar g As p Ar g Ly s Tr p As n Cy s Thr As p Hi s Val Cy s As p
                    850                           855                           860
                                                                    Page 17

                                                                    97047_1
<removed-date>
              Al a Thr Cy s Ser Thr I l e Gl y Met Al a Hi s Ty r Leu Thr Phe As p Gl y
              865                           870                           875                           880
              Leu Ly s Ty r Leu Phe Pr o Gl y Gl u Cy s Gl n Ty r Val Leu Val Gl n As p
                                      885                           890                           895
<removed-apn>
              Ty r Cy s Gl y Ser As n Pr o Gl y Thr Phe Ar g I l e Leu Val Gl y As n Ly s
                                900                           905                           910
              Gl y Cy s Ser Hi s Pr o Ser Val Ly s Cy s Ly s Ly s Ar g Val Thr I l e Leu
                          915                           920                           925
              Val Gl u Gl y Gl y Gl u I l e Gl u Leu Phe As p Gl y Gl u Val As n Val Ly s
                    930                           935                           940
              Ar g Pr o Met Ly s As p Gl u Thr Hi s Phe Gl u Val Val Gl u Ser Gl y Ar g
              945                           950                           955                           960
              Ty r I l e I l e Leu Leu Leu Gl y Ly s Al a Leu Ser Val Val Tr p As p Ar g
                                      965                           970                           975
              Hi s Leu Ser I l e Ser Val Val Leu Ly s Gl n Thr Ty r Gl n Gl u Ly s Val
                                980                           985                           990
              Cy s Gl y Leu Cy s Gl y As n Phe As p            Gl y I l e Gl n As n As n      As p Leu Thr
                                                                    Page 18

                                                                 97047_1
<removed-date>
                           995                         1000                          1005
              Ser Ser       As n Leu Gl n Val Gl u       Gl u As p Pr o Val As p       Phe Gl y As n
                   1010                         1015                          1020
<removed-apn>
              Ser Tr p      Ly s Val Ser Ser Gl n        Cy s Al a As p Thr Ar g       Ly s Val Pr o
                   1025                         1030                          1035
              Leu As p      Ser Ser Pr o Al a Thr        Cy s Hi s As n As n I l e     Met Ly s Gl n
                   1040                         1045                          1050
              Thr Met       Val As p Ser Ser Cy s        Ar g I l e Leu Thr Ser        As p Val Phe
                   1055                         1060                          1065
              Gl n As p     Cy s As n Ly s Leu Val       As p Pr o Gl u Pr o Ty r      Leu As p Val
                   1070                         1075                          1080
              Cy s I l e    Ty r As p Thr Cy s Ser       Cy s Gl u Ser I l e Gl y      As p Cy s Al a
                   1085                         1090                          1095
              Cy s Phe      Cy s As p Thr I l e Al a     Al a Ty r Al a Hi s Val       Cy s Al a Gl n
                   1100                         1105                          1110
              Hi s Gl y     Ly s Val Val Thr Tr p        Ar g Thr Al a Thr Leu         Cy s Pr o Gl n
                   1115                         1120                          1125
                                                                 Page 19

                                                              97047_1
<removed-date>
              Ser Cy s    Gl u Gl u Ar g As n Leu     Ar g Gl u As n Gl y Ty r   Gl u Cy s Gl u
                   1130                        1135                       1140
              Tr p Ar g   Ty r As n Ser Cy s Al a     Pr o Al a Cy s Gl n Val    Thr Cy s Gl n
                   1145                        1150                       1155
<removed-apn>
              Hi s Pr o   Gl u Pr o Leu Al a Cy s     Pr o Val Gl n Cy s Val     Gl u Gl y Cy s
                   1160                        1165                       1170
              Hi s Al a   Hi s Cy s Pr o Pr o Gl y    Ly s I l e Leu As p Gl u   Leu Leu Gl n
                   1175                        1180                       1185
              Thr Cy s    Val As p Pr o Gl u As p     Cy s Pr o Val Cy s Gl u    Val Al a Gl y
                   1190                        1195                       1200
              Ar g Ar g   Phe Al a Ser Gl y Ly s      Ly s Val Thr Leu As n      Pr o Ser As p
                   1205                        1210                       1215
              Pr o Gl u   Hi s Cy s Gl n I l e Cy s   Hi s Cy s As p Val Val     As n Leu Thr
                   1220                        1225                       1230
              Cy s Gl u   Al a Cy s Gl n Gl u Pr o    Gl y Gl y Leu Val Val      Pr o Pr o Thr
                   1235                        1240                       1245
              As p Al a   Pr o Val Ser Pr o Thr       Thr Leu Ty r Val Gl u      As p I l e Ser
                                                              Page 20

                                                              97047_1
<removed-date>
                   1250                        1255                       1260
              Gl u Pr o   Pr o Leu Hi s As p Phe      Ty r Cy s Ser Ar g Leu     Leu As p Leu
                   1265                        1270                       1275
<removed-apn>
              Val Phe     Leu Leu As p Gl y Ser       Ser Ar g Leu Ser Gl u      Al a Gl u Phe
                   1280                        1285                       1290
              Gl u Val    Leu Ly s Al a Phe Val       Val As p Met Met Gl u      Ar g Leu Ar g
                   1295                        1300                       1305
              I l e Ser   Gl n Ly s Tr p Val Ar g     Val Al a Val Val Gl u      Ty r Hi s As p
                   1310                        1315                       1320
              Gl y Ser    Hi s Al a Ty r I l e Gl y   Leu Ly s As p Ar g Ly s    Ar g Pr o Ser
                   1325                        1330                       1335
              Gl u Leu    Ar g Ar g I l e Al a Ser    Gl n Val Ly s Ty r Al a    Gl y Ser Gl n
                   1340                        1345                       1350
              Val Al a    Ser Thr Ser Gl u Val        Leu Ly s Ty r Thr Leu      Phe Gl n I l e
                   1355                        1360                       1365
              Phe Ser     Ly s I l e As p Ar g Pr o   Gl u Al a Ser Ar g I l e   Al a Leu Leu
                   1370                        1375                       1380
                                                              Page 21

                                                              97047_1
<removed-date>
              Leu Met     Al a Ser Gl n Gl u Pr o     Gl n Ar g Met Ser Ar g     As n Phe Val
                   1385                        1390                       1395
              Ar g Ty r   Val Gl n Gl y Leu Ly s      Ly s Ly s Ly s Val I l e   Val I l e Pr o
                   1400                        1405                       1410
<removed-apn>
              Val Gl y    I l e Gl y Pr o Hi s Al a   As n Leu Ly s Gl n I l e   Ar g Leu I l e
                   1415                        1420                       1425
              Gl u Ly s   Gl n Al a Pr o Gl u As n    Ly s Al a Phe Val Leu      Ser Ser Val
                   1430                        1435                       1440
              As p Gl u   Leu Gl u Gl n Gl n Ar g     As p Gl u I l e Val Ser    Ty r Leu Cy s
                   1445                        1450                       1455
              As p Leu    Al a Pr o Gl u Al a Pr o    Pr o Pr o Thr Leu Pr o     Pr o As p Met
                   1460                        1465                       1470
              Al a Gl n   Val Thr Val Gl y Pr o       Gl y Leu Leu Gl y Val      Ser Thr Leu
                   1475                        1480                       1485
              Gl y Pr o   Ly s Ar g As n Ser Met      Val Leu As p Val Al a      Phe Val Leu
                   1490                        1495                       1500
              Gl u Gl y   Ser As p Ly s I l e Gl y    Gl u Al a As p Phe As n    Ar g Ser Ly s
                                                              Page 22

                                                              97047_1
<removed-date>
                   1505                        1510                       1515
              Gl u Phe    Met Gl u Gl u Val I l e     Gl n Ar g Met As p Val     Gl y Gl n As p
                   1520                        1525                       1530
<removed-apn>
              Ser I l e   Hi s Val Thr Val Leu        Gl n Ty r Ser Ty r Met     Val Thr Val
                   1535                        1540                       1545
              Gl u Ty r   Pr o Phe Ser Gl u Al a      Gl n Ser Ly s Gl y As p    I l e Leu Gl n
                   1550                        1555                       1560
              Ar g Val    Ar g Gl u I l e Ar g Ty r   Gl n Gl y Gl y As n Ar g   Thr As n Thr
                   1565                        1570                       1575
              Gl y Leu    Al a Leu Ar g Ty r Leu      Ser As p Hi s Ser Phe      Leu Val Ser
                   1580                        1585                       1590
              Gl n Gl y   As p Ar g Gl u Gl n Al a    Pr o As n Leu Val Ty r     Met Val Thr
                   1595                        1600                       1605
              Gl y As n   Pr o Al a Ser As p Gl u     I l e Ly s Ar g Leu Pr o   Gl y As p I l e
                   1610                        1615                       1620
              Gl n Val    Val Pr o I l e Gl y Val     Gl y Pr o As n Al a As n   Val Gl n Gl u
                   1625                        1630                       1635
                                                              Page 23

                                                              97047_1
<removed-date>
              Leu Gl u    Ar g I l e Gl y Tr p Pr o   As n Al a Pr o I l e Leu    I l e Gl n As p
                   1640                        1645                        1650
              Phe Gl u    Thr Leu Pr o Ar g Gl u      Al a Pr o As p Leu Val      Leu Gl n Ar g
                   1655                        1660                        1665
<removed-apn>
              Cy s Cy s   Ser Gl y Gl u Gl y Leu      Gl n I l e Pr o Thr Leu     Ser Pr o Al a
                   1670                        1675                        1680
              Pr o As p   Cy s Ser Gl n Pr o Leu      As p Val I l e Leu Leu      Leu As p Gl y
                   1685                        1690                        1695
              Ser Ser     Ser Phe Pr o Al a Ser       Ty r Phe As p Gl u Met      Ly s Ser Phe
                   1700                        1705                        1710
              Al a Ly s   Al a Phe I l e Ser Ly s     Al a As n I l e Gl y Pr o   Ar g Leu Thr
                   1715                        1720                        1725
              Gl n Val    Ser Val Leu Gl n Ty r       Gl y Ser I l e Thr Thr      I l e As p Val
                   1730                        1735                        1740
              Pr o Tr p   As n Val Val Pr o Gl u      Ly s Al a Hi s Leu Leu      Ser Leu Val
                   1745                        1750                        1755
              As p Val    Met Gl n Ar g Gl u Gl y     Gl y Pr o Ser Gl n I l e    Gl y As p Al a
                                                              Page 24

                                                             97047_1
<removed-date>
                   1760                       1765                        1770
              Leu Gl y    Phe Al a Val Ar g Ty r     Leu Thr Ser Gl u Met        Hi s Gl y Al a
                   1775                       1780                        1785
<removed-apn>
              Ar g Pr o   Gl y Al a Ser Ly s Al a    Val Val I l e Leu Val       Thr As p Val
                   1790                       1795                        1800
              Ser Val     As p Ser Val As p Al a     Al a Al a As p Al a Al a    Ar g Ser As n
                   1805                       1810                        1815
              Ar g Val    Thr Val Phe Pr o I l e     Gl y I l e Gl y As p Ar g   Ty r As p Al a
                   1820                       1825                        1830
              Al a Gl n   Leu Ar g I l e Leu Al a    Gl y Pr o Al a Gl y As p    Ser As n Val
                   1835                       1840                        1845
              Val Ly s    Leu Gl n Ar g I l e Gl u   As p Leu Pr o Thr Met       Val Thr Leu
                   1850                       1855                        1860
              Gl y As n   Ser Phe Leu Hi s Ly s      Leu Cy s Ser Gl y Phe       Val Ar g I l e
                   1865                       1870                        1875
              Cy s Met    As p Gl u As p Gl y As n   Gl u Ly s Ar g Pr o Gl y    As p Val Tr p
                   1880                       1885                        1890
                                                             Page 25

                                                             97047_1
<removed-date>
              Thr Leu     Pr o As p Gl n Cy s Hi s   Thr Val Thr Cy s Gl n     Pr o As p Gl y
                   1895                       1900                      1905
              Gl n Thr    Leu Leu Ly s Ser Hi s      Ar g Val As n Cy s As p   Ar g Gl y Leu
                   1910                       1915                      1920
<removed-apn>
              Ar g Pr o   Ser Cy s Pr o As n Ser     Gl n Ser Pr o Val Ly s    Val Gl u Gl u
                   1925                       1930                      1935
              Thr Cy s    Gl y Cy s Ar g Tr p Thr    Cy s Pr o Cy s Val Cy s   Thr Gl y Ser
                   1940                       1945                      1950
              Ser Thr     Ar g Hi s I l e Val Thr    Phe As p Gl y Gl n As n   Phe Ly s Leu
                   1955                       1960                      1965
              Thr Gl y    Ser Cy s Ser Ty r Val      Leu Phe Gl n As n Ly s    Gl u Gl n As p
                   1970                       1975                      1980
              Leu Gl u    Val I l e Leu Hi s As n    Gl y Al a Cy s Ser Pr o   Gl y Al a Ar g
                   1985                       1990                      1995
              Gl n Gl y   Cy s Met Ly s Ser I l e    Gl u Val Ly s Hi s Ser    Al a Leu Ser
                   2000                       2005                      2010
              Val Gl u    Xaa Hi s Ser As p Met      Gl u Val Thr Val As n     Gl y Ar g Leu
                                                             Page 26

                                                             97047_1
<removed-date>
                   2015                       2020                       2025
              Val Ser     Val Pr o Ty r Val Gl y     Gl y As n Met Gl u Val     As n Val Ty r
                   2030                       2035                       2040
<removed-apn>
              Gl y Al a   I l e Met Hi s Gl u Val    Ar g Phe As n Hi s Leu     Gl y Hi s I l e
                   2045                       2050                       2055
              Phe Thr     Phe Thr Pr o Gl n As n     As n Gl u Phe Gl n Leu     Gl n Leu Ser
                   2060                       2065                       2070
              Pr o Ly s   Thr Phe Al a Ser Ly s      Thr Ty r Gl y Leu Cy s     Gl y I l e Cy s
                   2075                       2080                       2085
              As p Gl u   As n Gl y Al a As n As p   Phe Met Leu Ar g As p      Gl y Thr Val
                   2090                       2095                       2100
              Thr Thr     As p Tr p Ly s Thr Leu     Val Gl n Gl u Tr p Thr     Val Gl n Ar g
                   2105                       2110                       2115
              Pr o Gl y   Gl n Thr Cy s Gl n Pr o    I l e Leu Gl u Gl u Gl n   Cy s Leu Val
                   2120                       2125                       2130
              Pr o As p   Ser Ser Hi s Cy s Gl n     Val Leu Leu Leu Pr o       Leu Phe Al a
                   2135                       2140                       2145
                                                             Page 27

                                                              97047_1
<removed-date>
              Gl u Cy s   Hi s Ly s Val Leu Al a      Pr o Al a Thr Phe Ty r      Al a I l e Cy s
                   2150                        2155                        2160
              Gl n Gl n   As p Ser Cy s Hi s Gl n     Gl u Gl n Val Cy s Gl u     Val I l e Al a
                   2165                        2170                        2175
<removed-apn>
              Ser Ty r    Al a Hi s Leu Cy s Ar g     Thr As n Gl y Val Cy s      Val As p Tr p
                   2180                        2185                        2190
              Ar g Thr    Pr o As p Phe Cy s Al a     Met Ser Cy s Pr o Pr o      Ser Leu Val
                   2195                        2200                        2205
              Ty r As n   Hi s Cy s Gl u Hi s Gl y    Cy s Pr o Ar g Hi s Cy s    As p Gl y As n
                   2210                        2215                        2220
              Val Ser     Ser Cy s Gl y As p Hi s     Pr o Ser Gl u Gl y Cy s     Phe Cy s Pr o
                   2225                        2230                        2235
              Pr o As p   Ly s Val Met Leu Gl u       Gl y Ser Cy s Val Pr o      Gl u Gl u Al a
                   2240                        2245                        2250
              Cy s Thr    Gl n Cy s I l e Gl y Gl u   As p Gl y Val Gl n Hi s     Gl n Phe Leu
                   2255                        2260                        2265
              Gl u Al a   Tr p Val Pr o As p Hi s     Gl n Pr o Cy s Gl n I l e   Cy s Thr Cy s
                                                              Page 28

                                                             97047_1
<removed-date>
                   2270                       2275                       2280
              Leu Ser     Gl y Ar g Ly s Val As n    Cy s Thr Thr Gl n Pr o     Cy s Pr o Thr
                   2285                       2290                       2295
<removed-apn>
              Al a Ly s   Al a Pr o Thr Cy s Gl y    Leu Cy s Gl u Val Al a     Ar g Leu Ar g
                   2300                       2305                       2310
              Gl n As n   Al a As p Gl n Cy s Cy s   Pr o Gl u Ty r Gl u Cy s   Val Cy s As p
                   2315                       2320                       2325
              Pr o Val    Ser Cy s As p Leu Pr o     Pr o Val Pr o Hi s Cy s    Gl u Ar g Gl y
                   2330                       2335                       2340
              Leu Gl n    Pr o Thr Leu Thr As n      Pr o Gl y Gl u Cy s Ar g   Pr o As n Phe
                   2345                       2350                       2355
              Thr Cy s    Al a Cy s Ar g Ly s Gl u   Gl u Cy s Ly s Ar g Val    Ser Pr o Pr o
                   2360                       2365                       2370
              Ser Cy s    Pr o Pr o Hi s Ar g Leu    Pr o Thr Leu Ar g Ly s     Thr Gl n Cy s
                   2375                       2380                       2385
              Cy s As p   Gl u Ty r Gl u Cy s Al a   Cy s As n Cy s Val As n    Ser Thr Val
                   2390                       2395                       2400
                                                             Page 29

                                                             97047_1
<removed-date>
              Ser Cy s    Pr o Leu Gl y Ty r Leu     Al a Ser Thr Al a Thr      As n As p Cy s
                   2405                       2410                       2415
              Gl y Cy s   Thr Thr Thr Thr Cy s       Leu Pr o As p Ly s Val     Cy s Val Hi s
                   2420                       2425                       2430
<removed-apn>
              Ar g Ser    Thr I l e Ty r Pr o Val    Gl y Gl n Phe Tr p Gl u    Gl u Gl y Cy s
                   2435                       2440                       2445
              As p Val    Cy s Thr Cy s Thr As p     Met Gl u As p Al a Val     Met Gl y Leu
                   2450                       2455                       2460
              Ar g Val    Al a Gl n Cy s Ser Gl n    Ly s Pr o Cy s Gl u As p   Ser Cy s Ar g
                   2465                       2470                       2475
              Ser Gl y    Phe Thr Ty r Val Leu       Hi s Gl u Gl y Gl u Cy s   Cy s Gl y Ar g
                   2480                       2485                       2490
              Cy s Leu    Pr o Ser Al a Cy s Gl u    Val Val Thr Gl y Ser       Pr o Ar g Gl y
                   2495                       2500                       2505
              As p Ser    Gl n Ser Ser Tr p Ly s     Ser Val Gl y Ser Gl n      Tr p Al a Ser
                   2510                       2515                       2520
              Pr o Gl u   As n Pr o Cy s Leu I l e   As n Gl u Cy s Val Ar g    Val Ly s Gl u
                                                             Page 30

                                                             97047_1
<removed-date>
                   2525                       2530                       2535
              Gl u Val    Phe I l e Gl n Gl n Ar g   As n Val Ser Cy s Pr o     Gl n Leu Gl u
                   2540                       2545                       2550
<removed-apn>
              Val Pr o    Val Cy s Pr o Ser Gl y     Phe Gl n Leu Ser Cy s      Ly s Thr Ser
                   2555                       2560                       2565
              Al a Cy s   Cy s Pr o Ser Cy s Ar g    Cy s Gl u Ar g Met Gl u    Al a Cy s Met
                   2570                       2575                       2580
              Leu As n    Gl y Thr Val I l e Gl y    Pr o Gl y Ly s Thr Val     Met I l e As p
                   2585                       2590                       2595
              Val Cy s    Thr Thr Cy s Ar g Cy s     Met Val Gl n Val Gl y      Val I l e Ser
                   2600                       2605                       2610
              Gl y Phe    Ly s Leu Gl u Cy s Ar g    Ly s Thr Thr Cy s As n     Pr o Cy s Pr o
                   2615                       2620                       2625
              Leu Gl y    Ty r Ly s Gl u Gl u As n   As n Thr Gl y Gl u Cy s    Cy s Gl y Ar g
                   2630                       2635                       2640
              Cy s Leu    Pr o Thr Al a Cy s Thr     I l e Gl n Leu Ar g Gl y   Gl y Gl n I l e
                   2645                       2650                       2655
                                                             Page 31

                                                              97047_1
<removed-date>
              Met Thr      Leu Ly s Ar g As p Gl u    Thr Leu Gl n As p Gl y     Cy s As p Thr
                   2660                        2665                       2670
              Hi s Phe     Cy s Ly s Val As n Gl u    Ar g Gl y Gl u Ty r Phe    Tr p Gl u Ly s
                   2675                        2680                       2685
<removed-apn>
              Ar g Val     Thr Gl y Cy s Pr o Pr o    Phe As p Gl u Hi s Ly s    Cy s Leu Al a
                   2690                        2695                       2700
              Gl u Gl y    Gl y Ly s I l e Met Ly s   I l e Pr o Gl y Thr Cy s   Cy s As p Thr
                   2705                        2710                       2715
              Cy s Gl u    Gl u Pr o Gl u Cy s As n   As p I l e Thr Al a Ar g   Leu Gl n Ty r
                   2720                        2725                       2730
              Val Ly s     Val Gl y Ser Cy s Ly s     Ser Gl u Val Gl u Val      As p I l e Hi s
                   2735                        2740                       2745
              Ty r Cy s    Gl n Gl y Ly s Cy s Al a   Ser Ly s Al a Met Ty r     Ser I l e As p
                   2750                        2755                       2760
              I l e As n   As p Val Gl n As p Gl n    Cy s Ser Cy s Cy s Ser     Pr o Thr Ar g
                   2765                        2770                       2775
              Thr Gl u     Pr o Met Gl n Val Al a     Leu Hi s Cy s Thr As n     Gl y Ser Val
                                                              Page 32

                                                                97047_1
<removed-date>
                   2780                          2785                      2790
              Val Ty r         Hi s Gl u Val Leu As n   Al a Met Gl u Cy s Ly s   Cy s Ser Pr o
                   2795                          2800                      2805
<removed-apn>
              Ar g Ly s        Cy s Ser Ly s
                   2810
              <210>       3
              <211>       19
              <212>       PRT
              <213>       Homo s api ens
              <400>       3
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
              1                        5                       10                      15
              Cy s Phe Ser
              <210>       4
              <211>       2332
              <212>       PRT
              <213>       Homo s api ens
              <400>       4
              Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser Tr p As p Ty r
                                                                Page 33

                                                                  97047_1
<removed-date>
              1                      5                           10                           15
              Met Gl n Ser As p Leu Gl y Gl u Leu Pr o Val As p Al a Ar g Phe Pr o Pr o
                               20                          25                           30
<removed-apn>
              Ar g Val Pr o Ly s Ser Phe Pr o Phe As n Thr Ser Val Val Ty r Ly s Ly s
                         35                          40                           45
              Thr Leu Phe Val Gl u Phe Thr As p Hi s Leu Phe As n I l e Al a Ly s Pr o
                   50                          55                           60
              Ar g Pr o Pr o Tr p Met Gl y Leu Leu Gl y Pr o Thr I l e Gl n Al a Gl u Val
              65                          70                          75                           80
              Ty r As p Thr Val Val I l e Thr Leu Ly s As n Met Al a Ser Hi s Pr o Val
                                     85                          90                           95
              Ser Leu Hi s Al a Val Gl y Val Ser Ty r Tr p Ly s Al a Ser Gl u Gl y Al a
                               100                         105                          110
              Gl u Ty r As p As p Gl n Thr Ser Gl n Ar g Gl u Ly s Gl u As p As p Ly s Val
                         115                         120                          125
              Phe Pr o Gl y Gl y Ser Hi s Thr Ty r Val Tr p Gl n Val Leu Ly s Gl u As n
                   130                         135                          140
                                                                 Page 34

                                                                    97047_1
<removed-date>
              Gl y Pr o Met Al a Ser As p Pr o Leu Cy s Leu Thr Ty r Ser Ty r Leu Ser
              145                           150                           155                           160
              Hi s Val As p Leu Val Ly s As p Leu As n Ser Gl y Leu I l e Gl y Al a Leu
                                      165                           170                           175
<removed-apn>
              Leu Val Cy s Ar g Gl u Gl y Ser Leu Al a Ly s Gl u Ly s Thr Gl n Thr Leu
                                180                           185                           190
              Hi s Ly s Phe I l e Leu Leu Phe Al a Val Phe As p Gl u Gl y Ly s Ser Tr p
                          195                           200                           205
              Hi s Ser Gl u Thr Ly s As n Ser Leu Met Gl n As p Ar g As p Al a Al a Ser
                    210                           215                           220
              Al a Ar g Al a Tr p Pr o Ly s Met Hi s Thr Val As n Gl y Ty r Val As n Ar g
              225                           230                           235                           240
              Ser Leu Pr o Gl y Leu I l e Gl y Cy s Hi s Ar g Ly s Ser Val Ty r Tr p Hi s
                                      245                           250                           255
              Val I l e Gl y Met Gl y Thr Thr Pr o Gl u Val Hi s Ser I l e Phe Leu Gl u
                                260                           265                           270
              Gl y Hi s Thr Phe Leu Val Ar g As n Hi s Ar g Gl n Al a Ser Leu Gl u I l e
                                                                    Page 35

                                                                    97047_1
<removed-date>
                          275                           280                           285
              Ser Pr o I l e Thr Phe Leu Thr Al a Gl n Thr Leu Leu Met As p Leu Gl y
                    290                           295                           300
<removed-apn>
              Gl n Phe Leu Leu Phe Cy s Hi s I l e Ser Ser Hi s Gl n Hi s As p Gl y Met
              305                           310                           315                           320
              Gl u Al a Ty r Val Ly s Val As p Ser Cy s Pr o Gl u Gl u Pr o Gl n Leu Ar g
                                      325                           330                           335
              Met Ly s As n As n Gl u Gl u Al a Gl u As p Ty r As p As p As p Leu Thr As p
                                340                           345                           350
              Ser Gl u Met As p Val Val Ar g Phe As p As p As p As n Ser Pr o Ser Phe
                          355                           360                           365
              I l e Gl n I l e Ar g Ser Val Al a Ly s Ly s Hi s Pr o Ly s Thr Tr p Val Hi s
                    370                           375                           380
              Ty r I l e Al a Al a Gl u Gl u Gl u As p Tr p As p Ty r Al a Pr o Leu Val Leu
              385                           390                           395                           400
              Al a Pr o As p As p Ar g Ser Ty r Ly s Ser Gl n Ty r Leu As n As n Gl y Pr o
                                      405                           410                           415
                                                                    Page 36

                                                                    97047_1
<removed-date>
              Gl n Ar g I l e Gl y Ar g Ly s Ty r Ly s Ly s Val Ar g Phe Met Al a Ty r Thr
                                420                           425                           430
              As p Gl u Thr Phe Ly s Thr Ar g Gl u Al a I l e Gl n Hi s Gl u Ser Gl y I l e
                          435                           440                           445
<removed-apn>
              Leu Gl y Pr o Leu Leu Ty r Gl y Gl u Val Gl y As p Thr Leu Leu I l e I l e
                    450                           455                           460
              Phe Ly s As n Gl n Al a Ser Ar g Pr o Ty r As n I l e Ty r Pr o Hi s Gl y I l e
              465                           470                           475                           480
              Thr As p Val Ar g Pr o Leu Ty r Ser Ar g Ar g Leu Pr o Ly s Gl y Val Ly s
                                      485                           490                           495
              Hi s Leu Ly s As p Phe Pr o I l e Leu Pr o Gl y Gl u I l e Phe Ly s Ty r Ly s
                                500                           505                           510
              Tr p Thr Val Thr Val Gl u As p Gl y Pr o Thr Ly s Ser As p Pr o Ar g Cy s
                          515                           520                           525
              Leu Thr Ar g Ty r Ty r Ser Ser Phe Val As n Met Gl u Ar g As p Leu Al a
                    530                           535                           540
              Ser Gl y Leu I l e Gl y Pr o Leu Leu I l e Cy s Ty r Ly s Gl u Ser Val As p
                                                                    Page 37

                                                                    97047_1
<removed-date>
              545                           550                        555                              560
              Gl n Ar g Gl y As n Gl n I l e Met Ser As p Ly s Ar g As n Val I l e Leu Phe
                                      565                           570                           575
<removed-apn>
              Ser Val Phe As p Gl u As n Ar g Ser Tr p Ty r Leu Thr Gl u As n I l e Gl n
                                580                           585                           590
              Ar g Phe Leu Pr o As n Pr o Al a Gl y Val Gl n Leu Gl u As p Pr o Gl u Phe
                          595                           600                           605
              Gl n Al a Ser As n I l e Met Hi s Ser I l e As n Gl y Ty r Val Phe As p Ser
                    610                           615                           620
              Leu Gl n Leu Ser Val Cy s Leu Hi s Gl u Val Al a Ty r Tr p Ty r I l e Leu
              625                           630                           635                           640
              Ser I l e Gl y Al a Gl n Thr As p Phe Leu Ser Val Phe Phe Ser Gl y Ty r
                                      645                           650                           655
              Thr Phe Ly s Hi s Ly s Met Val Ty r Gl u As p Thr Leu Thr Leu Phe Pr o
                                660                           665                           670
              Phe Ser Gl y Gl u Thr Val Phe Met Ser Met Gl u As n Pr o Gl y Leu Tr p
                          675                           680                           685
                                                                    Page 38

                                                                    97047_1
<removed-date>
              I l e Leu Gl y Cy s Hi s As n Ser As p Phe Ar g As n Ar g Gl y Met Thr Al a
                    690                           695                           700
              Leu Leu Ly s Val Ser Ser Cy s As p Ly s As n Thr Gl y As p Ty r Ty r Gl u
              705                           710                           715                           720
<removed-apn>
              As p Ser Ty r Gl u As p I l e Ser Al a Ty r Leu Leu Ser Ly s As n As n Al a
                                      725                           730                           735
              I l e Gl u Pr o Ar g Ser Phe Ser Gl n As n Ser Ar g Hi s Pr o Ser Thr Ar g
                                740                           745                           750
              Gl n Ly s Gl n Phe As n Al a Thr Thr I l e Pr o Gl u As n As p I l e Gl u Ly s
                          755                           760                           765
              Thr As p Pr o Tr p Phe Al a Hi s Ar g Thr Pr o Met Pr o Ly s I l e Gl n As n
                    770                           775                           780
              Val Ser Ser Ser As p Leu Leu Met Leu Leu Ar g Gl n Ser Pr o Thr Pr o
              785                           790                           795                           800
              Hi s Gl y Leu Ser Leu Ser As p Leu Gl n Gl u Al a Ly s Ty r Gl u Thr Phe
                                      805                           810                           815
              Ser As p As p Pr o Ser Pr o Gl y Al a I l e As p Ser As n As n Ser Leu Ser
                                                                    Page 39

                                                                    97047_1
<removed-date>
                                820                           825                           830
              Gl u Met Thr Hi s Phe Ar g Pr o Gl n Leu Hi s Hi s Ser Gl y As p Met Val
                          835                           840                           845
<removed-apn>
              Phe Thr Pr o Gl u Ser Gl y Leu Gl n Leu Ar g Leu As n Gl u Ly s Leu Gl y
                    850                           855                           860
              Thr Thr Al a Al a Thr Gl u Leu Ly s Ly s Leu As p Phe Ly s Val Ser Ser
              865                           870                           875                           880
              Thr Ser As n As n Leu I l e Ser Thr I l e Pr o Ser As p As n Leu Al a Al a
                                      885                           890                           895
              Gl y Thr As p As n Thr Ser Ser Leu Gl y Pr o Pr o Ser Met Pr o Val Hi s
                                900                           905                           910
              Ty r As p Ser Gl n Leu As p Thr Thr Leu Phe Gl y Ly s Ly s Ser Ser Pr o
                          915                           920                           925
              Leu Thr Gl u Ser Gl y Gl y Pr o Leu Ser Leu Ser Gl u Gl u As n As n As p
                    930                           935                           940
              Ser Ly s Leu Leu Gl u Ser Gl y Leu Met As n Ser Gl n Gl u Ser Ser Tr p
              945                           950                           955                           960
                                                                    Page 40

                                                                    97047_1
<removed-date>
              Gl y Ly s As n Val Ser Ser Thr Gl u Ser Gl y Ar g Leu Phe Ly s Gl y Ly s
                                       965                          970                       975
              Ar g Al a Hi s Gl y Pr o Al a Leu Leu Thr Ly s As p As n Al a Leu Phe Ly s
                                 980                          985                       990
<removed-apn>
              Val Ser I l e Ser Leu Leu Ly s Thr               As n Ly s Thr Ser As n      As n Ser Al a
                           995                         1000                         1005
              Thr As n      Ar g Ly s Thr Hi s I l e     As p Gl y Pr o Ser Leu       Leu I l e Gl u
                   1010                         1015                          1020
              As n Ser      Pr o Ser Val Tr p Gl n       As n I l e Leu Gl u Ser      As p Thr Gl u
                   1025                         1030                          1035
              Phe Ly s      Ly s Val Thr Pr o Leu        I l e Hi s As p Ar g Met     Leu Met As p
                   1040                         1045                          1050
              Ly s As n     Al a Thr Al a Leu Ar g       Leu As n Hi s Met Ser        As n Ly s Thr
                   1055                         1060                          1065
              Thr Ser       Ser Ly s As n Met Gl u       Met Val Gl n Gl n Ly s       Ly s Gl u Gl y
                   1070                         1075                          1080
              Pr o I l e    Pr o Pr o As p Al a Gl n     As n Pr o As p Met Ser       Phe Phe Ly s
                                                                    Page 41

                                                              97047_1
<removed-date>
                   1085                        1090                        1095
              Met Leu     Phe Leu Pr o Gl u Ser       Al a Ar g Tr p I l e Gl n   Ar g Thr Hi s
                   1100                        1105                        1110
<removed-apn>
              Gl y Ly s   As n Ser Leu As n Ser       Gl y Gl n Gl y Pr o Ser     Pr o Ly s Gl n
                   1115                        1120                        1125
              Leu Val     Ser Leu Gl y Pr o Gl u      Ly s Ser Val Gl u Gl y      Gl n As n Phe
                   1130                        1135                        1140
              Leu Ser     Gl u Ly s As n Ly s Val     Val Val Gl y Ly s Gl y      Gl u Phe Thr
                   1145                        1150                        1155
              Ly s As p   Val Gl y Leu Ly s Gl u      Met Val Phe Pr o Ser        Ser Ar g As n
                   1160                        1165                        1170
              Leu Phe     Leu Thr As n Leu As p       As n Leu Hi s Gl u As n     As n Thr Hi s
                   1175                        1180                        1185
              As n Gl n   Gl u Ly s Ly s I l e Gl n   Gl u Gl u I l e Gl u Ly s   Ly s Gl u Thr
                   1190                        1195                        1200
              Leu I l e   Gl n Gl u As n Val Val      Leu Pr o Gl n I l e Hi s    Thr Val Thr
                   1205                        1210                        1215
                                                              Page 42

                                                             97047_1
<removed-date>
              Gl y Thr    Ly s As n Phe Met Ly s     As n Leu Phe Leu Leu        Ser Thr Ar g
                   1220                       1225                        1230
              Gl n As n   Val Gl u Gl y Ser Ty r     As p Gl y Al a Ty r Al a    Pr o Val Leu
                   1235                       1240                        1245
<removed-apn>
              Gl n As p   Phe Ar g Ser Leu As n      As p Ser Thr As n Ar g      Thr Ly s Ly s
                   1250                       1255                        1260
              Hi s Thr    Al a Hi s Phe Ser Ly s     Ly s Gl y Gl u Gl u Gl u    As n Leu Gl u
                   1265                       1270                        1275
              Gl y Leu    Gl y As n Gl n Thr Ly s    Gl n I l e Val Gl u Ly s    Ty r Al a Cy s
                   1280                       1285                        1290
              Thr Thr     Ar g I l e Ser Pr o As n   Thr Ser Gl n Gl n As n      Phe Val Thr
                   1295                       1300                        1305
              Gl n Ar g   Ser Ly s Ar g Al a Leu     Ly s Gl n Phe Ar g Leu      Pr o Leu Gl u
                   1310                       1315                        1320
              Gl u Thr    Gl u Leu Gl u Ly s Ar g    I l e I l e Val As p As p   Thr Ser Thr
                   1325                       1330                        1335
              Gl n Tr p   Ser Ly s As n Met Ly s     Hi s Leu Thr Pr o Ser       Thr Leu Thr
                                                             Page 43

                                                              97047_1
<removed-date>
                   1340                        1345                        1350
              Gl n I l e   As p Ty r As n Gl u Ly s   Gl u Ly s Gl y Al a I l e   Thr Gl n Ser
                   1355                        1360                        1365
<removed-apn>
              Pr o Leu     Ser As p Cy s Leu Thr      Ar g Ser Hi s Ser I l e     Pr o Gl n Al a
                   1370                        1375                        1380
              As n Ar g    Ser Pr o Leu Pr o I l e    Al a Ly s Val Ser Ser       Phe Pr o Ser
                   1385                        1390                        1395
              I l e Ar g   Pr o I l e Ty r Leu Thr    Ar g Val Leu Phe Gl n       As p As n Ser
                   1400                        1405                        1410
              Ser Hi s     Leu Pr o Al a Al a Ser     Ty r Ar g Ly s Ly s As p    Ser Gl y Val
                   1415                        1420                        1425
              Gl n Gl u    Ser Ser Hi s Phe Leu       Gl n Gl y Al a Ly s Ly s    As n As n Leu
                   1430                        1435                        1440
              Ser Leu      Al a I l e Leu Thr Leu     Gl u Met Thr Gl y As p      Gl n Ar g Gl u
                   1445                        1450                        1455
              Val Gl y     Ser Leu Gl y Thr Ser       Al a Thr As n Ser Val       Thr Ty r Ly s
                   1460                        1465                        1470
                                                              Page 44

                                                             97047_1
<removed-date>
              Ly s Val    Gl u As n Thr Val Leu      Pr o Ly s Pr o As p Leu    Pr o Ly s Thr
                   1475                       1480                       1485
              Ser Gl y    Ly s Val Gl u Leu Leu      Pr o Ly s Val Hi s I l e   Ty r Gl n Ly s
                   1490                       1495                       1500
<removed-apn>
              As p Leu    Phe Pr o Thr Gl u Thr      Ser As n Gl y Ser Pr o     Gl y Hi s Leu
                   1505                       1510                       1515
              As p Leu    Val Gl u Gl y Ser Leu      Leu Gl n Gl y Thr Gl u     Gl y Al a I l e
                   1520                       1525                       1530
              Ly s Tr p   As n Gl u Al a As n Ar g   Pr o Gl y Ly s Val Pr o    Phe Leu Ar g
                   1535                       1540                       1545
              Val Al a    Thr Gl u Ser Ser Al a      Ly s Thr Pr o Ser Ly s     Leu Leu As p
                   1550                       1555                       1560
              Pr o Leu    Al a Tr p As p As n Hi s   Ty r Gl y Thr Gl n I l e   Pr o Ly s Gl u
                   1565                       1570                       1575
              Gl u Tr p   Ly s Ser Gl n Gl u Ly s    Ser Pr o Gl u Ly s Thr     Al a Phe Ly s
                   1580                       1585                       1590
              Ly s Ly s   As p Thr I l e Leu Ser     Leu As n Al a Cy s Gl u    Ser As n Hi s
                                                             Page 45

                                                               97047_1
<removed-date>
                   1595                         1600                        1605
              Al a I l e   Al a Al a I l e As n Gl u   Gl y Gl n As n Ly s Pr o    Gl u I l e Gl u
                   1610                         1615                        1620
<removed-apn>
              Val Thr      Tr p Al a Ly s Gl n Gl y    Ar g Thr Gl u Ar g Leu      Cy s Ser Gl n
                   1625                         1630                        1635
              As n Pr o    Pr o Val Leu Ly s Ar g      Hi s Gl n Ar g Gl u I l e   Thr Ar g Thr
                   1640                         1645                        1650
              Thr Leu      Gl n Ser As p Gl n Gl u     Gl u I l e As p Ty r As p   As p Thr I l e
                   1655                         1660                        1665
              Ser Val      Gl u Met Ly s Ly s Gl u     As p Phe As p I l e Ty r    As p Gl u As p
                   1670                         1675                        1680
              Gl u As n    Gl n Ser Pr o Ar g Ser      Phe Gl n Ly s Ly s Thr      Ar g Hi s Ty r
                   1685                         1690                        1695
              Phe I l e    Al a Al a Val Gl u Ar g     Leu Tr p As p Ty r Gl y     Met Ser Ser
                   1700                         1705                        1710
              Ser Pr o     Hi s Val Leu Ar g As n      Ar g Al a Gl n Ser Gl y     Ser Val Pr o
                   1715                         1720                        1725
                                                               Page 46

                                                              97047_1
<removed-date>
              Gl n Phe    Ly s Ly s Val Val Phe       Gl n Gl u Phe Thr As p     Gl y Ser Phe
                   1730                        1735                       1740
              Thr Gl n    Pr o Leu Ty r Ar g Gl y     Gl u Leu As n Gl u Hi s    Leu Gl y Leu
                   1745                        1750                       1755
<removed-apn>
              Leu Gl y    Pr o Ty r I l e Ar g Al a   Gl u Val Gl u As p As n    I l e Met Val
                   1760                        1765                       1770
              Thr Phe     Ar g As n Gl n Al a Ser     Ar g Pr o Ty r Ser Phe     Ty r Ser Ser
                   1775                        1780                       1785
              Leu I l e   Ser Ty r Gl u Gl u As p     Gl n Ar g Gl n Gl y Al a   Gl u Pr o Ar g
                   1790                        1795                       1800
              Ly s As n   Phe Val Ly s Pr o As n      Gl u Thr Ly s Thr Ty r     Phe Tr p Ly s
                   1805                        1810                       1815
              Val Gl n    Hi s Hi s Met Al a Pr o     Thr Ly s As p Gl u Phe     As p Cy s Ly s
                   1820                        1825                       1830
              Al a Tr p   Al a Ty r Phe Ser As p      Val As p Leu Gl u Ly s     As p Val Hi s
                   1835                        1840                       1845
              Ser Gl y    Leu I l e Gl y Pr o Leu     Leu Val Cy s Hi s Thr      As n Thr Leu
                                                              Page 47

                                                              97047_1
<removed-date>
                   1850                        1855                        1860
              As n Pr o    Al a Hi s Gl y Ar g Gl n   Val Thr Val Gl n Gl u       Phe Al a Leu
                   1865                        1870                        1875
<removed-apn>
              Phe Phe      Thr I l e Phe As p Gl u    Thr Ly s Ser Tr p Ty r      Phe Thr Gl u
                   1880                        1885                        1890
              As n Met     Gl u Ar g As n Cy s Ar g   Al a Pr o Cy s As n I l e   Gl n Met Gl u
                   1895                        1900                        1905
              As p Pr o    Thr Phe Ly s Gl u As n     Ty r Ar g Phe Hi s Al a     I l e As n Gl y
                   1910                        1915                        1920
              Ty r I l e   Met As p Thr Leu Pr o      Gl y Leu Val Met Al a       Gl n As p Gl n
                   1925                        1930                        1935
              Ar g I l e   Ar g Tr p Ty r Leu Leu     Ser Met Gl y Ser As n       Gl u As n I l e
                   1940                        1945                        1950
              Hi s Ser     I l e Hi s Phe Ser Gl y    Hi s Val Phe Thr Val        Ar g Ly s Ly s
                   1955                        1960                        1965
              Gl u Gl u    Ty r Ly s Met Al a Leu     Ty r As n Leu Ty r Pr o     Gl y Val Phe
                   1970                        1975                        1980
                                                              Page 48

                                                               97047_1
<removed-date>
              Gl u Thr     Val Gl u Met Leu Pr o      Ser Ly s Al a Gl y I l e     Tr p Ar g Val
                   1985                        1990                         1995
              Gl u Cy s    Leu I l e Gl y Gl u Hi s   Leu Hi s Al a Gl y Met       Ser Thr Leu
                   2000                        2005                         2010
<removed-apn>
              Phe Leu      Val Ty r Ser As n Ly s     Cy s Gl n Thr Pr o Leu       Gl y Met Al a
                   2015                        2020                         2025
              Ser Gl y     Hi s I l e Ar g As p Phe   Gl n I l e Thr Al a Ser      Gl y Gl n Ty r
                   2030                        2035                         2040
              Gl y Gl n    Tr p Al a Pr o Ly s Leu    Al a Ar g Leu Hi s Ty r      Ser Gl y Ser
                   2045                        2050                         2055
              I l e As n   Al a Tr p Ser Thr Ly s     Gl u Pr o Phe Ser Tr p       I l e Ly s Val
                   2060                        2065                         2070
              As p Leu     Leu Al a Pr o Met I l e    I l e Hi s Gl y I l e Ly s   Thr Gl n Gl y
                   2075                        2080                         2085
              Al a Ar g    Gl n Ly s Phe Ser Ser      Leu Ty r I l e Ser Gl n      Phe I l e I l e
                   2090                        2095                         2100
              Met Ty r     Ser Leu As p Gl y Ly s     Ly s Tr p Gl n Thr Ty r      Ar g Gl y As n
                                                               Page 49

                                                               97047_1
<removed-date>
                   2105                        2110                        2115
              Ser Thr      Gl y Thr Leu Met Val       Phe Phe Gl y As n Val        As p Ser Ser
                   2120                        2125                        2130
<removed-apn>
              Gl y I l e   Ly s Hi s As n I l e Phe   As n Pr o Pr o I l e I l e   Al a Ar g Ty r
                   2135                        2140                        2145
              I l e Ar g   Leu Hi s Pr o Thr Hi s     Ty r Ser I l e Ar g Ser      Thr Leu Ar g
                   2150                        2155                        2160
              Met Gl u     Leu Met Gl y Cy s As p     Leu As n Ser Cy s Ser        Met Pr o Leu
                   2165                        2170                        2175
              Gl y Met     Gl u Ser Ly s Al a I l e   Ser As p Al a Gl n I l e     Thr Al a Ser
                   2180                        2185                        2190
              Ser Ty r     Phe Thr As n Met Phe       Al a Thr Tr p Ser Pr o       Ser Ly s Al a
                   2195                        2200                        2205
              Ar g Leu     Hi s Leu Gl n Gl y Ar g    Ser As n Al a Tr p Ar g      Pr o Gl n Val
                   2210                        2215                        2220
              As n As n    Pr o Ly s Gl u Tr p Leu    Gl n Val As p Phe Gl n       Ly s Thr Met
                   2225                        2230                        2235
                                                               Page 50

                                                                 97047_1
<removed-date>
              Ly s Val        Thr Gl y Val Thr Thr       Gl n Gl y Val Ly s Ser     Leu Leu Thr
                   2240                           2245                       2250
              Ser Met         Ty r Val Ly s Gl u Phe     Leu I l e Ser Ser Ser      Gl n As p Gl y
                   2255                           2260                       2265
<removed-apn>
              Hi s Gl n       Tr p Thr Leu Phe Phe       Gl n As n Gl y Ly s Val    Ly s Val Phe
                   2270                           2275                       2280
              Gl n Gl y       As n Gl n As p Ser Phe     Thr Pr o Val Val As n      Ser Leu As p
                   2285                           2290                       2295
              Pr o Pr o       Leu Leu Thr Ar g Ty r      Leu Ar g I l e Hi s Pr o   Gl n Ser Tr p
                   2300                           2305                       2310
              Val Hi s        Gl n I l e Al a Leu Ar g   Met Gl u Val Leu Gl y      Cy s Gl u Al a
                   2315                           2320                       2325
              Gl n As p       Leu Ty r
                   2330
              <210>       5
              <211>       7053
              <212>       DNA
              <213>       Homo s api ens
                                                                 Page 51

                                                                       97047_1
<removed-date>
              <400>     5
              at gc aaat ag agc t c t c c ac c t gc t t c t t t c t gt gc c t t t t gc gat t c t g c t t t agt gc c     60
              ac c agaagat ac t ac c t ggg t gc agt ggaa c t gt c at ggg ac t at at gc a aagt gat c t c                120
              ggt gagc t gc c t gt ggac gc aagat t t c c t c c t agagt gc c aaaat c t t t t c c at t c aac             180
<removed-apn>
              ac c t c agt c g t gt ac aaaaa gac t c t gt t t gt agaat t c a c ggat c ac c t t t t c aac at c          240
              gc t aagc c aa ggc c ac c c t g gat gggt c t g c t aggt c c t a c c at c c aggc t gaggt t t at           300
              gat ac agt gg t c at t ac ac t t aagaac at g gc t t c c c at c c t gt c agt c t t c at gc t gt t         360
              ggt gt at c c t ac t ggaaagc t t c t gaggga gc t gaat at g at gat c agac c agt c aaagg                   420
              gagaaagaag at gat aaagt c t t c c c t ggt ggaagc c at a c at at gt c t g gc aggt c c t g                 480
              aaagagaat g gt c c aat ggc c t c t gac c c a c t gt gc c t t a c c t ac t c at a t c t t t c t c at      540
              gt ggac c t gg t aaaagac t t gaat t c aggc c t c at t ggag c c c t ac t agt at gt agagaa                 600
              gggagt c t gg c c aaggaaaa gac ac agac c t t gc ac aaat t t at ac t ac t t t t t gc t gt a               660
              t t t gat gaag ggaaaagt t g gc ac t c agaa ac aaagaac t c c t t gat gc a ggat agggat                     720
              gc t gc at c t g c t c gggc c t g gc c t aaaat g c ac ac agt c a at ggt t at gt aaac aggt c t            780
              c t gc c aggt c t gat t ggat g c c ac aggaaa t c agt c t at t ggc at gt gat t ggaat gggc                 840
              ac c ac t c c t g aagt gc ac t c aat at t c c t c gaaggt c ac a c at t t c t t gt gaggaac c at           900
              c gc c aggc gt c c t t ggaaat c t c gc c aat a ac t t t c c t t a c t gc t c aaac ac t c t t gat g       960
              gac c t t ggac agt t t c t ac t gt t t t gt c at at c t c t t c c c ac c aac at ga t ggc at ggaa        1020
                                                                       Page 52

                                                                    97047_1
<removed-date>
              gc t t at gt c a aagt agac ag c t gt c c agag gaac c c c aac t ac gaat gaa aaat aat gaa             1080
              gaagc ggaag ac t at gat ga t gat c t t ac t gat t c t gaaa t ggat gt ggt c aggt t t gat             1140
              gat gac aac t c t c c t t c c t t t at c c aaat t c gc t c agt t g c c aagaagc a t c c t aaaac t    1200
<removed-apn>
              t gggt ac at t ac at t gc t gc t gaagaggag gac t gggac t at gc t c c c t t agt c c t c gc c         1260
              c c c gat gac a gaagt t at aa aagt c aat at t t gaac aat g gc c c t c agc g gat t ggt agg           1320
              aagt ac aaaa aagt c c gat t t at ggc at ac ac agat gaaa c c t t t aagac t c gt gaagc t              1380
              at t c agc at g aat c aggaat c t t gggac c t t t ac t t t at g gggaagt t gg agac ac ac t g          1440
              t t gat t at at t t aagaat c a agc aagc aga c c at at aac a t c t ac c c t c a c ggaat c ac t       1500
              gat gt c c gt c c t t t gt at t c aaggagat t a c c aaaaggt g t aaaac at t t gaaggat t t t           1560
              c c aat t c t gc c aggagaaat at t c aaat at aaat ggac ag t gac t gt aga agat gggc c a               1620
              ac t aaat c ag at c c t c ggt g c c t gac c c gc t at t ac t c t a gt t t c gt t aa t at ggagaga    1680
              gat c t agc t t c aggac t c at t ggc c c t c t c c t c at c t gc t ac aaagaat c t gt agat c aa      1740
              agaggaaac c agat aat gt c agac aagagg aat gt c at c c t gt t t t c t gt at t t gat gag              1800
              aac c gaagc t ggt ac c t c ac agagaat at a c aac gc t t t c t c c c c aat c c agc t ggagt g         1860
              c agc t t gagg at c c agagt t c c aagc c t c c aac at c at gc ac agc at c aa t ggc t at gt t        1920
              t t t gat agt t t gc agt t gt c agt t t gt t t g c at gaggt gg c at ac t ggt a c at t c t aagc      1980
              at t ggagc ac agac t gac t t c c t t t c t gt c t t c t t c t c t g gat at ac c t t c aaac ac aaa   2040
                                                                    Page 53

                                                                     97047_1
<removed-date>
              at ggt c t at g aagac ac ac t c ac c c t at t c c c at t c t c ag gagaaac t gt c t t c at gt c g    2100
              at ggaaaac c c aggt c t at g gat t c t gggg t gc c ac aac t c agac t t t c g gaac agaggc            2160
              at gac c gc c t t ac t gaaggt t t c t agt t gt gac aagaac a c t ggt gat t a t t ac gaggac           2220
<removed-apn>
              agt t at gaag at at t t c agc at ac t t gc t g agt aaaaac a at gc c at t ga ac c aagaagc            2280
              t t c t c c c aga at t c aagac a c c c t agc ac t aggc aaaagc aat t t aat gc c ac c ac aat t        2340
              c c agaaaat g ac at agagaa gac t gac c c t t ggt t t gc ac ac agaac ac c t at gc c t aaa            2400
              at ac aaaat g t c t c c t c t ag t gat t t gt t g at gc t c t t gc gac agagt c c t ac t c c ac at   2460
              gggc t at c c t t at c t gat c t c c aagaagc c aaat at gaga c t t t t t c t ga t gat c c at c a     2520
              c c t ggagc aa t agac agt aa t aac agc c t g t c t gaaat ga c ac ac t t c ag gc c ac agc t c        2580
              c at c ac agt g gggac at ggt at t t ac c c c t gagt c aggc c t c c aat t aag at t aaat gag          2640
              aaac t gggga c aac t gc agc aac agagt t g aagaaac t t g at t t c aaagt t t c t agt ac a             2700
              t c aaat aat c t gat t t c aac aat t c c at c a gac aat t t gg c agc aggt ac t gat aat ac a         2760
              agt t c c t t ag gac c c c c aag t at gc c agt t c at t at gat a gt c aat t aga t ac c ac t c t a   2820
              t t t ggc aaaa agt c at c t c c c c t t ac t gag t c t ggt ggac c t c t gagc t t gagt gaagaa        2880
              aat aat gat t c aaagt t gt t agaat c aggt t t aat gaat a gc c aagaaag t t c at gggga                2940
              aaaaat gt at c gt c aac aga gagt ggt agg t t at t t aaag ggaaaagagc t c at ggac c t                 3000
              gc t t t gt t ga c t aaagat aa t gc c t t at t c aaagt t agc a t c t c t t t gt t aaagac aaac       3060
                                                                     Page 54

                                                                   97047_1
<removed-date>
              aaaac t t c c a at aat t c agc aac t aat aga aagac t c ac a t t gat ggc c c at c at t at t a     3120
              at t gagaat a gt c c at c agt c t ggc aaaat at at t agaaa gt gac ac t ga gt t t aaaaaa           3180
              gt gac ac c t t t gat t c at ga c agaat gc t t at ggac aaaa at gc t ac agc t t t gaggc t a       3240
<removed-apn>
              aat c at at gt c aaat aaaac t ac t t c at c a aaaaac at gg aaat ggt c c a ac agaaaaaa            3300
              gagggc c c c a t t c c ac c aga t gc ac aaaat c c agat at gt c gt t c t t t aa gat gc t at t c   3360
              t t gc c agaat c agc aaggt g gat ac aaagg ac t c at ggaa agaac t c t c t gaac t c t ggg          3420
              c aaggc c c c a gt c c aaagc a at t agt at c c t t aggac c ag aaaaat c t gt ggaaggt c ag         3480
              aat t t c t t gt c t gagaaaaa c aaagt ggt a gt aggaaagg gt gaat t t ac aaaggac gt a              3540
              ggac t c aaag agat ggt t t t t c c aagc agc agaaac c t at t t c t t ac t aa c t t ggat aat       3600
              t t ac at gaaa at aat ac ac a c aat c aagaa aaaaaaat t c aggaagaaat agaaaagaag                   3660
              gaaac at t aa t c c aagagaa t gt agt t t t g c c t c agat ac at ac agt gac t ggc ac t aag        3720
              aat t t c at ga agaac c t t t t c t t ac t gagc ac t aggc aaa at gt agaagg t t c at at gac       3780
              ggggc at at g c t c c agt ac t t c aagat t t t aggt c at t aa at gat t c aac aaat agaac a        3840
              aagaaac ac a c agc t c at t t c t c aaaaaaa ggggaggaag aaaac t t gga aggc t t ggga               3900
              aat c aaac c a agc aaat t gt agagaaat at gc at gc ac c a c aaggat at c t c c t aat ac a          3960
              agc c agc aga at t t t gt c ac gc aac gt agt aagagagc t t t gaaac aat t c agac t c c c a         4020
              c t agaagaaa c agaac t t ga aaaaaggat a at t gt ggat g ac ac c t c aac c c agt ggt c c           4080
                                                                   Page 55

                                                                     97047_1
<removed-date>
              aaaaac at ga aac at t t gac c c c gagc ac c c t c ac ac aga t agac t ac aa t gagaaggag              4140
              aaaggggc c a t t ac t c agt c t c c c t t at c a gat t gc c t t a c gaggagt c a t agc at c c c t    4200
              c aagc aaat a gat c t c c at t ac c c at t gc a aaggt at c at c at t t c c at c t at t agac c t     4260
<removed-apn>
              at at at c t ga c c agggt c c t at t c c aagac aac t c t t c t c at c t t c c agc agc at c t t at   4320
              agaaagaaag at t c t ggggt c c aagaaagc agt c at t t c t t ac aaggagc c aaaaaaaat                    4380
              aac c t t t c t t t agc c at t c t aac c t t ggag at gac t ggt g at c aaagaga ggt t ggc t c c       4440
              c t ggggac aa gt gc c ac aaa t t c agt c ac a t ac aagaaag t t gagaac ac t gt t c t c c c g         4500
              aaac c agac t t gc c c aaaac at c t ggc aaa gt t gaat t gc t t c c aaaagt t c ac at t t at          4560
              c agaaggac c t at t c c c t ac ggaaac t agc aat gggt c t c c t ggc c at c t ggat c t c gt g         4620
              gaagggagc c t t c t t c aggg aac agaggga gc gat t aagt ggaat gaagc aaac agac c t                    4680
              ggaaaagt t c c c t t t c t gag agt agc aac a gaaagc t c t g c aaagac t c c c t c c aagc t a         4740
              t t ggat c c t c t t gc t t ggga t aac c ac t at ggt ac t c aga t ac c aaaaga agagt ggaaa           4800
              t c c c aagaga agt c ac c aga aaaaac agc t t t t aagaaaa aggat ac c at t t t gt c c c t g           4860
              aac gc t t gt g aaagc aat c a t gc aat agc a gc aat aaat g agggac aaaa t aagc c c gaa               4920
              at agaagt c a c c t gggc aaa gc aaggt agg ac t gaaaggc t gt gc t c t c a aaac c c ac c a            4980
              gt c t t gaaac gc c at c aac g ggaaat aac t c gt ac t ac t c t t c agt c aga t c aagaggaa           5040
              at t gac t at g at gat ac c at at c agt t gaa at gaagaagg aagat t t t ga c at t t at gat            5100
                                                                     Page 56

                                                                   97047_1
<removed-date>
              gaggat gaaa at c agagc c c c c gc agc t t t c aaaagaaaa c ac gac ac t a t t t t at t gc t        5160
              gc agt ggaga ggc t c t ggga t t at gggat g agt agc t c c c c ac at gt t c t aagaaac agg          5220
              gc t c agagt g gc agt gt c c c t c agt t c aag aaagt t gt t t t c c aggaat t t ac t gat ggc      5280
<removed-apn>
              t c c t t t ac t c agc c c t t at a c c gt ggagaa c t aaat gaac at t t gggac t c c t ggggc c a   5340
              t at at aagag c agaagt t ga agat aat at c at ggt aac t t t c agaaat c a ggc c t c t c gt         5400
              c c c t at t c c t t c t at t c t ag c c t t at t t c t t at gaggaag at c agaggc a aggagc agaa   5460
              c c t agaaaaa ac t t t gt c aa gc c t aat gaa ac c aaaac t t ac t t t t ggaa agt gc aac at       5520
              c at at ggc ac c c ac t aaaga t gagt t t gac t gc aaagc c t gggc t t at t t c t c t gat gt t     5580
              gac c t ggaaa aagat gt gc a c t c aggc c t g at t ggac c c c t t c t ggt c t g c c ac ac t aac   5640
              ac ac t gaac c c t gc t c at gg gagac aagt g ac agt ac agg aat t t gc t c t gt t t t t c ac c    5700
              at c t t t gat g agac c aaaag c t ggt ac t t c ac t gaaaat a t ggaaagaaa c t gc agggc t          5760
              c c c t gc aat a t c c agat gga agat c c c ac t t t t aaagaga at t at c gc t t c c at gc aat c   5820
              aat ggc t ac a t aat ggat ac ac t ac c t ggc t t agt aat gg c t c aggat c a aaggat t c ga        5880
              t ggt at c t gc t c agc at ggg c agc aat gaa aac at c c at t c t at t c at t t c agt ggac at     5940
              gt gt t c ac t g t ac gaaaaaa agaggagt at aaaat ggc ac t gt ac aat c t c t at c c aggt           6000
              gt t t t t gaga c agt ggaaat gt t ac c at c c aaagc t ggaa t t t ggc gggt ggaat gc c t t         6060
              at t ggc gagc at c t ac at gc t gggat gagc ac ac t t t t t c t ggt gt ac ag c aat aagt gt        6120
                                                                   Page 57

                                                                      97047_1
<removed-date>
              c agac t c c c c t gggaat ggc t t c t ggac ac at t agagat t t t c agat t ac agc t t c agga             6180
              c aat at ggac agt gggc c c c aaagc t ggc c agac t t c at t at t c c ggat c aat c aat gc c              6240
              t ggagc ac c a aggagc c c t t t t c t t ggat c aaggt ggat c t gt t ggc ac c aat gat t at t             6300
<removed-apn>
              c ac ggc at c a agac c c aggg t gc c c gt c ag aagt t c t c c a gc c t c t ac at c t c t c agt t t     6360
              at c at c at gt at agt c t t ga t gggaagaag t ggc agac t t at c gaggaaa t t c c ac t gga               6420
              ac c t t aat gg t c t t c t t t gg c aat gt ggat t c at c t ggga t aaaac ac aa t at t t t t aac        6480
              c c t c c aat t a t t gc t c gat a c at c c gt t t g c ac c c aac t c at t at agc at t c gc agc ac t   6540
              c t t c gc at gg agt t gat ggg c t gt gat t t a aat agt t gc a gc at gc c at t gggaat ggag             6600
              agt aaagc aa t at c agat gc ac agat t ac t gc t t c at c c t ac t t t ac c aa t at gt t t gc c         6660
              ac c t ggt c t c c t t c aaaagc t c gac t t c ac c t c c aaggga ggagt aat gc c t ggagac c t            6720
              c aggt gaat a at c c aaaaga gt ggc t gc aa gt ggac t t c c agaagac aat gaaagt c ac a                   6780
              ggagt aac t a c t c agggagt aaaat c t c t g c t t ac c agc a t gt at gt gaa ggagt t c c t c            6840
              at c t c c agc a gt c aagat gg c c at c agt gg ac t c t c t t t t t t c agaat gg c aaagt aaag          6900
              gt t t t t c agg gaaat c aaga c t c c t t c ac a c c t gt ggt ga ac t c t c t aga c c c ac c gt t a    6960
              c t gac t c gc t ac c t t c gaat t c ac c c c c ag agt t gggt gc ac c agat t gc c c t gaggat g         7020
              gaggt t c t gg gc t gc gaggc ac aggac c t c t ac                                                       7053
                                                                      Page 58

                                                                97047_1
<removed-date>
              <210>     6
              <211>     1438
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     BDDD FVI I I
<removed-apn>
              <400>     6
              Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser Tr p As p Ty r
              1                       5                         10                       15
              Met Gl n Ser As p Leu Gl y Gl u Leu Pr o Val As p Al a Ar g Phe Pr o Pr o
                                 20                        25                       30
              Ar g Val Pr o Ly s Ser Phe Pr o Phe As n Thr Ser Val Val Ty r Ly s Ly s
                            35                        40                       45
              Thr Leu Phe Val Gl u Phe Thr As p Hi s Leu Phe As n I l e Al a Ly s Pr o
                   50                           55                        60
              Ar g Pr o Pr o Tr p Met Gl y Leu Leu Gl y Pr o Thr I l e Gl n Al a Gl u Val
              65                           70                        75                       80
              Ty r As p Thr Val Val I l e Thr Leu Ly s As n Met Al a Ser Hi s Pr o Val
                                      85                        90                       95
                                                                Page 59

                                                       97047_1
<removed-date>
              Ser Leu Hi s Al a Val Gl y Val Ser Ty r Tr p Ly s Al a Ser Gl u Gl y Al a
                                100                           105                           110
              Gl u Ty r As p As p Gl n Thr Ser Gl n Ar g Gl u Ly s Gl u As p As p Ly s Val
                          115                           120                           125
<removed-apn>
              Phe Pr o Gl y Gl y Ser Hi s Thr Ty r Val Tr p Gl n Val Leu Ly s Gl u As n
                    130                           135                           140
              Gl y Pr o Met Al a Ser As p Pr o Leu Cy s Leu Thr Ty r Ser Ty r Leu Ser
              145                           150                           155                           160
              Hi s Val As p Leu Val Ly s As p Leu As n Ser Gl y Leu I l e Gl y Al a Leu
                                      165                           170                           175
              Leu Val Cy s Ar g Gl u Gl y Ser Leu Al a Ly s Gl u Ly s Thr Gl n Thr Leu
                                180                           185                           190
              Hi s Ly s Phe I l e Leu Leu Phe Al a Val Phe As p Gl u Gl y Ly s Ser Tr p
                          195                           200                           205
              Hi s Ser Gl u Thr Ly s As n Ser Leu Met Gl n As p Ar g As p Al a Al a Ser
                    210                           215                           220
              Al a Ar g Al a Tr p Pr o Ly s Met Hi s Thr Val As n Gl y Ty r Val As n Ar g
              225                           230                           235                           240
                                                                    Page 60

                                                                    97047_1
<removed-date>
              Ser Leu Pr o Gl y Leu I l e Gl y Cy s Hi s Ar g Ly s Ser Val Ty r Tr p Hi s
                                      245                           250                           255
              Val I l e Gl y Met Gl y Thr Thr Pr o Gl u Val Hi s Ser I l e Phe Leu Gl u
<removed-apn>
                                260                           265                           270
              Gl y Hi s Thr Phe Leu Val Ar g As n Hi s Ar g Gl n Al a Ser Leu Gl u I l e
                          275                           280                           285
              Ser Pr o I l e Thr Phe Leu Thr Al a Gl n Thr Leu Leu Met As p Leu Gl y
                    290                           295                           300
              Gl n Phe Leu Leu Phe Cy s Hi s I l e Ser Ser Hi s Gl n Hi s As p Gl y Met
              305                           310                           315                           320
              Gl u Al a Ty r Val Ly s Val As p Ser Cy s Pr o Gl u Gl u Pr o Gl n Leu Ar g
                                      325                           330                           335
              Met Ly s As n As n Gl u Gl u Al a Gl u As p Ty r As p As p As p Leu Thr As p
                                340                           345                           350
              Ser Gl u Met As p Val Val Ar g Phe As p As p As p As n Ser Pr o Ser Phe
                          355                           360                           365
                                                                    Page 61

                                                            97047_1
<removed-date>
              I l e Gl n I l e Ar g Ser Val Al a Ly s Ly s Hi s Pr o Ly s Thr Tr p Val Hi s
                    370                           375                           380
              Ty r I l e Al a Al a Gl u Gl u Gl u As p Tr p As p Ty r Al a Pr o Leu Val Leu
              385                           390                           395                           400
<removed-apn>
              Al a Pr o As p As p Ar g Ser Ty r Ly s Ser Gl n Ty r Leu As n As n Gl y Pr o
                                      405                           410                           415
              Gl n Ar g I l e Gl y Ar g Ly s Ty r Ly s Ly s Val Ar g Phe Met Al a Ty r Thr
                                420                           425                           430
              As p Gl u Thr Phe Ly s Thr Ar g Gl u Al a I l e Gl n Hi s Gl u Ser Gl y I l e
                          435                           440                           445
              Leu Gl y Pr o Leu Leu Ty r Gl y Gl u Val Gl y As p Thr Leu Leu I l e I l e
                    450                           455                           460
              Phe Ly s As n Gl n Al a Ser Ar g Pr o Ty r As n I l e Ty r Pr o Hi s Gl y I l e
              465                           470                           475                           480
              Thr As p Val Ar g Pr o Leu Ty r Ser Ar g Ar g Leu Pr o Ly s Gl y Val Ly s
                                      485                           490                           495
              Hi s Leu Ly s As p Phe Pr o I l e Leu Pr o Gl y Gl u I l e Phe Ly s Ty r Ly s
                                500                           505                           510
                                                                    Page 62

                                                                    97047_1
<removed-date>
              Tr p Thr Val Thr Val Gl u As p Gl y Pr o Thr Ly s Ser As p Pr o Ar g Cy s
                          515                           520                           525
              Leu Thr Ar g Ty r Ty r Ser Ser Phe Val As n Met Gl u Ar g As p Leu Al a
<removed-apn>
                    530                           535                           540
              Ser Gl y Leu I l e Gl y Pr o Leu Leu I l e Cy s Ty r Ly s Gl u Ser Val As p
              545                           550                           555                           560
              Gl n Ar g Gl y As n Gl n I l e Met Ser As p Ly s Ar g As n Val I l e Leu Phe
                                      565                           570                           575
              Ser Val Phe As p Gl u As n Ar g Ser Tr p Ty r Leu Thr Gl u As n I l e Gl n
                                580                           585                           590
              Ar g Phe Leu Pr o As n Pr o Al a Gl y Val Gl n Leu Gl u As p Pr o Gl u Phe
                          595                           600                           605
              Gl n Al a Ser As n I l e Met Hi s Ser I l e As n Gl y Ty r Val Phe As p Ser
                    610                           615                           620
              Leu Gl n Leu Ser Val Cy s Leu Hi s Gl u Val Al a Ty r Tr p Ty r I l e Leu
              625                           630                           635                           640
                                                                    Page 63

                                                         97047_1
<removed-date>
              Ser I l e Gl y Al a Gl n Thr As p Phe Leu Ser Val Phe Phe Ser Gl y Ty r
                                      645                           650                           655
              Thr Phe Ly s Hi s Ly s Met Val Ty r Gl u As p Thr Leu Thr Leu Phe Pr o
                                660                           665                           670
<removed-apn>
              Phe Ser Gl y Gl u Thr Val Phe Met Ser Met Gl u As n Pr o Gl y Leu Tr p
                          675                           680                           685
              I l e Leu Gl y Cy s Hi s As n Ser As p Phe Ar g As n Ar g Gl y Met Thr Al a
                    690                           695                           700
              Leu Leu Ly s Val Ser Ser Cy s As p Ly s As n Thr Gl y As p Ty r Ty r Gl u
              705                           710                           715                           720
              As p Ser Ty r Gl u As p I l e Ser Al a Ty r Leu Leu Ser Ly s As n As n Al a
                                      725                           730                           735
              I l e Gl u Pr o Ar g Ser Phe Ser Gl n As n Pr o Pr o Val Leu Ly s Ar g Hi s
                                740                           745                           750
              Gl n Ar g Gl u I l e Thr Ar g Thr Thr Leu Gl n Ser As p Gl n Gl u Gl u I l e
                          755                           760                           765
              As p Ty r As p As p Thr I l e Ser Val Gl u Met Ly s Ly s Gl u As p Phe As p
                    770                           775                           780
                                                                    Page 64

                                                                    97047_1
<removed-date>
              I l e Ty r As p Gl u As p Gl u As n Gl n Ser Pr o Ar g Ser Phe Gl n Ly s Ly s
              785                           790                           795                           800
              Thr Ar g Hi s Ty r Phe I l e Al a Al a Val Gl u Ar g Leu Tr p As p Ty r Gl y
<removed-apn>
                                      805                           810                           815
              Met Ser Ser Ser Pr o Hi s Val Leu Ar g As n Ar g Al a Gl n Ser Gl y Ser
                                820                           825                           830
              Val Pr o Gl n Phe Ly s Ly s Val Val Phe Gl n Gl u Phe Thr As p Gl y Ser
                          835                           840                           845
              Phe Thr Gl n Pr o Leu Ty r Ar g Gl y Gl u Leu As n Gl u Hi s Leu Gl y Leu
                    850                           855                           860
              Leu Gl y Pr o Ty r I l e Ar g Al a Gl u Val Gl u As p As n I l e Met Val Thr
              865                           870                           875                           880
              Phe Ar g As n Gl n Al a Ser Ar g Pr o Ty r Ser Phe Ty r Ser Ser Leu I l e
                                      885                           890                           895
              Ser Ty r Gl u Gl u As p Gl n Ar g Gl n Gl y Al a Gl u Pr o Ar g Ly s As n Phe
                                900                           905                           910
                                                                    Page 65

                                                         97047_1
<removed-date>
              Val Ly s Pr o As n Gl u Thr Ly s Thr Ty r Phe Tr p Ly s Val Gl n Hi s Hi s
                           915                           920                            925
              Met Al a Pr o Thr Ly s As p Gl u Phe As p Cy s Ly s Al a Tr p Al a Ty r Phe
                    930                            935                            940
<removed-apn>
              Ser As p Val As p Leu Gl u Ly s As p Val Hi s Ser Gl y Leu I l e Gl y Pr o
              945                            950                            955                            960
              Leu Leu Val Cy s Hi s Thr As n Thr Leu As n Pr o Al a Hi s Gl y Ar g Gl n
                                       965                            970                            975
              Val Thr Val Gl n Gl u Phe Al a Leu Phe Phe Thr I l e Phe As p Gl u Thr
                                 980                            985                            990
              Ly s Ser Tr p Ty r Phe Thr Gl u As n               Met Gl u Ar g As n Cy s         Ar g Al a Pr o
                           995                           1000                            1005
              Cy s As n     I l e Gl n Met Gl u As p       Pr o Thr Phe Ly s Gl u             As n Ty r Ar g
                    1010                            1015                            1020
              Phe Hi s      Al a I l e As n Gl y Ty r      I l e Met As p Thr Leu             Pr o Gl y Leu
                    1025                            1030                            1035
              Val Met       Al a Gl n As p Gl n Ar g       I l e Ar g Tr p Ty r Leu           Leu Ser Met
                    1040                            1045                            1050
                                                                      Page 66

                                                              97047_1
<removed-date>
              Gl y Ser    As n Gl u As n I l e Hi s   Ser I l e Hi s Phe Ser      Gl y Hi s Val
                   1055                        1060                        1065
              Phe Thr     Val Ar g Ly s Ly s Gl u     Gl u Ty r Ly s Met Al a     Leu Ty r As n
<removed-apn>
                   1070                        1075                        1080
              Leu Ty r    Pr o Gl y Val Phe Gl u      Thr Val Gl u Met Leu        Pr o Ser Ly s
                   1085                        1090                        1095
              Al a Gl y   I l e Tr p Ar g Val Gl u    Cy s Leu I l e Gl y Gl u    Hi s Leu Hi s
                   1100                        1105                        1110
              Al a Gl y   Met Ser Thr Leu Phe         Leu Val Ty r Ser As n       Ly s Cy s Gl n
                   1115                        1120                        1125
              Thr Pr o    Leu Gl y Met Al a Ser       Gl y Hi s I l e Ar g As p   Phe Gl n I l e
                   1130                        1135                        1140
              Thr Al a    Ser Gl y Gl n Ty r Gl y     Gl n Tr p Al a Pr o Ly s    Leu Al a Ar g
                   1145                        1150                        1155
              Leu Hi s    Ty r Ser Gl y Ser I l e     As n Al a Tr p Ser Thr      Ly s Gl u Pr o
                   1160                        1165                        1170
                                                              Page 67

                                                               97047_1
<removed-date>
              Phe Ser      Tr p I l e Ly s Val As p     Leu Leu Al a Pr o Met        I l e I l e Hi s
                   1175                         1180                         1185
              Gl y I l e   Ly s Thr Gl n Gl y Al a      Ar g Gl n Ly s Phe Ser       Ser Leu Ty r
                   1190                         1195                         1200
<removed-apn>
              I l e Ser    Gl n Phe I l e I l e Met     Ty r Ser Leu As p Gl y       Ly s Ly s Tr p
                   1205                         1210                         1215
              Gl n Thr     Ty r Ar g Gl y As n Ser      Thr Gl y Thr Leu Met         Val Phe Phe
                   1220                         1225                         1230
              Gl y As n    Val As p Ser Ser Gl y        I l e Ly s Hi s As n I l e   Phe As n Pr o
                   1235                         1240                         1245
              Pr o I l e   I l e Al a Ar g Ty r I l e   Ar g Leu Hi s Pr o Thr       Hi s Ty r Ser
                   1250                         1255                         1260
              I l e Ar g   Ser Thr Leu Ar g Met         Gl u Leu Met Gl y Cy s       As p Leu As n
                   1265                         1270                         1275
              Ser Cy s     Ser Met Pr o Leu Gl y        Met Gl u Ser Ly s Al a       I l e Ser As p
                   1280                         1285                         1290
              Al a Gl n    I l e Thr Al a Ser Ser       Ty r Phe Thr As n Met        Phe Al a Thr
                   1295                         1300                         1305
                                                                 Page 68

                                                             97047_1
<removed-date>
              Tr p Ser     Pr o Ser Ly s Al a Ar g   Leu Hi s Leu Gl n Gl y     Ar g Ser As n
                   1310                       1315                       1320
              Al a Tr p    Ar g Pr o Gl n Val As n   As n Pr o Ly s Gl u Tr p   Leu Gl n Val
<removed-apn>
                   1325                       1330                       1335
              As p Phe     Gl n Ly s Thr Met Ly s    Val Thr Gl y Val Thr       Thr Gl n Gl y
                   1340                       1345                       1350
              Val Ly s     Ser Leu Leu Thr Ser       Met Ty r Val Ly s Gl u     Phe Leu I l e
                   1355                       1360                       1365
              Ser Ser      Ser Gl n As p Gl y Hi s   Gl n Tr p Thr Leu Phe      Phe Gl n As n
                   1370                       1375                       1380
              Gl y Ly s    Val Ly s Val Phe Gl n     Gl y As n Gl n As p Ser    Phe Thr Pr o
                   1385                       1390                       1395
              Val Val      As n Ser Leu As p Pr o    Pr o Leu Leu Thr Ar g      Ty r Leu Ar g
                   1400                       1405                       1410
              I l e Hi s   Pr o Gl n Ser Tr p Val    Hi s Gl n I l e Al a Leu   Ar g Met Gl u
                   1415                       1420                       1425
                                                             Page 69

                                                                    97047_1
<removed-date>
              Val Leu       Gl y Cy s Gl u Al a Gl n        As p Leu Ty r
                    1430                            1435
              <210>     7
              <211>     4371
              <212>     DNA
<removed-apn>
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     BDDD FVI I I
              <400>     7
              at gc aaat ag agc t c t c c ac c t gc t t c t t t c t gt gc c t t t t gc gat t c t g c t t t agt gc c    60
              ac c agaagat ac t ac c t ggg t gc agt ggaa c t gt c at ggg ac t at at gc a aagt gat c t c               120
              ggt gagc t gc c t gt ggac gc aagat t t c c t c c t agagt gc c aaaat c t t t t c c at t c aac            180
              ac c t c agt c g t gt ac aaaaa gac t c t gt t t gt agaat t c a c ggat c ac c t t t t c aac at c         240
              gc t aagc c aa ggc c ac c c t g gat gggt c t g c t aggt c c t a c c at c c aggc t gaggt t t at          300
              gat ac agt gg t c at t ac ac t t aagaac at g gc t t c c c at c c t gt c agt c t t c at gc t gt t        360
              ggt gt at c c t ac t ggaaagc t t c t gaggga gc t gaat at g at gat c agac c agt c aaagg                  420
              gagaaagaag at gat aaagt c t t c c c t ggt ggaagc c at a c at at gt c t g gc aggt c c t g                480
              aaagagaat g gt c c aat ggc c t c t gac c c a c t gt gc c t t a c c t ac t c at a t c t t t c t c at     540
              gt ggac c t gg t aaaagac t t gaat t c aggc c t c at t ggag c c c t ac t agt at gt agagaa                600
              gggagt c t gg c c aaggaaaa gac ac agac c t t gc ac aaat t t at ac t ac t t t t t gc t gt a              660
                                                                       Page 70

                                                                     97047_1
<removed-date>
              t t t gat gaag ggaaaagt t g gc ac t c agaa ac aaagaac t c c t t gat gc a ggat agggat                  720
              gc t gc at c t g c t c gggc c t g gc c t aaaat g c ac ac agt c a at ggt t at gt aaac aggt c t         780
              c t gc c aggt c t gat t ggat g c c ac aggaaa t c agt c t at t ggc at gt gat t ggaat gggc              840
<removed-apn>
              ac c ac t c c t g aagt gc ac t c aat at t c c t c gaaggt c ac a c at t t c t t gt gaggaac c at        900
              c gc c aggc gt c c t t ggaaat c t c gc c aat a ac t t t c c t t a c t gc t c aaac ac t c t t gat g    960
              gac c t t ggac agt t t c t ac t gt t t t gt c at at c t c t t c c c ac c aac at ga t ggc at ggaa     1020
              gc t t at gt c a aagt agac ag c t gt c c agag gaac c c c aac t ac gaat gaa aaat aat gaa              1080
              gaagc ggaag ac t at gat ga t gat c t t ac t gat t c t gaaa t ggat gt ggt c aggt t t gat              1140
              gat gac aac t c t c c t t c c t t t at c c aaat t c gc t c agt t g c c aagaagc a t c c t aaaac t     1200
              t gggt ac at t ac at t gc t gc t gaagaggag gac t gggac t at gc t c c c t t agt c c t c gc c          1260
              c c c gat gac a gaagt t at aa aagt c aat at t t gaac aat g gc c c t c agc g gat t ggt agg            1320
              aagt ac aaaa aagt c c gat t t at ggc at ac ac agat gaaa c c t t t aagac t c gt gaagc t               1380
              at t c agc at g aat c aggaat c t t gggac c t t t ac t t t at g gggaagt t gg agac ac ac t g           1440
              t t gat t at at t t aagaat c a agc aagc aga c c at at aac a t c t ac c c t c a c ggaat c ac t        1500
              gat gt c c gt c c t t t gt at t c aaggagat t a c c aaaaggt g t aaaac at t t gaaggat t t t            1560
              c c aat t c t gc c aggagaaat at t c aaat at aaat ggac ag t gac t gt aga agat gggc c a                1620
              ac t aaat c ag at c c t c ggt g c c t gac c c gc t at t ac t c t a gt t t c gt t aa t at ggagaga     1680
                                                                     Page 71

                                                                    97047_1
<removed-date>
              gat c t agc t t c aggac t c at t ggc c c t c t c c t c at c t gc t ac aaagaat c t gt agat c aa      1740
              agaggaaac c agat aat gt c agac aagagg aat gt c at c c t gt t t t c t gt at t t gat gag              1800
              aac c gaagc t ggt ac c t c ac agagaat at a c aac gc t t t c t c c c c aat c c agc t ggagt g         1860
<removed-apn>
              c agc t t gagg at c c agagt t c c aagc c t c c aac at c at gc ac agc at c aa t ggc t at gt t        1920
              t t t gat agt t t gc agt t gt c agt t t gt t t g c at gaggt gg c at ac t ggt a c at t c t aagc      1980
              at t ggagc ac agac t gac t t c c t t t c t gt c t t c t t c t c t g gat at ac c t t c aaac ac aaa   2040
              at ggt c t at g aagac ac ac t c ac c c t at t c c c at t c t c ag gagaaac t gt c t t c at gt c g    2100
              at ggaaaac c c aggt c t at g gat t c t gggg t gc c ac aac t c agac t t t c g gaac agaggc            2160
              at gac c gc c t t ac t gaaggt t t c t agt t gt gac aagaac a c t ggt gat t a t t ac gaggac           2220
              agt t at gaag at at t t c agc at ac t t gc t g agt aaaaac a at gc c at t ga ac c aagaagc            2280
              t t c t c t c aaa ac c c ac c agt c t t gaaac gc c at c aac ggg aaat aac t c g t ac t ac t c t t    2340
              c agt c agat c aagaggaaat t gac t at gat gat ac c at at c agt t gaaat gaagaaggaa                    2400
              gat t t t gac a t t t at gat ga ggat gaaaat c agagc c c c c gc agc t t t c a aaagaaaac a            2460
              c gac ac t at t t t at t gc t gc agt ggagagg c t c t gggat t at gggat gag t agc t c c c c a         2520
              c at gt t c t aa gaaac agggc t c agagt ggc agt gt c c c t c agt t c aagaa agt t gt t t t c          2580
              c aggaat t t a c t gat ggc t c c t t t ac t c ag c c c t t at ac c gt ggagaac t aaat gaac at        2640
              t t gggac t c c t ggggc c at a t at aagagc a gaagt t gaag at aat at c at ggt aac t t t c            2700
                                                                    Page 72

                                                                     97047_1
<removed-date>
              agaaat c agg c c t c t c gt c c c t at t c c t t c t at t c t agc c t t at t t c t t a t gaggaagat   2760
              c agaggc aag gagc agaac c t agaaaaaac t t t gt c aagc c t aat gaaac c aaaac t t ac                   2820
              t t t t ggaaag t gc aac at c a t at ggc ac c c ac t aaagat g agt t t gac t g c aaagc c t gg          2880
<removed-apn>
              gc t t at t t c t c t gat gt t ga c c t ggaaaaa gat gt gc ac t c aggc c t gat t ggac c c c t t       2940
              c t ggt c t gc c ac ac t aac ac ac t gaac c c t gc t c at ggga gac aagt gac agt ac aggaa             3000
              t t t gc t c t gt t t t t c ac c at c t t t gat gag ac c aaaagc t ggt ac t t c ac t gaaaat at g      3060
              gaaagaaac t gc agggc t c c c t gc aat at c c agat ggaag at c c c ac t t t t aaagagaat                3120
              t at c gc t t c c at gc aat c aa t ggc t ac at a at ggat ac ac t ac c t ggc t t agt aat ggc t        3180
              c aggat c aaa ggat t c gat g gt at c t gc t c agc at gggc a gc aat gaaaa c at c c at t c t           3240
              at t c at t t c a gt ggac at gt gt t c ac t gt a c gaaaaaaag aggagt at aa aat ggc ac t g             3300
              t ac aat c t c t at c c aggt gt t t t t gagac a gt ggaaat gt t ac c at c c aa agc t ggaat t          3360
              t ggc gggt gg aat gc c t t at t ggc gagc at c t ac at gc t g ggat gagc ac ac t t t t t c t g         3420
              gt gt ac agc a at aagt gt c a gac t c c c c t g ggaat ggc t t c t ggac ac at t agagat t t t          3480
              c agat t ac ag c t t c aggac a at at ggac ag t gggc c c c aa agc t ggc c ag ac t t c at t at         3540
              t c c ggat c aa t c aat gc c t g gagc ac c aag gagc c c t t t t c t t ggat c aa ggt ggat c t g       3600
              t t ggc ac c aa t gat t at t c a c ggc at c aag ac c c agggt g c c c gt c agaa gt t c t c c agc      3660
              c t c t ac at c t c t c agt t t at c at c at gt at agt c t t gat g ggaagaagt g gc agac t t at        3720
                                                                     Page 73

                                                                      97047_1
<removed-date>
              c gaggaaat t c c ac t ggaac c t t aat ggt c t t c t t t ggc a at gt ggat t c at c t gggat a           3780
              aaac ac aat a t t t t t aac c c t c c aat t at t gc t c gat ac a t c c gt t t gc a c c c aac t c at   3840
              t at agc at t c gc agc ac t c t t c gc at ggag t t gat gggc t gt gat t t aaa t agt t gc agc           3900
<removed-apn>
              at gc c at t gg gaat ggagag t aaagc aat a t c agat gc ac agat t ac t gc t t c at c c t ac             3960
              t t t ac c aat a t gt t t gc c ac c t ggt c t c c t t c aaaagc t c gac t t c ac c t c c aagggagg      4020
              agt aat gc c t ggagac c t c a ggt gaat aat c c aaaagagt ggc t gc aagt ggac t t c c ag                 4080
              aagac aat ga aagt c ac agg agt aac t ac t c agggagt aa aat c t c t gc t t ac c agc at g               4140
              t at gt gaagg agt t c c t c at c t c c agc agt c aagat ggc c at c agt ggac t c t c t t t t t t        4200
              c agaat ggc a aagt aaaggt t t t t c aggga aat c aagac t c c t t c ac ac c t gt ggt gaac               4260
              t c t c t agac c c ac c gt t ac t gac t c gc t ac c t t c gaat t c ac c c c c agag t t gggt gc ac     4320
              c agat t gc c c t gaggat gga ggt t c t gggc t gc gaggc ac aggac c t c t a c                           4371
              <210>     8
              <211>     25
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     c l eav age s i t e
              <400>     8
                                                                      Page 74

                                                      97047_1
<removed-date>
              Thr Leu As p Pr o Ar g Ser Phe Leu Leu Ar g As n Pr o As n As p Ly s Ty r
              1                     5                       10                 15
              Gl u Pr o Phe Tr p Gl u As p Gl u Gl u Ly s
                             20                      25
<removed-apn>
              <210>   9
              <211>   4
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   9
              Ar g Ar g Ar g Ar g
              1
              <210>   10
              <211>   6
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   10
              Ar g Ly s Ar g Ar g Ly s Ar g
              1                     5
                                                            Page 75

                                                        97047_1
<removed-date>
              <210>   11
              <211>   5
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
<removed-apn>
              <220>
              <223>   c l eav age s i t e
              <400>   11
              Ar g Ar g Ar g Ar g Ser
              1                    5
              <210>   12
              <211>   9
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   12
              Thr Gl n Ser Phe As n As p Phe Thr Ar g
              1                    5
              <210>   13
              <211>   10
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
                                                        Page 76

                                                         97047_1
<removed-date>
              <220>
              <223>   c l eav age s i t e
              <400>   13
              Ser Val Ser Gl n Thr Ser Ly s Leu Thr Ar g
<removed-apn>
              1                    5                    10
              <210>   14
              <211>   10
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   14
              As p Phe Leu Al a Gl u Gl y Gl y Gl y Val Ar g
              1                    5                    10
              <210>   15
              <211>   7
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   15
                                                         Page 77

                                                    97047_1
<removed-date>
              Thr Thr Ly s I l e Ly s Pr o Ar g
              1                    5
              <210>   16
              <211>   5
              <212>   PRT
<removed-apn>
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   16
              Leu Val Pr o Ar g Gl y
              1                    5
              <210>   17
              <211>   5
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   17
              Al a Leu Ar g Pr o Ar g
              1                    5
              <210>   18
              <211>   7
                                                    Page 78

                                                    97047_1
<removed-date>
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   18
<removed-apn>
              Ly s Leu Thr Ar g Al a Gl u Thr
              1                    5
              <210>   19
              <211>   7
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   19
              As p Phe Thr Ar g Val Val Gl y
              1                    5
              <210>   20
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
                                                    Page 79

                                                      97047_1
<removed-date>
              <400>   20
              Thr Met Thr Ar g I l e Val Gl y Gl y
              1                    5
              <210>   21
<removed-apn>
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   21
              Ser Pr o Phe Ar g Ser Thr Gl y Gl y
              1                    5
              <210>   22
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   22
              Leu Gl n Val Ar g I l e Val Gl y Gl y
              1                    5
                                                      Page 80

                                                       97047_1
<removed-date>
              <210>   23
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
<removed-apn>
              <400>   23
              Pr o Leu Gl y Ar g I l e Val Gl y Gl y
              1                    5
              <210>   24
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   24
              I l e Gl u Gl y Ar g Thr Val Gl y Gl y
              1                    5
              <210>   25
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
                                                       Page 81

                                                     97047_1
<removed-date>
              <223>   c l eav age s i t e
              <400>   25
              Leu Thr Pr o Ar g Ser Leu Leu Val
              1                    5
<removed-apn>
              <210>   26
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   26
              Leu Gl y Pr o Val Ser Gl y Val Pr o
              1                    5
              <210>   27
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   27
              Val Al a Gl y As p Ser Leu Gl u Gl u
              1                    5
                                                     Page 82

                                                       97047_1
<removed-date>
              <210>   28
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
<removed-apn>
              <220>
              <223>   c l eav age s i t e
              <400>   28
              Gl y Pr o Al a Gl y Leu Gl y Gl y Al a
              1                    5
              <210>   29
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   29
              Gl y Pr o Al a Gl y Leu Ar g Gl y Al a
              1                    5
              <210>   30
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
                                                       Page 83

                                                     97047_1
<removed-date>
              <220>
              <223>   c l eav age s i t e
              <400>   30
              Al a Pr o Leu Gl y Leu Ar g Leu Ar g
<removed-apn>
              1                    5
              <210>   31
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   31
              Pr o Al a Leu Pr o Leu Val Al a Gl n
              1                    5
              <210>   32
              <211>   7
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   32
                                                     Page 84

                                                        97047_1
<removed-date>
              Gl u As n Leu Ty r Phe Gl n Gl y
              1                    5
              <210>   33
              <211>   8
              <212>   PRT
<removed-apn>
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   33
              As p As p As p Ly s I l e Val Gl y Gl y
              1                    5
              <210>   34
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   34
              Leu Gl u Val Leu Phe Gl n Gl y Pr o
              1                    5
              <210>   35
              <211>   8
                                                        Page 85

                                                              97047_1
<removed-date>
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   35
<removed-apn>
              Leu Pr o Ly s Thr Gl y Ser Gl u Ser
              1                    5
              <210>   36
              <211>   42
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   AE42
              <400>   36
              Gl y Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y
              1                    5                          10                15
              Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a
                             20                          25                30
              Thr Ser Gl y Ser Gl u Thr Pr o Al a Ser Ser
                       35                           40
                                                              Page 86

                                                                97047_1
<removed-date>
              <210>     37
              <211>     143
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     AE144
<removed-apn>
              <400>     37
              Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u
              1                      5                          10                       15
              Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y
                                20                         25                       30
              Ser Gl u Thr Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u
                         35                           40                       45
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Gl u Pr o
                   50                           55                        60
              Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y
              65                          70                         75                       80
              Ser Gl u Thr Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o
                                     85                         90                       95
                                                                Page 87

                                                        97047_1
<removed-date>
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u
                                100                         105                         110
              Ser Al a Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser
                         115                          120                         125
<removed-apn>
              Gl u Thr Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                  130                           135                         140
              <210>     38
              <211>     144
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     AG144
              <400>     38
              Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Ser Ser Thr
              1                       5                           10                          15
              Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr
                                20                          25                          30
              Gl y Thr Gl y Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o
                         35                           40                          45
                                                                  Page 88

                                                       97047_1
<removed-date>
              Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o
                   50                            55                          60
              Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a
              65                            70                          75                          80
<removed-apn>
              Thr Gl y Ser Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o
                                       85                          90                          95
              Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Ser Ser Pr o
                                 100                         105                         110
              Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a
                          115                          120                         125
              Ser Ser Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o
                   130                           135                         140
              <210>      39
              <211>      288
              <212>      PRT
              <213>      Ar t i f i c i al Sequenc e
              <220>
              <223>      AE288
              <400>      39
                                                                   Page 89

                                                        97047_1
<removed-date>
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o
              1                      5                           10                          15
              Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                               20                          25                          30
<removed-apn>
              Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o
                         35                          40                          45
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr
                   50                          55                          60
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr
              65                          70                          75                          80
              Ser Thr Gl u Gl u Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o
                                     85                          90                          95
              Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u
                               100                         105                         110
              Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr
                         115                         120                         125
              Ser Thr Gl u Gl u Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u
                   130                         135                         140
                                                                 Page 90

                                                                    97047_1
<removed-date>
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u
              145                           150                           155                           160
              Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
<removed-apn>
                                      165                           170                           175
              Gl u Ser Gl y Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o
                                180                           185                           190
              Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Ser Gl u Pr o
                          195                           200                           205
              Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr
                    210                           215                           220
              Ser Thr Gl u Gl u Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
              225                           230                           235                           240
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Gl u Pr o
                                      245                           250                           255
              Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                                260                           265                           270
                                                                    Page 91

                                                        97047_1
<removed-date>
              Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                         275                          280                       285
              <210>     40
              <211>     288
              <212>     PRT
<removed-apn>
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     AG288
              <400>     40
              Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a Ser
              1                      5                           10                        15
              Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Thr Pr o Gl y Ser Gl y Thr
                                20                          25                        30
              Al a Ser Ser Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser
                         35                           40                        45
              Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Ser Ser
                   50                           55                         60
              Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Thr Pr o Gl y Ser Gl y Thr
              65                          70                          75                        80
                                                                 Page 92

                                                      97047_1
<removed-date>
              Al a Ser Ser Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser
                                      85                            90                            95
              Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser
                                100                           105                           110
<removed-apn>
              Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Ser Ser Pr o Ser Al a Ser
                          115                           120                           125
              Thr Gl y Thr Gl y Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser
                    130                           135                           140
              Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Ser Ser
              145                           150                           155                           160
              Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Pr o Ser Al a Ser
                                      165                           170                           175
              Thr Gl y Thr Gl y Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y
                                180                           185                           190
              Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a Ser
                          195                           200                           205
              Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y
                    210                           215                           220
                                                                    Page 93

                                                                97047_1
<removed-date>
              Al a Thr Gl y Ser Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y
              225                         230                         235                     240
              Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Ser Ser
<removed-apn>
                                    245                         250                     255
              Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Thr Pr o Gl y Ser Gl y Thr
                              260                         265                     270
              Al a Ser Ser Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser
                       275                          280                     285
              <210>   41
              <211>   576
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   AE576
              <400>   41
              Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Gl u
              1                     5                           10                      15
              Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u
                              20                          25                      30
                                                                Page 94

                                                                   97047_1
<removed-date>
              Gl y Ser Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u
                          35                           40                           45
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr
<removed-apn>
                    50                           55                           60
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
              65                           70                           75                           80
              Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o
                                      85                           90                           95
              Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Ser Pr o Al a
                                100                          105                          110
              Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Gl u Ser Al a Thr Pr o
                          115                          120                          125
              Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                    130                          135                          140
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Pr o Al a
              145                          150                          155                          160
                                                                   Page 95

                                                        97047_1
<removed-date>
              Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Thr Gl u Pr o Ser Gl u
                                      165                           170                           175
              Gl y Ser Al a Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                                180                           185                           190
<removed-apn>
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr
                          195                           200                           205
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                    210                           215                           220
              Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o
              225                           230                           235                           240
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr
                                      245                           250                           255
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                                260                           265                           270
              Gl u Ser Gl y Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o
                          275                           280                           285
              Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Gl u
                    290                           295                           300
                                                                    Page 96

                                                                    97047_1
<removed-date>
              Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y
              305                           310                           315                           320
              Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o
<removed-apn>
                                      325                           330                           335
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr
                                340                           345                           350
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u
                          355                           360                           365
              Gl y Ser Al a Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                    370                           375                           380
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr
              385                           390                           395                           400
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr
                                      405                           410                           415
              Ser Thr Gl u Gl u Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                                420                           425                           430
                                                                    Page 97

                                                        97047_1
<removed-date>
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o
                          435                           440                           445
              Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                    450                           455                           460
<removed-apn>
              Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o
              465                           470                           475                           480
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr
                                      485                           490                           495
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                                500                           505                           510
              Gl u Ser Gl y Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u
                          515                           520                           525
              Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Ser Pr o Al a
                    530                           535                           540
              Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Gl u Ser Al a Thr Pr o
              545                           550                           555                           560
              Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                                      565                           570                           575
                                                                    Page 98

                                                                97047_1
<removed-date>
              <210>     42
              <211>     576
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
<removed-apn>
              <220>
              <223>     AG576
              <400>     42
              Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Ser Ser
              1                      5                          10                       15
              Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Pr o Ser Al a Ser
                                20                         25                       30
              Thr Gl y Thr Gl y Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y
                         35                           40                       45
              Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser
                   50                           55                        60
              Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser
              65                          70                         75                       80
              Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser
                                     85                         90                       95
                                                                Page 99

                                                                    97047_1
<removed-date>
              Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Thr Pr o
                                100                           105                           110
              Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser
<removed-apn>
                          115                           120                           125
              Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser
                    130                           135                           140
              Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Ser Ser
              145                           150                           155                           160
              Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Thr Pr o Gl y Ser Gl y Thr
                                      165                           170                           175
              Al a Ser Ser Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser
                                180                           185                           190
              Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a Ser
                          195                           200                           205
              Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y
                    210                           215                           220
                                                                    Page 100

                                                       97047_1
<removed-date>
              Al a Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser
              225                           230                           235                           240
              Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Thr Pr o
                                      245                           250                           255
<removed-apn>
              Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y
                                260                           265                           270
              Al a Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser
                          275                           280                           285
              Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser
                    290                           295                           300
              Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Al a Ser Pr o Gl y Thr Ser
              305                           310                           315                           320
              Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser
                                      325                           330                           335
              Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Al a Ser
                                340                           345                           350
              Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser
                          355                           360                           365
                                                                    Page 101

                                                                    97047_1
<removed-date>
              Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser
                    370                           375                           380
              Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Thr Pr o
<removed-apn>
              385                           390                           395                           400
              Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y
                                      405                           410                           415
              Al a Thr Gl y Ser Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser
                                420                           425                           430
              Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Thr Pr o
                          435                           440                           445
              Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y
                    450                           455                           460
              Al a Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser
              465                           470                           475                           480
              Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Ser Ser
                                      485                           490                           495
                                                                    Page 102

                                                        97047_1
<removed-date>
              Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Al a Ser Pr o Gl y Thr Ser
                                  500                           505                           510
              Ser Thr Gl y Ser Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser
                           515                            520                           525
<removed-apn>
              Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser
                    530                             535                           540
              Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Ser Ser Pr o Ser Al a Ser
              545                             550                           555                           560
              Thr Gl y Thr Gl y Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser
                                        565                           570                           575
              <210>       43
              <211>       864
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
              <220>
              <223>       AE864
              <400>       43
              Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Gl u
              1                         5                             10                            15
                                                                      Page 103

                                                         97047_1
<removed-date>
              Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u
                                20                           25                           30
              Gl y Ser Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u
                          35                           40                           45
<removed-apn>
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr
                    50                           55                           60
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
              65                           70                           75                           80
              Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o
                                      85                           90                           95
              Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Ser Pr o Al a
                                100                          105                          110
              Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Gl u Ser Al a Thr Pr o
                          115                          120                          125
              Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                    130                          135                          140
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Pr o Al a
              145                          150                          155                          160
                                                                   Page 104

                                                                    97047_1
<removed-date>
              Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Thr Gl u Pr o Ser Gl u
                                      165                           170                           175
              Gl y Ser Al a Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
<removed-apn>
                                180                           185                           190
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr
                          195                           200                           205
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                    210                           215                           220
              Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o
              225                           230                           235                           240
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr
                                      245                           250                           255
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                                260                           265                           270
              Gl u Ser Gl y Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o
                          275                           280                           285
                                                                    Page 105

                                                        97047_1
<removed-date>
              Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Gl u
                    290                           295                           300
              Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y
              305                           310                           315                           320
<removed-apn>
              Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o
                                      325                           330                           335
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr
                                340                           345                           350
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u
                          355                           360                           365
              Gl y Ser Al a Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                    370                           375                           380
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr
              385                           390                           395                           400
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr
                                      405                           410                           415
              Ser Thr Gl u Gl u Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                                420                           425                           430
                                                                    Page 106

                                                                    97047_1
<removed-date>
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o
                          435                           440                           445
              Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
<removed-apn>
                    450                           455                           460
              Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o
              465                           470                           475                           480
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr
                                      485                           490                           495
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                                500                           505                           510
              Gl u Ser Gl y Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u
                          515                           520                           525
              Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Ser Pr o Al a
                    530                           535                           540
              Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Gl u Ser Al a Thr Pr o
              545                           550                           555                           560
                                                                    Page 107

                                                        97047_1
<removed-date>
              Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                                      565                           570                           575
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o
                                580                           585                           590
<removed-apn>
              Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                          595                           600                           605
              Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o
                    610                           615                           620
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr
              625                           630                           635                           640
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr
                                      645                           650                           655
              Ser Thr Gl u Gl u Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o
                                660                           665                           670
              Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u
                          675                           680                           685
              Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr
                    690                           695                           700
                                                                    Page 108

                                                                    97047_1
<removed-date>
              Ser Thr Gl u Gl u Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u
              705                           710                           715                           720
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u
<removed-apn>
                                      725                           730                           735
              Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                                740                           745                           750
              Gl u Ser Gl y Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o
                          755                           760                           765
              Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Ser Gl u Pr o
                    770                           775                           780
              Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr
              785                           790                           795                           800
              Ser Thr Gl u Gl u Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                                      805                           810                           815
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Gl u Pr o
                                820                           825                           830
                                                                    Page 109

                                                        97047_1
<removed-date>
              Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                         835                          840                     845
              Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                  850                           855                     860
<removed-apn>
              <210>     44
              <211>     864
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     AG864
              <400>     44
              Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Ser Ser Pr o
              1                      5                           10                      15
              Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr
                                20                          25                      30
              Gl y Thr Gl y Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o
                         35                           40                      45
              Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Pr o
                  50                            55                      60
                                                                 Page 110

                                                        97047_1
<removed-date>
              Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
              65                            70                            75                            80
              Thr Gl y Ser Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o
                                      85                            90                            95
<removed-apn>
              Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Thr Pr o Gl y
                                100                           105                           110
              Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
                          115                           120                           125
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                    130                           135                           140
              Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Ser Ser Thr
              145                           150                           155                           160
              Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
                                      165                           170                           175
              Thr Gl y Ser Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o
                                180                           185                           190
              Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Pr o
                          195                           200                           205
                                                                    Page 111

                                                                    97047_1
<removed-date>
              Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr
                    210                           215                           220
              Gl y Thr Gl y Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o
<removed-apn>
              225                           230                           235                           240
              Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Al a Ser Pr o
                                      245                           250                           255
              Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
                                260                           265                           270
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                          275                           280                           285
              Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Al a Ser Pr o
                    290                           295                           300
              Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
              305                           310                           315                           320
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                                      325                           330                           335
                                                                    Page 112

                                                       97047_1
<removed-date>
              Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Thr Pr o Gl y
                                340                           345                           350
              Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
                          355                           360                           365
<removed-apn>
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                    370                           375                           380
              Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Ser Ser Thr
              385                           390                           395                           400
              Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a
                                      405                           410                           415
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                                420                           425                           430
              Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Ser Ser Thr
                          435                           440                           445
              Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a
                    450                           455                           460
              Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o
              465                           470                           475                           480
                                                                    Page 113

                                                                    97047_1
<removed-date>
              Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Al a Ser Pr o
                                      485                           490                           495
              Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
<removed-apn>
                                500                           505                           510
              Thr Gl y Ser Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o
                          515                           520                           525
              Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o
                    530                           535                           540
              Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
              545                           550                           555                           560
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                                      565                           570                           575
              Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Ser Ser Thr
                                580                           585                           590
              Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a
                          595                           600                           605
                                                                    Page 114

                                                      97047_1
<removed-date>
              Ser Ser Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o
                    610                           615                           620
              Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Ser Ser Thr
              625                           630                           635                           640
<removed-apn>
              Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a
                                      645                           650                           655
              Thr Gl y Ser Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o
                                660                           665                           670
              Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Al a Ser Pr o
                          675                           680                           685
              Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a
                    690                           695                           700
              Ser Ser Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o
              705                           710                           715                           720
              Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Ser Ser Pr o
                                      725                           730                           735
              Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
                                740                           745                           750
                                                                    Page 115

                                                                        97047_1
<removed-date>
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                              755                           760                           765
              Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Pr o
<removed-apn>
                    770                               775                           780
              Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
              785                               790                           795                           800
              Thr Gl y Ser Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o
                                          805                           810                           815
              Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Ser Ser Thr
                                    820                           825                           830
              Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a
                              835                           840                           845
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                    850                               855                           860
              <210>       45
              <211>       9
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
                                                                        Page 116

                                                        97047_1
<removed-date>
              <220>
              <223>   c l eav age s i t e
              <400>   45
              Thr Gl n Ser Phe As n As p Phe Thr Ar g
<removed-apn>
              1                    5
              <210>   46
              <211>   10
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   46
              Ser Val Ser Gl n Thr Ser Ly s Leu Thr Ar g
              1                    5                    10
              <210>   47
              <211>   10
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   47
                                                        Page 117

                                                         97047_1
<removed-date>
              As p Phe Leu Al a Gl u Gl y Gl y Gl y Val Ar g
              1                    5                   10
              <210>   48
              <211>   7
              <212>   PRT
<removed-apn>
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   48
              Thr Thr Ly s I l e Ly s Pr o Ar g
              1                    5
              <210>   49
              <211>   5
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   49
              Leu Val Pr o Ar g Gl y
              1                    5
              <210>   50
              <211>   5
                                                       Page 118

                                                             97047_1
<removed-date>
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   50
<removed-apn>
              Al a Leu Ar g Pr o Ar g
              1                       5
              <210>   51
              <211>   5
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   s or t as e r ec ogni t i on mot i f
              <220>
              <221>   mi s c _f eat ur e
              <222>   ( 3) . . ( 3)
              <223>   Xaa c an be any nat ur al l y oc c ur r i ng ami no ac i d
              <400>   51
              Leu Pr o Xaa Thr Gl y
              1                       5
              <210>   52
              <211>   11
                                                             Page 119

                                                        97047_1
<removed-date>
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   pol y pept i de
              <400>   52
<removed-apn>
              Pr o Ly s As n Ser Ser Met I l e Ser As n Thr Pr o
              1                   5                    10
              <210>   53
              <211>   7
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   pol y pept i de
              <400>   53
              Hi s Gl n Ser Leu Gl y Thr Gl n
              1                   5
              <210>   54
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   pol y pept i de
                                                        Page 120

                                                        97047_1
<removed-date>
              <400>   54
              Hi s Gl n As n Leu Ser As p Gl y Ly s
              1                   5
              <210>   55
<removed-apn>
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   pol y pept i de
              <400>   55
              Hi s Gl n As n I l e Ser As p Gl y Ly s
              1                   5
              <210>   56
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   pol y pept i de
              <400>   56
              Val I l e Ser Ser Hi s Leu Gl y Gl n
              1                   5
                                                        Page 121

                                                        97047_1
<removed-date>
              <210>   57
              <211>   4
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   l i nk er
<removed-apn>
              <220>
              <221>   REPEAT
              <222>   ( 1) . . ( 4)
              <223>   Repeat f r om 1 t o 100 t i mes
              <400>   57
              Gl y Gl y Gl y Ser
              1
              <210>   58
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   l i nk er
              <220>
              <221>   REPEAT
              <222>   ( 1) . . ( 3)
              <223>   May be r epeat ed 1 t o 100 t i mes
                                                        Page 122

                                                        97047_1
<removed-date>
              <220>
              <221>   REPEAT
              <222>   ( 4) . . ( 8)
              <223>   May be r epeat ed 1 t o 100 t i mes
              <400>   58
<removed-apn>
              Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser
              1                       5
              <210>   59
              <211>   7
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   l i nk er
              <400>   59
              Ser Gl y Gl y Ser Gl y Gl y Ser
              1                       5
              <210>   60
              <211>   15
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   l i nk er
              <400>   60
                                                        Page 123

                                                         97047_1
<removed-date>
              Gl y Gl y Ser Gl y Gl y Ser Gl y Gl y Ser Gl y Gl y Ser Gl y Gl y Gl y
              1                      5                   10                      15
              <210>      61
              <211>      16
<removed-apn>
              <212>      PRT
              <213>      Ar t i f i c i al Sequenc e
              <220>
              <223>      l i nk er
              <400>      61
              Gl y Gl y Ser Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser
              1                      5                   10                      15
              <210>      62
              <211>      18
              <212>      PRT
              <213>      Ar t i f i c i al Sequenc e
              <220>
              <223>      l i nk er
              <400>      62
              Gl y Gl y Ser Gl y Gl y Ser Gl y Gl y Ser Gl y Gl y Ser Gl y Gl y Ser Gl y
              1                      5                   10                      15
              Gl y Ser
                                                         Page 124

                                                          97047_1
<removed-date>   <210>   63
              <211>   15
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
<removed-apn>
              <220>
              <223>   l i nk er
              <400>   63
              Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser
              1                       5                  10                      15
              <210>   64
              <211>   5
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   l i nk er
              <220>
              <221>   REPEAT
              <222>   ( 1) . . ( 5)
              <223>   May be r epeat ed 1- 20 t i mes
              <400>   64
              Gl y Gl y Gl y Gl y Ser
                                                         Page 125

                                                    97047_1
<removed-date>
              1                       5
              <210>   65
              <211>   7
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
<removed-apn>
              <220>
              <223>   c l eav age s i t e
              <220>
              <221>   MI SC_FEATURE
              <222>   ( 4) . . ( 5)
              <223>   Cl eav age s i t e
              <400>   65
              Ly s Leu Thr Ar g Al a Gl u Thr
              1                       5
              <210>   66
              <211>   7
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <220>
              <221>   MI SC_FEATURE
                                                    Page 126

                                                     97047_1
<removed-date>
              <222>   ( 4) . . ( 5)
              <223>   Cl eav age s i t e
              <400>   66
              As p Phe Thr Ar g Val Val Gl y
              1                       5
<removed-apn>
              <210>   67
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <220>
              <221>   MI SC_FEATURE
              <222>   ( 4) . . ( 5)
              <223>   Cl eav age Si t e
              <400>   67
              Thr Met Thr Ar g I l e Val Gl y Gl y
              1                       5
              <210>   68
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
                                                     Page 127

                                                      97047_1
<removed-date>
              <220>
              <223>   c l eav age s i t e
              <220>
              <221>   MI SC_FEATURE
              <222>   ( 4) . . ( 5)
<removed-apn>
              <223>   Cl eav age s i t e
              <400>   68
              Ser Pr o Phe Ar g Ser Thr Gl y Gl y
              1                       5
              <210>   69
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <220>
              <221>   MI SC_FEATURE
              <222>   ( 4) . . ( 5)
              <223>   Cl eav age s i t e
              <400>   69
              Leu Gl n Val Ar g I l e Val Gl y Gl y
              1                       5
                                                      Page 128

                                                       97047_1
<removed-date>
              <210>   70
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
<removed-apn>
              <223>   c l eav age s i t e
              <220>
              <221>   MI SC_FEATURE
              <222>   ( 4) . . ( 5)
              <223>   Cl eav age s i t e
              <400>   70
              Pr o Leu Gl y Ar g I l e Val Gl y Gl y
              1                       5
              <210>   71
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <220>
              <221>   MI SC_FEATURE
              <222>   ( 4) . . ( 5)
              <223>   Cl eav age s i t e
                                                       Page 129

                                                       97047_1
<removed-date>
              <400>   71
              I l e Gl u Gl y Ar g Thr Val Gl y Gl y
              1                       5
<removed-apn>
              <210>   72
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <220>
              <221>   MI SC_FEATURE
              <222>   ( 4) . . ( 5)
              <223>   c l eav age s i t e
              <400>   72
              Leu Thr Pr o Ar g Ser Leu Leu Val
              1                       5
              <210>   73
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
                                                       Page 130

                                                     97047_1
<removed-date>
              <220>
              <221>   MI SC_FEATURE
              <222>   ( 4) . . ( 5)
              <223>   c l eav age s i t e
<removed-apn>
              <400>   73
              Leu Gl y Pr o Val Ser Gl y Val Pr o
              1                       5
              <210>   74
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <220>
              <221>   MI SC_FEATURE
              <222>   ( 4) . . ( 5)
              <223>   Cl eav age s i t e
              <400>   74
              Val Al a Gl y As p Ser Leu Gl u Gl u
              1                       5
              <210>   75
                                                     Page 131

                                                       97047_1
<removed-date>
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
<removed-apn>
              <220>
              <221>   MI SC_FEATURE
              <222>   ( 4) . . ( 5)
              <223>   Cl eav age s i t e
              <400>   75
              Gl y Pr o Al a Gl y Leu Gl y Gl y Al a
              1                       5
              <210>   76
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <220>
              <221>   MI SC_FEATURE
              <222>   ( 4) . . ( 5)
              <223>   Cl eav age s i t e
              <400>   76
                                                       Page 132

                                                       97047_1
<removed-date>
              Gl y Pr o Al a Gl y Leu Ar g Gl y Al a
              1                       5
              <210>   77
              <211>   8
<removed-apn>
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <220>
              <221>   MI SC_FEATURE
              <222>   ( 4) . . ( 5)
              <223>   Cl eav age s i t e
              <400>   77
              Al a Pr o Leu Gl y Leu Ar g Leu Ar g
              1                       5
              <210>   78
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
                                                       Page 133

                                                     97047_1
<removed-date>
              <220>
              <221>   MI SC_FEATURE
              <222>   ( 4) . . ( 5)
              <223>   Cl eav age s i t e
              <400>   78
<removed-apn>
              Pr o Al a Leu Pr o Leu Val Al a Gl n
              1                       5
              <210>   79
              <211>   7
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <220>
              <221>   MI SC_FEATURE
              <222>   ( 6) . . ( 7)
              <223>   Cl eav age s i t e
              <400>   79
              Gl u As n Leu Ty r Phe Gl n Gl y
              1                       5
              <210>   80
              <211>   8
              <212>   PRT
                                                     Page 134

                                                        97047_1
<removed-date>
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <220>
<removed-apn>
              <221>   MI SC_FEATURE
              <222>   ( 4) . . ( 5)
              <223>   Cl eav age s i t e
              <400>   80
              As p As p As p Ly s I l e Val Gl y Gl y
              1                       5
              <210>   81
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <220>
              <221>   MI SC_FEATURE
              <222>   ( 6) . . ( 7)
              <223>   Cl eav age s i t e
              <400>   81
              Leu Gl u Val Leu Phe Gl n Gl y Pr o
                                                        Page 135

                                                        97047_1
<removed-date>
              1                       5
              <210>   82
              <211>   8
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
<removed-apn>
              <220>
              <223>   c l eav age s i t e
              <220>
              <221>   MI SC_FEATURE
              <222>   ( 4) . . ( 5)
              <223>   Cl eav age s i t e
              <400>   82
              Leu Pr o Ly s Thr Gl y Ser Gl u Ser
              1                       5
              <210>   83
              <211>   9
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   83
              Thr Gl n Ser Phe As n As p Phe Thr Ar g
                                                        Page 136

                                                         97047_1
<removed-date>
              1                    5
              <210>   84
              <211>   10
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
<removed-apn>
              <220>
              <223>   c l eav age s i t e
              <400>   84
              Ser Val Ser Gl n Thr Ser Ly s Leu Thr Ar g
              1                    5                    10
              <210>   85
              <211>   10
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   85
              As p Phe Leu Al a Gl u Gl y Gl y Gl y Val Ar g
              1                    5                    10
              <210>   86
              <211>   7
              <212>   PRT
                                                        Page 137

                                                    97047_1
<removed-date>
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   86
<removed-apn>
              Thr Thr Ly s I l e Ly s Pr o Ar g
              1                    5
              <210>   87
              <211>   5
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   87
              Leu Val Pr o Ar g Gl y
              1                    5
              <210>   88
              <211>   10
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   c l eav age s i t e
              <400>   88
                                                    Page 138

                                                                97047_1
<removed-date>
              Al a Leu Ar g Pr o Ar g Val Val Gl y Gl y Al a
              1                       5                         10
              <210>     89
              <211>     1896
<removed-apn>
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     FVI I I 198
              <400>     89
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
              1                       5                         10                       15
              Cy s Phe Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser
                               20                          25                       30
              Tr p As p Ty r Met Gl n Ser As p Leu Gl y Gl u Leu Pr o Val As p Al a Ar g
                         35                           40                       45
              Phe Pr o Pr o Ar g Val Pr o Ly s Ser Phe Pr o Phe As n Thr Ser Val Val
                   50                           55                        60
              Ty r Ly s Ly s Thr Leu Phe Val Gl u Phe Thr As p Hi s Leu Phe As n I l e
              65                          70                         75                       80
                                                                Page 139

                                                                    97047_1
<removed-date>
              Al a Ly s Pr o Ar g Pr o Pr o Tr p Met Gl y Leu Leu Gl y Pr o Thr I l e Gl n
                                      85                            90                            95
              Al a Gl u Val Ty r As p Thr Val Val I l e Thr Leu Ly s As n Met Al a Ser
                                100                           105                           110
<removed-apn>
              Hi s Pr o Val Ser Leu Hi s Al a Val Gl y Val Ser Ty r Tr p Ly s Al a Ser
                          115                           120                           125
              Gl u Gl y Al a Gl u Ty r As p As p Gl n Thr Ser Gl n Ar g Gl u Ly s Gl u As p
                    130                           135                           140
              As p Ly s Val Phe Pr o Gl y Gl y Ser Hi s Thr Ty r Val Tr p Gl n Val Leu
              145                           150                           155                           160
              Ly s Gl u As n Gl y Pr o Met Al a Ser As p Pr o Leu Cy s Leu Thr Ty r Ser
                                      165                           170                           175
              Ty r Leu Ser Hi s Val As p Leu Val Ly s As p Leu As n Ser Gl y Leu I l e
                                180                           185                           190
              Gl y Al a Leu Leu Val Cy s Ar g Gl u Gl y Ser Leu Al a Ly s Gl u Ly s Thr
                          195                           200                           205
              Gl n Thr Leu Hi s Ly s Phe I l e Leu Leu Phe Al a Val Phe As p Gl u Gl y
                                                                    Page 140

                                                                    97047_1
<removed-date>
                    210                           215                           220
              Ly s Ser Tr p Hi s Ser Gl u Thr Ly s As n Ser Leu Met Gl n As p Ar g As p
              225                           230                           235                           240
<removed-apn>
              Al a Al a Ser Al a Ar g Al a Tr p Pr o Ly s Met Hi s Thr Val As n Gl y Ty r
                                      245                           250                           255
              Val As n Ar g Ser Leu Pr o Gl y Leu I l e Gl y Cy s Hi s Ar g Ly s Ser Val
                                260                           265                           270
              Ty r Tr p Hi s Val I l e Gl y Met Gl y Thr Thr Pr o Gl u Val Hi s Ser I l e
                          275                           280                           285
              Phe Leu Gl u Gl y Hi s Thr Phe Leu Val Ar g As n Hi s Ar g Gl n Al a Ser
                    290                           295                           300
              Leu Gl u I l e Ser Pr o I l e Thr Phe Leu Thr Al a Gl n Thr Leu Leu Met
              305                           310                           315                           320
              As p Leu Gl y Gl n Phe Leu Leu Phe Cy s Hi s I l e Ser Ser Hi s Gl n Hi s
                                      325                           330                           335
              As p Gl y Met Gl u Al a Ty r Val Ly s Val As p Ser Cy s Pr o Gl u Gl u Pr o
                                340                           345                           350
                                                                    Page 141

                                                                    97047_1
<removed-date>
              Gl n Leu Ar g Met Ly s As n As n Gl u Gl u Al a Gl u As p Ty r As p As p As p
                          355                           360                           365
              Leu Thr As p Ser Gl u Met As p Val Val Ar g Phe As p As p As p As n Ser
                    370                           375                           380
<removed-apn>
              Pr o Ser Phe I l e Gl n I l e Ar g Ser Val Al a Ly s Ly s Hi s Pr o Ly s Thr
              385                           390                           395                           400
              Tr p Val Hi s Ty r I l e Al a Al a Gl u Gl u Gl u As p Tr p As p Ty r Al a Pr o
                                      405                           410                           415
              Leu Val Leu Al a Pr o As p As p Ar g Ser Ty r Ly s Ser Gl n Ty r Leu As n
                                420                           425                           430
              As n Gl y Pr o Gl n Ar g I l e Gl y Ar g Ly s Ty r Ly s Ly s Val Ar g Phe Met
                          435                           440                           445
              Al a Ty r Thr As p Gl u Thr Phe Ly s Thr Ar g Gl u Al a I l e Gl n Hi s Gl u
                    450                           455                           460
              Ser Gl y I l e Leu Gl y Pr o Leu Leu Ty r Gl y Gl u Val Gl y As p Thr Leu
              465                           470                           475                           480
              Leu I l e I l e Phe Ly s As n Gl n Al a Ser Ar g Pr o Ty r As n I l e Ty r Pr o
                                                                    Page 142

                                                                     97047_1
<removed-date>
                                      485                           490                           495
              Hi s Gl y I l e Thr As p Val Ar g Pr o Leu Ty r Ser Ar g Ar g Leu Pr o Ly s
                                500                           505                           510
<removed-apn>
              Gl y Val Ly s Hi s Leu Ly s As p Phe Pr o I l e Leu Pr o Gl y Gl u I l e Phe
                          515                           520                           525
              Ly s Ty r Ly s Tr p Thr Val Thr Val Gl u As p Gl y Pr o Thr Ly s Ser As p
                    530                           535                           540
              Pr o Ar g Cy s Leu Thr Ar g Ty r Ty r Ser Ser Phe Val As n Met Gl u Ar g
              545                           550                           555                           560
              As p Leu Al a Ser Gl y Leu I l e Gl y Pr o Leu Leu I l e Cy s Ty r Ly s Gl u
                                      565                           570                           575
              Ser Val As p Gl n Ar g Gl y As n Gl n I l e Met Ser As p Ly s Ar g As n Val
                                580                           585                           590
              I l e Leu Phe Ser Val Phe As p Gl u As n Ar g Ser Tr p Ty r Leu Thr Gl u
                          595                           600                           605
              As n I l e Gl n Ar g Phe Leu Pr o As n Pr o Al a Gl y Val Gl n Leu Gl u As p
                    610                           615                           620
                                                                    Page 143

                                                                    97047_1
<removed-date>
              Pr o Gl u Phe Gl n Al a Ser As n I l e Met Hi s Ser I l e As n Gl y Ty r Val
              625                           630                           635                           640
              Phe As p Ser Leu Gl n Leu Ser Val Cy s Leu Hi s Gl u Val Al a Ty r Tr p
                                      645                           650                           655
<removed-apn>
              Ty r I l e Leu Ser I l e Gl y Al a Gl n Thr As p Phe Leu Ser Val Phe Phe
                                660                           665                           670
              Ser Gl y Ty r Thr Phe Ly s Hi s Ly s Met Val Ty r Gl u As p Thr Leu Thr
                          675                           680                           685
              Leu Phe Pr o Phe Ser Gl y Gl u Thr Val Phe Met Ser Met Gl u As n Pr o
                    690                           695                           700
              Gl y Leu Tr p I l e Leu Gl y Cy s Hi s As n Ser As p Phe Ar g As n Ar g Gl y
              705                           710                           715                           720
              Met Thr Al a Leu Leu Ly s Val Ser Ser Cy s As p Ly s As n Thr Gl y As p
                                      725                           730                           735
              Ty r Ty r Gl u As p Ser Ty r Gl u As p I l e Ser Al a Ty r Leu Leu Ser Ly s
                                740                           745                           750
              As n As n Al a I l e Gl u Pr o Ar g Ser Phe Ser Gl n As n Ser Ar g Hi s Pr o
                                                                    Page 144

                                                                    97047_1
<removed-date>
                          755                           760                           765
              Ser Thr Ar g Gl n Ly s Gl n Phe As n Al a Thr Thr I l e Pr o Gl u As n As p
                    770                           775                           780
<removed-apn>
              I l e Gl u Ly s Thr As p Pr o Tr p Phe Al a Hi s Ar g Thr Pr o Met Pr o Ly s
              785                           790                           795                           800
              I l e Gl n As n Val Ser Ser Ser As p Leu Leu Met Leu Leu Ar g Gl n Ser
                                      805                           810                           815
              Pr o Thr Pr o Hi s Gl y Leu Ser Leu Ser As p Leu Gl n Gl u Al a Ly s Ty r
                                820                           825                           830
              Gl u Thr Phe Ser As p As p Pr o Ser Pr o Gl y Al a I l e As p Ser As n As n
                          835                           840                           845
              Ser Leu Ser Gl u Met Thr Hi s Phe Ar g Pr o Gl n Leu Hi s Hi s Ser Gl y
                    850                           855                           860
              As p Met Val Phe Thr Pr o Gl u Ser Gl y Leu Gl n Leu Ar g Leu As n Gl u
              865                           870                           875                           880
              Ly s Leu Gl y Thr Thr Al a Al a Thr Gl u Leu Ly s Ly s Leu As p Phe Ly s
                                      885                           890                           895
                                                                    Page 145

                                                                      97047_1
<removed-date>
              Val Ser Ser Thr Ser As n As n Leu I l e Ser Thr I l e Pr o Ser As p As n
                                 900                            905                            910
              Leu Al a Al a Gl y Thr As p As n Thr Ser Ser Leu Gl y Pr o Pr o Ser Met
                           915                           920                            925
<removed-apn>
              Pr o Val Hi s Ty r As p Ser Gl n Leu As p Thr Thr Leu Phe Gl y Ly s Ly s
                    930                            935                            940
              Ser Ser Pr o Leu Thr Gl u Ser Gl y Gl y Pr o Leu Ser Leu Ser Gl u Gl u
              945                            950                            955                            960
              As n As n As p Ser Ly s Leu Leu Gl u Ser Gl y Leu Met As n Ser Gl n Gl u
                                       965                            970                            975
              Ser Ser Tr p Gl y Ly s As n Val Ser Ser Gl u I l e Thr Ar g Thr Thr Leu
                                 980                            985                            990
              Gl n Ser As p Gl n Gl u Gl u I l e As p            Ty r As p As p Thr I l e        Ser Val Gl u
                           995                           1000                            1005
              Met Ly s      Ly s Gl u As p Phe As p        I l e Ty r As p Gl u As p          Gl u As n Gl n
                    1010                            1015                            1020
              Ser Pr o      Ar g Ser Phe Gl n Ly s         Ly s Thr Ar g Hi s Ty r            Phe I l e Al a
                                                                      Page 146

                                                              97047_1
<removed-date>
                   1025                        1030                       1035
              Al a Val     Gl u Ar g Leu Tr p As p    Ty r Gl y Met Ser Ser      Ser Pr o Hi s
                   1040                        1045                       1050
<removed-apn>
              Val Leu      Ar g As n Ar g Al a Gl n   Ser Gl y Ser Val Pr o      Gl n Phe Ly s
                   1055                        1060                       1065
              Ly s Val     Val Phe Gl n Gl u Phe      Thr As p Gl y Ser Phe      Thr Gl n Pr o
                   1070                        1075                       1080
              Leu Ty r     Ar g Gl y Gl u Leu As n    Gl u Hi s Leu Gl y Leu     Leu Gl y Pr o
                   1085                        1090                       1095
              Ty r I l e   Ar g Al a Gl u Val Gl u    As p As n I l e Met Val    Thr Phe Ar g
                   1100                        1105                       1110
              As n Gl n    Al a Ser Ar g Pr o Ty r    Ser Phe Ty r Ser Ser       Leu I l e Ser
                   1115                        1120                       1125
              Ty r Gl u    Gl u As p Gl n Ar g Gl n   Gl y Al a Gl u Pr o Ar g   Ly s As n Phe
                   1130                        1135                       1140
              Val Ly s     Pr o As n Gl u Thr Ly s    Thr Ty r Phe Tr p Ly s     Val Gl n Hi s
                   1145                        1150                       1155
                                                             Page 147

                                                              97047_1
<removed-date>
              Hi s Met     Al a Pr o Thr Ly s As p    Gl u Phe As p Cy s Ly s     Al a Tr p Al a
                   1160                        1165                        1170
              Ty r Phe     Ser As p Val As p Leu      Gl u Ly s As p Val Hi s     Ser Gl y Leu
                   1175                        1180                        1185
<removed-apn>
              I l e Gl y   Pr o Leu Leu Val Cy s      Hi s Thr As n Thr Leu       As n Pr o Al a
                   1190                        1195                        1200
              Hi s Gl y    Ar g Gl n Val Thr Val      Gl n Gl u Phe Al a Leu      Phe Phe Thr
                   1205                        1210                        1215
              I l e Phe    As p Gl u Thr Ly s Ser     Tr p Ty r Phe Thr Gl u      As n Met Gl u
                   1220                        1225                        1230
              Ar g As n    Cy s Ar g Al a Pr o Cy s   As n I l e Gl n Met Gl u    As p Pr o Thr
                   1235                        1240                        1245
              Phe Ly s     Gl u As n Ty r Ar g Phe    Hi s Al a I l e As n Gl y   Ty r I l e Met
                   1250                        1255                        1260
              As p Thr     Leu Pr o Gl y Leu Val      Met Al a Gl n As p Gl n     Ar g I l e Ar g
                   1265                        1270                        1275
              Tr p Ty r    Leu Leu Ser Met Gl y       Ser As n Gl u As n I l e    Hi s Ser I l e
                                                              Page 148

                                                             97047_1
<removed-date>
                   1280                       1285                       1290
              Hi s Phe     Ser Gl y Hi s Val Phe     Thr Val Ar g Ly s Ly s     Gl u Gl u Ty r
                   1295                       1300                       1305
<removed-apn>
              Ly s Met     Al a Leu Ty r As n Leu    Ty r Pr o Gl y Val Phe     Gl u Thr Val
                   1310                       1315                       1320
              Gl u Met     Leu Pr o Ser Ly s Al a    Gl y I l e Tr p Ar g Val   Gl u Cy s Leu
                   1325                       1330                       1335
              I l e Gl y   Gl u Hi s Leu Hi s Al a   Gl y Met Ser Thr Leu       Phe Leu Val
                   1340                       1345                       1350
              Ty r Ser     As n Ly s Cy s Gl n Thr   Pr o Leu Gl y Met Al a     Ser Gl y Hi s
                   1355                       1360                       1365
              I l e Ar g   As p Phe Gl n I l e Thr   Al a Ser Gl y Gl n Ty r    Gl y Gl n Tr p
                   1370                       1375                       1380
              Al a Pr o    Ly s Leu Al a Ar g Leu    Hi s Ty r Ser Gl y Ser     I l e As n Al a
                   1385                       1390                       1395
              Tr p Ser     Thr Ly s Gl u Pr o Phe    Ser Tr p I l e Ly s Val    As p Leu Leu
                   1400                       1405                       1410
                                                            Page 149

                                                               97047_1
<removed-date>
              Al a Pr o   Met I l e I l e Hi s Gl y   I l e Ly s Thr Gl n Gl y     Al a Ar g Gl n
                   1415                        1420                         1425
              Ly s Phe    Ser Ser Leu Ty r I l e      Ser Gl n Phe I l e I l e     Met Ty r Ser
                   1430                        1435                         1440
<removed-apn>
              Leu As p    Gl y Ly s Ly s Tr p Gl n    Thr Ty r Ar g Gl y As n      Ser Thr Gl y
                   1445                        1450                         1455
              Thr Leu     Met Val Phe Phe Gl y        As n Val As p Ser Ser        Gl y I l e Ly s
                   1460                        1465                         1470
              Hi s As n   I l e Phe As n Pr o Pr o    I l e I l e Al a Ar g Ty r   I l e Ar g Leu
                   1475                        1480                         1485
              Hi s Pr o   Thr Hi s Ty r Ser I l e     Ar g Ser Thr Leu Ar g        Met Gl u Leu
                   1490                        1495                         1500
              Met Gl y    Cy s As p Leu As n Ser      Cy s Ser Met Pr o Leu        Gl y Met Gl u
                   1505                        1510                         1515
              Ser Ly s    Al a I l e Ser As p Al a    Gl n I l e Thr Al a Ser      Ser Ty r Phe
                   1520                        1525                         1530
              Thr As n    Met Phe Al a Thr Tr p       Ser Pr o Ser Ly s Al a       Ar g Leu Hi s
                                                              Page 150

                                                              97047_1
<removed-date>
                   1535                        1540                       1545
              Leu Gl n     Gl y Ar g Ser As n Al a    Tr p Ar g Pr o Gl n Val    As n As n Pr o
                   1550                        1555                       1560
<removed-apn>
              Ly s Gl u    Tr p Leu Gl n Val As p     Phe Gl n Ly s Thr Met      Ly s Val Thr
                   1565                        1570                       1575
              Gl y Val     Thr Thr Gl n Gl y Val      Ly s Ser Leu Leu Thr       Ser Met Ty r
                   1580                        1585                       1590
              Val Ly s     Gl u Phe Leu I l e Ser     Ser Ser Gl n As p Gl y     Hi s Gl n Tr p
                   1595                        1600                       1605
              Thr Leu      Phe Phe Gl n As n Gl y     Ly s Val Ly s Val Phe      Gl n Gl y As n
                   1610                        1615                       1620
              Gl n As p    Ser Phe Thr Pr o Val       Val As n Ser Leu As p      Pr o Pr o Leu
                   1625                        1630                       1635
              Leu Thr      Ar g Ty r Leu Ar g I l e   Hi s Pr o Gl n Ser Tr p    Val Hi s Gl n
                   1640                        1645                       1650
              I l e Al a   Leu Ar g Met Gl u Val      Leu Gl y Cy s Gl u Al a    Gl n As p Leu
                   1655                        1660                       1665
                                                             Page 151

                                                             97047_1
<removed-date>
              Ty r As p   Ly s Thr Hi s Thr Cy s     Pr o Pr o Cy s Pr o Al a    Pr o Gl u Leu
                   1670                       1675                        1680
              Leu Gl y    Gl y Pr o Ser Val Phe      Leu Phe Pr o Pr o Ly s      Pr o Ly s As p
                   1685                       1690                        1695
<removed-apn>
              Thr Leu     Met I l e Ser Ar g Thr     Pr o Gl u Val Thr Cy s      Val Val Val
                   1700                       1705                        1710
              As p Val    Ser Hi s Gl u As p Pr o    Gl u Val Ly s Phe As n      Tr p Ty r Val
                   1715                       1720                        1725
              As p Gl y   Val Gl u Val Hi s As n     Al a Ly s Thr Ly s Pr o     Ar g Gl u Gl u
                   1730                       1735                        1740
              Gl n Ty r   As n Ser Thr Ty r Ar g     Val Val Ser Val Leu         Thr Val Leu
                   1745                       1750                        1755
              Hi s Gl n   As p Tr p Leu As n Gl y    Ly s Gl u Ty r Ly s Cy s    Ly s Val Ser
                   1760                       1765                        1770
              As n Ly s   Al a Leu Pr o Al a Pr o    I l e Gl u Ly s Thr I l e   Ser Ly s Al a
                   1775                       1780                        1785
              Ly s Gl y   Gl n Pr o Ar g Gl u Pr o   Gl n Val Ty r Thr Leu       Pr o Pr o Ser
                                                             Page 152

                                                                  97047_1
<removed-date>
                   1790                            1795                       1800
              Ar g As p        Gl u Leu Thr Ly s As n     Gl n Val Ser Leu Thr       Cy s Leu Val
                   1805                            1810                       1815
<removed-apn>
              Ly s Gl y        Phe Ty r Pr o Ser As p     I l e Al a Val Gl u Tr p   Gl u Ser As n
                   1820                            1825                       1830
              Gl y Gl n        Pr o Gl u As n As n Ty r   Ly s Thr Thr Pr o Pr o     Val Leu As p
                   1835                            1840                       1845
              Ser As p         Gl y Ser Phe Phe Leu       Ty r Ser Ly s Leu Thr      Val As p Ly s
                   1850                            1855                       1860
              Ser Ar g         Tr p Gl n Gl n Gl y As n   Val Phe Ser Cy s Ser       Val Met Hi s
                   1865                            1870                       1875
              Gl u Al a        Leu Hi s As n Hi s Ty r    Thr Gl n Ly s Ser Leu      Ser Leu Ser
                   1880                            1885                       1890
              Pr o Gl y        Ly s
                   1895
              <210>       90
              <211>       99
              <212>       DNA
                                                                 Page 153

                                                                        97047_1
<removed-date>
              <213>      Ar t i f i c i al Sequenc e
              <220>
              <223>      ESC48- Fwd - VWF- D' D3 wi t h VI I I s i gnal and Bs i W1 s i t e
              <400>      90
              t c gc gac gt a c ggc c gc c ac c at gc aaat a gagc t c t c c a c c t gc t t c t t t c t gt gc c t t   60
<removed-apn>
              t t gc gat t c t gc t t t agc c t at c c t gt c gg c c c c c c at g                                    99
              <210>      91
              <211>      74
              <212>      DNA
              <213>      Ar t i f i c i al Sequenc e
              <220>
              <223>      ESC51- Rev - VWF D' D3 ( 1- 477 ami no ac i d) wi t h 6Hi s and Not 1 s i t e
              <400>      91
              t gac c t c gag c ggc c gc t c a gt ggt gat gg t gat gat gc g gc t c c t ggc a ggc t t c ac ag         60
              gt gaggt t ga c aac                                                                                    74
              <210>      92
              <211>      32
              <212>      DNA
              <213>      Ar t i f i c i al Sequenc e
              <220>
              <223>      ESC 89- f wd wi t h Nhe1s i t e
              <400>      92
                                                                       Page 154

                                                                  97047_1
<removed-date>
              c t c ac t at ag ggagac c c aa gc t ggc t agc c g                              32
              <210>    93
              <211>    43
              <212>    DNA
              <213>    Ar t i f i c i al Sequenc e
<removed-apn>
              <220>
              <223>    ESC 91- r ev wi t h Sal 1
              <400>    93
              c t ggat c c c g ggagt c gac t c gt c agt ggt gat ggt gat g at g               43
              <210>    94
              <211>    40
              <212>    PRT
              <213>    Ar t i f i c i al Sequenc e
              <220>
              <223>    l i nk er
              <400>    94
              Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser Gl y
              1                     5                             10                  15
              Gl y Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser Gl y Gl y
                               20                         25                     30
              Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser
                                                                  Page 155

                                                                          97047_1
<removed-date>
                           35                              40
              <210>      95
              <211>      92
              <212>      DNA
              <213>      Ar t i f i c i al Sequenc e
<removed-apn>
              <220>
              <223>      LW 22- FWD- VWF- D' D3 wi t h FVI I I s i gnal s equenc e and Bs i W1 s i t e
              <400>      95
              gc gc c ggc c g t ac gat gc aa at agagc t c t c c ac c t gc t t c t t t c t gt gc c t t t t gc gat   60
              t c t gc t t t ag c c t at c c t gt c ggc c c c c c a t g                                            92
              <210>      96
              <211>      47
              <212>      DNA
              <213>      Ar t i f i c i al Sequenc e
              <220>
              <223>      LW 23- Rev - Fc wi t h s t op c odon and Not 1 s i t e
              <400>      96
              t c at c aat gt at c t t at c at gt c t gaat t c gc ggc c gc t c at t t ac c                         47
              <210>      97
              <211>      41
              <212>      DNA
              <213>      Ar t i f i c i al Sequenc e
                                                                          Page 156

                                                                  97047_1
<removed-date>
              <220>
              <223>    LW24- Fwd- VWF D1D2D' D3 c l oni ng ol i go wi t h Bs i W1 s i t e
              <400>    97
              gc gc c ggc c g t ac gat gat t c c t gc c agat t t gc c ggggt g               41
<removed-apn>
              <210>    98
              <211>    41
              <212>    DNA
              <213>    Ar t i f i c i al Sequenc e
              <220>
              <223>    LW27- Rev - VWF     D' D3 ol i go wi t h Ec oRV
              <400>    98
              c c ac c gc c ag at at c ggc t c c t ggc aggc t t c ac aggt ga g              41
              <210>    99
              <211>    1240
              <212>    PRT
              <213>    Ar t i f i c i al Sequenc e
              <220>
              <223>    VWF- D1D2D' D3 pr ot ei n s equenc e 1
              <400>    99
              Met I l e Pr o Al a Ar g Phe Al a Gl y Val Leu Leu Al a Leu Al a Leu I l e
              1                     5                            10                 15
              Leu Pr o Gl y Thr Leu Cy s Al a Gl u Gl y Thr Ar g Gl y Ar g Ser Ser Thr
                                                                 Page 157

                                                                   97047_1
<removed-date>
                                20                           25                           30
              Al a Ar g Cy s Ser Leu Phe Gl y Ser As p Phe Val As n Thr Phe As p Gl y
                          35                           40                           45
<removed-apn>
              Ser Met Ty r Ser Phe Al a Gl y Ty r Cy s Ser Ty r Leu Leu Al a Gl y Gl y
                    50                           55                           60
              Cy s Gl n Ly s Ar g Ser Phe Ser I l e I l e Gl y As p Phe Gl n As n Gl y Ly s
              65                           70                           75                           80
              Ar g Val Ser Leu Ser Val Ty r Leu Gl y Gl u Phe Phe As p I l e Hi s Leu
                                      85                           90                           95
              Phe Val As n Gl y Thr Val Thr Gl n Gl y As p Gl n Ar g Val Ser Met Pr o
                                100                          105                          110
              Ty r Al a Ser Ly s Gl y Leu Ty r Leu Gl u Thr Gl u Al a Gl y Ty r Ty r Ly s
                          115                          120                          125
              Leu Ser Gl y Gl u Al a Ty r Gl y Phe Val Al a Ar g I l e As p Gl y Ser Gl y
                    130                          135                          140
              As n Phe Gl n Val Leu Leu Ser As p Ar g Ty r Phe As n Ly s Thr Cy s Gl y
              145                          150                          155                          160
                                                                   Page 158

                                                                    97047_1
<removed-date>
              Leu Cy s Gl y As n Phe As n I l e Phe Al a Gl u As p As p Phe Met Thr Gl n
                                      165                           170                           175
              Gl u Gl y Thr Leu Thr Ser As p Pr o Ty r As p Phe Al a As n Ser Tr p Al a
                                180                           185                           190
<removed-apn>
              Leu Ser Ser Gl y Gl u Gl n Tr p Cy s Gl u Ar g Al a Ser Pr o Pr o Ser Ser
                          195                           200                           205
              Ser Cy s As n I l e Ser Ser Gl y Gl u Met Gl n Ly s Gl y Leu Tr p Gl u Gl n
                    210                           215                           220
              Cy s Gl n Leu Leu Ly s Ser Thr Ser Val Phe Al a Ar g Cy s Hi s Pr o Leu
              225                           230                           235                           240
              Val As p Pr o Gl u Pr o Phe Val Al a Leu Cy s Gl u Ly s Thr Leu Cy s Gl u
                                      245                           250                           255
              Cy s Al a Gl y Gl y Leu Gl u Cy s Al a Cy s Pr o Al a Leu Leu Gl u Ty r Al a
                                260                           265                           270
              Ar g Thr Cy s Al a Gl n Gl u Gl y Met Val Leu Ty r Gl y Tr p Thr As p Hi s
                          275                           280                           285
              Ser Al a Cy s Ser Pr o Val Cy s Pr o Al a Gl y Met Gl u Ty r Ar g Gl n Cy s
                                                                    Page 159

                                                                    97047_1
<removed-date>
                    290                           295                           300
              Val Ser Pr o Cy s Al a Ar g Thr Cy s Gl n Ser Leu Hi s I l e As n Gl u Met
              305                           310                           315                           320
<removed-apn>
              Cy s Gl n Gl u Ar g Cy s Val As p Gl y Cy s Ser Cy s Pr o Gl u Gl y Gl n Leu
                                      325                           330                           335
              Leu As p Gl u Gl y Leu Cy s Val Gl u Ser Thr Gl u Cy s Pr o Cy s Val Hi s
                                340                           345                           350
              Ser Gl y Ly s Ar g Ty r Pr o Pr o Gl y Thr Ser Leu Ser Ar g As p Cy s As n
                          355                           360                           365
              Thr Cy s I l e Cy s Ar g As n Ser Gl n Tr p I l e Cy s Ser As n Gl u Gl u Cy s
                    370                           375                           380
              Pr o Gl y Gl u Cy s Leu Val Thr Gl y Gl n Ser Hi s Phe Ly s Ser Phe As p
              385                           390                           395                           400
              As n Ar g Ty r Phe Thr Phe Ser Gl y I l e Cy s Gl n Ty r Leu Leu Al a Ar g
                                      405                           410                           415
              As p Cy s Gl n As p Hi s Ser Phe Ser I l e Val I l e Gl u Thr Val Gl n Cy s
                                420                           425                           430
                                                                    Page 160

                                                                    97047_1
<removed-date>
              Al a As p As p Ar g As p Al a Val Cy s Thr Ar g Ser Val Thr Val Ar g Leu
                          435                           440                           445
              Pr o Gl y Leu Hi s As n Ser Leu Val Ly s Leu Ly s Hi s Gl y Al a Gl y Val
                    450                           455                           460
<removed-apn>
              Al a Met As p Gl y Gl n As p I l e Gl n Leu Pr o Leu Leu Ly s Gl y As p Leu
              465                           470                           475                           480
              Ar g I l e Gl n Hi s Thr Val Thr Al a Ser Val Ar g Leu Ser Ty r Gl y Gl u
                                      485                           490                           495
              As p Leu Gl n Met As p Tr p As p Gl y Ar g Gl y Ar g Leu Leu Val Ly s Leu
                                500                           505                           510
              Ser Pr o Val Ty r Al a Gl y Ly s Thr Cy s Gl y Leu Cy s Gl y As n Ty r As n
                          515                           520                           525
              Gl y As n Gl n Gl y As p As p Phe Leu Thr Pr o Ser Gl y Leu Al a Gl u Pr o
                    530                           535                           540
              Ar g Val Gl u As p Phe Gl y As n Al a Tr p Ly s Leu Hi s Gl y As p Cy s Gl n
              545                           550                           555                           560
              As p Leu Gl n Ly s Gl n Hi s Ser As p Pr o Cy s Al a Leu As n Pr o Ar g Met
                                                                    Page 161

                                                                     97047_1
<removed-date>
                                      565                           570                           575
              Thr Ar g Phe Ser Gl u Gl u Al a Cy s Al a Val Leu Thr Ser Pr o Thr Phe
                                580                           585                           590
<removed-apn>
              Gl u Al a Cy s Hi s Ar g Al a Val Ser Pr o Leu Pr o Ty r Leu Ar g As n Cy s
                          595                           600                           605
              Ar g Ty r As p Val Cy s Ser Cy s Ser As p Gl y Ar g Gl u Cy s Leu Cy s Gl y
                    610                           615                           620
              Al a Leu Al a Ser Ty r Al a Al a Al a Cy s Al a Gl y Ar g Gl y Val Ar g Val
              625                           630                           635                           640
              Al a Tr p Ar g Gl u Pr o Gl y Ar g Cy s Gl u Leu As n Cy s Pr o Ly s Gl y Gl n
                                      645                           650                           655
              Val Ty r Leu Gl n Cy s Gl y Thr Pr o Cy s As n Leu Thr Cy s Ar g Ser Leu
                                660                           665                           670
              Ser Ty r Pr o As p Gl u Gl u Cy s As n Gl u Al a Cy s Leu Gl u Gl y Cy s Phe
                          675                           680                           685
              Cy s Pr o Pr o Gl y Leu Ty r Met As p Gl u Ar g Gl y As p Cy s Val Pr o Ly s
                    690                           695                           700
                                                                    Page 162

                                                                    97047_1
<removed-date>
              Al a Gl n Cy s Pr o Cy s Ty r Ty r As p Gl y Gl u I l e Phe Gl n Pr o Gl u As p
              705                           710                           715                           720
              I l e Phe Ser As p Hi s Hi s Thr Met Cy s Ty r Cy s Gl u As p Gl y Phe Met
                                      725                           730                           735
<removed-apn>
              Hi s Cy s Thr Met Ser Gl y Val Pr o Gl y Ser Leu Leu Pr o As p Al a Val
                                740                           745                           750
              Leu Ser Ser Pr o Leu Ser Hi s Ar g Ser Ly s Ar g Ser Leu Ser Cy s Ar g
                          755                           760                           765
              Pr o Pr o Met Val Ly s Leu Val Cy s Pr o Al a As p As n Leu Ar g Al a Gl u
                    770                           775                           780
              Gl y Leu Gl u Cy s Thr Ly s Thr Cy s Gl n As n Ty r As p Leu Gl u Cy s Met
              785                           790                           795                           800
              Ser Met Gl y Cy s Val Ser Gl y Cy s Leu Cy s Pr o Pr o Gl y Met Val Ar g
                                      805                           810                           815
              Hi s Gl u As n Ar g Cy s Val Al a Leu Gl u Ar g Cy s Pr o Cy s Phe Hi s Gl n
                                820                           825                           830
              Gl y Ly s Gl u Ty r Al a Pr o Gl y Gl u Thr Val Ly s I l e Gl y Cy s As n Thr
                                                                    Page 163

                                                                    97047_1
<removed-date>
                          835                           840                           845
              Cy s Val Cy s Ar g As p Ar g Ly s Tr p As n Cy s Thr As p Hi s Val Cy s As p
                    850                           855                           860
<removed-apn>
              Al a Thr Cy s Ser Thr I l e Gl y Met Al a Hi s Ty r Leu Thr Phe As p Gl y
              865                           870                           875                           880
              Leu Ly s Ty r Leu Phe Pr o Gl y Gl u Cy s Gl n Ty r Val Leu Val Gl n As p
                                      885                           890                           895
              Ty r Cy s Gl y Ser As n Pr o Gl y Thr Phe Ar g I l e Leu Val Gl y As n Ly s
                                900                           905                           910
              Gl y Cy s Ser Hi s Pr o Ser Val Ly s Cy s Ly s Ly s Ar g Val Thr I l e Leu
                          915                           920                           925
              Val Gl u Gl y Gl y Gl u I l e Gl u Leu Phe As p Gl y Gl u Val As n Val Ly s
                    930                           935                           940
              Ar g Pr o Met Ly s As p Gl u Thr Hi s Phe Gl u Val Val Gl u Ser Gl y Ar g
              945                           950                           955                           960
              Ty r I l e I l e Leu Leu Leu Gl y Ly s Al a Leu Ser Val Val Tr p As p Ar g
                                      965                           970                           975
                                                                    Page 164

                                                                    97047_1
<removed-date>
              Hi s Leu Ser I l e Ser Val Val Leu Ly s Gl n Thr Ty r Gl n Gl u Ly s Val
                                 980                          985                          990
              Cy s Gl y Leu Cy s Gl y As n Phe As p            Gl y I l e Gl n As n As n     As p Leu Thr
                           995                         1000                          1005
<removed-apn>
              Ser Ser       As n Leu Gl n Val Gl u       Gl u As p Pr o Val As p       Phe Gl y As n
                   1010                         1015                            1020
              Ser Tr p      Ly s Val Ser Ser Gl n        Cy s Al a As p Thr Ar g       Ly s Val Pr o
                   1025                         1030                            1035
              Leu As p      Ser Ser Pr o Al a Thr        Cy s Hi s As n As n I l e     Met Ly s Gl n
                   1040                         1045                            1050
              Thr Met       Val As p Ser Ser Cy s        Ar g I l e Leu Thr Ser        As p Val Phe
                   1055                         1060                            1065
              Gl n As p     Cy s As n Ly s Leu Val       As p Pr o Gl u Pr o Ty r      Leu As p Val
                   1070                         1075                            1080
              Cy s I l e    Ty r As p Thr Cy s Ser       Cy s Gl u Ser I l e Gl y      As p Cy s Al a
                   1085                         1090                            1095
              Cy s Phe      Cy s As p Thr I l e Al a     Al a Ty r Al a Hi s Val       Cy s Al a Gl n
                                                                    Page 165

                                                              97047_1
<removed-date>
                   1100                        1105                       1110
              Hi s Gl y   Ly s Val Val Thr Tr p       Ar g Thr Al a Thr Leu      Cy s Pr o Gl n
                   1115                        1120                       1125
<removed-apn>
              Ser Cy s    Gl u Gl u Ar g As n Leu     Ar g Gl u As n Gl y Ty r   Gl u Cy s Gl u
                   1130                        1135                       1140
              Tr p Ar g   Ty r As n Ser Cy s Al a     Pr o Al a Cy s Gl n Val    Thr Cy s Gl n
                   1145                        1150                       1155
              Hi s Pr o   Gl u Pr o Leu Al a Cy s     Pr o Val Gl n Cy s Val     Gl u Gl y Cy s
                   1160                        1165                       1170
              Hi s Al a   Hi s Cy s Pr o Pr o Gl y    Ly s I l e Leu As p Gl u   Leu Leu Gl n
                   1175                        1180                       1185
              Thr Cy s    Val As p Pr o Gl u As p     Cy s Pr o Val Cy s Gl u    Val Al a Gl y
                   1190                        1195                       1200
              Ar g Ar g   Phe Al a Ser Gl y Ly s      Ly s Val Thr Leu As n      Pr o Ser As p
                   1205                        1210                       1215
              Pr o Gl u   Hi s Cy s Gl n I l e Cy s   Hi s Cy s As p Val Val     As n Leu Thr
                   1220                        1225                       1230
                                                             Page 166

                                                                  97047_1
<removed-date>
              Cy s Gl u     Al a Cy s Gl n Gl u Pr o
                   1235                            1240
              <210>       100
              <211>       477
<removed-apn>
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
              <220>
              <223>       VWF- D' D3 pr ot ei n s equenc e 2
              <400>       100
              Ser Leu Ser Cy s Ar g Pr o Pr o Met Val Ly s Leu Val Cy s Pr o Al a As p
              1                       5                           10                       15
              As n Leu Ar g Al a Gl u Gl y Leu Gl u Cy s Thr Ly s Thr Cy s Gl n As n Ty r
                                 20                          25                       30
              As p Leu Gl u Cy s Met Ser Met Gl y Cy s Val Ser Gl y Cy s Leu Cy s Pr o
                           35                           40                       45
              Pr o Gl y Met Val Ar g Hi s Gl u As n Ar g Cy s Val Al a Leu Gl u Ar g Cy s
                   50                             55                        60
              Pr o Cy s Phe Hi s Gl n Gl y Ly s Gl u Ty r Al a Pr o Gl y Gl u Thr Val Ly s
              65                            70                         75                       80
                                                                  Page 167

                                                                    97047_1
<removed-date>
              I l e Gl y Cy s As n Thr Cy s Val Cy s Ar g As p Ar g Ly s Tr p As n Cy s Thr
                                      85                            90                            95
              As p Hi s Val Cy s As p Al a Thr Cy s Ser Thr I l e Gl y Met Al a Hi s Ty r
                                100                           105                           110
<removed-apn>
              Leu Thr Phe As p Gl y Leu Ly s Ty r Leu Phe Pr o Gl y Gl u Cy s Gl n Ty r
                          115                           120                           125
              Val Leu Val Gl n As p Ty r Cy s Gl y Ser As n Pr o Gl y Thr Phe Ar g I l e
                    130                           135                           140
              Leu Val Gl y As n Ly s Gl y Cy s Ser Hi s Pr o Ser Val Ly s Cy s Ly s Ly s
              145                           150                           155                           160
              Ar g Val Thr I l e Leu Val Gl u Gl y Gl y Gl u I l e Gl u Leu Phe As p Gl y
                                      165                           170                           175
              Gl u Val As n Val Ly s Ar g Pr o Met Ly s As p Gl u Thr Hi s Phe Gl u Val
                                180                           185                           190
              Val Gl u Ser Gl y Ar g Ty r I l e I l e Leu Leu Leu Gl y Ly s Al a Leu Ser
                          195                           200                           205
              Val Val Tr p As p Ar g Hi s Leu Ser I l e Ser Val Val Leu Ly s Gl n Thr
                                                                    Page 168

                                                                    97047_1
<removed-date>
                    210                           215                           220
              Ty r Gl n Gl u Ly s Val Cy s Gl y Leu Cy s Gl y As n Phe As p Gl y I l e Gl n
              225                           230                           235                           240
<removed-apn>
              As n As n As p Leu Thr Ser Ser As n Leu Gl n Val Gl u Gl u As p Pr o Val
                                      245                           250                           255
              As p Phe Gl y As n Ser Tr p Ly s Val Ser Ser Gl n Cy s Al a As p Thr Ar g
                                260                           265                           270
              Ly s Val Pr o Leu As p Ser Ser Pr o Al a Thr Cy s Hi s As n As n I l e Met
                          275                           280                           285
              Ly s Gl n Thr Met Val As p Ser Ser Cy s Ar g I l e Leu Thr Ser As p Val
                    290                           295                           300
              Phe Gl n As p Cy s As n Ly s Leu Val As p Pr o Gl u Pr o Ty r Leu As p Val
              305                           310                           315                           320
              Cy s I l e Ty r As p Thr Cy s Ser Cy s Gl u Ser I l e Gl y As p Cy s Al a Cy s
                                      325                           330                           335
              Phe Cy s As p Thr I l e Al a Al a Ty r Al a Hi s Val Cy s Al a Gl n Hi s Gl y
                                340                           345                           350
                                                                    Page 169

                                                                     97047_1
<removed-date>
              Ly s Val Val Thr Tr p Ar g Thr Al a Thr Leu Cy s Pr o Gl n Ser Cy s Gl u
                           355                           360                           365
              Gl u Ar g As n Leu Ar g Gl u As n Gl y Ty r Gl u Cy s Gl u Tr p Ar g Ty r As n
                    370                            375                           380
<removed-apn>
              Ser Cy s Al a Pr o Al a Cy s Gl n Val Thr Cy s Gl n Hi s Pr o Gl u Pr o Leu
              385                            390                           395                           400
              Al a Cy s Pr o Val Gl n Cy s Val Gl u Gl y Cy s Hi s Al a Hi s Cy s Pr o Pr o
                                       405                           410                           415
              Gl y Ly s I l e Leu As p Gl u Leu Leu Gl n Thr Cy s Val As p Pr o Gl u As p
                                 420                           425                           430
              Cy s Pr o Val Cy s Gl u Val Al a Gl y Ar g Ar g Phe Al a Ser Gl y Ly s Ly s
                           435                           440                           445
              Val Thr Leu As n Pr o Ser As p Pr o Gl u Hi s Cy s Gl n I l e Cy s Hi s Cy s
                    450                            455                           460
              As p Val Val As n Leu Thr Cy s Gl u Al a Cy s Gl n Gl u Pr o
              465                            470                           475
              <210>       101
                                                                     Page 170

                                                                97047_1
<removed-date>
              <211>     2754
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     pSYN- FVI I I - 161
<removed-apn>
              <400>     101
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
              1                     5                           10                       15
              Cy s Phe Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser
                               20                          25                       30
              Tr p As p Ty r Met Gl n Ser As p Leu Gl y Gl u Leu Pr o Val As p Al a Ar g
                         35                           40                       45
              Phe Pr o Pr o Ar g Val Pr o Ly s Ser Phe Pr o Phe As n Thr Ser Val Val
                   50                           55                        60
              Ty r Ly s Ly s Thr Leu Phe Val Gl u Phe Thr As p Hi s Leu Phe As n I l e
              65                          70                         75                       80
              Al a Ly s Pr o Ar g Pr o Pr o Tr p Met Gl y Leu Leu Gl y Pr o Thr I l e Gl n
                                    85                          90                       95
              Al a Gl u Val Ty r As p Thr Val Val I l e Thr Leu Ly s As n Met Al a Ser
                                                                Page 171

                                                                    97047_1
<removed-date>
                                100                           105                           110
              Hi s Pr o Val Ser Leu Hi s Al a Val Gl y Val Ser Ty r Tr p Ly s Al a Ser
                          115                           120                           125
<removed-apn>
              Gl u Gl y Al a Gl u Ty r As p As p Gl n Thr Ser Gl n Ar g Gl u Ly s Gl u As p
                    130                           135                           140
              As p Ly s Val Phe Pr o Gl y Gl y Ser Hi s Thr Ty r Val Tr p Gl n Val Leu
              145                           150                           155                           160
              Ly s Gl u As n Gl y Pr o Met Al a Ser As p Pr o Leu Cy s Leu Thr Ty r Ser
                                      165                           170                           175
              Ty r Leu Ser Hi s Val As p Leu Val Ly s As p Leu As n Ser Gl y Leu I l e
                                180                           185                           190
              Gl y Al a Leu Leu Val Cy s Ar g Gl u Gl y Ser Leu Al a Ly s Gl u Ly s Thr
                          195                           200                           205
              Gl n Thr Leu Hi s Ly s Phe I l e Leu Leu Phe Al a Val Phe As p Gl u Gl y
                    210                           215                           220
              Ly s Ser Tr p Hi s Ser Gl u Thr Ly s As n Ser Leu Met Gl n As p Ar g As p
              225                           230                           235                           240
                                                                    Page 172

                                                                    97047_1
<removed-date>
              Al a Al a Ser Al a Ar g Al a Tr p Pr o Ly s Met Hi s Thr Val As n Gl y Ty r
                                      245                           250                           255
              Val As n Ar g Ser Leu Pr o Gl y Leu I l e Gl y Cy s Hi s Ar g Ly s Ser Val
                                260                           265                           270
<removed-apn>
              Ty r Tr p Hi s Val I l e Gl y Met Gl y Thr Thr Pr o Gl u Val Hi s Ser I l e
                          275                           280                           285
              Phe Leu Gl u Gl y Hi s Thr Phe Leu Val Ar g As n Hi s Ar g Gl n Al a Ser
                    290                           295                           300
              Leu Gl u I l e Ser Pr o I l e Thr Phe Leu Thr Al a Gl n Thr Leu Leu Met
              305                           310                           315                           320
              As p Leu Gl y Gl n Phe Leu Leu Phe Cy s Hi s I l e Ser Ser Hi s Gl n Hi s
                                      325                           330                           335
              As p Gl y Met Gl u Al a Ty r Val Ly s Val As p Ser Cy s Pr o Gl u Gl u Pr o
                                340                           345                           350
              Gl n Leu Ar g Met Ly s As n As n Gl u Gl u Al a Gl u As p Ty r As p As p As p
                          355                           360                           365
              Leu Thr As p Ser Gl u Met As p Val Val Ar g Phe As p As p As p As n Ser
                                                                    Page 173

                                                                    97047_1
<removed-date>
                    370                           375                           380
              Pr o Ser Phe I l e Gl n I l e Ar g Ser Val Al a Ly s Ly s Hi s Pr o Ly s Thr
              385                           390                           395                           400
<removed-apn>
              Tr p Val Hi s Ty r I l e Al a Al a Gl u Gl u Gl u As p Tr p As p Ty r Al a Pr o
                                      405                           410                           415
              Leu Val Leu Al a Pr o As p As p Ar g Ser Ty r Ly s Ser Gl n Ty r Leu As n
                                420                           425                           430
              As n Gl y Pr o Gl n Ar g I l e Gl y Ar g Ly s Ty r Ly s Ly s Val Ar g Phe Met
                          435                           440                           445
              Al a Ty r Thr As p Gl u Thr Phe Ly s Thr Ar g Gl u Al a I l e Gl n Hi s Gl u
                    450                           455                           460
              Ser Gl y I l e Leu Gl y Pr o Leu Leu Ty r Gl y Gl u Val Gl y As p Thr Leu
              465                           470                           475                           480
              Leu I l e I l e Phe Ly s As n Gl n Al a Ser Ar g Pr o Ty r As n I l e Ty r Pr o
                                      485                           490                           495
              Hi s Gl y I l e Thr As p Val Ar g Pr o Leu Ty r Ser Ar g Ar g Leu Pr o Ly s
                                500                           505                           510
                                                                    Page 174

                                                                    97047_1
<removed-date>
              Gl y Val Ly s Hi s Leu Ly s As p Phe Pr o I l e Leu Pr o Gl y Gl u I l e Phe
                          515                           520                           525
              Ly s Ty r Ly s Tr p Thr Val Thr Val Gl u As p Gl y Pr o Thr Ly s Ser As p
                    530                           535                           540
<removed-apn>
              Pr o Ar g Cy s Leu Thr Ar g Ty r Ty r Ser Ser Phe Val As n Met Gl u Ar g
              545                           550                           555                           560
              As p Leu Al a Ser Gl y Leu I l e Gl y Pr o Leu Leu I l e Cy s Ty r Ly s Gl u
                                      565                           570                           575
              Ser Val As p Gl n Ar g Gl y As n Gl n I l e Met Ser As p Ly s Ar g As n Val
                                580                           585                           590
              I l e Leu Phe Ser Val Phe As p Gl u As n Ar g Ser Tr p Ty r Leu Thr Gl u
                          595                           600                           605
              As n I l e Gl n Ar g Phe Leu Pr o As n Pr o Al a Gl y Val Gl n Leu Gl u As p
                    610                           615                           620
              Pr o Gl u Phe Gl n Al a Ser As n I l e Met Hi s Ser I l e As n Gl y Ty r Val
              625                           630                           635                           640
              Phe As p Ser Leu Gl n Leu Ser Val Cy s Leu Hi s Gl u Val Al a Ty r Tr p
                                                                    Page 175

                                                                     97047_1
<removed-date>
                                      645                           650                           655
              Ty r I l e Leu Ser I l e Gl y Al a Gl n Thr As p Phe Leu Ser Val Phe Phe
                                660                           665                           670
<removed-apn>
              Ser Gl y Ty r Thr Phe Ly s Hi s Ly s Met Val Ty r Gl u As p Thr Leu Thr
                          675                           680                           685
              Leu Phe Pr o Phe Ser Gl y Gl u Thr Val Phe Met Ser Met Gl u As n Pr o
                    690                           695                           700
              Gl y Leu Tr p I l e Leu Gl y Cy s Hi s As n Ser As p Phe Ar g As n Ar g Gl y
              705                           710                           715                           720
              Met Thr Al a Leu Leu Ly s Val Ser Ser Cy s As p Ly s As n Thr Gl y As p
                                      725                           730                           735
              Ty r Ty r Gl u As p Ser Ty r Gl u As p I l e Ser Al a Ty r Leu Leu Ser Ly s
                                740                           745                           750
              As n As n Al a I l e Gl u Pr o Ar g Ser Phe Ser Gl n As n Pr o Pr o Val Leu
                          755                           760                           765
              Ly s Ar g Hi s Gl n Ar g Gl u I l e Thr Ar g Thr Thr Leu Gl n Ser As p Gl n
                    770                           775                           780
                                                                    Page 176

                                                                    97047_1
<removed-date>
              Gl u Gl u I l e As p Ty r As p As p Thr I l e Ser Val Gl u Met Ly s Ly s Gl u
              785                           790                           795                           800
              As p Phe As p I l e Ty r As p Gl u As p Gl u As n Gl n Ser Pr o Ar g Ser Phe
                                      805                           810                           815
<removed-apn>
              Gl n Ly s Ly s Thr Ar g Hi s Ty r Phe I l e Al a Al a Val Gl u Ar g Leu Tr p
                                820                           825                           830
              As p Ty r Gl y Met Ser Ser Ser Pr o Hi s Val Leu Ar g As n Ar g Al a Gl n
                          835                           840                           845
              Ser Gl y Ser Val Pr o Gl n Phe Ly s Ly s Val Val Phe Gl n Gl u Phe Thr
                    850                           855                           860
              As p Gl y Ser Phe Thr Gl n Pr o Leu Ty r Ar g Gl y Gl u Leu As n Gl u Hi s
              865                           870                           875                           880
              Leu Gl y Leu Leu Gl y Pr o Ty r I l e Ar g Al a Gl u Val Gl u As p As n I l e
                                      885                           890                           895
              Met Val Thr Phe Ar g As n Gl n Al a Ser Ar g Pr o Ty r Ser Phe Ty r Ser
                                900                           905                           910
              Ser Leu I l e Ser Ty r Gl u Gl u As p Gl n Ar g Gl n Gl y Al a Gl u Pr o Ar g
                                                                    Page 177

                                                                      97047_1
<removed-date>
                           915                           920                            925
              Ly s As n Phe Val Ly s Pr o As n Gl u Thr Ly s Thr Ty r Phe Tr p Ly s Val
                    930                            935                            940
<removed-apn>
              Gl n Hi s Hi s Met Al a Pr o Thr Ly s As p Gl u Phe As p Cy s Ly s Al a Tr p
              945                            950                            955                            960
              Al a Ty r Phe Ser As p Val As p Leu Gl u Ly s As p Val Hi s Ser Gl y Leu
                                       965                            970                            975
              I l e Gl y Pr o Leu Leu Val Cy s Hi s Thr As n Thr Leu As n Pr o Al a Hi s
                                 980                            985                            990
              Gl y Ar g Gl n Val Thr Val Gl n Gl u               Phe Al a Leu Phe Phe            Thr I l e Phe
                           995                           1000                            1005
              As p Gl u     Thr Ly s Ser Tr p Ty r         Phe Thr Gl u As n Met              Gl u Ar g As n
                    1010                            1015                            1020
              Cy s Ar g     Al a Pr o Cy s As n I l e      Gl n Met Gl u As p Pr o            Thr Phe Ly s
                    1025                            1030                            1035
              Gl u As n     Ty r Ar g Phe Hi s Al a        I l e As n Gl y Ty r I l e         Met As p Thr
                    1040                            1045                            1050
                                                                      Page 178

                                                             97047_1
<removed-date>
              Leu Pr o    Gl y Leu Val Met Al a      Gl n As p Gl n Ar g I l e   Ar g Tr p Ty r
                   1055                       1060                        1065
              Leu Leu     Ser Met Gl y Ser As n      Gl u As n I l e Hi s Ser    I l e Hi s Phe
                   1070                       1075                        1080
<removed-apn>
              Ser Gl y    Hi s Val Phe Thr Val       Ar g Ly s Ly s Gl u Gl u    Ty r Ly s Met
                   1085                       1090                        1095
              Al a Leu    Ty r As n Leu Ty r Pr o    Gl y Val Phe Gl u Thr       Val Gl u Met
                   1100                       1105                        1110
              Leu Pr o    Ser Ly s Al a Gl y I l e   Tr p Ar g Val Gl u Cy s     Leu I l e Gl y
                   1115                       1120                        1125
              Gl u Hi s   Leu Hi s Al a Gl y Met     Ser Thr Leu Phe Leu         Val Ty r Ser
                   1130                       1135                        1140
              As n Ly s   Cy s Gl n Thr Pr o Leu     Gl y Met Al a Ser Gl y      Hi s I l e Ar g
                   1145                       1150                        1155
              As p Phe    Gl n I l e Thr Al a Ser    Gl y Gl n Ty r Gl y Gl n    Tr p Al a Pr o
                   1160                       1165                        1170
              Ly s Leu    Al a Ar g Leu Hi s Ty r    Ser Gl y Ser I l e As n     Al a Tr p Ser
                                                             Page 179

                                                               97047_1
<removed-date>
                   1175                         1180                        1185
              Thr Ly s    Gl u Pr o Phe Ser Tr p       I l e Ly s Val As p Leu     Leu Al a Pr o
                   1190                         1195                        1200
<removed-apn>
              Met I l e   I l e Hi s Gl y I l e Ly s   Thr Gl n Gl y Al a Ar g     Gl n Ly s Phe
                   1205                         1210                        1215
              Ser Ser     Leu Ty r I l e Ser Gl n      Phe I l e I l e Met Ty r    Ser Leu As p
                   1220                         1225                        1230
              Gl y Ly s   Ly s Tr p Gl n Thr Ty r      Ar g Gl y As n Ser Thr      Gl y Thr Leu
                   1235                         1240                        1245
              Met Val     Phe Phe Gl y As n Val        As p Ser Ser Gl y I l e     Ly s Hi s As n
                   1250                         1255                        1260
              I l e Phe   As n Pr o Pr o I l e I l e   Al a Ar g Ty r I l e Ar g   Leu Hi s Pr o
                   1265                         1270                        1275
              Thr Hi s    Ty r Ser I l e Ar g Ser      Thr Leu Ar g Met Gl u       Leu Met Gl y
                   1280                         1285                        1290
              Cy s As p   Leu As n Ser Cy s Ser        Met Pr o Leu Gl y Met       Gl u Ser Ly s
                   1295                         1300                        1305
                                                               Page 180

                                                              97047_1
<removed-date>
              Al a I l e   Ser As p Al a Gl n I l e   Thr Al a Ser Ser Ty r      Phe Thr As n
                   1310                        1315                       1320
              Met Phe      Al a Thr Tr p Ser Pr o     Ser Ly s Al a Ar g Leu     Hi s Leu Gl n
                   1325                        1330                       1335
<removed-apn>
              Gl y Ar g    Ser As n Al a Tr p Ar g    Pr o Gl n Val As n As n    Pr o Ly s Gl u
                   1340                        1345                       1350
              Tr p Leu     Gl n Val As p Phe Gl n     Ly s Thr Met Ly s Val      Thr Gl y Val
                   1355                        1360                       1365
              Thr Thr      Gl n Gl y Val Ly s Ser     Leu Leu Thr Ser Met        Ty r Val Ly s
                   1370                        1375                       1380
              Gl u Phe     Leu I l e Ser Ser Ser      Gl n As p Gl y Hi s Gl n   Tr p Thr Leu
                   1385                        1390                       1395
              Phe Phe      Gl n As n Gl y Ly s Val    Ly s Val Phe Gl n Gl y     As n Gl n As p
                   1400                        1405                       1410
              Ser Phe      Thr Pr o Val Val As n      Ser Leu As p Pr o Pr o     Leu Leu Thr
                   1415                        1420                       1425
              Ar g Ty r    Leu Ar g I l e Hi s Pr o   Gl n Ser Tr p Val Hi s     Gl n I l e Al a
                                                             Page 181

                                                             97047_1
<removed-date>
                   1430                       1435                       1440
              Leu Ar g    Met Gl u Val Leu Gl y      Cy s Gl u Al a Gl n As p   Leu Ty r As p
                   1445                       1450                       1455
<removed-apn>
              Ly s Thr    Hi s Thr Cy s Pr o Pr o    Cy s Pr o Al a Pr o Gl u   Leu Leu Gl y
                   1460                       1465                       1470
              Gl y Pr o   Ser Val Phe Leu Phe        Pr o Pr o Ly s Pr o Ly s   As p Thr Leu
                   1475                       1480                       1485
              Met I l e   Ser Ar g Thr Pr o Gl u     Val Thr Cy s Val Val       Val As p Val
                   1490                       1495                       1500
              Ser Hi s    Gl u As p Pr o Gl u Val    Ly s Phe As n Tr p Ty r    Val As p Gl y
                   1505                       1510                       1515
              Val Gl u    Val Hi s As n Al a Ly s    Thr Ly s Pr o Ar g Gl u    Gl u Gl n Ty r
                   1520                       1525                       1530
              As n Ser    Thr Ty r Ar g Val Val      Ser Val Leu Thr Val        Leu Hi s Gl n
                   1535                       1540                       1545
              As p Tr p   Leu As n Gl y Ly s Gl u    Ty r Ly s Cy s Ly s Val    Ser As n Ly s
                   1550                       1555                       1560
                                                            Page 182

                                                              97047_1
<removed-date>
              Al a Leu    Pr o Al a Pr o I l e Gl u   Ly s Thr I l e Ser Ly s   Al a Ly s Gl y
                   1565                        1570                      1575
              Gl n Pr o   Ar g Gl u Pr o Gl n Val     Ty r Thr Leu Pr o Pr o    Ser Ar g As p
                   1580                        1585                      1590
<removed-apn>
              Gl u Leu    Thr Ly s As n Gl n Val      Ser Leu Thr Cy s Leu      Val Ly s Gl y
                   1595                        1600                      1605
              Phe Ty r    Pr o Ser As p I l e Al a    Val Gl u Tr p Gl u Ser    As n Gl y Gl n
                   1610                        1615                      1620
              Pr o Gl u   As n As n Ty r Ly s Thr     Thr Pr o Pr o Val Leu     As p Ser As p
                   1625                        1630                      1635
              Gl y Ser    Phe Phe Leu Ty r Ser        Ly s Leu Thr Val As p     Ly s Ser Ar g
                   1640                        1645                      1650
              Tr p Gl n   Gl n Gl y As n Val Phe      Ser Cy s Ser Val Met      Hi s Gl u Al a
                   1655                        1660                      1665
              Leu Hi s    As n Hi s Ty r Thr Gl n     Ly s Ser Leu Ser Leu      Ser Pr o Gl y
                   1670                        1675                      1680
              Ly s Ar g   Ar g Ar g Ar g Ser Gl y     Gl y Gl y Gl y Ser Gl y   Gl y Gl y Gl y
                                                             Page 183

                                                             97047_1
<removed-date>
                   1685                       1690                       1695
              Ser Gl y    Gl y Gl y Gl y Ser Gl y    Gl y Gl y Gl y Ser Gl y    Gl y Gl y Gl y
                   1700                       1705                       1710
<removed-apn>
              Ser Gl y    Gl y Gl y Gl y Ser Ar g    Ly s Ar g Ar g Ly s Ar g   Ser Leu Ser
                   1715                       1720                       1725
              Cy s Ar g   Pr o Pr o Met Val Ly s     Leu Val Cy s Pr o Al a     As p As n Leu
                   1730                       1735                       1740
              Ar g Al a   Gl u Gl y Leu Gl u Cy s    Thr Ly s Thr Cy s Gl n     As n Ty r As p
                   1745                       1750                       1755
              Leu Gl u    Cy s Met Ser Met Gl y      Cy s Val Ser Gl y Cy s     Leu Cy s Pr o
                   1760                       1765                       1770
              Pr o Gl y   Met Val Ar g Hi s Gl u     As n Ar g Cy s Val Al a    Leu Gl u Ar g
                   1775                       1780                       1785
              Cy s Pr o   Cy s Phe Hi s Gl n Gl y    Ly s Gl u Ty r Al a Pr o   Gl y Gl u Thr
                   1790                       1795                       1800
              Val Ly s    I l e Gl y Cy s As n Thr   Cy s Val Cy s Ar g As p    Ar g Ly s Tr p
                   1805                       1810                       1815
                                                            Page 184

                                                            97047_1
<removed-date>
              As n Cy s   Thr As p Hi s Val Cy s    As p Al a Thr Cy s Ser    Thr I l e Gl y
                   1820                      1825                      1830
              Met Al a    Hi s Ty r Leu Thr Phe     As p Gl y Leu Ly s Ty r   Leu Phe Pr o
                   1835                      1840                      1845
<removed-apn>
              Gl y Gl u   Cy s Gl n Ty r Val Leu    Val Gl n As p Ty r Cy s   Gl y Ser As n
                   1850                      1855                      1860
              Pr o Gl y   Thr Phe Ar g I l e Leu    Val Gl y As n Ly s Gl y   Cy s Ser Hi s
                   1865                      1870                      1875
              Pr o Ser    Val Ly s Cy s Ly s Ly s   Ar g Val Thr I l e Leu    Val Gl u Gl y
                   1880                      1885                      1890
              Gl y Gl u   I l e Gl u Leu Phe As p   Gl y Gl u Val As n Val    Ly s Ar g Pr o
                   1895                      1900                      1905
              Met Ly s    As p Gl u Thr Hi s Phe    Gl u Val Val Gl u Ser     Gl y Ar g Ty r
                   1910                      1915                      1920
              Ile Ile     Leu Leu Leu Gl y Ly s     Al a Leu Ser Val Val      Tr p As p Ar g
                   1925                      1930                      1935
              Hi s Leu    Ser I l e Ser Val Val     Leu Ly s Gl n Thr Ty r    Gl n Gl u Ly s
                                                           Page 185

                                                             97047_1
<removed-date>
                   1940                       1945                        1950
              Val Cy s    Gl y Leu Cy s Gl y As n    Phe As p Gl y I l e Gl n    As n As n As p
                   1955                       1960                        1965
<removed-apn>
              Leu Thr     Ser Ser As n Leu Gl n      Val Gl u Gl u As p Pr o     Val As p Phe
                   1970                       1975                        1980
              Gl y As n   Ser Tr p Ly s Val Ser      Ser Gl n Cy s Al a As p     Thr Ar g Ly s
                   1985                       1990                        1995
              Val Pr o    Leu As p Ser Ser Pr o      Al a Thr Cy s Hi s As n     As n I l e Met
                   2000                       2005                        2010
              Ly s Gl n   Thr Met Val As p Ser       Ser Cy s Ar g I l e Leu     Thr Ser As p
                   2015                       2020                        2025
              Val Phe     Gl n As p Cy s As n Ly s   Leu Val As p Pr o Gl u      Pr o Ty r Leu
                   2030                       2035                        2040
              As p Val    Cy s I l e Ty r As p Thr   Cy s Ser Cy s Gl u Ser      I l e Gl y As p
                   2045                       2050                        2055
              Cy s Al a   Al a Phe Cy s As p Thr     I l e Al a Al a Ty r Al a   Hi s Val Cy s
                   2060                       2065                        2070
                                                             Page 186

                                                             97047_1
<removed-date>
              Al a Gl n   Hi s Gl y Ly s Val Val     Thr Tr p Ar g Thr Al a      Thr Leu Cy s
                   2075                       2080                        2085
              Pr o Gl n   Ser Cy s Gl u Gl u Ar g    As n Leu Ar g Gl u As n     Gl y Ty r Gl u
                   2090                       2095                        2100
<removed-apn>
              Al a Gl u   Tr p Ar g Ty r As n Ser    Cy s Al a Pr o Al a Cy s    Gl n Val Thr
                   2105                       2110                        2115
              Cy s Gl n   Hi s Pr o Gl u Pr o Leu    Al a Cy s Pr o Val Gl n     Cy s Val Gl u
                   2120                       2125                        2130
              Gl y Cy s   Hi s Al a Hi s Cy s Pr o   Pr o Gl y Ly s I l e Leu    As p Gl u Leu
                   2135                       2140                        2145
              Leu Gl n    Thr Cy s Val As p Pr o     Gl u As p Cy s Pr o Val     Cy s Gl u Val
                   2150                       2155                        2160
              Al a Gl y   Ar g Ar g Phe Al a Ser     Gl y Ly s Ly s Val Thr      Leu As n Pr o
                   2165                       2170                        2175
              Ser As p    Pr o Gl u Hi s Cy s Gl n   I l e Cy s Hi s Cy s As p   Val Val As n
                   2180                       2185                        2190
              Leu Thr     Cy s Gl u Al a Cy s Gl n   Gl u Pr o I l e Ser Gl y    Thr Ser Gl u
                                                             Page 187

                                                            97047_1
<removed-date>
                   2195                      2200                      2205
              Ser Al a    Thr Pr o Gl u Ser Gl y    Pr o Gl y Ser Gl u Pr o   Al a Thr Ser
                   2210                      2215                      2220
<removed-apn>
              Gl y Ser    Gl u Thr Pr o Gl y Thr    Ser Gl u Ser Al a Thr     Pr o Gl u Ser
                   2225                      2230                      2235
              Gl y Pr o   Gl y Ser Gl u Pr o Al a   Thr Ser Gl y Ser Gl u     Thr Pr o Gl y
                   2240                      2245                      2250
              Thr Ser     Gl u Ser Al a Thr Pr o    Gl u Ser Gl y Pr o Gl y   Thr Ser Thr
                   2255                      2260                      2265
              Gl u Pr o   Ser Gl u Gl y Ser Al a    Pr o Gl y Ser Pr o Al a   Gl y Ser Pr o
                   2270                      2275                      2280
              Thr Ser     Thr Gl u Gl u Gl y Thr    Ser Gl u Ser Al a Thr     Pr o Gl u Ser
                   2285                      2290                      2295
              Gl y Pr o   Gl y Ser Gl u Pr o Al a   Thr Ser Gl y Ser Gl u     Thr Pr o Gl y
                   2300                      2305                      2310
              Thr Ser     Gl u Ser Al a Thr Pr o    Gl u Ser Gl y Pr o Gl y   Ser Pr o Al a
                   2315                      2320                      2325
                                                           Page 188

                                                            97047_1
<removed-date>
              Gl y Ser    Pr o Thr Ser Thr Gl u     Gl u Gl y Ser Pr o Al a   Gl y Ser Pr o
                   2330                      2335                      2340
              Thr Ser     Thr Gl u Gl u Gl y Thr    Ser Thr Gl u Pr o Ser     Gl u Gl y Ser
                   2345                      2350                      2355
<removed-apn>
              Al a Pr o   Gl y Thr Ser Gl u Ser     Al a Thr Pr o Gl u Ser    Gl y Pr o Gl y
                   2360                      2365                      2370
              Thr Ser     Gl u Ser Al a Thr Pr o    Gl u Ser Gl y Pr o Gl y   Thr Ser Gl u
                   2375                      2380                      2385
              Ser Al a    Thr Pr o Gl u Ser Gl y    Pr o Gl y Ser Gl u Pr o   Al a Thr Ser
                   2390                      2395                      2400
              Gl y Ser    Gl u Thr Pr o Gl y Ser    Gl u Pr o Al a Thr Ser    Gl y Ser Gl u
                   2405                      2410                      2415
              Thr Pr o    Gl y Ser Pr o Al a Gl y   Ser Pr o Thr Ser Thr      Gl u Gl u Gl y
                   2420                      2425                      2430
              Thr Ser     Thr Gl u Pr o Ser Gl u    Gl y Ser Al a Pr o Gl y   Thr Ser Thr
                   2435                      2440                      2445
              Gl u Pr o   Ser Gl u Gl y Ser Al a    Pr o Gl y Ser Gl u Pr o   Al a Thr Ser
                                                           Page 189

                                                            97047_1
<removed-date>
                   2450                      2455                       2460
              Gl y Ser    Gl u Thr Pr o Gl y Thr    Ser Gl u Ser Al a Thr      Pr o Gl u Ser
                   2465                      2470                       2475
<removed-apn>
              Gl y Pr o   Gl y Thr Ser Thr Gl u     Pr o Ser Gl u Gl y Ser     Al a Pr o As p
                   2480                      2485                       2490
              Ser Gl y    Gl y Gl y Gl y Ser Gl y   Gl y Gl y Gl y Ser Gl y    Gl y Gl y Gl y
                   2495                      2500                       2505
              Ser Gl y    Gl y Gl y Gl y Ser Gl y   Gl y Gl y Gl y Ser Leu     Val Pr o Ar g
                   2510                      2515                       2520
              Gl y Ser    Gl y Gl y As p Ly s Thr   Hi s Thr Cy s Pr o Pr o    Cy s Pr o Al a
                   2525                      2530                       2535
              Pr o Gl u   Leu Leu Gl y Gl y Pr o    Ser Val Phe Leu Phe        Pr o Pr o Ly s
                   2540                      2545                       2550
              Pr o Ly s   As p Thr Leu Met I l e    Ser Ar g Thr Pr o Gl u     Val Thr Cy s
                   2555                      2560                       2565
              Val Val     Val As p Val Ser Hi s     Gl u As p Pr o Gl u Val    Ly s Phe As n
                   2570                      2575                       2580
                                                           Page 190

                                                             97047_1
<removed-date>
              Tr p Ty r   Val As p Gl y Val Gl u     Val Hi s As n Al a Ly s     Thr Ly s Pr o
                   2585                       2590                        2595
              Ar g Gl u   Gl u Gl n Ty r As n Ser    Thr Ty r Ar g Val Val       Ser Val Leu
                   2600                       2605                        2610
<removed-apn>
              Thr Val     Leu Hi s Gl n As p Tr p    Leu As n Gl y Ly s Gl u     Ty r Ly s Cy s
                   2615                       2620                        2625
              Ly s Val    Ser As n Ly s Al a Leu     Pr o Al a Pr o I l e Gl u   Ly s Thr I l e
                   2630                       2635                        2640
              Ser Ly s    Al a Ly s Gl y Gl n Pr o   Ar g Gl u Pr o Gl n Val     Ty r Thr Leu
                   2645                       2650                        2655
              Pr o Pr o   Ser Ar g As p Gl u Leu     Thr Ly s As n Gl n Val      Ser Leu Thr
                   2660                       2665                        2670
              Cy s Leu    Val Ly s Gl y Phe Ty r     Pr o Ser As p I l e Al a    Val Gl u Tr p
                   2675                       2680                        2685
              Gl u Ser    As n Gl y Gl n Pr o Gl u   As n As n Ty r Ly s Thr     Thr Pr o Pr o
                   2690                       2695                        2700
              Val Leu     As p Ser As p Gl y Ser     Phe Phe Leu Ty r Ser        Ly s Leu Thr
                                                             Page 191

                                                                 97047_1
<removed-date>
                  2705                            2710                      2715
              Val As p     Ly s Ser Ar g Tr p Gl n       Gl n Gl y As n Val Phe    Ser Cy s Ser
                  2720                            2725                      2730
<removed-apn>
              Val Met      Hi s Gl u Al a Leu Hi s       As n Hi s Ty r Thr Gl n   Ly s Ser Leu
                  2735                            2740                      2745
              Ser Leu      Ser Pr o Gl y Ly s
                  2750
              <210>      102
              <211>      2242
              <212>      PRT
              <213>      Ar t i f i c i al Sequenc e
              <220>
              <223>      pSYN- FVI I I - 170 pr ot ei n s equenc e
              <400>      102
              Ser Leu Ser Cy s Ar g Pr o Pr o Met Val Ly s Leu Val Cy s Pr o Al a As p
              1                      5                          10                       15
              As n Leu Ar g Al a Gl u Gl y Leu Gl u Cy s Thr Ly s Thr Cy s Gl n As n Ty r
                                20                         25                       30
              As p Leu Gl u Cy s Met Ser Met Gl y Cy s Val Ser Gl y Cy s Leu Cy s Pr o
                                                                Page 192

                                                                    97047_1
<removed-date>
                          35                            40                            45
              Pr o Gl y Met Val Ar g Hi s Gl u As n Ar g Cy s Val Al a Leu Gl u Ar g Cy s
                    50                            55                            60
<removed-apn>
              Pr o Cy s Phe Hi s Gl n Gl y Ly s Gl u Ty r Al a Pr o Gl y Gl u Thr Val Ly s
              65                            70                            75                            80
              I l e Gl y Cy s As n Thr Cy s Val Cy s Ar g As p Ar g Ly s Tr p As n Cy s Thr
                                      85                            90                            95
              As p Hi s Val Cy s As p Al a Thr Cy s Ser Thr I l e Gl y Met Al a Hi s Ty r
                                100                           105                           110
              Leu Thr Phe As p Gl y Leu Ly s Ty r Leu Phe Pr o Gl y Gl u Cy s Gl n Ty r
                          115                           120                           125
              Val Leu Val Gl n As p Ty r Cy s Gl y Ser As n Pr o Gl y Thr Phe Ar g I l e
                    130                           135                           140
              Leu Val Gl y As n Ly s Gl y Cy s Ser Hi s Pr o Ser Val Ly s Cy s Ly s Ly s
              145                           150                           155                           160
              Ar g Val Thr I l e Leu Val Gl u Gl y Gl y Gl u I l e Gl u Leu Phe As p Gl y
                                      165                           170                           175
                                                                    Page 193

                                                                    97047_1
<removed-date>
              Gl u Val As n Val Ly s Ar g Pr o Met Ly s As p Gl u Thr Hi s Phe Gl u Val
                                180                           185                           190
              Val Gl u Ser Gl y Ar g Ty r I l e I l e Leu Leu Leu Gl y Ly s Al a Leu Ser
                          195                           200                           205
<removed-apn>
              Val Val Tr p As p Ar g Hi s Leu Ser I l e Ser Val Val Leu Ly s Gl n Thr
                    210                           215                           220
              Ty r Gl n Gl u Ly s Val Cy s Gl y Leu Cy s Gl y As n Phe As p Gl y I l e Gl n
              225                           230                           235                           240
              As n As n As p Leu Thr Ser Ser As n Leu Gl n Val Gl u Gl u As p Pr o Val
                                      245                           250                           255
              As p Phe Gl y As n Ser Tr p Ly s Val Ser Ser Gl n Cy s Al a As p Thr Ar g
                                260                           265                           270
              Ly s Val Pr o Leu As p Ser Ser Pr o Al a Thr Cy s Hi s As n As n I l e Met
                          275                           280                           285
              Ly s Gl n Thr Met Val As p Ser Ser Cy s Ar g I l e Leu Thr Ser As p Val
                    290                           295                           300
              Phe Gl n As p Cy s As n Ly s Leu Val As p Pr o Gl u Pr o Ty r Leu As p Val
                                                                    Page 194

                                                                    97047_1
<removed-date>
              305                           310                        315                              320
              Cy s I l e Ty r As p Thr Cy s Ser Cy s Gl u Ser I l e Gl y As p Cy s Al a Al a
                                      325                           330                           335
<removed-apn>
              Phe Cy s As p Thr I l e Al a Al a Ty r Al a Hi s Val Cy s Al a Gl n Hi s Gl y
                                340                           345                           350
              Ly s Val Val Thr Tr p Ar g Thr Al a Thr Leu Cy s Pr o Gl n Ser Cy s Gl u
                          355                           360                           365
              Gl u Ar g As n Leu Ar g Gl u As n Gl y Ty r Gl u Al a Gl u Tr p Ar g Ty r As n
                    370                           375                           380
              Ser Cy s Al a Pr o Al a Cy s Gl n Val Thr Cy s Gl n Hi s Pr o Gl u Pr o Leu
              385                           390                           395                           400
              Al a Cy s Pr o Val Gl n Cy s Val Gl u Gl y Cy s Hi s Al a Hi s Cy s Pr o Pr o
                                      405                           410                           415
              Gl y Ly s I l e Leu As p Gl u Leu Leu Gl n Thr Cy s Val As p Pr o Gl u As p
                                420                           425                           430
              Cy s Pr o Val Cy s Gl u Val Al a Gl y Ar g Ar g Phe Al a Ser Gl y Ly s Ly s
                          435                           440                           445
                                                                    Page 195

                                                                    97047_1
<removed-date>
              Val Thr Leu As n Pr o Ser As p Pr o Gl u Hi s Cy s Gl n I l e Cy s Hi s Cy s
                    450                           455                           460
              As p Val Val As n Leu Thr Cy s Gl u Al a Cy s Gl n Gl u Pr o I l e Ser Gl y
              465                           470                           475                           480
<removed-apn>
              Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a
                                      485                           490                           495
              Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
                                500                           505                           510
              Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y
                          515                           520                           525
              Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u
                    530                           535                           540
              Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser
              545                           550                           555                           560
              Thr Gl u Gl u Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y
                                      565                           570                           575
              Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser
                                                                    Page 196

                                                                    97047_1
<removed-date>
                                580                           585                           590
              Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser
                          595                           600                           605
<removed-apn>
              Thr Gl u Gl u Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y
                    610                           615                           620
              Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser
              625                           630                           635                           640
              Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
                                      645                           650                           655
              Ser Gl y Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y
                                660                           665                           670
              Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Ser Gl u Pr o Al a
                          675                           680                           685
              Thr Ser Gl y Ser Gl u Thr Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser
                    690                           695                           700
              Thr Gl u Gl u Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y
              705                           710                           715                           720
                                                                    Page 197

                                                                    97047_1
<removed-date>
              Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Gl u Pr o Al a
                                      725                           730                           735
              Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
                                740                           745                           750
<removed-apn>
              Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o As p
                          755                           760                           765
              Ser Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser
                    770                           775                           780
              Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser Leu Val Pr o Ar g Gl y Ser
              785                           790                           795                           800
              Gl y Gl y Al a Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu
                                      805                           810                           815
              Ser Tr p As p Ty r Met Gl n Ser As p Leu Gl y Gl u Leu Pr o Val As p Al a
                                820                           825                           830
              Ar g Phe Pr o Pr o Ar g Val Pr o Ly s Ser Phe Pr o Phe As n Thr Ser Val
                          835                           840                           845
              Val Ty r Ly s Ly s Thr Leu Phe Val Gl u Phe Thr As p Hi s Leu Phe As n
                                                                    Page 198

                                                                    97047_1
<removed-date>
                    850                           855                           860
              I l e Al a Ly s Pr o Ar g Pr o Pr o Tr p Met Gl y Leu Leu Gl y Pr o Thr I l e
              865                           870                           875                           880
<removed-apn>
              Gl n Al a Gl u Val Ty r As p Thr Val Val I l e Thr Leu Ly s As n Met Al a
                                      885                           890                           895
              Ser Hi s Pr o Val Ser Leu Hi s Al a Val Gl y Val Ser Ty r Tr p Ly s Al a
                                900                           905                           910
              Ser Gl u Gl y Al a Gl u Ty r As p As p Gl n Thr Ser Gl n Ar g Gl u Ly s Gl u
                          915                           920                           925
              As p As p Ly s Val Phe Pr o Gl y Gl y Ser Hi s Thr Ty r Val Tr p Gl n Val
                    930                           935                           940
              Leu Ly s Gl u As n Gl y Pr o Met Al a Ser As p Pr o Leu Cy s Leu Thr Ty r
              945                           950                           955                           960
              Ser Ty r Leu Ser Hi s Val As p Leu Val Ly s As p Leu As n Ser Gl y Leu
                                      965                           970                           975
              I l e Gl y Al a Leu Leu Val Cy s Ar g Gl u Gl y Ser Leu Al a Ly s Gl u Ly s
                                980                           985                           990
                                                                    Page 199

                                                               97047_1
<removed-date>
              Thr Gl n Thr Leu Hi s Ly s Phe I l e          Leu Leu Phe Al a Val          Phe As p Gl u
                          995                        1000                          1005
              Gl y Ly s    Ser Tr p Hi s Ser Gl u      Thr Ly s As n Ser Leu         Met Gl n As p
                   1010                       1015                          1020
<removed-apn>
              Ar g As p    Al a Al a Ser Al a Ar g     Al a Tr p Pr o Ly s Met       Hi s Thr Val
                   1025                       1030                          1035
              As n Gl y    Ty r Val As n Ar g Ser      Leu Pr o Gl y Leu I l e       Gl y Cy s Hi s
                   1040                       1045                          1050
              Ar g Ly s    Ser Val Ty r Tr p Hi s      Val I l e Gl y Met Gl y       Thr Thr Pr o
                   1055                       1060                          1065
              Gl u Val     Hi s Ser I l e Phe Leu      Gl u Gl y Hi s Thr Phe        Leu Val Ar g
                   1070                       1075                          1080
              As n Hi s    Ar g Gl n Al a Ser Leu      Gl u I l e Ser Pr o I l e     Thr Phe Leu
                   1085                       1090                          1095
              Thr Al a     Gl n Thr Leu Leu Met        As p Leu Gl y Gl n Phe        Leu Leu Phe
                   1100                       1105                          1110
              Cy s Hi s    I l e Ser Ser Hi s Gl n     Hi s As p Gl y Met Gl u       Al a Ty r Val
                                                               Page 200

                                                               97047_1
<removed-date>
                   1115                         1120                       1125
              Ly s Val     As p Ser Cy s Pr o Gl u     Gl u Pr o Gl n Leu Ar g    Met Ly s As n
                   1130                         1135                       1140
<removed-apn>
              As n Gl u    Gl u Al a Gl u As p Ty r    As p As p As p Leu Thr     As p Ser Gl u
                   1145                         1150                       1155
              Met As p     Val Val Ar g Phe As p       As p As p As n Ser Pr o    Ser Phe I l e
                   1160                         1165                       1170
              Gl n I l e   Ar g Ser Val Al a Ly s      Ly s Hi s Pr o Ly s Thr    Tr p Val Hi s
                   1175                         1180                       1185
              Ty r I l e   Al a Al a Gl u Gl u Gl u    As p Tr p As p Ty r Al a   Pr o Leu Val
                   1190                         1195                       1200
              Leu Al a     Pr o As p As p Ar g Ser     Ty r Ly s Ser Gl n Ty r    Leu As n As n
                   1205                         1210                       1215
              Gl y Pr o    Gl n Ar g I l e Gl y Ar g   Ly s Ty r Ly s Ly s Val    Ar g Phe Met
                   1220                         1225                       1230
              Al a Ty r    Thr As p Gl u Thr Phe       Ly s Thr Ar g Gl u Al a    I l e Gl n Hi s
                   1235                         1240                       1245
                                                              Page 201

                                                              97047_1
<removed-date>
              Gl u Ser     Gl y I l e Leu Gl y Pr o   Leu Leu Ty r Gl y Gl u    Val Gl y As p
                    1250                       1255                      1260
              Thr Leu      Leu I l e I l e Phe Ly s   As n Gl n Al a Ser Ar g   Pr o Ty r As n
                    1265                       1270                      1275
<removed-apn>
              I l e Ty r   Pr o Hi s Gl y I l e Thr   As p Val Ar g Pr o Leu    Ty r Ser Ar g
                    1280                       1285                      1290
              Ar g Leu     Pr o Ly s Gl y Val Ly s    Hi s Leu Ly s As p Phe    Pr o I l e Leu
                    1295                       1300                      1305
              Pr o Gl y    Gl u I l e Phe Ly s Ty r   Ly s Tr p Thr Val Thr     Val Gl u As p
                    1310                       1315                      1320
              Gl y Pr o    Thr Ly s Ser As p Pr o     Ar g Cy s Leu Thr Ar g    Ty r Ty r Ser
                    1325                       1330                      1335
              Ser Phe      Val As n Met Gl u Ar g     As p Leu Al a Ser Gl y    Leu I l e Gl y
                    1340                       1345                      1350
              Pr o Leu     Leu I l e Cy s Ty r Ly s   Gl u Ser Val As p Gl n    Ar g Gl y As n
                    1355                       1360                      1365
              Gl n I l e   Met Ser As p Ly s Ar g     As n Val I l e Leu Phe    Ser Val Phe
                                                             Page 202

                                                             97047_1
<removed-date>
                   1370                       1375                       1380
              As p Gl u   As n Ar g Ser Tr p Ty r    Leu Thr Gl u As n I l e    Gl n Ar g Phe
                   1385                       1390                       1395
<removed-apn>
              Leu Pr o    As n Pr o Al a Gl y Val    Gl n Leu Gl u As p Pr o    Gl u Phe Gl n
                   1400                       1405                       1410
              Al a Ser    As n I l e Met Hi s Ser    I l e As n Gl y Ty r Val   Phe As p Ser
                   1415                       1420                       1425
              Leu Gl n    Leu Ser Val Cy s Leu       Hi s Gl u Val Al a Ty r    Tr p Ty r I l e
                   1430                       1435                       1440
              Leu Ser     I l e Gl y Al a Gl n Thr   As p Phe Leu Ser Val       Phe Phe Ser
                   1445                       1450                       1455
              Gl y Ty r   Thr Phe Ly s Hi s Ly s     Met Val Ty r Gl u As p     Thr Leu Thr
                   1460                       1465                       1470
              Leu Phe     Pr o Phe Ser Gl y Gl u     Thr Val Phe Met Ser        Met Gl u As n
                   1475                       1480                       1485
              Pr o Gl y   Leu Tr p I l e Leu Gl y    Cy s Hi s As n Ser As p    Phe Ar g As n
                   1490                       1495                       1500
                                                            Page 203

                                                             97047_1
<removed-date>
              Ar g Gl y   Met Thr Al a Leu Leu       Ly s Val Ser Ser Cy s       As p Ly s As n
                   1505                       1510                        1515
              Thr Gl y    As p Ty r Ty r Gl u As p   Ser Ty r Gl u As p I l e    Ser Al a Ty r
                   1520                       1525                        1530
<removed-apn>
              Leu Leu     Ser Ly s As n As n Al a    I l e Gl u Pr o Ar g Ser    Phe Ser Gl n
                   1535                       1540                        1545
              As n Pr o   Pr o Val Leu Ly s Ar g     Hi s Gl n Ar g Gl u I l e   Thr Ar g Thr
                   1550                       1555                        1560
              Thr Leu     Gl n Ser As p Gl n Gl u    Gl u I l e As p Ty r As p   As p Thr I l e
                   1565                       1570                        1575
              Ser Val     Gl u Met Ly s Ly s Gl u    As p Phe As p I l e Ty r    As p Gl u As p
                   1580                       1585                        1590
              Gl u As n   Gl n Ser Pr o Ar g Ser     Phe Gl n Ly s Ly s Thr      Ar g Hi s Ty r
                   1595                       1600                        1605
              Phe I l e   Al a Al a Val Gl u Ar g    Leu Tr p As p Ty r Gl y     Met Ser Ser
                   1610                       1615                        1620
              Ser Pr o    Hi s Val Leu Ar g As n     Ar g Al a Gl n Ser Gl y     Ser Val Pr o
                                                             Page 204

                                                              97047_1
<removed-date>
                   1625                        1630                       1635
              Gl n Phe    Ly s Ly s Val Val Phe       Gl n Gl u Phe Thr As p     Gl y Ser Phe
                   1640                        1645                       1650
<removed-apn>
              Thr Gl n    Pr o Leu Ty r Ar g Gl y     Gl u Leu As n Gl u Hi s    Leu Gl y Leu
                   1655                        1660                       1665
              Leu Gl y    Pr o Ty r I l e Ar g Al a   Gl u Val Gl u As p As n    I l e Met Val
                   1670                        1675                       1680
              Thr Phe     Ar g As n Gl n Al a Ser     Ar g Pr o Ty r Ser Phe     Ty r Ser Ser
                   1685                        1690                       1695
              Leu I l e   Ser Ty r Gl u Gl u As p     Gl n Ar g Gl n Gl y Al a   Gl u Pr o Ar g
                   1700                        1705                       1710
              Ly s As n   Phe Val Ly s Pr o As n      Gl u Thr Ly s Thr Ty r     Phe Tr p Ly s
                   1715                        1720                       1725
              Val Gl n    Hi s Hi s Met Al a Pr o     Thr Ly s As p Gl u Phe     As p Cy s Ly s
                   1730                        1735                       1740
              Al a Tr p   Al a Ty r Phe Ser As p      Val As p Leu Gl u Ly s     As p Val Hi s
                   1745                        1750                       1755
                                                             Page 205

                                                              97047_1
<removed-date>
              Ser Gl y     Leu I l e Gl y Pr o Leu    Leu Val Cy s Hi s Thr       As n Thr Leu
                   1760                        1765                        1770
              As n Pr o    Al a Hi s Gl y Ar g Gl n   Val Thr Val Gl n Gl u       Phe Al a Leu
                   1775                        1780                        1785
<removed-apn>
              Phe Phe      Thr I l e Phe As p Gl u    Thr Ly s Ser Tr p Ty r      Phe Thr Gl u
                   1790                        1795                        1800
              As n Met     Gl u Ar g As n Cy s Ar g   Al a Pr o Cy s As n I l e   Gl n Met Gl u
                   1805                        1810                        1815
              As p Pr o    Thr Phe Ly s Gl u As n     Ty r Ar g Phe Hi s Al a     I l e As n Gl y
                   1820                        1825                        1830
              Ty r I l e   Met As p Thr Leu Pr o      Gl y Leu Val Met Al a       Gl n As p Gl n
                   1835                        1840                        1845
              Ar g I l e   Ar g Tr p Ty r Leu Leu     Ser Met Gl y Ser As n       Gl u As n I l e
                   1850                        1855                        1860
              Hi s Ser     I l e Hi s Phe Ser Gl y    Hi s Val Phe Thr Val        Ar g Ly s Ly s
                   1865                        1870                        1875
              Gl u Gl u    Ty r Ly s Met Al a Leu     Ty r As n Leu Ty r Pr o     Gl y Val Phe
                                                              Page 206

                                                               97047_1
<removed-date>
                   1880                        1885                         1890
              Gl u Thr     Val Gl u Met Leu Pr o      Ser Ly s Al a Gl y I l e     Tr p Ar g Val
                   1895                        1900                         1905
<removed-apn>
              Gl u Cy s    Leu I l e Gl y Gl u Hi s   Leu Hi s Al a Gl y Met       Ser Thr Leu
                   1910                        1915                         1920
              Phe Leu      Val Ty r Ser As n Ly s     Cy s Gl n Thr Pr o Leu       Gl y Met Al a
                   1925                        1930                         1935
              Ser Gl y     Hi s I l e Ar g As p Phe   Gl n I l e Thr Al a Ser      Gl y Gl n Ty r
                   1940                        1945                         1950
              Gl y Gl n    Tr p Al a Pr o Ly s Leu    Al a Ar g Leu Hi s Ty r      Ser Gl y Ser
                   1955                        1960                         1965
              I l e As n   Al a Tr p Ser Thr Ly s     Gl u Pr o Phe Ser Tr p       I l e Ly s Val
                   1970                        1975                         1980
              As p Leu     Leu Al a Pr o Met I l e    I l e Hi s Gl y I l e Ly s   Thr Gl n Gl y
                   1985                        1990                         1995
              Al a Ar g    Gl n Ly s Phe Ser Ser      Leu Ty r I l e Ser Gl n      Phe I l e I l e
                   2000                        2005                         2010
                                                              Page 207

                                                               97047_1
<removed-date>
              Met Ty r     Ser Leu As p Gl y Ly s     Ly s Tr p Gl n Thr Ty r      Ar g Gl y As n
                   2015                        2020                        2025
              Ser Thr      Gl y Thr Leu Met Val       Phe Phe Gl y As n Val        As p Ser Ser
                   2030                        2035                        2040
<removed-apn>
              Gl y I l e   Ly s Hi s As n I l e Phe   As n Pr o Pr o I l e I l e   Al a Ar g Ty r
                   2045                        2050                        2055
              I l e Ar g   Leu Hi s Pr o Thr Hi s     Ty r Ser I l e Ar g Ser      Thr Leu Ar g
                   2060                        2065                        2070
              Met Gl u     Leu Met Gl y Cy s As p     Leu As n Ser Cy s Ser        Met Pr o Leu
                   2075                        2080                        2085
              Gl y Met     Gl u Ser Ly s Al a I l e   Ser As p Al a Gl n I l e     Thr Al a Ser
                   2090                        2095                        2100
              Ser Ty r     Phe Thr As n Met Phe       Al a Thr Tr p Ser Pr o       Ser Ly s Al a
                   2105                        2110                        2115
              Ar g Leu     Hi s Leu Gl n Gl y Ar g    Ser As n Al a Tr p Ar g      Pr o Gl n Val
                   2120                        2125                        2130
              As n As n    Pr o Ly s Gl u Tr p Leu    Gl n Val As p Phe Gl n       Ly s Thr Met
                                                              Page 208

                                                               97047_1
<removed-date>
                   2135                         2140                       2145
              Ly s Val      Thr Gl y Val Thr Thr       Gl n Gl y Val Ly s Ser     Leu Leu Thr
                   2150                         2155                       2160
<removed-apn>
              Ser Met       Ty r Val Ly s Gl u Phe     Leu I l e Ser Ser Ser      Gl n As p Gl y
                   2165                         2170                       2175
              Hi s Gl n     Tr p Thr Leu Phe Phe       Gl n As n Gl y Ly s Val    Ly s Val Phe
                   2180                         2185                       2190
              Gl n Gl y     As n Gl n As p Ser Phe     Thr Pr o Val Val As n      Ser Leu As p
                   2195                         2200                       2205
              Pr o Pr o     Leu Leu Thr Ar g Ty r      Leu Ar g I l e Hi s Pr o   Gl n Ser Tr p
                   2210                         2215                       2220
              Val Hi s      Gl n I l e Al a Leu Ar g   Met Gl u Val Leu Gl y      Cy s Gl u Al a
                   2225                         2230                       2235
              Gl n As p     Leu Ty r
                   2240
              <210>       103
              <211>       1959
              <212>       PRT
                                                              Page 209

                                                                 97047_1
<removed-date>
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     pSYN- FVI I I - 169 mat ur e Pr ot ei n s equenc e
              <400>     103
<removed-apn>
              Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser Tr p As p Ty r
              1                      5                           10                        15
              Met Gl n Ser As p Leu Gl y Gl u Leu Pr o Val As p Al a Ar g Phe Pr o Pr o
                               20                          25                        30
              Ar g Val Pr o Ly s Ser Phe Pr o Phe As n Thr Ser Val Val Ty r Ly s Ly s
                         35                           40                        45
              Thr Leu Phe Val Gl u Phe Thr As p Hi s Leu Phe As n I l e Al a Ly s Pr o
                   50                           55                         60
              Ar g Pr o Pr o Tr p Met Gl y Leu Leu Gl y Pr o Thr I l e Gl n Al a Gl u Val
              65                          70                          75                        80
              Ty r As p Thr Val Val I l e Thr Leu Ly s As n Met Al a Ser Hi s Pr o Val
                                     85                          90                        95
              Ser Leu Hi s Al a Val Gl y Val Ser Ty r Tr p Ly s Al a Ser Gl u Gl y Al a
                               100                         105                       110
                                                                 Page 210

                                                                    97047_1
<removed-date>
              Gl u Ty r As p As p Gl n Thr Ser Gl n Ar g Gl u Ly s Gl u As p As p Ly s Val
                          115                           120                           125
              Phe Pr o Gl y Gl y Ser Hi s Thr Ty r Val Tr p Gl n Val Leu Ly s Gl u As n
                    130                           135                           140
<removed-apn>
              Gl y Pr o Met Al a Ser As p Pr o Leu Cy s Leu Thr Ty r Ser Ty r Leu Ser
              145                           150                           155                           160
              Hi s Val As p Leu Val Ly s As p Leu As n Ser Gl y Leu I l e Gl y Al a Leu
                                      165                           170                           175
              Leu Val Cy s Ar g Gl u Gl y Ser Leu Al a Ly s Gl u Ly s Thr Gl n Thr Leu
                                180                           185                           190
              Hi s Ly s Phe I l e Leu Leu Phe Al a Val Phe As p Gl u Gl y Ly s Ser Tr p
                          195                           200                           205
              Hi s Ser Gl u Thr Ly s As n Ser Leu Met Gl n As p Ar g As p Al a Al a Ser
                    210                           215                           220
              Al a Ar g Al a Tr p Pr o Ly s Met Hi s Thr Val As n Gl y Ty r Val As n Ar g
              225                           230                           235                           240
              Ser Leu Pr o Gl y Leu I l e Gl y Cy s Hi s Ar g Ly s Ser Val Ty r Tr p Hi s
                                                                    Page 211

                                                                     97047_1
<removed-date>
                                      245                           250                           255
              Val I l e Gl y Met Gl y Thr Thr Pr o Gl u Val Hi s Ser I l e Phe Leu Gl u
                                260                           265                           270
<removed-apn>
              Gl y Hi s Thr Phe Leu Val Ar g As n Hi s Ar g Gl n Al a Ser Leu Gl u I l e
                          275                           280                           285
              Ser Pr o I l e Thr Phe Leu Thr Al a Gl n Thr Leu Leu Met As p Leu Gl y
                    290                           295                           300
              Gl n Phe Leu Leu Phe Cy s Hi s I l e Ser Ser Hi s Gl n Hi s As p Gl y Met
              305                           310                           315                           320
              Gl u Al a Ty r Val Ly s Val As p Ser Cy s Pr o Gl u Gl u Pr o Gl n Leu Ar g
                                      325                           330                           335
              Met Ly s As n As n Gl u Gl u Al a Gl u As p Ty r As p As p As p Leu Thr As p
                                340                           345                           350
              Ser Gl u Met As p Val Val Ar g Phe As p As p As p As n Ser Pr o Ser Phe
                          355                           360                           365
              I l e Gl n I l e Ar g Ser Val Al a Ly s Ly s Hi s Pr o Ly s Thr Tr p Val Hi s
                    370                           375                           380
                                                                    Page 212

                                                                    97047_1
<removed-date>
              Ty r I l e Al a Al a Gl u Gl u Gl u As p Tr p As p Ty r Al a Pr o Leu Val Leu
              385                           390                           395                           400
              Al a Pr o As p As p Ar g Ser Ty r Ly s Ser Gl n Ty r Leu As n As n Gl y Pr o
                                      405                           410                           415
<removed-apn>
              Gl n Ar g I l e Gl y Ar g Ly s Ty r Ly s Ly s Val Ar g Phe Met Al a Ty r Thr
                                420                           425                           430
              As p Gl u Thr Phe Ly s Thr Ar g Gl u Al a I l e Gl n Hi s Gl u Ser Gl y I l e
                          435                           440                           445
              Leu Gl y Pr o Leu Leu Ty r Gl y Gl u Val Gl y As p Thr Leu Leu I l e I l e
                    450                           455                           460
              Phe Ly s As n Gl n Al a Ser Ar g Pr o Ty r As n I l e Ty r Pr o Hi s Gl y I l e
              465                           470                           475                           480
              Thr As p Val Ar g Pr o Leu Ty r Ser Ar g Ar g Leu Pr o Ly s Gl y Val Ly s
                                      485                           490                           495
              Hi s Leu Ly s As p Phe Pr o I l e Leu Pr o Gl y Gl u I l e Phe Ly s Ty r Ly s
                                500                           505                           510
              Tr p Thr Val Thr Val Gl u As p Gl y Pr o Thr Ly s Ser As p Pr o Ar g Cy s
                                                                    Page 213

                                                                    97047_1
<removed-date>
                          515                           520                           525
              Leu Thr Ar g Ty r Ty r Ser Ser Phe Val As n Met Gl u Ar g As p Leu Al a
                    530                           535                           540
<removed-apn>
              Ser Gl y Leu I l e Gl y Pr o Leu Leu I l e Cy s Ty r Ly s Gl u Ser Val As p
              545                           550                           555                           560
              Gl n Ar g Gl y As n Gl n I l e Met Ser As p Ly s Ar g As n Val I l e Leu Phe
                                      565                           570                           575
              Ser Val Phe As p Gl u As n Ar g Ser Tr p Ty r Leu Thr Gl u As n I l e Gl n
                                580                           585                           590
              Ar g Phe Leu Pr o As n Pr o Al a Gl y Val Gl n Leu Gl u As p Pr o Gl u Phe
                          595                           600                           605
              Gl n Al a Ser As n I l e Met Hi s Ser I l e As n Gl y Ty r Val Phe As p Ser
                    610                           615                           620
              Leu Gl n Leu Ser Val Cy s Leu Hi s Gl u Val Al a Ty r Tr p Ty r I l e Leu
              625                           630                           635                           640
              Ser I l e Gl y Al a Gl n Thr As p Phe Leu Ser Val Phe Phe Ser Gl y Ty r
                                      645                           650                           655
                                                                    Page 214

                                                                    97047_1
<removed-date>
              Thr Phe Ly s Hi s Ly s Met Val Ty r Gl u As p Thr Leu Thr Leu Phe Pr o
                                660                           665                           670
              Phe Ser Gl y Gl u Thr Val Phe Met Ser Met Gl u As n Pr o Gl y Leu Tr p
                          675                           680                           685
<removed-apn>
              I l e Leu Gl y Cy s Hi s As n Ser As p Phe Ar g As n Ar g Gl y Met Thr Al a
                    690                           695                           700
              Leu Leu Ly s Val Ser Ser Cy s As p Ly s As n Thr Gl y As p Ty r Ty r Gl u
              705                           710                           715                           720
              As p Ser Ty r Gl u As p I l e Ser Al a Ty r Leu Leu Ser Ly s As n As n Al a
                                      725                           730                           735
              I l e Gl u Pr o Ar g Ser Phe Ser Gl n As n Gl y Al a Pr o Gl y Thr Ser Gl u
                                740                           745                           750
              Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y
                          755                           760                           765
              Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o
                    770                           775                           780
              Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u
                                                                    Page 215

                                                                    97047_1
<removed-date>
              785                           790                        795                              800
              Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u
                                      805                           810                           815
<removed-apn>
              Gl y Ser Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u
                                820                           825                           830
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o
                          835                           840                           845
              Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                    850                           855                           860
              Gl u Ser Gl y Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u
              865                           870                           875                           880
              Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Thr
                                      885                           890                           895
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                                900                           905                           910
              Gl u Ser Gl y Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o
                          915                           920                           925
                                                                    Page 216

                                                                      97047_1
<removed-date>
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o
                    930                            935                            940
              Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y
              945                            950                            955                         960
<removed-apn>
              Ser Gl u Thr Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u
                                       965                            970                         975
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr
                                 980                            985                         990
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o              Gl y Ser Gl u Pr o Al a       Thr Ser Gl y
                           995                           1000                           1005
              Ser Gl u      Thr Pr o Gl y Thr Ser          Gl u Ser Al a Thr Pr o          Gl u Ser Gl y
                    1010                            1015                            1020
              Pr o Gl y     Thr Ser Thr Gl u Pr o          Ser Gl u Gl y Ser Al a          Pr o Al a Ser
                    1025                            1030                            1035
              Ser Pr o      Pr o Val Leu Ly s Ar g         Hi s Gl n Al a Gl u I l e       Thr Ar g Thr
                    1040                            1045                            1050
              Thr Leu       Gl n Ser As p Gl n Gl u        Gl u I l e As p Ty r As p       As p Thr I l e
                                                                      Page 217

                                                              97047_1
<removed-date>
                   1055                        1060                       1065
              Ser Val     Gl u Met Ly s Ly s Gl u     As p Phe As p I l e Ty r   As p Gl u As p
                   1070                        1075                       1080
<removed-apn>
              Gl u As n   Gl n Ser Pr o Ar g Ser      Phe Gl n Ly s Ly s Thr     Ar g Hi s Ty r
                   1085                        1090                       1095
              Phe I l e   Al a Al a Val Gl u Ar g     Leu Tr p As p Ty r Gl y    Met Ser Ser
                   1100                        1105                       1110
              Ser Pr o    Hi s Val Leu Ar g As n      Ar g Al a Gl n Ser Gl y    Ser Val Pr o
                   1115                        1120                       1125
              Gl n Phe    Ly s Ly s Val Val Phe       Gl n Gl u Phe Thr As p     Gl y Ser Phe
                   1130                        1135                       1140
              Thr Gl n    Pr o Leu Ty r Ar g Gl y     Gl u Leu As n Gl u Hi s    Leu Gl y Leu
                   1145                        1150                       1155
              Leu Gl y    Pr o Ty r I l e Ar g Al a   Gl u Val Gl u As p As n    I l e Met Val
                   1160                        1165                       1170
              Thr Phe     Ar g As n Gl n Al a Ser     Ar g Pr o Ty r Ser Phe     Ty r Ser Ser
                   1175                        1180                       1185
                                                             Page 218

                                                             97047_1
<removed-date>
              Leu I l e   Ser Ty r Gl u Gl u As p    Gl n Ar g Gl n Gl y Al a    Gl u Pr o Ar g
                   1190                       1195                        1200
              Ly s As n   Phe Val Ly s Pr o As n     Gl u Thr Ly s Thr Ty r      Phe Tr p Ly s
                   1205                       1210                        1215
<removed-apn>
              Val Gl n    Hi s Hi s Met Al a Pr o    Thr Ly s As p Gl u Phe      As p Cy s Ly s
                   1220                       1225                        1230
              Al a Tr p   Al a Ty r Phe Ser As p     Val As p Leu Gl u Ly s      As p Val Hi s
                   1235                       1240                        1245
              Ser Gl y    Leu I l e Gl y Pr o Leu    Leu Val Cy s Hi s Thr       As n Thr Leu
                   1250                       1255                        1260
              As n Pr o   Al a Hi s Gl y Ar g Gl n   Val Thr Val Gl n Gl u       Phe Al a Leu
                   1265                       1270                        1275
              Phe Phe     Thr I l e Phe As p Gl u    Thr Ly s Ser Tr p Ty r      Phe Thr Gl u
                   1280                       1285                        1290
              As n Met    Gl u Ar g As n Cy s Ar g   Al a Pr o Cy s As n I l e   Gl n Met Gl u
                   1295                       1300                        1305
              As p Pr o   Thr Phe Ly s Gl u As n     Ty r Ar g Phe Hi s Al a     I l e As n Gl y
                                                             Page 219

                                                              97047_1
<removed-date>
                   1310                        1315                       1320
              Ty r I l e   Met As p Thr Leu Pr o      Gl y Leu Val Met Al a      Gl n As p Gl n
                   1325                        1330                       1335
<removed-apn>
              Ar g I l e   Ar g Tr p Ty r Leu Leu     Ser Met Gl y Ser As n      Gl u As n I l e
                   1340                        1345                       1350
              Hi s Ser     I l e Hi s Phe Ser Gl y    Hi s Val Phe Thr Val       Ar g Ly s Ly s
                   1355                        1360                       1365
              Gl u Gl u    Ty r Ly s Met Al a Leu     Ty r As n Leu Ty r Pr o    Gl y Val Phe
                   1370                        1375                       1380
              Gl u Thr     Val Gl u Met Leu Pr o      Ser Ly s Al a Gl y I l e   Tr p Ar g Val
                   1385                        1390                       1395
              Gl u Cy s    Leu I l e Gl y Gl u Hi s   Leu Hi s Al a Gl y Met     Ser Thr Leu
                   1400                        1405                       1410
              Phe Leu      Val Ty r Ser As n Ly s     Cy s Gl n Thr Pr o Leu     Gl y Met Al a
                   1415                        1420                       1425
              Ser Gl y     Hi s I l e Ar g As p Phe   Gl n I l e Thr Al a Ser    Gl y Gl n Ty r
                   1430                        1435                       1440
                                                             Page 220

                                                               97047_1
<removed-date>
              Gl y Gl n    Tr p Al a Pr o Ly s Leu    Al a Ar g Leu Hi s Ty r      Ser Gl y Ser
                   1445                        1450                         1455
              I l e As n   Al a Tr p Ser Thr Ly s     Gl u Pr o Phe Ser Tr p       I l e Ly s Val
                   1460                        1465                         1470
<removed-apn>
              As p Leu     Leu Al a Pr o Met I l e    I l e Hi s Gl y I l e Ly s   Thr Gl n Gl y
                   1475                        1480                         1485
              Al a Ar g    Gl n Ly s Phe Ser Ser      Leu Ty r I l e Ser Gl n      Phe I l e I l e
                   1490                        1495                         1500
              Met Ty r     Ser Leu As p Gl y Ly s     Ly s Tr p Gl n Thr Ty r      Ar g Gl y As n
                   1505                        1510                         1515
              Ser Thr      Gl y Thr Leu Met Val       Phe Phe Gl y As n Val        As p Ser Ser
                   1520                        1525                         1530
              Gl y I l e   Ly s Hi s As n I l e Phe   As n Pr o Pr o I l e I l e   Al a Ar g Ty r
                   1535                        1540                         1545
              I l e Ar g   Leu Hi s Pr o Thr Hi s     Ty r Ser I l e Ar g Ser      Thr Leu Ar g
                   1550                        1555                         1560
              Met Gl u     Leu Met Gl y Cy s As p     Leu As n Ser Cy s Ser        Met Pr o Leu
                                                              Page 221

                                                             97047_1
<removed-date>
                   1565                       1570                       1575
              Gl y Met    Gl u Ser Ly s Al a I l e   Ser As p Al a Gl n I l e   Thr Al a Ser
                   1580                       1585                       1590
<removed-apn>
              Ser Ty r    Phe Thr As n Met Phe       Al a Thr Tr p Ser Pr o     Ser Ly s Al a
                   1595                       1600                       1605
              Ar g Leu    Hi s Leu Gl n Gl y Ar g    Ser As n Al a Tr p Ar g    Pr o Gl n Val
                   1610                       1615                       1620
              As n As n   Pr o Ly s Gl u Tr p Leu    Gl n Val As p Phe Gl n     Ly s Thr Met
                   1625                       1630                       1635
              Ly s Val    Thr Gl y Val Thr Thr       Gl n Gl y Val Ly s Ser     Leu Leu Thr
                   1640                       1645                       1650
              Ser Met     Ty r Val Ly s Gl u Phe     Leu I l e Ser Ser Ser      Gl n As p Gl y
                   1655                       1660                       1665
              Hi s Gl n   Tr p Thr Leu Phe Phe       Gl n As n Gl y Ly s Val    Ly s Val Phe
                   1670                       1675                       1680
              Gl n Gl y   As n Gl n As p Ser Phe     Thr Pr o Val Val As n      Ser Leu As p
                   1685                       1690                       1695
                                                            Page 222

                                                             97047_1
<removed-date>
              Pr o Pr o   Leu Leu Thr Ar g Ty r      Leu Ar g I l e Hi s Pr o   Gl n Ser Tr p
                   1700                       1705                       1710
              Val Hi s    Gl n I l e Al a Leu Ar g   Met Gl u Val Leu Gl y      Cy s Gl u Al a
                   1715                       1720                       1725
<removed-apn>
              Gl n As p   Leu Ty r As p Ly s Thr     Hi s Thr Cy s Pr o Pr o    Cy s Pr o Al a
                   1730                       1735                       1740
              Pr o Gl u   Leu Leu Gl y Gl y Pr o     Ser Val Phe Leu Phe        Pr o Pr o Ly s
                   1745                       1750                       1755
              Pr o Ly s   As p Thr Leu Met I l e     Ser Ar g Thr Pr o Gl u     Val Thr Cy s
                   1760                       1765                       1770
              Val Val     Val As p Val Ser Hi s      Gl u As p Pr o Gl u Val    Ly s Phe As n
                   1775                       1780                       1785
              Tr p Ty r   Val As p Gl y Val Gl u     Val Hi s As n Al a Ly s    Thr Ly s Pr o
                   1790                       1795                       1800
              Ar g Gl u   Gl u Gl n Ty r As n Ser    Thr Ty r Ar g Val Val      Ser Val Leu
                   1805                       1810                       1815
              Thr Val     Leu Hi s Gl n As p Tr p    Leu As n Gl y Ly s Gl u    Ty r Ly s Cy s
                                                            Page 223

                                                             97047_1
<removed-date>
                   1820                       1825                        1830
              Ly s Val    Ser As n Ly s Al a Leu     Pr o Al a Pr o I l e Gl u   Ly s Thr I l e
                   1835                       1840                        1845
<removed-apn>
              Ser Ly s    Al a Ly s Gl y Gl n Pr o   Ar g Gl u Pr o Gl n Val     Ty r Thr Leu
                   1850                       1855                        1860
              Pr o Pr o   Ser Ar g As p Gl u Leu     Thr Ly s As n Gl n Val      Ser Leu Thr
                   1865                       1870                        1875
              Cy s Leu    Val Ly s Gl y Phe Ty r     Pr o Ser As p I l e Al a    Val Gl u Tr p
                   1880                       1885                        1890
              Gl u Ser    As n Gl y Gl n Pr o Gl u   As n As n Ty r Ly s Thr     Thr Pr o Pr o
                   1895                       1900                        1905
              Val Leu     As p Ser As p Gl y Ser     Phe Phe Leu Ty r Ser        Ly s Leu Thr
                   1910                       1915                        1920
              Val As p    Ly s Ser Ar g Tr p Gl n    Gl n Gl y As n Val Phe      Ser Cy s Ser
                   1925                       1930                        1935
              Val Met     Hi s Gl u Al a Leu Hi s    As n Hi s Ty r Thr Gl n     Ly s Ser Leu
                   1940                       1945                        1950
                                                             Page 224

                                                                  97047_1
<removed-date>
              Ser Leu      Ser Pr o Gl y Ly s
                   1955
              <210>     104
              <211>     1959
<removed-apn>
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     pSYN- FVI I I - 173 mat ur e Pr ot ei n
              <400>     104
              Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser Tr p As p Ty r
              1                     5                             10                       15
              Met Gl n Ser As p Leu Gl y Gl u Leu Pr o Val As p Al a Ar g Phe Pr o Pr o
                               20                          25                         30
              Ar g Val Pr o Ly s Ser Phe Pr o Phe As n Thr Ser Val Val Ty r Ly s Ly s
                          35                          40                         45
              Thr Leu Phe Val Gl u Phe Thr As p Hi s Leu Phe As n I l e Al a Ly s Pr o
                   50                           55                          60
              Ar g Pr o Pr o Tr p Met Gl y Leu Leu Gl y Pr o Thr I l e Gl n Al a Gl u Val
              65                          70                           75                       80
                                                                  Page 225

                                                                    97047_1
<removed-date>
              Ty r As p Thr Val Val I l e Thr Leu Ly s As n Met Al a Ser Hi s Pr o Val
                                      85                            90                            95
              Ser Leu Hi s Al a Val Gl y Val Ser Ty r Tr p Ly s Al a Ser Gl u Gl y Al a
                                100                           105                           110
<removed-apn>
              Gl u Ty r As p As p Gl n Thr Ser Gl n Ar g Gl u Ly s Gl u As p As p Ly s Val
                          115                           120                           125
              Phe Pr o Gl y Gl y Ser Hi s Thr Ty r Val Tr p Gl n Val Leu Ly s Gl u As n
                    130                           135                           140
              Gl y Pr o Met Al a Ser As p Pr o Leu Cy s Leu Thr Ty r Ser Ty r Leu Ser
              145                           150                           155                           160
              Hi s Val As p Leu Val Ly s As p Leu As n Ser Gl y Leu I l e Gl y Al a Leu
                                      165                           170                           175
              Leu Val Cy s Ar g Gl u Gl y Ser Leu Al a Ly s Gl u Ly s Thr Gl n Thr Leu
                                180                           185                           190
              Hi s Ly s Phe I l e Leu Leu Phe Al a Val Phe As p Gl u Gl y Ly s Ser Tr p
                          195                           200                           205
              Hi s Ser Gl u Thr Ly s As n Ser Leu Met Gl n As p Ar g As p Al a Al a Ser
                                                                    Page 226

                                                                    97047_1
<removed-date>
                    210                           215                           220
              Al a Ar g Al a Tr p Pr o Ly s Met Hi s Thr Val As n Gl y Ty r Val As n Ar g
              225                           230                           235                           240
<removed-apn>
              Ser Leu Pr o Gl y Leu I l e Gl y Cy s Hi s Ar g Ly s Ser Val Ty r Tr p Hi s
                                      245                           250                           255
              Val I l e Gl y Met Gl y Thr Thr Pr o Gl u Val Hi s Ser I l e Phe Leu Gl u
                                260                           265                           270
              Gl y Hi s Thr Phe Leu Val Ar g As n Hi s Ar g Gl n Al a Ser Leu Gl u I l e
                          275                           280                           285
              Ser Pr o I l e Thr Phe Leu Thr Al a Gl n Thr Leu Leu Met As p Leu Gl y
                    290                           295                           300
              Gl n Phe Leu Leu Phe Cy s Hi s I l e Ser Ser Hi s Gl n Hi s As p Gl y Met
              305                           310                           315                           320
              Gl u Al a Ty r Val Ly s Val As p Ser Cy s Pr o Gl u Gl u Pr o Gl n Leu Ar g
                                      325                           330                           335
              Met Ly s As n As n Gl u Gl u Al a Gl u As p Ty r As p As p As p Leu Thr As p
                                340                           345                           350
                                                                    Page 227

                                                                    97047_1
<removed-date>
              Ser Gl u Met As p Val Val Ar g Phe As p As p As p As n Ser Pr o Ser Phe
                          355                           360                           365
              I l e Gl n I l e Ar g Ser Val Al a Ly s Ly s Hi s Pr o Ly s Thr Tr p Val Hi s
                    370                           375                           380
<removed-apn>
              Ty r I l e Al a Al a Gl u Gl u Gl u As p Tr p As p Ty r Al a Pr o Leu Val Leu
              385                           390                           395                           400
              Al a Pr o As p As p Ar g Ser Ty r Ly s Ser Gl n Ty r Leu As n As n Gl y Pr o
                                      405                           410                           415
              Gl n Ar g I l e Gl y Ar g Ly s Ty r Ly s Ly s Val Ar g Phe Met Al a Ty r Thr
                                420                           425                           430
              As p Gl u Thr Phe Ly s Thr Ar g Gl u Al a I l e Gl n Hi s Gl u Ser Gl y I l e
                          435                           440                           445
              Leu Gl y Pr o Leu Leu Ty r Gl y Gl u Val Gl y As p Thr Leu Leu I l e I l e
                    450                           455                           460
              Phe Ly s As n Gl n Al a Ser Ar g Pr o Ty r As n I l e Ty r Pr o Hi s Gl y I l e
              465                           470                           475                           480
              Thr As p Val Ar g Pr o Leu Ty r Ser Ar g Ar g Leu Pr o Ly s Gl y Val Ly s
                                                                    Page 228

                                                                     97047_1
<removed-date>
                                      485                           490                           495
              Hi s Leu Ly s As p Phe Pr o I l e Leu Pr o Gl y Gl u I l e Phe Ly s Ty r Ly s
                                500                           505                           510
<removed-apn>
              Tr p Thr Val Thr Val Gl u As p Gl y Pr o Thr Ly s Ser As p Pr o Ar g Cy s
                          515                           520                           525
              Leu Thr Ar g Ty r Ty r Ser Ser Phe Val As n Met Gl u Ar g As p Leu Al a
                    530                           535                           540
              Ser Gl y Leu I l e Gl y Pr o Leu Leu I l e Cy s Ty r Ly s Gl u Ser Val As p
              545                           550                           555                           560
              Gl n Ar g Gl y As n Gl n I l e Met Ser As p Ly s Ar g As n Val I l e Leu Phe
                                      565                           570                           575
              Ser Val Phe As p Gl u As n Ar g Ser Tr p Ty r Leu Thr Gl u As n I l e Gl n
                                580                           585                           590
              Ar g Phe Leu Pr o As n Pr o Al a Gl y Val Gl n Leu Gl u As p Pr o Gl u Phe
                          595                           600                           605
              Gl n Al a Ser As n I l e Met Hi s Ser I l e As n Gl y Ty r Val Phe As p Ser
                    610                           615                           620
                                                                    Page 229

                                                                    97047_1
<removed-date>
              Leu Gl n Leu Ser Val Cy s Leu Hi s Gl u Val Al a Ty r Tr p Ty r I l e Leu
              625                           630                           635                           640
              Ser I l e Gl y Al a Gl n Thr As p Phe Leu Ser Val Phe Phe Ser Gl y Ty r
                                      645                           650                           655
<removed-apn>
              Thr Phe Ly s Hi s Ly s Met Val Ty r Gl u As p Thr Leu Thr Leu Phe Pr o
                                660                           665                           670
              Phe Ser Gl y Gl u Thr Val Phe Met Ser Met Gl u As n Pr o Gl y Leu Tr p
                          675                           680                           685
              I l e Leu Gl y Cy s Hi s As n Ser As p Phe Ar g As n Ar g Gl y Met Thr Al a
                    690                           695                           700
              Leu Leu Ly s Val Ser Ser Cy s As p Ly s As n Thr Gl y As p Ty r Ty r Gl u
              705                           710                           715                           720
              As p Ser Ty r Gl u As p I l e Ser Al a Ty r Leu Leu Ser Ly s As n As n Al a
                                      725                           730                           735
              I l e Gl u Pr o Ar g Ser Phe Ser Gl n As n Gl y Al a Pr o Gl y Thr Ser Gl u
                                740                           745                           750
              Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y
                                                                    Page 230

                                                                    97047_1
<removed-date>
                          755                           760                           765
              Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o
                    770                           775                           780
<removed-apn>
              Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u
              785                           790                           795                           800
              Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u
                                      805                           810                           815
              Gl y Ser Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u
                                820                           825                           830
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o
                          835                           840                           845
              Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                    850                           855                           860
              Gl u Ser Gl y Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u
              865                           870                           875                           880
              Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Thr
                                      885                           890                           895
                                                                    Page 231

                                                                      97047_1
<removed-date>
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                                 900                            905                            910
              Gl u Ser Gl y Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o
                           915                           920                            925
<removed-apn>
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o
                    930                            935                            940
              Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y
              945                            950                            955                            960
              Ser Gl u Thr Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u
                                       965                            970                            975
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr
                                 980                            985                            990
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o              Gl y Ser Gl u Pr o Al a         Thr Ser Gl y
                           995                           1000                            1005
              Ser Gl u      Thr Pr o Gl y Thr Ser          Gl u Ser Al a Thr Pr o             Gl u Ser Gl y
                    1010                            1015                            1020
              Pr o Gl y     Thr Ser Thr Gl u Pr o          Ser Gl u Gl y Ser Al a             Pr o Al a Ser
                                                                      Page 232

                                                            97047_1
<removed-date>
                   1025                      1030                        1035
              Ser Pr o    Pr o Val Leu Ly s Ar g    Hi s Gl n Ar g Gl u I l e   Thr Ar g Thr
                   1040                      1045                        1050
<removed-apn>
              Thr Leu     Gl n Ser As p Gl n Gl u   Gl u I l e As p Ty r As p   As p Thr I l e
                   1055                      1060                        1065
              Ser Val     Gl u Met Ly s Ly s Gl u   As p Phe As p I l e Ty r    As p Gl u As p
                   1070                      1075                        1080
              Gl u As n   Gl n Ser Pr o Ar g Ser    Phe Gl n Ly s Ly s Thr      Ar g Hi s Ty r
                   1085                      1090                        1095
              Phe I l e   Al a Al a Val Gl u Ar g   Leu Tr p As p Ty r Gl y     Met Ser Ser
                   1100                      1105                        1110
              Ser Pr o    Hi s Val Leu Ar g As n    Ar g Al a Gl n Ser Gl y     Ser Val Pr o
                   1115                      1120                        1125
              Gl n Phe    Ly s Ly s Val Val Phe     Gl n Gl u Phe Thr As p      Gl y Ser Phe
                   1130                      1135                        1140
              Thr Gl n    Pr o Leu Ty r Ar g Gl y   Gl u Leu As n Gl u Hi s     Leu Gl y Leu
                   1145                      1150                        1155
                                                            Page 233

                                                              97047_1
<removed-date>
              Leu Gl y    Pr o Ty r I l e Ar g Al a   Gl u Val Gl u As p As n    I l e Met Val
                   1160                        1165                       1170
              Thr Phe     Ar g As n Gl n Al a Ser     Ar g Pr o Ty r Ser Phe     Ty r Ser Ser
                   1175                        1180                       1185
<removed-apn>
              Leu I l e   Ser Ty r Gl u Gl u As p     Gl n Ar g Gl n Gl y Al a   Gl u Pr o Ar g
                   1190                        1195                       1200
              Ly s As n   Phe Val Ly s Pr o As n      Gl u Thr Ly s Thr Ty r     Phe Tr p Ly s
                   1205                        1210                       1215
              Val Gl n    Hi s Hi s Met Al a Pr o     Thr Ly s As p Gl u Phe     As p Cy s Ly s
                   1220                        1225                       1230
              Al a Tr p   Al a Ty r Phe Ser As p      Val As p Leu Gl u Ly s     As p Val Hi s
                   1235                        1240                       1245
              Ser Gl y    Leu I l e Gl y Pr o Leu     Leu Val Cy s Hi s Thr      As n Thr Leu
                   1250                        1255                       1260
              As n Pr o   Al a Hi s Gl y Ar g Gl n    Val Thr Val Gl n Gl u      Phe Al a Leu
                   1265                        1270                       1275
              Phe Phe     Thr I l e Phe As p Gl u     Thr Ly s Ser Tr p Ty r     Phe Thr Gl u
                                                             Page 234

                                                              97047_1
<removed-date>
                   1280                        1285                        1290
              As n Met     Gl u Ar g As n Cy s Ar g   Al a Pr o Cy s As n I l e   Gl n Met Gl u
                   1295                        1300                        1305
<removed-apn>
              As p Pr o    Thr Phe Ly s Gl u As n     Ty r Ar g Phe Hi s Al a     I l e As n Gl y
                   1310                        1315                        1320
              Ty r I l e   Met As p Thr Leu Pr o      Gl y Leu Val Met Al a       Gl n As p Gl n
                   1325                        1330                        1335
              Ar g I l e   Ar g Tr p Ty r Leu Leu     Ser Met Gl y Ser As n       Gl u As n I l e
                   1340                        1345                        1350
              Hi s Ser     I l e Hi s Phe Ser Gl y    Hi s Val Phe Thr Val        Ar g Ly s Ly s
                   1355                        1360                        1365
              Gl u Gl u    Ty r Ly s Met Al a Leu     Ty r As n Leu Ty r Pr o     Gl y Val Phe
                   1370                        1375                        1380
              Gl u Thr     Val Gl u Met Leu Pr o      Ser Ly s Al a Gl y I l e    Tr p Ar g Val
                   1385                        1390                        1395
              Gl u Cy s    Leu I l e Gl y Gl u Hi s   Leu Hi s Al a Gl y Met      Ser Thr Leu
                   1400                        1405                        1410
                                                              Page 235

                                                               97047_1
<removed-date>
              Phe Leu      Val Ty r Ser As n Ly s     Cy s Gl n Thr Pr o Leu       Gl y Met Al a
                   1415                        1420                         1425
              Ser Gl y     Hi s I l e Ar g As p Phe   Gl n I l e Thr Al a Ser      Gl y Gl n Ty r
                   1430                        1435                         1440
<removed-apn>
              Gl y Gl n    Tr p Al a Pr o Ly s Leu    Al a Ar g Leu Hi s Ty r      Ser Gl y Ser
                   1445                        1450                         1455
              I l e As n   Al a Tr p Ser Thr Ly s     Gl u Pr o Phe Ser Tr p       I l e Ly s Val
                   1460                        1465                         1470
              As p Leu     Leu Al a Pr o Met I l e    I l e Hi s Gl y I l e Ly s   Thr Gl n Gl y
                   1475                        1480                         1485
              Al a Ar g    Gl n Ly s Phe Ser Ser      Leu Ty r I l e Ser Gl n      Phe I l e I l e
                   1490                        1495                         1500
              Met Ty r     Ser Leu As p Gl y Ly s     Ly s Tr p Gl n Thr Ty r      Ar g Gl y As n
                   1505                        1510                         1515
              Ser Thr      Gl y Thr Leu Met Val       Phe Phe Gl y As n Val        As p Ser Ser
                   1520                        1525                         1530
              Gl y I l e   Ly s Hi s As n I l e Phe   As n Pr o Pr o I l e I l e   Al a Ar g Ty r
                                                              Page 236

                                                              97047_1
<removed-date>
                   1535                        1540                       1545
              I l e Ar g   Leu Hi s Pr o Thr Hi s     Ty r Ser I l e Ar g Ser    Thr Leu Ar g
                   1550                        1555                       1560
<removed-apn>
              Met Gl u     Leu Met Gl y Cy s As p     Leu As n Ser Cy s Ser      Met Pr o Leu
                   1565                        1570                       1575
              Gl y Met     Gl u Ser Ly s Al a I l e   Ser As p Al a Gl n I l e   Thr Al a Ser
                   1580                        1585                       1590
              Ser Ty r     Phe Thr As n Met Phe       Al a Thr Tr p Ser Pr o     Ser Ly s Al a
                   1595                        1600                       1605
              Ar g Leu     Hi s Leu Gl n Gl y Ar g    Ser As n Al a Tr p Ar g    Pr o Gl n Val
                   1610                        1615                       1620
              As n As n    Pr o Ly s Gl u Tr p Leu    Gl n Val As p Phe Gl n     Ly s Thr Met
                   1625                        1630                       1635
              Ly s Val     Thr Gl y Val Thr Thr       Gl n Gl y Val Ly s Ser     Leu Leu Thr
                   1640                        1645                       1650
              Ser Met      Ty r Val Ly s Gl u Phe     Leu I l e Ser Ser Ser      Gl n As p Gl y
                   1655                        1660                       1665
                                                             Page 237

                                                             97047_1
<removed-date>
              Hi s Gl n   Tr p Thr Leu Phe Phe       Gl n As n Gl y Ly s Val    Ly s Val Phe
                   1670                       1675                       1680
              Gl n Gl y   As n Gl n As p Ser Phe     Thr Pr o Val Val As n      Ser Leu As p
                   1685                       1690                       1695
<removed-apn>
              Pr o Pr o   Leu Leu Thr Ar g Ty r      Leu Ar g I l e Hi s Pr o   Gl n Ser Tr p
                   1700                       1705                       1710
              Val Hi s    Gl n I l e Al a Leu Ar g   Met Gl u Val Leu Gl y      Cy s Gl u Al a
                   1715                       1720                       1725
              Gl n As p   Leu Ty r As p Ly s Thr     Hi s Thr Cy s Pr o Pr o    Cy s Pr o Al a
                   1730                       1735                       1740
              Pr o Gl u   Leu Leu Gl y Gl y Pr o     Ser Val Phe Leu Phe        Pr o Pr o Ly s
                   1745                       1750                       1755
              Pr o Ly s   As p Thr Leu Met I l e     Ser Ar g Thr Pr o Gl u     Val Thr Cy s
                   1760                       1765                       1770
              Val Val     Val As p Val Ser Hi s      Gl u As p Pr o Gl u Val    Ly s Phe As n
                   1775                       1780                       1785
              Tr p Ty r   Val As p Gl y Val Gl u     Val Hi s As n Al a Ly s    Thr Ly s Pr o
                                                            Page 238

                                                             97047_1
<removed-date>
                   1790                       1795                        1800
              Ar g Gl u   Gl u Gl n Ty r As n Ser    Thr Ty r Ar g Val Val       Ser Val Leu
                   1805                       1810                        1815
<removed-apn>
              Thr Val     Leu Hi s Gl n As p Tr p    Leu As n Gl y Ly s Gl u     Ty r Ly s Cy s
                   1820                       1825                        1830
              Ly s Val    Ser As n Ly s Al a Leu     Pr o Al a Pr o I l e Gl u   Ly s Thr I l e
                   1835                       1840                        1845
              Ser Ly s    Al a Ly s Gl y Gl n Pr o   Ar g Gl u Pr o Gl n Val     Ty r Thr Leu
                   1850                       1855                        1860
              Pr o Pr o   Ser Ar g As p Gl u Leu     Thr Ly s As n Gl n Val      Ser Leu Thr
                   1865                       1870                        1875
              Cy s Leu    Val Ly s Gl y Phe Ty r     Pr o Ser As p I l e Al a    Val Gl u Tr p
                   1880                       1885                        1890
              Gl u Ser    As n Gl y Gl n Pr o Gl u   As n As n Ty r Ly s Thr     Thr Pr o Pr o
                   1895                       1900                        1905
              Val Leu     As p Ser As p Gl y Ser     Phe Phe Leu Ty r Ser        Ly s Leu Thr
                   1910                       1915                        1920
                                                             Page 239

                                                                    97047_1
<removed-date>
              Val As p     Ly s Ser Ar g Tr p Gl n          Gl n Gl y As n Val Phe    Ser Cy s Ser
                  1925                            1930                         1935
              Val Met      Hi s Gl u Al a Leu Hi s          As n Hi s Ty r Thr Gl n   Ly s Ser Leu
                  1940                            1945                         1950
<removed-apn>
              Ser Leu      Ser Pr o Gl y Ly s
                  1955
              <210>      105
              <211>      1984
              <212>      PRT
              <213>      Ar t i f i c i al Sequenc e
              <220>
              <223>      FVI I I 195 pr ot ei n s equenc e
              <400>      105
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
              1                      5                             10                       15
              Cy s Phe Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser
                                20                            25                       30
              Tr p As p Ty r Met Gl n Ser As p Leu Gl y Gl u Leu Pr o Val As p Al a Ar g
                          35                           40                        45
                                                                   Page 240

                                                                    97047_1
<removed-date>
              Phe Pr o Pr o Ar g Val Pr o Ly s Ser Phe Pr o Phe As n Thr Ser Val Val
                    50                            55                            60
              Ty r Ly s Ly s Thr Leu Phe Val Gl u Phe Thr As p Hi s Leu Phe As n I l e
              65                            70                            75                            80
<removed-apn>
              Al a Ly s Pr o Ar g Pr o Pr o Tr p Met Gl y Leu Leu Gl y Pr o Thr I l e Gl n
                                      85                            90                            95
              Al a Gl u Val Ty r As p Thr Val Val I l e Thr Leu Ly s As n Met Al a Ser
                                100                           105                           110
              Hi s Pr o Val Ser Leu Hi s Al a Val Gl y Val Ser Ty r Tr p Ly s Al a Ser
                          115                           120                           125
              Gl u Gl y Al a Gl u Ty r As p As p Gl n Thr Ser Gl n Ar g Gl u Ly s Gl u As p
                    130                           135                           140
              As p Ly s Val Phe Pr o Gl y Gl y Ser Hi s Thr Ty r Val Tr p Gl n Val Leu
              145                           150                           155                           160
              Ly s Gl u As n Gl y Pr o Met Al a Ser As p Pr o Leu Cy s Leu Thr Ty r Ser
                                      165                           170                           175
              Ty r Leu Ser Hi s Val As p Leu Val Ly s As p Leu As n Ser Gl y Leu I l e
                                                                    Page 241

                                                                    97047_1
<removed-date>
                                180                           185                           190
              Gl y Al a Leu Leu Val Cy s Ar g Gl u Gl y Ser Leu Al a Ly s Gl u Ly s Thr
                          195                           200                           205
<removed-apn>
              Gl n Thr Leu Hi s Ly s Phe I l e Leu Leu Phe Al a Val Phe As p Gl u Gl y
                    210                           215                           220
              Ly s Ser Tr p Hi s Ser Gl u Thr Ly s As n Ser Leu Met Gl n As p Ar g As p
              225                           230                           235                           240
              Al a Al a Ser Al a Ar g Al a Tr p Pr o Ly s Met Hi s Thr Val As n Gl y Ty r
                                      245                           250                           255
              Val As n Ar g Ser Leu Pr o Gl y Leu I l e Gl y Cy s Hi s Ar g Ly s Ser Val
                                260                           265                           270
              Ty r Tr p Hi s Val I l e Gl y Met Gl y Thr Thr Pr o Gl u Val Hi s Ser I l e
                          275                           280                           285
              Phe Leu Gl u Gl y Hi s Thr Phe Leu Val Ar g As n Hi s Ar g Gl n Al a Ser
                    290                           295                           300
              Leu Gl u I l e Ser Pr o I l e Thr Phe Leu Thr Al a Gl n Thr Leu Leu Met
              305                           310                           315                           320
                                                                    Page 242

                                                                    97047_1
<removed-date>
              As p Leu Gl y Gl n Phe Leu Leu Phe Cy s Hi s I l e Ser Ser Hi s Gl n Hi s
                                      325                           330                           335
              As p Gl y Met Gl u Al a Ty r Val Ly s Val As p Ser Cy s Pr o Gl u Gl u Pr o
                                340                           345                           350
<removed-apn>
              Gl n Leu Ar g Met Ly s As n As n Gl u Gl u Al a Gl u As p Ty r As p As p As p
                          355                           360                           365
              Leu Thr As p Ser Gl u Met As p Val Val Ar g Phe As p As p As p As n Ser
                    370                           375                           380
              Pr o Ser Phe I l e Gl n I l e Ar g Ser Val Al a Ly s Ly s Hi s Pr o Ly s Thr
              385                           390                           395                           400
              Tr p Val Hi s Ty r I l e Al a Al a Gl u Gl u Gl u As p Tr p As p Ty r Al a Pr o
                                      405                           410                           415
              Leu Val Leu Al a Pr o As p As p Ar g Ser Ty r Ly s Ser Gl n Ty r Leu As n
                                420                           425                           430
              As n Gl y Pr o Gl n Ar g I l e Gl y Ar g Ly s Ty r Ly s Ly s Val Ar g Phe Met
                          435                           440                           445
              Al a Ty r Thr As p Gl u Thr Phe Ly s Thr Ar g Gl u Al a I l e Gl n Hi s Gl u
                                                                    Page 243

                                                                    97047_1
<removed-date>
                    450                           455                           460
              Ser Gl y I l e Leu Gl y Pr o Leu Leu Ty r Gl y Gl u Val Gl y As p Thr Leu
              465                           470                           475                           480
<removed-apn>
              Leu I l e I l e Phe Ly s As n Gl n Al a Ser Ar g Pr o Ty r As n I l e Ty r Pr o
                                      485                           490                           495
              Hi s Gl y I l e Thr As p Val Ar g Pr o Leu Ty r Ser Ar g Ar g Leu Pr o Ly s
                                500                           505                           510
              Gl y Val Ly s Hi s Leu Ly s As p Phe Pr o I l e Leu Pr o Gl y Gl u I l e Phe
                          515                           520                           525
              Ly s Ty r Ly s Tr p Thr Val Thr Val Gl u As p Gl y Pr o Thr Ly s Ser As p
                    530                           535                           540
              Pr o Ar g Cy s Leu Thr Ar g Ty r Ty r Ser Ser Phe Val As n Met Gl u Ar g
              545                           550                           555                           560
              As p Leu Al a Ser Gl y Leu I l e Gl y Pr o Leu Leu I l e Cy s Ty r Ly s Gl u
                                      565                           570                           575
              Ser Val As p Gl n Ar g Gl y As n Gl n I l e Met Ser As p Ly s Ar g As n Val
                                580                           585                           590
                                                                    Page 244

                                                                    97047_1
<removed-date>
              I l e Leu Phe Ser Val Phe As p Gl u As n Ar g Ser Tr p Ty r Leu Thr Gl u
                          595                           600                           605
              As n I l e Gl n Ar g Phe Leu Pr o As n Pr o Al a Gl y Val Gl n Leu Gl u As p
                    610                           615                           620
<removed-apn>
              Pr o Gl u Phe Gl n Al a Ser As n I l e Met Hi s Ser I l e As n Gl y Ty r Val
              625                           630                           635                           640
              Phe As p Ser Leu Gl n Leu Ser Val Cy s Leu Hi s Gl u Val Al a Ty r Tr p
                                      645                           650                           655
              Ty r I l e Leu Ser I l e Gl y Al a Gl n Thr As p Phe Leu Ser Val Phe Phe
                                660                           665                           670
              Ser Gl y Ty r Thr Phe Ly s Hi s Ly s Met Val Ty r Gl u As p Thr Leu Thr
                          675                           680                           685
              Leu Phe Pr o Phe Ser Gl y Gl u Thr Val Phe Met Ser Met Gl u As n Pr o
                    690                           695                           700
              Gl y Leu Tr p I l e Leu Gl y Cy s Hi s As n Ser As p Phe Ar g As n Ar g Gl y
              705                           710                           715                           720
              Met Thr Al a Leu Leu Ly s Val Ser Ser Cy s As p Ly s As n Thr Gl y As p
                                                                    Page 245

                                                                     97047_1
<removed-date>
                                      725                           730                           735
              Ty r Ty r Gl u As p Ser Ty r Gl u As p I l e Ser Al a Ty r Leu Leu Ser Ly s
                                740                           745                           750
<removed-apn>
              As n As n Al a I l e Gl u Pr o Ar g Ser Phe Ser Gl n As n Pr o Pr o Val Leu
                          755                           760                           765
              Ly s Ar g Hi s Gl n Ar g Gl u I l e Thr Ar g Thr Thr Leu Gl n Gl y Al a Pr o
                    770                           775                           780
              Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Al a Ser Pr o
              785                           790                           795                           800
              Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
                                      805                           810                           815
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                                820                           825                           830
              Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Thr Pr o Gl y
                          835                           840                           845
              Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
                    850                           855                           860
                                                                    Page 246

                                                                    97047_1
<removed-date>
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
              865                           870                           875                           880
              Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Ser Ser Thr
                                      885                           890                           895
<removed-apn>
              Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a
                                900                           905                           910
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                          915                           920                           925
              Al a Ser Ser Ser As p Gl n Gl u Gl u I l e As p Ty r As p As p Thr I l e Ser
                    930                           935                           940
              Val Gl u Met Ly s Ly s Gl u As p Phe As p I l e Ty r As p Gl u As p Gl u As n
              945                           950                           955                           960
              Gl n Ser Pr o Ar g Ser Phe Gl n Ly s Ly s Thr Ar g Hi s Ty r Phe I l e Al a
                                      965                           970                           975
              Al a Val Gl u Ar g Leu Tr p As p Ty r Gl y Met Ser Ser Ser Pr o Hi s Val
                                980                           985                           990
              Leu Ar g As n Ar g Al a Gl n Ser Gl y            Ser Val Pr o Gl n Phe          Ly s Ly s Val
                                                                    Page 247

                                                                97047_1
<removed-date>
                          995                         1000                         1005
              Val Phe      Gl n Gl u Phe Thr As p       Gl y Ser Phe Thr Gl n        Pr o Leu Ty r
                   1010                        1015                         1020
<removed-apn>
              Ar g Gl y    Gl u Leu As n Gl u Hi s      Leu Gl y Leu Leu Gl y        Pr o Ty r I l e
                   1025                        1030                         1035
              Ar g Al a    Gl u Val Gl u As p As n      I l e Met Val Thr Phe        Ar g As n Gl n
                   1040                        1045                         1050
              Al a Ser     Ar g Pr o Ty r Ser Phe       Ty r Ser Ser Leu I l e       Ser Ty r Gl u
                   1055                        1060                         1065
              Gl u As p    Gl n Ar g Gl n Gl y Al a     Gl u Pr o Ar g Ly s As n     Phe Val Ly s
                   1070                        1075                         1080
              Pr o As n    Gl u Thr Ly s Thr Ty r       Phe Tr p Ly s Val Gl n       Hi s Hi s Met
                   1085                        1090                         1095
              Al a Pr o    Thr Ly s As p Gl u Phe       As p Cy s Ly s Al a Tr p     Al a Ty r Phe
                   1100                        1105                         1110
              Ser As p     Val As p Leu Gl u Ly s       As p Val Hi s Ser Gl y       Leu I l e Gl y
                   1115                        1120                         1125
                                                               Page 248

                                                          97047_1
<removed-date>
              Pr o Leu    Leu Val Cy s Hi s Thr    As n Thr Leu As n Pr o   Al a Hi s Gl y
                   1130                     1135                     1140
              Ar g Gl n   Val Thr Val Gl n Gl u    Phe Al a Leu Phe Phe     Thr I l e Phe
                   1145                     1150                     1155
<removed-apn>
              As p Gl u   Thr Ly s Ser Tr p Ty r   Phe Thr Gl u As n Met    Gl u Ar g As n
                   1160                     1165                     1170
              Cy s Ar g   Gl y Al a Pr o Thr Ser   Gl u Ser Al a Thr Pr o   Gl u Ser Gl y
                   1175                     1180                     1185
              Pr o Gl y   Ser Gl u Pr o Al a Thr   Ser Gl y Ser Gl u Thr    Pr o Gl y Thr
                   1190                     1195                     1200
              Ser Gl u    Ser Al a Thr Pr o Gl u   Ser Gl y Pr o Gl y Ser   Gl u Pr o Al a
                   1205                     1210                     1215
              Thr Ser     Gl y Ser Gl u Thr Pr o   Gl y Thr Ser Gl u Ser    Al a Thr Pr o
                   1220                     1225                     1230
              Gl u Ser    Gl y Pr o Gl y Thr Ser   Thr Gl u Pr o Ser Gl u   Gl y Ser Al a
                   1235                     1240                     1245
              Pr o Gl y   Thr Ser Gl u Ser Al a    Thr Pr o Gl u Ser Gl y   Pr o Gl y Ser
                                                          Page 249

                                                               97047_1
<removed-date>
                   1250                        1255                        1260
              Pr o Al a   Gl y Ser Pr o Thr Ser       Thr Gl u Gl u Gl y Ser       Pr o Al a Gl y
                   1265                        1270                        1275
<removed-apn>
              Ser Pr o    Thr Ser Thr Gl u Gl u       Gl y Ser Pr o Al a Gl y      Ser Pr o Thr
                   1280                        1285                        1290
              Ser Thr     Gl u Gl u Gl y Thr Ser      Gl u Ser Al a Thr Pr o       Gl u Ser Gl y
                   1295                        1300                        1305
              Pr o Gl y   Thr Ser Thr Gl u Pr o       Ser Gl u Gl y Ser Al a       Pr o Gl y Al a
                   1310                        1315                        1320
              Ser Ser     Al a Pr o Cy s As n I l e   Gl n Met Gl u As p Pr o      Thr Phe Ly s
                   1325                        1330                        1335
              Gl u As n   Ty r Ar g Phe Hi s Al a     I l e As n Gl y Ty r I l e   Met As p Thr
                   1340                        1345                        1350
              Leu Pr o    Gl y Leu Val Met Al a       Gl n As p Gl n Ar g I l e    Ar g Tr p Ty r
                   1355                        1360                        1365
              Leu Leu     Ser Met Gl y Ser As n       Gl u As n I l e Hi s Ser     I l e Hi s Phe
                   1370                        1375                        1380
                                                              Page 250

                                                               97047_1
<removed-date>
              Ser Gl y    Hi s Val Phe Thr Val         Ar g Ly s Ly s Gl u Gl u   Ty r Ly s Met
                   1385                         1390                       1395
              Al a Leu    Ty r As n Leu Ty r Pr o      Gl y Val Phe Gl u Thr      Val Gl u Met
                   1400                         1405                       1410
<removed-apn>
              Leu Pr o    Ser Ly s Al a Gl y I l e     Tr p Ar g Val Gl u Cy s    Leu I l e Gl y
                   1415                         1420                       1425
              Gl u Hi s   Leu Hi s Al a Gl y Met       Ser Thr Leu Phe Leu        Val Ty r Ser
                   1430                         1435                       1440
              As n Ly s   Cy s Gl n Thr Pr o Leu       Gl y Met Al a Ser Gl y     Hi s I l e Ar g
                   1445                         1450                       1455
              As p Phe    Gl n I l e Thr Al a Ser      Gl y Gl n Ty r Gl y Gl n   Tr p Al a Pr o
                   1460                         1465                       1470
              Ly s Leu    Al a Ar g Leu Hi s Ty r      Ser Gl y Ser I l e As n    Al a Tr p Ser
                   1475                         1480                       1485
              Thr Ly s    Gl u Pr o Phe Ser Tr p       I l e Ly s Val As p Leu    Leu Al a Pr o
                   1490                         1495                       1500
              Met I l e   I l e Hi s Gl y I l e Ly s   Thr Gl n Gl y Al a Ar g    Gl n Ly s Phe
                                                              Page 251

                                                                97047_1
<removed-date>
                   1505                         1510                         1515
              Ser Ser      Leu Ty r I l e Ser Gl n      Phe I l e I l e Met Ty r    Ser Leu As p
                   1520                         1525                         1530
<removed-apn>
              Gl y Ly s    Ly s Tr p Gl n Thr Ty r      Ar g Gl y As n Ser Thr      Gl y Thr Leu
                   1535                         1540                         1545
              Met Val      Phe Phe Gl y As n Val        As p Ser Ser Gl y I l e     Ly s Hi s As n
                   1550                         1555                         1560
              I l e Phe    As n Pr o Pr o I l e I l e   Al a Ar g Ty r I l e Ar g   Leu Hi s Pr o
                   1565                         1570                         1575
              Thr Hi s     Ty r Ser I l e Ar g Ser      Thr Leu Ar g Met Gl u       Leu Met Gl y
                   1580                         1585                         1590
              Cy s As p    Leu As n Ser Cy s Ser        Met Pr o Leu Gl y Met       Gl u Ser Ly s
                   1595                         1600                         1605
              Al a I l e   Ser As p Al a Gl n I l e     Thr Al a Ser Ser Ty r       Phe Thr As n
                   1610                         1615                         1620
              Met Phe      Al a Thr Tr p Ser Pr o       Ser Ly s Al a Ar g Leu      Hi s Leu Gl n
                   1625                         1630                         1635
                                                                Page 252

                                                             97047_1
<removed-date>
              Gl y Ar g   Ser As n Al a Tr p Ar g    Pr o Gl n Val As n As n    Pr o Ly s Gl u
                   1640                       1645                       1650
              Tr p Leu    Gl n Val As p Phe Gl n     Ly s Thr Met Ly s Val      Thr Gl y Val
                   1655                       1660                       1665
<removed-apn>
              Thr Thr     Gl n Gl y Val Ly s Ser     Leu Leu Thr Ser Met        Ty r Val Ly s
                   1670                       1675                       1680
              Gl u Phe    Leu I l e Ser Ser Ser      Gl n As p Gl y Hi s Gl n   Tr p Thr Leu
                   1685                       1690                       1695
              Phe Phe     Gl n As n Gl y Ly s Val    Ly s Val Phe Gl n Gl y     As n Gl n As p
                   1700                       1705                       1710
              Ser Phe     Thr Pr o Val Val As n      Ser Leu As p Pr o Pr o     Leu Leu Thr
                   1715                       1720                       1725
              Ar g Ty r   Leu Ar g I l e Hi s Pr o   Gl n Ser Tr p Val Hi s     Gl n I l e Al a
                   1730                       1735                       1740
              Leu Ar g    Met Gl u Val Leu Gl y      Cy s Gl u Al a Gl n As p   Leu Ty r As p
                   1745                       1750                       1755
              Ly s Thr    Hi s Thr Cy s Pr o Pr o    Cy s Pr o Al a Pr o Gl u   Leu Leu Gl y
                                                            Page 253

                                                              97047_1
<removed-date>
                   1760                        1765                       1770
              Gl y Pr o   Ser Val Phe Leu Phe         Pr o Pr o Ly s Pr o Ly s   As p Thr Leu
                   1775                        1780                       1785
<removed-apn>
              Met I l e   Ser Ar g Thr Pr o Gl u      Val Thr Cy s Val Val       Val As p Val
                   1790                        1795                       1800
              Ser Hi s    Gl u As p Pr o Gl u Val     Ly s Phe As n Tr p Ty r    Val As p Gl y
                   1805                        1810                       1815
              Val Gl u    Val Hi s As n Al a Ly s     Thr Ly s Pr o Ar g Gl u    Gl u Gl n Ty r
                   1820                        1825                       1830
              As n Ser    Thr Ty r Ar g Val Val       Ser Val Leu Thr Val        Leu Hi s Gl n
                   1835                        1840                       1845
              As p Tr p   Leu As n Gl y Ly s Gl u     Ty r Ly s Cy s Ly s Val    Ser As n Ly s
                   1850                        1855                       1860
              Al a Leu    Pr o Al a Pr o I l e Gl u   Ly s Thr I l e Ser Ly s    Al a Ly s Gl y
                   1865                        1870                       1875
              Gl n Pr o   Ar g Gl u Pr o Gl n Val     Ty r Thr Leu Pr o Pr o     Ser Ar g As p
                   1880                        1885                       1890
                                                             Page 254

                                                                 97047_1
<removed-date>
              Gl u Leu      Thr Ly s As n Gl n Val        Ser Leu Thr Cy s Leu     Val Ly s Gl y
                     1895                          1900                     1905
              Phe Ty r      Pr o Ser As p I l e Al a      Val Gl u Tr p Gl u Ser   As n Gl y Gl n
                     1910                          1915                     1920
<removed-apn>
              Pr o Gl u     As n As n Ty r Ly s Thr       Thr Pr o Pr o Val Leu    As p Ser As p
                     1925                          1930                     1935
              Gl y Ser      Phe Phe Leu Ty r Ser          Ly s Leu Thr Val As p    Ly s Ser Ar g
                     1940                          1945                     1950
              Tr p Gl n     Gl n Gl y As n Val Phe        Ser Cy s Ser Val Met     Hi s Gl u Al a
                     1955                          1960                     1965
              Leu Hi s      As n Hi s Ty r Thr Gl n       Ly s Ser Leu Ser Leu     Ser Pr o Gl y
                     1970                          1975                     1980
              Ly s
              <210>       106
              <211>       2134
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
                                                                 Page 255

                                                              97047_1
<removed-date>
              <220>
              <223>     FVI I I 196 pr ot ei n s equenc e
              <400>     106
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
              1                     5                         10                        15
<removed-apn>
              Cy s Phe Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser
                              20                        25                        30
              Tr p As p Ty r Met Gl n Ser As p Leu Gl y Gl u Leu Pr o Val Gl y Al a Pr o
                         35                        40                        45
              Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Ser Ser Pr o
                   50                         55                        60
              Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
              65                         70                        75                        80
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                                    85                        90                        95
              Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Pr o
                              100                       105                       110
              Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
                                                              Page 256

                                                                    97047_1
<removed-date>
                          115                           120                           125
              Thr Gl y Ser Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o
                    130                           135                           140
<removed-apn>
              Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Ser Ser Thr
              145                           150                           155                           160
              Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a
                                      165                           170                           175
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                                180                           185                           190
              Al a Ser Ser As p Al a Ar g Phe Pr o Pr o Ar g Val Pr o Ly s Ser Phe Pr o
                          195                           200                           205
              Phe As n Thr Ser Val Val Ty r Ly s Ly s Thr Leu Phe Val Gl u Phe Thr
                    210                           215                           220
              As p Hi s Leu Phe As n I l e Al a Ly s Pr o Ar g Pr o Pr o Tr p Met Gl y Leu
              225                           230                           235                           240
              Leu Gl y Pr o Thr I l e Gl n Al a Gl u Val Ty r As p Thr Val Val I l e Thr
                                      245                           250                           255
                                                                    Page 257

                                                                    97047_1
<removed-date>
              Leu Ly s As n Met Al a Ser Hi s Pr o Val Ser Leu Hi s Al a Val Gl y Val
                                260                           265                           270
              Ser Ty r Tr p Ly s Al a Ser Gl u Gl y Al a Gl u Ty r As p As p Gl n Thr Ser
                          275                           280                           285
<removed-apn>
              Gl n Ar g Gl u Ly s Gl u As p As p Ly s Val Phe Pr o Gl y Gl y Ser Hi s Thr
                    290                           295                           300
              Ty r Val Tr p Gl n Val Leu Ly s Gl u As n Gl y Pr o Met Al a Ser As p Pr o
              305                           310                           315                           320
              Leu Cy s Leu Thr Ty r Ser Ty r Leu Ser Hi s Val As p Leu Val Ly s As p
                                      325                           330                           335
              Leu As n Ser Gl y Leu I l e Gl y Al a Leu Leu Val Cy s Ar g Gl u Gl y Ser
                                340                           345                           350
              Leu Al a Ly s Gl u Ly s Thr Gl n Thr Leu Hi s Ly s Phe I l e Leu Leu Phe
                          355                           360                           365
              Al a Val Phe As p Gl u Gl y Ly s Ser Tr p Hi s Ser Gl u Thr Ly s As n Ser
                    370                           375                           380
              Leu Met Gl n As p Ar g As p Al a Al a Ser Al a Ar g Al a Tr p Pr o Ly s Met
                                                                    Page 258

                                                                    97047_1
<removed-date>
              385                           390                        395                              400
              Hi s Thr Val As n Gl y Ty r Val As n Ar g Ser Leu Pr o Gl y Leu I l e Gl y
                                      405                           410                           415
<removed-apn>
              Cy s Hi s Ar g Ly s Ser Val Ty r Tr p Hi s Val I l e Gl y Met Gl y Thr Thr
                                420                           425                           430
              Pr o Gl u Val Hi s Ser I l e Phe Leu Gl u Gl y Hi s Thr Phe Leu Val Ar g
                          435                           440                           445
              As n Hi s Ar g Gl n Al a Ser Leu Gl u I l e Ser Pr o I l e Thr Phe Leu Thr
                    450                           455                           460
              Al a Gl n Thr Leu Leu Met As p Leu Gl y Gl n Phe Leu Leu Phe Cy s Hi s
              465                           470                           475                           480
              I l e Ser Ser Hi s Gl n Hi s As p Gl y Met Gl u Al a Ty r Val Ly s Val As p
                                      485                           490                           495
              Ser Cy s Pr o Gl u Gl u Pr o Gl n Leu Ar g Met Ly s As n As n Gl u Gl u Al a
                                500                           505                           510
              Gl u As p Ty r As p As p As p Leu Thr As p Ser Gl u Met As p Val Val Ar g
                          515                           520                           525
                                                                    Page 259

                                                                    97047_1
<removed-date>
              Phe As p As p As p As n Ser Pr o Ser Phe I l e Gl n I l e Ar g Ser Val Al a
                    530                           535                           540
              Ly s Ly s Hi s Pr o Ly s Thr Tr p Val Hi s Ty r I l e Al a Al a Gl u Gl u Gl u
              545                           550                           555                           560
<removed-apn>
              As p Tr p As p Ty r Al a Pr o Leu Val Leu Al a Pr o As p As p Ar g Ser Ty r
                                      565                           570                           575
              Ly s Ser Gl n Ty r Leu As n As n Gl y Pr o Gl n Ar g I l e Gl y Ar g Ly s Ty r
                                580                           585                           590
              Ly s Ly s Val Ar g Phe Met Al a Ty r Thr As p Gl u Thr Phe Ly s Thr Ar g
                          595                           600                           605
              Gl u Al a I l e Gl n Hi s Gl u Ser Gl y I l e Leu Gl y Pr o Leu Leu Ty r Gl y
                    610                           615                           620
              Gl u Val Gl y As p Thr Leu Leu I l e I l e Phe Ly s As n Gl n Al a Ser Ar g
              625                           630                           635                           640
              Pr o Ty r As n I l e Ty r Pr o Hi s Gl y I l e Thr As p Val Ar g Pr o Leu Ty r
                                      645                           650                           655
              Ser Ar g Ar g Leu Pr o Ly s Gl y Val Ly s Hi s Leu Ly s As p Phe Pr o I l e
                                                                    Page 260

                                                                    97047_1
<removed-date>
                                660                           665                           670
              Leu Pr o Gl y Gl u I l e Phe Ly s Ty r Ly s Tr p Thr Val Thr Val Gl u As p
                          675                           680                           685
<removed-apn>
              Gl y Pr o Thr Ly s Ser As p Pr o Ar g Cy s Leu Thr Ar g Ty r Ty r Ser Ser
                    690                           695                           700
              Phe Val As n Met Gl u Ar g As p Leu Al a Ser Gl y Leu I l e Gl y Pr o Leu
              705                           710                           715                           720
              Leu I l e Cy s Ty r Ly s Gl u Ser Val As p Gl n Ar g Gl y As n Gl n I l e Met
                                      725                           730                           735
              Ser As p Ly s Ar g As n Val I l e Leu Phe Ser Val Phe As p Gl u As n Ar g
                                740                           745                           750
              Ser Tr p Ty r Leu Thr Gl u As n I l e Gl n Ar g Phe Leu Pr o As n Pr o Al a
                          755                           760                           765
              Gl y Val Gl n Leu Gl u As p Pr o Gl u Phe Gl n Al a Ser As n I l e Met Hi s
                    770                           775                           780
              Ser I l e As n Gl y Ty r Val Phe As p Ser Leu Gl n Leu Ser Val Cy s Leu
              785                           790                           795                           800
                                                                    Page 261

                                                                    97047_1
<removed-date>
              Hi s Gl u Val Al a Ty r Tr p Ty r I l e Leu Ser I l e Gl y Al a Gl n Thr As p
                                      805                           810                           815
              Phe Leu Ser Val Phe Phe Ser Gl y Ty r Thr Phe Ly s Hi s Ly s Met Val
                                820                           825                           830
<removed-apn>
              Ty r Gl u As p Thr Leu Thr Leu Phe Pr o Phe Ser Gl y Gl u Thr Val Phe
                          835                           840                           845
              Met Ser Met Gl u As n Pr o Gl y Leu Tr p I l e Leu Gl y Cy s Hi s As n Ser
                    850                           855                           860
              As p Phe Ar g As n Ar g Gl y Met Thr Al a Leu Leu Ly s Val Ser Ser Cy s
              865                           870                           875                           880
              As p Ly s As n Thr Gl y As p Ty r Ty r Gl u As p Ser Ty r Gl u As p I l e Ser
                                      885                           890                           895
              Al a Ty r Leu Leu Ser Ly s As n As n Al a I l e Gl u Pr o Ar g Ser Phe Ser
                                900                           905                           910
              Gl n As n Pr o Pr o Val Leu Ly s Ar g Hi s Gl n Ar g Gl u I l e Thr Ar g Thr
                          915                           920                           925
              Thr Leu Gl n Gl y Al a Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser
                                                                    Page 262

                                                                      97047_1
<removed-date>
                    930                            935                            940
              Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a
              945                            950                            955                         960
<removed-apn>
              Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr
                                       965                            970                         975
              Ser Ser Thr Gl y Ser Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr
                                 980                            985                         990
              Gl y Pr o Gl y Thr Pr o Gl y Ser Gl y              Thr Al a Ser Ser Ser          Pr o Gl y Al a
                           995                           1000                           1005
              Ser Pr o      Gl y Thr Ser Ser Thr           Gl y Ser Pr o Gl y Al a         Ser Pr o Gl y
                    1010                            1015                            1020
              Thr Ser       Ser Thr Gl y Ser Pr o          Gl y Al a Ser Pr o Gl y         Thr Ser Ser
                    1025                            1030                            1035
              Thr Gl y      Ser Pr o Gl y Ser Ser          Thr Pr o Ser Gl y Al a          Thr Gl y Ser
                    1040                            1045                            1050
              Pr o Gl y     Ser Ser Thr Pr o Ser           Gl y Al a Thr Gl y Ser          Pr o Gl y Al a
                    1055                            1060                            1065
                                                                      Page 263

                                                              97047_1
<removed-date>
              Ser Pr o    Gl y Thr Ser Ser Thr        Gl y Ser Pr o Al a Ser     Ser Ser As p
                   1070                        1075                       1080
              Gl n Gl u   Gl u I l e As p Ty r As p   As p Thr I l e Ser Val     Gl u Met Ly s
                   1085                        1090                       1095
<removed-apn>
              Ly s Gl u   As p Phe As p I l e Ty r    As p Gl u As p Gl u As n   Gl n Ser Pr o
                   1100                        1105                       1110
              Ar g Ser    Phe Gl n Ly s Ly s Thr      Ar g Hi s Ty r Phe I l e   Al a Al a Val
                   1115                        1120                       1125
              Gl u Ar g   Leu Tr p As p Ty r Gl y     Met Ser Ser Ser Pr o       Hi s Val Leu
                   1130                        1135                       1140
              Ar g As n   Ar g Al a Gl n Ser Gl y     Ser Val Pr o Gl n Phe      Ly s Ly s Val
                   1145                        1150                       1155
              Val Phe     Gl n Gl u Phe Thr As p      Gl y Ser Phe Thr Gl n      Pr o Leu Ty r
                   1160                        1165                       1170
              Ar g Gl y   Gl u Leu As n Gl u Hi s     Leu Gl y Leu Leu Gl y      Pr o Ty r I l e
                   1175                        1180                       1185
              Ar g Al a   Gl u Val Gl u As p As n     I l e Met Val Thr Phe      Ar g As n Gl n
                                                             Page 264

                                                             97047_1
<removed-date>
                   1190                       1195                       1200
              Al a Ser    Ar g Pr o Ty r Ser Phe     Ty r Ser Ser Leu I l e     Ser Ty r Gl u
                   1205                       1210                       1215
<removed-apn>
              Gl u As p   Gl n Ar g Gl n Gl y Al a   Gl u Pr o Ar g Ly s As n   Phe Val Ly s
                   1220                       1225                       1230
              Pr o As n   Gl u Thr Ly s Thr Ty r     Phe Tr p Ly s Val Gl n     Hi s Hi s Met
                   1235                       1240                       1245
              Al a Pr o   Thr Ly s As p Gl u Phe     As p Cy s Ly s Al a Tr p   Al a Ty r Phe
                   1250                       1255                       1260
              Ser As p    Val As p Leu Gl u Ly s     As p Val Hi s Ser Gl y     Leu I l e Gl y
                   1265                       1270                       1275
              Pr o Leu    Leu Val Cy s Hi s Thr      As n Thr Leu As n Pr o     Al a Hi s Gl y
                   1280                       1285                       1290
              Ar g Gl n   Val Thr Val Gl n Gl u      Phe Al a Leu Phe Phe       Thr I l e Phe
                   1295                       1300                       1305
              As p Gl u   Thr Ly s Ser Tr p Ty r     Phe Thr Gl u As n Met      Gl u Ar g As n
                   1310                       1315                       1320
                                                            Page 265

                                                           97047_1
<removed-date>
              Cy s Ar g   Gl y Al a Pr o Thr Ser   Gl u Ser Al a Thr Pr o    Gl u Ser Gl y
                   1325                     1330                      1335
              Pr o Gl y   Ser Gl u Pr o Al a Thr   Ser Gl y Ser Gl u Thr     Pr o Gl y Thr
                   1340                     1345                      1350
<removed-apn>
              Ser Gl u    Ser Al a Thr Pr o Gl u   Ser Gl y Pr o Gl y Ser    Gl u Pr o Al a
                   1355                     1360                      1365
              Thr Ser     Gl y Ser Gl u Thr Pr o   Gl y Thr Ser Gl u Ser     Al a Thr Pr o
                   1370                     1375                      1380
              Gl u Ser    Gl y Pr o Gl y Thr Ser   Thr Gl u Pr o Ser Gl u    Gl y Ser Al a
                   1385                     1390                      1395
              Pr o Gl y   Thr Ser Gl u Ser Al a    Thr Pr o Gl u Ser Gl y    Pr o Gl y Ser
                   1400                     1405                      1410
              Pr o Al a   Gl y Ser Pr o Thr Ser    Thr Gl u Gl u Gl y Ser    Pr o Al a Gl y
                   1415                     1420                      1425
              Ser Pr o    Thr Ser Thr Gl u Gl u    Gl y Ser Pr o Al a Gl y   Ser Pr o Thr
                   1430                     1435                      1440
              Ser Thr     Gl u Gl u Gl y Thr Ser   Gl u Ser Al a Thr Pr o    Gl u Ser Gl y
                                                          Page 266

                                                               97047_1
<removed-date>
                   1445                        1450                        1455
              Pr o Gl y   Thr Ser Thr Gl u Pr o       Ser Gl u Gl y Ser Al a       Pr o Gl y Al a
                   1460                        1465                        1470
<removed-apn>
              Ser Ser     Al a Pr o Cy s As n I l e   Gl n Met Gl u As p Pr o      Thr Phe Ly s
                   1475                        1480                        1485
              Gl u As n   Ty r Ar g Phe Hi s Al a     I l e As n Gl y Ty r I l e   Met As p Thr
                   1490                        1495                        1500
              Leu Pr o    Gl y Leu Val Met Al a       Gl n As p Gl n Ar g I l e    Ar g Tr p Ty r
                   1505                        1510                        1515
              Leu Leu     Ser Met Gl y Ser As n       Gl u As n I l e Hi s Ser     I l e Hi s Phe
                   1520                        1525                        1530
              Ser Gl y    Hi s Val Phe Thr Val        Ar g Ly s Ly s Gl u Gl u     Ty r Ly s Met
                   1535                        1540                        1545
              Al a Leu    Ty r As n Leu Ty r Pr o     Gl y Val Phe Gl u Thr        Val Gl u Met
                   1550                        1555                        1560
              Leu Pr o    Ser Ly s Al a Gl y I l e    Tr p Ar g Val Gl u Cy s      Leu I l e Gl y
                   1565                        1570                        1575
                                                              Page 267

                                                               97047_1
<removed-date>
              Gl u Hi s   Leu Hi s Al a Gl y Met       Ser Thr Leu Phe Leu        Val Ty r Ser
                   1580                         1585                       1590
              As n Ly s   Cy s Gl n Thr Pr o Leu       Gl y Met Al a Ser Gl y     Hi s I l e Ar g
                   1595                         1600                       1605
<removed-apn>
              As p Phe    Gl n I l e Thr Al a Ser      Gl y Gl n Ty r Gl y Gl n   Tr p Al a Pr o
                   1610                         1615                       1620
              Ly s Leu    Al a Ar g Leu Hi s Ty r      Ser Gl y Ser I l e As n    Al a Tr p Ser
                   1625                         1630                       1635
              Thr Ly s    Gl u Pr o Phe Ser Tr p       I l e Ly s Val As p Leu    Leu Al a Pr o
                   1640                         1645                       1650
              Met I l e   I l e Hi s Gl y I l e Ly s   Thr Gl n Gl y Al a Ar g    Gl n Ly s Phe
                   1655                         1660                       1665
              Ser Ser     Leu Ty r I l e Ser Gl n      Phe I l e I l e Met Ty r   Ser Leu As p
                   1670                         1675                       1680
              Gl y Ly s   Ly s Tr p Gl n Thr Ty r      Ar g Gl y As n Ser Thr     Gl y Thr Leu
                   1685                         1690                       1695
              Met Val     Phe Phe Gl y As n Val        As p Ser Ser Gl y I l e    Ly s Hi s As n
                                                              Page 268

                                                                97047_1
<removed-date>
                   1700                         1705                         1710
              I l e Phe    As n Pr o Pr o I l e I l e   Al a Ar g Ty r I l e Ar g   Leu Hi s Pr o
                   1715                         1720                         1725
<removed-apn>
              Thr Hi s     Ty r Ser I l e Ar g Ser      Thr Leu Ar g Met Gl u       Leu Met Gl y
                   1730                         1735                         1740
              Cy s As p    Leu As n Ser Cy s Ser        Met Pr o Leu Gl y Met       Gl u Ser Ly s
                   1745                         1750                         1755
              Al a I l e   Ser As p Al a Gl n I l e     Thr Al a Ser Ser Ty r       Phe Thr As n
                   1760                         1765                         1770
              Met Phe      Al a Thr Tr p Ser Pr o       Ser Ly s Al a Ar g Leu      Hi s Leu Gl n
                   1775                         1780                         1785
              Gl y Ar g    Ser As n Al a Tr p Ar g      Pr o Gl n Val As n As n     Pr o Ly s Gl u
                   1790                         1795                         1800
              Tr p Leu     Gl n Val As p Phe Gl n       Ly s Thr Met Ly s Val       Thr Gl y Val
                   1805                         1810                         1815
              Thr Thr      Gl n Gl y Val Ly s Ser       Leu Leu Thr Ser Met         Ty r Val Ly s
                   1820                         1825                         1830
                                                                Page 269

                                                             97047_1
<removed-date>
              Gl u Phe    Leu I l e Ser Ser Ser      Gl n As p Gl y Hi s Gl n   Tr p Thr Leu
                   1835                       1840                       1845
              Phe Phe     Gl n As n Gl y Ly s Val    Ly s Val Phe Gl n Gl y     As n Gl n As p
                   1850                       1855                       1860
<removed-apn>
              Ser Phe     Thr Pr o Val Val As n      Ser Leu As p Pr o Pr o     Leu Leu Thr
                   1865                       1870                       1875
              Ar g Ty r   Leu Ar g I l e Hi s Pr o   Gl n Ser Tr p Val Hi s     Gl n I l e Al a
                   1880                       1885                       1890
              Leu Ar g    Met Gl u Val Leu Gl y      Cy s Gl u Al a Gl n As p   Leu Ty r As p
                   1895                       1900                       1905
              Ly s Thr    Hi s Thr Cy s Pr o Pr o    Cy s Pr o Al a Pr o Gl u   Leu Leu Gl y
                   1910                       1915                       1920
              Gl y Pr o   Ser Val Phe Leu Phe        Pr o Pr o Ly s Pr o Ly s   As p Thr Leu
                   1925                       1930                       1935
              Met I l e   Ser Ar g Thr Pr o Gl u     Val Thr Cy s Val Val       Val As p Val
                   1940                       1945                       1950
              Ser Hi s    Gl u As p Pr o Gl u Val    Ly s Phe As n Tr p Ty r    Val As p Gl y
                                                            Page 270

                                                              97047_1
<removed-date>
                   1955                        1960                       1965
              Val Gl u    Val Hi s As n Al a Ly s     Thr Ly s Pr o Ar g Gl u    Gl u Gl n Ty r
                   1970                        1975                       1980
<removed-apn>
              As n Ser    Thr Ty r Ar g Val Val       Ser Val Leu Thr Val        Leu Hi s Gl n
                   1985                        1990                       1995
              As p Tr p   Leu As n Gl y Ly s Gl u     Ty r Ly s Cy s Ly s Val    Ser As n Ly s
                   2000                        2005                       2010
              Al a Leu    Pr o Al a Pr o I l e Gl u   Ly s Thr I l e Ser Ly s    Al a Ly s Gl y
                   2015                        2020                       2025
              Gl n Pr o   Ar g Gl u Pr o Gl n Val     Ty r Thr Leu Pr o Pr o     Ser Ar g As p
                   2030                        2035                       2040
              Gl u Leu    Thr Ly s As n Gl n Val      Ser Leu Thr Cy s Leu       Val Ly s Gl y
                   2045                        2050                       2055
              Phe Ty r    Pr o Ser As p I l e Al a    Val Gl u Tr p Gl u Ser     As n Gl y Gl n
                   2060                        2065                       2070
              Pr o Gl u   As n As n Ty r Ly s Thr     Thr Pr o Pr o Val Leu      As p Ser As p
                   2075                        2080                       2085
                                                             Page 271

                                                                 97047_1
<removed-date>
              Gl y Ser      Phe Phe Leu Ty r Ser          Ly s Leu Thr Val As p    Ly s Ser Ar g
                     2090                          2095                     2100
              Tr p Gl n     Gl n Gl y As n Val Phe        Ser Cy s Ser Val Met     Hi s Gl u Al a
                     2105                          2110                     2115
<removed-apn>
              Leu Hi s      As n Hi s Ty r Thr Gl n       Ly s Ser Leu Ser Leu     Ser Pr o Gl y
                     2120                          2125                     2130
              Ly s
              <210>       107
              <211>       1984
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
              <220>
              <223>       FVI I I 199 pr ot ei n s equenc e
              <400>       107
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
              1                       5                          10                      15
              Cy s Phe Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser
                                 20                         25                      30
                                                                 Page 272

                                                                   97047_1
<removed-date>
              Tr p As p Ty r Met Gl n Ser As p Leu Gl y Gl u Leu Pr o Val As p Al a Ar g
                          35                           40                           45
              Phe Pr o Pr o Ar g Val Pr o Ly s Ser Phe Pr o Phe As n Thr Ser Val Val
                    50                           55                           60
<removed-apn>
              Ty r Ly s Ly s Thr Leu Phe Val Gl u Phe Thr As p Hi s Leu Phe As n I l e
              65                           70                           75                           80
              Al a Ly s Pr o Ar g Pr o Pr o Tr p Met Gl y Leu Leu Gl y Pr o Thr I l e Gl n
                                      85                           90                           95
              Al a Gl u Val Ty r As p Thr Val Val I l e Thr Leu Ly s As n Met Al a Ser
                                100                          105                          110
              Hi s Pr o Val Ser Leu Hi s Al a Val Gl y Val Ser Ty r Tr p Ly s Al a Ser
                          115                          120                          125
              Gl u Gl y Al a Gl u Ty r As p As p Gl n Thr Ser Gl n Ar g Gl u Ly s Gl u As p
                    130                          135                          140
              As p Ly s Val Phe Pr o Gl y Gl y Ser Hi s Thr Ty r Val Tr p Gl n Val Leu
              145                          150                          155                          160
              Ly s Gl u As n Gl y Pr o Met Al a Ser As p Pr o Leu Cy s Leu Thr Ty r Ser
                                                                   Page 273

                                                                     97047_1
<removed-date>
                                      165                           170                           175
              Ty r Leu Ser Hi s Val As p Leu Val Ly s As p Leu As n Ser Gl y Leu I l e
                                180                           185                           190
<removed-apn>
              Gl y Al a Leu Leu Val Cy s Ar g Gl u Gl y Ser Leu Al a Ly s Gl u Ly s Thr
                          195                           200                           205
              Gl n Thr Leu Hi s Ly s Phe I l e Leu Leu Phe Al a Val Phe As p Gl u Gl y
                    210                           215                           220
              Ly s Ser Tr p Hi s Ser Gl u Thr Ly s As n Ser Leu Met Gl n As p Ar g As p
              225                           230                           235                           240
              Al a Al a Ser Al a Ar g Al a Tr p Pr o Ly s Met Hi s Thr Val As n Gl y Ty r
                                      245                           250                           255
              Val As n Ar g Ser Leu Pr o Gl y Leu I l e Gl y Cy s Hi s Ar g Ly s Ser Val
                                260                           265                           270
              Ty r Tr p Hi s Val I l e Gl y Met Gl y Thr Thr Pr o Gl u Val Hi s Ser I l e
                          275                           280                           285
              Phe Leu Gl u Gl y Hi s Thr Phe Leu Val Ar g As n Hi s Ar g Gl n Al a Ser
                    290                           295                           300
                                                                    Page 274

                                                                    97047_1
<removed-date>
              Leu Gl u I l e Ser Pr o I l e Thr Phe Leu Thr Al a Gl n Thr Leu Leu Met
              305                           310                           315                           320
              As p Leu Gl y Gl n Phe Leu Leu Phe Cy s Hi s I l e Ser Ser Hi s Gl n Hi s
                                      325                           330                           335
<removed-apn>
              As p Gl y Met Gl u Al a Ty r Val Ly s Val As p Ser Cy s Pr o Gl u Gl u Pr o
                                340                           345                           350
              Gl n Leu Ar g Met Ly s As n As n Gl u Gl u Al a Gl u As p Ty r As p As p As p
                          355                           360                           365
              Leu Thr As p Ser Gl u Met As p Val Val Ar g Phe As p As p As p As n Ser
                    370                           375                           380
              Pr o Ser Phe I l e Gl n I l e Ar g Ser Val Al a Ly s Ly s Hi s Pr o Ly s Thr
              385                           390                           395                           400
              Tr p Val Hi s Ty r I l e Al a Al a Gl u Gl u Gl u As p Tr p As p Ty r Al a Pr o
                                      405                           410                           415
              Leu Val Leu Al a Pr o As p As p Ar g Ser Ty r Ly s Ser Gl n Ty r Leu As n
                                420                           425                           430
              As n Gl y Pr o Gl n Ar g I l e Gl y Ar g Ly s Ty r Ly s Ly s Val Ar g Phe Met
                                                                    Page 275

                                                                    97047_1
<removed-date>
                          435                           440                           445
              Al a Ty r Thr As p Gl u Thr Phe Ly s Thr Ar g Gl u Al a I l e Gl n Hi s Gl u
                    450                           455                           460
<removed-apn>
              Ser Gl y I l e Leu Gl y Pr o Leu Leu Ty r Gl y Gl u Val Gl y As p Thr Leu
              465                           470                           475                           480
              Leu I l e I l e Phe Ly s As n Gl n Al a Ser Ar g Pr o Ty r As n I l e Ty r Pr o
                                      485                           490                           495
              Hi s Gl y I l e Thr As p Val Ar g Pr o Leu Ty r Ser Ar g Ar g Leu Pr o Ly s
                                500                           505                           510
              Gl y Val Ly s Hi s Leu Ly s As p Phe Pr o I l e Leu Pr o Gl y Gl u I l e Phe
                          515                           520                           525
              Ly s Ty r Ly s Tr p Thr Val Thr Val Gl u As p Gl y Pr o Thr Ly s Ser As p
                    530                           535                           540
              Pr o Ar g Cy s Leu Thr Ar g Ty r Ty r Ser Ser Phe Val As n Met Gl u Ar g
              545                           550                           555                           560
              As p Leu Al a Ser Gl y Leu I l e Gl y Pr o Leu Leu I l e Cy s Ty r Ly s Gl u
                                      565                           570                           575
                                                                    Page 276

                                                                    97047_1
<removed-date>
              Ser Val As p Gl n Ar g Gl y As n Gl n I l e Met Ser As p Ly s Ar g As n Val
                                580                           585                           590
              I l e Leu Phe Ser Val Phe As p Gl u As n Ar g Ser Tr p Ty r Leu Thr Gl u
                          595                           600                           605
<removed-apn>
              As n I l e Gl n Ar g Phe Leu Pr o As n Pr o Al a Gl y Val Gl n Leu Gl u As p
                    610                           615                           620
              Pr o Gl u Phe Gl n Al a Ser As n I l e Met Hi s Ser I l e As n Gl y Ty r Val
              625                           630                           635                           640
              Phe As p Ser Leu Gl n Leu Ser Val Cy s Leu Hi s Gl u Val Al a Ty r Tr p
                                      645                           650                           655
              Ty r I l e Leu Ser I l e Gl y Al a Gl n Thr As p Phe Leu Ser Val Phe Phe
                                660                           665                           670
              Ser Gl y Ty r Thr Phe Ly s Hi s Ly s Met Val Ty r Gl u As p Thr Leu Thr
                          675                           680                           685
              Leu Phe Pr o Phe Ser Gl y Gl u Thr Val Phe Met Ser Met Gl u As n Pr o
                    690                           695                           700
              Gl y Leu Tr p I l e Leu Gl y Cy s Hi s As n Ser As p Phe Ar g As n Ar g Gl y
                                                                    Page 277

                                                                    97047_1
<removed-date>
              705                           710                        715                              720
              Met Thr Al a Leu Leu Ly s Val Ser Ser Cy s As p Ly s As n Thr Gl y As p
                                      725                           730                           735
<removed-apn>
              Ty r Ty r Gl u As p Ser Ty r Gl u As p I l e Ser Al a Ty r Leu Leu Ser Ly s
                                740                           745                           750
              As n As n Al a I l e Gl u Pr o Ar g Ser Phe Ser Gl n As n Pr o Pr o Val Leu
                          755                           760                           765
              Ly s Ar g Hi s Gl n Al a Gl u I l e Thr Ar g Thr Thr Leu Gl n Gl y Al a Pr o
                    770                           775                           780
              Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Al a Ser Pr o
              785                           790                           795                           800
              Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
                                      805                           810                           815
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                                820                           825                           830
              Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Thr Pr o Gl y
                          835                           840                           845
                                                                    Page 278

                                                                    97047_1
<removed-date>
              Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
                    850                           855                           860
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
              865                           870                           875                           880
<removed-apn>
              Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Ser Ser Thr
                                      885                           890                           895
              Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a
                                900                           905                           910
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                          915                           920                           925
              Al a Ser Ser Ser As p Gl n Gl u Gl u I l e As p Ty r As p As p Thr I l e Ser
                    930                           935                           940
              Val Gl u Met Ly s Ly s Gl u As p Phe As p I l e Ty r As p Gl u As p Gl u As n
              945                           950                           955                           960
              Gl n Ser Pr o Ar g Ser Phe Gl n Ly s Ly s Thr Ar g Hi s Ty r Phe I l e Al a
                                      965                           970                           975
              Al a Val Gl u Ar g Leu Tr p As p Ty r Gl y Met Ser Ser Ser Pr o Hi s Val
                                                                    Page 279

                                                                   97047_1
<removed-date>
                                980                          985                      990
              Leu Ar g As n Ar g Al a Gl n Ser Gl y           Ser Val Pr o Gl n Phe       Ly s Ly s Val
                          995                         1000                         1005
<removed-apn>
              Val Phe      Gl n Gl u Phe Thr As p       Gl y Ser Phe Thr Gl n        Pr o Leu Ty r
                   1010                        1015                           1020
              Ar g Gl y    Gl u Leu As n Gl u Hi s      Leu Gl y Leu Leu Gl y        Pr o Ty r I l e
                   1025                        1030                           1035
              Ar g Al a    Gl u Val Gl u As p As n      I l e Met Val Thr Phe        Ar g As n Gl n
                   1040                        1045                           1050
              Al a Ser     Ar g Pr o Ty r Ser Phe       Ty r Ser Ser Leu I l e       Ser Ty r Gl u
                   1055                        1060                           1065
              Gl u As p    Gl n Ar g Gl n Gl y Al a     Gl u Pr o Ar g Ly s As n     Phe Val Ly s
                   1070                        1075                           1080
              Pr o As n    Gl u Thr Ly s Thr Ty r       Phe Tr p Ly s Val Gl n       Hi s Hi s Met
                   1085                        1090                           1095
              Al a Pr o    Thr Ly s As p Gl u Phe       As p Cy s Ly s Al a Tr p     Al a Ty r Phe
                   1100                        1105                           1110
                                                                   Page 280

                                                          97047_1
<removed-date>
              Ser As p    Val As p Leu Gl u Ly s   As p Val Hi s Ser Gl y   Leu I l e Gl y
                   1115                     1120                     1125
              Pr o Leu    Leu Val Cy s Hi s Thr    As n Thr Leu As n Pr o   Al a Hi s Gl y
                   1130                     1135                     1140
<removed-apn>
              Ar g Gl n   Val Thr Val Gl n Gl u    Phe Al a Leu Phe Phe     Thr I l e Phe
                   1145                     1150                     1155
              As p Gl u   Thr Ly s Ser Tr p Ty r   Phe Thr Gl u As n Met    Gl u Ar g As n
                   1160                     1165                     1170
              Cy s Ar g   Gl y Al a Pr o Thr Ser   Gl u Ser Al a Thr Pr o   Gl u Ser Gl y
                   1175                     1180                     1185
              Pr o Gl y   Ser Gl u Pr o Al a Thr   Ser Gl y Ser Gl u Thr    Pr o Gl y Thr
                   1190                     1195                     1200
              Ser Gl u    Ser Al a Thr Pr o Gl u   Ser Gl y Pr o Gl y Ser   Gl u Pr o Al a
                   1205                     1210                     1215
              Thr Ser     Gl y Ser Gl u Thr Pr o   Gl y Thr Ser Gl u Ser    Al a Thr Pr o
                   1220                     1225                     1230
              Gl u Ser    Gl y Pr o Gl y Thr Ser   Thr Gl u Pr o Ser Gl u   Gl y Ser Al a
                                                          Page 281

                                                               97047_1
<removed-date>
                   1235                        1240                        1245
              Pr o Gl y   Thr Ser Gl u Ser Al a       Thr Pr o Gl u Ser Gl y       Pr o Gl y Ser
                   1250                        1255                        1260
<removed-apn>
              Pr o Al a   Gl y Ser Pr o Thr Ser       Thr Gl u Gl u Gl y Ser       Pr o Al a Gl y
                   1265                        1270                        1275
              Ser Pr o    Thr Ser Thr Gl u Gl u       Gl y Ser Pr o Al a Gl y      Ser Pr o Thr
                   1280                        1285                        1290
              Ser Thr     Gl u Gl u Gl y Thr Ser      Gl u Ser Al a Thr Pr o       Gl u Ser Gl y
                   1295                        1300                        1305
              Pr o Gl y   Thr Ser Thr Gl u Pr o       Ser Gl u Gl y Ser Al a       Pr o Gl y Al a
                   1310                        1315                        1320
              Ser Ser     Al a Pr o Cy s As n I l e   Gl n Met Gl u As p Pr o      Thr Phe Ly s
                   1325                        1330                        1335
              Gl u As n   Ty r Ar g Phe Hi s Al a     I l e As n Gl y Ty r I l e   Met As p Thr
                   1340                        1345                        1350
              Leu Pr o    Gl y Leu Val Met Al a       Gl n As p Gl n Ar g I l e    Ar g Tr p Ty r
                   1355                        1360                        1365
                                                              Page 282

                                                             97047_1
<removed-date>
              Leu Leu     Ser Met Gl y Ser As n      Gl u As n I l e Hi s Ser   I l e Hi s Phe
                   1370                       1375                       1380
              Ser Gl y    Hi s Val Phe Thr Val       Ar g Ly s Ly s Gl u Gl u   Ty r Ly s Met
                   1385                       1390                       1395
<removed-apn>
              Al a Leu    Ty r As n Leu Ty r Pr o    Gl y Val Phe Gl u Thr      Val Gl u Met
                   1400                       1405                       1410
              Leu Pr o    Ser Ly s Al a Gl y I l e   Tr p Ar g Val Gl u Cy s    Leu I l e Gl y
                   1415                       1420                       1425
              Gl u Hi s   Leu Hi s Al a Gl y Met     Ser Thr Leu Phe Leu        Val Ty r Ser
                   1430                       1435                       1440
              As n Ly s   Cy s Gl n Thr Pr o Leu     Gl y Met Al a Ser Gl y     Hi s I l e Ar g
                   1445                       1450                       1455
              As p Phe    Gl n I l e Thr Al a Ser    Gl y Gl n Ty r Gl y Gl n   Tr p Al a Pr o
                   1460                       1465                       1470
              Ly s Leu    Al a Ar g Leu Hi s Ty r    Ser Gl y Ser I l e As n    Al a Tr p Ser
                   1475                       1480                       1485
              Thr Ly s    Gl u Pr o Phe Ser Tr p     I l e Ly s Val As p Leu    Leu Al a Pr o
                                                            Page 283

                                                                97047_1
<removed-date>
                   1490                          1495                        1500
              Met I l e    I l e Hi s Gl y I l e Ly s   Thr Gl n Gl y Al a Ar g     Gl n Ly s Phe
                   1505                          1510                        1515
<removed-apn>
              Ser Ser      Leu Ty r I l e Ser Gl n      Phe I l e I l e Met Ty r    Ser Leu As p
                   1520                          1525                        1530
              Gl y Ly s    Ly s Tr p Gl n Thr Ty r      Ar g Gl y As n Ser Thr      Gl y Thr Leu
                   1535                          1540                        1545
              Met Val      Phe Phe Gl y As n Val        As p Ser Ser Gl y I l e     Ly s Hi s As n
                   1550                          1555                        1560
              I l e Phe    As n Pr o Pr o I l e I l e   Al a Ar g Ty r I l e Ar g   Leu Hi s Pr o
                   1565                          1570                        1575
              Thr Hi s     Ty r Ser I l e Ar g Ser      Thr Leu Ar g Met Gl u       Leu Met Gl y
                   1580                          1585                        1590
              Cy s As p    Leu As n Ser Cy s Ser        Met Pr o Leu Gl y Met       Gl u Ser Ly s
                   1595                          1600                        1605
              Al a I l e   Ser As p Al a Gl n I l e     Thr Al a Ser Ser Ty r       Phe Thr As n
                   1610                          1615                        1620
                                                                Page 284

                                                             97047_1
<removed-date>
              Met Phe     Al a Thr Tr p Ser Pr o     Ser Ly s Al a Ar g Leu     Hi s Leu Gl n
                   1625                       1630                       1635
              Gl y Ar g   Ser As n Al a Tr p Ar g    Pr o Gl n Val As n As n    Pr o Ly s Gl u
                   1640                       1645                       1650
<removed-apn>
              Tr p Leu    Gl n Val As p Phe Gl n     Ly s Thr Met Ly s Val      Thr Gl y Val
                   1655                       1660                       1665
              Thr Thr     Gl n Gl y Val Ly s Ser     Leu Leu Thr Ser Met        Ty r Val Ly s
                   1670                       1675                       1680
              Gl u Phe    Leu I l e Ser Ser Ser      Gl n As p Gl y Hi s Gl n   Tr p Thr Leu
                   1685                       1690                       1695
              Phe Phe     Gl n As n Gl y Ly s Val    Ly s Val Phe Gl n Gl y     As n Gl n As p
                   1700                       1705                       1710
              Ser Phe     Thr Pr o Val Val As n      Ser Leu As p Pr o Pr o     Leu Leu Thr
                   1715                       1720                       1725
              Ar g Ty r   Leu Ar g I l e Hi s Pr o   Gl n Ser Tr p Val Hi s     Gl n I l e Al a
                   1730                       1735                       1740
              Leu Ar g    Met Gl u Val Leu Gl y      Cy s Gl u Al a Gl n As p   Leu Ty r As p
                                                            Page 285

                                                              97047_1
<removed-date>
                   1745                        1750                       1755
              Ly s Thr    Hi s Thr Cy s Pr o Pr o     Cy s Pr o Al a Pr o Gl u   Leu Leu Gl y
                   1760                        1765                       1770
<removed-apn>
              Gl y Pr o   Ser Val Phe Leu Phe         Pr o Pr o Ly s Pr o Ly s   As p Thr Leu
                   1775                        1780                       1785
              Met I l e   Ser Ar g Thr Pr o Gl u      Val Thr Cy s Val Val       Val As p Val
                   1790                        1795                       1800
              Ser Hi s    Gl u As p Pr o Gl u Val     Ly s Phe As n Tr p Ty r    Val As p Gl y
                   1805                        1810                       1815
              Val Gl u    Val Hi s As n Al a Ly s     Thr Ly s Pr o Ar g Gl u    Gl u Gl n Ty r
                   1820                        1825                       1830
              As n Ser    Thr Ty r Ar g Val Val       Ser Val Leu Thr Val        Leu Hi s Gl n
                   1835                        1840                       1845
              As p Tr p   Leu As n Gl y Ly s Gl u     Ty r Ly s Cy s Ly s Val    Ser As n Ly s
                   1850                        1855                       1860
              Al a Leu    Pr o Al a Pr o I l e Gl u   Ly s Thr I l e Ser Ly s    Al a Ly s Gl y
                   1865                        1870                       1875
                                                             Page 286

                                                              97047_1
<removed-date>
              Gl n Pr o     Ar g Gl u Pr o Gl n Val    Ty r Thr Leu Pr o Pr o   Ser Ar g As p
                     1880                       1885                     1890
              Gl u Leu      Thr Ly s As n Gl n Val     Ser Leu Thr Cy s Leu     Val Ly s Gl y
                     1895                       1900                     1905
<removed-apn>
              Phe Ty r      Pr o Ser As p I l e Al a   Val Gl u Tr p Gl u Ser   As n Gl y Gl n
                     1910                       1915                     1920
              Pr o Gl u     As n As n Ty r Ly s Thr    Thr Pr o Pr o Val Leu    As p Ser As p
                     1925                       1930                     1935
              Gl y Ser      Phe Phe Leu Ty r Ser       Ly s Leu Thr Val As p    Ly s Ser Ar g
                     1940                       1945                     1950
              Tr p Gl n     Gl n Gl y As n Val Phe     Ser Cy s Ser Val Met     Hi s Gl u Al a
                     1955                       1960                     1965
              Leu Hi s      As n Hi s Ty r Thr Gl n    Ly s Ser Leu Ser Leu     Ser Pr o Gl y
                     1970                       1975                     1980
              Ly s
              <210>       108
                                                              Page 287

                                                                97047_1
<removed-date>
              <211>     2134
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     FVI I I 201 pr ot ei n s equenc e
<removed-apn>
              <400>     108
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
              1                     5                           10                       15
              Cy s Phe Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser
                               20                          25                       30
              Tr p As p Ty r Met Gl n Ser As p Leu Gl y Gl u Leu Pr o Val Gl y Al a Pr o
                         35                           40                       45
              Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Ser Ser Pr o
                   50                           55                        60
              Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
              65                          70                         75                       80
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                                    85                          90                       95
              Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Pr o
                                                                Page 288

                                                                    97047_1
<removed-date>
                                100                           105                           110
              Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
                          115                           120                           125
<removed-apn>
              Thr Gl y Ser Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o
                    130                           135                           140
              Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Ser Ser Thr
              145                           150                           155                           160
              Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a
                                      165                           170                           175
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                                180                           185                           190
              Al a Ser Ser As p Al a Ar g Phe Pr o Pr o Ar g Val Pr o Ly s Ser Phe Pr o
                          195                           200                           205
              Phe As n Thr Ser Val Val Ty r Ly s Ly s Thr Leu Phe Val Gl u Phe Thr
                    210                           215                           220
              As p Hi s Leu Phe As n I l e Al a Ly s Pr o Ar g Pr o Pr o Tr p Met Gl y Leu
              225                           230                           235                           240
                                                                    Page 289

                                                                    97047_1
<removed-date>
              Leu Gl y Pr o Thr I l e Gl n Al a Gl u Val Ty r As p Thr Val Val I l e Thr
                                      245                           250                           255
              Leu Ly s As n Met Al a Ser Hi s Pr o Val Ser Leu Hi s Al a Val Gl y Val
                                260                           265                           270
<removed-apn>
              Ser Ty r Tr p Ly s Al a Ser Gl u Gl y Al a Gl u Ty r As p As p Gl n Thr Ser
                          275                           280                           285
              Gl n Ar g Gl u Ly s Gl u As p As p Ly s Val Phe Pr o Gl y Gl y Ser Hi s Thr
                    290                           295                           300
              Ty r Val Tr p Gl n Val Leu Ly s Gl u As n Gl y Pr o Met Al a Ser As p Pr o
              305                           310                           315                           320
              Leu Cy s Leu Thr Ty r Ser Ty r Leu Ser Hi s Val As p Leu Val Ly s As p
                                      325                           330                           335
              Leu As n Ser Gl y Leu I l e Gl y Al a Leu Leu Val Cy s Ar g Gl u Gl y Ser
                                340                           345                           350
              Leu Al a Ly s Gl u Ly s Thr Gl n Thr Leu Hi s Ly s Phe I l e Leu Leu Phe
                          355                           360                           365
              Al a Val Phe As p Gl u Gl y Ly s Ser Tr p Hi s Ser Gl u Thr Ly s As n Ser
                                                                    Page 290

                                                                    97047_1
<removed-date>
                    370                           375                           380
              Leu Met Gl n As p Ar g As p Al a Al a Ser Al a Ar g Al a Tr p Pr o Ly s Met
              385                           390                           395                           400
<removed-apn>
              Hi s Thr Val As n Gl y Ty r Val As n Ar g Ser Leu Pr o Gl y Leu I l e Gl y
                                      405                           410                           415
              Cy s Hi s Ar g Ly s Ser Val Ty r Tr p Hi s Val I l e Gl y Met Gl y Thr Thr
                                420                           425                           430
              Pr o Gl u Val Hi s Ser I l e Phe Leu Gl u Gl y Hi s Thr Phe Leu Val Ar g
                          435                           440                           445
              As n Hi s Ar g Gl n Al a Ser Leu Gl u I l e Ser Pr o I l e Thr Phe Leu Thr
                    450                           455                           460
              Al a Gl n Thr Leu Leu Met As p Leu Gl y Gl n Phe Leu Leu Phe Cy s Hi s
              465                           470                           475                           480
              I l e Ser Ser Hi s Gl n Hi s As p Gl y Met Gl u Al a Ty r Val Ly s Val As p
                                      485                           490                           495
              Ser Cy s Pr o Gl u Gl u Pr o Gl n Leu Ar g Met Ly s As n As n Gl u Gl u Al a
                                500                           505                           510
                                                                    Page 291

                                                                    97047_1
<removed-date>
              Gl u As p Ty r As p As p As p Leu Thr As p Ser Gl u Met As p Val Val Ar g
                          515                           520                           525
              Phe As p As p As p As n Ser Pr o Ser Phe I l e Gl n I l e Ar g Ser Val Al a
                    530                           535                           540
<removed-apn>
              Ly s Ly s Hi s Pr o Ly s Thr Tr p Val Hi s Ty r I l e Al a Al a Gl u Gl u Gl u
              545                           550                           555                           560
              As p Tr p As p Ty r Al a Pr o Leu Val Leu Al a Pr o As p As p Ar g Ser Ty r
                                      565                           570                           575
              Ly s Ser Gl n Ty r Leu As n As n Gl y Pr o Gl n Ar g I l e Gl y Ar g Ly s Ty r
                                580                           585                           590
              Ly s Ly s Val Ar g Phe Met Al a Ty r Thr As p Gl u Thr Phe Ly s Thr Ar g
                          595                           600                           605
              Gl u Al a I l e Gl n Hi s Gl u Ser Gl y I l e Leu Gl y Pr o Leu Leu Ty r Gl y
                    610                           615                           620
              Gl u Val Gl y As p Thr Leu Leu I l e I l e Phe Ly s As n Gl n Al a Ser Ar g
              625                           630                           635                           640
              Pr o Ty r As n I l e Ty r Pr o Hi s Gl y I l e Thr As p Val Ar g Pr o Leu Ty r
                                                                    Page 292

                                                                     97047_1
<removed-date>
                                      645                           650                           655
              Ser Ar g Ar g Leu Pr o Ly s Gl y Val Ly s Hi s Leu Ly s As p Phe Pr o I l e
                                660                           665                           670
<removed-apn>
              Leu Pr o Gl y Gl u I l e Phe Ly s Ty r Ly s Tr p Thr Val Thr Val Gl u As p
                          675                           680                           685
              Gl y Pr o Thr Ly s Ser As p Pr o Ar g Cy s Leu Thr Ar g Ty r Ty r Ser Ser
                    690                           695                           700
              Phe Val As n Met Gl u Ar g As p Leu Al a Ser Gl y Leu I l e Gl y Pr o Leu
              705                           710                           715                           720
              Leu I l e Cy s Ty r Ly s Gl u Ser Val As p Gl n Ar g Gl y As n Gl n I l e Met
                                      725                           730                           735
              Ser As p Ly s Ar g As n Val I l e Leu Phe Ser Val Phe As p Gl u As n Ar g
                                740                           745                           750
              Ser Tr p Ty r Leu Thr Gl u As n I l e Gl n Ar g Phe Leu Pr o As n Pr o Al a
                          755                           760                           765
              Gl y Val Gl n Leu Gl u As p Pr o Gl u Phe Gl n Al a Ser As n I l e Met Hi s
                    770                           775                           780
                                                                    Page 293

                                                                    97047_1
<removed-date>
              Ser I l e As n Gl y Ty r Val Phe As p Ser Leu Gl n Leu Ser Val Cy s Leu
              785                           790                           795                           800
              Hi s Gl u Val Al a Ty r Tr p Ty r I l e Leu Ser I l e Gl y Al a Gl n Thr As p
                                      805                           810                           815
<removed-apn>
              Phe Leu Ser Val Phe Phe Ser Gl y Ty r Thr Phe Ly s Hi s Ly s Met Val
                                820                           825                           830
              Ty r Gl u As p Thr Leu Thr Leu Phe Pr o Phe Ser Gl y Gl u Thr Val Phe
                          835                           840                           845
              Met Ser Met Gl u As n Pr o Gl y Leu Tr p I l e Leu Gl y Cy s Hi s As n Ser
                    850                           855                           860
              As p Phe Ar g As n Ar g Gl y Met Thr Al a Leu Leu Ly s Val Ser Ser Cy s
              865                           870                           875                           880
              As p Ly s As n Thr Gl y As p Ty r Ty r Gl u As p Ser Ty r Gl u As p I l e Ser
                                      885                           890                           895
              Al a Ty r Leu Leu Ser Ly s As n As n Al a I l e Gl u Pr o Ar g Ser Phe Ser
                                900                           905                           910
              Gl n As n Pr o Pr o Val Leu Ly s Ar g Hi s Gl n Al a Gl u I l e Thr Ar g Thr
                                                                    Page 294

                                                                      97047_1
<removed-date>
                           915                           920                            925
              Thr Leu Gl n Gl y Al a Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser
                    930                            935                            940
<removed-apn>
              Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a
              945                            950                            955                            960
              Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr
                                       965                            970                            975
              Ser Ser Thr Gl y Ser Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr
                                 980                            985                            990
              Gl y Pr o Gl y Thr Pr o Gl y Ser Gl y              Thr Al a Ser Ser Ser            Pr o Gl y Al a
                           995                           1000                            1005
              Ser Pr o      Gl y Thr Ser Ser Thr           Gl y Ser Pr o Gl y Al a            Ser Pr o Gl y
                    1010                            1015                            1020
              Thr Ser       Ser Thr Gl y Ser Pr o          Gl y Al a Ser Pr o Gl y            Thr Ser Ser
                    1025                            1030                            1035
              Thr Gl y      Ser Pr o Gl y Ser Ser          Thr Pr o Ser Gl y Al a             Thr Gl y Ser
                    1040                            1045                            1050
                                                                      Page 295

                                                              97047_1
<removed-date>
              Pr o Gl y   Ser Ser Thr Pr o Ser        Gl y Al a Thr Gl y Ser     Pr o Gl y Al a
                   1055                        1060                       1065
              Ser Pr o    Gl y Thr Ser Ser Thr        Gl y Ser Pr o Al a Ser     Ser Ser As p
                   1070                        1075                       1080
<removed-apn>
              Gl n Gl u   Gl u I l e As p Ty r As p   As p Thr I l e Ser Val     Gl u Met Ly s
                   1085                        1090                       1095
              Ly s Gl u   As p Phe As p I l e Ty r    As p Gl u As p Gl u As n   Gl n Ser Pr o
                   1100                        1105                       1110
              Ar g Ser    Phe Gl n Ly s Ly s Thr      Ar g Hi s Ty r Phe I l e   Al a Al a Val
                   1115                        1120                       1125
              Gl u Ar g   Leu Tr p As p Ty r Gl y     Met Ser Ser Ser Pr o       Hi s Val Leu
                   1130                        1135                       1140
              Ar g As n   Ar g Al a Gl n Ser Gl y     Ser Val Pr o Gl n Phe      Ly s Ly s Val
                   1145                        1150                       1155
              Val Phe     Gl n Gl u Phe Thr As p      Gl y Ser Phe Thr Gl n      Pr o Leu Ty r
                   1160                        1165                       1170
              Ar g Gl y   Gl u Leu As n Gl u Hi s     Leu Gl y Leu Leu Gl y      Pr o Ty r I l e
                                                             Page 296

                                                             97047_1
<removed-date>
                   1175                       1180                       1185
              Ar g Al a   Gl u Val Gl u As p As n    I l e Met Val Thr Phe      Ar g As n Gl n
                   1190                       1195                       1200
<removed-apn>
              Al a Ser    Ar g Pr o Ty r Ser Phe     Ty r Ser Ser Leu I l e     Ser Ty r Gl u
                   1205                       1210                       1215
              Gl u As p   Gl n Ar g Gl n Gl y Al a   Gl u Pr o Ar g Ly s As n   Phe Val Ly s
                   1220                       1225                       1230
              Pr o As n   Gl u Thr Ly s Thr Ty r     Phe Tr p Ly s Val Gl n     Hi s Hi s Met
                   1235                       1240                       1245
              Al a Pr o   Thr Ly s As p Gl u Phe     As p Cy s Ly s Al a Tr p   Al a Ty r Phe
                   1250                       1255                       1260
              Ser As p    Val As p Leu Gl u Ly s     As p Val Hi s Ser Gl y     Leu I l e Gl y
                   1265                       1270                       1275
              Pr o Leu    Leu Val Cy s Hi s Thr      As n Thr Leu As n Pr o     Al a Hi s Gl y
                   1280                       1285                       1290
              Ar g Gl n   Val Thr Val Gl n Gl u      Phe Al a Leu Phe Phe       Thr I l e Phe
                   1295                       1300                       1305
                                                            Page 297

                                                           97047_1
<removed-date>
              As p Gl u   Thr Ly s Ser Tr p Ty r   Phe Thr Gl u As n Met     Gl u Ar g As n
                   1310                     1315                      1320
              Cy s Ar g   Gl y Al a Pr o Thr Ser   Gl u Ser Al a Thr Pr o    Gl u Ser Gl y
                   1325                     1330                      1335
<removed-apn>
              Pr o Gl y   Ser Gl u Pr o Al a Thr   Ser Gl y Ser Gl u Thr     Pr o Gl y Thr
                   1340                     1345                      1350
              Ser Gl u    Ser Al a Thr Pr o Gl u   Ser Gl y Pr o Gl y Ser    Gl u Pr o Al a
                   1355                     1360                      1365
              Thr Ser     Gl y Ser Gl u Thr Pr o   Gl y Thr Ser Gl u Ser     Al a Thr Pr o
                   1370                     1375                      1380
              Gl u Ser    Gl y Pr o Gl y Thr Ser   Thr Gl u Pr o Ser Gl u    Gl y Ser Al a
                   1385                     1390                      1395
              Pr o Gl y   Thr Ser Gl u Ser Al a    Thr Pr o Gl u Ser Gl y    Pr o Gl y Ser
                   1400                     1405                      1410
              Pr o Al a   Gl y Ser Pr o Thr Ser    Thr Gl u Gl u Gl y Ser    Pr o Al a Gl y
                   1415                     1420                      1425
              Ser Pr o    Thr Ser Thr Gl u Gl u    Gl y Ser Pr o Al a Gl y   Ser Pr o Thr
                                                          Page 298

                                                               97047_1
<removed-date>
                   1430                        1435                        1440
              Ser Thr     Gl u Gl u Gl y Thr Ser      Gl u Ser Al a Thr Pr o       Gl u Ser Gl y
                   1445                        1450                        1455
<removed-apn>
              Pr o Gl y   Thr Ser Thr Gl u Pr o       Ser Gl u Gl y Ser Al a       Pr o Gl y Al a
                   1460                        1465                        1470
              Ser Ser     Al a Pr o Cy s As n I l e   Gl n Met Gl u As p Pr o      Thr Phe Ly s
                   1475                        1480                        1485
              Gl u As n   Ty r Ar g Phe Hi s Al a     I l e As n Gl y Ty r I l e   Met As p Thr
                   1490                        1495                        1500
              Leu Pr o    Gl y Leu Val Met Al a       Gl n As p Gl n Ar g I l e    Ar g Tr p Ty r
                   1505                        1510                        1515
              Leu Leu     Ser Met Gl y Ser As n       Gl u As n I l e Hi s Ser     I l e Hi s Phe
                   1520                        1525                        1530
              Ser Gl y    Hi s Val Phe Thr Val        Ar g Ly s Ly s Gl u Gl u     Ty r Ly s Met
                   1535                        1540                        1545
              Al a Leu    Ty r As n Leu Ty r Pr o     Gl y Val Phe Gl u Thr        Val Gl u Met
                   1550                        1555                        1560
                                                              Page 299

                                                               97047_1
<removed-date>
              Leu Pr o    Ser Ly s Al a Gl y I l e     Tr p Ar g Val Gl u Cy s    Leu I l e Gl y
                   1565                         1570                       1575
              Gl u Hi s   Leu Hi s Al a Gl y Met       Ser Thr Leu Phe Leu        Val Ty r Ser
                   1580                         1585                       1590
<removed-apn>
              As n Ly s   Cy s Gl n Thr Pr o Leu       Gl y Met Al a Ser Gl y     Hi s I l e Ar g
                   1595                         1600                       1605
              As p Phe    Gl n I l e Thr Al a Ser      Gl y Gl n Ty r Gl y Gl n   Tr p Al a Pr o
                   1610                         1615                       1620
              Ly s Leu    Al a Ar g Leu Hi s Ty r      Ser Gl y Ser I l e As n    Al a Tr p Ser
                   1625                         1630                       1635
              Thr Ly s    Gl u Pr o Phe Ser Tr p       I l e Ly s Val As p Leu    Leu Al a Pr o
                   1640                         1645                       1650
              Met I l e   I l e Hi s Gl y I l e Ly s   Thr Gl n Gl y Al a Ar g    Gl n Ly s Phe
                   1655                         1660                       1665
              Ser Ser     Leu Ty r I l e Ser Gl n      Phe I l e I l e Met Ty r   Ser Leu As p
                   1670                         1675                       1680
              Gl y Ly s   Ly s Tr p Gl n Thr Ty r      Ar g Gl y As n Ser Thr     Gl y Thr Leu
                                                              Page 300

                                                                97047_1
<removed-date>
                   1685                         1690                         1695
              Met Val      Phe Phe Gl y As n Val        As p Ser Ser Gl y I l e     Ly s Hi s As n
                   1700                         1705                         1710
<removed-apn>
              I l e Phe    As n Pr o Pr o I l e I l e   Al a Ar g Ty r I l e Ar g   Leu Hi s Pr o
                   1715                         1720                         1725
              Thr Hi s     Ty r Ser I l e Ar g Ser      Thr Leu Ar g Met Gl u       Leu Met Gl y
                   1730                         1735                         1740
              Cy s As p    Leu As n Ser Cy s Ser        Met Pr o Leu Gl y Met       Gl u Ser Ly s
                   1745                         1750                         1755
              Al a I l e   Ser As p Al a Gl n I l e     Thr Al a Ser Ser Ty r       Phe Thr As n
                   1760                         1765                         1770
              Met Phe      Al a Thr Tr p Ser Pr o       Ser Ly s Al a Ar g Leu      Hi s Leu Gl n
                   1775                         1780                         1785
              Gl y Ar g    Ser As n Al a Tr p Ar g      Pr o Gl n Val As n As n     Pr o Ly s Gl u
                   1790                         1795                         1800
              Tr p Leu     Gl n Val As p Phe Gl n       Ly s Thr Met Ly s Val       Thr Gl y Val
                   1805                         1810                         1815
                                                                Page 301

                                                             97047_1
<removed-date>
              Thr Thr     Gl n Gl y Val Ly s Ser     Leu Leu Thr Ser Met        Ty r Val Ly s
                   1820                       1825                       1830
              Gl u Phe    Leu I l e Ser Ser Ser      Gl n As p Gl y Hi s Gl n   Tr p Thr Leu
                   1835                       1840                       1845
<removed-apn>
              Phe Phe     Gl n As n Gl y Ly s Val    Ly s Val Phe Gl n Gl y     As n Gl n As p
                   1850                       1855                       1860
              Ser Phe     Thr Pr o Val Val As n      Ser Leu As p Pr o Pr o     Leu Leu Thr
                   1865                       1870                       1875
              Ar g Ty r   Leu Ar g I l e Hi s Pr o   Gl n Ser Tr p Val Hi s     Gl n I l e Al a
                   1880                       1885                       1890
              Leu Ar g    Met Gl u Val Leu Gl y      Cy s Gl u Al a Gl n As p   Leu Ty r As p
                   1895                       1900                       1905
              Ly s Thr    Hi s Thr Cy s Pr o Pr o    Cy s Pr o Al a Pr o Gl u   Leu Leu Gl y
                   1910                       1915                       1920
              Gl y Pr o   Ser Val Phe Leu Phe        Pr o Pr o Ly s Pr o Ly s   As p Thr Leu
                   1925                       1930                       1935
              Met I l e   Ser Ar g Thr Pr o Gl u     Val Thr Cy s Val Val       Val As p Val
                                                            Page 302

                                                              97047_1
<removed-date>
                   1940                        1945                       1950
              Ser Hi s    Gl u As p Pr o Gl u Val     Ly s Phe As n Tr p Ty r    Val As p Gl y
                   1955                        1960                       1965
<removed-apn>
              Val Gl u    Val Hi s As n Al a Ly s     Thr Ly s Pr o Ar g Gl u    Gl u Gl n Ty r
                   1970                        1975                       1980
              As n Ser    Thr Ty r Ar g Val Val       Ser Val Leu Thr Val        Leu Hi s Gl n
                   1985                        1990                       1995
              As p Tr p   Leu As n Gl y Ly s Gl u     Ty r Ly s Cy s Ly s Val    Ser As n Ly s
                   2000                        2005                       2010
              Al a Leu    Pr o Al a Pr o I l e Gl u   Ly s Thr I l e Ser Ly s    Al a Ly s Gl y
                   2015                        2020                       2025
              Gl n Pr o   Ar g Gl u Pr o Gl n Val     Ty r Thr Leu Pr o Pr o     Ser Ar g As p
                   2030                        2035                       2040
              Gl u Leu    Thr Ly s As n Gl n Val      Ser Leu Thr Cy s Leu       Val Ly s Gl y
                   2045                        2050                       2055
              Phe Ty r    Pr o Ser As p I l e Al a    Val Gl u Tr p Gl u Ser     As n Gl y Gl n
                   2060                        2065                       2070
                                                             Page 303

                                                                 97047_1
<removed-date>
              Pr o Gl u     As n As n Ty r Ly s Thr       Thr Pr o Pr o Val Leu   As p Ser As p
                     2075                          2080                    2085
              Gl y Ser      Phe Phe Leu Ty r Ser          Ly s Leu Thr Val As p   Ly s Ser Ar g
                     2090                          2095                    2100
<removed-apn>
              Tr p Gl n     Gl n Gl y As n Val Phe        Ser Cy s Ser Val Met    Hi s Gl u Al a
                     2105                          2110                    2115
              Leu Hi s      As n Hi s Ty r Thr Gl n       Ly s Ser Leu Ser Leu    Ser Pr o Gl y
                     2120                          2125                    2130
              Ly s
              <210>       109
              <211>       2128
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
              <220>
              <223>       FVI I I 203 pr ot ei n s equenc e
              <400>       109
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
              1                       5                         10                      15
                                                                Page 304

                                                                 97047_1
<removed-date>
              Cy s Phe Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser
                               20                          25                          30
              Tr p As p Ty r Met Gl n Ser As p Leu Gl y Gl u Leu Pr o Val As p Al a Ar g
                         35                          40                          45
<removed-apn>
              Phe Pr o Pr o Ar g Val Pr o Ly s Ser Phe Pr o Phe As n Thr Ser Val Val
                   50                          55                          60
              Ty r Ly s Ly s Thr Leu Phe Val Gl u Phe Thr As p Hi s Leu Phe As n I l e
              65                          70                          75                          80
              Al a Ly s Pr o Ar g Pr o Pr o Tr p Met Gl y Leu Leu Gl y Pr o Thr I l e Gl n
                                     85                          90                          95
              Al a Gl u Val Ty r As p Thr Val Val I l e Thr Leu Ly s As n Met Al a Ser
                               100                         105                         110
              Hi s Pr o Val Ser Leu Hi s Al a Val Gl y Val Ser Ty r Tr p Ly s Al a Ser
                         115                         120                         125
              Gl u Gl y Al a Gl u Ty r As p As p Gl n Thr Ser Gl n Ar g Gl u Ly s Gl u As p
                   130                         135                         140
              As p Ly s Val Phe Pr o Gl y Gl y Ser Hi s Thr Ty r Val Tr p Gl n Val Leu
                                                                 Page 305

                                                                    97047_1
<removed-date>
              145                           150                        155                              160
              Ly s Gl u As n Gl y Pr o Met Al a Ser As p Pr o Leu Cy s Leu Thr Ty r Ser
                                      165                           170                           175
<removed-apn>
              Ty r Leu Ser Hi s Val As p Leu Val Ly s As p Leu As n Ser Gl y Leu I l e
                                180                           185                           190
              Gl y Al a Leu Leu Val Cy s Ar g Gl u Gl y Ser Leu Al a Ly s Gl u Ly s Thr
                          195                           200                           205
              Gl n Thr Leu Hi s Ly s Phe I l e Leu Leu Phe Al a Val Phe As p Gl u Gl y
                    210                           215                           220
              Ly s Ser Tr p Hi s Ser Gl u Thr Ly s As n Ser Leu Met Gl n As p Ar g As p
              225                           230                           235                           240
              Al a Al a Ser Al a Ar g Al a Tr p Pr o Ly s Met Hi s Thr Val As n Gl y Ty r
                                      245                           250                           255
              Val As n Ar g Ser Leu Pr o Gl y Leu I l e Gl y Cy s Hi s Ar g Ly s Ser Val
                                260                           265                           270
              Ty r Tr p Hi s Val I l e Gl y Met Gl y Thr Thr Pr o Gl u Val Hi s Ser I l e
                          275                           280                           285
                                                                    Page 306

                                                                    97047_1
<removed-date>
              Phe Leu Gl u Gl y Hi s Thr Phe Leu Val Ar g As n Hi s Ar g Gl n Al a Ser
                    290                           295                           300
              Leu Gl u I l e Ser Pr o I l e Thr Phe Leu Thr Al a Gl n Thr Leu Leu Met
              305                           310                           315                           320
<removed-apn>
              As p Leu Gl y Gl n Phe Leu Leu Phe Cy s Hi s I l e Ser Ser Hi s Gl n Hi s
                                      325                           330                           335
              As p Gl y Met Gl u Al a Ty r Val Ly s Val As p Ser Cy s Pr o Gl u Gl u Pr o
                                340                           345                           350
              Gl n Leu Ar g Met Ly s As n As n Gl u Gl u Al a Gl u As p Ty r As p As p As p
                          355                           360                           365
              Leu Thr As p Ser Gl u Met As p Val Val Ar g Phe As p As p As p As n Ser
                    370                           375                           380
              Pr o Ser Phe I l e Gl n I l e Ar g Ser Val Al a Ly s Ly s Hi s Pr o Ly s Thr
              385                           390                           395                           400
              Tr p Val Hi s Ty r I l e Al a Al a Gl u Gl u Gl u As p Tr p As p Ty r Al a Pr o
                                      405                           410                           415
              Leu Val Leu Al a Pr o As p As p Ar g Ser Ty r Ly s Ser Gl n Ty r Leu As n
                                                                    Page 307

                                                                    97047_1
<removed-date>
                                420                           425                           430
              As n Gl y Pr o Gl n Ar g I l e Gl y Ar g Ly s Ty r Ly s Ly s Val Ar g Phe Met
                          435                           440                           445
<removed-apn>
              Al a Ty r Thr As p Gl u Thr Phe Ly s Thr Ar g Gl u Al a I l e Gl n Hi s Gl u
                    450                           455                           460
              Ser Gl y I l e Leu Gl y Pr o Leu Leu Ty r Gl y Gl u Val Gl y As p Thr Leu
              465                           470                           475                           480
              Leu I l e I l e Phe Ly s As n Gl n Al a Ser Ar g Pr o Ty r As n I l e Ty r Pr o
                                      485                           490                           495
              Hi s Gl y I l e Thr As p Val Ar g Pr o Leu Ty r Ser Ar g Ar g Leu Pr o Ly s
                                500                           505                           510
              Gl y Val Ly s Hi s Leu Ly s As p Phe Pr o I l e Leu Pr o Gl y Gl u I l e Phe
                          515                           520                           525
              Ly s Ty r Ly s Tr p Thr Val Thr Val Gl u As p Gl y Pr o Thr Ly s Ser As p
                    530                           535                           540
              Pr o Ar g Cy s Leu Thr Ar g Ty r Ty r Ser Ser Phe Val As n Met Gl u Ar g
              545                           550                           555                           560
                                                                    Page 308

                                                                    97047_1
<removed-date>
              As p Leu Al a Ser Gl y Leu I l e Gl y Pr o Leu Leu I l e Cy s Ty r Ly s Gl u
                                      565                           570                           575
              Ser Val As p Gl n Ar g Gl y As n Gl n I l e Met Ser As p Ly s Ar g As n Val
                                580                           585                           590
<removed-apn>
              I l e Leu Phe Ser Val Phe As p Gl u As n Ar g Ser Tr p Ty r Leu Thr Gl u
                          595                           600                           605
              As n I l e Gl n Ar g Phe Leu Pr o As n Pr o Al a Gl y Val Gl n Leu Gl u As p
                    610                           615                           620
              Pr o Gl u Phe Gl n Al a Ser As n I l e Met Hi s Ser I l e As n Gl y Ty r Val
              625                           630                           635                           640
              Phe As p Ser Leu Gl n Leu Ser Val Cy s Leu Hi s Gl u Val Al a Ty r Tr p
                                      645                           650                           655
              Ty r I l e Leu Ser I l e Gl y Al a Gl n Thr As p Phe Leu Ser Val Phe Phe
                                660                           665                           670
              Ser Gl y Ty r Thr Phe Ly s Hi s Ly s Met Val Ty r Gl u As p Thr Leu Thr
                          675                           680                           685
              Leu Phe Pr o Phe Ser Gl y Gl u Thr Val Phe Met Ser Met Gl u As n Pr o
                                                                    Page 309

                                                                    97047_1
<removed-date>
                    690                           695                           700
              Gl y Leu Tr p I l e Leu Gl y Cy s Hi s As n Ser As p Phe Ar g As n Ar g Gl y
              705                           710                           715                           720
<removed-apn>
              Met Thr Al a Leu Leu Ly s Val Ser Ser Cy s As p Ly s As n Thr Gl y As p
                                      725                           730                           735
              Ty r Ty r Gl u As p Ser Ty r Gl u As p I l e Ser Al a Ty r Leu Leu Ser Ly s
                                740                           745                           750
              As n As n Al a I l e Gl u Pr o Ar g Ser Phe Ser Gl n As n Gl y Al a Pr o Gl y
                          755                           760                           765
              Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a
                    770                           775                           780
              Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
              785                           790                           795                           800
              Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y
                                      805                           810                           815
              Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u
                                820                           825                           830
                                                                    Page 310

                                                                    97047_1
<removed-date>
              Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser
                          835                           840                           845
              Thr Gl u Gl u Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y
                    850                           855                           860
<removed-apn>
              Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser
              865                           870                           875                           880
              Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser
                                      885                           890                           895
              Thr Gl u Gl u Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y
                                900                           905                           910
              Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser
                          915                           920                           925
              Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
                    930                           935                           940
              Ser Gl y Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y
              945                           950                           955                           960
              Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Ser Gl u Pr o Al a
                                                                    Page 311

                                                                  97047_1
<removed-date>
                                      965                        970                       975
              Thr Ser Gl y Ser Gl u Thr Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser
                                980                        985                       990
<removed-apn>
              Thr Gl u Gl u Gl y Thr Ser Thr Gl u           Pr o Ser Gl u Gl y Ser     Al a Pr o Gl y
                          995                       1000                        1005
              Thr Ser      Thr Gl u Pr o Ser Gl u     Gl y Ser Al a Pr o Gl y      Ser Gl u Pr o
                   1010                      1015                           1020
              Al a Thr     Ser Gl y Ser Gl u Thr      Pr o Gl y Thr Ser Gl u       Ser Al a Thr
                   1025                      1030                           1035
              Pr o Gl u    Ser Gl y Pr o Gl y Thr     Ser Thr Gl u Pr o Ser        Gl u Gl y Ser
                   1040                      1045                           1050
              Al a Pr o    Al a Ser Ser Pr o Pr o     Val Leu Ly s Ar g Hi s       Gl n Al a Gl u
                   1055                      1060                           1065
              I l e Thr    Ar g Thr Thr Leu Gl n      Ser As p Gl n Gl u Gl u      I l e As p Ty r
                   1070                      1075                           1080
              As p As p    Thr I l e Ser Val Gl u     Met Ly s Ly s Gl u As p      Phe As p I l e
                   1085                      1090                           1095
                                                                 Page 312

                                                              97047_1
<removed-date>
              Ty r As p    Gl u As p Gl u As n Gl n   Ser Pr o Ar g Ser Phe       Gl n Ly s Ly s
                   1100                        1105                        1110
              Thr Ar g     Hi s Ty r Phe I l e Al a   Al a Val Gl u Ar g Leu      Tr p As p Ty r
                   1115                        1120                        1125
<removed-apn>
              Gl y Met     Ser Ser Ser Pr o Hi s      Val Leu Ar g As n Ar g      Al a Gl n Ser
                   1130                        1135                        1140
              Gl y Ser     Val Pr o Gl n Phe Ly s     Ly s Val Val Phe Gl n       Gl u Phe Thr
                   1145                        1150                        1155
              As p Gl y    Ser Phe Thr Gl n Pr o      Leu Ty r Ar g Gl y Gl u     Leu As n Gl u
                   1160                        1165                        1170
              Hi s Leu     Gl y Leu Leu Gl y Pr o     Ty r I l e Ar g Al a Gl u   Val Gl u As p
                   1175                        1180                        1185
              As n I l e   Met Val Thr Phe Ar g       As n Gl n Al a Ser Ar g     Pr o Ty r Ser
                   1190                        1195                        1200
              Phe Ty r     Ser Ser Leu I l e Ser      Ty r Gl u Gl u As p Gl n    Ar g Gl n Gl y
                   1205                        1210                        1215
              Al a Gl u    Pr o Ar g Ly s As n Phe    Val Ly s Pr o As n Gl u     Thr Ly s Thr
                                                              Page 313

                                                             97047_1
<removed-date>
                   1220                       1225                       1230
              Ty r Phe    Tr p Ly s Val Gl n Hi s    Hi s Met Al a Pr o Thr     Ly s As p Gl u
                   1235                       1240                       1245
<removed-apn>
              Phe As p    Cy s Ly s Al a Tr p Al a   Ty r Phe Ser As p Val      As p Leu Gl u
                   1250                       1255                       1260
              Ly s As p   Val Hi s Ser Gl y Leu      I l e Gl y Pr o Leu Leu    Val Cy s Hi s
                   1265                       1270                       1275
              Thr As n    Thr Leu As n Pr o Al a     Hi s Gl y Ar g Gl n Val    Thr Val Gl n
                   1280                       1285                       1290
              Gl u Phe    Al a Leu Phe Phe Thr       I l e Phe As p Gl u Thr    Ly s Ser Tr p
                   1295                       1300                       1305
              Ty r Phe    Thr Gl u As n Met Gl u     Ar g As n Cy s Ar g Gl y   Al a Pr o Thr
                   1310                       1315                       1320
              Ser Gl u    Ser Al a Thr Pr o Gl u     Ser Gl y Pr o Gl y Ser     Gl u Pr o Al a
                   1325                       1330                       1335
              Thr Ser     Gl y Ser Gl u Thr Pr o     Gl y Thr Ser Gl u Ser      Al a Thr Pr o
                   1340                       1345                       1350
                                                            Page 314

                                                             97047_1
<removed-date>
              Gl u Ser     Gl y Pr o Gl y Ser Gl u   Pr o Al a Thr Ser Gl y    Ser Gl u Thr
                   1355                       1360                      1365
              Pr o Gl y    Thr Ser Gl u Ser Al a     Thr Pr o Gl u Ser Gl y    Pr o Gl y Thr
                   1370                       1375                      1380
<removed-apn>
              Ser Thr      Gl u Pr o Ser Gl u Gl y   Ser Al a Pr o Gl y Thr    Ser Gl u Ser
                   1385                       1390                      1395
              Al a Thr     Pr o Gl u Ser Gl y Pr o   Gl y Ser Pr o Al a Gl y   Ser Pr o Thr
                   1400                       1405                      1410
              Ser Thr      Gl u Gl u Gl y Ser Pr o   Al a Gl y Ser Pr o Thr    Ser Thr Gl u
                   1415                       1420                      1425
              Gl u Gl y    Ser Pr o Al a Gl y Ser    Pr o Thr Ser Thr Gl u     Gl u Gl y Thr
                   1430                       1435                      1440
              Ser Gl u     Ser Al a Thr Pr o Gl u    Ser Gl y Pr o Gl y Thr    Ser Thr Gl u
                   1445                       1450                      1455
              Pr o Ser     Gl u Gl y Ser Al a Pr o   Gl y Al a Ser Ser Al a    Pr o Cy s As n
                   1460                       1465                      1470
              I l e Gl n   Met Gl u As p Pr o Thr    Phe Ly s Gl u As n Ty r   Ar g Phe Hi s
                                                            Page 315

                                                               97047_1
<removed-date>
                   1475                         1480                       1485
              Al a I l e   As n Gl y Ty r I l e Met    As p Thr Leu Pr o Gl y     Leu Val Met
                   1490                         1495                       1500
<removed-apn>
              Al a Gl n    As p Gl n Ar g I l e Ar g   Tr p Ty r Leu Leu Ser      Met Gl y Ser
                   1505                         1510                       1515
              As n Gl u    As n I l e Hi s Ser I l e   Hi s Phe Ser Gl y Hi s     Val Phe Thr
                   1520                         1525                       1530
              Val Ar g     Ly s Ly s Gl u Gl u Ty r    Ly s Met Al a Leu Ty r     As n Leu Ty r
                   1535                         1540                       1545
              Pr o Gl y    Val Phe Gl u Thr Val        Gl u Met Leu Pr o Ser      Ly s Al a Gl y
                   1550                         1555                       1560
              I l e Tr p   Ar g Val Gl u Cy s Leu      I l e Gl y Gl u Hi s Leu   Hi s Al a Gl y
                   1565                         1570                       1575
              Met Ser      Thr Leu Phe Leu Val         Ty r Ser As n Ly s Cy s    Gl n Thr Pr o
                   1580                         1585                       1590
              Leu Gl y     Met Al a Ser Gl y Hi s      I l e Ar g As p Phe Gl n   I l e Thr Al a
                   1595                         1600                       1605
                                                              Page 316

                                                              97047_1
<removed-date>
              Ser Gl y     Gl n Ty r Gl y Gl n Tr p   Al a Pr o Ly s Leu Al a     Ar g Leu Hi s
                   1610                        1615                        1620
              Ty r Ser     Gl y Ser I l e As n Al a   Tr p Ser Thr Ly s Gl u      Pr o Phe Ser
                   1625                        1630                        1635
<removed-apn>
              Tr p I l e   Ly s Val As p Leu Leu      Al a Pr o Met I l e I l e   Hi s Gl y I l e
                   1640                        1645                        1650
              Ly s Thr     Gl n Gl y Al a Ar g Gl n   Ly s Phe Ser Ser Leu        Ty r I l e Ser
                   1655                        1660                        1665
              Gl n Phe     I l e I l e Met Ty r Ser   Leu As p Gl y Ly s Ly s     Tr p Gl n Thr
                   1670                        1675                        1680
              Ty r Ar g    Gl y As n Ser Thr Gl y     Thr Leu Met Val Phe         Phe Gl y As n
                   1685                        1690                        1695
              Val As p     Ser Ser Gl y I l e Ly s    Hi s As n I l e Phe As n    Pr o Pr o I l e
                   1700                        1705                        1710
              I l e Al a   Ar g Ty r I l e Ar g Leu   Hi s Pr o Thr Hi s Ty r     Ser I l e Ar g
                   1715                        1720                        1725
              Ser Thr      Leu Ar g Met Gl u Leu      Met Gl y Cy s As p Leu      As n Ser Cy s
                                                              Page 317

                                                             97047_1
<removed-date>
                   1730                       1735                      1740
              Ser Met     Pr o Leu Gl y Met Gl u     Ser Ly s Al a I l e Ser   As p Al a Gl n
                   1745                       1750                      1755
<removed-apn>
              I l e Thr   Al a Ser Ser Ty r Phe      Thr As n Met Phe Al a     Thr Tr p Ser
                   1760                       1765                      1770
              Pr o Ser    Ly s Al a Ar g Leu Hi s    Leu Gl n Gl y Ar g Ser    As n Al a Tr p
                   1775                       1780                      1785
              Ar g Pr o   Gl n Val As n As n Pr o    Ly s Gl u Tr p Leu Gl n   Val As p Phe
                   1790                       1795                      1800
              Gl n Ly s   Thr Met Ly s Val Thr       Gl y Val Thr Thr Gl n     Gl y Val Ly s
                   1805                       1810                      1815
              Ser Leu     Leu Thr Ser Met Ty r       Val Ly s Gl u Phe Leu     I l e Ser Ser
                   1820                       1825                      1830
              Ser Gl n    As p Gl y Hi s Gl n Tr p   Thr Leu Phe Phe Gl n      As n Gl y Ly s
                   1835                       1840                      1845
              Val Ly s    Val Phe Gl n Gl y As n     Gl n As p Ser Phe Thr     Pr o Val Val
                   1850                       1855                      1860
                                                            Page 318

                                                             97047_1
<removed-date>
              As n Ser    Leu As p Pr o Pr o Leu     Leu Thr Ar g Ty r Leu     Ar g I l e Hi s
                   1865                       1870                      1875
              Pr o Gl n   Ser Tr p Val Hi s Gl n     I l e Al a Leu Ar g Met   Gl u Val Leu
                   1880                       1885                      1890
<removed-apn>
              Gl y Cy s   Gl u Al a Gl n As p Leu    Ty r As p Ly s Thr Hi s   Thr Cy s Pr o
                   1895                       1900                      1905
              Pr o Cy s   Pr o Al a Pr o Gl u Leu    Leu Gl y Gl y Pr o Ser    Val Phe Leu
                   1910                       1915                      1920
              Phe Pr o    Pr o Ly s Pr o Ly s As p   Thr Leu Met I l e Ser     Ar g Thr Pr o
                   1925                       1930                      1935
              Gl u Val    Thr Cy s Val Val Val       As p Val Ser Hi s Gl u    As p Pr o Gl u
                   1940                       1945                      1950
              Val Ly s    Phe As n Tr p Ty r Val     As p Gl y Val Gl u Val    Hi s As n Al a
                   1955                       1960                      1965
              Ly s Thr    Ly s Pr o Ar g Gl u Gl u   Gl n Ty r As n Ser Thr    Ty r Ar g Val
                   1970                       1975                      1980
              Val Ser     Val Leu Thr Val Leu        Hi s Gl n As p Tr p Leu   As n Gl y Ly s
                                                            Page 319

                                                            97047_1
<removed-date>
                   1985                      1990                       1995
              Gl u Ty r   Ly s Cy s Ly s Val Ser    As n Ly s Al a Leu Pr o    Al a Pr o I l e
                   2000                      2005                       2010
<removed-apn>
              Gl u Ly s   Thr I l e Ser Ly s Al a   Ly s Gl y Gl n Pr o Ar g   Gl u Pr o Gl n
                   2015                      2020                       2025
              Val Ty r    Thr Leu Pr o Pr o Ser     Ar g As p Gl u Leu Thr     Ly s As n Gl n
                   2030                      2035                       2040
              Val Ser     Leu Thr Cy s Leu Val      Ly s Gl y Phe Ty r Pr o    Ser As p I l e
                   2045                      2050                       2055
              Al a Val    Gl u Tr p Gl u Ser As n   Gl y Gl n Pr o Gl u As n   As n Ty r Ly s
                   2060                      2065                       2070
              Thr Thr     Pr o Pr o Val Leu As p    Ser As p Gl y Ser Phe      Phe Leu Ty r
                   2075                      2080                       2085
              Ser Ly s    Leu Thr Val As p Ly s     Ser Ar g Tr p Gl n Gl n    Gl y As n Val
                   2090                      2095                       2100
              Phe Ser     Cy s Ser Val Met Hi s     Gl u Al a Leu Hi s As n    Hi s Ty r Thr
                   2105                      2110                       2115
                                                           Page 320

                                                                     97047_1
<removed-date>
              Gl n Ly s     Ser Leu Ser Leu Ser              Pr o Gl y Ly s
                   2120                            2125
              <210>       110
              <211>       2128
<removed-apn>
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
              <220>
              <223>       FVI I I 204 pr ot ei n s equenc e
              <400>       110
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
              1                       5                             10                        15
              Cy s Phe Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser
                                 20                            25                        30
              Tr p As p Ty r Met Gl n Ser As p Leu Gl y Gl u Leu Pr o Val As p Al a Ar g
                           35                           40                          45
              Phe Pr o Pr o Ar g Val Pr o Ly s Ser Phe Pr o Phe As n Thr Ser Val Val
                   50                             55                           60
              Ty r Ly s Ly s Thr Leu Phe Val Gl u Phe Thr As p Hi s Leu Phe As n I l e
              65                            70                           75                        80
                                                                    Page 321

                                                                    97047_1
<removed-date>
              Al a Ly s Pr o Ar g Pr o Pr o Tr p Met Gl y Leu Leu Gl y Pr o Thr I l e Gl n
                                      85                            90                            95
              Al a Gl u Val Ty r As p Thr Val Val I l e Thr Leu Ly s As n Met Al a Ser
                                100                           105                           110
<removed-apn>
              Hi s Pr o Val Ser Leu Hi s Al a Val Gl y Val Ser Ty r Tr p Ly s Al a Ser
                          115                           120                           125
              Gl u Gl y Al a Gl u Ty r As p As p Gl n Thr Ser Gl n Ar g Gl u Ly s Gl u As p
                    130                           135                           140
              As p Ly s Val Phe Pr o Gl y Gl y Ser Hi s Thr Ty r Val Tr p Gl n Val Leu
              145                           150                           155                           160
              Ly s Gl u As n Gl y Pr o Met Al a Ser As p Pr o Leu Cy s Leu Thr Ty r Ser
                                      165                           170                           175
              Ty r Leu Ser Hi s Val As p Leu Val Ly s As p Leu As n Ser Gl y Leu I l e
                                180                           185                           190
              Gl y Al a Leu Leu Val Cy s Ar g Gl u Gl y Ser Leu Al a Ly s Gl u Ly s Thr
                          195                           200                           205
              Gl n Thr Leu Hi s Ly s Phe I l e Leu Leu Phe Al a Val Phe As p Gl u Gl y
                                                                    Page 322

                                                                    97047_1
<removed-date>
                    210                           215                           220
              Ly s Ser Tr p Hi s Ser Gl u Thr Ly s As n Ser Leu Met Gl n As p Ar g As p
              225                           230                           235                           240
<removed-apn>
              Al a Al a Ser Al a Ar g Al a Tr p Pr o Ly s Met Hi s Thr Val As n Gl y Ty r
                                      245                           250                           255
              Val As n Ar g Ser Leu Pr o Gl y Leu I l e Gl y Cy s Hi s Ar g Ly s Ser Val
                                260                           265                           270
              Ty r Tr p Hi s Val I l e Gl y Met Gl y Thr Thr Pr o Gl u Val Hi s Ser I l e
                          275                           280                           285
              Phe Leu Gl u Gl y Hi s Thr Phe Leu Val Ar g As n Hi s Ar g Gl n Al a Ser
                    290                           295                           300
              Leu Gl u I l e Ser Pr o I l e Thr Phe Leu Thr Al a Gl n Thr Leu Leu Met
              305                           310                           315                           320
              As p Leu Gl y Gl n Phe Leu Leu Phe Cy s Hi s I l e Ser Ser Hi s Gl n Hi s
                                      325                           330                           335
              As p Gl y Met Gl u Al a Ty r Val Ly s Val As p Ser Cy s Pr o Gl u Gl u Pr o
                                340                           345                           350
                                                                    Page 323

                                                                    97047_1
<removed-date>
              Gl n Leu Ar g Met Ly s As n As n Gl u Gl u Al a Gl u As p Ty r As p As p As p
                          355                           360                           365
              Leu Thr As p Ser Gl u Met As p Val Val Ar g Phe As p As p As p As n Ser
                    370                           375                           380
<removed-apn>
              Pr o Ser Phe I l e Gl n I l e Ar g Ser Val Al a Ly s Ly s Hi s Pr o Ly s Thr
              385                           390                           395                           400
              Tr p Val Hi s Ty r I l e Al a Al a Gl u Gl u Gl u As p Tr p As p Ty r Al a Pr o
                                      405                           410                           415
              Leu Val Leu Al a Pr o As p Gl y Al a Pr o Thr Ser Thr Gl u Pr o Ser Gl u
                                420                           425                           430
              Gl y Ser Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u
                          435                           440                           445
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr
                    450                           455                           460
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
              465                           470                           475                           480
              Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                                                                    Page 324

                                                                     97047_1
<removed-date>
                                      485                           490                           495
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o
                                500                           505                           510
<removed-apn>
              Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u
                          515                           520                           525
              Gl y Ser Al a Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                    530                           535                           540
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Gl u
              545                           550                           555                           560
              Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Al a Ser Ser As p Ar g Ser Ty r
                                      565                           570                           575
              Ly s Ser Gl n Ty r Leu As n As n Gl y Pr o Gl n Ar g I l e Gl y Ar g Ly s Ty r
                                580                           585                           590
              Ly s Ly s Val Ar g Phe Met Al a Ty r Thr As p Gl u Thr Phe Ly s Thr Ar g
                          595                           600                           605
              Gl u Al a I l e Gl n Hi s Gl u Ser Gl y I l e Leu Gl y Pr o Leu Leu Ty r Gl y
                    610                           615                           620
                                                                    Page 325

                                                                    97047_1
<removed-date>
              Gl u Val Gl y As p Thr Leu Leu I l e I l e Phe Ly s As n Gl n Al a Ser Ar g
              625                           630                           635                           640
              Pr o Ty r As n I l e Ty r Pr o Hi s Gl y I l e Thr As p Val Ar g Pr o Leu Ty r
                                      645                           650                           655
<removed-apn>
              Ser Ar g Ar g Leu Pr o Ly s Gl y Val Ly s Hi s Leu Ly s As p Phe Pr o I l e
                                660                           665                           670
              Leu Pr o Gl y Gl u I l e Phe Ly s Ty r Ly s Tr p Thr Val Thr Val Gl u As p
                          675                           680                           685
              Gl y Pr o Thr Ly s Ser As p Pr o Ar g Cy s Leu Thr Ar g Ty r Ty r Ser Ser
                    690                           695                           700
              Phe Val As n Met Gl u Ar g As p Leu Al a Ser Gl y Leu I l e Gl y Pr o Leu
              705                           710                           715                           720
              Leu I l e Cy s Ty r Ly s Gl u Ser Val As p Gl n Ar g Gl y As n Gl n I l e Met
                                      725                           730                           735
              Ser As p Ly s Ar g As n Val I l e Leu Phe Ser Val Phe As p Gl u As n Ar g
                                740                           745                           750
              Ser Tr p Ty r Leu Thr Gl u As n I l e Gl n Ar g Phe Leu Pr o As n Pr o Al a
                                                                    Page 326

                                                                    97047_1
<removed-date>
                          755                           760                           765
              Gl y Val Gl n Leu Gl u As p Pr o Gl u Phe Gl n Al a Ser As n I l e Met Hi s
                    770                           775                           780
<removed-apn>
              Ser I l e As n Gl y Ty r Val Phe As p Ser Leu Gl n Leu Ser Val Cy s Leu
              785                           790                           795                           800
              Hi s Gl u Val Al a Ty r Tr p Ty r I l e Leu Ser I l e Gl y Al a Gl n Thr As p
                                      805                           810                           815
              Phe Leu Ser Val Phe Phe Ser Gl y Ty r Thr Phe Ly s Hi s Ly s Met Val
                                820                           825                           830
              Ty r Gl u As p Thr Leu Thr Leu Phe Pr o Phe Ser Gl y Gl u Thr Val Phe
                          835                           840                           845
              Met Ser Met Gl u As n Pr o Gl y Leu Tr p I l e Leu Gl y Cy s Hi s As n Ser
                    850                           855                           860
              As p Phe Ar g As n Ar g Gl y Met Thr Al a Leu Leu Ly s Val Ser Ser Cy s
              865                           870                           875                           880
              As p Ly s As n Thr Gl y As p Ty r Ty r Gl u As p Ser Ty r Gl u As p I l e Ser
                                      885                           890                           895
                                                                    Page 327

                                                                      97047_1
<removed-date>
              Al a Ty r Leu Leu Ser Ly s As n As n Al a I l e Gl u Pr o Ar g Ser Phe Ser
                                 900                            905                            910
              Gl n As n Gl y Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y
                           915                           920                            925
<removed-apn>
              Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser
                    930                            935                            940
              Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser
              945                            950                            955                            960
              Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y
                                       965                            970                            975
              Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Pr o
                                 980                            985                            990
              Al a Gl y Ser Pr o Thr Ser Thr Gl u                Gl u Gl y Thr Ser Gl u          Ser Al a Thr
                           995                           1000                            1005
              Pr o Gl u     Ser Gl y Pr o Gl y Ser         Gl u Pr o Al a Thr Ser             Gl y Ser Gl u
                    1010                            1015                            1020
              Thr Pr o      Gl y Thr Ser Gl u Ser          Al a Thr Pr o Gl u Ser             Gl y Pr o Gl y
                                                                      Page 328

                                                           97047_1
<removed-date>
                   1025                     1030                      1035
              Ser Pr o    Al a Gl y Ser Pr o Thr   Ser Thr Gl u Gl u Gl y    Ser Pr o Al a
                   1040                     1045                      1050
<removed-apn>
              Gl y Ser    Pr o Thr Ser Thr Gl u    Gl u Gl y Thr Ser Thr     Gl u Pr o Ser
                   1055                     1060                      1065
              Gl u Gl y   Ser Al a Pr o Gl y Thr   Ser Gl u Ser Al a Thr     Pr o Gl u Ser
                   1070                     1075                      1080
              Gl y Pr o   Gl y Thr Ser Gl u Ser    Al a Thr Pr o Gl u Ser    Gl y Pr o Gl y
                   1085                     1090                      1095
              Thr Ser     Gl u Ser Al a Thr Pr o   Gl u Ser Gl y Pr o Gl y   Ser Gl u Pr o
                   1100                     1105                      1110
              Al a Thr    Ser Gl y Ser Gl u Thr    Pr o Gl y Ser Gl u Pr o   Al a Thr Ser
                   1115                     1120                      1125
              Gl y Ser    Gl u Thr Pr o Gl y Ser   Pr o Al a Gl y Ser Pr o   Thr Ser Thr
                   1130                     1135                      1140
              Gl u Gl u   Gl y Thr Ser Thr Gl u    Pr o Ser Gl u Gl y Ser    Al a Pr o Gl y
                   1145                     1150                      1155
                                                          Page 329

                                                             97047_1
<removed-date>
              Thr Ser     Thr Gl u Pr o Ser Gl u     Gl y Ser Al a Pr o Gl y   Ser Gl u Pr o
                   1160                       1165                      1170
              Al a Thr    Ser Gl y Ser Gl u Thr      Pr o Gl y Thr Ser Gl u    Ser Al a Thr
                   1175                       1180                      1185
<removed-apn>
              Pr o Gl u   Ser Gl y Pr o Gl y Thr     Ser Thr Gl u Pr o Ser     Gl u Gl y Ser
                   1190                       1195                      1200
              Al a Pr o   Al a Ser Ser Pr o Pr o     Val Leu Ly s Ar g Hi s    Gl n Al a Gl u
                   1205                       1210                      1215
              I l e Thr   Ar g Thr Thr Leu Gl n      Ser As p Gl n Gl u Gl u   I l e As p Ty r
                   1220                       1225                      1230
              As p As p   Thr I l e Ser Val Gl u     Met Ly s Ly s Gl u As p   Phe As p I l e
                   1235                       1240                      1245
              Ty r As p   Gl u As p Gl u As n Gl n   Ser Pr o Ar g Ser Phe     Gl n Ly s Ly s
                   1250                       1255                      1260
              Thr Ar g    Hi s Ty r Phe I l e Al a   Al a Val Gl u Ar g Leu    Tr p As p Ty r
                   1265                       1270                      1275
              Gl y Met    Ser Ser Ser Pr o Hi s      Val Leu Ar g As n Ar g    Al a Gl n Ser
                                                            Page 330

                                                              97047_1
<removed-date>
                   1280                        1285                        1290
              Gl y Ser     Val Pr o Gl n Phe Ly s     Ly s Val Val Phe Gl n       Gl u Phe Thr
                   1295                        1300                        1305
<removed-apn>
              As p Gl y    Ser Phe Thr Gl n Pr o      Leu Ty r Ar g Gl y Gl u     Leu As n Gl u
                   1310                        1315                        1320
              Hi s Leu     Gl y Leu Leu Gl y Pr o     Ty r I l e Ar g Al a Gl u   Val Gl u As p
                   1325                        1330                        1335
              As n I l e   Met Val Thr Phe Ar g       As n Gl n Al a Ser Ar g     Pr o Ty r Ser
                   1340                        1345                        1350
              Phe Ty r     Ser Ser Leu I l e Ser      Ty r Gl u Gl u As p Gl n    Ar g Gl n Gl y
                   1355                        1360                        1365
              Al a Gl u    Pr o Ar g Ly s As n Phe    Val Ly s Pr o As n Gl u     Thr Ly s Thr
                   1370                        1375                        1380
              Ty r Phe     Tr p Ly s Val Gl n Hi s    Hi s Met Al a Pr o Thr      Ly s As p Gl u
                   1385                        1390                        1395
              Phe As p     Cy s Ly s Al a Tr p Al a   Ty r Phe Ser As p Val       As p Leu Gl u
                   1400                        1405                        1410
                                                              Page 331

                                                               97047_1
<removed-date>
              Ly s As p    Val Hi s Ser Gl y Leu       I l e Gl y Pr o Leu Leu    Val Cy s Hi s
                   1415                         1420                       1425
              Thr As n     Thr Leu As n Pr o Al a      Hi s Gl y Ar g Gl n Val    Thr Val Gl n
                   1430                         1435                       1440
<removed-apn>
              Gl u Phe     Al a Leu Phe Phe Thr        I l e Phe As p Gl u Thr    Ly s Ser Tr p
                   1445                         1450                       1455
              Ty r Phe     Thr Gl u As n Met Gl u      Ar g As n Cy s Ar g Al a   Pr o Cy s As n
                   1460                         1465                       1470
              I l e Gl n   Met Gl u As p Pr o Thr      Phe Ly s Gl u As n Ty r    Ar g Phe Hi s
                   1475                         1480                       1485
              Al a I l e   As n Gl y Ty r I l e Met    As p Thr Leu Pr o Gl y     Leu Val Met
                   1490                         1495                       1500
              Al a Gl n    As p Gl n Ar g I l e Ar g   Tr p Ty r Leu Leu Ser      Met Gl y Ser
                   1505                         1510                       1515
              As n Gl u    As n I l e Hi s Ser I l e   Hi s Phe Ser Gl y Hi s     Val Phe Thr
                   1520                         1525                       1530
              Val Ar g     Ly s Ly s Gl u Gl u Ty r    Ly s Met Al a Leu Ty r     As n Leu Ty r
                                                              Page 332

                                                              97047_1
<removed-date>
                   1535                        1540                        1545
              Pr o Gl y    Val Phe Gl u Thr Val       Gl u Met Leu Pr o Ser       Ly s Al a Gl y
                   1550                        1555                        1560
<removed-apn>
              I l e Tr p   Ar g Val Gl u Cy s Leu     I l e Gl y Gl u Hi s Leu    Hi s Al a Gl y
                   1565                        1570                        1575
              Met Ser      Thr Leu Phe Leu Val        Ty r Ser As n Ly s Cy s     Gl n Thr Pr o
                   1580                        1585                        1590
              Leu Gl y     Met Al a Ser Gl y Hi s     I l e Ar g As p Phe Gl n    I l e Thr Al a
                   1595                        1600                        1605
              Ser Gl y     Gl n Ty r Gl y Gl n Tr p   Al a Pr o Ly s Leu Al a     Ar g Leu Hi s
                   1610                        1615                        1620
              Ty r Ser     Gl y Ser I l e As n Al a   Tr p Ser Thr Ly s Gl u      Pr o Phe Ser
                   1625                        1630                        1635
              Tr p I l e   Ly s Val As p Leu Leu      Al a Pr o Met I l e I l e   Hi s Gl y I l e
                   1640                        1645                        1650
              Ly s Thr     Gl n Gl y Al a Ar g Gl n   Ly s Phe Ser Ser Leu        Ty r I l e Ser
                   1655                        1660                        1665
                                                              Page 333

                                                              97047_1
<removed-date>
              Gl n Phe     I l e I l e Met Ty r Ser   Leu As p Gl y Ly s Ly s    Tr p Gl n Thr
                   1670                        1675                       1680
              Ty r Ar g    Gl y As n Ser Thr Gl y     Thr Leu Met Val Phe        Phe Gl y As n
                   1685                        1690                       1695
<removed-apn>
              Val As p     Ser Ser Gl y I l e Ly s    Hi s As n I l e Phe As n   Pr o Pr o I l e
                   1700                        1705                       1710
              I l e Al a   Ar g Ty r I l e Ar g Leu   Hi s Pr o Thr Hi s Ty r    Ser I l e Ar g
                   1715                        1720                       1725
              Ser Thr      Leu Ar g Met Gl u Leu      Met Gl y Cy s As p Leu     As n Ser Cy s
                   1730                        1735                       1740
              Ser Met      Pr o Leu Gl y Met Gl u     Ser Ly s Al a I l e Ser    As p Al a Gl n
                   1745                        1750                       1755
              I l e Thr    Al a Ser Ser Ty r Phe      Thr As n Met Phe Al a      Thr Tr p Ser
                   1760                        1765                       1770
              Pr o Ser     Ly s Al a Ar g Leu Hi s    Leu Gl n Gl y Ar g Ser     As n Al a Tr p
                   1775                        1780                       1785
              Ar g Pr o    Gl n Val As n As n Pr o    Ly s Gl u Tr p Leu Gl n    Val As p Phe
                                                             Page 334

                                                             97047_1
<removed-date>
                   1790                       1795                      1800
              Gl n Ly s   Thr Met Ly s Val Thr       Gl y Val Thr Thr Gl n     Gl y Val Ly s
                   1805                       1810                      1815
<removed-apn>
              Ser Leu     Leu Thr Ser Met Ty r       Val Ly s Gl u Phe Leu     I l e Ser Ser
                   1820                       1825                      1830
              Ser Gl n    As p Gl y Hi s Gl n Tr p   Thr Leu Phe Phe Gl n      As n Gl y Ly s
                   1835                       1840                      1845
              Val Ly s    Val Phe Gl n Gl y As n     Gl n As p Ser Phe Thr     Pr o Val Val
                   1850                       1855                      1860
              As n Ser    Leu As p Pr o Pr o Leu     Leu Thr Ar g Ty r Leu     Ar g I l e Hi s
                   1865                       1870                      1875
              Pr o Gl n   Ser Tr p Val Hi s Gl n     I l e Al a Leu Ar g Met   Gl u Val Leu
                   1880                       1885                      1890
              Gl y Cy s   Gl u Al a Gl n As p Leu    Ty r As p Ly s Thr Hi s   Thr Cy s Pr o
                   1895                       1900                      1905
              Pr o Cy s   Pr o Al a Pr o Gl u Leu    Leu Gl y Gl y Pr o Ser    Val Phe Leu
                   1910                       1915                      1920
                                                            Page 335

                                                             97047_1
<removed-date>
              Phe Pr o    Pr o Ly s Pr o Ly s As p   Thr Leu Met I l e Ser      Ar g Thr Pr o
                   1925                       1930                       1935
              Gl u Val    Thr Cy s Val Val Val       As p Val Ser Hi s Gl u     As p Pr o Gl u
                   1940                       1945                       1950
<removed-apn>
              Val Ly s    Phe As n Tr p Ty r Val     As p Gl y Val Gl u Val     Hi s As n Al a
                   1955                       1960                       1965
              Ly s Thr    Ly s Pr o Ar g Gl u Gl u   Gl n Ty r As n Ser Thr     Ty r Ar g Val
                   1970                       1975                       1980
              Val Ser     Val Leu Thr Val Leu        Hi s Gl n As p Tr p Leu    As n Gl y Ly s
                   1985                       1990                       1995
              Gl u Ty r   Ly s Cy s Ly s Val Ser     As n Ly s Al a Leu Pr o    Al a Pr o I l e
                   2000                       2005                       2010
              Gl u Ly s   Thr I l e Ser Ly s Al a    Ly s Gl y Gl n Pr o Ar g   Gl u Pr o Gl n
                   2015                       2020                       2025
              Val Ty r    Thr Leu Pr o Pr o Ser      Ar g As p Gl u Leu Thr     Ly s As n Gl n
                   2030                       2035                       2040
              Val Ser     Leu Thr Cy s Leu Val       Ly s Gl y Phe Ty r Pr o    Ser As p I l e
                                                            Page 336

                                                                  97047_1
<removed-date>
                   2045                            2050                       2055
              Al a Val      Gl u Tr p Gl u Ser As n       Gl y Gl n Pr o Gl u As n   As n Ty r Ly s
                   2060                            2065                       2070
<removed-apn>
              Thr Thr       Pr o Pr o Val Leu As p        Ser As p Gl y Ser Phe      Phe Leu Ty r
                   2075                            2080                       2085
              Ser Ly s      Leu Thr Val As p Ly s         Ser Ar g Tr p Gl n Gl n    Gl y As n Val
                   2090                            2095                       2100
              Phe Ser       Cy s Ser Val Met Hi s         Gl u Al a Leu Hi s As n    Hi s Ty r Thr
                   2105                            2110                       2115
              Gl n Ly s     Ser Leu Ser Leu Ser           Pr o Gl y Ly s
                   2120                            2125
              <210>       111
              <211>       2128
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
              <220>
              <223>       FVI I I 205 pr ot ei n s equenc e
              <400>       111
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
                                                                 Page 337

                                                                  97047_1
<removed-date>
              1                      5                           10                           15
              Cy s Phe Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser
                               20                          25                           30
<removed-apn>
              Tr p As p Ty r Met Gl n Gl y Al a Pr o Thr Ser Gl u Ser Al a Thr Pr o Gl u
                         35                          40                           45
              Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y
                   50                          55                           60
              Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a
              65                          70                          75                           80
              Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
                                     85                          90                           95
              Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y
                               100                         105                          110
              Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Gl u Ser
                         115                         120                          125
              Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser
                   130                         135                          140
                                                                 Page 338

                                                                    97047_1
<removed-date>
              Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y
              145                           150                           155                           160
              Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Ser Pr o Al a Gl y
                                      165                           170                           175
<removed-apn>
              Ser Pr o Thr Ser Thr Gl u Gl u Gl y Al a Ser Ser Ser As p Leu Gl y Gl u
                                180                           185                           190
              Leu Pr o Val As p Al a Ar g Phe Pr o Pr o Ar g Val Pr o Ly s Ser Phe Pr o
                          195                           200                           205
              Phe As n Thr Ser Val Val Ty r Ly s Ly s Thr Leu Phe Val Gl u Phe Thr
                    210                           215                           220
              As p Hi s Leu Phe As n I l e Al a Ly s Pr o Ar g Pr o Pr o Tr p Met Gl y Leu
              225                           230                           235                           240
              Leu Gl y Pr o Thr I l e Gl n Al a Gl u Val Ty r As p Thr Val Val I l e Thr
                                      245                           250                           255
              Leu Ly s As n Met Al a Ser Hi s Pr o Val Ser Leu Hi s Al a Val Gl y Val
                                260                           265                           270
              Ser Ty r Tr p Ly s Al a Ser Gl u Gl y Al a Gl u Ty r As p As p Gl n Thr Ser
                                                                    Page 339

                                                                    97047_1
<removed-date>
                          275                           280                           285
              Gl n Ar g Gl u Ly s Gl u As p As p Ly s Val Phe Pr o Gl y Gl y Ser Hi s Thr
                    290                           295                           300
<removed-apn>
              Ty r Val Tr p Gl n Val Leu Ly s Gl u As n Gl y Pr o Met Al a Ser As p Pr o
              305                           310                           315                           320
              Leu Cy s Leu Thr Ty r Ser Ty r Leu Ser Hi s Val As p Leu Val Ly s As p
                                      325                           330                           335
              Leu As n Ser Gl y Leu I l e Gl y Al a Leu Leu Val Cy s Ar g Gl u Gl y Ser
                                340                           345                           350
              Leu Al a Ly s Gl u Ly s Thr Gl n Thr Leu Hi s Ly s Phe I l e Leu Leu Phe
                          355                           360                           365
              Al a Val Phe As p Gl u Gl y Ly s Ser Tr p Hi s Ser Gl u Thr Ly s As n Ser
                    370                           375                           380
              Leu Met Gl n As p Ar g As p Al a Al a Ser Al a Ar g Al a Tr p Pr o Ly s Met
              385                           390                           395                           400
              Hi s Thr Val As n Gl y Ty r Val As n Ar g Ser Leu Pr o Gl y Leu I l e Gl y
                                      405                           410                           415
                                                                    Page 340

                                                                    97047_1
<removed-date>
              Cy s Hi s Ar g Ly s Ser Val Ty r Tr p Hi s Val I l e Gl y Met Gl y Thr Thr
                                420                           425                           430
              Pr o Gl u Val Hi s Ser I l e Phe Leu Gl u Gl y Hi s Thr Phe Leu Val Ar g
                          435                           440                           445
<removed-apn>
              As n Hi s Ar g Gl n Al a Ser Leu Gl u I l e Ser Pr o I l e Thr Phe Leu Thr
                    450                           455                           460
              Al a Gl n Thr Leu Leu Met As p Leu Gl y Gl n Phe Leu Leu Phe Cy s Hi s
              465                           470                           475                           480
              I l e Ser Ser Hi s Gl n Hi s As p Gl y Met Gl u Al a Ty r Val Ly s Val As p
                                      485                           490                           495
              Ser Cy s Pr o Gl u Gl u Pr o Gl n Leu Ar g Met Ly s As n As n Gl u Gl u Al a
                                500                           505                           510
              Gl u As p Ty r As p As p As p Leu Thr As p Ser Gl u Met As p Val Val Ar g
                          515                           520                           525
              Phe As p As p As p As n Ser Pr o Ser Phe I l e Gl n I l e Ar g Ser Val Al a
                    530                           535                           540
              Ly s Ly s Hi s Pr o Ly s Thr Tr p Val Hi s Ty r I l e Al a Al a Gl u Gl u Gl u
                                                                    Page 341

                                                                    97047_1
<removed-date>
              545                           550                        555                              560
              As p Tr p As p Ty r Al a Pr o Leu Val Leu Al a Pr o As p As p Ar g Ser Ty r
                                      565                           570                           575
<removed-apn>
              Ly s Ser Gl n Ty r Leu As n As n Gl y Pr o Gl n Ar g I l e Gl y Ar g Ly s Ty r
                                580                           585                           590
              Ly s Ly s Val Ar g Phe Met Al a Ty r Thr As p Gl u Thr Phe Ly s Thr Ar g
                          595                           600                           605
              Gl u Al a I l e Gl n Hi s Gl u Ser Gl y I l e Leu Gl y Pr o Leu Leu Ty r Gl y
                    610                           615                           620
              Gl u Val Gl y As p Thr Leu Leu I l e I l e Phe Ly s As n Gl n Al a Ser Ar g
              625                           630                           635                           640
              Pr o Ty r As n I l e Ty r Pr o Hi s Gl y I l e Thr As p Val Ar g Pr o Leu Ty r
                                      645                           650                           655
              Ser Ar g Ar g Leu Pr o Ly s Gl y Val Ly s Hi s Leu Ly s As p Phe Pr o I l e
                                660                           665                           670
              Leu Pr o Gl y Gl u I l e Phe Ly s Ty r Ly s Tr p Thr Val Thr Val Gl u As p
                          675                           680                           685
                                                                    Page 342

                                                                    97047_1
<removed-date>
              Gl y Pr o Thr Ly s Ser As p Pr o Ar g Cy s Leu Thr Ar g Ty r Ty r Ser Ser
                    690                           695                           700
              Phe Val As n Met Gl u Ar g As p Leu Al a Ser Gl y Leu I l e Gl y Pr o Leu
              705                           710                           715                           720
<removed-apn>
              Leu I l e Cy s Ty r Ly s Gl u Ser Val As p Gl n Ar g Gl y As n Gl n I l e Met
                                      725                           730                           735
              Ser As p Ly s Ar g As n Val I l e Leu Phe Ser Val Phe As p Gl u As n Ar g
                                740                           745                           750
              Ser Tr p Ty r Leu Thr Gl u As n I l e Gl n Ar g Phe Leu Pr o As n Pr o Al a
                          755                           760                           765
              Gl y Val Gl n Leu Gl u As p Pr o Gl u Phe Gl n Al a Ser As n I l e Met Hi s
                    770                           775                           780
              Ser I l e As n Gl y Ty r Val Phe As p Ser Leu Gl n Leu Ser Val Cy s Leu
              785                           790                           795                           800
              Hi s Gl u Val Al a Ty r Tr p Ty r I l e Leu Ser I l e Gl y Al a Gl n Thr As p
                                      805                           810                           815
              Phe Leu Ser Val Phe Phe Ser Gl y Ty r Thr Phe Ly s Hi s Ly s Met Val
                                                                    Page 343

                                                                    97047_1
<removed-date>
                                820                           825                           830
              Ty r Gl u As p Thr Leu Thr Leu Phe Pr o Phe Ser Gl y Gl u Thr Val Phe
                          835                           840                           845
<removed-apn>
              Met Ser Met Gl u As n Pr o Gl y Leu Tr p I l e Leu Gl y Cy s Hi s As n Ser
                    850                           855                           860
              As p Phe Ar g As n Ar g Gl y Met Thr Al a Leu Leu Ly s Val Ser Ser Cy s
              865                           870                           875                           880
              As p Ly s As n Thr Gl y As p Ty r Ty r Gl u As p Ser Ty r Gl u As p I l e Ser
                                      885                           890                           895
              Al a Ty r Leu Leu Ser Ly s As n As n Al a I l e Gl u Pr o Ar g Ser Phe Ser
                                900                           905                           910
              Gl n As n Gl y Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y
                          915                           920                           925
              Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser
                    930                           935                           940
              Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser
              945                           950                           955                           960
                                                                    Page 344

                                                                 97047_1
<removed-date>
              Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y
                                      965                        970                       975
              Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Pr o
                                980                        985                       990
<removed-apn>
              Al a Gl y Ser Pr o Thr Ser Thr Gl u           Gl u Gl y Thr Ser Gl u     Ser Al a Thr
                          995                       1000                       1005
              Pr o Gl u    Ser Gl y Pr o Gl y Ser     Gl u Pr o Al a Thr Ser       Gl y Ser Gl u
                   1010                      1015                           1020
              Thr Pr o     Gl y Thr Ser Gl u Ser      Al a Thr Pr o Gl u Ser       Gl y Pr o Gl y
                   1025                      1030                           1035
              Ser Pr o     Al a Gl y Ser Pr o Thr     Ser Thr Gl u Gl u Gl y       Ser Pr o Al a
                   1040                      1045                           1050
              Gl y Ser     Pr o Thr Ser Thr Gl u      Gl u Gl y Thr Ser Thr        Gl u Pr o Ser
                   1055                      1060                           1065
              Gl u Gl y    Ser Al a Pr o Gl y Thr     Ser Gl u Ser Al a Thr        Pr o Gl u Ser
                   1070                      1075                           1080
              Gl y Pr o    Gl y Thr Ser Gl u Ser      Al a Thr Pr o Gl u Ser       Gl y Pr o Gl y
                                                                 Page 345

                                                           97047_1
<removed-date>
                   1085                     1090                      1095
              Thr Ser     Gl u Ser Al a Thr Pr o   Gl u Ser Gl y Pr o Gl y   Ser Gl u Pr o
                   1100                     1105                      1110
<removed-apn>
              Al a Thr    Ser Gl y Ser Gl u Thr    Pr o Gl y Ser Gl u Pr o   Al a Thr Ser
                   1115                     1120                      1125
              Gl y Ser    Gl u Thr Pr o Gl y Ser   Pr o Al a Gl y Ser Pr o   Thr Ser Thr
                   1130                     1135                      1140
              Gl u Gl u   Gl y Thr Ser Thr Gl u    Pr o Ser Gl u Gl y Ser    Al a Pr o Gl y
                   1145                     1150                      1155
              Thr Ser     Thr Gl u Pr o Ser Gl u   Gl y Ser Al a Pr o Gl y   Ser Gl u Pr o
                   1160                     1165                      1170
              Al a Thr    Ser Gl y Ser Gl u Thr    Pr o Gl y Thr Ser Gl u    Ser Al a Thr
                   1175                     1180                      1185
              Pr o Gl u   Ser Gl y Pr o Gl y Thr   Ser Thr Gl u Pr o Ser     Gl u Gl y Ser
                   1190                     1195                      1200
              Al a Pr o   Al a Ser Ser Pr o Pr o   Val Leu Ly s Ar g Hi s    Gl n Al a Gl u
                   1205                     1210                      1215
                                                          Page 346

                                                              97047_1
<removed-date>
              I l e Thr    Ar g Thr Thr Leu Gl n      Ser As p Gl n Gl u Gl u     I l e As p Ty r
                   1220                        1225                        1230
              As p As p    Thr I l e Ser Val Gl u     Met Ly s Ly s Gl u As p     Phe As p I l e
                   1235                        1240                        1245
<removed-apn>
              Ty r As p    Gl u As p Gl u As n Gl n   Ser Pr o Ar g Ser Phe       Gl n Ly s Ly s
                   1250                        1255                        1260
              Thr Ar g     Hi s Ty r Phe I l e Al a   Al a Val Gl u Ar g Leu      Tr p As p Ty r
                   1265                        1270                        1275
              Gl y Met     Ser Ser Ser Pr o Hi s      Val Leu Ar g As n Ar g      Al a Gl n Ser
                   1280                        1285                        1290
              Gl y Ser     Val Pr o Gl n Phe Ly s     Ly s Val Val Phe Gl n       Gl u Phe Thr
                   1295                        1300                        1305
              As p Gl y    Ser Phe Thr Gl n Pr o      Leu Ty r Ar g Gl y Gl u     Leu As n Gl u
                   1310                        1315                        1320
              Hi s Leu     Gl y Leu Leu Gl y Pr o     Ty r I l e Ar g Al a Gl u   Val Gl u As p
                   1325                        1330                        1335
              As n I l e   Met Val Thr Phe Ar g       As n Gl n Al a Ser Ar g     Pr o Ty r Ser
                                                              Page 347

                                                             97047_1
<removed-date>
                   1340                       1345                       1350
              Phe Ty r    Ser Ser Leu I l e Ser      Ty r Gl u Gl u As p Gl n   Ar g Gl n Gl y
                   1355                       1360                       1365
<removed-apn>
              Al a Gl u   Pr o Ar g Ly s As n Phe    Val Ly s Pr o As n Gl u    Thr Ly s Thr
                   1370                       1375                       1380
              Ty r Phe    Tr p Ly s Val Gl n Hi s    Hi s Met Al a Pr o Thr     Ly s As p Gl u
                   1385                       1390                       1395
              Phe As p    Cy s Ly s Al a Tr p Al a   Ty r Phe Ser As p Val      As p Leu Gl u
                   1400                       1405                       1410
              Ly s As p   Val Hi s Ser Gl y Leu      I l e Gl y Pr o Leu Leu    Val Cy s Hi s
                   1415                       1420                       1425
              Thr As n    Thr Leu As n Pr o Al a     Hi s Gl y Ar g Gl n Val    Thr Val Gl n
                   1430                       1435                       1440
              Gl u Phe    Al a Leu Phe Phe Thr       I l e Phe As p Gl u Thr    Ly s Ser Tr p
                   1445                       1450                       1455
              Ty r Phe    Thr Gl u As n Met Gl u     Ar g As n Cy s Ar g Al a   Pr o Cy s As n
                   1460                       1465                       1470
                                                            Page 348

                                                               97047_1
<removed-date>
              I l e Gl n   Met Gl u As p Pr o Thr      Phe Ly s Gl u As n Ty r    Ar g Phe Hi s
                   1475                         1480                       1485
              Al a I l e   As n Gl y Ty r I l e Met    As p Thr Leu Pr o Gl y     Leu Val Met
                   1490                         1495                       1500
<removed-apn>
              Al a Gl n    As p Gl n Ar g I l e Ar g   Tr p Ty r Leu Leu Ser      Met Gl y Ser
                   1505                         1510                       1515
              As n Gl u    As n I l e Hi s Ser I l e   Hi s Phe Ser Gl y Hi s     Val Phe Thr
                   1520                         1525                       1530
              Val Ar g     Ly s Ly s Gl u Gl u Ty r    Ly s Met Al a Leu Ty r     As n Leu Ty r
                   1535                         1540                       1545
              Pr o Gl y    Val Phe Gl u Thr Val        Gl u Met Leu Pr o Ser      Ly s Al a Gl y
                   1550                         1555                       1560
              I l e Tr p   Ar g Val Gl u Cy s Leu      I l e Gl y Gl u Hi s Leu   Hi s Al a Gl y
                   1565                         1570                       1575
              Met Ser      Thr Leu Phe Leu Val         Ty r Ser As n Ly s Cy s    Gl n Thr Pr o
                   1580                         1585                       1590
              Leu Gl y     Met Al a Ser Gl y Hi s      I l e Ar g As p Phe Gl n   I l e Thr Al a
                                                              Page 349

                                                              97047_1
<removed-date>
                   1595                        1600                        1605
              Ser Gl y     Gl n Ty r Gl y Gl n Tr p   Al a Pr o Ly s Leu Al a     Ar g Leu Hi s
                   1610                        1615                        1620
<removed-apn>
              Ty r Ser     Gl y Ser I l e As n Al a   Tr p Ser Thr Ly s Gl u      Pr o Phe Ser
                   1625                        1630                        1635
              Tr p I l e   Ly s Val As p Leu Leu      Al a Pr o Met I l e I l e   Hi s Gl y I l e
                   1640                        1645                        1650
              Ly s Thr     Gl n Gl y Al a Ar g Gl n   Ly s Phe Ser Ser Leu        Ty r I l e Ser
                   1655                        1660                        1665
              Gl n Phe     I l e I l e Met Ty r Ser   Leu As p Gl y Ly s Ly s     Tr p Gl n Thr
                   1670                        1675                        1680
              Ty r Ar g    Gl y As n Ser Thr Gl y     Thr Leu Met Val Phe         Phe Gl y As n
                   1685                        1690                        1695
              Val As p     Ser Ser Gl y I l e Ly s    Hi s As n I l e Phe As n    Pr o Pr o I l e
                   1700                        1705                        1710
              I l e Al a   Ar g Ty r I l e Ar g Leu   Hi s Pr o Thr Hi s Ty r     Ser I l e Ar g
                   1715                        1720                        1725
                                                              Page 350

                                                             97047_1
<removed-date>
              Ser Thr     Leu Ar g Met Gl u Leu      Met Gl y Cy s As p Leu    As n Ser Cy s
                   1730                       1735                      1740
              Ser Met     Pr o Leu Gl y Met Gl u     Ser Ly s Al a I l e Ser   As p Al a Gl n
                   1745                       1750                      1755
<removed-apn>
              I l e Thr   Al a Ser Ser Ty r Phe      Thr As n Met Phe Al a     Thr Tr p Ser
                   1760                       1765                      1770
              Pr o Ser    Ly s Al a Ar g Leu Hi s    Leu Gl n Gl y Ar g Ser    As n Al a Tr p
                   1775                       1780                      1785
              Ar g Pr o   Gl n Val As n As n Pr o    Ly s Gl u Tr p Leu Gl n   Val As p Phe
                   1790                       1795                      1800
              Gl n Ly s   Thr Met Ly s Val Thr       Gl y Val Thr Thr Gl n     Gl y Val Ly s
                   1805                       1810                      1815
              Ser Leu     Leu Thr Ser Met Ty r       Val Ly s Gl u Phe Leu     I l e Ser Ser
                   1820                       1825                      1830
              Ser Gl n    As p Gl y Hi s Gl n Tr p   Thr Leu Phe Phe Gl n      As n Gl y Ly s
                   1835                       1840                      1845
              Val Ly s    Val Phe Gl n Gl y As n     Gl n As p Ser Phe Thr     Pr o Val Val
                                                            Page 351

                                                             97047_1
<removed-date>
                   1850                       1855                      1860
              As n Ser    Leu As p Pr o Pr o Leu     Leu Thr Ar g Ty r Leu     Ar g I l e Hi s
                   1865                       1870                      1875
<removed-apn>
              Pr o Gl n   Ser Tr p Val Hi s Gl n     I l e Al a Leu Ar g Met   Gl u Val Leu
                   1880                       1885                      1890
              Gl y Cy s   Gl u Al a Gl n As p Leu    Ty r As p Ly s Thr Hi s   Thr Cy s Pr o
                   1895                       1900                      1905
              Pr o Cy s   Pr o Al a Pr o Gl u Leu    Leu Gl y Gl y Pr o Ser    Val Phe Leu
                   1910                       1915                      1920
              Phe Pr o    Pr o Ly s Pr o Ly s As p   Thr Leu Met I l e Ser     Ar g Thr Pr o
                   1925                       1930                      1935
              Gl u Val    Thr Cy s Val Val Val       As p Val Ser Hi s Gl u    As p Pr o Gl u
                   1940                       1945                      1950
              Val Ly s    Phe As n Tr p Ty r Val     As p Gl y Val Gl u Val    Hi s As n Al a
                   1955                       1960                      1965
              Ly s Thr    Ly s Pr o Ar g Gl u Gl u   Gl n Ty r As n Ser Thr    Ty r Ar g Val
                   1970                       1975                      1980
                                                            Page 352

                                                            97047_1
<removed-date>
              Val Ser     Val Leu Thr Val Leu       Hi s Gl n As p Tr p Leu    As n Gl y Ly s
                   1985                      1990                       1995
              Gl u Ty r   Ly s Cy s Ly s Val Ser    As n Ly s Al a Leu Pr o    Al a Pr o I l e
                   2000                      2005                       2010
<removed-apn>
              Gl u Ly s   Thr I l e Ser Ly s Al a   Ly s Gl y Gl n Pr o Ar g   Gl u Pr o Gl n
                   2015                      2020                       2025
              Val Ty r    Thr Leu Pr o Pr o Ser     Ar g As p Gl u Leu Thr     Ly s As n Gl n
                   2030                      2035                       2040
              Val Ser     Leu Thr Cy s Leu Val      Ly s Gl y Phe Ty r Pr o    Ser As p I l e
                   2045                      2050                       2055
              Al a Val    Gl u Tr p Gl u Ser As n   Gl y Gl n Pr o Gl u As n   As n Ty r Ly s
                   2060                      2065                       2070
              Thr Thr     Pr o Pr o Val Leu As p    Ser As p Gl y Ser Phe      Phe Leu Ty r
                   2075                      2080                       2085
              Ser Ly s    Leu Thr Val As p Ly s     Ser Ar g Tr p Gl n Gl n    Gl y As n Val
                   2090                      2095                       2100
              Phe Ser     Cy s Ser Val Met Hi s     Gl u Al a Leu Hi s As n    Hi s Ty r Thr
                                                           Page 353

                                                                     97047_1
<removed-date>
                   2105                            2110                             2115
              Gl n Ly s     Ser Leu Ser Leu Ser              Pr o Gl y Ly s
                   2120                            2125
<removed-apn>
              <210>       112
              <211>       2020
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
              <220>
              <223>       pSYN FVI I I 266 pr ot ei n s equenc e
              <400>       112
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
              1                       5                             10                          15
              Cy s Phe Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser
                                 20                            25                          30
              Tr p As p Ty r Met Gl n Gl y Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr
                           35                           40                            45
              Ser Thr Gl u Gl u Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o
                   50                             55                           60
              Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Al a Ser Ser Ser
                                                                    Page 354

                                                                    97047_1
<removed-date>
              65                            70                         75                               80
              As p Leu Gl y Gl u Leu Pr o Val As p Al a Ar g Phe Pr o Pr o Ar g Val Pr o
                                      85                            90                            95
<removed-apn>
              Ly s Ser Phe Pr o Phe As n Thr Ser Val Val Ty r Ly s Ly s Thr Leu Phe
                                100                           105                           110
              Val Gl u Phe Thr As p Hi s Leu Phe As n I l e Al a Ly s Pr o Ar g Pr o Pr o
                          115                           120                           125
              Tr p Met Gl y Leu Leu Gl y Pr o Thr I l e Gl n Al a Gl u Val Ty r As p Thr
                    130                           135                           140
              Val Val I l e Thr Leu Ly s As n Met Al a Ser Hi s Pr o Val Ser Leu Hi s
              145                           150                           155                           160
              Al a Val Gl y Val Ser Ty r Tr p Ly s Al a Ser Gl u Gl y Al a Gl u Ty r As p
                                      165                           170                           175
              As p Gl n Thr Ser Gl n Ar g Gl u Ly s Gl u As p As p Ly s Val Phe Pr o Gl y
                                180                           185                           190
              Gl y Ser Hi s Thr Ty r Val Tr p Gl n Val Leu Ly s Gl u As n Gl y Pr o Met
                          195                           200                           205
                                                                    Page 355

                                                                    97047_1
<removed-date>
              Al a Ser As p Pr o Leu Cy s Leu Thr Ty r Ser Ty r Leu Ser Hi s Val As p
                    210                           215                           220
              Leu Val Ly s As p Leu As n Ser Gl y Leu I l e Gl y Al a Leu Leu Val Cy s
              225                           230                           235                           240
<removed-apn>
              Ar g Gl u Gl y Ser Leu Al a Ly s Gl u Ly s Thr Gl n Thr Leu Hi s Ly s Phe
                                      245                           250                           255
              I l e Leu Leu Phe Al a Val Phe As p Gl u Gl y Ly s Ser Tr p Hi s Ser Gl u
                                260                           265                           270
              Thr Ly s As n Ser Leu Met Gl n As p Ar g As p Al a Al a Ser Al a Ar g Al a
                          275                           280                           285
              Tr p Pr o Ly s Met Hi s Thr Val As n Gl y Ty r Val As n Ar g Ser Leu Pr o
                    290                           295                           300
              Gl y Leu I l e Gl y Cy s Hi s Ar g Ly s Ser Val Ty r Tr p Hi s Val I l e Gl y
              305                           310                           315                           320
              Met Gl y Thr Thr Pr o Gl u Val Hi s Ser I l e Phe Leu Gl u Gl y Hi s Thr
                                      325                           330                           335
              Phe Leu Val Ar g As n Hi s Ar g Gl n Al a Ser Leu Gl u I l e Ser Pr o I l e
                                                                    Page 356

                                                                    97047_1
<removed-date>
                                340                           345                           350
              Thr Phe Leu Thr Al a Gl n Thr Leu Leu Met As p Leu Gl y Gl n Phe Leu
                          355                           360                           365
<removed-apn>
              Leu Phe Cy s Hi s I l e Ser Ser Hi s Gl n Hi s As p Gl y Met Gl u Al a Ty r
                    370                           375                           380
              Val Ly s Val As p Ser Cy s Pr o Gl u Gl u Pr o Gl n Leu Ar g Met Ly s As n
              385                           390                           395                           400
              As n Gl u Gl u Al a Gl u As p Ty r As p As p As p Leu Thr As p Ser Gl u Met
                                      405                           410                           415
              As p Val Val Ar g Phe As p As p As p As n Ser Pr o Ser Phe I l e Gl n I l e
                                420                           425                           430
              Ar g Ser Val Al a Ly s Ly s Hi s Pr o Ly s Thr Tr p Val Hi s Ty r I l e Al a
                          435                           440                           445
              Al a Gl u Gl u Gl u As p Tr p As p Ty r Al a Pr o Leu Val Leu Al a Pr o As p
                    450                           455                           460
              As p Ar g Ser Ty r Ly s Ser Gl n Ty r Leu As n As n Gl y Pr o Gl n Ar g I l e
              465                           470                           475                           480
                                                                    Page 357

                                                                    97047_1
<removed-date>
              Gl y Ar g Ly s Ty r Ly s Ly s Val Ar g Phe Met Al a Ty r Thr As p Gl u Thr
                                      485                           490                           495
              Phe Ly s Thr Ar g Gl u Al a I l e Gl n Hi s Gl u Ser Gl y I l e Leu Gl y Pr o
                                500                           505                           510
<removed-apn>
              Leu Leu Ty r Gl y Gl u Val Gl y As p Thr Leu Leu I l e I l e Phe Ly s As n
                          515                           520                           525
              Gl n Al a Ser Ar g Pr o Ty r As n I l e Ty r Pr o Hi s Gl y I l e Thr As p Val
                    530                           535                           540
              Ar g Pr o Leu Ty r Ser Ar g Ar g Leu Pr o Ly s Gl y Val Ly s Hi s Leu Ly s
              545                           550                           555                           560
              As p Phe Pr o I l e Leu Pr o Gl y Gl u I l e Phe Ly s Ty r Ly s Tr p Thr Val
                                      565                           570                           575
              Thr Val Gl u As p Gl y Pr o Thr Ly s Ser As p Pr o Ar g Cy s Leu Thr Ar g
                                580                           585                           590
              Ty r Ty r Ser Ser Phe Val As n Met Gl u Ar g As p Leu Al a Ser Gl y Leu
                          595                           600                           605
              I l e Gl y Pr o Leu Leu I l e Cy s Ty r Ly s Gl u Ser Val As p Gl n Ar g Gl y
                                                                    Page 358

                                                                    97047_1
<removed-date>
                    610                           615                           620
              As n Gl n I l e Met Ser As p Ly s Ar g As n Val I l e Leu Phe Ser Val Phe
              625                           630                           635                           640
<removed-apn>
              As p Gl u As n Ar g Ser Tr p Ty r Leu Thr Gl u As n I l e Gl n Ar g Phe Leu
                                      645                           650                           655
              Pr o As n Pr o Al a Gl y Val Gl n Leu Gl u As p Pr o Gl u Phe Gl n Al a Ser
                                660                           665                           670
              As n I l e Met Hi s Ser I l e As n Gl y Ty r Val Phe As p Ser Leu Gl n Leu
                          675                           680                           685
              Ser Val Cy s Leu Hi s Gl u Val Al a Ty r Tr p Ty r I l e Leu Ser I l e Gl y
                    690                           695                           700
              Al a Gl n Thr As p Phe Leu Ser Val Phe Phe Ser Gl y Ty r Thr Phe Ly s
              705                           710                           715                           720
              Hi s Ly s Met Val Ty r Gl u As p Thr Leu Thr Leu Phe Pr o Phe Ser Gl y
                                      725                           730                           735
              Gl u Thr Val Phe Met Ser Met Gl u As n Pr o Gl y Leu Tr p I l e Leu Gl y
                                740                           745                           750
                                                                    Page 359

                                                                    97047_1
<removed-date>
              Cy s Hi s As n Ser As p Phe Ar g As n Ar g Gl y Met Thr Al a Leu Leu Ly s
                          755                           760                           765
              Val Ser Ser Cy s As p Ly s As n Thr Gl y As p Ty r Ty r Gl u As p Ser Ty r
                    770                           775                           780
<removed-apn>
              Gl u As p I l e Ser Al a Ty r Leu Leu Ser Ly s As n As n Al a I l e Gl u Pr o
              785                           790                           795                           800
              Ar g Ser Phe Ser Gl n As n Gl y Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr
                                      805                           810                           815
              Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr
                                820                           825                           830
              Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u
                          835                           840                           845
              Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr
                    850                           855                           860
              Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a
              865                           870                           875                           880
              Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser
                                                                    Page 360

                                                                       97047_1
<removed-date>
                                       885                            890                            895
              Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser
                                 900                            905                            910
<removed-apn>
              Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y
                           915                           920                            925
              Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Ser Pr o
                    930                            935                            940
              Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Thr Gl u Pr o Ser
              945                            950                            955                            960
              Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y
                                       965                            970                            975
              Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser
                                 980                            985                            990
              Gl u Ser Al a Thr Pr o Gl u Ser Gl y               Pr o Gl y Ser Gl u Pr o         Al a Thr Ser
                           995                           1000                            1005
              Gl y Ser      Gl u Thr Pr o Gl y Ser         Gl u Pr o Al a Thr Ser             Gl y Ser Gl u
                    1010                            1015                            1020
                                                                      Page 361

                                                            97047_1
<removed-date>
              Thr Pr o    Gl y Ser Pr o Al a Gl y   Ser Pr o Thr Ser Thr        Gl u Gl u Gl y
                   1025                      1030                        1035
              Thr Ser     Thr Gl u Pr o Ser Gl u    Gl y Ser Al a Pr o Gl y     Thr Ser Thr
                   1040                      1045                        1050
<removed-apn>
              Gl u Pr o   Ser Gl u Gl y Ser Al a    Pr o Gl y Ser Gl u Pr o     Al a Thr Ser
                   1055                      1060                        1065
              Gl y Ser    Gl u Thr Pr o Gl y Thr    Ser Gl u Ser Al a Thr       Pr o Gl u Ser
                   1070                      1075                        1080
              Gl y Pr o   Gl y Thr Ser Thr Gl u     Pr o Ser Gl u Gl y Ser      Al a Pr o Al a
                   1085                      1090                        1095
              Ser Ser     Pr o Pr o Val Leu Ly s    Ar g Hi s Gl n Al a Gl u    I l e Thr Ar g
                   1100                      1105                        1110
              Thr Thr     Leu Gl n Ser As p Gl n    Gl u Gl u I l e As p Ty r   As p As p Thr
                   1115                      1120                        1125
              I l e Ser   Val Gl u Met Ly s Ly s    Gl u As p Phe As p I l e    Ty r As p Gl u
                   1130                      1135                        1140
              As p Gl u   As n Gl n Ser Pr o Ar g   Ser Phe Gl n Ly s Ly s      Thr Ar g Hi s
                                                            Page 362

                                                              97047_1
<removed-date>
                   1145                        1150                       1155
              Ty r Phe    I l e Al a Al a Val Gl u    Ar g Leu Tr p As p Ty r    Gl y Met Ser
                   1160                        1165                       1170
<removed-apn>
              Ser Ser     Pr o Hi s Val Leu Ar g      As n Ar g Al a Gl n Ser    Gl y Ser Val
                   1175                        1180                       1185
              Pr o Gl n   Phe Ly s Ly s Val Val       Phe Gl n Gl u Phe Thr      As p Gl y Ser
                   1190                        1195                       1200
              Phe Thr     Gl n Pr o Leu Ty r Ar g     Gl y Gl u Leu As n Gl u    Hi s Leu Gl y
                   1205                        1210                       1215
              Leu Leu     Gl y Pr o Ty r I l e Ar g   Al a Gl u Val Gl u As p    As n I l e Met
                   1220                        1225                       1230
              Val Thr     Phe Ar g As n Gl n Al a     Ser Ar g Pr o Ty r Ser     Phe Ty r Ser
                   1235                        1240                       1245
              Ser Leu     I l e Ser Ty r Gl u Gl u    As p Gl n Ar g Gl n Gl y   Al a Gl u Pr o
                   1250                        1255                       1260
              Ar g Ly s   As n Phe Val Ly s Pr o      As n Gl u Thr Ly s Thr     Ty r Phe Tr p
                   1265                        1270                       1275
                                                             Page 363

                                                             97047_1
<removed-date>
              Ly s Val    Gl n Hi s Hi s Met Al a    Pr o Thr Ly s As p Gl u    Phe As p Cy s
                   1280                       1285                       1290
              Ly s Al a   Tr p Al a Ty r Phe Ser     As p Val As p Leu Gl u     Ly s As p Val
                   1295                       1300                       1305
<removed-apn>
              Hi s Ser    Gl y Leu I l e Gl y Pr o   Leu Leu Val Cy s Hi s      Thr As n Thr
                   1310                       1315                       1320
              Leu As n    Pr o Al a Hi s Gl y Ar g   Gl n Val Thr Val Gl n      Gl u Phe Al a
                   1325                       1330                       1335
              Leu Phe     Phe Thr I l e Phe As p     Gl u Thr Ly s Ser Tr p     Ty r Phe Thr
                   1340                       1345                       1350
              Gl u As n   Met Gl u Ar g As n Cy s    Ar g Al a Pr o Cy s As n   I l e Gl n Met
                   1355                       1360                       1365
              Gl u As p   Pr o Thr Phe Ly s Gl u     As n Ty r Ar g Phe Hi s    Al a I l e As n
                   1370                       1375                       1380
              Gl y Ty r   I l e Met As p Thr Leu     Pr o Gl y Leu Val Met      Al a Gl n As p
                   1385                       1390                       1395
              Gl n Ar g   I l e Ar g Tr p Ty r Leu   Leu Ser Met Gl y Ser       As n Gl u As n
                                                            Page 364

                                                               97047_1
<removed-date>
                   1400                         1405                      1410
              I l e Hi s   Ser I l e Hi s Phe Ser      Gl y Hi s Val Phe Thr     Val Ar g Ly s
                   1415                         1420                      1425
<removed-apn>
              Ly s Gl u    Gl u Ty r Ly s Met Al a     Leu Ty r As n Leu Ty r    Pr o Gl y Val
                   1430                         1435                      1440
              Phe Gl u     Thr Val Gl u Met Leu        Pr o Ser Ly s Al a Gl y   I l e Tr p Ar g
                   1445                         1450                      1455
              Val Gl u     Cy s Leu I l e Gl y Gl u    Hi s Leu Hi s Al a Gl y   Met Ser Thr
                   1460                         1465                      1470
              Leu Phe      Leu Val Ty r Ser As n       Ly s Cy s Gl n Thr Pr o   Leu Gl y Met
                   1475                         1480                      1485
              Al a Ser     Gl y Hi s I l e Ar g As p   Phe Gl n I l e Thr Al a   Ser Gl y Gl n
                   1490                         1495                      1500
              Ty r Gl y    Gl n Tr p Al a Pr o Ly s    Leu Al a Ar g Leu Hi s    Ty r Ser Gl y
                   1505                         1510                      1515
              Ser I l e    As n Al a Tr p Ser Thr      Ly s Gl u Pr o Phe Ser    Tr p I l e Ly s
                   1520                         1525                      1530
                                                              Page 365

                                                                 97047_1
<removed-date>
              Val As p     Leu Leu Al a Pr o Met        I l e I l e Hi s Gl y I l e   Ly s Thr Gl n
                   1535                         1540                          1545
              Gl y Al a    Ar g Gl n Ly s Phe Ser       Ser Leu Ty r I l e Ser        Gl n Phe I l e
                   1550                         1555                          1560
<removed-apn>
              I l e Met    Ty r Ser Leu As p Gl y       Ly s Ly s Tr p Gl n Thr       Ty r Ar g Gl y
                   1565                         1570                          1575
              As n Ser     Thr Gl y Thr Leu Met         Val Phe Phe Gl y As n         Val As p Ser
                   1580                         1585                          1590
              Ser Gl y     I l e Ly s Hi s As n I l e   Phe As n Pr o Pr o I l e      I l e Al a Ar g
                   1595                         1600                          1605
              Ty r I l e   Ar g Leu Hi s Pr o Thr       Hi s Ty r Ser I l e Ar g      Ser Thr Leu
                   1610                         1615                          1620
              Ar g Met     Gl u Leu Met Gl y Cy s       As p Leu As n Ser Cy s        Ser Met Pr o
                   1625                         1630                          1635
              Leu Gl y     Met Gl u Ser Ly s Al a       I l e Ser As p Al a Gl n      I l e Thr Al a
                   1640                         1645                          1650
              Ser Ser      Ty r Phe Thr As n Met        Phe Al a Thr Tr p Ser         Pr o Ser Ly s
                                                                Page 366

                                                             97047_1
<removed-date>
                   1655                       1660                       1665
              Al a Ar g   Leu Hi s Leu Gl n Gl y     Ar g Ser As n Al a Tr p    Ar g Pr o Gl n
                   1670                       1675                       1680
<removed-apn>
              Val As n    As n Pr o Ly s Gl u Tr p   Leu Gl n Val As p Phe      Gl n Ly s Thr
                   1685                       1690                       1695
              Met Ly s    Val Thr Gl y Val Thr       Thr Gl n Gl y Val Ly s     Ser Leu Leu
                   1700                       1705                       1710
              Thr Ser     Met Ty r Val Ly s Gl u     Phe Leu I l e Ser Ser      Ser Gl n As p
                   1715                       1720                       1725
              Gl y Hi s   Gl n Tr p Thr Leu Phe      Phe Gl n As n Gl y Ly s    Val Ly s Val
                   1730                       1735                       1740
              Phe Gl n    Gl y As n Gl n As p Ser    Phe Thr Pr o Val Val       As n Ser Leu
                   1745                       1750                       1755
              As p Pr o   Pr o Leu Leu Thr Ar g      Ty r Leu Ar g I l e Hi s   Pr o Gl n Ser
                   1760                       1765                       1770
              Tr p Val    Hi s Gl n I l e Al a Leu   Ar g Met Gl u Val Leu      Gl y Cy s Gl u
                   1775                       1780                       1785
                                                            Page 367

                                                             97047_1
<removed-date>
              Al a Gl n   As p Leu Ty r As p Ly s    Thr Hi s Thr Cy s Pr o     Pr o Cy s Pr o
                   1790                       1795                       1800
              Al a Pr o   Gl u Leu Leu Gl y Gl y     Pr o Ser Val Phe Leu       Phe Pr o Pr o
                   1805                       1810                       1815
<removed-apn>
              Ly s Pr o   Ly s As p Thr Leu Met      I l e Ser Ar g Thr Pr o    Gl u Val Thr
                   1820                       1825                       1830
              Cy s Val    Val Val As p Val Ser       Hi s Gl u As p Pr o Gl u   Val Ly s Phe
                   1835                       1840                       1845
              As n Tr p   Ty r Val As p Gl y Val     Gl u Val Hi s As n Al a    Ly s Thr Ly s
                   1850                       1855                       1860
              Pr o Ar g   Gl u Gl u Gl n Ty r As n   Ser Thr Ty r Ar g Val      Val Ser Val
                   1865                       1870                       1875
              Leu Thr     Val Leu Hi s Gl n As p     Tr p Leu As n Gl y Ly s    Gl u Ty r Ly s
                   1880                       1885                       1890
              Cy s Ly s   Val Ser As n Ly s Al a     Leu Pr o Al a Pr o I l e   Gl u Ly s Thr
                   1895                       1900                       1905
              I l e Ser   Ly s Al a Ly s Gl y Gl n   Pr o Ar g Gl u Pr o Gl n   Val Ty r Thr
                                                            Page 368

                                                              97047_1
<removed-date>
                   1910                        1915                       1920
              Leu Pr o      Pr o Ser Ar g As p Gl u   Leu Thr Ly s As n Gl n     Val Ser Leu
                   1925                        1930                       1935
<removed-apn>
              Thr Cy s      Leu Val Ly s Gl y Phe     Ty r Pr o Ser As p I l e   Al a Val Gl u
                   1940                        1945                       1950
              Tr p Gl u     Ser As n Gl y Gl n Pr o   Gl u As n As n Ty r Ly s   Thr Thr Pr o
                   1955                        1960                       1965
              Pr o Val      Leu As p Ser As p Gl y    Ser Phe Phe Leu Ty r       Ser Ly s Leu
                   1970                        1975                       1980
              Thr Val       As p Ly s Ser Ar g Tr p   Gl n Gl n Gl y As n Val    Phe Ser Cy s
                   1985                        1990                       1995
              Ser Val       Met Hi s Gl u Al a Leu    Hi s As n Hi s Ty r Thr    Gl n Ly s Ser
                   2000                        2005                       2010
              Leu Ser       Leu Ser Pr o Gl y Ly s
                   2015                        2020
              <210>       113
              <211>       2056
              <212>       PRT
                                                             Page 369

                                                                 97047_1
<removed-date>
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     pSYN FVI I I 267 pr ot ei n s equenc e
              <400>     113
<removed-apn>
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
              1                      5                           10                        15
              Cy s Phe Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser
                               20                          25                        30
              Tr p As p Ty r Met Gl n Gl y Al a Pr o Thr Ser Gl u Ser Al a Thr Pr o Gl u
                         35                           40                        45
              Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y
                   50                           55                         60
              Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a
              65                          70                          75                        80
              Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
                                     85                          90                        95
              Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y
                               100                         105                       110
                                                                 Page 370

                                                                    97047_1
<removed-date>
              Al a Ser Ser Ser As p Leu Gl y Gl u Leu Pr o Val As p Al a Ar g Phe Pr o
                          115                           120                           125
              Pr o Ar g Val Pr o Ly s Ser Phe Pr o Phe As n Thr Ser Val Val Ty r Ly s
                    130                           135                           140
<removed-apn>
              Ly s Thr Leu Phe Val Gl u Phe Thr As p Hi s Leu Phe As n I l e Al a Ly s
              145                           150                           155                           160
              Pr o Ar g Pr o Pr o Tr p Met Gl y Leu Leu Gl y Pr o Thr I l e Gl n Al a Gl u
                                      165                           170                           175
              Val Ty r As p Thr Val Val I l e Thr Leu Ly s As n Met Al a Ser Hi s Pr o
                                180                           185                           190
              Val Ser Leu Hi s Al a Val Gl y Val Ser Ty r Tr p Ly s Al a Ser Gl u Gl y
                          195                           200                           205
              Al a Gl u Ty r As p As p Gl n Thr Ser Gl n Ar g Gl u Ly s Gl u As p As p Ly s
                    210                           215                           220
              Val Phe Pr o Gl y Gl y Ser Hi s Thr Ty r Val Tr p Gl n Val Leu Ly s Gl u
              225                           230                           235                           240
              As n Gl y Pr o Met Al a Ser As p Pr o Leu Cy s Leu Thr Ty r Ser Ty r Leu
                                                                    Page 371

                                                                     97047_1
<removed-date>
                                      245                           250                           255
              Ser Hi s Val As p Leu Val Ly s As p Leu As n Ser Gl y Leu I l e Gl y Al a
                                260                           265                           270
<removed-apn>
              Leu Leu Val Cy s Ar g Gl u Gl y Ser Leu Al a Ly s Gl u Ly s Thr Gl n Thr
                          275                           280                           285
              Leu Hi s Ly s Phe I l e Leu Leu Phe Al a Val Phe As p Gl u Gl y Ly s Ser
                    290                           295                           300
              Tr p Hi s Ser Gl u Thr Ly s As n Ser Leu Met Gl n As p Ar g As p Al a Al a
              305                           310                           315                           320
              Ser Al a Ar g Al a Tr p Pr o Ly s Met Hi s Thr Val As n Gl y Ty r Val As n
                                      325                           330                           335
              Ar g Ser Leu Pr o Gl y Leu I l e Gl y Cy s Hi s Ar g Ly s Ser Val Ty r Tr p
                                340                           345                           350
              Hi s Val I l e Gl y Met Gl y Thr Thr Pr o Gl u Val Hi s Ser I l e Phe Leu
                          355                           360                           365
              Gl u Gl y Hi s Thr Phe Leu Val Ar g As n Hi s Ar g Gl n Al a Ser Leu Gl u
                    370                           375                           380
                                                                    Page 372

                                                                    97047_1
<removed-date>
              I l e Ser Pr o I l e Thr Phe Leu Thr Al a Gl n Thr Leu Leu Met As p Leu
              385                           390                           395                           400
              Gl y Gl n Phe Leu Leu Phe Cy s Hi s I l e Ser Ser Hi s Gl n Hi s As p Gl y
                                      405                           410                           415
<removed-apn>
              Met Gl u Al a Ty r Val Ly s Val As p Ser Cy s Pr o Gl u Gl u Pr o Gl n Leu
                                420                           425                           430
              Ar g Met Ly s As n As n Gl u Gl u Al a Gl u As p Ty r As p As p As p Leu Thr
                          435                           440                           445
              As p Ser Gl u Met As p Val Val Ar g Phe As p As p As p As n Ser Pr o Ser
                    450                           455                           460
              Phe I l e Gl n I l e Ar g Ser Val Al a Ly s Ly s Hi s Pr o Ly s Thr Tr p Val
              465                           470                           475                           480
              Hi s Ty r I l e Al a Al a Gl u Gl u Gl u As p Tr p As p Ty r Al a Pr o Leu Val
                                      485                           490                           495
              Leu Al a Pr o As p As p Ar g Ser Ty r Ly s Ser Gl n Ty r Leu As n As n Gl y
                                500                           505                           510
              Pr o Gl n Ar g I l e Gl y Ar g Ly s Ty r Ly s Ly s Val Ar g Phe Met Al a Ty r
                                                                    Page 373

                                                                    97047_1
<removed-date>
                          515                           520                           525
              Thr As p Gl u Thr Phe Ly s Thr Ar g Gl u Al a I l e Gl n Hi s Gl u Ser Gl y
                    530                           535                           540
<removed-apn>
              I l e Leu Gl y Pr o Leu Leu Ty r Gl y Gl u Val Gl y As p Thr Leu Leu I l e
              545                           550                           555                           560
              I l e Phe Ly s As n Gl n Al a Ser Ar g Pr o Ty r As n I l e Ty r Pr o Hi s Gl y
                                      565                           570                           575
              I l e Thr As p Val Ar g Pr o Leu Ty r Ser Ar g Ar g Leu Pr o Ly s Gl y Val
                                580                           585                           590
              Ly s Hi s Leu Ly s As p Phe Pr o I l e Leu Pr o Gl y Gl u I l e Phe Ly s Ty r
                          595                           600                           605
              Ly s Tr p Thr Val Thr Val Gl u As p Gl y Pr o Thr Ly s Ser As p Pr o Ar g
                    610                           615                           620
              Cy s Leu Thr Ar g Ty r Ty r Ser Ser Phe Val As n Met Gl u Ar g As p Leu
              625                           630                           635                           640
              Al a Ser Gl y Leu I l e Gl y Pr o Leu Leu I l e Cy s Ty r Ly s Gl u Ser Val
                                      645                           650                           655
                                                                    Page 374

                                                                    97047_1
<removed-date>
              As p Gl n Ar g Gl y As n Gl n I l e Met Ser As p Ly s Ar g As n Val I l e Leu
                                660                           665                           670
              Phe Ser Val Phe As p Gl u As n Ar g Ser Tr p Ty r Leu Thr Gl u As n I l e
                          675                           680                           685
<removed-apn>
              Gl n Ar g Phe Leu Pr o As n Pr o Al a Gl y Val Gl n Leu Gl u As p Pr o Gl u
                    690                           695                           700
              Phe Gl n Al a Ser As n I l e Met Hi s Ser I l e As n Gl y Ty r Val Phe As p
              705                           710                           715                           720
              Ser Leu Gl n Leu Ser Val Cy s Leu Hi s Gl u Val Al a Ty r Tr p Ty r I l e
                                      725                           730                           735
              Leu Ser I l e Gl y Al a Gl n Thr As p Phe Leu Ser Val Phe Phe Ser Gl y
                                740                           745                           750
              Ty r Thr Phe Ly s Hi s Ly s Met Val Ty r Gl u As p Thr Leu Thr Leu Phe
                          755                           760                           765
              Pr o Phe Ser Gl y Gl u Thr Val Phe Met Ser Met Gl u As n Pr o Gl y Leu
                    770                           775                           780
              Tr p I l e Leu Gl y Cy s Hi s As n Ser As p Phe Ar g As n Ar g Gl y Met Thr
                                                                    Page 375

                                                                    97047_1
<removed-date>
              785                           790                        795                              800
              Al a Leu Leu Ly s Val Ser Ser Cy s As p Ly s As n Thr Gl y As p Ty r Ty r
                                      805                           810                           815
<removed-apn>
              Gl u As p Ser Ty r Gl u As p I l e Ser Al a Ty r Leu Leu Ser Ly s As n As n
                                820                           825                           830
              Al a I l e Gl u Pr o Ar g Ser Phe Ser Gl n As n Gl y Al a Pr o Gl y Thr Ser
                          835                           840                           845
              Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser
                    850                           855                           860
              Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y
              865                           870                           875                           880
              Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser
                                      885                           890                           895
              Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser
                                900                           905                           910
              Gl u Gl y Ser Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u
                          915                           920                           925
                                                                    Page 376

                                                                      97047_1
<removed-date>
              Gl u Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u
                    930                            935                            940
              Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr
              945                            950                            955                         960
<removed-apn>
              Pr o Gl u Ser Gl y Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u
                                       965                            970                         975
              Gl u Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser
                                 980                            985                         990
              Thr Gl u Pr o Ser Gl u Gl y Ser Al a               Pr o Gl y Thr Ser Gl u        Ser Al a Thr
                           995                           1000                           1005
              Pr o Gl u     Ser Gl y Pr o Gl y Thr         Ser Gl u Ser Al a Thr           Pr o Gl u Ser
                    1010                            1015                            1020
              Gl y Pr o     Gl y Thr Ser Gl u Ser          Al a Thr Pr o Gl u Ser          Gl y Pr o Gl y
                    1025                            1030                            1035
              Ser Gl u      Pr o Al a Thr Ser Gl y         Ser Gl u Thr Pr o Gl y          Ser Gl u Pr o
                    1040                            1045                            1050
              Al a Thr      Ser Gl y Ser Gl u Thr          Pr o Gl y Ser Pr o Al a         Gl y Ser Pr o
                                                                      Page 377

                                                               97047_1
<removed-date>
                   1055                         1060                      1065
              Thr Ser      Thr Gl u Gl u Gl y Thr      Ser Thr Gl u Pr o Ser     Gl u Gl y Ser
                   1070                         1075                      1080
<removed-apn>
              Al a Pr o    Gl y Thr Ser Thr Gl u       Pr o Ser Gl u Gl y Ser    Al a Pr o Gl y
                   1085                         1090                      1095
              Ser Gl u     Pr o Al a Thr Ser Gl y      Ser Gl u Thr Pr o Gl y    Thr Ser Gl u
                   1100                         1105                      1110
              Ser Al a     Thr Pr o Gl u Ser Gl y      Pr o Gl y Thr Ser Thr     Gl u Pr o Ser
                   1115                         1120                      1125
              Gl u Gl y    Ser Al a Pr o Al a Ser      Ser Pr o Pr o Val Leu     Ly s Ar g Hi s
                   1130                         1135                      1140
              Gl n Al a    Gl u I l e Thr Ar g Thr     Thr Leu Gl n Ser As p     Gl n Gl u Gl u
                   1145                         1150                      1155
              I l e As p   Ty r As p As p Thr I l e    Ser Val Gl u Met Ly s     Ly s Gl u As p
                   1160                         1165                      1170
              Phe As p     I l e Ty r As p Gl u As p   Gl u As n Gl n Ser Pr o   Ar g Ser Phe
                   1175                         1180                      1185
                                                              Page 378

                                                             97047_1
<removed-date>
              Gl n Ly s   Ly s Thr Ar g Hi s Ty r    Phe I l e Al a Al a Val    Gl u Ar g Leu
                   1190                       1195                       1200
              Tr p As p   Ty r Gl y Met Ser Ser      Ser Pr o Hi s Val Leu      Ar g As n Ar g
                   1205                       1210                       1215
<removed-apn>
              Al a Gl n   Ser Gl y Ser Val Pr o      Gl n Phe Ly s Ly s Val     Val Phe Gl n
                   1220                       1225                       1230
              Gl u Phe    Thr As p Gl y Ser Phe      Thr Gl n Pr o Leu Ty r     Ar g Gl y Gl u
                   1235                       1240                       1245
              Leu As n    Gl u Hi s Leu Gl y Leu     Leu Gl y Pr o Ty r I l e   Ar g Al a Gl u
                   1250                       1255                       1260
              Val Gl u    As p As n I l e Met Val    Thr Phe Ar g As n Gl n     Al a Ser Ar g
                   1265                       1270                       1275
              Pr o Ty r   Ser Phe Ty r Ser Ser       Leu I l e Ser Ty r Gl u    Gl u As p Gl n
                   1280                       1285                       1290
              Ar g Gl n   Gl y Al a Gl u Pr o Ar g   Ly s As n Phe Val Ly s     Pr o As n Gl u
                   1295                       1300                       1305
              Thr Ly s    Thr Ty r Phe Tr p Ly s     Val Gl n Hi s Hi s Met     Al a Pr o Thr
                                                            Page 379

                                                              97047_1
<removed-date>
                   1310                        1315                        1320
              Ly s As p   Gl u Phe As p Cy s Ly s     Al a Tr p Al a Ty r Phe     Ser As p Val
                   1325                        1330                        1335
<removed-apn>
              As p Leu    Gl u Ly s As p Val Hi s     Ser Gl y Leu I l e Gl y     Pr o Leu Leu
                   1340                        1345                        1350
              Val Cy s    Hi s Thr As n Thr Leu       As n Pr o Al a Hi s Gl y    Ar g Gl n Val
                   1355                        1360                        1365
              Thr Val     Gl n Gl u Phe Al a Leu      Phe Phe Thr I l e Phe       As p Gl u Thr
                   1370                        1375                        1380
              Ly s Ser    Tr p Ty r Phe Thr Gl u      As n Met Gl u Ar g As n     Cy s Ar g Al a
                   1385                        1390                        1395
              Pr o Cy s   As n I l e Gl n Met Gl u    As p Pr o Thr Phe Ly s      Gl u As n Ty r
                   1400                        1405                        1410
              Ar g Phe    Hi s Al a I l e As n Gl y   Ty r I l e Met As p Thr     Leu Pr o Gl y
                   1415                        1420                        1425
              Leu Val     Met Al a Gl n As p Gl n     Ar g I l e Ar g Tr p Ty r   Leu Leu Ser
                   1430                        1435                        1440
                                                              Page 380

                                                             97047_1
<removed-date>
              Met Gl y    Ser As n Gl u As n I l e   Hi s Ser I l e Hi s Phe    Ser Gl y Hi s
                   1445                       1450                       1455
              Val Phe     Thr Val Ar g Ly s Ly s     Gl u Gl u Ty r Ly s Met    Al a Leu Ty r
                   1460                       1465                       1470
<removed-apn>
              As n Leu    Ty r Pr o Gl y Val Phe     Gl u Thr Val Gl u Met      Leu Pr o Ser
                   1475                       1480                       1485
              Ly s Al a   Gl y I l e Tr p Ar g Val   Gl u Cy s Leu I l e Gl y   Gl u Hi s Leu
                   1490                       1495                       1500
              Hi s Al a   Gl y Met Ser Thr Leu       Phe Leu Val Ty r Ser       As n Ly s Cy s
                   1505                       1510                       1515
              Gl n Thr    Pr o Leu Gl y Met Al a     Ser Gl y Hi s I l e Ar g   As p Phe Gl n
                   1520                       1525                       1530
              I l e Thr   Al a Ser Gl y Gl n Ty r    Gl y Gl n Tr p Al a Pr o   Ly s Leu Al a
                   1535                       1540                       1545
              Ar g Leu    Hi s Ty r Ser Gl y Ser     I l e As n Al a Tr p Ser   Thr Ly s Gl u
                   1550                       1555                       1560
              Pr o Phe    Ser Tr p I l e Ly s Val    As p Leu Leu Al a Pr o     Met I l e I l e
                                                            Page 381

                                                                97047_1
<removed-date>
                   1565                          1570                        1575
              Hi s Gl y    I l e Ly s Thr Gl n Gl y     Al a Ar g Gl n Ly s Phe     Ser Ser Leu
                   1580                          1585                        1590
<removed-apn>
              Ty r I l e   Ser Gl n Phe I l e I l e     Met Ty r Ser Leu As p       Gl y Ly s Ly s
                   1595                          1600                        1605
              Tr p Gl n    Thr Ty r Ar g Gl y As n      Ser Thr Gl y Thr Leu        Met Val Phe
                   1610                          1615                        1620
              Phe Gl y     As n Val As p Ser Ser        Gl y I l e Ly s Hi s As n   I l e Phe As n
                   1625                          1630                        1635
              Pr o Pr o    I l e I l e Al a Ar g Ty r   I l e Ar g Leu Hi s Pr o    Thr Hi s Ty r
                   1640                          1645                        1650
              Ser I l e    Ar g Ser Thr Leu Ar g        Met Gl u Leu Met Gl y       Cy s As p Leu
                   1655                          1660                        1665
              As n Ser     Cy s Ser Met Pr o Leu        Gl y Met Gl u Ser Ly s      Al a I l e Ser
                   1670                          1675                        1680
              As p Al a    Gl n I l e Thr Al a Ser      Ser Ty r Phe Thr As n       Met Phe Al a
                   1685                          1690                        1695
                                                                Page 382

                                                              97047_1
<removed-date>
              Thr Tr p     Ser Pr o Ser Ly s Al a     Ar g Leu Hi s Leu Gl n     Gl y Ar g Ser
                   1700                        1705                       1710
              As n Al a    Tr p Ar g Pr o Gl n Val    As n As n Pr o Ly s Gl u   Tr p Leu Gl n
                   1715                        1720                       1725
<removed-apn>
              Val As p     Phe Gl n Ly s Thr Met      Ly s Val Thr Gl y Val      Thr Thr Gl n
                   1730                        1735                       1740
              Gl y Val     Ly s Ser Leu Leu Thr       Ser Met Ty r Val Ly s      Gl u Phe Leu
                   1745                        1750                       1755
              I l e Ser    Ser Ser Gl n As p Gl y     Hi s Gl n Tr p Thr Leu     Phe Phe Gl n
                   1760                        1765                       1770
              As n Gl y    Ly s Val Ly s Val Phe      Gl n Gl y As n Gl n As p   Ser Phe Thr
                   1775                        1780                       1785
              Pr o Val     Val As n Ser Leu As p      Pr o Pr o Leu Leu Thr      Ar g Ty r Leu
                   1790                        1795                       1800
              Ar g I l e   Hi s Pr o Gl n Ser Tr p    Val Hi s Gl n I l e Al a   Leu Ar g Met
                   1805                        1810                       1815
              Gl u Val     Leu Gl y Cy s Gl u Al a    Gl n As p Leu Ty r As p    Ly s Thr Hi s
                                                             Page 383

                                                              97047_1
<removed-date>
                   1820                        1825                       1830
              Thr Cy s    Pr o Pr o Cy s Pr o Al a    Pr o Gl u Leu Leu Gl y     Gl y Pr o Ser
                   1835                        1840                       1845
<removed-apn>
              Val Phe     Leu Phe Pr o Pr o Ly s      Pr o Ly s As p Thr Leu     Met I l e Ser
                   1850                        1855                       1860
              Ar g Thr    Pr o Gl u Val Thr Cy s      Val Val Val As p Val       Ser Hi s Gl u
                   1865                        1870                       1875
              As p Pr o   Gl u Val Ly s Phe As n      Tr p Ty r Val As p Gl y    Val Gl u Val
                   1880                        1885                       1890
              Hi s As n   Al a Ly s Thr Ly s Pr o     Ar g Gl u Gl u Gl n Ty r   As n Ser Thr
                   1895                        1900                       1905
              Ty r Ar g   Val Val Ser Val Leu         Thr Val Leu Hi s Gl n      As p Tr p Leu
                   1910                        1915                       1920
              As n Gl y   Ly s Gl u Ty r Ly s Cy s    Ly s Val Ser As n Ly s     Al a Leu Pr o
                   1925                        1930                       1935
              Al a Pr o   I l e Gl u Ly s Thr I l e   Ser Ly s Al a Ly s Gl y    Gl n Pr o Ar g
                   1940                        1945                       1950
                                                             Page 384

                                                                  97047_1
<removed-date>
              Gl u Pr o     Gl n Val Ty r Thr Leu         Pr o Pr o Ser Ar g As p   Gl u Leu Thr
                   1955                            1960                      1965
              Ly s As n     Gl n Val Ser Leu Thr          Cy s Leu Val Ly s Gl y    Phe Ty r Pr o
                   1970                            1975                      1980
<removed-apn>
              Ser As p      I l e Al a Val Gl u Tr p      Gl u Ser As n Gl y Gl n   Pr o Gl u As n
                   1985                            1990                      1995
              As n Ty r     Ly s Thr Thr Pr o Pr o        Val Leu As p Ser As p     Gl y Ser Phe
                   2000                            2005                      2010
              Phe Leu       Ty r Ser Ly s Leu Thr         Val As p Ly s Ser Ar g    Tr p Gl n Gl n
                   2015                            2020                      2025
              Gl y As n     Val Phe Ser Cy s Ser          Val Met Hi s Gl u Al a    Leu Hi s As n
                   2030                            2035                      2040
              Hi s Ty r     Thr Gl n Ly s Ser Leu         Ser Leu Ser Pr o Gl y     Ly s
                   2045                            2050                      2055
              <210>       114
              <211>       1834
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
                                                                 Page 385

                                                              97047_1
<removed-date>
              <220>
              <223>     pSYN FVI I I 268 pr ot ei n s equenc e
              <400>     114
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
              1                     5                         10                        15
<removed-apn>
              Cy s Phe Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser
                              20                        25                        30
              Tr p As p Ty r Met Gl n Gl y Al a Pr o Thr Ser Gl u Ser Al a Thr Pr o Gl u
                         35                        40                        45
              Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y
                   50                         55                        60
              Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a
              65                         70                        75                        80
              Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
                                    85                        90                        95
              Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y
                              100                       105                       110
              Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Gl u Ser
                                                              Page 386

                                                                    97047_1
<removed-date>
                          115                           120                           125
              Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser
                    130                           135                           140
<removed-apn>
              Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y
              145                           150                           155                           160
              Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Ser Pr o Al a Gl y
                                      165                           170                           175
              Ser Pr o Thr Ser Thr Gl u Gl u Gl y Al a Ser Ser Ser As p Leu Gl y Gl u
                                180                           185                           190
              Leu Pr o Val As p Al a Ar g Phe Pr o Pr o Ar g Val Pr o Ly s Ser Phe Pr o
                          195                           200                           205
              Phe As n Thr Ser Val Val Ty r Ly s Ly s Thr Leu Phe Val Gl u Phe Thr
                    210                           215                           220
              As p Hi s Leu Phe As n I l e Al a Ly s Pr o Ar g Pr o Pr o Tr p Met Gl y Leu
              225                           230                           235                           240
              Leu Gl y Pr o Thr I l e Gl n Al a Gl u Val Ty r As p Thr Val Val I l e Thr
                                      245                           250                           255
                                                                    Page 387

                                                                    97047_1
<removed-date>
              Leu Ly s As n Met Al a Ser Hi s Pr o Val Ser Leu Hi s Al a Val Gl y Val
                                260                           265                           270
              Ser Ty r Tr p Ly s Al a Ser Gl u Gl y Al a Gl u Ty r As p As p Gl n Thr Ser
                          275                           280                           285
<removed-apn>
              Gl n Ar g Gl u Ly s Gl u As p As p Ly s Val Phe Pr o Gl y Gl y Ser Hi s Thr
                    290                           295                           300
              Ty r Val Tr p Gl n Val Leu Ly s Gl u As n Gl y Pr o Met Al a Ser As p Pr o
              305                           310                           315                           320
              Leu Cy s Leu Thr Ty r Ser Ty r Leu Ser Hi s Val As p Leu Val Ly s As p
                                      325                           330                           335
              Leu As n Ser Gl y Leu I l e Gl y Al a Leu Leu Val Cy s Ar g Gl u Gl y Ser
                                340                           345                           350
              Leu Al a Ly s Gl u Ly s Thr Gl n Thr Leu Hi s Ly s Phe I l e Leu Leu Phe
                          355                           360                           365
              Al a Val Phe As p Gl u Gl y Ly s Ser Tr p Hi s Ser Gl u Thr Ly s As n Ser
                    370                           375                           380
              Leu Met Gl n As p Ar g As p Al a Al a Ser Al a Ar g Al a Tr p Pr o Ly s Met
                                                                    Page 388

                                                                    97047_1
<removed-date>
              385                           390                        395                              400
              Hi s Thr Val As n Gl y Ty r Val As n Ar g Ser Leu Pr o Gl y Leu I l e Gl y
                                      405                           410                           415
<removed-apn>
              Cy s Hi s Ar g Ly s Ser Val Ty r Tr p Hi s Val I l e Gl y Met Gl y Thr Thr
                                420                           425                           430
              Pr o Gl u Val Hi s Ser I l e Phe Leu Gl u Gl y Hi s Thr Phe Leu Val Ar g
                          435                           440                           445
              As n Hi s Ar g Gl n Al a Ser Leu Gl u I l e Ser Pr o I l e Thr Phe Leu Thr
                    450                           455                           460
              Al a Gl n Thr Leu Leu Met As p Leu Gl y Gl n Phe Leu Leu Phe Cy s Hi s
              465                           470                           475                           480
              I l e Ser Ser Hi s Gl n Hi s As p Gl y Met Gl u Al a Ty r Val Ly s Val As p
                                      485                           490                           495
              Ser Cy s Pr o Gl u Gl u Pr o Gl n Leu Ar g Met Ly s As n As n Gl u Gl u Al a
                                500                           505                           510
              Gl u As p Ty r As p As p As p Leu Thr As p Ser Gl u Met As p Val Val Ar g
                          515                           520                           525
                                                                    Page 389

                                                                    97047_1
<removed-date>
              Phe As p As p As p As n Ser Pr o Ser Phe I l e Gl n I l e Ar g Ser Val Al a
                    530                           535                           540
              Ly s Ly s Hi s Pr o Ly s Thr Tr p Val Hi s Ty r I l e Al a Al a Gl u Gl u Gl u
              545                           550                           555                           560
<removed-apn>
              As p Tr p As p Ty r Al a Pr o Leu Val Leu Al a Pr o As p As p Ar g Ser Ty r
                                      565                           570                           575
              Ly s Ser Gl n Ty r Leu As n As n Gl y Pr o Gl n Ar g I l e Gl y Ar g Ly s Ty r
                                580                           585                           590
              Ly s Ly s Val Ar g Phe Met Al a Ty r Thr As p Gl u Thr Phe Ly s Thr Ar g
                          595                           600                           605
              Gl u Al a I l e Gl n Hi s Gl u Ser Gl y I l e Leu Gl y Pr o Leu Leu Ty r Gl y
                    610                           615                           620
              Gl u Val Gl y As p Thr Leu Leu I l e I l e Phe Ly s As n Gl n Al a Ser Ar g
              625                           630                           635                           640
              Pr o Ty r As n I l e Ty r Pr o Hi s Gl y I l e Thr As p Val Ar g Pr o Leu Ty r
                                      645                           650                           655
              Ser Ar g Ar g Leu Pr o Ly s Gl y Val Ly s Hi s Leu Ly s As p Phe Pr o I l e
                                                                    Page 390

                                                                    97047_1
<removed-date>
                                660                           665                           670
              Leu Pr o Gl y Gl u I l e Phe Ly s Ty r Ly s Tr p Thr Val Thr Val Gl u As p
                          675                           680                           685
<removed-apn>
              Gl y Pr o Thr Ly s Ser As p Pr o Ar g Cy s Leu Thr Ar g Ty r Ty r Ser Ser
                    690                           695                           700
              Phe Val As n Met Gl u Ar g As p Leu Al a Ser Gl y Leu I l e Gl y Pr o Leu
              705                           710                           715                           720
              Leu I l e Cy s Ty r Ly s Gl u Ser Val As p Gl n Ar g Gl y As n Gl n I l e Met
                                      725                           730                           735
              Ser As p Ly s Ar g As n Val I l e Leu Phe Ser Val Phe As p Gl u As n Ar g
                                740                           745                           750
              Ser Tr p Ty r Leu Thr Gl u As n I l e Gl n Ar g Phe Leu Pr o As n Pr o Al a
                          755                           760                           765
              Gl y Val Gl n Leu Gl u As p Pr o Gl u Phe Gl n Al a Ser As n I l e Met Hi s
                    770                           775                           780
              Ser I l e As n Gl y Ty r Val Phe As p Ser Leu Gl n Leu Ser Val Cy s Leu
              785                           790                           795                           800
                                                                    Page 391

                                                                    97047_1
<removed-date>
              Hi s Gl u Val Al a Ty r Tr p Ty r I l e Leu Ser I l e Gl y Al a Gl n Thr As p
                                      805                           810                           815
              Phe Leu Ser Val Phe Phe Ser Gl y Ty r Thr Phe Ly s Hi s Ly s Met Val
                                820                           825                           830
<removed-apn>
              Ty r Gl u As p Thr Leu Thr Leu Phe Pr o Phe Ser Gl y Gl u Thr Val Phe
                          835                           840                           845
              Met Ser Met Gl u As n Pr o Gl y Leu Tr p I l e Leu Gl y Cy s Hi s As n Ser
                    850                           855                           860
              As p Phe Ar g As n Ar g Gl y Met Thr Al a Leu Leu Ly s Val Ser Ser Cy s
              865                           870                           875                           880
              As p Ly s As n Thr Gl y As p Ty r Ty r Gl u As p Ser Ty r Gl u As p I l e Ser
                                      885                           890                           895
              Al a Ty r Leu Leu Ser Ly s As n As n Al a I l e Gl u Pr o Ar g Ser Phe Ser
                                900                           905                           910
              Gl n As n Pr o Pr o Val Leu Ly s Ar g Hi s Gl n Al a Gl u I l e Thr Ar g Thr
                          915                           920                           925
              Thr Leu Gl n Ser As p Gl n Gl u Gl u I l e As p Ty r As p As p Thr I l e Ser
                                                                    Page 392

                                                                      97047_1
<removed-date>
                    930                            935                            940
              Val Gl u Met Ly s Ly s Gl u As p Phe As p I l e Ty r As p Gl u As p Gl u As n
              945                            950                            955                         960
<removed-apn>
              Gl n Ser Pr o Ar g Ser Phe Gl n Ly s Ly s Thr Ar g Hi s Ty r Phe I l e Al a
                                       965                            970                         975
              Al a Val Gl u Ar g Leu Tr p As p Ty r Gl y Met Ser Ser Ser Pr o Hi s Val
                                 980                            985                         990
              Leu Ar g As n Ar g Al a Gl n Ser Gl y              Ser Val Pr o Gl n Phe         Ly s Ly s Val
                           995                           1000                           1005
              Val Phe       Gl n Gl u Phe Thr As p         Gl y Ser Phe Thr Gl n           Pr o Leu Ty r
                    1010                            1015                            1020
              Ar g Gl y     Gl u Leu As n Gl u Hi s        Leu Gl y Leu Leu Gl y           Pr o Ty r I l e
                    1025                            1030                            1035
              Ar g Al a     Gl u Val Gl u As p As n        I l e Met Val Thr Phe           Ar g As n Gl n
                    1040                            1045                            1050
              Al a Ser      Ar g Pr o Ty r Ser Phe         Ty r Ser Ser Leu I l e          Ser Ty r Gl u
                    1055                            1060                            1065
                                                                      Page 393

                                                               97047_1
<removed-date>
              Gl u As p   Gl n Ar g Gl n Gl y Al a    Gl u Pr o Ar g Ly s As n     Phe Val Ly s
                   1070                        1075                        1080
              Pr o As n   Gl u Thr Ly s Thr Ty r      Phe Tr p Ly s Val Gl n       Hi s Hi s Met
                   1085                        1090                        1095
<removed-apn>
              Al a Pr o   Thr Ly s As p Gl u Phe      As p Cy s Ly s Al a Tr p     Al a Ty r Phe
                   1100                        1105                        1110
              Ser As p    Val As p Leu Gl u Ly s      As p Val Hi s Ser Gl y       Leu I l e Gl y
                   1115                        1120                        1125
              Pr o Leu    Leu Val Cy s Hi s Thr       As n Thr Leu As n Pr o       Al a Hi s Gl y
                   1130                        1135                        1140
              Ar g Gl n   Val Thr Val Gl n Gl u       Phe Al a Leu Phe Phe         Thr I l e Phe
                   1145                        1150                        1155
              As p Gl u   Thr Ly s Ser Tr p Ty r      Phe Thr Gl u As n Met        Gl u Ar g As n
                   1160                        1165                        1170
              Cy s Ar g   Al a Pr o Cy s As n I l e   Gl n Met Gl u As p Pr o      Thr Phe Ly s
                   1175                        1180                        1185
              Gl u As n   Ty r Ar g Phe Hi s Al a     I l e As n Gl y Ty r I l e   Met As p Thr
                                                              Page 394

                                                             97047_1
<removed-date>
                   1190                       1195                        1200
              Leu Pr o    Gl y Leu Val Met Al a      Gl n As p Gl n Ar g I l e   Ar g Tr p Ty r
                   1205                       1210                        1215
<removed-apn>
              Leu Leu     Ser Met Gl y Ser As n      Gl u As n I l e Hi s Ser    I l e Hi s Phe
                   1220                       1225                        1230
              Ser Gl y    Hi s Val Phe Thr Val       Ar g Ly s Ly s Gl u Gl u    Ty r Ly s Met
                   1235                       1240                        1245
              Al a Leu    Ty r As n Leu Ty r Pr o    Gl y Val Phe Gl u Thr       Val Gl u Met
                   1250                       1255                        1260
              Leu Pr o    Ser Ly s Al a Gl y I l e   Tr p Ar g Val Gl u Cy s     Leu I l e Gl y
                   1265                       1270                        1275
              Gl u Hi s   Leu Hi s Al a Gl y Met     Ser Thr Leu Phe Leu         Val Ty r Ser
                   1280                       1285                        1290
              As n Ly s   Cy s Gl n Thr Pr o Leu     Gl y Met Al a Ser Gl y      Hi s I l e Ar g
                   1295                       1300                        1305
              As p Phe    Gl n I l e Thr Al a Ser    Gl y Gl n Ty r Gl y Gl n    Tr p Al a Pr o
                   1310                       1315                        1320
                                                             Page 395

                                                               97047_1
<removed-date>
              Ly s Leu    Al a Ar g Leu Hi s Ty r      Ser Gl y Ser I l e As n     Al a Tr p Ser
                   1325                         1330                        1335
              Thr Ly s    Gl u Pr o Phe Ser Tr p       I l e Ly s Val As p Leu     Leu Al a Pr o
                   1340                         1345                        1350
<removed-apn>
              Met I l e   I l e Hi s Gl y I l e Ly s   Thr Gl n Gl y Al a Ar g     Gl n Ly s Phe
                   1355                         1360                        1365
              Ser Ser     Leu Ty r I l e Ser Gl n      Phe I l e I l e Met Ty r    Ser Leu As p
                   1370                         1375                        1380
              Gl y Ly s   Ly s Tr p Gl n Thr Ty r      Ar g Gl y As n Ser Thr      Gl y Thr Leu
                   1385                         1390                        1395
              Met Val     Phe Phe Gl y As n Val        As p Ser Ser Gl y I l e     Ly s Hi s As n
                   1400                         1405                        1410
              I l e Phe   As n Pr o Pr o I l e I l e   Al a Ar g Ty r I l e Ar g   Leu Hi s Pr o
                   1415                         1420                        1425
              Thr Hi s    Ty r Ser I l e Ar g Ser      Thr Leu Ar g Met Gl u       Leu Met Gl y
                   1430                         1435                        1440
              Cy s As p   Leu As n Ser Cy s Ser        Met Pr o Leu Gl y Met       Gl u Ser Ly s
                                                               Page 396

                                                              97047_1
<removed-date>
                   1445                        1450                       1455
              Al a I l e   Ser As p Al a Gl n I l e   Thr Al a Ser Ser Ty r      Phe Thr As n
                   1460                        1465                       1470
<removed-apn>
              Met Phe      Al a Thr Tr p Ser Pr o     Ser Ly s Al a Ar g Leu     Hi s Leu Gl n
                   1475                        1480                       1485
              Gl y Ar g    Ser As n Al a Tr p Ar g    Pr o Gl n Val As n As n    Pr o Ly s Gl u
                   1490                        1495                       1500
              Tr p Leu     Gl n Val As p Phe Gl n     Ly s Thr Met Ly s Val      Thr Gl y Val
                   1505                        1510                       1515
              Thr Thr      Gl n Gl y Val Ly s Ser     Leu Leu Thr Ser Met        Ty r Val Ly s
                   1520                        1525                       1530
              Gl u Phe     Leu I l e Ser Ser Ser      Gl n As p Gl y Hi s Gl n   Tr p Thr Leu
                   1535                        1540                       1545
              Phe Phe      Gl n As n Gl y Ly s Val    Ly s Val Phe Gl n Gl y     As n Gl n As p
                   1550                        1555                       1560
              Ser Phe      Thr Pr o Val Val As n      Ser Leu As p Pr o Pr o     Leu Leu Thr
                   1565                        1570                       1575
                                                             Page 397

                                                             97047_1
<removed-date>
              Ar g Ty r   Leu Ar g I l e Hi s Pr o   Gl n Ser Tr p Val Hi s     Gl n I l e Al a
                   1580                       1585                       1590
              Leu Ar g    Met Gl u Val Leu Gl y      Cy s Gl u Al a Gl n As p   Leu Ty r As p
                   1595                       1600                       1605
<removed-apn>
              Ly s Thr    Hi s Thr Cy s Pr o Pr o    Cy s Pr o Al a Pr o Gl u   Leu Leu Gl y
                   1610                       1615                       1620
              Gl y Pr o   Ser Val Phe Leu Phe        Pr o Pr o Ly s Pr o Ly s   As p Thr Leu
                   1625                       1630                       1635
              Met I l e   Ser Ar g Thr Pr o Gl u     Val Thr Cy s Val Val       Val As p Val
                   1640                       1645                       1650
              Ser Hi s    Gl u As p Pr o Gl u Val    Ly s Phe As n Tr p Ty r    Val As p Gl y
                   1655                       1660                       1665
              Val Gl u    Val Hi s As n Al a Ly s    Thr Ly s Pr o Ar g Gl u    Gl u Gl n Ty r
                   1670                       1675                       1680
              As n Ser    Thr Ty r Ar g Val Val      Ser Val Leu Thr Val        Leu Hi s Gl n
                   1685                       1690                       1695
              As p Tr p   Leu As n Gl y Ly s Gl u    Ty r Ly s Cy s Ly s Val    Ser As n Ly s
                                                            Page 398

                                                              97047_1
<removed-date>
                   1700                        1705                      1710
              Al a Leu    Pr o Al a Pr o I l e Gl u   Ly s Thr I l e Ser Ly s   Al a Ly s Gl y
                   1715                        1720                      1725
<removed-apn>
              Gl n Pr o   Ar g Gl u Pr o Gl n Val     Ty r Thr Leu Pr o Pr o    Ser Ar g As p
                   1730                        1735                      1740
              Gl u Leu    Thr Ly s As n Gl n Val      Ser Leu Thr Cy s Leu      Val Ly s Gl y
                   1745                        1750                      1755
              Phe Ty r    Pr o Ser As p I l e Al a    Val Gl u Tr p Gl u Ser    As n Gl y Gl n
                   1760                        1765                      1770
              Pr o Gl u   As n As n Ty r Ly s Thr     Thr Pr o Pr o Val Leu     As p Ser As p
                   1775                        1780                      1785
              Gl y Ser    Phe Phe Leu Ty r Ser        Ly s Leu Thr Val As p     Ly s Ser Ar g
                   1790                        1795                      1800
              Tr p Gl n   Gl n Gl y As n Val Phe      Ser Cy s Ser Val Met      Hi s Gl u Al a
                   1805                        1810                      1815
              Leu Hi s    As n Hi s Ty r Thr Gl n     Ly s Ser Leu Ser Leu      Ser Pr o Gl y
                   1820                        1825                      1830
                                                             Page 399

                                                                  97047_1
<removed-date>
              Ly s
              <210>       115
              <211>       1762
<removed-apn>
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
              <220>
              <223>       pSYN FVI I I 269 pr ot ei n s equenc e
              <400>       115
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
              1                       5                           10                       15
              Cy s Phe Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser
                                 20                          25                       30
              Tr p As p Ty r Met Gl n Gl y Al a Pr o Thr Ser Gl u Ser Al a Thr Pr o Gl u
                           35                           40                       45
              Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y
                     50                           55                        60
              Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a
              65                            70                         75                       80
                                                                  Page 400

                                                                    97047_1
<removed-date>
              Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
                                      85                            90                            95
              Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y
                                100                           105                           110
<removed-apn>
              Al a Ser Ser Ser As p Leu Gl y Gl u Leu Pr o Val As p Al a Ar g Phe Pr o
                          115                           120                           125
              Pr o Ar g Val Pr o Ly s Ser Phe Pr o Phe As n Thr Ser Val Val Ty r Ly s
                    130                           135                           140
              Ly s Thr Leu Phe Val Gl u Phe Thr As p Hi s Leu Phe As n I l e Al a Ly s
              145                           150                           155                           160
              Pr o Ar g Pr o Pr o Tr p Met Gl y Leu Leu Gl y Pr o Thr I l e Gl n Al a Gl u
                                      165                           170                           175
              Val Ty r As p Thr Val Val I l e Thr Leu Ly s As n Met Al a Ser Hi s Pr o
                                180                           185                           190
              Val Ser Leu Hi s Al a Val Gl y Val Ser Ty r Tr p Ly s Al a Ser Gl u Gl y
                          195                           200                           205
              Al a Gl u Ty r As p As p Gl n Thr Ser Gl n Ar g Gl u Ly s Gl u As p As p Ly s
                                                                    Page 401

                                                                    97047_1
<removed-date>
                    210                           215                           220
              Val Phe Pr o Gl y Gl y Ser Hi s Thr Ty r Val Tr p Gl n Val Leu Ly s Gl u
              225                           230                           235                           240
<removed-apn>
              As n Gl y Pr o Met Al a Ser As p Pr o Leu Cy s Leu Thr Ty r Ser Ty r Leu
                                      245                           250                           255
              Ser Hi s Val As p Leu Val Ly s As p Leu As n Ser Gl y Leu I l e Gl y Al a
                                260                           265                           270
              Leu Leu Val Cy s Ar g Gl u Gl y Ser Leu Al a Ly s Gl u Ly s Thr Gl n Thr
                          275                           280                           285
              Leu Hi s Ly s Phe I l e Leu Leu Phe Al a Val Phe As p Gl u Gl y Ly s Ser
                    290                           295                           300
              Tr p Hi s Ser Gl u Thr Ly s As n Ser Leu Met Gl n As p Ar g As p Al a Al a
              305                           310                           315                           320
              Ser Al a Ar g Al a Tr p Pr o Ly s Met Hi s Thr Val As n Gl y Ty r Val As n
                                      325                           330                           335
              Ar g Ser Leu Pr o Gl y Leu I l e Gl y Cy s Hi s Ar g Ly s Ser Val Ty r Tr p
                                340                           345                           350
                                                                    Page 402

                                                                    97047_1
<removed-date>
              Hi s Val I l e Gl y Met Gl y Thr Thr Pr o Gl u Val Hi s Ser I l e Phe Leu
                          355                           360                           365
              Gl u Gl y Hi s Thr Phe Leu Val Ar g As n Hi s Ar g Gl n Al a Ser Leu Gl u
                    370                           375                           380
<removed-apn>
              I l e Ser Pr o I l e Thr Phe Leu Thr Al a Gl n Thr Leu Leu Met As p Leu
              385                           390                           395                           400
              Gl y Gl n Phe Leu Leu Phe Cy s Hi s I l e Ser Ser Hi s Gl n Hi s As p Gl y
                                      405                           410                           415
              Met Gl u Al a Ty r Val Ly s Val As p Ser Cy s Pr o Gl u Gl u Pr o Gl n Leu
                                420                           425                           430
              Ar g Met Ly s As n As n Gl u Gl u Al a Gl u As p Ty r As p As p As p Leu Thr
                          435                           440                           445
              As p Ser Gl u Met As p Val Val Ar g Phe As p As p As p As n Ser Pr o Ser
                    450                           455                           460
              Phe I l e Gl n I l e Ar g Ser Val Al a Ly s Ly s Hi s Pr o Ly s Thr Tr p Val
              465                           470                           475                           480
              Hi s Ty r I l e Al a Al a Gl u Gl u Gl u As p Tr p As p Ty r Al a Pr o Leu Val
                                                                    Page 403

                                                                     97047_1
<removed-date>
                                      485                           490                           495
              Leu Al a Pr o As p As p Ar g Ser Ty r Ly s Ser Gl n Ty r Leu As n As n Gl y
                                500                           505                           510
<removed-apn>
              Pr o Gl n Ar g I l e Gl y Ar g Ly s Ty r Ly s Ly s Val Ar g Phe Met Al a Ty r
                          515                           520                           525
              Thr As p Gl u Thr Phe Ly s Thr Ar g Gl u Al a I l e Gl n Hi s Gl u Ser Gl y
                    530                           535                           540
              I l e Leu Gl y Pr o Leu Leu Ty r Gl y Gl u Val Gl y As p Thr Leu Leu I l e
              545                           550                           555                           560
              I l e Phe Ly s As n Gl n Al a Ser Ar g Pr o Ty r As n I l e Ty r Pr o Hi s Gl y
                                      565                           570                           575
              I l e Thr As p Val Ar g Pr o Leu Ty r Ser Ar g Ar g Leu Pr o Ly s Gl y Val
                                580                           585                           590
              Ly s Hi s Leu Ly s As p Phe Pr o I l e Leu Pr o Gl y Gl u I l e Phe Ly s Ty r
                          595                           600                           605
              Ly s Tr p Thr Val Thr Val Gl u As p Gl y Pr o Thr Ly s Ser As p Pr o Ar g
                    610                           615                           620
                                                                    Page 404

                                                                    97047_1
<removed-date>
              Cy s Leu Thr Ar g Ty r Ty r Ser Ser Phe Val As n Met Gl u Ar g As p Leu
              625                           630                           635                           640
              Al a Ser Gl y Leu I l e Gl y Pr o Leu Leu I l e Cy s Ty r Ly s Gl u Ser Val
                                      645                           650                           655
<removed-apn>
              As p Gl n Ar g Gl y As n Gl n I l e Met Ser As p Ly s Ar g As n Val I l e Leu
                                660                           665                           670
              Phe Ser Val Phe As p Gl u As n Ar g Ser Tr p Ty r Leu Thr Gl u As n I l e
                          675                           680                           685
              Gl n Ar g Phe Leu Pr o As n Pr o Al a Gl y Val Gl n Leu Gl u As p Pr o Gl u
                    690                           695                           700
              Phe Gl n Al a Ser As n I l e Met Hi s Ser I l e As n Gl y Ty r Val Phe As p
              705                           710                           715                           720
              Ser Leu Gl n Leu Ser Val Cy s Leu Hi s Gl u Val Al a Ty r Tr p Ty r I l e
                                      725                           730                           735
              Leu Ser I l e Gl y Al a Gl n Thr As p Phe Leu Ser Val Phe Phe Ser Gl y
                                740                           745                           750
              Ty r Thr Phe Ly s Hi s Ly s Met Val Ty r Gl u As p Thr Leu Thr Leu Phe
                                                                    Page 405

                                                                    97047_1
<removed-date>
                          755                           760                           765
              Pr o Phe Ser Gl y Gl u Thr Val Phe Met Ser Met Gl u As n Pr o Gl y Leu
                    770                           775                           780
<removed-apn>
              Tr p I l e Leu Gl y Cy s Hi s As n Ser As p Phe Ar g As n Ar g Gl y Met Thr
              785                           790                           795                           800
              Al a Leu Leu Ly s Val Ser Ser Cy s As p Ly s As n Thr Gl y As p Ty r Ty r
                                      805                           810                           815
              Gl u As p Ser Ty r Gl u As p I l e Ser Al a Ty r Leu Leu Ser Ly s As n As n
                                820                           825                           830
              Al a I l e Gl u Pr o Ar g Ser Phe Ser Gl n As n Pr o Pr o Val Leu Ly s Ar g
                          835                           840                           845
              Hi s Gl n Al a Gl u I l e Thr Ar g Thr Thr Leu Gl n Ser As p Gl n Gl u Gl u
                    850                           855                           860
              I l e As p Ty r As p As p Thr I l e Ser Val Gl u Met Ly s Ly s Gl u As p Phe
              865                           870                           875                           880
              As p I l e Ty r As p Gl u As p Gl u As n Gl n Ser Pr o Ar g Ser Phe Gl n Ly s
                                      885                           890                           895
                                                                    Page 406

                                                                      97047_1
<removed-date>
              Ly s Thr Ar g Hi s Ty r Phe I l e Al a Al a Val Gl u Ar g Leu Tr p As p Ty r
                                 900                            905                            910
              Gl y Met Ser Ser Ser Pr o Hi s Val Leu Ar g As n Ar g Al a Gl n Ser Gl y
                           915                           920                            925
<removed-apn>
              Ser Val Pr o Gl n Phe Ly s Ly s Val Val Phe Gl n Gl u Phe Thr As p Gl y
                    930                            935                            940
              Ser Phe Thr Gl n Pr o Leu Ty r Ar g Gl y Gl u Leu As n Gl u Hi s Leu Gl y
              945                            950                            955                            960
              Leu Leu Gl y Pr o Ty r I l e Ar g Al a Gl u Val Gl u As p As n I l e Met Val
                                       965                            970                            975
              Thr Phe Ar g As n Gl n Al a Ser Ar g Pr o Ty r Ser Phe Ty r Ser Ser Leu
                                 980                            985                            990
              I l e Ser Ty r Gl u Gl u As p Gl n Ar g            Gl n Gl y Al a Gl u Pr o        Ar g Ly s As n
                           995                           1000                            1005
              Phe Val       Ly s Pr o As n Gl u Thr        Ly s Thr Ty r Phe Tr p             Ly s Val Gl n
                    1010                            1015                            1020
              Hi s Hi s     Met Al a Pr o Thr Ly s         As p Gl u Phe As p Cy s            Ly s Al a Tr p
                                                                      Page 407

                                                             97047_1
<removed-date>
                   1025                       1030                       1035
              Al a Ty r   Phe Ser As p Val As p      Leu Gl u Ly s As p Val     Hi s Ser Gl y
                   1040                       1045                       1050
<removed-apn>
              Leu I l e   Gl y Pr o Leu Leu Val      Cy s Hi s Thr As n Thr     Leu As n Pr o
                   1055                       1060                       1065
              Al a Hi s   Gl y Ar g Gl n Val Thr     Val Gl n Gl u Phe Al a     Leu Phe Phe
                   1070                       1075                       1080
              Thr I l e   Phe As p Gl u Thr Ly s     Ser Tr p Ty r Phe Thr      Gl u As n Met
                   1085                       1090                       1095
              Gl u Ar g   As n Cy s Ar g Al a Pr o   Cy s As n I l e Gl n Met   Gl u As p Pr o
                   1100                       1105                       1110
              Thr Phe     Ly s Gl u As n Ty r Ar g   Phe Hi s Al a I l e As n   Gl y Ty r I l e
                   1115                       1120                       1125
              Met As p    Thr Leu Pr o Gl y Leu      Val Met Al a Gl n As p     Gl n Ar g I l e
                   1130                       1135                       1140
              Ar g Tr p   Ty r Leu Leu Ser Met       Gl y Ser As n Gl u As n    I l e Hi s Ser
                   1145                       1150                       1155
                                                            Page 408

                                                               97047_1
<removed-date>
              I l e Hi s   Phe Ser Gl y Hi s Val       Phe Thr Val Ar g Ly s       Ly s Gl u Gl u
                   1160                         1165                        1170
              Ty r Ly s    Met Al a Leu Ty r As n      Leu Ty r Pr o Gl y Val      Phe Gl u Thr
                   1175                         1180                        1185
<removed-apn>
              Val Gl u     Met Leu Pr o Ser Ly s       Al a Gl y I l e Tr p Ar g   Val Gl u Cy s
                   1190                         1195                        1200
              Leu I l e    Gl y Gl u Hi s Leu Hi s     Al a Gl y Met Ser Thr       Leu Phe Leu
                   1205                         1210                        1215
              Val Ty r     Ser As n Ly s Cy s Gl n     Thr Pr o Leu Gl y Met       Al a Ser Gl y
                   1220                         1225                        1230
              Hi s I l e   Ar g As p Phe Gl n I l e    Thr Al a Ser Gl y Gl n      Ty r Gl y Gl n
                   1235                         1240                        1245
              Tr p Al a    Pr o Ly s Leu Al a Ar g     Leu Hi s Ty r Ser Gl y      Ser I l e As n
                   1250                         1255                        1260
              Al a Tr p    Ser Thr Ly s Gl u Pr o      Phe Ser Tr p I l e Ly s     Val As p Leu
                   1265                         1270                        1275
              Leu Al a     Pr o Met I l e I l e Hi s   Gl y I l e Ly s Thr Gl n    Gl y Al a Ar g
                                                               Page 409

                                                              97047_1
<removed-date>
                   1280                       1285                        1290
              Gl n Ly s   Phe Ser Ser Leu Ty r       I l e Ser Gl n Phe I l e     I l e Met Ty r
                   1295                       1300                        1305
<removed-apn>
              Ser Leu     As p Gl y Ly s Ly s Tr p   Gl n Thr Ty r Ar g Gl y      As n Ser Thr
                   1310                       1315                        1320
              Gl y Thr    Leu Met Val Phe Phe        Gl y As n Val As p Ser       Ser Gl y I l e
                   1325                       1330                        1335
              Ly s Hi s   As n I l e Phe As n Pr o   Pr o I l e I l e Al a Ar g   Ty r I l e Ar g
                   1340                       1345                        1350
              Leu Hi s    Pr o Thr Hi s Ty r Ser     I l e Ar g Ser Thr Leu       Ar g Met Gl u
                   1355                       1360                        1365
              Leu Met     Gl y Cy s As p Leu As n    Ser Cy s Ser Met Pr o        Leu Gl y Met
                   1370                       1375                        1380
              Gl u Ser    Ly s Al a I l e Ser As p   Al a Gl n I l e Thr Al a     Ser Ser Ty r
                   1385                       1390                        1395
              Phe Thr     As n Met Phe Al a Thr      Tr p Ser Pr o Ser Ly s       Al a Ar g Leu
                   1400                       1405                        1410
                                                             Page 410

                                                             97047_1
<removed-date>
              Hi s Leu     Gl n Gl y Ar g Ser As n   Al a Tr p Ar g Pr o Gl n   Val As n As n
                   1415                       1420                       1425
              Pr o Ly s    Gl u Tr p Leu Gl n Val    As p Phe Gl n Ly s Thr     Met Ly s Val
                   1430                       1435                       1440
<removed-apn>
              Thr Gl y     Val Thr Thr Gl n Gl y     Val Ly s Ser Leu Leu       Thr Ser Met
                   1445                       1450                       1455
              Ty r Val     Ly s Gl u Phe Leu I l e   Ser Ser Ser Gl n As p      Gl y Hi s Gl n
                   1460                       1465                       1470
              Tr p Thr     Leu Phe Phe Gl n As n     Gl y Ly s Val Ly s Val     Phe Gl n Gl y
                   1475                       1480                       1485
              As n Gl n    As p Ser Phe Thr Pr o     Val Val As n Ser Leu       As p Pr o Pr o
                   1490                       1495                       1500
              Leu Leu      Thr Ar g Ty r Leu Ar g    I l e Hi s Pr o Gl n Ser   Tr p Val Hi s
                   1505                       1510                       1515
              Gl n I l e   Al a Leu Ar g Met Gl u    Val Leu Gl y Cy s Gl u     Al a Gl n As p
                   1520                       1525                       1530
              Leu Ty r     As p Ly s Thr Hi s Thr    Cy s Pr o Pr o Cy s Pr o   Al a Pr o Gl u
                                                            Page 411

                                                             97047_1
<removed-date>
                   1535                       1540                       1545
              Leu Leu     Gl y Gl y Pr o Ser Val     Phe Leu Phe Pr o Pr o      Ly s Pr o Ly s
                   1550                       1555                       1560
<removed-apn>
              As p Thr    Leu Met I l e Ser Ar g     Thr Pr o Gl u Val Thr      Cy s Val Val
                   1565                       1570                       1575
              Val As p    Val Ser Hi s Gl u As p     Pr o Gl u Val Ly s Phe     As n Tr p Ty r
                   1580                       1585                       1590
              Val As p    Gl y Val Gl u Val Hi s     As n Al a Ly s Thr Ly s    Pr o Ar g Gl u
                   1595                       1600                       1605
              Gl u Gl n   Ty r As n Ser Thr Ty r     Ar g Val Val Ser Val       Leu Thr Val
                   1610                       1615                       1620
              Leu Hi s    Gl n As p Tr p Leu As n    Gl y Ly s Gl u Ty r Ly s   Cy s Ly s Val
                   1625                       1630                       1635
              Ser As n    Ly s Al a Leu Pr o Al a    Pr o I l e Gl u Ly s Thr   I l e Ser Ly s
                   1640                       1645                       1650
              Al a Ly s   Gl y Gl n Pr o Ar g Gl u   Pr o Gl n Val Ty r Thr     Leu Pr o Pr o
                   1655                       1660                       1665
                                                            Page 412

                                                                  97047_1
<removed-date>
              Ser Ar g      As p Gl u Leu Thr Ly s        As n Gl n Val Ser Leu      Thr Cy s Leu
                   1670                            1675                       1680
              Val Ly s      Gl y Phe Ty r Pr o Ser        As p I l e Al a Val Gl u   Tr p Gl u Ser
                   1685                            1690                       1695
<removed-apn>
              As n Gl y     Gl n Pr o Gl u As n As n      Ty r Ly s Thr Thr Pr o     Pr o Val Leu
                   1700                            1705                       1710
              As p Ser      As p Gl y Ser Phe Phe         Leu Ty r Ser Ly s Leu      Thr Val As p
                   1715                            1720                       1725
              Ly s Ser      Ar g Tr p Gl n Gl n Gl y      As n Val Phe Ser Cy s      Ser Val Met
                   1730                            1735                       1740
              Hi s Gl u     Al a Leu Hi s As n Hi s       Ty r Thr Gl n Ly s Ser     Leu Ser Leu
                   1745                            1750                       1755
              Ser Pr o      Gl y Ly s
                   1760
              <210>       116
              <211>       1726
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
                                                                 Page 413

                                                                  97047_1
<removed-date>
              <220>
              <223>     pSYNFVI I I        271 pr ot ei n s equenc e
              <400>     116
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
              1                       5                           10                        15
<removed-apn>
              Cy s Phe Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser
                              20                            25                        30
              Tr p As p Ty r Met Gl n Gl y Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr
                         35                            40                        45
              Ser Thr Gl u Gl u Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o
                   50                             55                        60
              Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Al a Ser Ser Ser
              65                             70                        75                        80
              As p Leu Gl y Gl u Leu Pr o Val As p Al a Ar g Phe Pr o Pr o Ar g Val Pr o
                                      85                          90                        95
              Ly s Ser Phe Pr o Phe As n Thr Ser Val Val Ty r Ly s Ly s Thr Leu Phe
                              100                           105                       110
              Val Gl u Phe Thr As p Hi s Leu Phe As n I l e Al a Ly s Pr o Ar g Pr o Pr o
                                                                  Page 414

                                                                    97047_1
<removed-date>
                          115                           120                           125
              Tr p Met Gl y Leu Leu Gl y Pr o Thr I l e Gl n Al a Gl u Val Ty r As p Thr
                    130                           135                           140
<removed-apn>
              Val Val I l e Thr Leu Ly s As n Met Al a Ser Hi s Pr o Val Ser Leu Hi s
              145                           150                           155                           160
              Al a Val Gl y Val Ser Ty r Tr p Ly s Al a Ser Gl u Gl y Al a Gl u Ty r As p
                                      165                           170                           175
              As p Gl n Thr Ser Gl n Ar g Gl u Ly s Gl u As p As p Ly s Val Phe Pr o Gl y
                                180                           185                           190
              Gl y Ser Hi s Thr Ty r Val Tr p Gl n Val Leu Ly s Gl u As n Gl y Pr o Met
                          195                           200                           205
              Al a Ser As p Pr o Leu Cy s Leu Thr Ty r Ser Ty r Leu Ser Hi s Val As p
                    210                           215                           220
              Leu Val Ly s As p Leu As n Ser Gl y Leu I l e Gl y Al a Leu Leu Val Cy s
              225                           230                           235                           240
              Ar g Gl u Gl y Ser Leu Al a Ly s Gl u Ly s Thr Gl n Thr Leu Hi s Ly s Phe
                                      245                           250                           255
                                                                    Page 415

                                                                    97047_1
<removed-date>
              I l e Leu Leu Phe Al a Val Phe As p Gl u Gl y Ly s Ser Tr p Hi s Ser Gl u
                                260                           265                           270
              Thr Ly s As n Ser Leu Met Gl n As p Ar g As p Al a Al a Ser Al a Ar g Al a
                          275                           280                           285
<removed-apn>
              Tr p Pr o Ly s Met Hi s Thr Val As n Gl y Ty r Val As n Ar g Ser Leu Pr o
                    290                           295                           300
              Gl y Leu I l e Gl y Cy s Hi s Ar g Ly s Ser Val Ty r Tr p Hi s Val I l e Gl y
              305                           310                           315                           320
              Met Gl y Thr Thr Pr o Gl u Val Hi s Ser I l e Phe Leu Gl u Gl y Hi s Thr
                                      325                           330                           335
              Phe Leu Val Ar g As n Hi s Ar g Gl n Al a Ser Leu Gl u I l e Ser Pr o I l e
                                340                           345                           350
              Thr Phe Leu Thr Al a Gl n Thr Leu Leu Met As p Leu Gl y Gl n Phe Leu
                          355                           360                           365
              Leu Phe Cy s Hi s I l e Ser Ser Hi s Gl n Hi s As p Gl y Met Gl u Al a Ty r
                    370                           375                           380
              Val Ly s Val As p Ser Cy s Pr o Gl u Gl u Pr o Gl n Leu Ar g Met Ly s As n
                                                                    Page 416

                                                                    97047_1
<removed-date>
              385                           390                        395                              400
              As n Gl u Gl u Al a Gl u As p Ty r As p As p As p Leu Thr As p Ser Gl u Met
                                      405                           410                           415
<removed-apn>
              As p Val Val Ar g Phe As p As p As p As n Ser Pr o Ser Phe I l e Gl n I l e
                                420                           425                           430
              Ar g Ser Val Al a Ly s Ly s Hi s Pr o Ly s Thr Tr p Val Hi s Ty r I l e Al a
                          435                           440                           445
              Al a Gl u Gl u Gl u As p Tr p As p Ty r Al a Pr o Leu Val Leu Al a Pr o As p
                    450                           455                           460
              As p Ar g Ser Ty r Ly s Ser Gl n Ty r Leu As n As n Gl y Pr o Gl n Ar g I l e
              465                           470                           475                           480
              Gl y Ar g Ly s Ty r Ly s Ly s Val Ar g Phe Met Al a Ty r Thr As p Gl u Thr
                                      485                           490                           495
              Phe Ly s Thr Ar g Gl u Al a I l e Gl n Hi s Gl u Ser Gl y I l e Leu Gl y Pr o
                                500                           505                           510
              Leu Leu Ty r Gl y Gl u Val Gl y As p Thr Leu Leu I l e I l e Phe Ly s As n
                          515                           520                           525
                                                                    Page 417

                                                                    97047_1
<removed-date>
              Gl n Al a Ser Ar g Pr o Ty r As n I l e Ty r Pr o Hi s Gl y I l e Thr As p Val
                    530                           535                           540
              Ar g Pr o Leu Ty r Ser Ar g Ar g Leu Pr o Ly s Gl y Val Ly s Hi s Leu Ly s
              545                           550                           555                           560
<removed-apn>
              As p Phe Pr o I l e Leu Pr o Gl y Gl u I l e Phe Ly s Ty r Ly s Tr p Thr Val
                                      565                           570                           575
              Thr Val Gl u As p Gl y Pr o Thr Ly s Ser As p Pr o Ar g Cy s Leu Thr Ar g
                                580                           585                           590
              Ty r Ty r Ser Ser Phe Val As n Met Gl u Ar g As p Leu Al a Ser Gl y Leu
                          595                           600                           605
              I l e Gl y Pr o Leu Leu I l e Cy s Ty r Ly s Gl u Ser Val As p Gl n Ar g Gl y
                    610                           615                           620
              As n Gl n I l e Met Ser As p Ly s Ar g As n Val I l e Leu Phe Ser Val Phe
              625                           630                           635                           640
              As p Gl u As n Ar g Ser Tr p Ty r Leu Thr Gl u As n I l e Gl n Ar g Phe Leu
                                      645                           650                           655
              Pr o As n Pr o Al a Gl y Val Gl n Leu Gl u As p Pr o Gl u Phe Gl n Al a Ser
                                                                    Page 418

                                                                    97047_1
<removed-date>
                                660                           665                           670
              As n I l e Met Hi s Ser I l e As n Gl y Ty r Val Phe As p Ser Leu Gl n Leu
                          675                           680                           685
<removed-apn>
              Ser Val Cy s Leu Hi s Gl u Val Al a Ty r Tr p Ty r I l e Leu Ser I l e Gl y
                    690                           695                           700
              Al a Gl n Thr As p Phe Leu Ser Val Phe Phe Ser Gl y Ty r Thr Phe Ly s
              705                           710                           715                           720
              Hi s Ly s Met Val Ty r Gl u As p Thr Leu Thr Leu Phe Pr o Phe Ser Gl y
                                      725                           730                           735
              Gl u Thr Val Phe Met Ser Met Gl u As n Pr o Gl y Leu Tr p I l e Leu Gl y
                                740                           745                           750
              Cy s Hi s As n Ser As p Phe Ar g As n Ar g Gl y Met Thr Al a Leu Leu Ly s
                          755                           760                           765
              Val Ser Ser Cy s As p Ly s As n Thr Gl y As p Ty r Ty r Gl u As p Ser Ty r
                    770                           775                           780
              Gl u As p I l e Ser Al a Ty r Leu Leu Ser Ly s As n As n Al a I l e Gl u Pr o
              785                           790                           795                           800
                                                                    Page 419

                                                                    97047_1
<removed-date>
              Ar g Ser Phe Ser Gl n As n Pr o Pr o Val Leu Ly s Ar g Hi s Gl n Al a Gl u
                                      805                           810                           815
              I l e Thr Ar g Thr Thr Leu Gl n Ser As p Gl n Gl u Gl u I l e As p Ty r As p
                                820                           825                           830
<removed-apn>
              As p Thr I l e Ser Val Gl u Met Ly s Ly s Gl u As p Phe As p I l e Ty r As p
                          835                           840                           845
              Gl u As p Gl u As n Gl n Ser Pr o Ar g Ser Phe Gl n Ly s Ly s Thr Ar g Hi s
                    850                           855                           860
              Ty r Phe I l e Al a Al a Val Gl u Ar g Leu Tr p As p Ty r Gl y Met Ser Ser
              865                           870                           875                           880
              Ser Pr o Hi s Val Leu Ar g As n Ar g Al a Gl n Ser Gl y Ser Val Pr o Gl n
                                      885                           890                           895
              Phe Ly s Ly s Val Val Phe Gl n Gl u Phe Thr As p Gl y Ser Phe Thr Gl n
                                900                           905                           910
              Pr o Leu Ty r Ar g Gl y Gl u Leu As n Gl u Hi s Leu Gl y Leu Leu Gl y Pr o
                          915                           920                           925
              Ty r I l e Ar g Al a Gl u Val Gl u As p As n I l e Met Val Thr Phe Ar g As n
                                                                    Page 420

                                                                      97047_1
<removed-date>
                    930                            935                            940
              Gl n Al a Ser Ar g Pr o Ty r Ser Phe Ty r Ser Ser Leu I l e Ser Ty r Gl u
              945                            950                            955                         960
<removed-apn>
              Gl u As p Gl n Ar g Gl n Gl y Al a Gl u Pr o Ar g Ly s As n Phe Val Ly s Pr o
                                       965                            970                         975
              As n Gl u Thr Ly s Thr Ty r Phe Tr p Ly s Val Gl n Hi s Hi s Met Al a Pr o
                                 980                            985                         990
              Thr Ly s As p Gl u Phe As p Cy s Ly s              Al a Tr p Al a Ty r Phe       Ser As p Val
                           995                           1000                           1005
              As p Leu      Gl u Ly s As p Val Hi s        Ser Gl y Leu I l e Gl y         Pr o Leu Leu
                    1010                            1015                            1020
              Val Cy s      Hi s Thr As n Thr Leu          As n Pr o Al a Hi s Gl y        Ar g Gl n Val
                    1025                            1030                            1035
              Thr Val       Gl n Gl u Phe Al a Leu         Phe Phe Thr I l e Phe           As p Gl u Thr
                    1040                            1045                            1050
              Ly s Ser      Tr p Ty r Phe Thr Gl u         As n Met Gl u Ar g As n         Cy s Ar g Al a
                    1055                            1060                            1065
                                                                      Page 421

                                                              97047_1
<removed-date>
              Pr o Cy s   As n I l e Gl n Met Gl u    As p Pr o Thr Phe Ly s      Gl u As n Ty r
                   1070                        1075                        1080
              Ar g Phe    Hi s Al a I l e As n Gl y   Ty r I l e Met As p Thr     Leu Pr o Gl y
                   1085                        1090                        1095
<removed-apn>
              Leu Val     Met Al a Gl n As p Gl n     Ar g I l e Ar g Tr p Ty r   Leu Leu Ser
                   1100                        1105                        1110
              Met Gl y    Ser As n Gl u As n I l e    Hi s Ser I l e Hi s Phe     Ser Gl y Hi s
                   1115                        1120                        1125
              Val Phe     Thr Val Ar g Ly s Ly s      Gl u Gl u Ty r Ly s Met     Al a Leu Ty r
                   1130                        1135                        1140
              As n Leu    Ty r Pr o Gl y Val Phe      Gl u Thr Val Gl u Met       Leu Pr o Ser
                   1145                        1150                        1155
              Ly s Al a   Gl y I l e Tr p Ar g Val    Gl u Cy s Leu I l e Gl y    Gl u Hi s Leu
                   1160                        1165                        1170
              Hi s Al a   Gl y Met Ser Thr Leu        Phe Leu Val Ty r Ser        As n Ly s Cy s
                   1175                        1180                        1185
              Gl n Thr    Pr o Leu Gl y Met Al a      Ser Gl y Hi s I l e Ar g    As p Phe Gl n
                                                              Page 422

                                                                97047_1
<removed-date>
                   1190                          1195                        1200
              I l e Thr    Al a Ser Gl y Gl n Ty r      Gl y Gl n Tr p Al a Pr o    Ly s Leu Al a
                   1205                          1210                        1215
<removed-apn>
              Ar g Leu     Hi s Ty r Ser Gl y Ser       I l e As n Al a Tr p Ser    Thr Ly s Gl u
                   1220                          1225                        1230
              Pr o Phe     Ser Tr p I l e Ly s Val      As p Leu Leu Al a Pr o      Met I l e I l e
                   1235                          1240                        1245
              Hi s Gl y    I l e Ly s Thr Gl n Gl y     Al a Ar g Gl n Ly s Phe     Ser Ser Leu
                   1250                          1255                        1260
              Ty r I l e   Ser Gl n Phe I l e I l e     Met Ty r Ser Leu As p       Gl y Ly s Ly s
                   1265                          1270                        1275
              Tr p Gl n    Thr Ty r Ar g Gl y As n      Ser Thr Gl y Thr Leu        Met Val Phe
                   1280                          1285                        1290
              Phe Gl y     As n Val As p Ser Ser        Gl y I l e Ly s Hi s As n   I l e Phe As n
                   1295                          1300                        1305
              Pr o Pr o    I l e I l e Al a Ar g Ty r   I l e Ar g Leu Hi s Pr o    Thr Hi s Ty r
                   1310                          1315                        1320
                                                                Page 423

                                                             97047_1
<removed-date>
              Ser I l e   Ar g Ser Thr Leu Ar g      Met Gl u Leu Met Gl y      Cy s As p Leu
                   1325                       1330                       1335
              As n Ser    Cy s Ser Met Pr o Leu      Gl y Met Gl u Ser Ly s     Al a I l e Ser
                   1340                       1345                       1350
<removed-apn>
              As p Al a   Gl n I l e Thr Al a Ser    Ser Ty r Phe Thr As n      Met Phe Al a
                   1355                       1360                       1365
              Thr Tr p    Ser Pr o Ser Ly s Al a     Ar g Leu Hi s Leu Gl n     Gl y Ar g Ser
                   1370                       1375                       1380
              As n Al a   Tr p Ar g Pr o Gl n Val    As n As n Pr o Ly s Gl u   Tr p Leu Gl n
                   1385                       1390                       1395
              Val As p    Phe Gl n Ly s Thr Met      Ly s Val Thr Gl y Val      Thr Thr Gl n
                   1400                       1405                       1410
              Gl y Val    Ly s Ser Leu Leu Thr       Ser Met Ty r Val Ly s      Gl u Phe Leu
                   1415                       1420                       1425
              I l e Ser   Ser Ser Gl n As p Gl y     Hi s Gl n Tr p Thr Leu     Phe Phe Gl n
                   1430                       1435                       1440
              As n Gl y   Ly s Val Ly s Val Phe      Gl n Gl y As n Gl n As p   Ser Phe Thr
                                                            Page 424

                                                              97047_1
<removed-date>
                   1445                        1450                       1455
              Pr o Val     Val As n Ser Leu As p      Pr o Pr o Leu Leu Thr      Ar g Ty r Leu
                   1460                        1465                       1470
<removed-apn>
              Ar g I l e   Hi s Pr o Gl n Ser Tr p    Val Hi s Gl n I l e Al a   Leu Ar g Met
                   1475                        1480                       1485
              Gl u Val     Leu Gl y Cy s Gl u Al a    Gl n As p Leu Ty r As p    Ly s Thr Hi s
                   1490                        1495                       1500
              Thr Cy s     Pr o Pr o Cy s Pr o Al a   Pr o Gl u Leu Leu Gl y     Gl y Pr o Ser
                   1505                        1510                       1515
              Val Phe      Leu Phe Pr o Pr o Ly s     Pr o Ly s As p Thr Leu     Met I l e Ser
                   1520                        1525                       1530
              Ar g Thr     Pr o Gl u Val Thr Cy s     Val Val Val As p Val       Ser Hi s Gl u
                   1535                        1540                       1545
              As p Pr o    Gl u Val Ly s Phe As n     Tr p Ty r Val As p Gl y    Val Gl u Val
                   1550                        1555                       1560
              Hi s As n    Al a Ly s Thr Ly s Pr o    Ar g Gl u Gl u Gl n Ty r   As n Ser Thr
                   1565                        1570                       1575
                                                             Page 425

                                                              97047_1
<removed-date>
              Ty r Ar g   Val Val Ser Val Leu         Thr Val Leu Hi s Gl n     As p Tr p Leu
                   1580                        1585                      1590
              As n Gl y   Ly s Gl u Ty r Ly s Cy s    Ly s Val Ser As n Ly s    Al a Leu Pr o
                   1595                        1600                      1605
<removed-apn>
              Al a Pr o   I l e Gl u Ly s Thr I l e   Ser Ly s Al a Ly s Gl y   Gl n Pr o Ar g
                   1610                        1615                      1620
              Gl u Pr o   Gl n Val Ty r Thr Leu       Pr o Pr o Ser Ar g As p   Gl u Leu Thr
                   1625                        1630                      1635
              Ly s As n   Gl n Val Ser Leu Thr        Cy s Leu Val Ly s Gl y    Phe Ty r Pr o
                   1640                        1645                      1650
              Ser As p    I l e Al a Val Gl u Tr p    Gl u Ser As n Gl y Gl n   Pr o Gl u As n
                   1655                        1660                      1665
              As n Ty r   Ly s Thr Thr Pr o Pr o      Val Leu As p Ser As p     Gl y Ser Phe
                   1670                        1675                      1680
              Phe Leu     Ty r Ser Ly s Leu Thr       Val As p Ly s Ser Ar g    Tr p Gl n Gl n
                   1685                        1690                      1695
              Gl y As n   Val Phe Ser Cy s Ser        Val Met Hi s Gl u Al a    Leu Hi s As n
                                                             Page 426

                                                                    97047_1
<removed-date>
                   1700                            1705                            1710
              Hi s Ty r     Thr Gl n Ly s Ser Leu            Ser Leu Ser Pr o Gl y        Ly s
                   1715                            1720                            1725
<removed-apn>
              <210>       117
              <211>       1901
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
              <220>
              <223>       pSYN FVI I I pr ot ei n s equenc e 272
              <400>       117
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
              1                       5                             10                           15
              Cy s Phe Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser
                                 20                            25                          30
              Tr p As p Ty r Met Gl n Gl y Al a Pr o Thr Ser Gl u Ser Al a Thr Pr o Gl u
                           35                           40                           45
              Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y
                   50                             55                          60
              Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a
                                                                    Page 427

                                                                    97047_1
<removed-date>
              65                            70                         75                               80
              Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
                                      85                            90                            95
<removed-apn>
              Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y
                                100                           105                           110
              Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Gl u Ser
                          115                           120                           125
              Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser
                    130                           135                           140
              Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y
              145                           150                           155                           160
              Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Ser Pr o Al a Gl y
                                      165                           170                           175
              Ser Pr o Thr Ser Thr Gl u Gl u Gl y Al a Ser Ser Ser As p Leu Gl y Gl u
                                180                           185                           190
              Leu Pr o Val As p Al a Ar g Phe Pr o Pr o Ar g Val Pr o Ly s Ser Phe Pr o
                          195                           200                           205
                                                                    Page 428

                                                                    97047_1
<removed-date>
              Phe As n Thr Ser Val Val Ty r Ly s Ly s Thr Leu Phe Val Gl u Phe Thr
                    210                           215                           220
              As p Hi s Leu Phe As n I l e Al a Ly s Pr o Ar g Pr o Pr o Tr p Met Gl y Leu
              225                           230                           235                           240
<removed-apn>
              Leu Gl y Pr o Thr I l e Gl n Al a Gl u Val Ty r As p Thr Val Val I l e Thr
                                      245                           250                           255
              Leu Ly s As n Met Al a Ser Hi s Pr o Val Ser Leu Hi s Al a Val Gl y Val
                                260                           265                           270
              Ser Ty r Tr p Ly s Al a Ser Gl u Gl y Al a Gl u Ty r As p As p Gl n Thr Ser
                          275                           280                           285
              Gl n Ar g Gl u Ly s Gl u As p As p Ly s Val Phe Pr o Gl y Gl y Ser Hi s Thr
                    290                           295                           300
              Ty r Val Tr p Gl n Val Leu Ly s Gl u As n Gl y Pr o Met Al a Ser As p Pr o
              305                           310                           315                           320
              Leu Cy s Leu Thr Ty r Ser Ty r Leu Ser Hi s Val As p Leu Val Ly s As p
                                      325                           330                           335
              Leu As n Ser Gl y Leu I l e Gl y Al a Leu Leu Val Cy s Ar g Gl u Gl y Ser
                                                                    Page 429

                                                                    97047_1
<removed-date>
                                340                           345                           350
              Leu Al a Ly s Gl u Ly s Thr Gl n Thr Leu Hi s Ly s Phe I l e Leu Leu Phe
                          355                           360                           365
<removed-apn>
              Al a Val Phe As p Gl u Gl y Ly s Ser Tr p Hi s Ser Gl u Thr Ly s As n Ser
                    370                           375                           380
              Leu Met Gl n As p Ar g As p Al a Al a Ser Al a Ar g Al a Tr p Pr o Ly s Met
              385                           390                           395                           400
              Hi s Thr Val As n Gl y Ty r Val As n Ar g Ser Leu Pr o Gl y Leu I l e Gl y
                                      405                           410                           415
              Cy s Hi s Ar g Ly s Ser Val Ty r Tr p Hi s Val I l e Gl y Met Gl y Thr Thr
                                420                           425                           430
              Pr o Gl u Val Hi s Ser I l e Phe Leu Gl u Gl y Hi s Thr Phe Leu Val Ar g
                          435                           440                           445
              As n Hi s Ar g Gl n Al a Ser Leu Gl u I l e Ser Pr o I l e Thr Phe Leu Thr
                    450                           455                           460
              Al a Gl n Thr Leu Leu Met As p Leu Gl y Gl n Phe Leu Leu Phe Cy s Hi s
              465                           470                           475                           480
                                                                    Page 430

                                                                    97047_1
<removed-date>
              I l e Ser Ser Hi s Gl n Hi s As p Gl y Met Gl u Al a Ty r Val Ly s Val As p
                                      485                           490                           495
              Ser Cy s Pr o Gl u Gl u Pr o Gl n Leu Ar g Met Ly s As n As n Gl u Gl u Al a
                                500                           505                           510
<removed-apn>
              Gl u As p Ty r As p As p As p Leu Thr As p Ser Gl u Met As p Val Val Ar g
                          515                           520                           525
              Phe As p As p As p As n Ser Pr o Ser Phe I l e Gl n I l e Ar g Ser Val Al a
                    530                           535                           540
              Ly s Ly s Hi s Pr o Ly s Thr Tr p Val Hi s Ty r I l e Al a Al a Gl u Gl u Gl u
              545                           550                           555                           560
              As p Tr p As p Ty r Al a Pr o Leu Val Leu Al a Pr o As p As p Ar g Ser Ty r
                                      565                           570                           575
              Ly s Ser Gl n Ty r Leu As n As n Gl y Pr o Gl n Ar g I l e Gl y Ar g Ly s Ty r
                                580                           585                           590
              Ly s Ly s Val Ar g Phe Met Al a Ty r Thr As p Gl u Thr Phe Ly s Thr Ar g
                          595                           600                           605
              Gl u Al a I l e Gl n Hi s Gl u Ser Gl y I l e Leu Gl y Pr o Leu Leu Ty r Gl y
                                                                    Page 431

                                                                    97047_1
<removed-date>
                    610                           615                           620
              Gl u Val Gl y As p Thr Leu Leu I l e I l e Phe Ly s As n Gl n Al a Ser Ar g
              625                           630                           635                           640
<removed-apn>
              Pr o Ty r As n I l e Ty r Pr o Hi s Gl y I l e Thr As p Val Ar g Pr o Leu Ty r
                                      645                           650                           655
              Ser Ar g Ar g Leu Pr o Ly s Gl y Val Ly s Hi s Leu Ly s As p Phe Pr o I l e
                                660                           665                           670
              Leu Pr o Gl y Gl u I l e Phe Ly s Ty r Ly s Tr p Thr Val Thr Val Gl u As p
                          675                           680                           685
              Gl y Pr o Thr Ly s Ser As p Pr o Ar g Cy s Leu Thr Ar g Ty r Ty r Ser Ser
                    690                           695                           700
              Phe Val As n Met Gl u Ar g As p Leu Al a Ser Gl y Leu I l e Gl y Pr o Leu
              705                           710                           715                           720
              Leu I l e Cy s Ty r Ly s Gl u Ser Val As p Gl n Ar g Gl y As n Gl n I l e Met
                                      725                           730                           735
              Ser As p Ly s Ar g As n Val I l e Leu Phe Ser Val Phe As p Gl u As n Ar g
                                740                           745                           750
                                                                    Page 432

                                                                    97047_1
<removed-date>
              Ser Tr p Ty r Leu Thr Gl u As n I l e Gl n Ar g Phe Leu Pr o As n Pr o Al a
                          755                           760                           765
              Gl y Val Gl n Leu Gl u As p Pr o Gl u Phe Gl n Al a Ser As n I l e Met Hi s
                    770                           775                           780
<removed-apn>
              Ser I l e As n Gl y Ty r Val Phe As p Ser Leu Gl n Leu Ser Val Cy s Leu
              785                           790                           795                           800
              Hi s Gl u Val Al a Ty r Tr p Ty r I l e Leu Ser I l e Gl y Al a Gl n Thr As p
                                      805                           810                           815
              Phe Leu Ser Val Phe Phe Ser Gl y Ty r Thr Phe Ly s Hi s Ly s Met Val
                                820                           825                           830
              Ty r Gl u As p Thr Leu Thr Leu Phe Pr o Phe Ser Gl y Gl u Thr Val Phe
                          835                           840                           845
              Met Ser Met Gl u As n Pr o Gl y Leu Tr p I l e Leu Gl y Cy s Hi s As n Ser
                    850                           855                           860
              As p Phe Ar g As n Ar g Gl y Met Thr Al a Leu Leu Ly s Val Ser Ser Cy s
              865                           870                           875                           880
              As p Ly s As n Thr Gl y As p Ty r Ty r Gl u As p Ser Ty r Gl u As p I l e Ser
                                                                    Page 433

                                                                       97047_1
<removed-date>
                                       885                            890                            895
              Al a Ty r Leu Leu Ser Ly s As n As n Al a I l e Gl u Pr o Ar g Ser Phe Ser
                                 900                            905                            910
<removed-apn>
              Gl n As n Gl y Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y
                           915                           920                            925
              Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser
                    930                            935                            940
              Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser
              945                            950                            955                            960
              Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y
                                       965                            970                            975
              Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Pr o
                                 980                            985                            990
              Al a Gl y Ser Pr o Thr Ser Thr Gl u                Gl u Gl y Thr Ser Gl u          Ser Al a Thr
                           995                           1000                            1005
              Pr o Gl u     Ser Gl y Pr o Gl y Ser         Gl u Pr o Al a Thr Ser             Gl y Ser Gl u
                    1010                            1015                            1020
                                                                      Page 434

                                                           97047_1
<removed-date>
              Thr Pr o    Gl y Thr Ser Gl u Ser    Al a Thr Pr o Gl u Ser    Gl y Pr o Gl y
                   1025                     1030                      1035
              Ser Pr o    Al a Gl y Ser Pr o Thr   Ser Thr Gl u Gl u Gl y    Ser Pr o Al a
                   1040                     1045                      1050
<removed-apn>
              Gl y Ser    Pr o Thr Ser Thr Gl u    Gl u Gl y Thr Ser Thr     Gl u Pr o Ser
                   1055                     1060                      1065
              Gl u Gl y   Ser Al a Pr o Gl y Thr   Ser Gl u Ser Al a Thr     Pr o Gl u Ser
                   1070                     1075                      1080
              Gl y Pr o   Gl y Thr Ser Gl u Ser    Al a Thr Pr o Gl u Ser    Gl y Pr o Gl y
                   1085                     1090                      1095
              Thr Ser     Gl u Ser Al a Thr Pr o   Gl u Ser Gl y Pr o Gl y   Ser Gl u Pr o
                   1100                     1105                      1110
              Al a Thr    Ser Gl y Ser Gl u Thr    Pr o Gl y Ser Gl u Pr o   Al a Thr Ser
                   1115                     1120                      1125
              Gl y Ser    Gl u Thr Pr o Gl y Ser   Pr o Al a Gl y Ser Pr o   Thr Ser Thr
                   1130                     1135                      1140
              Gl u Gl u   Gl y Thr Ser Thr Gl u    Pr o Ser Gl u Gl y Ser    Al a Pr o Gl y
                                                          Page 435

                                                             97047_1
<removed-date>
                   1145                       1150                      1155
              Thr Ser     Thr Gl u Pr o Ser Gl u     Gl y Ser Al a Pr o Gl y   Ser Gl u Pr o
                   1160                       1165                      1170
<removed-apn>
              Al a Thr    Ser Gl y Ser Gl u Thr      Pr o Gl y Thr Ser Gl u    Ser Al a Thr
                   1175                       1180                      1185
              Pr o Gl u   Ser Gl y Pr o Gl y Thr     Ser Thr Gl u Pr o Ser     Gl u Gl y Ser
                   1190                       1195                      1200
              Al a Pr o   Al a Ser Ser Pr o Pr o     Val Leu Ly s Ar g Hi s    Gl n Al a Gl u
                   1205                       1210                      1215
              I l e Thr   Ar g Thr Thr Leu Gl n      Ser As p Gl n Gl u Gl u   I l e As p Ty r
                   1220                       1225                      1230
              As p As p   Thr I l e Ser Val Gl u     Met Ly s Ly s Gl u As p   Phe As p I l e
                   1235                       1240                      1245
              Ty r As p   Gl u As p Gl u As n Gl n   Ser Pr o Ar g Ser Phe     Gl n Ly s Ly s
                   1250                       1255                      1260
              Thr Ar g    Hi s Ty r Phe I l e Al a   Al a Val Gl u Ar g Leu    Tr p As p Ty r
                   1265                       1270                      1275
                                                            Page 436

                                                              97047_1
<removed-date>
              Gl y Met     Ser Ser Ser Pr o Hi s      Val Leu Ar g As n Ar g      Al a Gl n Ser
                   1280                        1285                        1290
              Gl y Ser     Val Pr o Gl n Phe Ly s     Ly s Val Val Phe Gl n       Gl u Phe Thr
                   1295                        1300                        1305
<removed-apn>
              As p Gl y    Ser Phe Thr Gl n Pr o      Leu Ty r Ar g Gl y Gl u     Leu As n Gl u
                   1310                        1315                        1320
              Hi s Leu     Gl y Leu Leu Gl y Pr o     Ty r I l e Ar g Al a Gl u   Val Gl u As p
                   1325                        1330                        1335
              As n I l e   Met Val Thr Phe Ar g       As n Gl n Al a Ser Ar g     Pr o Ty r Ser
                   1340                        1345                        1350
              Phe Ty r     Ser Ser Leu I l e Ser      Ty r Gl u Gl u As p Gl n    Ar g Gl n Gl y
                   1355                        1360                        1365
              Al a Gl u    Pr o Ar g Ly s As n Phe    Val Ly s Pr o As n Gl u     Thr Ly s Thr
                   1370                        1375                        1380
              Ty r Phe     Tr p Ly s Val Gl n Hi s    Hi s Met Al a Pr o Thr      Ly s As p Gl u
                   1385                        1390                        1395
              Phe As p     Cy s Ly s Al a Tr p Al a   Ty r Phe Ser As p Val       As p Leu Gl u
                                                              Page 437

                                                               97047_1
<removed-date>
                   1400                         1405                       1410
              Ly s As p    Val Hi s Ser Gl y Leu       I l e Gl y Pr o Leu Leu    Val Cy s Hi s
                   1415                         1420                       1425
<removed-apn>
              Thr As n     Thr Leu As n Pr o Al a      Hi s Gl y Ar g Gl n Val    Thr Val Gl n
                   1430                         1435                       1440
              Gl u Phe     Al a Leu Phe Phe Thr        I l e Phe As p Gl u Thr    Ly s Ser Tr p
                   1445                         1450                       1455
              Ty r Phe     Thr Gl u As n Met Gl u      Ar g As n Cy s Ar g Al a   Pr o Cy s As n
                   1460                         1465                       1470
              I l e Gl n   Met Gl u As p Pr o Thr      Phe Ly s Gl u As n Ty r    Ar g Phe Hi s
                   1475                         1480                       1485
              Al a I l e   As n Gl y Ty r I l e Met    As p Thr Leu Pr o Gl y     Leu Val Met
                   1490                         1495                       1500
              Al a Gl n    As p Gl n Ar g I l e Ar g   Tr p Ty r Leu Leu Ser      Met Gl y Ser
                   1505                         1510                       1515
              As n Gl u    As n I l e Hi s Ser I l e   Hi s Phe Ser Gl y Hi s     Val Phe Thr
                   1520                         1525                       1530
                                                              Page 438

                                                              97047_1
<removed-date>
              Val Ar g     Ly s Ly s Gl u Gl u Ty r   Ly s Met Al a Leu Ty r      As n Leu Ty r
                   1535                        1540                        1545
              Pr o Gl y    Val Phe Gl u Thr Val       Gl u Met Leu Pr o Ser       Ly s Al a Gl y
                   1550                        1555                        1560
<removed-apn>
              I l e Tr p   Ar g Val Gl u Cy s Leu     I l e Gl y Gl u Hi s Leu    Hi s Al a Gl y
                   1565                        1570                        1575
              Met Ser      Thr Leu Phe Leu Val        Ty r Ser As n Ly s Cy s     Gl n Thr Pr o
                   1580                        1585                        1590
              Leu Gl y     Met Al a Ser Gl y Hi s     I l e Ar g As p Phe Gl n    I l e Thr Al a
                   1595                        1600                        1605
              Ser Gl y     Gl n Ty r Gl y Gl n Tr p   Al a Pr o Ly s Leu Al a     Ar g Leu Hi s
                   1610                        1615                        1620
              Ty r Ser     Gl y Ser I l e As n Al a   Tr p Ser Thr Ly s Gl u      Pr o Phe Ser
                   1625                        1630                        1635
              Tr p I l e   Ly s Val As p Leu Leu      Al a Pr o Met I l e I l e   Hi s Gl y I l e
                   1640                        1645                        1650
              Ly s Thr     Gl n Gl y Al a Ar g Gl n   Ly s Phe Ser Ser Leu        Ty r I l e Ser
                                                              Page 439

                                                              97047_1
<removed-date>
                   1655                        1660                       1665
              Gl n Phe     I l e I l e Met Ty r Ser   Leu As p Gl y Ly s Ly s    Tr p Gl n Thr
                   1670                        1675                       1680
<removed-apn>
              Ty r Ar g    Gl y As n Ser Thr Gl y     Thr Leu Met Val Phe        Phe Gl y As n
                   1685                        1690                       1695
              Val As p     Ser Ser Gl y I l e Ly s    Hi s As n I l e Phe As n   Pr o Pr o I l e
                   1700                        1705                       1710
              I l e Al a   Ar g Ty r I l e Ar g Leu   Hi s Pr o Thr Hi s Ty r    Ser I l e Ar g
                   1715                        1720                       1725
              Ser Thr      Leu Ar g Met Gl u Leu      Met Gl y Cy s As p Leu     As n Ser Cy s
                   1730                        1735                       1740
              Ser Met      Pr o Leu Gl y Met Gl u     Ser Ly s Al a I l e Ser    As p Al a Gl n
                   1745                        1750                       1755
              I l e Thr    Al a Ser Ser Ty r Phe      Thr As n Met Phe Al a      Thr Tr p Ser
                   1760                        1765                       1770
              Pr o Ser     Ly s Al a Ar g Leu Hi s    Leu Gl n Gl y Ar g Ser     As n Al a Tr p
                   1775                        1780                       1785
                                                             Page 440

                                                               97047_1
<removed-date>
              Ar g Pr o     Gl n Val As n As n Pr o    Ly s Gl u Tr p Leu Gl n   Val As p Phe
                   1790                         1795                      1800
              Gl n Ly s     Thr Met Ly s Val Thr       Gl y Val Thr Thr Gl n     Gl y Val Ly s
                   1805                         1810                      1815
<removed-apn>
              Ser Leu       Leu Thr Ser Met Ty r       Val Ly s Gl u Phe Leu     I l e Ser Ser
                   1820                         1825                      1830
              Ser Gl n      As p Gl y Hi s Gl n Tr p   Thr Leu Phe Phe Gl n      As n Gl y Ly s
                   1835                         1840                      1845
              Val Ly s      Val Phe Gl n Gl y As n     Gl n As p Ser Phe Thr     Pr o Val Val
                   1850                         1855                      1860
              As n Ser      Leu As p Pr o Pr o Leu     Leu Thr Ar g Ty r Leu     Ar g I l e Hi s
                   1865                         1870                      1875
              Pr o Gl n     Ser Tr p Val Hi s Gl n     I l e Al a Leu Ar g Met   Gl u Val Leu
                   1880                         1885                      1890
              Gl y Cy s     Gl u Al a Gl n As p Leu    Ty r
                   1895                         1900
              <210>       118
                                                              Page 441

                                                                97047_1
<removed-date>
              <211>     1515
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     pSYN VWF 031 pr ot ei n s equenc e
<removed-apn>
              <400>     118
              Met I l e Pr o Al a Ar g Phe Al a Gl y Val Leu Leu Al a Leu Al a Leu I l e
              1                     5                           10                       15
              Leu Pr o Gl y Thr Leu Cy s Al a Gl u Gl y Thr Ar g Gl y Ar g Ser Ser Thr
                               20                          25                       30
              Al a Ar g Cy s Ser Leu Phe Gl y Ser As p Phe Val As n Thr Phe As p Gl y
                         35                           40                       45
              Ser Met Ty r Ser Phe Al a Gl y Ty r Cy s Ser Ty r Leu Leu Al a Gl y Gl y
                   50                           55                        60
              Cy s Gl n Ly s Ar g Ser Phe Ser I l e I l e Gl y As p Phe Gl n As n Gl y Ly s
              65                          70                         75                       80
              Ar g Val Ser Leu Ser Val Ty r Leu Gl y Gl u Phe Phe As p I l e Hi s Leu
                                    85                          90                       95
              Phe Val As n Gl y Thr Val Thr Gl n Gl y As p Gl n Ar g Val Ser Met Pr o
                                                                Page 442

                                                                    97047_1
<removed-date>
                                100                           105                           110
              Ty r Al a Ser Ly s Gl y Leu Ty r Leu Gl u Thr Gl u Al a Gl y Ty r Ty r Ly s
                          115                           120                           125
<removed-apn>
              Leu Ser Gl y Gl u Al a Ty r Gl y Phe Val Al a Ar g I l e As p Gl y Ser Gl y
                    130                           135                           140
              As n Phe Gl n Val Leu Leu Ser As p Ar g Ty r Phe As n Ly s Thr Cy s Gl y
              145                           150                           155                           160
              Leu Cy s Gl y As n Phe As n I l e Phe Al a Gl u As p As p Phe Met Thr Gl n
                                      165                           170                           175
              Gl u Gl y Thr Leu Thr Ser As p Pr o Ty r As p Phe Al a As n Ser Tr p Al a
                                180                           185                           190
              Leu Ser Ser Gl y Gl u Gl n Tr p Cy s Gl u Ar g Al a Ser Pr o Pr o Ser Ser
                          195                           200                           205
              Ser Cy s As n I l e Ser Ser Gl y Gl u Met Gl n Ly s Gl y Leu Tr p Gl u Gl n
                    210                           215                           220
              Cy s Gl n Leu Leu Ly s Ser Thr Ser Val Phe Al a Ar g Cy s Hi s Pr o Leu
              225                           230                           235                           240
                                                                    Page 443

                                                                    97047_1
<removed-date>
              Val As p Pr o Gl u Pr o Phe Val Al a Leu Cy s Gl u Ly s Thr Leu Cy s Gl u
                                      245                           250                           255
              Cy s Al a Gl y Gl y Leu Gl u Cy s Al a Cy s Pr o Al a Leu Leu Gl u Ty r Al a
                                260                           265                           270
<removed-apn>
              Ar g Thr Cy s Al a Gl n Gl u Gl y Met Val Leu Ty r Gl y Tr p Thr As p Hi s
                          275                           280                           285
              Ser Al a Cy s Ser Pr o Val Cy s Pr o Al a Gl y Met Gl u Ty r Ar g Gl n Cy s
                    290                           295                           300
              Val Ser Pr o Cy s Al a Ar g Thr Cy s Gl n Ser Leu Hi s I l e As n Gl u Met
              305                           310                           315                           320
              Cy s Gl n Gl u Ar g Cy s Val As p Gl y Cy s Ser Cy s Pr o Gl u Gl y Gl n Leu
                                      325                           330                           335
              Leu As p Gl u Gl y Leu Cy s Val Gl u Ser Thr Gl u Cy s Pr o Cy s Val Hi s
                                340                           345                           350
              Ser Gl y Ly s Ar g Ty r Pr o Pr o Gl y Thr Ser Leu Ser Ar g As p Cy s As n
                          355                           360                           365
              Thr Cy s I l e Cy s Ar g As n Ser Gl n Tr p I l e Cy s Ser As n Gl u Gl u Cy s
                                                                    Page 444

                                                                    97047_1
<removed-date>
                    370                           375                           380
              Pr o Gl y Gl u Cy s Leu Val Thr Gl y Gl n Ser Hi s Phe Ly s Ser Phe As p
              385                           390                           395                           400
<removed-apn>
              As n Ar g Ty r Phe Thr Phe Ser Gl y I l e Cy s Gl n Ty r Leu Leu Al a Ar g
                                      405                           410                           415
              As p Cy s Gl n As p Hi s Ser Phe Ser I l e Val I l e Gl u Thr Val Gl n Cy s
                                420                           425                           430
              Al a As p As p Ar g As p Al a Val Cy s Thr Ar g Ser Val Thr Val Ar g Leu
                          435                           440                           445
              Pr o Gl y Leu Hi s As n Ser Leu Val Ly s Leu Ly s Hi s Gl y Al a Gl y Val
                    450                           455                           460
              Al a Met As p Gl y Gl n As p I l e Gl n Leu Pr o Leu Leu Ly s Gl y As p Leu
              465                           470                           475                           480
              Ar g I l e Gl n Hi s Thr Val Thr Al a Ser Val Ar g Leu Ser Ty r Gl y Gl u
                                      485                           490                           495
              As p Leu Gl n Met As p Tr p As p Gl y Ar g Gl y Ar g Leu Leu Val Ly s Leu
                                500                           505                           510
                                                                    Page 445

                                                                    97047_1
<removed-date>
              Ser Pr o Val Ty r Al a Gl y Ly s Thr Cy s Gl y Leu Cy s Gl y As n Ty r As n
                          515                           520                           525
              Gl y As n Gl n Gl y As p As p Phe Leu Thr Pr o Ser Gl y Leu Al a Gl u Pr o
                    530                           535                           540
<removed-apn>
              Ar g Val Gl u As p Phe Gl y As n Al a Tr p Ly s Leu Hi s Gl y As p Cy s Gl n
              545                           550                           555                           560
              As p Leu Gl n Ly s Gl n Hi s Ser As p Pr o Cy s Al a Leu As n Pr o Ar g Met
                                      565                           570                           575
              Thr Ar g Phe Ser Gl u Gl u Al a Cy s Al a Val Leu Thr Ser Pr o Thr Phe
                                580                           585                           590
              Gl u Al a Cy s Hi s Ar g Al a Val Ser Pr o Leu Pr o Ty r Leu Ar g As n Cy s
                          595                           600                           605
              Ar g Ty r As p Val Cy s Ser Cy s Ser As p Gl y Ar g Gl u Cy s Leu Cy s Gl y
                    610                           615                           620
              Al a Leu Al a Ser Ty r Al a Al a Al a Cy s Al a Gl y Ar g Gl y Val Ar g Val
              625                           630                           635                           640
              Al a Tr p Ar g Gl u Pr o Gl y Ar g Cy s Gl u Leu As n Cy s Pr o Ly s Gl y Gl n
                                                                    Page 446

                                                                     97047_1
<removed-date>
                                      645                           650                           655
              Val Ty r Leu Gl n Cy s Gl y Thr Pr o Cy s As n Leu Thr Cy s Ar g Ser Leu
                                660                           665                           670
<removed-apn>
              Ser Ty r Pr o As p Gl u Gl u Cy s As n Gl u Al a Cy s Leu Gl u Gl y Cy s Phe
                          675                           680                           685
              Cy s Pr o Pr o Gl y Leu Ty r Met As p Gl u Ar g Gl y As p Cy s Val Pr o Ly s
                    690                           695                           700
              Al a Gl n Cy s Pr o Cy s Ty r Ty r As p Gl y Gl u I l e Phe Gl n Pr o Gl u As p
              705                           710                           715                           720
              I l e Phe Ser As p Hi s Hi s Thr Met Cy s Ty r Cy s Gl u As p Gl y Phe Met
                                      725                           730                           735
              Hi s Cy s Thr Met Ser Gl y Val Pr o Gl y Ser Leu Leu Pr o As p Al a Val
                                740                           745                           750
              Leu Ser Ser Pr o Leu Ser Hi s Ar g Ser Ly s Ar g Ser Leu Ser Cy s Ar g
                          755                           760                           765
              Pr o Pr o Met Val Ly s Leu Val Cy s Pr o Al a As p As n Leu Ar g Al a Gl u
                    770                           775                           780
                                                                    Page 447

                                                                    97047_1
<removed-date>
              Gl y Leu Gl u Cy s Thr Ly s Thr Cy s Gl n As n Ty r As p Leu Gl u Cy s Met
              785                           790                           795                           800
              Ser Met Gl y Cy s Val Ser Gl y Cy s Leu Cy s Pr o Pr o Gl y Met Val Ar g
                                      805                           810                           815
<removed-apn>
              Hi s Gl u As n Ar g Cy s Val Al a Leu Gl u Ar g Cy s Pr o Cy s Phe Hi s Gl n
                                820                           825                           830
              Gl y Ly s Gl u Ty r Al a Pr o Gl y Gl u Thr Val Ly s I l e Gl y Cy s As n Thr
                          835                           840                           845
              Cy s Val Cy s Ar g As p Ar g Ly s Tr p As n Cy s Thr As p Hi s Val Cy s As p
                    850                           855                           860
              Al a Thr Cy s Ser Thr I l e Gl y Met Al a Hi s Ty r Leu Thr Phe As p Gl y
              865                           870                           875                           880
              Leu Ly s Ty r Leu Phe Pr o Gl y Gl u Cy s Gl n Ty r Val Leu Val Gl n As p
                                      885                           890                           895
              Ty r Cy s Gl y Ser As n Pr o Gl y Thr Phe Ar g I l e Leu Val Gl y As n Ly s
                                900                           905                           910
              Gl y Cy s Ser Hi s Pr o Ser Val Ly s Cy s Ly s Ly s Ar g Val Thr I l e Leu
                                                                    Page 448

                                                                      97047_1
<removed-date>
                           915                           920                            925
              Val Gl u Gl y Gl y Gl u I l e Gl u Leu Phe As p Gl y Gl u Val As n Val Ly s
                    930                            935                            940
<removed-apn>
              Ar g Pr o Met Ly s As p Gl u Thr Hi s Phe Gl u Val Val Gl u Ser Gl y Ar g
              945                            950                            955                            960
              Ty r I l e I l e Leu Leu Leu Gl y Ly s Al a Leu Ser Val Val Tr p As p Ar g
                                       965                            970                            975
              Hi s Leu Ser I l e Ser Val Val Leu Ly s Gl n Thr Ty r Gl n Gl u Ly s Val
                                 980                            985                            990
              Cy s Gl y Leu Cy s Gl y As n Phe As p              Gl y I l e Gl n As n As n       As p Leu Thr
                           995                           1000                            1005
              Ser Ser       As n Leu Gl n Val Gl u         Gl u As p Pr o Val As p            Phe Gl y As n
                    1010                            1015                            1020
              Ser Tr p      Ly s Val Ser Ser Gl n          Cy s Al a As p Thr Ar g            Ly s Val Pr o
                    1025                            1030                            1035
              Leu As p      Ser Ser Pr o Al a Thr          Cy s Hi s As n As n I l e          Met Ly s Gl n
                    1040                            1045                            1050
                                                                      Page 449

                                                              97047_1
<removed-date>
              Thr Met      Val As p Ser Ser Cy s      Ar g I l e Leu Thr Ser     As p Val Phe
                   1055                        1060                       1065
              Gl n As p    Cy s As n Ly s Leu Val     As p Pr o Gl u Pr o Ty r   Leu As p Val
                   1070                        1075                       1080
<removed-apn>
              Cy s I l e   Ty r As p Thr Cy s Ser     Cy s Gl u Ser I l e Gl y   As p Cy s Al a
                   1085                        1090                       1095
              Al a Phe     Cy s As p Thr I l e Al a   Al a Ty r Al a Hi s Val    Cy s Al a Gl n
                   1100                        1105                       1110
              Hi s Gl y    Ly s Val Val Thr Tr p      Ar g Thr Al a Thr Leu      Cy s Pr o Gl n
                   1115                        1120                       1125
              Ser Cy s     Gl u Gl u Ar g As n Leu    Ar g Gl u As n Gl y Ty r   Gl u Al a Gl u
                   1130                        1135                       1140
              Tr p Ar g    Ty r As n Ser Cy s Al a    Pr o Al a Cy s Gl n Val    Thr Cy s Gl n
                   1145                        1150                       1155
              Hi s Pr o    Gl u Pr o Leu Al a Cy s    Pr o Val Gl n Cy s Val     Gl u Gl y Cy s
                   1160                        1165                       1170
              Hi s Al a    Hi s Cy s Pr o Pr o Gl y   Ly s I l e Leu As p Gl u   Leu Leu Gl n
                                                             Page 450

                                                              97047_1
<removed-date>
                   1175                        1180                       1185
              Thr Cy s    Val As p Pr o Gl u As p     Cy s Pr o Val Cy s Gl u    Val Al a Gl y
                   1190                        1195                       1200
<removed-apn>
              Ar g Ar g   Phe Al a Ser Gl y Ly s      Ly s Val Thr Leu As n      Pr o Ser As p
                   1205                        1210                       1215
              Pr o Gl u   Hi s Cy s Gl n I l e Cy s   Hi s Cy s As p Val Val     As n Leu Thr
                   1220                        1225                       1230
              Cy s Gl u   Al a Cy s Gl n Gl u Pr o    I l e Ser Gl y Gl y Gl y   Gl y Ser Gl y
                   1235                        1240                       1245
              Gl y Gl y   Gl y Ser Gl y Gl y Gl y     Gl y Ser Gl y Gl y Gl y    Gl y Ser Gl y
                   1250                        1255                       1260
              Gl y Gl y   Gl y Ser Gl y Gl y Gl y     Gl y Ser Leu Val Pr o      Ar g Gl y Ser
                   1265                        1270                       1275
              Gl y Gl y   Gl y Gl y Ser Gl y Gl y     Gl y Gl y Ser As p Ly s    Thr Hi s Thr
                   1280                        1285                       1290
              Cy s Pr o   Pr o Cy s Pr o Al a Pr o    Gl u Leu Leu Gl y Gl y     Pr o Ser Val
                   1295                        1300                       1305
                                                             Page 451

                                                              97047_1
<removed-date>
              Phe Leu      Phe Pr o Pr o Ly s Pr o    Ly s As p Thr Leu Met      I l e Ser Ar g
                   1310                        1315                       1320
              Thr Pr o     Gl u Val Thr Cy s Val      Val Val As p Val Ser       Hi s Gl u As p
                   1325                        1330                       1335
<removed-apn>
              Pr o Gl u    Val Ly s Phe As n Tr p     Ty r Val As p Gl y Val     Gl u Val Hi s
                   1340                        1345                       1350
              As n Al a    Ly s Thr Ly s Pr o Ar g    Gl u Gl u Gl n Ty r As n   Ser Thr Ty r
                   1355                        1360                       1365
              Ar g Val     Val Ser Val Leu Thr        Val Leu Hi s Gl n As p     Tr p Leu As n
                   1370                        1375                       1380
              Gl y Ly s    Gl u Ty r Ly s Cy s Ly s   Val Ser As n Ly s Al a     Leu Pr o Al a
                   1385                        1390                       1395
              Pr o I l e   Gl u Ly s Thr I l e Ser    Ly s Al a Ly s Gl y Gl n   Pr o Ar g Gl u
                   1400                        1405                       1410
              Pr o Gl n    Val Ty r Thr Leu Pr o      Pr o Ser Ar g As p Gl u    Leu Thr Ly s
                   1415                        1420                       1425
              As n Gl n    Val Ser Leu Thr Cy s       Leu Val Ly s Gl y Phe      Ty r Pr o Ser
                                                             Page 452

                                                                   97047_1
<removed-date>
                   1430                             1435                      1440
              As p I l e     Al a Val Gl u Tr p Gl u       Ser As n Gl y Gl n Pr o   Gl u As n As n
                   1445                             1450                      1455
<removed-apn>
              Ty r Ly s      Thr Thr Pr o Pr o Val         Leu As p Ser As p Gl y    Ser Phe Phe
                   1460                             1465                      1470
              Leu Ty r       Ser Ly s Leu Thr Val          As p Ly s Ser Ar g Tr p   Gl n Gl n Gl y
                   1475                             1480                      1485
              As n Val       Phe Ser Cy s Ser Val          Met Hi s Gl u Al a Leu    Hi s As n Hi s
                   1490                             1495                      1500
              Ty r Thr       Gl n Ly s Ser Leu Ser         Leu Ser Pr o Gl y Ly s
                   1505                             1510                      1515
              <210>        119
              <211>        1778
              <212>        PRT
              <213>        Ar t i f i c i al Sequenc e
              <220>
              <223>        pSYN VWF 034 pr ot ei n s equenc e
              <400>        119
              Met I l e Pr o Al a Ar g Phe Al a Gl y Val Leu Leu Al a Leu Al a Leu I l e
                                                                  Page 453

                                                                  97047_1
<removed-date>
              1                      5                           10                           15
              Leu Pr o Gl y Thr Leu Cy s Al a Gl u Gl y Thr Ar g Gl y Ar g Ser Ser Thr
                               20                          25                           30
<removed-apn>
              Al a Ar g Cy s Ser Leu Phe Gl y Ser As p Phe Val As n Thr Phe As p Gl y
                         35                          40                           45
              Ser Met Ty r Ser Phe Al a Gl y Ty r Cy s Ser Ty r Leu Leu Al a Gl y Gl y
                   50                          55                           60
              Cy s Gl n Ly s Ar g Ser Phe Ser I l e I l e Gl y As p Phe Gl n As n Gl y Ly s
              65                          70                          75                           80
              Ar g Val Ser Leu Ser Val Ty r Leu Gl y Gl u Phe Phe As p I l e Hi s Leu
                                     85                          90                           95
              Phe Val As n Gl y Thr Val Thr Gl n Gl y As p Gl n Ar g Val Ser Met Pr o
                               100                         105                          110
              Ty r Al a Ser Ly s Gl y Leu Ty r Leu Gl u Thr Gl u Al a Gl y Ty r Ty r Ly s
                         115                         120                          125
              Leu Ser Gl y Gl u Al a Ty r Gl y Phe Val Al a Ar g I l e As p Gl y Ser Gl y
                   130                         135                          140
                                                                 Page 454

                                                                    97047_1
<removed-date>
              As n Phe Gl n Val Leu Leu Ser As p Ar g Ty r Phe As n Ly s Thr Cy s Gl y
              145                           150                           155                           160
              Leu Cy s Gl y As n Phe As n I l e Phe Al a Gl u As p As p Phe Met Thr Gl n
                                      165                           170                           175
<removed-apn>
              Gl u Gl y Thr Leu Thr Ser As p Pr o Ty r As p Phe Al a As n Ser Tr p Al a
                                180                           185                           190
              Leu Ser Ser Gl y Gl u Gl n Tr p Cy s Gl u Ar g Al a Ser Pr o Pr o Ser Ser
                          195                           200                           205
              Ser Cy s As n I l e Ser Ser Gl y Gl u Met Gl n Ly s Gl y Leu Tr p Gl u Gl n
                    210                           215                           220
              Cy s Gl n Leu Leu Ly s Ser Thr Ser Val Phe Al a Ar g Cy s Hi s Pr o Leu
              225                           230                           235                           240
              Val As p Pr o Gl u Pr o Phe Val Al a Leu Cy s Gl u Ly s Thr Leu Cy s Gl u
                                      245                           250                           255
              Cy s Al a Gl y Gl y Leu Gl u Cy s Al a Cy s Pr o Al a Leu Leu Gl u Ty r Al a
                                260                           265                           270
              Ar g Thr Cy s Al a Gl n Gl u Gl y Met Val Leu Ty r Gl y Tr p Thr As p Hi s
                                                                    Page 455

                                                                    97047_1
<removed-date>
                          275                           280                           285
              Ser Al a Cy s Ser Pr o Val Cy s Pr o Al a Gl y Met Gl u Ty r Ar g Gl n Cy s
                    290                           295                           300
<removed-apn>
              Val Ser Pr o Cy s Al a Ar g Thr Cy s Gl n Ser Leu Hi s I l e As n Gl u Met
              305                           310                           315                           320
              Cy s Gl n Gl u Ar g Cy s Val As p Gl y Cy s Ser Cy s Pr o Gl u Gl y Gl n Leu
                                      325                           330                           335
              Leu As p Gl u Gl y Leu Cy s Val Gl u Ser Thr Gl u Cy s Pr o Cy s Val Hi s
                                340                           345                           350
              Ser Gl y Ly s Ar g Ty r Pr o Pr o Gl y Thr Ser Leu Ser Ar g As p Cy s As n
                          355                           360                           365
              Thr Cy s I l e Cy s Ar g As n Ser Gl n Tr p I l e Cy s Ser As n Gl u Gl u Cy s
                    370                           375                           380
              Pr o Gl y Gl u Cy s Leu Val Thr Gl y Gl n Ser Hi s Phe Ly s Ser Phe As p
              385                           390                           395                           400
              As n Ar g Ty r Phe Thr Phe Ser Gl y I l e Cy s Gl n Ty r Leu Leu Al a Ar g
                                      405                           410                           415
                                                                    Page 456

                                                                    97047_1
<removed-date>
              As p Cy s Gl n As p Hi s Ser Phe Ser I l e Val I l e Gl u Thr Val Gl n Cy s
                                420                           425                           430
              Al a As p As p Ar g As p Al a Val Cy s Thr Ar g Ser Val Thr Val Ar g Leu
                          435                           440                           445
<removed-apn>
              Pr o Gl y Leu Hi s As n Ser Leu Val Ly s Leu Ly s Hi s Gl y Al a Gl y Val
                    450                           455                           460
              Al a Met As p Gl y Gl n As p I l e Gl n Leu Pr o Leu Leu Ly s Gl y As p Leu
              465                           470                           475                           480
              Ar g I l e Gl n Hi s Thr Val Thr Al a Ser Val Ar g Leu Ser Ty r Gl y Gl u
                                      485                           490                           495
              As p Leu Gl n Met As p Tr p As p Gl y Ar g Gl y Ar g Leu Leu Val Ly s Leu
                                500                           505                           510
              Ser Pr o Val Ty r Al a Gl y Ly s Thr Cy s Gl y Leu Cy s Gl y As n Ty r As n
                          515                           520                           525
              Gl y As n Gl n Gl y As p As p Phe Leu Thr Pr o Ser Gl y Leu Al a Gl u Pr o
                    530                           535                           540
              Ar g Val Gl u As p Phe Gl y As n Al a Tr p Ly s Leu Hi s Gl y As p Cy s Gl n
                                                                    Page 457

                                                                    97047_1
<removed-date>
              545                           550                        555                              560
              As p Leu Gl n Ly s Gl n Hi s Ser As p Pr o Cy s Al a Leu As n Pr o Ar g Met
                                      565                           570                           575
<removed-apn>
              Thr Ar g Phe Ser Gl u Gl u Al a Cy s Al a Val Leu Thr Ser Pr o Thr Phe
                                580                           585                           590
              Gl u Al a Cy s Hi s Ar g Al a Val Ser Pr o Leu Pr o Ty r Leu Ar g As n Cy s
                          595                           600                           605
              Ar g Ty r As p Val Cy s Ser Cy s Ser As p Gl y Ar g Gl u Cy s Leu Cy s Gl y
                    610                           615                           620
              Al a Leu Al a Ser Ty r Al a Al a Al a Cy s Al a Gl y Ar g Gl y Val Ar g Val
              625                           630                           635                           640
              Al a Tr p Ar g Gl u Pr o Gl y Ar g Cy s Gl u Leu As n Cy s Pr o Ly s Gl y Gl n
                                      645                           650                           655
              Val Ty r Leu Gl n Cy s Gl y Thr Pr o Cy s As n Leu Thr Cy s Ar g Ser Leu
                                660                           665                           670
              Ser Ty r Pr o As p Gl u Gl u Cy s As n Gl u Al a Cy s Leu Gl u Gl y Cy s Phe
                          675                           680                           685
                                                                    Page 458

                                                                    97047_1
<removed-date>
              Cy s Pr o Pr o Gl y Leu Ty r Met As p Gl u Ar g Gl y As p Cy s Val Pr o Ly s
                    690                           695                           700
              Al a Gl n Cy s Pr o Cy s Ty r Ty r As p Gl y Gl u I l e Phe Gl n Pr o Gl u As p
              705                           710                           715                           720
<removed-apn>
              I l e Phe Ser As p Hi s Hi s Thr Met Cy s Ty r Cy s Gl u As p Gl y Phe Met
                                      725                           730                           735
              Hi s Cy s Thr Met Ser Gl y Val Pr o Gl y Ser Leu Leu Pr o As p Al a Val
                                740                           745                           750
              Leu Ser Ser Pr o Leu Ser Hi s Ar g Ser Ly s Ar g Ser Leu Ser Cy s Ar g
                          755                           760                           765
              Pr o Pr o Met Val Ly s Leu Val Cy s Pr o Al a As p As n Leu Ar g Al a Gl u
                    770                           775                           780
              Gl y Leu Gl u Cy s Thr Ly s Thr Cy s Gl n As n Ty r As p Leu Gl u Cy s Met
              785                           790                           795                           800
              Ser Met Gl y Cy s Val Ser Gl y Cy s Leu Cy s Pr o Pr o Gl y Met Val Ar g
                                      805                           810                           815
              Hi s Gl u As n Ar g Cy s Val Al a Leu Gl u Ar g Cy s Pr o Cy s Phe Hi s Gl n
                                                                    Page 459

                                                                    97047_1
<removed-date>
                                820                           825                           830
              Gl y Ly s Gl u Ty r Al a Pr o Gl y Gl u Thr Val Ly s I l e Gl y Cy s As n Thr
                          835                           840                           845
<removed-apn>
              Cy s Val Cy s Ar g As p Ar g Ly s Tr p As n Cy s Thr As p Hi s Val Cy s As p
                    850                           855                           860
              Al a Thr Cy s Ser Thr I l e Gl y Met Al a Hi s Ty r Leu Thr Phe As p Gl y
              865                           870                           875                           880
              Leu Ly s Ty r Leu Phe Pr o Gl y Gl u Cy s Gl n Ty r Val Leu Val Gl n As p
                                      885                           890                           895
              Ty r Cy s Gl y Ser As n Pr o Gl y Thr Phe Ar g I l e Leu Val Gl y As n Ly s
                                900                           905                           910
              Gl y Cy s Ser Hi s Pr o Ser Val Ly s Cy s Ly s Ly s Ar g Val Thr I l e Leu
                          915                           920                           925
              Val Gl u Gl y Gl y Gl u I l e Gl u Leu Phe As p Gl y Gl u Val As n Val Ly s
                    930                           935                           940
              Ar g Pr o Met Ly s As p Gl u Thr Hi s Phe Gl u Val Val Gl u Ser Gl y Ar g
              945                           950                           955                           960
                                                                    Page 460

                                                                  97047_1
<removed-date>
              Ty r I l e I l e Leu Leu Leu Gl y Ly s Al a Leu Ser Val Val Tr p As p Ar g
                                       965                        970                          975
              Hi s Leu Ser I l e Ser Val Val Leu Ly s Gl n Thr Ty r Gl n Gl u Ly s Val
                                 980                        985                          990
<removed-apn>
              Cy s Gl y Leu Cy s Gl y As n Phe As p          Gl y I l e Gl n As n As n     As p Leu Thr
                           995                       1000                          1005
              Ser Ser       As n Leu Gl n Val Gl u     Gl u As p Pr o Val As p       Phe Gl y As n
                   1010                        1015                           1020
              Ser Tr p      Ly s Val Ser Ser Gl n      Cy s Al a As p Thr Ar g       Ly s Val Pr o
                   1025                        1030                           1035
              Leu As p      Ser Ser Pr o Al a Thr      Cy s Hi s As n As n I l e     Met Ly s Gl n
                   1040                        1045                           1050
              Thr Met       Val As p Ser Ser Cy s      Ar g I l e Leu Thr Ser        As p Val Phe
                   1055                        1060                           1065
              Gl n As p     Cy s As n Ly s Leu Val     As p Pr o Gl u Pr o Ty r      Leu As p Val
                   1070                        1075                           1080
              Cy s I l e    Ty r As p Thr Cy s Ser     Cy s Gl u Ser I l e Gl y      As p Cy s Al a
                                                                  Page 461

                                                             97047_1
<removed-date>
                   1085                       1090                       1095
              Al a Phe    Cy s As p Thr I l e Al a   Al a Ty r Al a Hi s Val    Cy s Al a Gl n
                   1100                       1105                       1110
<removed-apn>
              Hi s Gl y   Ly s Val Val Thr Tr p      Ar g Thr Al a Thr Leu      Cy s Pr o Gl n
                   1115                       1120                       1125
              Ser Cy s    Gl u Gl u Ar g As n Leu    Ar g Gl u As n Gl y Ty r   Gl u Al a Gl u
                   1130                       1135                       1140
              Tr p Ar g   Ty r As n Ser Cy s Al a    Pr o Al a Cy s Gl n Val    Thr Cy s Gl n
                   1145                       1150                       1155
              Hi s Pr o   Gl u Pr o Leu Al a Cy s    Pr o Val Gl n Cy s Val     Gl u Gl y Cy s
                   1160                       1165                       1170
              Hi s Al a   Hi s Cy s Pr o Pr o Gl y   Ly s I l e Leu As p Gl u   Leu Leu Gl n
                   1175                       1180                       1185
              Thr Cy s    Val As p Pr o Gl u As p    Cy s Pr o Val Cy s Gl u    Val Al a Gl y
                   1190                       1195                       1200
              Ar g Ar g   Phe Al a Ser Gl y Ly s     Ly s Val Thr Leu As n      Pr o Ser As p
                   1205                       1210                       1215
                                                            Page 462

                                                             97047_1
<removed-date>
              Pr o Gl u   Hi s Cy s Gl n I l e Cy s   Hi s Cy s As p Val Val    As n Leu Thr
                   1220                        1225                      1230
              Cy s Gl u   Al a Cy s Gl n Gl u Pr o    I l e Ser Gl y Thr Ser    Gl u Ser Al a
                   1235                        1240                      1245
<removed-apn>
              Thr Pr o    Gl u Ser Gl y Pr o Gl y     Ser Gl u Pr o Al a Thr    Ser Gl y Ser
                   1250                        1255                      1260
              Gl u Thr    Pr o Gl y Thr Ser Gl u      Ser Al a Thr Pr o Gl u    Ser Gl y Pr o
                   1265                        1270                      1275
              Gl y Ser    Gl u Pr o Al a Thr Ser      Gl y Ser Gl u Thr Pr o    Gl y Thr Ser
                   1280                        1285                      1290
              Gl u Ser    Al a Thr Pr o Gl u Ser      Gl y Pr o Gl y Thr Ser    Thr Gl u Pr o
                   1295                        1300                      1305
              Ser Gl u    Gl y Ser Al a Pr o Gl y     Ser Pr o Al a Gl y Ser    Pr o Thr Ser
                   1310                        1315                      1320
              Thr Gl u    Gl u Gl y Thr Ser Gl u      Ser Al a Thr Pr o Gl u    Ser Gl y Pr o
                   1325                        1330                      1335
              Gl y Ser    Gl u Pr o Al a Thr Ser      Gl y Ser Gl u Thr Pr o    Gl y Thr Ser
                                                             Page 463

                                                           97047_1
<removed-date>
                  1340                      1345                      1350
              Gl u Ser   Al a Thr Pr o Gl u Ser    Gl y Pr o Gl y Ser Pr o   Al a Gl y Ser
                  1355                      1360                      1365
<removed-apn>
              Pr o Thr   Ser Thr Gl u Gl u Gl y    Ser Pr o Al a Gl y Ser    Pr o Thr Ser
                  1370                      1375                      1380
              Thr Gl u   Gl u Gl y Thr Ser Thr     Gl u Pr o Ser Gl u Gl y   Ser Al a Pr o
                  1385                      1390                      1395
              Gl y Thr   Ser Gl u Ser Al a Thr     Pr o Gl u Ser Gl y Pr o   Gl y Thr Ser
                  1400                      1405                      1410
              Gl u Ser   Al a Thr Pr o Gl u Ser    Gl y Pr o Gl y Thr Ser    Gl u Ser Al a
                  1415                      1420                      1425
              Thr Pr o   Gl u Ser Gl y Pr o Gl y   Ser Gl u Pr o Al a Thr    Ser Gl y Ser
                  1430                      1435                      1440
              Gl u Thr   Pr o Gl y Ser Gl u Pr o   Al a Thr Ser Gl y Ser     Gl u Thr Pr o
                  1445                      1450                      1455
              Gl y Ser   Pr o Al a Gl y Ser Pr o   Thr Ser Thr Gl u Gl u     Gl y Thr Ser
                  1460                      1465                      1470
                                                          Page 464

                                                            97047_1
<removed-date>
              Thr Gl u    Pr o Ser Gl u Gl y Ser    Al a Pr o Gl y Thr Ser    Thr Gl u Pr o
                   1475                      1480                      1485
              Ser Gl u    Gl y Ser Al a Pr o Gl y   Ser Gl u Pr o Al a Thr    Ser Gl y Ser
                   1490                      1495                      1500
<removed-apn>
              Gl u Thr    Pr o Gl y Thr Ser Gl u    Ser Al a Thr Pr o Gl u    Ser Gl y Pr o
                   1505                      1510                      1515
              Gl y Thr    Ser Thr Gl u Pr o Ser     Gl u Gl y Ser Al a Pr o   As p I l e Gl y
                   1520                      1525                      1530
              Gl y Gl y   Gl y Gl y Ser Gl y Gl y   Gl y Gl y Ser Leu Val     Pr o Ar g Gl y
                   1535                      1540                      1545
              Ser Gl y    Gl y As p Ly s Thr Hi s   Thr Cy s Pr o Pr o Cy s   Pr o Al a Pr o
                   1550                      1555                      1560
              Gl u Leu    Leu Gl y Gl y Pr o Ser    Val Phe Leu Phe Pr o      Pr o Ly s Pr o
                   1565                      1570                      1575
              Ly s As p   Thr Leu Met I l e Ser     Ar g Thr Pr o Gl u Val    Thr Cy s Val
                   1580                      1585                      1590
              Val Val     As p Val Ser Hi s Gl u    As p Pr o Gl u Val Ly s   Phe As n Tr p
                                                           Page 465

                                                             97047_1
<removed-date>
                   1595                       1600                        1605
              Ty r Val    As p Gl y Val Gl u Val     Hi s As n Al a Ly s Thr     Ly s Pr o Ar g
                   1610                       1615                        1620
<removed-apn>
              Gl u Gl u   Gl n Ty r As n Ser Thr     Ty r Ar g Val Val Ser       Val Leu Thr
                   1625                       1630                        1635
              Val Leu     Hi s Gl n As p Tr p Leu    As n Gl y Ly s Gl u Ty r    Ly s Cy s Ly s
                   1640                       1645                        1650
              Val Ser     As n Ly s Al a Leu Pr o    Al a Pr o I l e Gl u Ly s   Thr I l e Ser
                   1655                       1660                        1665
              Ly s Al a   Ly s Gl y Gl n Pr o Ar g   Gl u Pr o Gl n Val Ty r     Thr Leu Pr o
                   1670                       1675                        1680
              Pr o Ser    Ar g As p Gl u Leu Thr     Ly s As n Gl n Val Ser      Leu Thr Cy s
                   1685                       1690                        1695
              Leu Val     Ly s Gl y Phe Ty r Pr o    Ser As p I l e Al a Val     Gl u Tr p Gl u
                   1700                       1705                        1710
              Ser As n    Gl y Gl n Pr o Gl u As n   As n Ty r Ly s Thr Thr      Pr o Pr o Val
                   1715                       1720                        1725
                                                             Page 466

                                                                  97047_1
<removed-date>
              Leu As p      Ser As p Gl y Ser Phe         Phe Leu Ty r Ser Ly s     Leu Thr Val
                   1730                            1735                      1740
              As p Ly s     Ser Ar g Tr p Gl n Gl n       Gl y As n Val Phe Ser     Cy s Ser Val
                   1745                            1750                      1755
<removed-apn>
              Met Hi s      Gl u Al a Leu Hi s As n       Hi s Ty r Thr Gl n Ly s   Ser Leu Ser
                   1760                            1765                      1770
              Leu Ser       Pr o Gl y Ly s
                   1775
              <210>       120
              <211>       1565
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
              <220>
              <223>       pSYN VWF 036       pr ot ei n s equenc e
              <400>       120
              Met I l e Pr o Al a Ar g Phe Al a Gl y Val Leu Leu Al a Leu Al a Leu I l e
              1                       5                          10                       15
              Leu Pr o Gl y Thr Leu Cy s Al a Gl u Gl y Thr Ar g Gl y Ar g Ser Ser Thr
                                 20                         25                       30
                                                                 Page 467

                                                                   97047_1
<removed-date>
              Al a Ar g Cy s Ser Leu Phe Gl y Ser As p Phe Val As n Thr Phe As p Gl y
                          35                           40                           45
              Ser Met Ty r Ser Phe Al a Gl y Ty r Cy s Ser Ty r Leu Leu Al a Gl y Gl y
                    50                           55                           60
<removed-apn>
              Cy s Gl n Ly s Ar g Ser Phe Ser I l e I l e Gl y As p Phe Gl n As n Gl y Ly s
              65                           70                           75                           80
              Ar g Val Ser Leu Ser Val Ty r Leu Gl y Gl u Phe Phe As p I l e Hi s Leu
                                      85                           90                           95
              Phe Val As n Gl y Thr Val Thr Gl n Gl y As p Gl n Ar g Val Ser Met Pr o
                                100                          105                          110
              Ty r Al a Ser Ly s Gl y Leu Ty r Leu Gl u Thr Gl u Al a Gl y Ty r Ty r Ly s
                          115                          120                          125
              Leu Ser Gl y Gl u Al a Ty r Gl y Phe Val Al a Ar g I l e As p Gl y Ser Gl y
                    130                          135                          140
              As n Phe Gl n Val Leu Leu Ser As p Ar g Ty r Phe As n Ly s Thr Cy s Gl y
              145                          150                          155                          160
              Leu Cy s Gl y As n Phe As n I l e Phe Al a Gl u As p As p Phe Met Thr Gl n
                                                                   Page 468

                                                                     97047_1
<removed-date>
                                      165                           170                           175
              Gl u Gl y Thr Leu Thr Ser As p Pr o Ty r As p Phe Al a As n Ser Tr p Al a
                                180                           185                           190
<removed-apn>
              Leu Ser Ser Gl y Gl u Gl n Tr p Cy s Gl u Ar g Al a Ser Pr o Pr o Ser Ser
                          195                           200                           205
              Ser Cy s As n I l e Ser Ser Gl y Gl u Met Gl n Ly s Gl y Leu Tr p Gl u Gl n
                    210                           215                           220
              Cy s Gl n Leu Leu Ly s Ser Thr Ser Val Phe Al a Ar g Cy s Hi s Pr o Leu
              225                           230                           235                           240
              Val As p Pr o Gl u Pr o Phe Val Al a Leu Cy s Gl u Ly s Thr Leu Cy s Gl u
                                      245                           250                           255
              Cy s Al a Gl y Gl y Leu Gl u Cy s Al a Cy s Pr o Al a Leu Leu Gl u Ty r Al a
                                260                           265                           270
              Ar g Thr Cy s Al a Gl n Gl u Gl y Met Val Leu Ty r Gl y Tr p Thr As p Hi s
                          275                           280                           285
              Ser Al a Cy s Ser Pr o Val Cy s Pr o Al a Gl y Met Gl u Ty r Ar g Gl n Cy s
                    290                           295                           300
                                                                    Page 469

                                                                    97047_1
<removed-date>
              Val Ser Pr o Cy s Al a Ar g Thr Cy s Gl n Ser Leu Hi s I l e As n Gl u Met
              305                           310                           315                           320
              Cy s Gl n Gl u Ar g Cy s Val As p Gl y Cy s Ser Cy s Pr o Gl u Gl y Gl n Leu
                                      325                           330                           335
<removed-apn>
              Leu As p Gl u Gl y Leu Cy s Val Gl u Ser Thr Gl u Cy s Pr o Cy s Val Hi s
                                340                           345                           350
              Ser Gl y Ly s Ar g Ty r Pr o Pr o Gl y Thr Ser Leu Ser Ar g As p Cy s As n
                          355                           360                           365
              Thr Cy s I l e Cy s Ar g As n Ser Gl n Tr p I l e Cy s Ser As n Gl u Gl u Cy s
                    370                           375                           380
              Pr o Gl y Gl u Cy s Leu Val Thr Gl y Gl n Ser Hi s Phe Ly s Ser Phe As p
              385                           390                           395                           400
              As n Ar g Ty r Phe Thr Phe Ser Gl y I l e Cy s Gl n Ty r Leu Leu Al a Ar g
                                      405                           410                           415
              As p Cy s Gl n As p Hi s Ser Phe Ser I l e Val I l e Gl u Thr Val Gl n Cy s
                                420                           425                           430
              Al a As p As p Ar g As p Al a Val Cy s Thr Ar g Ser Val Thr Val Ar g Leu
                                                                    Page 470

                                                                    97047_1
<removed-date>
                          435                           440                           445
              Pr o Gl y Leu Hi s As n Ser Leu Val Ly s Leu Ly s Hi s Gl y Al a Gl y Val
                    450                           455                           460
<removed-apn>
              Al a Met As p Gl y Gl n As p I l e Gl n Leu Pr o Leu Leu Ly s Gl y As p Leu
              465                           470                           475                           480
              Ar g I l e Gl n Hi s Thr Val Thr Al a Ser Val Ar g Leu Ser Ty r Gl y Gl u
                                      485                           490                           495
              As p Leu Gl n Met As p Tr p As p Gl y Ar g Gl y Ar g Leu Leu Val Ly s Leu
                                500                           505                           510
              Ser Pr o Val Ty r Al a Gl y Ly s Thr Cy s Gl y Leu Cy s Gl y As n Ty r As n
                          515                           520                           525
              Gl y As n Gl n Gl y As p As p Phe Leu Thr Pr o Ser Gl y Leu Al a Gl u Pr o
                    530                           535                           540
              Ar g Val Gl u As p Phe Gl y As n Al a Tr p Ly s Leu Hi s Gl y As p Cy s Gl n
              545                           550                           555                           560
              As p Leu Gl n Ly s Gl n Hi s Ser As p Pr o Cy s Al a Leu As n Pr o Ar g Met
                                      565                           570                           575
                                                                    Page 471

                                                                    97047_1
<removed-date>
              Thr Ar g Phe Ser Gl u Gl u Al a Cy s Al a Val Leu Thr Ser Pr o Thr Phe
                                580                           585                           590
              Gl u Al a Cy s Hi s Ar g Al a Val Ser Pr o Leu Pr o Ty r Leu Ar g As n Cy s
                          595                           600                           605
<removed-apn>
              Ar g Ty r As p Val Cy s Ser Cy s Ser As p Gl y Ar g Gl u Cy s Leu Cy s Gl y
                    610                           615                           620
              Al a Leu Al a Ser Ty r Al a Al a Al a Cy s Al a Gl y Ar g Gl y Val Ar g Val
              625                           630                           635                           640
              Al a Tr p Ar g Gl u Pr o Gl y Ar g Cy s Gl u Leu As n Cy s Pr o Ly s Gl y Gl n
                                      645                           650                           655
              Val Ty r Leu Gl n Cy s Gl y Thr Pr o Cy s As n Leu Thr Cy s Ar g Ser Leu
                                660                           665                           670
              Ser Ty r Pr o As p Gl u Gl u Cy s As n Gl u Al a Cy s Leu Gl u Gl y Cy s Phe
                          675                           680                           685
              Cy s Pr o Pr o Gl y Leu Ty r Met As p Gl u Ar g Gl y As p Cy s Val Pr o Ly s
                    690                           695                           700
              Al a Gl n Cy s Pr o Cy s Ty r Ty r As p Gl y Gl u I l e Phe Gl n Pr o Gl u As p
                                                                    Page 472

                                                                    97047_1
<removed-date>
              705                           710                        715                              720
              I l e Phe Ser As p Hi s Hi s Thr Met Cy s Ty r Cy s Gl u As p Gl y Phe Met
                                      725                           730                           735
<removed-apn>
              Hi s Cy s Thr Met Ser Gl y Val Pr o Gl y Ser Leu Leu Pr o As p Al a Val
                                740                           745                           750
              Leu Ser Ser Pr o Leu Ser Hi s Ar g Ser Ly s Ar g Ser Leu Ser Cy s Ar g
                          755                           760                           765
              Pr o Pr o Met Val Ly s Leu Val Cy s Pr o Al a As p As n Leu Ar g Al a Gl u
                    770                           775                           780
              Gl y Leu Gl u Cy s Thr Ly s Thr Cy s Gl n As n Ty r As p Leu Gl u Cy s Met
              785                           790                           795                           800
              Ser Met Gl y Cy s Val Ser Gl y Cy s Leu Cy s Pr o Pr o Gl y Met Val Ar g
                                      805                           810                           815
              Hi s Gl u As n Ar g Cy s Val Al a Leu Gl u Ar g Cy s Pr o Cy s Phe Hi s Gl n
                                820                           825                           830
              Gl y Ly s Gl u Ty r Al a Pr o Gl y Gl u Thr Val Ly s I l e Gl y Cy s As n Thr
                          835                           840                           845
                                                                    Page 473

                                                                    97047_1
<removed-date>
              Cy s Val Cy s Ar g As p Ar g Ly s Tr p As n Cy s Thr As p Hi s Val Cy s As p
                    850                           855                           860
              Al a Thr Cy s Ser Thr I l e Gl y Met Al a Hi s Ty r Leu Thr Phe As p Gl y
              865                           870                           875                           880
<removed-apn>
              Leu Ly s Ty r Leu Phe Pr o Gl y Gl u Cy s Gl n Ty r Val Leu Val Gl n As p
                                      885                           890                           895
              Ty r Cy s Gl y Ser As n Pr o Gl y Thr Phe Ar g I l e Leu Val Gl y As n Ly s
                                900                           905                           910
              Gl y Cy s Ser Hi s Pr o Ser Val Ly s Cy s Ly s Ly s Ar g Val Thr I l e Leu
                          915                           920                           925
              Val Gl u Gl y Gl y Gl u I l e Gl u Leu Phe As p Gl y Gl u Val As n Val Ly s
                    930                           935                           940
              Ar g Pr o Met Ly s As p Gl u Thr Hi s Phe Gl u Val Val Gl u Ser Gl y Ar g
              945                           950                           955                           960
              Ty r I l e I l e Leu Leu Leu Gl y Ly s Al a Leu Ser Val Val Tr p As p Ar g
                                      965                           970                           975
              Hi s Leu Ser I l e Ser Val Val Leu Ly s Gl n Thr Ty r Gl n Gl u Ly s Val
                                                                    Page 474

                                                                    97047_1
<removed-date>
                                 980                          985                          990
              Cy s Gl y Leu Cy s Gl y As n Phe As p            Gl y I l e Gl n As n As n     As p Leu Thr
                           995                         1000                          1005
<removed-apn>
              Ser Ser       As n Leu Gl n Val Gl u       Gl u As p Pr o Val As p       Phe Gl y As n
                   1010                         1015                            1020
              Ser Tr p      Ly s Val Ser Ser Gl n        Cy s Al a As p Thr Ar g       Ly s Val Pr o
                   1025                         1030                            1035
              Leu As p      Ser Ser Pr o Al a Thr        Cy s Hi s As n As n I l e     Met Ly s Gl n
                   1040                         1045                            1050
              Thr Met       Val As p Ser Ser Cy s        Ar g I l e Leu Thr Ser        As p Val Phe
                   1055                         1060                            1065
              Gl n As p     Cy s As n Ly s Leu Val       As p Pr o Gl u Pr o Ty r      Leu As p Val
                   1070                         1075                            1080
              Cy s I l e    Ty r As p Thr Cy s Ser       Cy s Gl u Ser I l e Gl y      As p Cy s Al a
                   1085                         1090                            1095
              Al a Phe      Cy s As p Thr I l e Al a     Al a Ty r Al a Hi s Val       Cy s Al a Gl n
                   1100                         1105                            1110
                                                                    Page 475

                                                              97047_1
<removed-date>
              Hi s Gl y   Ly s Val Val Thr Tr p       Ar g Thr Al a Thr Leu      Cy s Pr o Gl n
                   1115                        1120                       1125
              Ser Cy s    Gl u Gl u Ar g As n Leu     Ar g Gl u As n Gl y Ty r   Gl u Al a Gl u
                   1130                        1135                       1140
<removed-apn>
              Tr p Ar g   Ty r As n Ser Cy s Al a     Pr o Al a Cy s Gl n Val    Thr Cy s Gl n
                   1145                        1150                       1155
              Hi s Pr o   Gl u Pr o Leu Al a Cy s     Pr o Val Gl n Cy s Val     Gl u Gl y Cy s
                   1160                        1165                       1170
              Hi s Al a   Hi s Cy s Pr o Pr o Gl y    Ly s I l e Leu As p Gl u   Leu Leu Gl n
                   1175                        1180                       1185
              Thr Cy s    Val As p Pr o Gl u As p     Cy s Pr o Val Cy s Gl u    Val Al a Gl y
                   1190                        1195                       1200
              Ar g Ar g   Phe Al a Ser Gl y Ly s      Ly s Val Thr Leu As n      Pr o Ser As p
                   1205                        1210                       1215
              Pr o Gl u   Hi s Cy s Gl n I l e Cy s   Hi s Cy s As p Val Val     As n Leu Thr
                   1220                        1225                       1230
              Cy s Gl u   Al a Cy s Gl n Gl u Pr o    I l e Ser Gl y Gl y Gl y   Gl y Ser Gl y
                                                             Page 476

                                                            97047_1
<removed-date>
                   1235                      1240                       1245
              Gl y Gl y   Gl y Ser Gl y Gl y Gl y   Gl y Ser Gl y Gl y Gl y    Gl y Ser Gl y
                   1250                      1255                       1260
<removed-apn>
              Gl y Gl y   Gl y Ser Gl y Gl y Gl y   Gl y Ser Gl y Gl y Gl y    Gl y Ser Gl y
                   1265                      1270                       1275
              Gl y Gl y   Gl y Ser Gl y Gl y Gl y   Gl y Ser Gl y Gl y Gl y    Gl y Ser Gl y
                   1280                      1285                       1290
              Gl y Gl y   Gl y Ser Gl y Gl y Gl y   Gl y Ser Gl y Gl y Gl y    Gl y Ser Gl y
                   1295                      1300                       1305
              Gl y Gl y   Gl y Ser Gl y Gl y Gl y   Gl y Ser Gl y Gl y Gl y    Gl y Ser Leu
                   1310                      1315                       1320
              Val Pr o    Ar g Gl y Ser Gl y Gl y   Gl y Gl y Ser Gl y Gl y    Gl y Gl y Ser
                   1325                      1330                       1335
              As p Ly s   Thr Hi s Thr Cy s Pr o    Pr o Cy s Pr o Al a Pr o   Gl u Leu Leu
                   1340                      1345                       1350
              Gl y Gl y   Pr o Ser Val Phe Leu      Phe Pr o Pr o Ly s Pr o    Ly s As p Thr
                   1355                      1360                       1365
                                                           Page 477

                                                             97047_1
<removed-date>
              Leu Met     I l e Ser Ar g Thr Pr o    Gl u Val Thr Cy s Val      Val Val As p
                   1370                       1375                       1380
              Val Ser     Hi s Gl u As p Pr o Gl u   Val Ly s Phe As n Tr p     Ty r Val As p
                   1385                       1390                       1395
<removed-apn>
              Gl y Val    Gl u Val Hi s As n Al a    Ly s Thr Ly s Pr o Ar g    Gl u Gl u Gl n
                   1400                       1405                       1410
              Ty r As n   Ser Thr Ty r Ar g Val      Val Ser Val Leu Thr        Val Leu Hi s
                   1415                       1420                       1425
              Gl n As p   Tr p Leu As n Gl y Ly s    Gl u Ty r Ly s Cy s Ly s   Val Ser As n
                   1430                       1435                       1440
              Ly s Al a   Leu Pr o Al a Pr o I l e   Gl u Ly s Thr I l e Ser    Ly s Al a Ly s
                   1445                       1450                       1455
              Gl y Gl n   Pr o Ar g Gl u Pr o Gl n   Val Ty r Thr Leu Pr o      Pr o Ser Ar g
                   1460                       1465                       1470
              As p Gl u   Leu Thr Ly s As n Gl n     Val Ser Leu Thr Cy s       Leu Val Ly s
                   1475                       1480                       1485
              Gl y Phe    Ty r Pr o Ser As p I l e   Al a Val Gl u Tr p Gl u    Ser As n Gl y
                                                            Page 478

                                                                    97047_1
<removed-date>
                   1490                            1495                        1500
              Gl n Pr o     Gl u As n As n Ty r Ly s      Thr Thr Pr o Pr o Val       Leu As p Ser
                   1505                            1510                        1515
<removed-apn>
              As p Gl y     Ser Phe Phe Leu Ty r          Ser Ly s Leu Thr Val        As p Ly s Ser
                   1520                            1525                        1530
              Ar g Tr p     Gl n Gl n Gl y As n Val       Phe Ser Cy s Ser Val        Met Hi s Gl u
                   1535                            1540                        1545
              Al a Leu      Hi s As n Hi s Ty r Thr       Gl n Ly s Ser Leu Ser       Leu Ser Pr o
                   1550                            1555                        1560
              Gl y Ly s
                   1565
              <210>       121
              <211>       247
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
              <220>
              <223>       pSYN Fc - 015     pr ot ei n s equenc e
              <400>       121
              Met Gl u Thr As p Thr Leu Leu Leu Tr p Val Leu Leu Leu Tr p Val Pr o
                                                                    Page 479

                                                                  97047_1
<removed-date>
              1                      5                           10                           15
              Gl y Ser Thr Gl y As p Ly s Thr Hi s Thr Cy s Pr o Pr o Cy s Pr o Al a Pr o
                               20                          25                           30
<removed-apn>
              Gl u Leu Leu Gl y Gl y Pr o Ser Val Phe Leu Phe Pr o Pr o Ly s Pr o Ly s
                         35                          40                           45
              As p Thr Leu Met I l e Ser Ar g Thr Pr o Gl u Val Thr Cy s Val Val Val
                   50                          55                           60
              As p Val Ser Hi s Gl u As p Pr o Gl u Val Ly s Phe As n Tr p Ty r Val As p
              65                          70                          75                           80
              Gl y Val Gl u Val Hi s As n Al a Ly s Thr Ly s Pr o Ar g Gl u Gl u Gl n Ty r
                                     85                          90                           95
              As n Ser Thr Ty r Ar g Val Val Ser Val Leu Thr Val Leu Hi s Gl n As p
                               100                         105                          110
              Tr p Leu As n Gl y Ly s Gl u Ty r Ly s Cy s Ly s Val Ser As n Ly s Al a Leu
                         115                         120                          125
              Pr o Al a Pr o I l e Gl u Ly s Thr I l e Ser Ly s Al a Ly s Gl y Gl n Pr o Ar g
                   130                         135                          140
                                                                 Page 480

                                                                     97047_1
<removed-date>
              Gl u Pr o Gl n Val Ty r Thr Leu Pr o Pr o Ser Ar g As p Gl u Leu Thr Ly s
              145                            150                           155                           160
              As n Gl n Val Ser Leu Thr Cy s Leu Val Ly s Gl y Phe Ty r Pr o Ser As p
                                       165                           170                           175
<removed-apn>
              I l e Al a Val Gl u Tr p Gl u Ser As n Gl y Gl n Pr o Gl u As n As n Ty r Ly s
                                 180                           185                           190
              Thr Thr Pr o Pr o Val Leu As p Ser As p Gl y Ser Phe Phe Leu Ty r Ser
                           195                           200                           205
              Ly s Leu Thr Val As p Ly s Ser Ar g Tr p Gl n Gl n Gl y As n Val Phe Ser
                    210                            215                           220
              Cy s Ser Val Met Hi s Gl u Al a Leu Hi s As n Hi s Ty r Thr Gl n Ly s Ser
              225                            230                           235                           240
              Leu Ser Leu Ser Pr o Gl y Ly s
                                       245
              <210>       122
              <211>       33
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
                                                                     Page 481

                                                          97047_1
<removed-date>
              <220>
              <223>   pol y pept i de
              <400>   122
              Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser Gl y
              1                   5                      10                      15
<removed-apn>
              Gl y Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser Leu Val Pr o Ar g Gl y Ser Gl y
                             20                     25                      30
              Gl y
              <210>   123
              <211>   1240
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   VWF- D1D2D' D3
              <400>   123
              Met I l e Pr o Al a Ar g Phe Al a Gl y Val Leu Leu Al a Leu Al a Leu I l e
              1                   5                      10                      15
              Leu Pr o Gl y Thr Leu Cy s Al a Gl u Gl y Thr Ar g Gl y Ar g Ser Ser Thr
                             20                     25                      30
                                                         Page 482

                                                                   97047_1
<removed-date>
              Al a Ar g Cy s Ser Leu Phe Gl y Ser As p Phe Val As n Thr Phe As p Gl y
                          35                           40                           45
              Ser Met Ty r Ser Phe Al a Gl y Ty r Cy s Ser Ty r Leu Leu Al a Gl y Gl y
                    50                           55                           60
<removed-apn>
              Cy s Gl n Ly s Ar g Ser Phe Ser I l e I l e Gl y As p Phe Gl n As n Gl y Ly s
              65                           70                           75                           80
              Ar g Val Ser Leu Ser Val Ty r Leu Gl y Gl u Phe Phe As p I l e Hi s Leu
                                      85                           90                           95
              Phe Val As n Gl y Thr Val Thr Gl n Gl y As p Gl n Ar g Val Ser Met Pr o
                                100                          105                          110
              Ty r Al a Ser Ly s Gl y Leu Ty r Leu Gl u Thr Gl u Al a Gl y Ty r Ty r Ly s
                          115                          120                          125
              Leu Ser Gl y Gl u Al a Ty r Gl y Phe Val Al a Ar g I l e As p Gl y Ser Gl y
                    130                          135                          140
              As n Phe Gl n Val Leu Leu Ser As p Ar g Ty r Phe As n Ly s Thr Cy s Gl y
              145                          150                          155                          160
              Leu Cy s Gl y As n Phe As n I l e Phe Al a Gl u As p As p Phe Met Thr Gl n
                                                                   Page 483

                                                                     97047_1
<removed-date>
                                      165                           170                           175
              Gl u Gl y Thr Leu Thr Ser As p Pr o Ty r As p Phe Al a As n Ser Tr p Al a
                                180                           185                           190
<removed-apn>
              Leu Ser Ser Gl y Gl u Gl n Tr p Cy s Gl u Ar g Al a Ser Pr o Pr o Ser Ser
                          195                           200                           205
              Ser Cy s As n I l e Ser Ser Gl y Gl u Met Gl n Ly s Gl y Leu Tr p Gl u Gl n
                    210                           215                           220
              Cy s Gl n Leu Leu Ly s Ser Thr Ser Val Phe Al a Ar g Cy s Hi s Pr o Leu
              225                           230                           235                           240
              Val As p Pr o Gl u Pr o Phe Val Al a Leu Cy s Gl u Ly s Thr Leu Cy s Gl u
                                      245                           250                           255
              Cy s Al a Gl y Gl y Leu Gl u Cy s Al a Cy s Pr o Al a Leu Leu Gl u Ty r Al a
                                260                           265                           270
              Ar g Thr Cy s Al a Gl n Gl u Gl y Met Val Leu Ty r Gl y Tr p Thr As p Hi s
                          275                           280                           285
              Ser Al a Cy s Ser Pr o Val Cy s Pr o Al a Gl y Met Gl u Ty r Ar g Gl n Cy s
                    290                           295                           300
                                                                    Page 484

                                                                    97047_1
<removed-date>
              Val Ser Pr o Cy s Al a Ar g Thr Cy s Gl n Ser Leu Hi s I l e As n Gl u Met
              305                           310                           315                           320
              Cy s Gl n Gl u Ar g Cy s Val As p Gl y Cy s Ser Cy s Pr o Gl u Gl y Gl n Leu
                                      325                           330                           335
<removed-apn>
              Leu As p Gl u Gl y Leu Cy s Val Gl u Ser Thr Gl u Cy s Pr o Cy s Val Hi s
                                340                           345                           350
              Ser Gl y Ly s Ar g Ty r Pr o Pr o Gl y Thr Ser Leu Ser Ar g As p Cy s As n
                          355                           360                           365
              Thr Cy s I l e Cy s Ar g As n Ser Gl n Tr p I l e Cy s Ser As n Gl u Gl u Cy s
                    370                           375                           380
              Pr o Gl y Gl u Cy s Leu Val Thr Gl y Gl n Ser Hi s Phe Ly s Ser Phe As p
              385                           390                           395                           400
              As n Ar g Ty r Phe Thr Phe Ser Gl y I l e Cy s Gl n Ty r Leu Leu Al a Ar g
                                      405                           410                           415
              As p Cy s Gl n As p Hi s Ser Phe Ser I l e Val I l e Gl u Thr Val Gl n Cy s
                                420                           425                           430
              Al a As p As p Ar g As p Al a Val Cy s Thr Ar g Ser Val Thr Val Ar g Leu
                                                                    Page 485

                                                                    97047_1
<removed-date>
                          435                           440                           445
              Pr o Gl y Leu Hi s As n Ser Leu Val Ly s Leu Ly s Hi s Gl y Al a Gl y Val
                    450                           455                           460
<removed-apn>
              Al a Met As p Gl y Gl n As p I l e Gl n Leu Pr o Leu Leu Ly s Gl y As p Leu
              465                           470                           475                           480
              Ar g I l e Gl n Hi s Thr Val Thr Al a Ser Val Ar g Leu Ser Ty r Gl y Gl u
                                      485                           490                           495
              As p Leu Gl n Met As p Tr p As p Gl y Ar g Gl y Ar g Leu Leu Val Ly s Leu
                                500                           505                           510
              Ser Pr o Val Ty r Al a Gl y Ly s Thr Cy s Gl y Leu Cy s Gl y As n Ty r As n
                          515                           520                           525
              Gl y As n Gl n Gl y As p As p Phe Leu Thr Pr o Ser Gl y Leu Al a Gl u Pr o
                    530                           535                           540
              Ar g Val Gl u As p Phe Gl y As n Al a Tr p Ly s Leu Hi s Gl y As p Cy s Gl n
              545                           550                           555                           560
              As p Leu Gl n Ly s Gl n Hi s Ser As p Pr o Cy s Al a Leu As n Pr o Ar g Met
                                      565                           570                           575
                                                                    Page 486

                                                                    97047_1
<removed-date>
              Thr Ar g Phe Ser Gl u Gl u Al a Cy s Al a Val Leu Thr Ser Pr o Thr Phe
                                580                           585                           590
              Gl u Al a Cy s Hi s Ar g Al a Val Ser Pr o Leu Pr o Ty r Leu Ar g As n Cy s
                          595                           600                           605
<removed-apn>
              Ar g Ty r As p Val Cy s Ser Cy s Ser As p Gl y Ar g Gl u Cy s Leu Cy s Gl y
                    610                           615                           620
              Al a Leu Al a Ser Ty r Al a Al a Al a Cy s Al a Gl y Ar g Gl y Val Ar g Val
              625                           630                           635                           640
              Al a Tr p Ar g Gl u Pr o Gl y Ar g Cy s Gl u Leu As n Cy s Pr o Ly s Gl y Gl n
                                      645                           650                           655
              Val Ty r Leu Gl n Cy s Gl y Thr Pr o Cy s As n Leu Thr Cy s Ar g Ser Leu
                                660                           665                           670
              Ser Ty r Pr o As p Gl u Gl u Cy s As n Gl u Al a Cy s Leu Gl u Gl y Cy s Phe
                          675                           680                           685
              Cy s Pr o Pr o Gl y Leu Ty r Met As p Gl u Ar g Gl y As p Cy s Val Pr o Ly s
                    690                           695                           700
              Al a Gl n Cy s Pr o Cy s Ty r Ty r As p Gl y Gl u I l e Phe Gl n Pr o Gl u As p
                                                                    Page 487

                                                                    97047_1
<removed-date>
              705                           710                        715                              720
              I l e Phe Ser As p Hi s Hi s Thr Met Cy s Ty r Cy s Gl u As p Gl y Phe Met
                                      725                           730                           735
<removed-apn>
              Hi s Cy s Thr Met Ser Gl y Val Pr o Gl y Ser Leu Leu Pr o As p Al a Val
                                740                           745                           750
              Leu Ser Ser Pr o Leu Ser Hi s Ar g Ser Ly s Ar g Ser Leu Ser Cy s Ar g
                          755                           760                           765
              Pr o Pr o Met Val Ly s Leu Val Cy s Pr o Al a As p As n Leu Ar g Al a Gl u
                    770                           775                           780
              Gl y Leu Gl u Cy s Thr Ly s Thr Cy s Gl n As n Ty r As p Leu Gl u Cy s Met
              785                           790                           795                           800
              Ser Met Gl y Cy s Val Ser Gl y Cy s Leu Cy s Pr o Pr o Gl y Met Val Ar g
                                      805                           810                           815
              Hi s Gl u As n Ar g Cy s Val Al a Leu Gl u Ar g Cy s Pr o Cy s Phe Hi s Gl n
                                820                           825                           830
              Gl y Ly s Gl u Ty r Al a Pr o Gl y Gl u Thr Val Ly s I l e Gl y Cy s As n Thr
                          835                           840                           845
                                                                    Page 488

                                                                    97047_1
<removed-date>
              Cy s Val Cy s Ar g As p Ar g Ly s Tr p As n Cy s Thr As p Hi s Val Cy s As p
                    850                           855                           860
              Al a Thr Cy s Ser Thr I l e Gl y Met Al a Hi s Ty r Leu Thr Phe As p Gl y
              865                           870                           875                           880
<removed-apn>
              Leu Ly s Ty r Leu Phe Pr o Gl y Gl u Cy s Gl n Ty r Val Leu Val Gl n As p
                                      885                           890                           895
              Ty r Cy s Gl y Ser As n Pr o Gl y Thr Phe Ar g I l e Leu Val Gl y As n Ly s
                                900                           905                           910
              Gl y Cy s Ser Hi s Pr o Ser Val Ly s Cy s Ly s Ly s Ar g Val Thr I l e Leu
                          915                           920                           925
              Val Gl u Gl y Gl y Gl u I l e Gl u Leu Phe As p Gl y Gl u Val As n Val Ly s
                    930                           935                           940
              Ar g Pr o Met Ly s As p Gl u Thr Hi s Phe Gl u Val Val Gl u Ser Gl y Ar g
              945                           950                           955                           960
              Ty r I l e I l e Leu Leu Leu Gl y Ly s Al a Leu Ser Val Val Tr p As p Ar g
                                      965                           970                           975
              Hi s Leu Ser I l e Ser Val Val Leu Ly s Gl n Thr Ty r Gl n Gl u Ly s Val
                                                                    Page 489

                                                                    97047_1
<removed-date>
                                 980                          985                          990
              Cy s Gl y Leu Cy s Gl y As n Phe As p            Gl y I l e Gl n As n As n     As p Leu Thr
                           995                         1000                          1005
<removed-apn>
              Ser Ser       As n Leu Gl n Val Gl u       Gl u As p Pr o Val As p       Phe Gl y As n
                   1010                         1015                            1020
              Ser Tr p      Ly s Val Ser Ser Gl n        Cy s Al a As p Thr Ar g       Ly s Val Pr o
                   1025                         1030                            1035
              Leu As p      Ser Ser Pr o Al a Thr        Cy s Hi s As n As n I l e     Met Ly s Gl n
                   1040                         1045                            1050
              Thr Met       Val As p Ser Ser Cy s        Ar g I l e Leu Thr Ser        As p Val Phe
                   1055                         1060                            1065
              Gl n As p     Cy s As n Ly s Leu Val       As p Pr o Gl u Pr o Ty r      Leu As p Val
                   1070                         1075                            1080
              Cy s I l e    Ty r As p Thr Cy s Ser       Cy s Gl u Ser I l e Gl y      As p Cy s Al a
                   1085                         1090                            1095
              Cy s Phe      Cy s As p Thr I l e Al a     Al a Ty r Al a Hi s Val       Cy s Al a Gl n
                   1100                         1105                            1110
                                                                    Page 490

                                                              97047_1
<removed-date>
              Hi s Gl y   Ly s Val Val Thr Tr p       Ar g Thr Al a Thr Leu      Cy s Pr o Gl n
                   1115                        1120                       1125
              Ser Cy s    Gl u Gl u Ar g As n Leu     Ar g Gl u As n Gl y Ty r   Gl u Cy s Gl u
                   1130                        1135                       1140
<removed-apn>
              Tr p Ar g   Ty r As n Ser Cy s Al a     Pr o Al a Cy s Gl n Val    Thr Cy s Gl n
                   1145                        1150                       1155
              Hi s Pr o   Gl u Pr o Leu Al a Cy s     Pr o Val Gl n Cy s Val     Gl u Gl y Cy s
                   1160                        1165                       1170
              Hi s Al a   Hi s Cy s Pr o Pr o Gl y    Ly s I l e Leu As p Gl u   Leu Leu Gl n
                   1175                        1180                       1185
              Thr Cy s    Val As p Pr o Gl u As p     Cy s Pr o Val Cy s Gl u    Val Al a Gl y
                   1190                        1195                       1200
              Ar g Ar g   Phe Al a Ser Gl y Ly s      Ly s Val Thr Leu As n      Pr o Ser As p
                   1205                        1210                       1215
              Pr o Gl u   Hi s Cy s Gl n I l e Cy s   Hi s Cy s As p Val Val     As n Leu Thr
                   1220                        1225                       1230
              Cy s Gl u   Al a Cy s Gl n Gl u Pr o
                                                             Page 491

                                                                97047_1
<removed-date>
                   1235                          1240
              <210>     124
              <211>     477
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
<removed-apn>
              <220>
              <223>     VWF- D' D3
              <400>     124
              Ser Leu Ser Cy s Ar g Pr o Pr o Met Val Ly s Leu Val Cy s Pr o Al a As p
              1                      5                          10                       15
              As n Leu Ar g Al a Gl u Gl y Leu Gl u Cy s Thr Ly s Thr Cy s Gl n As n Ty r
                               20                          25                       30
              As p Leu Gl u Cy s Met Ser Met Gl y Cy s Val Ser Gl y Cy s Leu Cy s Pr o
                          35                          40                       45
              Pr o Gl y Met Val Ar g Hi s Gl u As n Ar g Cy s Val Al a Leu Gl u Ar g Cy s
                   50                           55                        60
              Pr o Cy s Phe Hi s Gl n Gl y Ly s Gl u Ty r Al a Pr o Gl y Gl u Thr Val Ly s
              65                          70                         75                       80
              I l e Gl y Cy s As n Thr Cy s Val Cy s Ar g As p Ar g Ly s Tr p As n Cy s Thr
                                                                Page 492

                                                                     97047_1
<removed-date>
                                      85                            90                            95
              As p Hi s Val Cy s As p Al a Thr Cy s Ser Thr I l e Gl y Met Al a Hi s Ty r
                                100                           105                           110
<removed-apn>
              Leu Thr Phe As p Gl y Leu Ly s Ty r Leu Phe Pr o Gl y Gl u Cy s Gl n Ty r
                          115                           120                           125
              Val Leu Val Gl n As p Ty r Cy s Gl y Ser As n Pr o Gl y Thr Phe Ar g I l e
                    130                           135                           140
              Leu Val Gl y As n Ly s Gl y Cy s Ser Hi s Pr o Ser Val Ly s Cy s Ly s Ly s
              145                           150                           155                           160
              Ar g Val Thr I l e Leu Val Gl u Gl y Gl y Gl u I l e Gl u Leu Phe As p Gl y
                                      165                           170                           175
              Gl u Val As n Val Ly s Ar g Pr o Met Ly s As p Gl u Thr Hi s Phe Gl u Val
                                180                           185                           190
              Val Gl u Ser Gl y Ar g Ty r I l e I l e Leu Leu Leu Gl y Ly s Al a Leu Ser
                          195                           200                           205
              Val Val Tr p As p Ar g Hi s Leu Ser I l e Ser Val Val Leu Ly s Gl n Thr
                    210                           215                           220
                                                                    Page 493

                                                                    97047_1
<removed-date>
              Ty r Gl n Gl u Ly s Val Cy s Gl y Leu Cy s Gl y As n Phe As p Gl y I l e Gl n
              225                           230                           235                           240
              As n As n As p Leu Thr Ser Ser As n Leu Gl n Val Gl u Gl u As p Pr o Val
                                      245                           250                           255
<removed-apn>
              As p Phe Gl y As n Ser Tr p Ly s Val Ser Ser Gl n Cy s Al a As p Thr Ar g
                                260                           265                           270
              Ly s Val Pr o Leu As p Ser Ser Pr o Al a Thr Cy s Hi s As n As n I l e Met
                          275                           280                           285
              Ly s Gl n Thr Met Val As p Ser Ser Cy s Ar g I l e Leu Thr Ser As p Val
                    290                           295                           300
              Phe Gl n As p Cy s As n Ly s Leu Val As p Pr o Gl u Pr o Ty r Leu As p Val
              305                           310                           315                           320
              Cy s I l e Ty r As p Thr Cy s Ser Cy s Gl u Ser I l e Gl y As p Cy s Al a Cy s
                                      325                           330                           335
              Phe Cy s As p Thr I l e Al a Al a Ty r Al a Hi s Val Cy s Al a Gl n Hi s Gl y
                                340                           345                           350
              Ly s Val Val Thr Tr p Ar g Thr Al a Thr Leu Cy s Pr o Gl n Ser Cy s Gl u
                                                                    Page 494

                                                                     97047_1
<removed-date>
                           355                           360                           365
              Gl u Ar g As n Leu Ar g Gl u As n Gl y Ty r Gl u Cy s Gl u Tr p Ar g Ty r As n
                    370                            375                           380
<removed-apn>
              Ser Cy s Al a Pr o Al a Cy s Gl n Val Thr Cy s Gl n Hi s Pr o Gl u Pr o Leu
              385                            390                           395                           400
              Al a Cy s Pr o Val Gl n Cy s Val Gl u Gl y Cy s Hi s Al a Hi s Cy s Pr o Pr o
                                       405                           410                           415
              Gl y Ly s I l e Leu As p Gl u Leu Leu Gl n Thr Cy s Val As p Pr o Gl u As p
                                 420                           425                           430
              Cy s Pr o Val Cy s Gl u Val Al a Gl y Ar g Ar g Phe Al a Ser Gl y Ly s Ly s
                           435                           440                           445
              Val Thr Leu As n Pr o Ser As p Pr o Gl u Hi s Cy s Gl n I l e Cy s Hi s Cy s
                    450                            455                           460
              As p Val Val As n Leu Thr Cy s Gl u Al a Cy s Gl n Gl u Pr o
              465                            470                           475
              <210>       125
              <211>       5055
              <212>       DNA
                                                                     Page 495

                                                                       97047_1
<removed-date>
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     pSYNFVI I I 010
              <400>     125
              at gc aaat ag agc t c t c c ac c t gc t t c t t t c t gt gc c t t t t gc gat t c t g c t t t agt gc c    60
<removed-apn>
              ac c agaagat ac t ac c t ggg t gc agt ggaa c t gt c at ggg ac t at at gc a aagt gat c t c               120
              ggt gagc t gc c t gt ggac gc aagat t t c c t c c t agagt gc c aaaat c t t t t c c at t c aac            180
              ac c t c agt c g t gt ac aaaaa gac t c t gt t t gt agaat t c a c ggat c ac c t t t t c aac at c         240
              gc t aagc c aa ggc c ac c c t g gat gggt c t g c t aggt c c t a c c at c c aggc t gaggt t t at          300
              gat ac agt gg t c at t ac ac t t aagaac at g gc t t c c c at c c t gt c agt c t t c at gc t gt t        360
              ggt gt at c c t ac t ggaaagc t t c t gaggga gc t gaat at g at gat c agac c agt c aaagg                  420
              gagaaagaag at gat aaagt c t t c c c t ggt ggaagc c at a c at at gt c t g gc aggt c c t g                480
              aaagagaat g gt c c aat ggc c t c t gac c c a c t gt gc c t t a c c t ac t c at a t c t t t c t c at     540
              gt ggac c t gg t aaaagac t t gaat t c aggc c t c at t ggag c c c t ac t agt at gt agagaa                600
              gggagt c t gg c c aaggaaaa gac ac agac c t t gc ac aaat t t at ac t ac t t t t t gc t gt a              660
              t t t gat gaag ggaaaagt t g gc ac t c agaa ac aaagaac t c c t t gat gc a ggat agggat                    720
              gc t gc at c t g c t c gggc c t g gc c t aaaat g c ac ac agt c a at ggt t at gt aaac aggt c t           780
              c t gc c aggt c t gat t ggat g c c ac aggaaa t c agt c t at t ggc at gt gat t ggaat gggc                840
                                                                      Page 496

                                                                    97047_1
<removed-date>
              ac c ac t c c t g aagt gc ac t c aat at t c c t c gaaggt c ac a c at t t c t t gt gaggaac c at        900
              c gc c aggc gt c c t t ggaaat c t c gc c aat a ac t t t c c t t a c t gc t c aaac ac t c t t gat g    960
              gac c t t ggac agt t t c t ac t gt t t t gt c at at c t c t t c c c ac c aac at ga t ggc at ggaa     1020
              gc t t at gt c a aagt agac ag c t gt c c agag gaac c c c aac t ac gaat gaa aaat aat gaa              1080
<removed-apn>
              gaagc ggaag ac t at gat ga t gat c t t ac t gat t c t gaaa t ggat gt ggt c aggt t t gat              1140
              gat gac aac t c t c c t t c c t t t at c c aaat t c gc t c agt t g c c aagaagc a t c c t aaaac t     1200
              t gggt ac at t ac at t gc t gc t gaagaggag gac t gggac t at gc t c c c t t agt c c t c gc c          1260
              c c c gat gac a gaagt t at aa aagt c aat at t t gaac aat g gc c c t c agc g gat t ggt agg            1320
              aagt ac aaaa aagt c c gat t t at ggc at ac ac agat gaaa c c t t t aagac t c gt gaagc t               1380
              at t c agc at g aat c aggaat c t t gggac c t t t ac t t t at g gggaagt t gg agac ac ac t g           1440
              t t gat t at at t t aagaat c a agc aagc aga c c at at aac a t c t ac c c t c a c ggaat c ac t        1500
              gat gt c c gt c c t t t gt at t c aaggagat t a c c aaaaggt g t aaaac at t t gaaggat t t t            1560
              c c aat t c t gc c aggagaaat at t c aaat at aaat ggac ag t gac t gt aga agat gggc c a                1620
              ac t aaat c ag at c c t c ggt g c c t gac c c gc t at t ac t c t a gt t t c gt t aa t at ggagaga     1680
              gat c t agc t t c aggac t c at t ggc c c t c t c c t c at c t gc t ac aaagaat c t gt agat c aa       1740
              agaggaaac c agat aat gt c agac aagagg aat gt c at c c t gt t t t c t gt at t t gat gag               1800
              aac c gaagc t ggt ac c t c ac agagaat at a c aac gc t t t c t c c c c aat c c agc t ggagt g          1860
                                                                    Page 497

                                                                  97047_1
<removed-date>
              c agc t t gagg at c c agagt t c c aagc c t c c aac at c at gc ac agc at c aa t ggc t at gt t         1920
              t t t gat agt t t gc agt t gt c agt t t gt t t g c at gaggt gg c at ac t ggt a c at t c t aagc       1980
              at t ggagc ac agac t gac t t c c t t t c t gt c t t c t t c t c t g gat at ac c t t c aaac ac aaa    2040
              at ggt c t at g aagac ac ac t c ac c c t at t c c c at t c t c ag gagaaac t gt c t t c at gt c g     2100
<removed-apn>
              at ggaaaac c c aggt c t at g gat t c t gggg t gc c ac aac t c agac t t t c g gaac agaggc             2160
              at gac c gc c t t ac t gaaggt t t c t agt t gt gac aagaac a c t ggt gat t a t t ac gaggac            2220
              agt t at gaag at at t t c agc at ac t t gc t g agt aaaaac a at gc c at t ga ac c aagaagc             2280
              t t c t c t c aaa ac c c ac c agt c t t gaaac gc c at c aac ggg aaat aac t c g t ac t ac t c t t     2340
              c agt c agat c aagaggaaat t gac t at gat gat ac c at at c agt t gaaat gaagaaggaa                     2400
              gat t t t gac a t t t at gat ga ggat gaaaat c agagc c c c c gc agc t t t c a aaagaaaac a             2460
              c gac ac t at t t t at t gc t gc agt ggagagg c t c t gggat t at gggat gag t agc t c c c c a          2520
              c at gt t c t aa gaaac agggc t c agagt ggc agt gt c c c t c agt t c aagaa agt t gt t t t c           2580
              c aggaat t t a c t gat ggc t c c t t t ac t c ag c c c t t at ac c gt ggagaac t aaat gaac at         2640
              t t gggac t c c t ggggc c at a t at aagagc a gaagt t gaag at aat at c at ggt aac t t t c             2700
              agaaat c agg c c t c t c gt c c c t at t c c t t c t at t c t agc c t t at t t c t t a t gaggaagat   2760
              c agaggc aag gagc agaac c t agaaaaaac t t t gt c aagc c t aat gaaac c aaaac t t ac                   2820
              t t t t ggaaag t gc aac at c a t at ggc ac c c ac t aaagat g agt t t gac t g c aaagc c t gg          2880
                                                                    Page 498

                                                                   97047_1
<removed-date>
              gc t t at t t c t c t gat gt t ga c c t ggaaaaa gat gt gc ac t c aggc c t gat t ggac c c c t t        2940
              c t ggt c t gc c ac ac t aac ac ac t gaac c c t gc t c at ggga gac aagt gac agt ac aggaa              3000
              t t t gc t c t gt t t t t c ac c at c t t t gat gag ac c aaaagc t ggt ac t t c ac t gaaaat at g       3060
              gaaagaaac t gc agggc t c c c t gc aat at c c agat ggaag at c c c ac t t t t aaagagaat                 3120
<removed-apn>
              t at c gc t t c c at gc aat c aa t ggc t ac at a at ggat ac ac t ac c t ggc t t agt aat ggc t         3180
              c aggat c aaa ggat t c gat g gt at c t gc t c agc at gggc a gc aat gaaaa c at c c at t c t            3240
              at t c at t t c a gt ggac at gt gt t c ac t gt a c gaaaaaaag aggagt at aa aat ggc ac t g              3300
              t ac aat c t c t at c c aggt gt t t t t gagac a gt ggaaat gt t ac c at c c aa agc t ggaat t           3360
              t ggc gggt gg aat gc c t t at t ggc gagc at c t ac at gc t g ggat gagc ac ac t t t t t c t g          3420
              gt gt ac agc a at aagt gt c a gac t c c c c t g ggaat ggc t t c t ggac ac at t agagat t t t           3480
              c agat t ac ag c t t c aggac a at at ggac ag t gggc c c c aa agc t ggc c ag ac t t c at t at          3540
              t c c ggat c aa t c aat gc c t g gagc ac c aag gagc c c t t t t c t t ggat c aa ggt ggat c t g        3600
              t t ggc ac c aa t gat t at t c a c ggc at c aag ac c c agggt g c c c gt c agaa gt t c t c c agc       3660
              c t c t ac at c t c t c agt t t at c at c at gt at agt c t t gat g ggaagaagt g gc agac t t at         3720
              c gaggaaat t c c ac t ggaac c t t aat ggt c t t c t t t ggc a at gt ggat t c at c t gggat a           3780
              aaac ac aat a t t t t t aac c c t c c aat t at t gc t c gat ac a t c c gt t t gc a c c c aac t c at   3840
              t at agc at t c gc agc ac t c t t c gc at ggag t t gat gggc t gt gat t t aaa t agt t gc agc           3900
                                                                     Page 499

                                                              97047_1
<removed-date>
              at gc c at t gg gaat ggagag t aaagc aat a t c agat gc ac agat t ac t gc t t c at c c t ac             3960
              t t t ac c aat a t gt t t gc c ac c t ggt c t c c t t c aaaagc t c gac t t c ac c t c c aagggagg      4020
              agt aat gc c t ggagac c t c a ggt gaat aat c c aaaagagt ggc t gc aagt ggac t t c c ag                 4080
              aagac aat ga aagt c ac agg agt aac t ac t c agggagt aa aat c t c t gc t t ac c agc at g               4140
<removed-apn>
              t at gt gaagg agt t c c t c at c t c c agc agt c aagat ggc c at c agt ggac t c t c t t t t t t        4200
              c agaat ggc a aagt aaaggt t t t t c aggga aat c aagac t c c t t c ac ac c t gt ggt gaac               4260
              t c t c t agac c c ac c gt t ac t gac t c gc t ac c t t c gaat t c ac c c c c agag t t gggt gc ac     4320
              c agat t gc c c t gaggat gga ggt t c t gggc t gc gaggc ac aggac c t c t a c gac aaaac t               4380
              c ac ac at gc c c ac c gt gc c c agc t c c agaa c t c c t gggc g gac c gt c agt c t t c c t c t t c   4440
              c c c c c aaaac c c aaggac ac c c t c at gat c t c c c ggac c c c t gaggt c ac at gc gt ggt g         4500
              gt ggac gt ga gc c ac gaaga c c c t gaggt c aagt t c aac t ggt ac gt gga c ggc gt ggag                4560
              gt gc at aat g c c aagac aaa gc c gc gggag gagc agt ac a ac agc ac gt a c c gt gt ggt c               4620
              agc gt c c t c a c c gt c c t gc a c c aggac t gg c t gaat ggc a aggagt ac aa gt gc aaggt c           4680
              t c c aac aaag c c c t c c c agc c c c c at c gag aaaac c at c t c c aaagc c aa agggc agc c c         4740
              c gagaac c ac aggt gt ac ac c c t gc c c c c a t c c c gggat g agc t gac c aa gaac c aggt c           4800
              agc c t gac c t gc c t ggt c aa aggc t t c t at c c c agc gac a t c gc c gt gga gt gggagagc           4860
              aat gggc agc c ggagaac aa c t ac aagac c ac gc c t c c c g t gt t ggac t c c gac ggc t c c            4920
                                                                     Page 500

                                                                   97047_1
<removed-date>
              t t c t t c c t c t ac agc aagc t c ac c gt ggac aagagc aggt ggc agc aggg gaac gt c t t c           4980
              t c at gc t c c g t gat gc at ga ggc t c t gc ac aac c ac t ac a c gc agaagag c c t c t c c c t g   5040
              t c t c c gggt a aat ga                                                                             5055
<removed-apn>
              <210>     126
              <211>     1684
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     pSYNFVI I I 010
              <400>     126
              Met Gl n I l e Gl u Leu Ser Thr Cy s Phe Phe Leu Cy s Leu Leu Ar g Phe
              1                         5                          10                            15
              Cy s Phe Ser Al a Thr Ar g Ar g Ty r Ty r Leu Gl y Al a Val Gl u Leu Ser
                               20                            25                            30
              Tr p As p Ty r Met Gl n Ser As p Leu Gl y Gl u Leu Pr o Val As p Al a Ar g
                         35                            40                            45
              Phe Pr o Pr o Ar g Val Pr o Ly s Ser Phe Pr o Phe As n Thr Ser Val Val
                   50                            55                            60
              Ty r Ly s Ly s Thr Leu Phe Val Gl u Phe Thr As p Hi s Leu Phe As n I l e
                                                                   Page 501

                                                                    97047_1
<removed-date>
              65                            70                         75                               80
              Al a Ly s Pr o Ar g Pr o Pr o Tr p Met Gl y Leu Leu Gl y Pr o Thr I l e Gl n
                                      85                            90                            95
<removed-apn>
              Al a Gl u Val Ty r As p Thr Val Val I l e Thr Leu Ly s As n Met Al a Ser
                                100                           105                           110
              Hi s Pr o Val Ser Leu Hi s Al a Val Gl y Val Ser Ty r Tr p Ly s Al a Ser
                          115                           120                           125
              Gl u Gl y Al a Gl u Ty r As p As p Gl n Thr Ser Gl n Ar g Gl u Ly s Gl u As p
                    130                           135                           140
              As p Ly s Val Phe Pr o Gl y Gl y Ser Hi s Thr Ty r Val Tr p Gl n Val Leu
              145                           150                           155                           160
              Ly s Gl u As n Gl y Pr o Met Al a Ser As p Pr o Leu Cy s Leu Thr Ty r Ser
                                      165                           170                           175
              Ty r Leu Ser Hi s Val As p Leu Val Ly s As p Leu As n Ser Gl y Leu I l e
                                180                           185                           190
              Gl y Al a Leu Leu Val Cy s Ar g Gl u Gl y Ser Leu Al a Ly s Gl u Ly s Thr
                          195                           200                           205
                                                                    Page 502

                                                                    97047_1
<removed-date>
              Gl n Thr Leu Hi s Ly s Phe I l e Leu Leu Phe Al a Val Phe As p Gl u Gl y
                    210                           215                           220
              Ly s Ser Tr p Hi s Ser Gl u Thr Ly s As n Ser Leu Met Gl n As p Ar g As p
              225                           230                           235                           240
<removed-apn>
              Al a Al a Ser Al a Ar g Al a Tr p Pr o Ly s Met Hi s Thr Val As n Gl y Ty r
                                      245                           250                           255
              Val As n Ar g Ser Leu Pr o Gl y Leu I l e Gl y Cy s Hi s Ar g Ly s Ser Val
                                260                           265                           270
              Ty r Tr p Hi s Val I l e Gl y Met Gl y Thr Thr Pr o Gl u Val Hi s Ser I l e
                          275                           280                           285
              Phe Leu Gl u Gl y Hi s Thr Phe Leu Val Ar g As n Hi s Ar g Gl n Al a Ser
                    290                           295                           300
              Leu Gl u I l e Ser Pr o I l e Thr Phe Leu Thr Al a Gl n Thr Leu Leu Met
              305                           310                           315                           320
              As p Leu Gl y Gl n Phe Leu Leu Phe Cy s Hi s I l e Ser Ser Hi s Gl n Hi s
                                      325                           330                           335
              As p Gl y Met Gl u Al a Ty r Val Ly s Val As p Ser Cy s Pr o Gl u Gl u Pr o
                                                                    Page 503

                                                                    97047_1
<removed-date>
                                340                           345                           350
              Gl n Leu Ar g Met Ly s As n As n Gl u Gl u Al a Gl u As p Ty r As p As p As p
                          355                           360                           365
<removed-apn>
              Leu Thr As p Ser Gl u Met As p Val Val Ar g Phe As p As p As p As n Ser
                    370                           375                           380
              Pr o Ser Phe I l e Gl n I l e Ar g Ser Val Al a Ly s Ly s Hi s Pr o Ly s Thr
              385                           390                           395                           400
              Tr p Val Hi s Ty r I l e Al a Al a Gl u Gl u Gl u As p Tr p As p Ty r Al a Pr o
                                      405                           410                           415
              Leu Val Leu Al a Pr o As p As p Ar g Ser Ty r Ly s Ser Gl n Ty r Leu As n
                                420                           425                           430
              As n Gl y Pr o Gl n Ar g I l e Gl y Ar g Ly s Ty r Ly s Ly s Val Ar g Phe Met
                          435                           440                           445
              Al a Ty r Thr As p Gl u Thr Phe Ly s Thr Ar g Gl u Al a I l e Gl n Hi s Gl u
                    450                           455                           460
              Ser Gl y I l e Leu Gl y Pr o Leu Leu Ty r Gl y Gl u Val Gl y As p Thr Leu
              465                           470                           475                           480
                                                                    Page 504

                                                                    97047_1
<removed-date>
              Leu I l e I l e Phe Ly s As n Gl n Al a Ser Ar g Pr o Ty r As n I l e Ty r Pr o
                                      485                           490                           495
              Hi s Gl y I l e Thr As p Val Ar g Pr o Leu Ty r Ser Ar g Ar g Leu Pr o Ly s
                                500                           505                           510
<removed-apn>
              Gl y Val Ly s Hi s Leu Ly s As p Phe Pr o I l e Leu Pr o Gl y Gl u I l e Phe
                          515                           520                           525
              Ly s Ty r Ly s Tr p Thr Val Thr Val Gl u As p Gl y Pr o Thr Ly s Ser As p
                    530                           535                           540
              Pr o Ar g Cy s Leu Thr Ar g Ty r Ty r Ser Ser Phe Val As n Met Gl u Ar g
              545                           550                           555                           560
              As p Leu Al a Ser Gl y Leu I l e Gl y Pr o Leu Leu I l e Cy s Ty r Ly s Gl u
                                      565                           570                           575
              Ser Val As p Gl n Ar g Gl y As n Gl n I l e Met Ser As p Ly s Ar g As n Val
                                580                           585                           590
              I l e Leu Phe Ser Val Phe As p Gl u As n Ar g Ser Tr p Ty r Leu Thr Gl u
                          595                           600                           605
              As n I l e Gl n Ar g Phe Leu Pr o As n Pr o Al a Gl y Val Gl n Leu Gl u As p
                                                                    Page 505

                                                                    97047_1
<removed-date>
                    610                           615                           620
              Pr o Gl u Phe Gl n Al a Ser As n I l e Met Hi s Ser I l e As n Gl y Ty r Val
              625                           630                           635                           640
<removed-apn>
              Phe As p Ser Leu Gl n Leu Ser Val Cy s Leu Hi s Gl u Val Al a Ty r Tr p
                                      645                           650                           655
              Ty r I l e Leu Ser I l e Gl y Al a Gl n Thr As p Phe Leu Ser Val Phe Phe
                                660                           665                           670
              Ser Gl y Ty r Thr Phe Ly s Hi s Ly s Met Val Ty r Gl u As p Thr Leu Thr
                          675                           680                           685
              Leu Phe Pr o Phe Ser Gl y Gl u Thr Val Phe Met Ser Met Gl u As n Pr o
                    690                           695                           700
              Gl y Leu Tr p I l e Leu Gl y Cy s Hi s As n Ser As p Phe Ar g As n Ar g Gl y
              705                           710                           715                           720
              Met Thr Al a Leu Leu Ly s Val Ser Ser Cy s As p Ly s As n Thr Gl y As p
                                      725                           730                           735
              Ty r Ty r Gl u As p Ser Ty r Gl u As p I l e Ser Al a Ty r Leu Leu Ser Ly s
                                740                           745                           750
                                                                    Page 506

                                                                    97047_1
<removed-date>
              As n As n Al a I l e Gl u Pr o Ar g Ser Phe Ser Gl n As n Pr o Pr o Val Leu
                          755                           760                           765
              Ly s Ar g Hi s Gl n Ar g Gl u I l e Thr Ar g Thr Thr Leu Gl n Ser As p Gl n
                    770                           775                           780
<removed-apn>
              Gl u Gl u I l e As p Ty r As p As p Thr I l e Ser Val Gl u Met Ly s Ly s Gl u
              785                           790                           795                           800
              As p Phe As p I l e Ty r As p Gl u As p Gl u As n Gl n Ser Pr o Ar g Ser Phe
                                      805                           810                           815
              Gl n Ly s Ly s Thr Ar g Hi s Ty r Phe I l e Al a Al a Val Gl u Ar g Leu Tr p
                                820                           825                           830
              As p Ty r Gl y Met Ser Ser Ser Pr o Hi s Val Leu Ar g As n Ar g Al a Gl n
                          835                           840                           845
              Ser Gl y Ser Val Pr o Gl n Phe Ly s Ly s Val Val Phe Gl n Gl u Phe Thr
                    850                           855                           860
              As p Gl y Ser Phe Thr Gl n Pr o Leu Ty r Ar g Gl y Gl u Leu As n Gl u Hi s
              865                           870                           875                           880
              Leu Gl y Leu Leu Gl y Pr o Ty r I l e Ar g Al a Gl u Val Gl u As p As n I l e
                                                                    Page 507

                                                                       97047_1
<removed-date>
                                       885                            890                            895
              Met Val Thr Phe Ar g As n Gl n Al a Ser Ar g Pr o Ty r Ser Phe Ty r Ser
                                 900                            905                            910
<removed-apn>
              Ser Leu I l e Ser Ty r Gl u Gl u As p Gl n Ar g Gl n Gl y Al a Gl u Pr o Ar g
                           915                           920                            925
              Ly s As n Phe Val Ly s Pr o As n Gl u Thr Ly s Thr Ty r Phe Tr p Ly s Val
                    930                            935                            940
              Gl n Hi s Hi s Met Al a Pr o Thr Ly s As p Gl u Phe As p Cy s Ly s Al a Tr p
              945                            950                            955                            960
              Al a Ty r Phe Ser As p Val As p Leu Gl u Ly s As p Val Hi s Ser Gl y Leu
                                       965                            970                            975
              I l e Gl y Pr o Leu Leu Val Cy s Hi s Thr As n Thr Leu As n Pr o Al a Hi s
                                 980                            985                            990
              Gl y Ar g Gl n Val Thr Val Gl n Gl u               Phe Al a Leu Phe Phe            Thr I l e Phe
                           995                           1000                            1005
              As p Gl u     Thr Ly s Ser Tr p Ty r         Phe Thr Gl u As n Met              Gl u Ar g As n
                    1010                            1015                            1020
                                                                      Page 508

                                                               97047_1
<removed-date>
              Cy s Ar g   Al a Pr o Cy s As n I l e   Gl n Met Gl u As p Pr o      Thr Phe Ly s
                   1025                        1030                        1035
              Gl u As n   Ty r Ar g Phe Hi s Al a     I l e As n Gl y Ty r I l e   Met As p Thr
                   1040                        1045                        1050
<removed-apn>
              Leu Pr o    Gl y Leu Val Met Al a       Gl n As p Gl n Ar g I l e    Ar g Tr p Ty r
                   1055                        1060                        1065
              Leu Leu     Ser Met Gl y Ser As n       Gl u As n I l e Hi s Ser     I l e Hi s Phe
                   1070                        1075                        1080
              Ser Gl y    Hi s Val Phe Thr Val        Ar g Ly s Ly s Gl u Gl u     Ty r Ly s Met
                   1085                        1090                        1095
              Al a Leu    Ty r As n Leu Ty r Pr o     Gl y Val Phe Gl u Thr        Val Gl u Met
                   1100                        1105                        1110
              Leu Pr o    Ser Ly s Al a Gl y I l e    Tr p Ar g Val Gl u Cy s      Leu I l e Gl y
                   1115                        1120                        1125
              Gl u Hi s   Leu Hi s Al a Gl y Met      Ser Thr Leu Phe Leu          Val Ty r Ser
                   1130                        1135                        1140
              As n Ly s   Cy s Gl n Thr Pr o Leu      Gl y Met Al a Ser Gl y       Hi s I l e Ar g
                                                              Page 509

                                                               97047_1
<removed-date>
                   1145                         1150                        1155
              As p Phe    Gl n I l e Thr Al a Ser      Gl y Gl n Ty r Gl y Gl n    Tr p Al a Pr o
                   1160                         1165                        1170
<removed-apn>
              Ly s Leu    Al a Ar g Leu Hi s Ty r      Ser Gl y Ser I l e As n     Al a Tr p Ser
                   1175                         1180                        1185
              Thr Ly s    Gl u Pr o Phe Ser Tr p       I l e Ly s Val As p Leu     Leu Al a Pr o
                   1190                         1195                        1200
              Met I l e   I l e Hi s Gl y I l e Ly s   Thr Gl n Gl y Al a Ar g     Gl n Ly s Phe
                   1205                         1210                        1215
              Ser Ser     Leu Ty r I l e Ser Gl n      Phe I l e I l e Met Ty r    Ser Leu As p
                   1220                         1225                        1230
              Gl y Ly s   Ly s Tr p Gl n Thr Ty r      Ar g Gl y As n Ser Thr      Gl y Thr Leu
                   1235                         1240                        1245
              Met Val     Phe Phe Gl y As n Val        As p Ser Ser Gl y I l e     Ly s Hi s As n
                   1250                         1255                        1260
              I l e Phe   As n Pr o Pr o I l e I l e   Al a Ar g Ty r I l e Ar g   Leu Hi s Pr o
                   1265                         1270                        1275
                                                               Page 510

                                                              97047_1
<removed-date>
              Thr Hi s     Ty r Ser I l e Ar g Ser    Thr Leu Ar g Met Gl u      Leu Met Gl y
                   1280                        1285                       1290
              Cy s As p    Leu As n Ser Cy s Ser      Met Pr o Leu Gl y Met      Gl u Ser Ly s
                   1295                        1300                       1305
<removed-apn>
              Al a I l e   Ser As p Al a Gl n I l e   Thr Al a Ser Ser Ty r      Phe Thr As n
                   1310                        1315                       1320
              Met Phe      Al a Thr Tr p Ser Pr o     Ser Ly s Al a Ar g Leu     Hi s Leu Gl n
                   1325                        1330                       1335
              Gl y Ar g    Ser As n Al a Tr p Ar g    Pr o Gl n Val As n As n    Pr o Ly s Gl u
                   1340                        1345                       1350
              Tr p Leu     Gl n Val As p Phe Gl n     Ly s Thr Met Ly s Val      Thr Gl y Val
                   1355                        1360                       1365
              Thr Thr      Gl n Gl y Val Ly s Ser     Leu Leu Thr Ser Met        Ty r Val Ly s
                   1370                        1375                       1380
              Gl u Phe     Leu I l e Ser Ser Ser      Gl n As p Gl y Hi s Gl n   Tr p Thr Leu
                   1385                        1390                       1395
              Phe Phe      Gl n As n Gl y Ly s Val    Ly s Val Phe Gl n Gl y     As n Gl n As p
                                                             Page 511

                                                             97047_1
<removed-date>
                   1400                       1405                       1410
              Ser Phe     Thr Pr o Val Val As n      Ser Leu As p Pr o Pr o     Leu Leu Thr
                   1415                       1420                       1425
<removed-apn>
              Ar g Ty r   Leu Ar g I l e Hi s Pr o   Gl n Ser Tr p Val Hi s     Gl n I l e Al a
                   1430                       1435                       1440
              Leu Ar g    Met Gl u Val Leu Gl y      Cy s Gl u Al a Gl n As p   Leu Ty r As p
                   1445                       1450                       1455
              Ly s Thr    Hi s Thr Cy s Pr o Pr o    Cy s Pr o Al a Pr o Gl u   Leu Leu Gl y
                   1460                       1465                       1470
              Gl y Pr o   Ser Val Phe Leu Phe        Pr o Pr o Ly s Pr o Ly s   As p Thr Leu
                   1475                       1480                       1485
              Met I l e   Ser Ar g Thr Pr o Gl u     Val Thr Cy s Val Val       Val As p Val
                   1490                       1495                       1500
              Ser Hi s    Gl u As p Pr o Gl u Val    Ly s Phe As n Tr p Ty r    Val As p Gl y
                   1505                       1510                       1515
              Val Gl u    Val Hi s As n Al a Ly s    Thr Ly s Pr o Ar g Gl u    Gl u Gl n Ty r
                   1520                       1525                       1530
                                                            Page 512

                                                              97047_1
<removed-date>
              As n Ser    Thr Ty r Ar g Val Val       Ser Val Leu Thr Val        Leu Hi s Gl n
                   1535                        1540                       1545
              As p Tr p   Leu As n Gl y Ly s Gl u     Ty r Ly s Cy s Ly s Val    Ser As n Ly s
                   1550                        1555                       1560
<removed-apn>
              Al a Leu    Pr o Al a Pr o I l e Gl u   Ly s Thr I l e Ser Ly s    Al a Ly s Gl y
                   1565                        1570                       1575
              Gl n Pr o   Ar g Gl u Pr o Gl n Val     Ty r Thr Leu Pr o Pr o     Ser Ar g As p
                   1580                        1585                       1590
              Gl u Leu    Thr Ly s As n Gl n Val      Ser Leu Thr Cy s Leu       Val Ly s Gl y
                   1595                        1600                       1605
              Phe Ty r    Pr o Ser As p I l e Al a    Val Gl u Tr p Gl u Ser     As n Gl y Gl n
                   1610                        1615                       1620
              Pr o Gl u   As n As n Ty r Ly s Thr     Thr Pr o Pr o Val Leu      As p Ser As p
                   1625                        1630                       1635
              Gl y Ser    Phe Phe Leu Ty r Ser        Ly s Leu Thr Val As p      Ly s Ser Ar g
                   1640                        1645                       1650
              Tr p Gl n   Gl n Gl y As n Val Phe      Ser Cy s Ser Val Met       Hi s Gl u Al a
                                                             Page 513

                                                                    97047_1
<removed-date>
                     1655                         1660                         1665
              Leu Hi s        As n Hi s Ty r Thr Gl n        Ly s Ser Leu Ser Leu     Ser Pr o Gl y
                     1670                         1675                         1680
<removed-apn>
              Ly s
              <210>      127
              <211>      78
              <212>      PRT
              <213>      Ar t i f i c i al Sequenc e
              <220>
              <223>      AE72 XTEN
              <400>      127
              Gl y Al a Pr o Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser
              1                       5                             10                      15
              Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a
                                 20                            25                      30
              Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u
                            35                          40                       45
              Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr
                                                                    Page 514

                                                                97047_1
<removed-date>
                   50                           55                        60
              Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Al a Ser Ser
              65                          70                         75
<removed-apn>
              <210>     128
              <211>     144
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     AE144_2A
              <400>     128
              Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Pr o Al a Gl y
              1                     5                           10                       15
              Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y
                               20                          25                       30
              Ser Al a Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y
                         35                           40                       45
              Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u
                   50                           55                        60
              Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
                                                                Page 515

                                                                   97047_1
<removed-date>
              65                           70                         75                            80
              Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y
                                      85                           90                          95
<removed-apn>
              Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr Gl u
                                100                          105                         110
              Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
                          115                          120                         125
              Ser Gl y Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y
                   130                           135                         140
              <210>      129
              <211>      144
              <212>      PRT
              <213>      Ar t i f i c i al Sequenc e
              <220>
              <223>      AE144_3B
              <400>      129
              Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Gl u Ser
              1                       5                            10                          15
              Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser
                                                                   Page 516

                                                                  97047_1
<removed-date>
                                20                          25                          30
              Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y
                          35                          40                          45
<removed-apn>
              Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr Gl u
                   50                           55                          60
              Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y
              65                           70                          75                          80
              Ser Al a Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y
                                      85                          90                          95
              Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr Gl u
                                100                         105                         110
              Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser
                          115                         120                         125
              Thr Gl u Gl u Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y
                   130                          135                         140
              <210>      130
              <211>      144
              <212>      PRT
                                                                  Page 517

                                                                 97047_1
<removed-date>
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     AE144_4A
              <400>     130
<removed-apn>
              Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a
              1                      5                           10                        15
              Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
                               20                          25                        30
              Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y
                         35                           40                        45
              Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u
                   50                           55                         60
              Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
              65                          70                          75                        80
              Ser Gl y Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y
                                     85                          90                        95
              Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Ser Pr o Al a Gl y
                               100                         105                       110
                                                                 Page 518

                                                                 97047_1
<removed-date>
              Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
                         115                          120                        125
              Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y
                  130                           135                        140
<removed-apn>
              <210>     131
              <211>     144
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     AE144_5A
              <400>     131
              Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a
              1                     5                            10                         15
              Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
                               20                           25                         30
              Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y
                         35                           40                         45
              Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u
                  50                            55                         60
                                                                 Page 519

                                                                   97047_1
<removed-date>
              Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser
              65                           70                           75                          80
              Thr Gl u Gl u Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y
                                      85                           90                          95
<removed-apn>
              Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser
                                100                          105                         110
              Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser
                          115                          120                         125
              Thr Gl u Gl u Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y
                   130                           135                         140
              <210>      132
              <211>      144
              <212>      PRT
              <213>      Ar t i f i c i al Sequenc e
              <220>
              <223>      AE144_6B
              <400>      132
              Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser
              1                       5                            10                          15
                                                                   Page 520

                                                                  97047_1
<removed-date>
              Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
                                20                          25                          30
              Ser Gl y Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y
                          35                          40                          45
<removed-apn>
              Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Ser Gl u Pr o Al a
                   50                           55                          60
              Thr Ser Gl y Ser Gl u Thr Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser
              65                           70                          75                          80
              Thr Gl u Gl u Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y
                                      85                          90                          95
              Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Gl u Pr o Al a
                                100                         105                         110
              Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u
                          115                         120                         125
              Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y
                   130                          135                         140
              <210>      133
                                                                  Page 521

                                                                97047_1
<removed-date>
              <211>     144
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     AG144_A
<removed-apn>
              <400>     133
              Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Ser Ser Pr o
              1                     5                           10                       15
              Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr
                               20                          25                       30
              Gl y Thr Gl y Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o
                         35                           40                       45
              Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Pr o
                   50                           55                        60
              Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
              65                          70                         75                       80
              Thr Gl y Ser Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o
                                    85                          90                       95
              Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Thr Pr o Gl y
                                                                Page 522

                                                                  97047_1
<removed-date>
                               100                          105                         110
              Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
                         115                          120                         125
<removed-apn>
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                  130                           135                         140
              <210>     134
              <211>     144
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     AG144_B
              <400>     134
              Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Ser Ser Thr
              1                      5                            10                          15
              Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
                               20                           25                          30
              Thr Gl y Ser Pr o Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o
                         35                           40                          45
              Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Pr o
                                                                  Page 523

                                                                   97047_1
<removed-date>
                   50                            55                          60
              Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr
              65                           70                           75                          80
<removed-apn>
              Gl y Thr Gl y Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o
                                      85                           90                          95
              Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Al a Ser Pr o
                                100                          105                         110
              Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
                          115                          120                         125
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                   130                           135                         140
              <210>      135
              <211>      144
              <212>      PRT
              <213>      Ar t i f i c i al Sequenc e
              <220>
              <223>      AG144_C
              <400>      135
              Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Al a Ser Pr o
                                                                   Page 524

                                                                  97047_1
<removed-date>
              1                      5                           10                           15
              Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
                               20                          25                           30
<removed-apn>
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                         35                          40                           45
              Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Thr Pr o Gl y
                   50                          55                           60
              Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
              65                          70                          75                           80
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                                     85                          90                           95
              Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o Gl y Ser Ser Thr
                               100                         105                          110
              Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a
                         115                         120                          125
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                   130                         135                          140
                                                                 Page 525

                                                                97047_1
<removed-date>
              <210>     136
              <211>     144
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
<removed-apn>
              <223>     AG144_F
              <400>     136
              Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Ser Ser Pr o
              1                     5                           10                       15
              Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
                               20                          25                       30
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                         35                           40                       45
              Gl y Ser Ser Thr Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Pr o
                   50                           55                        60
              Ser Al a Ser Thr Gl y Thr Gl y Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser
              65                          70                         75                       80
              Thr Gl y Ser Pr o Gl y Ser Ser Pr o Ser Al a Ser Thr Gl y Thr Gl y Pr o
                                    85                          90                       95
                                                                Page 526

                                                                  97047_1
<removed-date>
              Gl y Thr Pr o Gl y Ser Gl y Thr Al a Ser Ser Ser Pr o Gl y Ser Ser Thr
                               100                          105                         110
              Pr o Ser Gl y Al a Thr Gl y Ser Pr o Gl y Ser Ser Thr Pr o Ser Gl y Al a
                         115                          120                         125
<removed-apn>
              Thr Gl y Ser Pr o Gl y Al a Ser Pr o Gl y Thr Ser Ser Thr Gl y Ser Pr o
                  130                           135                         140
              <210>     137
              <211>     288
              <212>     PRT
              <213>     Ar t i f i c i al Sequenc e
              <220>
              <223>     AE288_2
              <400>     137
              Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Gl u
              1                      5                            10                          15
              Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y
                               20                           25                          30
              Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o
                         35                           40                          45
                                                                  Page 527

                                                                    97047_1
<removed-date>
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr
                    50                            55                            60
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u
              65                            70                            75                            80
<removed-apn>
              Gl y Ser Al a Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                                      85                            90                            95
              Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Thr
                                100                           105                           110
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr
                          115                           120                           125
              Ser Thr Gl u Gl u Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                    130                           135                           140
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o
              145                           150                           155                           160
              Al a Thr Ser Gl y Ser Gl u Thr Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                                      165                           170                           175
              Gl u Ser Gl y Pr o Gl y Ser Gl u Pr o Al a Thr Ser Gl y Ser Gl u Thr Pr o
                                                                    Page 528

                                                                      97047_1
<removed-date>
                                  180                           185                           190
              Gl y Thr Ser Gl u Ser Al a Thr Pr o Gl u Ser Gl y Pr o Gl y Thr Ser Thr
                           195                            200                           205
<removed-apn>
              Gl u Pr o Ser Gl u Gl y Ser Al a Pr o Gl y Thr Ser Gl u Ser Al a Thr Pr o
                    210                             215                           220
              Gl u Ser Gl y Pr o Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u
              225                             230                           235                           240
              Gl y Ser Pr o Al a Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Ser Pr o Al a
                                        245                           250                           255
              Gl y Ser Pr o Thr Ser Thr Gl u Gl u Gl y Thr Ser Gl u Ser Al a Thr Pr o
                                  260                           265                           270
              Gl u Ser Gl y Pr o Gl y Thr Ser Thr Gl u Pr o Ser Gl u Gl y Ser Al a Pr o
                           275                            280                           285
              <210>       138
              <211>       20
              <212>       PRT
              <213>       Ar t i f i c i al Sequenc e
              <220>
              <223>       l i nk er
                                                                      Page 529

                                                           97047_1
<removed-date>
              <400>   138
              Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y Gl y Ser Gl y
              1                       5                    10                    15
<removed-apn>
              Gl y Gl y Gl y Ser
                              20
              <210>   139
              <211>   5
              <212>   PRT
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   l i nk er
              <220>
              <221>   REPEAT
              <222>   ( 1) . . ( 5)
              <223>   May be r epeat ed 1 t o 10 t i mes
              <400>   139
              Gl y Gl y Gl y Gl y Ser
              1                       5
              <210>   140
              <211>   6
              <212>   PRT
                                                           Page 530

                                                           97047_1
<removed-date>
              <213>   Ar t i f i c i al Sequenc e
              <220>
              <223>   l i nk er
              <220>
<removed-apn>
              <221>   REPEAT
              <222>   ( 2) . . ( 6)
              <223>   May be r epeat ed 1 t o 10 t i mes
              <400>   140
              Ser Gl y Gl y Gl y Gl y Ser
              1                       5
                                                           Page 531

